<SEC-DOCUMENT>0001040130-24-000046.txt : 20240614
<SEC-HEADER>0001040130-24-000046.hdr.sgml : 20240614
<ACCEPTANCE-DATETIME>20240614083034
ACCESSION NUMBER:		0001040130-24-000046
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240614
DATE AS OF CHANGE:		20240614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PETMED EXPRESS INC
		CENTRAL INDEX KEY:			0001040130
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				650680967
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-28827
		FILM NUMBER:		241043226

	BUSINESS ADDRESS:	
		STREET 1:		420 SOUTH CONGRESS AVENUE
		CITY:			DELRAY BEACH
		STATE:			FL
		ZIP:			33445
		BUSINESS PHONE:		(561) 426-4444

	MAIL ADDRESS:	
		STREET 1:		420 SOUTH CONGRESS AVENUE
		CITY:			DELRAY BEACH
		STATE:			FL
		ZIP:			33445
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pets-20240331.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b431201b-f537-4396-8d13-986e96a3bf3a,g:5ff869d6-f8b6-477d-8b92-37fe9911b79a,d:6c215bb864894b15adb92ac1022d7659-->
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:pets="http://www.1800petmeds.com/20240331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pets-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-32">0001040130</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-33">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-36" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-317">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-43" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-331">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-43" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="f-558">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-130" name="pets:RestrictionPeriod" id="f-736">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-136" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-746">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-158" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-794">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-136" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-838">0.333333333333333</ix:nonFraction><ix:nonNumeric contextRef="c-193" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-933">3</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-199" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-934">0.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-200" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-935">0.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-201" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-936">0.3333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pets-20240331.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="reporting_unit"><xbrli:measure>pets:reporting_unit</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="tenant"><xbrli:measure>pets:tenant</xbrli:measure></xbrli:unit><xbrli:unit id="performanceobligation"><xbrli:measure>pets:performanceObligation</xbrli:measure></xbrli:unit><xbrli:unit id="model"><xbrli:measure>pets:model</xbrli:measure></xbrli:unit><xbrli:unit id="category"><xbrli:measure>pets:category</xbrli:measure></xbrli:unit><xbrli:unit id="payment"><xbrli:measure>pets:payment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pets:FurnitureFixturesEquipmentAndComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pets:FurnitureFixturesEquipmentAndComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pets:MeasurementInputWeightedAverageCostOfCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputControlPremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">pets:SevenSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">pets:SixSuppliersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pets:PartnerProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:ReorderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:ReorderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:NewOrderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:NewOrderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:ReorderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:NewOrderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:ReorderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:NewOrderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-03</xbrli:startDate><xbrli:endDate>2023-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pets:TollFreeTelephoneNumberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pets:TollFreeTelephoneNumberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pets:VetsterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-03</xbrli:startDate><xbrli:endDate>2023-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pets:VetsterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:SEC382LimitedUtilizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:SEC382LimitedUtilizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:SEC382LimitedUtilizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:SEC382LimitedUtilizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>1998-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>1998-04-01</xbrli:startDate><xbrli:endDate>1998-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-01</xbrli:startDate><xbrli:endDate>2015-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pets:FiscalYear2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pets:FiscalYear2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">pets:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:EmployeeAndDirectorEquityCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:NonvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:EmployeeAndDirectorEquityCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:NonvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:EmployeeAndDirectorEquityCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:NonvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:EmployeeAndDirectorEquityCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:NonvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-13</xbrli:startDate><xbrli:endDate>2023-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-02</xbrli:startDate><xbrli:endDate>2022-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-29</xbrli:startDate><xbrli:endDate>2024-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-29</xbrli:startDate><xbrli:endDate>2024-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-29</xbrli:startDate><xbrli:endDate>2024-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-29</xbrli:startDate><xbrli:endDate>2024-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-29</xbrli:startDate><xbrli:endDate>2024-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-29</xbrli:startDate><xbrli:endDate>2024-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6c215bb864894b15adb92ac1022d7659_1"></div><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:7.2pt;padding-right:7.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">March 31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from __________ to __________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">000-28827</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">PETMED EXPRESS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">65-0680967</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(State or other jurisdiction of <br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">420 South Congress Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Delray Beach</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Florida</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">33445</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Address of principal executive offices) (Zip Code)</span></td></tr><tr style="height:8pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">561</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">526-4444</ix:nonNumeric></span></div></td></tr><tr style="height:8pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:8pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, PETS <br/>$.001 Par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">PETS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" id="f-18">NASDAQ</ix:nonNumeric> Stock Market LLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(NASDAQ Global Select Market)</span></div></td></tr><tr style="height:8pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Securities registered under Section 12(g) of the Act:</span></td></tr><tr style="height:8pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">NONE</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________________________________________</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.267%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">x</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s Common Stock held by non-affiliates of the registrant as of September 29, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-29">209.2</ix:nonFraction> million based on the closing sales price of the registrant&#8217;s Common Stock on that date, as reported on the NASDAQ Global Select Market.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant&#8217;s Common Stock outstanding as of June&#160;14, 2024, was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">20,606,692</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information to be set forth in our proxy statement relating to our 2024 Annual Meeting of Shareholders is incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of our fiscal year ended March 31, 2024.</span></div></ix:nonNumeric><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_7"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">PETMED EXPRESS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2024 Annual Report on Form 10-K </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_10">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_13">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_16">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_16">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_16">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_19">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_19">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cybersecurity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_635">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_22">Item 2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_22">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_22">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_25">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_25">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_25">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_28">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_28">24</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_31">PART II</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_31">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_34">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_34">Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_34">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_37">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_37">[Reserved]</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_37">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_40">Item 7.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_40">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_67">Item 7A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_67">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_67">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_70">Item 8.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_70">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_70">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_136">Item 9.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_136">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_136">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_139">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_139">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_139">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_142">Item 9B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_142">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_142">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_145">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_145">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_145">78</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_148">PART III</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_148">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_151">Item 10.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_151">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_151">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_154">Item 11.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_154">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_154">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_157">Item 12.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_157">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_157">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_160">Item 13.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_160">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_160">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_163">Item 14.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_163">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_163">79</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_166">PART IV</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_166">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_169">Item 15.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_169">Exhibit and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_169">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_172">Item 16.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_172">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_172">82</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_175">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_175">83</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_10"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information in this Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plan," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of this Annual Report on Form 10-K under the heading &#8220;Risk Factors.&#8221; A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of the filing of this Annual Report on Form 10-K. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When used in this Annual Report on Form 10-K, unless otherwise stated or the context otherwise indicates, "PetMed Express,"  &#8220;PetMeds,&#8221; "PetMed," "the Company," "we," "our," and "us" refers collectively to PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries, taken as a whole.  "PetCareRx" refers to PetCareRx, Inc., a wholly owned subsidiary of PetMed Express, Inc..</span></div><div id="i6c215bb864894b15adb92ac1022d7659_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Since 1996, PetMeds has been a pioneer in digital retail, serving as a trusted source for pet medicines across North America. Similarly, since 1998, PetCareRx has been providing pet healthcare products directly to consumers. Together, our brands are dedicated to delivering exceptional quality wellness products from innovative suppliers, making it easier for families to address preventive and chronic health needs in order to support the longevity of their companion animals. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are deeply committed to the mission and purpose that has driven our business from the start. The support of millions of customers nationwide has been the cornerstone of our success. Honoring our combined legacy, we bring our core values to every role we undertake. Our primary goal is to empower pet families, ensuring they can provide the best possible care for their dogs, cats, and horses and help them lead long, healthy lives.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PetMed Express, Inc. and subsidiaries, d/b/a PetMeds&#174;, and as parent company of PetCareRx&#174;, is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. PetMeds and PetCareRx market and sell directly to consumers through their websites, toll-free numbers, and employer benefits partnerships. Through thousands of veterinary partners and a loyal customer base who rely on our services, our in-house pharmacies and extended pet healthcare partnerships seek to offer unparalleled value and convenience to families at every stage of their pets' lives. Over the years, our organization has made significant investments in our pharmacies to ensure compliance. By employing licensed pharmacists who specialize in veterinary medicine, it allows us to provide focused and specialized care. Additionally, we have implemented a rigorous 5-point verification process from order to shipment to ensure quality control. We continuously monitor and update our regulatory licenses in every state, including the U.S. Virgin Islands. Our pharmacies are accredited by the NABP.Com and LegitScript and are focused on excelling in meeting all federal and state regulatory requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a premier service to our customers, our in-house pet health specialists in our call center support over 100,000 pet parents each month. Pet owners have the ability to contact our agents and pharmacists for assistance with their animals' wellness needs via telephone, chat, and email. We offer extended services, including pet insurance, telehealth, and employee benefits programs, through our core partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company's executive headquarters offices are currently located at 420 South Congress Avenue, Delray Beach, Florida 33445, and our telephone number is (561) 526-4444. The Company has a March 31 fiscal year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR INDUSTRY</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business focuses on a specific segment of the pet industry: pet wellness for dogs, cats, and horses. Within this segment, our merchandise categories include prescription medications, over-the-counter (OTC) medications, supplements, prescription food, non-prescription food, and a comprehensive assortment of pet supplies. The total addressable market for pet medications, foods, and health products and services is vast and continuously expanding. According to the American Pet Products Association, pet spending in the United States increased by 7% to $147.0&#160;billion in 2023, with veterinary care and prescription medications accounting for $38.3&#160;billion or 26% of that total. The increasing demand for pet wellness products presents significant potential for us to expand our footprint and capture a larger share of this thriving market.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE PET CONSUMER</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">According to a Mintel Services report in 2023:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Eighty-six percent of the total pet customers prefer maintaining a routine pet care regimen.  </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">To support this, we offer auto-ship options for our core products, ensuring convenient and consistent care for their pets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Eighty-one percent of customers believe that investing more in pet products and services is worthwhile for their pet's well-being. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Our core products address the most common preventive and acute pet care needs. To cater to a diverse range of budgets, we offer a tiered pricing strategy ensuring that every customer can find products that meet their needs and preferences. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Thirty-five percent of pet owners rely on social media to guide their choices in pet products and services. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Ensuring we effectively engage our pet families through social platforms, we have a wellness guide which will be further developed utilizing an integrated marketing  approach through our five social media channels inclusive of Instagram, TikTok, Facebook, YouTube and X, </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">More than 2.0&#160;million customers have purchased from us within the last three fiscal years, including customers acquired in April 2023 as a part of our PetCareRx acquisition. We attracted approximately 302,000 and 274,000 new customers in fiscal 2024 and 2023, respectively. Our customers are located throughout the United States, with approximately 49% of customers residing in California, Florida, Texas, New York, Pennsylvania, North Carolina, Georgia, and Virginia. The average order value increased slightly year over year and was approximately $94 for fiscal 2024 and $93 for fiscal 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCTS AND SERVICES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a broad selection of products and services for dogs, cats, and horses. Our current product line contains more than 15,000 SKUs of popular pet medications, health products, foods, and supplies. This includes a majority of well-known brands of pet medications. With our April 2023 acquisition of PetCareRx, we have expanded our product catalog beyond medications to include a wider assortment of pet products. Additionally, we offer various pet supplies on our websites, some of which are drop-shipped to customers by third parties. These supplies include beds, crates, stairs, and other popular items. We periodically assess and adjust our merchandise categories based on seasonal and industry trends. Designed for flexibility, our websites allow us to change featured products or promotions. This approach provides customers with a wide variety of selections across the most popular health categories for dogs, cats, and horses. Through robust partnerships with our vendors, our current products include: </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prescription Medications (Rx)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Heartworm and flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Prescription Medications (OTC) and supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pet Foods:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium and non Premium Pet Foods, including Veterinary Prescription Rx Diets</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Label</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our exclusive range of private label products offers exceptional value and affordability. From shampoos and flea collars to joint enhancers, vitachews, and soft toys, our proprietary line provides high-quality, cost-effective solutions for pet care. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Holistic Wellness Services:</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pet Telemedicine: Our VetLive service, powered by Vetster, provides pet owners with the convenience of consultations, diagnoses, and in some states, prescriptions from board-certified veterinarians&#8212; all from the comfort of their homes. This service saves time and ensures expert care without the need to visit a clinic. Additionally, AI-assisted remote veterinary technicians, through our partnership with AskVet, provide a wide range of telehealth services, from dietary advice to training.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pet Insurance: We partner with Pumpkin Insurance, a premium provider owned by JAB Holding Company, to offer our customers discounted premium pet insurance options.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employee Pet Benefits: Our partnership with PetAssure (Synergy Pet Group) allows us to be part of their employer bundled service, offering discounted pet care solutions that provide employees with access to our PetPlus membership. This membership includes a variety of exclusive perks, discounts, and valuable services that significantly enhance the well-being of pets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">OUR EXPERT VETERINARY ADVISORY BOARD</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To further our commitment to connecting with customers through education and professional credibility, the Company recently launched its Veterinary Advisory Board (VAB) with the goal of ensuring that all of our initiatives result in improved patient care. This esteemed board currently consists of five expert veterinarians across the country, each with decades of experience in private practice and academia, shaping the future of veterinary medicine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dr. Lori Teller, DMV, DABVP (Canine/Feline), CVJ, and Clinical Professor in the Department of Small Animal Clinical Sciences at Texas A&amp;M University&#8217;s School of Veterinary Medicine and Biomedical Sciences, serves as the Chair of the VAB and the liaison between the Company and the VAB. We believe that Dr. Teller and her fellow VAB colleagues bring a wealth of knowledge and experience to our company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RECENT DEVELOPMENTS AND STRATEGIC TRANSACTIONS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACQUISITION OF PetCareRx</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we acquired PetCareRx, Inc. (&#8220;PetCareRx&#8221;), an online supplier of pet medications, foods, and supplies based in New York. This acquisition added a catalog of food and supplies and approximately 286,000 new and renewal customers to our company, allowing us to rapidly expand beyond our core offering of pet prescriptions. We now provide a more extensive selection of premium food, supplements, treats, and other pet supplies as a result of this acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PetCareRx boasts a thriving membership program, which constitutes two-thirds of their customer base, enhancing customer loyalty and engagement. The collaboration between PetCareRx and PetAssure is being expanded across both brands in fiscal 2025, significantly increasing the number of members within our platform. Their telehealth services,, powered by AI-driven AskVet, are being expanded across the organization, further enriching our member service offerings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PET INSURANCE PARTNERSHIP</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced a strategic partnership with Pumpkin Insurance Services, Inc. (&#8220;Pumpkin&#8221;), a leading provider of premium pet insurance plans. Through this collaboration, we offer our customers access to high-quality health and wellness pet insurance benefits as part of our holistic wellness ecosystem. This partnership enables our customers to purchase co-branded insurance plans, developed in conjunction with Pumpkin and their underwriters, and offered by our subsidiary, PetMeds Insurance Services, LLC. These innovative insurance products became available for purchase in October 2023, providing pet owners with peace of mind as they navigate all stages of their pets' lives.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PET TELEHEALTH PARTNERSHIP</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022, we announced a multi-year exclusive partnership with Vetster Inc., a veterinary telehealth startup based in Canada. This strategic alliance provides pet owners in the United States with seamless online access to veterinary services through Vetster&#8217;s innovative platform. Customers have the option to purchase any prescriptions or OTC products that have been uploaded from the PetMeds catalog. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We invested approximately $5.0 million  in Vetster as part of their Series B financing round in April 2022, followed by a $0.3 million investment in a Series B extension round in September 2023. These investments underscore our commitment to complementing the vet/patient relationship with telehealth and expanding access to high-quality care for pets as part of our holistic wellness ecosystem.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STRATEGY AND KEY BUSINESS PRIORITIES</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PetMeds is committed to a long-term vision of becoming a leading digital-first pet wellness company. The Company is incorporating new leadership and new strategic opportunities to make progress against initiatives that support this vision, while balancing the near-term challenges and business headwinds.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-Term Strategy Fiscal 2025</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidate our brands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We believe that our primary brands, namely &#8220;PetMeds,&#8221; and "PetCareRx" are  known as being credible experts among pet owners and are synonymous with pet health and well-being.The consolidation of our brands into a single united company is driven by our commitment to streamline operations, enhance efficiency, and provide a more cohesive customer experience. By bringing together brands that have the same mission and value proposition, we can leverage our combined strengths, reduce redundancies, and offer a unified, stronger presence in the market. This strategic move allows us to unite our resources and expertise, better serve our customers with an expanded product range, improve service quality, and add greater value, ultimately fostering growth and innovation within our sector.  The consolidation allows us to capitalize on the distinct strengths of each brand, ensuring that our customers benefit from enhanced capabilities and a superior overall experience.This approach not only strengthens our position in the market but also drives growth and sets new industry standards for excellence. This strategic move also enables us to integrate the best practices and unique attributes of each organization, fostering innovation and excellence.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preserve Cash While Preserving Key Partnerships and Investing in Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company entered fiscal 2025 with a healthy liquidity position and will continue to monitor and manage cash flow as we right-size our operations through the consolidation of our two brands. To preserve liquidity and maximize cash flows during fiscal 2025, we will undertake the following actions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Partnering with key suppliers to optimize supply chain availability with corresponding discounts and co-op/rebates, along with payment terms thus improving gross margin.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Manage future inventory through properly forecasting supply with expected demand for improved product availability, ensuring that customers can find the products they need when they need them.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Reduce expenses to better align operating costs with sales through elimination of duplicative resources including agency and vendor consolidation.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Focusing on operational efficiency and reducing order processing time through our warehouse fulfillment centers, pharmacy, and call centers through tech enablement and automation.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Focus on Customer Retention, Loyalty, and Frequency of Visits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the heart of our marketing strategy is a commitment to reinvigorate our growth and deepen our engagement with customers. In today&#8217;s competitive market, a multi-faceted approach is essential in order to thrive.  This includes:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Enhancing the technology supporting our Auto-ship program that drives ease and repeat purchases. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Personalizing the customer journey through customer segmentation optimization.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Bundling and cross-selling opportunities across merchandise categories.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Enrichment of our digital content library. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Modern Technology: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To enhance our customer experience and drive growth, we are making technology investments to consolidate our two websites into a single, integrated platform and improve our veterinary portal experience. This new tech stack is designed to increase engagement, improve conversion rates, and provide a seamless customer journey.  Investments and initiatives include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Integration of PetMeds and PCRx as one destination.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Enhancement of Pharmacy Software for increased digitization.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Fulfillment logic to optimize operations across enterprise. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Digital analytics/Business Intelligence tools revamp to enable faster decision making that drive growth and profitability. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Consolidation of in-house customer health specialist phone, chat, email systems within our customer call center for seamless communication with our customers and veterinary partners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Long Term Strategy</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ultimate goal is to position our company as the go-to resource for high quality pet health and wellness products, services, and experiences through our 360 ecosystem, ensuring sustained growth and a thriving customer community.To achieve this, we will focus on the following strategic initiatives:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Create best-in-class customer experiences across channels through modern technology that incorporates AI, automation, and product management that drives personalized journeys across all touchpoints.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Improve the speed and efficiency from order to customer's doorstep.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Develop mission-first, purposeful marketing campaigns that are authentic in order to improve customer engagement while increasing brand awareness.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Leverage data analytics to gain timely customer insights that will accelerate responsiveness to customer demands.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Innovate product offerings, increasing high-margin private label assortments.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Enhance and curate strategic partnerships that further promote the health and wellness during all life stages for dogs, cats, and horses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISTRIBUTION CHANNELS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our products through three main sales channels: (1) the Internet, through our websites, (2) our health specialist customer support center through our toll-free numbers and (3) through PetAssure's broker network for employer benefits. We have a roadmap for fiscal 2025 that will optimize our websites, and provide a convenient and personalized shopping experience. Our customer service pet health specialists support more than 100,000 calls per month, a testament to the pet owner's need for, and our ability to deliver, a personalized experience. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internet</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s digital operations across various brands have consistently catered to our customers on multiple platforms. To create a more seamless shopping experience, we will continue to invest in our digital infrastructure. Currently, each brand operates separate desktop and mobile websites, but we plan to integrate these into a unified environment in fiscal 2025. Additionally, we are revitalizing our mobile applications in fiscal 2025 to offer improved features and enhanced quality, further developing our mobile capabilities as mobile engagement continues to grow.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In fiscal 2024, we attracted approximately 36&#160;million visits to our websites, with about 5% of these visits converting to orders. Through our websites, pet owners have access to comprehensive health information covering pet behavior, illnesses, and both natural and pharmaceutical remedies tailored to their pets&#8217; needs. Our PetMeds.com website's pet education content is periodically updated with the latest research for pet owners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our multichannel strategy, we offer mobile versions of our websites (www.petmeds.com and www.petcarerx.com) and will have an optimized mobile application compatible with mobile phones, tablets, and other devices in fiscal 2025. Key features of our websites include AutoShip subscriptions (Approximately 54% of our sales were generated via our AutoShip program in our fourth quarter ended March&#160;31, 2024), "ask-the-vet" services, VetLive consultations, live web chat, easy refill medication reminders, a local veterinarian finder, and express checkout options. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pet Health Specialists - Customer Support Center</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that a high level of customer care and support is critical in retaining and expanding our customer base. We provide ongoing training programs under the supervision of our training managers that include a variety of topics such as product knowledge, computer usage, customer service tips, and the relationship between our Company and veterinarians. Our customer support center agents respond to customers&#8217; e-mails, calls, and live web chats that are related to products, order status, prices, and shipping. Consolidating our two branded teams and incorporating the best-in-class tech provider, our specialists will be fully equipped with advanced telephone systems so that we can maximize our representatives&#8217; time, ensuring top-tier customer care, service, and support. Managing over 100,000 calls per month, our team of 150 in-house agents consistently delivers outstanding assistance to our valued customers.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Marketing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goal of our fiscal 2025 marketing strategy aims to integrate our two brands (Petmeds and PetCareRX) into a customer centric relevant brand which resonates with our mission and provides direct value to our customers.  This includes establishing and building  brand recognition to increase customer traffic, better align with current customer needs and wants, add new customers, build strong lifetime customer loyalty, that ultimately will maximize reorders, and develop incremental revenue opportunities. We have built, and will deliver, an integrated marketing campaign that includes digital marketing and direct mail/print and e-mail. Our campaigns strive to convey our dedicated focus on the well-being of pets and our commitment to accompanying our customers on their pet's wellness journey, which includes both preventative and chronic solutions for cats, dogs and equines across diverse breeds, sizes, ages and conditions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently utilize digital marketing through performance and acquisition marketing strategies, deliver content via streaming channels, direct mail, and email. The Company aims to create a best-in-class marketing operation through a continuous test-and-learn approach as we progress into fiscal 2025.  This will be visible across all customer touchpoints.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW OF PHARMACY OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information is needed to process prescription orders: pet information, prescription information, and the veterinarian&#8217;s name and phone number. This information is entered into our order processing system. Then our pharmacists and pharmacy technicians verify all prescriptions. The order processing system checks for the verification for prescription medication orders and a valid payment method for all orders. Verified orders are then sent to our fulfillment centers, where items are picked, and then shipped via the United States Postal Service, United Parcel Service, and Federal Ex.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SOURCING OF MERCHANDISE INVENTORY</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We source our products from a diverse array of vendors, including manufacturers and domestic distributors. In fiscal 2024, approximately 78.1% of all products were purchased from seven key suppliers. We believe that deepening our relationships with manufacturers and distributors is crucial to ensuring a reliable supply of the products our customers need.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our growth strategy, we prioritize maintaining direct relationships with leading pharmaceutical manufacturers, providing both popular prescription and non-prescription medications. These direct relationships not only help us secure an adequate volume of products but also enable us to offer the latest and most trusted pet health solutions. Our continued partnerships with these major manufacturers are a testament to our commitment to quality and reliability in serving our customers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISTRIBUTION OF MERCHANDISE INVENTORY</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company implements rigorous quality control measures to guarantee the authenticity and safety of all medications. We efficiently manage our inventory and fulfill customer orders from our corporate headquarters in Delray Beach, Florida, and our Northeast warehouse location in Lynbrook, New York while conducting thorough checks on every order received for veterinary approval and prescription labeling accuracy. Our in-house pharmacy, fulfillment and distribution operations oversee the entire supply chain&#8212;from order placement and processing to fulfillment and shipping. Our pharmacists oversee the processing of every order and follow a regimented 5-step verification process which is the cornerstone of our credibility. For prescription medications, we strive to ship immediately upon authorization by the customer&#8217;s veterinarian. During fiscal 2025, we will be adding third party logistics locations that allow us closer proximity to our customers, which should result in lower shipping costs and higher product margins.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION SYSTEMS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Company-owned and third-party-operated management information systems consist of a full range of retail, merchandising, human resource and financial systems. These systems include applications related to digital operations, inventory management, supply chain, planning, sourcing, merchandising, payroll, scheduling and financial reporting. The Company continues to invest in technology to upgrade its core systems to create efficiencies and to support its digital operations, pharmacy operations, fulfillment center effectiveness, customer relationship management tools and loyalty programs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DIGITAL TECHNOLOGY SYSTEMS</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal 2025, we will invest in our digital technology platforms in order to seamlessly integrate advanced technologies across various facets of our operations. Our call centers, e-commerce, order entry systems, order management system (OMS) and inventory control/fulfillment processes will benefit from simplified, custom-configured solutions. Our ongoing efforts will focus on unifying talent, technology frameworks, and business operations in order to drive growth and profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a rapidly evolving, highly competitive, and fragmented business environment. Our competitors include veterinarians, local and national chain specialty retailers, and vendors' own e-commerce stores. Additionally, consumers' discretionary spending on pets extends to categories like apparel, grooming, boarding, and dog-walking. Operating in a highly competitive industry environment can cause the Company to engage in greater than expected promotional activity at times, which would result in pressure on average unit retail and gross profit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our distinct advantage lies in our commitment to high-quality products and our team of highly qualified pharmacists and technicians with specialized training in veterinary pharmacology that are licensed across all fifty states. Our teams execute a rigorous 5-point verification process and are compliant with all federal regulations set by the FDA and DEA. PetMeds and PetCareRx's pharmacies are accredited by the National Association of Boards of Pharmacy and LegitScripts. This combination of quality, expertise, and efficiency sets us apart in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our business under the trade names &#8220;PetMeds&#8221; and "PetCareRx" and use a family of trade names all containing the terms &#8220;PetMeds&#8221;, &#8220;PetMed&#8221; or "PetCareRx" in some form. We believe the &#8220;PetMeds&#8221; and "PetCareRx" family of trademarks, have added significant value and are important factors in the marketing of our products. We have also obtained the right to use and control the Internet addresses which include but are not limited to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.1800petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.1888petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmedexpress.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmed.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petcarerx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also obtained the right to use and control the Internet addresses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">www.petmeds.pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">www.petmed.pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">www.1800petmeds.pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">petcare.pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">petcarerx.pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, through a National Association of Boards of Pharmacy&#174; initiative to ensure high standards for online pharmacies. We do not expect to lose the ability to use the Internet addresses; however, there can be no assurance in this regard and the loss of these addresses may have a material adverse effect on our financial position and results of operations. We are the exclusive owners of United States trademark registrations for &#8220;America&#8217;s Largest Pet Pharmacy&#174;,&#8221; &#8220;America&#8217;s Most Trusted Pet Pharmacy&#174;,&#8221; &#8220;Trusted Pet Medication Experts&#174;,&#8221; &#8220;PetMed Express, Inc.&#174;,&#8221;1-800-PetMeds and Design&#174;,&#8221; 1-800-PetMeds&#174;,&#8221; &#8220;PetMeds&#174;,&#8221; &#8220;Your Trusted Pet Health Expert&#174;," "PetPlus&#174;," "PetCareRx&#174;," "Nose to Tail&#174;," "Nose to Tail Health&#174;," and "Nose to Tail Savings&#174;," among numerous others. We have also applied for trademark protection for "VetLive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">."</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a broad range of federal, state, and local laws and regulations that relate to our business. Dispensing prescription medications is governed at the state level by Boards of Pharmacy, or similar regulatory agencies, of each state where prescription medications are dispensed. PetMeds is subject to regulation by the State of Florida and is licensed as a community pharmacy by the Florida Board of Pharmacy, and PetCareRx is subject to regulation by the State of New York and is licensed as a community pharmacy by the New York Pharmacy Board.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our pharmacy practices are also licensed and/or regulated by 49 other state pharmacy boards, the District of Columbia Board of Pharmacy, the U.S. Virgin Islands Board of Pharmacy, and the United States Drug Enforcement Administration ("DEA"), and with respect to our products, by other regulatory authorities including, but not necessarily limited to, the United States Food and Drug Administration (&#8220;FDA&#8221;) and the United States Environmental Protection Agency ("EPA"). Our registration with the DEA, and state registrations/permits as required, permit us to dispense Schedule IV and Schedule V controlled substances. As a licensed pharmacy in the State of Florida, we are subject to the Florida Pharmacy Act and regulations promulgated thereunder. If we fail to maintain our licenses with the Florida Board of Pharmacy, or if we do not maintain the licenses/registrations/permits from other state pharmacy boards (including our home state pharmacy license in New York for PetCareRx), or if we face actions from the DEA, FDA EPA, or other enforcement regulators, our ability to dispense prescription medications to pet owners could be halted, which could have a material adverse effect on our financial condition and operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing, the FDA regulates animal feed, including pet food, under the Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) and its implementing regulations. Although pet foods are not required to obtain premarket approval from the FDA, the FFDCA requires that all animal foods are safe for consumption, produced under sanitary conditions, contain no harmful substances, and are truthfully labeled. Most states also require that pet foods distributed in the state be registered or licensed with the appropriate state regulatory agency. In addition, most facilities that manufacture, process, pack, or hold foods, including pet foods, must register with the FDA and renew their registration every two years, and are subject to periodic FDA inspection. This includes most foreign, as well as domestic facilities. Registration must occur before the facility begins its pet food manufacturing, processing, packing, or holding operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The labeling of pet foods is regulated by both the FDA and some state regulatory authorities. FDA regulations require proper identification of the product, a net quantity statement, a statement of the name and place of business of the manufacturer or distributor, and proper  listing of all the ingredients in order of predominance by weight. Most states also enforce their own labeling regulations. The degree of oversight of the implementation of these regulations varies by state, but typically includes a state review and approval of each product label as a condition of sale in that state.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA also regulates the inclusion of specific claims in pet food labeling. For example, pet food products that are labeled or marketed with claims that may suggest that they are intended to treat or prevent disease in pets would potentially meet the statutory definitions of both a food and a drug.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our distribution of pet insurance products under our strategic partnership with Pumpkin also subjects us to state laws and regulations relating to the sale of insurance products, including registering as an insurance distributor in states in which we offer and sell the Pumpkin co-branded pet insurance products and otherwise complying with state and federal laws relating to the sale and distribution of insurance products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on legal and operational compliance programs, as well as outside counsel, to guide our business in complying with applicable laws and regulations in the areas in which we do business. In addition, regulatory regime changes may add cost and complexity to our compliance efforts. It is difficult to predict with certainty the potential impact of future regulatory compliance efforts and future costs associated with such matters. Our failure to comply with such laws and regulations may result in adverse actions that could disrupt our operations and adversely affect our financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is committed to fostering a culture that not only advances strategic and key business priorities but also empowers employees to make a positive impact in their communities. We believe that attracting, retaining, and managing a diverse and talented workforce is crucial to our success. Our commitment to diversity, equity, and inclusion encompasses individuals of different ages, colors, disabilities, ethnicities, family or marital statuses, gender identities or expressions, languages, national origins, physical and mental abilities, political affiliations, races, religions, sexual orientations, socio-economic statuses, veteran statuses, and other characteristics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To ensure our employees have the opportunity to develop and excel, human capital management is a top priority for our executives and Board of Directors, as evidenced by the recent expansion of the Compensation Committee to the Compensation and Human Capital Committee. We are dedicated to identifying and nurturing the talent necessary for our long-term success. Our employees have access to a wide range of resources to enhance their skills and advance their careers, including internal leadership development classes, online development resources, mentorship programs, individual development opportunities, and key projects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we offer functional management training, learning management systems-based educational opportunities, certification programs, and educational assistance to support our future leaders in their professional growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We pride ourselves on maintaining a strong corporate culture that upholds high standards of ethics and compliance. Our Code of Business Conduct and Ethics outlines the principles that guide the behavior of our employees, officers, directors, and vendors. To ensure adherence to these standards, we have implemented a whistleblower policy and an anonymous hotline for confidential reporting of any suspected policy violations or unethical conduct. Furthermore, all staff members are required to complete anti-harassment training.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By fostering a supportive and inclusive environment, we empower our employees to thrive both professionally and personally, driving our company forward and making a meaningful impact in our communities.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;14, 2024 we had 287 full time employees. None of our employees are represented by a labor union or governed by any collective bargaining agreements. We consider relations with our employees to be good. The majority of our employees are connected to our Delray Beach, Florida headquarters and distribution center, and approximately 78 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">employees work at the office and distribution center and are connected to our New York location that we acquired as a part of the PetCareRx acquisition. Many of our personnel are currently working remotely or in a hybrid work model with the exception of essential on-site workers. Similar to many companies, we are exploring the benefits of bringing teams back into the office.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We offer our employees a wide array and highly competitive benefits such as life and health (medical, dental, and vision) insurance, medical and dependent care flexible spending accounts, legal services provider network, paid time off (including gender neutral parental leave) and retirement benefits, as well as emotional well-being services through our health insurance program.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website addresses are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petcarerx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information on our websites is not, and shall not be deemed to be, a part of or incorporated into this Annual Report on Form 10-K or any other filings we make with the Securities and Exchange Commission ("SEC"). We file annual, quarterly, and current reports, proxy statements, and other information with the SEC. Our SEC filings, including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to the Exchange Act are available free of charge over the Internet on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or at the SEC's website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our SEC filings will be available through our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as soon as reasonably practicable after we have electronically filed or furnished them to the SEC.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_16"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and financial results are subject to various risks and uncertainties, including those described below, that could materially and adversely affect our business, financial condition, operating results and the trading price of our common stock. Because of the following factors, as well as other factors affecting the Company&#8217;s results of operations and financial condition, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods. This discussion of risk factors contains forward-looking statements. This section should be read in conjunction with Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the consolidated financial statements and accompanying notes in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Regulatory Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Any failure to comply with various state or federal regulations covering our pet health business, including the dispensing of prescription pet medications may subject us to reprimands, sanctions, probations, fines, suspensions, or the loss of one or more of our pharmacy licenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our pet health business, which includes the sale and delivery of prescription pet medications is generally governed by state laws and state regulations, and with respect to controlled substances, also by federal law. Governmental authorities that regulate our business have broad latitude to make, interpret, and enforce the laws and regulations that govern us. Since our pharmacy is located in the State of Florida, the Company is governed by the laws and regulations of the State of Florida. Each prescription pet medication sale we make is likely also to be covered by the laws of the state where the customer is located. The laws and regulations relating to the sale and delivery of prescription pet medications vary from state to state, but generally require that prescription pet medications be dispensed with the authorization from a prescribing veterinarian. Our current home-state license with the Florida Board of Pharmacy is valid until February&#160;28, 2025, and PetCareRx&#8217;s home-state license in the State of New York is valid until April&#160;30, 2025, and there is no guarantee that we will be able to renew such licenses when required. To the extent that we are unable to maintain our license as a community pharmacy with the Florida Board of Pharmacy (and to the extent we are unable to maintain PetCareRx&#8217;s license in New York), or if we do not maintain the licenses granted by other state boards, or if we become subject to actions by the FDA, or other enforcement regulators, our dispensing of prescription medications to pet owners could cease, which could have a material adverse effect on our operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The expansion of our business into the offer and sale of pet insurance products also subjects us to additional laws and regulations regarding those activities, including as a registered insurance distributor in states in which we offer and sell the Pumpkin co-branded pet insurance products and otherwise complying with state and federal laws relating to the sale and distribution of insurance products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to routine litigation and administrative complaints incidental to its business. Management does not believe that the resolution of any or all of such routine litigation and administrative complaints is likely to have a material adverse effect on the Company&#8217;s financial condition or results of operations. While we make every effort to fully comply with all applicable state rules, laws, and regulations, from time to time we have been the subject of administrative complaints regarding the authorization of prescriptions prior to shipment. We cannot assure you that we will not be the subject of administrative complaints in the future. We cannot guarantee you that we will not be subject to reprimands, sanctions, probations, or fines, or that one or more of our pharmacy licenses will not be suspended or revoked. If we were unable to maintain our license as a community pharmacy in the States of Florida or New York, or if we are not granted licensure in a state that begins to require licensure, or if one or more of the licenses granted by other state boards should be suspended or revoked, our ability to continue to sell prescription medications and to continue our business as it is presently conducted could be in jeopardy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Business Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our failure to properly manage our inventory may result in excessive inventory carrying costs, or inadequate supply of products, which could materially adversely affect our financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current product line contains approximately 15,000 SKUs including the SKUs acquired in our acquisition of PetCareRx. A significant portion of PetMeds sales is attributable to products representing approximately 100 SKUs, including the most popular flea and tick, and heartworm preventative brands. We need to properly manage our inventory to provide an adequate supply of these products and avoid excessive inventory of the products representing the balance of the SKUs. We generally place orders for products with our suppliers based upon our internal estimates of the amounts of inventory we will need to fill future orders. These estimates may be significantly different from the actual orders we receive.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that subsequent orders fall short of original estimates, we may be left with excess inventory. Significant excess inventory could result in price discounts, increased inventory carrying costs, and obsolescence. Similarly, if we fail to have an adequate supply of some SKUs, we may lose sales opportunities. We cannot guarantee that we will maintain appropriate inventory levels. Any failure on our part to maintain appropriate inventory levels may have a material adverse effect on our financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Resistance from veterinarians to authorize prescriptions, or attempts or efforts by veterinarians to discourage pet owners from purchasing from us could cause our sales to decrease and could materially adversely affect our financial condition and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we began our operations, some veterinarians have resisted providing our customers with a copy of their pet&#8217;s prescription or authorizing the prescription to our pharmacy staff, thereby effectively preventing us from filling such prescriptions under state law. We have also been informed by customers and consumers that veterinarians have tried to discourage pet owners from purchasing from internet mail-order pharmacies.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The laws and regulations relating to the sale and delivery of prescription pet medications vary from state to state. Although veterinarians in some states are required by law to provide a pet owner with a prescription if medically appropriate, if the number of veterinarians who refuse to authorize prescriptions should increase, or if veterinarians are successful in discouraging pet owners from purchasing from internet mail-order pharmacies, our sales could decrease, and our financial condition and results of operations may be materially adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant portions of our sales are made to residents of eight states. If we should lose our pharmacy license in one or more of these states, our financial condition and results of operations would be materially adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we ship pet medications to customers in all 50 states, approximately 49% of our sales for the fiscal year ended March&#160;31, 2024, were made to customers located in the states of California, Florida, Texas, New York, Pennsylvania, North Carolina, Georgia, and Virginia. If for any reason our license to operate a pharmacy in one or more of those states should be suspended or revoked, or if it is not renewed, our ability to sell prescription medications to residents of those states would cease and our financial condition and results of operations in future periods would be materially adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">We have direct buying relationships with all the major pet medication manufacturers and each contractual relationship depends on our compliance with each respective manufacturer&#8217;s minimum advertised pricing policies (MAPP).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains direct purchasing relationships with all the major pet medication manufacturers. These relationships entitle the Company to buy directly from the manufacturer under the terms and conditions of a purchasing agreement which dictates purchase pricing of inventory and criteria to obtain additional discounts and rebates. The terms of these agreements also require the Company to comply with the manufacturers&#8217; MAPP. Each advertisement and/or promotion of a product below the MAPP price, should they occur, would be a violation of the policy. This policy applies to all advertisements of products in all media including, without limitation, flyers, posters, coupons, mailers, inserts, newspapers, magazines, on-line catalogs, mail order catalogs, public signage and all Internet or similar electronic media, television, radio and public signage, including websites, email newsletters, forums, and auction sites.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the discretion of the manufacturers, non-compliance with the MAPP can result in one or more of the following actions: (1) forfeiture of future rebates or discounts from the manufacturer, (2) suspension of future purchases from the manufacturer, (3) or termination of current or future business relationship. The Company has and will continue to make every attempt to abide by the manufacturers MAPP. However, no assurances can be made that the Company will not violate MAPP inadvertently. A reduction or discontinuance of these rebates or discounts would increase our costs and could reduce our profitability. If any of these major pet medication manufacturers were to terminate our purchasing relationship it could materially adversely affect our business. If the manufacturers are not able to enforce their MAPP industry-wide, then our profit margins and results of operations may also be impacted negatively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The loss of any of our key suppliers would negatively impact our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have direct purchasing relationships with all of the major pet medication manufacturers, from the majority of which we purchase significant quantities of pet medication products.. We do maintain annual purchasing contracts with these major manufacturers. While we believe that our supplier relationships are good, a supplier could discontinue selling to us at any time. The loss of any of our key suppliers of pet medications offered by us would have a negative impact on our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shipping is a critical part of our business and any changes in, or disruptions to, our shipping arrangements could adversely affect our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on third-party national, regional, and local logistics providers to deliver the products we offer on our websites. If we are not able to negotiate acceptable pricing and other terms with these providers, or if these providers experience performance problems or other difficulties in processing our orders or delivering our products to customers, it could negatively impact our results of operations and our customers&#8217; experience. In addition, our ability to receive inbound inventory efficiently and ship merchandise to customers may be negatively affected by factors beyond our and these providers&#8217; control, including inclement weather, fire, flood, power loss, earthquakes, acts of war or terrorism or other events, such as labor shortages and disputes, financial difficulties, volatility in the prices of fuel, gasoline and commodities such as paper and packing supplies, system failures and other disruptions to the operations of the shipping companies on which we rely. We are also subject to risks of damage or loss during delivery by our shipping vendors. If the products ordered by our customers are not delivered in a timely fashion or are damaged or lost during the delivery process, our customers could become dissatisfied and cease buying products through our websites and mobile application, which would adversely affect our business, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The quality of our customer service and support is important to our customers, and if we fail to provide adequate levels of customer service and support, we could lose customers, which would harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that a high level of customer care and support is critical in retaining and expanding our customer base. Although our customer care representatives participate in ongoing training programs on a variety of topics, such as product knowledge, computer usage, customer service tips, and the relationship between our Company and veterinarians, any perceived or actual decline in our customer-service response times or in the quality of our customer care representatives, even if episodic or temporary, could hurt our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If customers perceive that our customer care and support does not compare favorably to our competitors, then we may lose customers to such competitors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The content of our websites could expose us to various kinds of liability, which, if prosecuted successfully, could negatively impact our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we post product and pet health information and other content on our websites, we face potential liability for negligence, copyright infringement, patent infringement, trademark infringement, defamation, and/or other claims based on the nature and content of the materials we post. Various claims have been brought, and sometimes successfully prosecuted, against Internet content distributors. We could be exposed to liability with respect to the unauthorized duplication of content or unauthorized use of other parties&#8217; proprietary technology. Although we maintain general liability insurance, our insurance may not cover potential claims of this type or may not be adequate to indemnify us for all liability that may be imposed. Any imposition of liability that is not covered by insurance, or is in excess of insurance coverage, could materially adversely affect our financial condition and results of operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to protect our intellectual property rights, and/or we may be found to infringe on the proprietary rights of others.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of trademarks, trade secrets, copyright laws, and contractual restrictions to protect our intellectual property rights. These afford only limited protection. Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to copy our proprietary property, including our non-prescription private label or generic equivalents, when and if developed, as well as aspects of our sales formats, or to obtain and use information that we regard as proprietary, including the technology used to operate our websites and our content, and our trademarks. Litigation or proceedings before the United States Patent and Trademark Office or other bodies may be necessary in the future to enforce our intellectual property rights, to protect our trade secrets and domain names, or to determine the validity and scope of the proprietary rights of others. Any litigation or adverse proceeding could result in substantial costs and diversion of resources and could seriously harm our business and operating results. Third parties may also claim infringement by us with respect to past, current, or future technologies or intellectual property. We expect that participants in our market will be increasingly involved in infringement claims as the number of services and competitors in our industry segment grows. Any claim, whether meritorious or not, could be time-consuming, result in costly litigation, cause service upgrade delays, or require us to enter into royalty or licensing agreements. These royalty or licensing agreements might not be available on terms acceptable to us or at all. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to protect our Internet addresses or to prevent others from using Internet addresses that are confusingly similar, our business may be adversely impacted.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet addresses, including; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.1800petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.1888petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmedexpress.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmed.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmeds.pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmed.pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.1800petmeds.pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">petcarerx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are critical to our brand recognition and our overall success. If we are unable to protect these Internet addresses, our competitors could capitalize on our brand recognition. There may be similar Internet addresses used by competitors. Governmental agencies and their designees generally regulate the acquisition and maintenance of Internet addresses. The regulation of Internet addresses in the United States and in foreign countries has changed and may undergo further change in the near future. Furthermore, the relationship between regulations governing Internet addresses and laws protecting trademarks and similar proprietary rights is unclear. Therefore, we may not be able to protect our own Internet addresses or prevent third parties from acquiring Internet addresses that are confusingly similar to, infringe upon, or otherwise decrease the value of our Internet addresses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Since most of our operations are housed in a single location, we are more susceptible to a business interruption in the event of damage to, or disruptions in, our facility, particularly with respect to extreme weather events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The PetMeds headquarters and principal distribution center are currently located in one location in South Florida, and most of our shipments of products to our customers are made from this primary distribution center. Our PetcareRx principal distribution center is located in one location in New York.  Because we consolidate our operations for each brand in one location, we are more susceptible to power and equipment failures, and business interruptions in the event of fires, floods, and other natural disasters than if we had additional locations. Furthermore, because our largest distribution center is located in South Florida, which is a hurricane-sensitive area and is susceptible to sea-level rise, we are particularly susceptible to the risk of damage to, or total destruction of, our headquarters and distribution center and surrounding transportation infrastructure caused by a hurricane or rising sea levels. Additionally, intense weather conditions may cause property insurance premiums to significantly increase in the future. We recognize that the frequency and intensity of extreme weather events, sea-level rise, and other climatic changes may continue to increase and, as a result, our exposure to these events may increase. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot assure you that we are adequately insured to cover the amount of any losses relating to any of these potential events, including business interruptions resulting from damage to or destruction of our headquarters and distribution centers, or power and equipment failures relating to our call center or websites, or interruptions or disruptions to major transportation infrastructure, or other events that do not occur on our premises. The occurrence of one or more of these events could adversely impact our ability to generate revenues in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A failure or misuse of our information systems and customer-facing technology systems, including our online payment methods, could adversely affect our results of operations, expose us to third-party claims, or increase our exposure to fraud and other risks.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is dependent upon the efficient operation of our information systems. In particular, we rely on our information systems to effectively manage our business model strategy, with tools to track and manage sales, inventory, marketing, customer service efforts, the preparation of our consolidated financial and operating data, credit card information, and customer information. The failure of our information systems to perform as designed or the failure to maintain and enhance or protect the integrity of these systems could disrupt our business operations, adversely impact sales and the results of operations, expose us to customer or third-party claims, or result in adverse publicity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our information technology, we are able to provide an improved overall shopping and interconnected retail experience that empowers our customers to shop and interact with us from computers, tablets, smartphones and other mobile devices. We use our websites and our mobile application both as sales channels for our products and also as methods of providing product and other relevant information to our customers to drive online sales. Our online programs, communities and knowledge center allow us to inform, assist and interact with our customers. We also continually seek to enhance all of our online properties to provide an attractive user-friendly interface for our customers. Disruptions, failures or other performance issues with these customer-facing technology systems could impair the benefits that they provide to our online business and negatively affect our relationship with our customers.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we currently accept payments using a variety of different payment methods which may subject us to additional regulations and compliance requirements, and may also increase our exposure to fraud, criminal activity, and other risks. In the future, as technology develops and we begin to offer new payment options to consumers, including by integrating emerging mobile and other payment methods, we may be subject to additional regulations, compliance requirements, or fraud. If we fail to comply with the rules or requirements of any provider of a payment method we accept, if the volume of fraud in our transactions limits or terminates our rights to use payment methods we currently accept, or if a data breach occurs relating to our payment systems, we may, among other things, be subject to fines or higher transaction fees and may lose, or face restrictions placed upon, our ability to accept credit card payments from consumers or facilitate other types of online payments. If any of these events were to occur, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our failure or the failure of third-party service providers to protect our websites, networks, and systems against cybersecurity incidents, or otherwise to protect our confidential information, could damage our reputation and brands and substantially harm our business, financial condition, and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our services being web based, we collect, process, transmit and store large amounts of data about our customers, employees, suppliers and others, including credit card information and personally identifiable information, as well as other confidential and proprietary information. We also employ third-party service providers for a variety of reasons, including storing, processing and transmitting proprietary, personal and confidential information on our behalf. While we rely on tokenization solutions licensed from third parties in an effort to securely transmit confidential and sensitive information, including credit card numbers, advances in computer capabilities, new technological discoveries or other developments may result in the whole or partial failure of these solutions to protect confidential and sensitive information from being breached or compromised. Similarly, our security measures, and those of our third-party service providers, may not detect or prevent all attempts to hack our systems or those of our third-party service providers. Distributed Denial-of-Service ("DDoS") attacks, viruses, malicious software, break-ins, phishing attacks, ransomware, social engineering, security breaches or other cybersecurity incidents and similar disruptions that may jeopardize the security of information stored in or transmitted by our websites, networks and systems or that we or our third-party service providers otherwise maintain, including payment card systems, may subject us to fines or higher transaction fees or limit or terminate our access to certain payment methods. We and our service providers may not anticipate or prevent all types of attacks until after they have already been launched, and techniques used to obtain unauthorized access to or sabotage systems change frequently and may not be known until launched against us or our third-party service providers. In </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, cybersecurity incidents can also occur as a result of non-technical issues, including intentional or inadvertent breaches by our employees or by persons with whom we have commercial relationships.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breaches of our security measures or those of our third-party service providers or any cybersecurity incident could result in unauthorized access to our websites, networks and systems; unauthorized access to and misappropriation of consumer and/or employee information, including personally identifiable information, or other confidential or proprietary information of ourselves or third parties; viruses, worms, spyware or other malware being served from our websites, networks or systems; deletion or modification of content or the display of unauthorized content on our websites; interruption, disruption or malfunction of operations; costs relating to cybersecurity incident remediation, deployment of additional personnel and protection technologies, response to governmental investigations and media inquiries and coverage; engagement of third party experts and consultants; litigation, regulatory action and other potential liabilities. If any of these cybersecurity incidents occur, or there is a public perception that we, or our third-party service providers, have suffered such a breach, or we are unable to determine materiality within a reasonable timeframe under the new Cybersecurity rules, our reputation and brands could also be damaged and we could be required to expend significant capital and other resources to alleviate problems caused by such cybersecurity incidents. As a consequence, our business could be materially and adversely affected and we could also be exposed to litigation and regulatory action and possible liability. In addition, any party who is able to illicitly obtain a customer&#8217;s password could access the customer&#8217;s transaction data or personal information. Any compromise or breach of our security measures, or those of our third-party service providers, or our failure to protect our customer's confidential information and data, could violate applicable privacy, data security and other laws, and cause significant legal and financial exposure, adverse publicity and a loss of confidence in our security measures, which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of mitigating cybersecurity risks are significant and are likely to increase in the future. These costs include, but are not limited to, retaining the services of cybersecurity providers; compliance costs arising out of existing and future cybersecurity, data protection and privacy laws and regulations; and costs related to maintaining redundant networks, data backups and other damage-mitigation measures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently carry cyber insurance, which may expose us to certain potential losses for damages or result in penalization with fines in an amount exceeding our resources.However, we are actively working to obtain coverage.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Our migration of data and systems to a new information technology platform may disrupt our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As an established web-based seller of pet products, we rely on a combination of legacy public-facing websites, internal applications and services, and back-end business intelligence systems.  We are in the process of migrating and upgrading many of our platforms and applications to more modular, web-based and SaaS systems.  If we are not able to realize the anticipated benefits of our migration to this new infrastructure, our business could be harmed.  There may be unforeseen issues as a result of these migrations that may cause disruptions to the availability of our products due to service outages, downtime or other similar issues that could harm our business. We also may be subject to additional risk of cybersecurity breaches or other improper access to our data or confidential information following our migration to these new computing platforms. In addition, our new platforms may operate differently than anticipated when introduced or when new versions or enhancements are released. As we increase our reliance on our systems, our exposure to damage from service interruptions may increase. Further, our transition could involve significant time and expense and could negatively impact our ability to deliver our products and services, which could harm our financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our marketing, e-commerce, and other business activities are subject to a variety of federal and state laws and regulations relating to privacy, data protection, marketing and advertising and consumer protection, many of which may evolve or expand beyond their current scope, and our failure to comply with this complex set of evolving laws and regulations could adversely affect our business, financial condition, and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect, maintain, use, and share personal information provided to us through our various marketing activities, including email and social media marketing and postal mailings, as well as other consumer, employee, and business-to-business interactions, in order to provide a better experience for our customers, employees, and vendors. Our current and future marketing and advertising practices depend on our ability to collect, maintain, use, and share this personal information with certain service providers and other third-party vendors, and we are subject to various federal and state laws and regulations that govern such marketing and advertising practices. In addition, we also collect, store, and transmit employees&#8217; health information for certain reasons, such as administering employee benefits; accommodating disabilities and injuries; complying with public health requirements; and maintaining employee safety in the workplace.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations relating to privacy, data protection, cybersecurity, marketing and advertising, and consumer protection are evolving and subject to potentially differing interpretations. While we strive to comply with all such regulations and believe that we are good stewards of our customers&#8217; data, this area is rapidly evolving, and it is possible that these requirements may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with other rules or our practices. If so, we may be subject to proceedings or actions against us by governmental entities or others, and we may suffer damage to our reputation as a result of such proceedings or actions. We may also be contractually required to indemnify and hold harmless third parties from the costs or consequences of non-compliance with any laws, regulations or other legal obligations relating to privacy, data protection, cybersecurity or consumer protection or any inadvertent or unauthorized use or disclosure of data that we store or handle as part of operating our business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governmental authorities continue to evaluate the privacy implications inherent in the use of third-party &#8220;cookies&#8221; and other methods of online tracking for behavioral advertising and other purposes. The U.S. government and state governments have enacted, have considered or are considering enacting, legislation or regulations that could significantly restrict the ability of companies and individuals to engage in these activities, such as by regulating the level of consumer notice and consent required before a company can employ cookies or other electronic tracking tools or the use of data gathered with such tools. Additionally, some providers of consumer devices and web browsers have implemented, or announced plans to implement, means to make it easier for Internet users to prevent the placement of cookies or to block other tracking technologies, which could result in the use of third-party cookies and other methods of online tracking becoming significantly less effective. The regulation of the use of these cookies and other current online tracking and advertising practices or a loss in our ability to make effective use of services that employ such technologies could increase our costs of operations and limit our ability to acquire new customers on cost-effective terms and consequently, materially and adversely affect our business, financial condition, and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, various federal and state legislative and regulatory bodies, or self-regulatory organizations, may expand current laws or regulations, enact new laws or regulations or issue revised rules or guidance regarding privacy, data protection, cybersecurity, consumer protection, and advertising. For example, in June 2018, the State of California enacted the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), which became effective on January 1, 2020. The CCPA requires companies that process information of California residents to make new disclosures to consumers about their data collection, use and sharing practices, and allows consumers to opt out of selling their data to third parties and provides a new cause of action for data breaches. Further, on November 3, 2020, the California Privacy Rights Act (the &#8220;CPRA&#8221;) was voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which could result in increased regulatory scrutiny of businesses conducting activities in California in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA went into effect on January 1, 2023, and will be enforced effective from July 1, 2023. Other states in which we operate have also enacted laws similar to CPRA and similar laws have been proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging. Additionally, the Federal Trade Commission (the &#8220;FTC&#8221;) and many state attorneys general are interpreting federal and state consumer protection laws to impose standards for the online collection, use, dissemination and security of data. Consumer protection laws require us to publish statements that describe how we handle personal data and choices individuals may have about the way we handle their personal data. If such information that we publish is considered untrue, we may be subject to government claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences. Further, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal data secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. Each of these privacy, security, and data protection laws and regulations, and any other such changes or new laws or regulations, could impose significant limitations, require changes to our business, impose fines and other penalties or restrict our use or storage of personal information, which may increase our compliance expenses and make our business more costly or less efficient to conduct. Any such changes could compromise our ability to develop an adequate marketing strategy and pursue our growth strategy effectively, which, in turn, could adversely affect our business, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We face the risk of litigation resulting from unauthorized text messages sent in violation of the Telephone Consumer Protection Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We send short message service, or SMS, text messages to customers and job candidates. The actual or perceived improper sending of text messages may subject us to potential risks, including liabilities or claims relating to consumer protection laws. For example, the Telephone Consumer Protection Act of 1991, a federal statute that protects consumers from unwanted telephone calls, faxes, and text messages, restricts telemarketing and the use of automated SMS text messages without proper consent. Numerous class-action suits under federal and state laws have been filed in recent years against companies who conduct SMS texting programs, with many resulting in multi-million-dollar settlements to the plaintiffs. Federal or state regulatory authorities or private litigants may claim that the notices and disclosures we provide, form of consents we obtain, or our SMS texting practices are not adequate or violate applicable law, resulting in civil claims against us. While we strive to comply with all applicable laws and regulations, the scope and interpretation of the laws that are or may be applicable to the delivery of text messages are continuously evolving and developing. If we do not comply with these laws or regulations or if we become liable under these laws or regulations, we could face direct liability, could be required to change some portions of our business model, or could face negative publicity, and our business, financial condition, and results of operations could be adversely affected as a result. Even an unsuccessful challenge of our SMS texting practices by our customers, regulatory authorities, or other third parties could result in negative publicity and could require a costly response from and defense by us. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operating results are difficult to predict and may fluctuate, and a portion of our sales are seasonal.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may cause our operating results to fluctuate include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to obtain new customers at a reasonable cost, retain existing customers, or encourage reorders;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to increase the number of visitors to our websites, or our ability to convert visitors to our websites into customers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The mix of medications and other pet products sold by us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to manage inventory levels or obtain an adequate supply of products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to adequately maintain, upgrade, and develop our websites, the systems that we use to process customers&#8217; orders and payments, or our computer network;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased competition within our market niche;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Price competition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New products introduced to the market, including generics;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increases in the cost of advertising;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The amount and timing of operating costs and capital expenditures relating to expansion of our product line or operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential disruption to the distribution network;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruption of our toll-free telephone service, technical difficulties, or systems and Internet outages or slowdowns;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of further outbreaks of COVID-19, and any future similar outbreak, on our business operations and generally on the economy, including the measures taken by governmental authorities to address it; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable general economic trends.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual and quarterly operating results have fluctuated in the past and may fluctuate significantly in the future due to a variety of factors, including weather, many of which are out of our control. Any change in one or more of these factors could materially adversely affect our financial condition and results of operations in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uncertainties in economic conditions and their impact on consumer spending patterns could adversely impact our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are sensitive to changes in certain macro-economic conditions that impact consumer spending on pet products and services. Some of the factors that may affect consumer spending on pet products and services include consumer confidence, levels of unemployment, inflation, interest rates, tax rates and general uncertainty regarding the overall future economic environment. We may experience declines in sales or changes in the types of products sold during economic downturns. Any material decline in the amount of consumer spending or other adverse economic changes could reduce our sales, and a decrease in the sales of higher-margin products could reduce profitability and, in each case, harm our business, financial condition, and results of operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have grown, and continue to seek to grow our business through acquisitions of, or investments in, new or complementary businesses, facilities, technologies, offerings, or products, or through strategic alliances, and the failure to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">manage these acquisitions, investments, or other strategic alliances, or to integrate them with our existing business, could have a material adverse effect on us.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the past two years, we acquired one company (PetCareRx) and entered into two strategic partnerships to enable us to offer telehealth services and pet insurance to our customers. We expect that we may in the future consider additional opportunities to acquire or make investments in new or complementary businesses, facilities, technologies, offerings, or products, or enter into other strategic alliances, which may enhance our capabilities, complement our current products and services or expand the breadth of our markets. Acquisitions, investments and other strategic alliances, including our acquisition of PetCareRx, involve numerous risks, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">problems integrating the acquired business, facilities, technologies or products, including issues maintaining uniform standards, procedures, controls and policies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated costs associated with acquisitions, investments or strategic alliances;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">losses we may incur as a result of declines in the value of an investment or as a result of incorporating an investee&#8217;s financial performance into our financial results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management&#8217;s attention from our existing business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with entering new markets in which we may have limited or no experience;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with businesses we acquire or invest in, which may differ from or be more significant than the risks our other businesses face;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential unknown liabilities associated with a business we acquire or in which we invest; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased legal and accounting compliance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses, facilities, technologies, products and services. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations. Also, our acquisitions may not result in the benefits or growth originally anticipated from such acquisitions. As a result of future strategic transactions, we might need to issue additional equity securities, spend our cash, or incur debt (which may only be available on unfavorable terms, if at all) or contingent liabilities, any of which could reduce our profitability and harm our business. If we are unable to identify suitable acquisitions, investments or strategic relationships, or if we are unable to integrate any acquired businesses, facilities, technologies, offerings and products effectively, our business, financial condition, and results of operations could be materially and adversely affected. Also, while we employ several different methodologies to assess potential business opportunities, the new businesses or investments may not meet or exceed our expectations or desired objectives in the timeframe expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The market for pet telemedicine is immature and uncertain. If the telemedicine market does not develop, develops more slowly than we expect, or encounters negative publicity, or if our approach does not achieve a high level of customer acceptance, the growth and results of our partnership with Vetster may be adversely affected which could result in an impairment of  our investment.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pet telehealth market is, in general, immature and uncertain. It is uncertain whether the telemedicine market and our approach to pet telehealth with Vetster will achieve and sustain high levels of demand, consumer acceptance and market adoption. The COVID-19 pandemic increased acceptance and utilization of telemedicine services, but it is uncertain whether such increase in demand will continue.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Demand for pet telemedicine and telehealth services is affected by a number of factors, many of which are beyond our control. Some of these potential factors include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market adoption and ongoing usage of pet telehealth and telemedicine services and solutions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">awareness and adoption of technology in healthcare generally;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of products and services that compete with ours;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to maintain and expand a network of qualified providers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ease of adoption and use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">features and platform experience;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">brand;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">security and privacy; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend to a substantial extent on the willingness of our customers to use, and to increase the frequency and extent of their utilization of, our solution being offered in conjunction with Vetster, as well as on our ability to demonstrate the value of pet telehealth and telemedicine to veterinarians and pet owners. Negative publicity concerning the pet telehealth and telemedicine market could limit market acceptance of our solutions and services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to payment-related risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and potentially disrupt our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accept payments using a variety of methods, including credit and debit cards, PayPal, and Apple Pay, and we may offer new payment options over time. Acceptance of these payment options subjects us to rules, regulations, contractual obligations and compliance requirements, including payment network rules and operating guidelines, data security standards and certification requirements, and rules governing electronic funds transfers. These requirements may change over time or be reinterpreted, making compliance more difficult or costly. For certain payment methods, including credit and debit cards, we pay interchange and other fees, which may increase over time and raise our operating costs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties to provide payment processing services, including the processing of credit cards, debit cards, and other forms of electronic payment. If these companies become unable to provide these services to us, or if their systems are compromised, it could potentially disrupt our business. The payment methods that we offer also subject us to potential fraud and theft by criminals, who are becoming increasingly more sophisticated, seeking to obtain unauthorized access to or exploit weaknesses that may exist in the payment systems. If we fail to comply with applicable rules or requirements for the payment methods we accept, or if payment-related data is compromised due to a breach or misuse of data, we may be liable for costs incurred by payment card issuing banks and other third parties or subject to fines and higher transaction fees, or our ability to accept or facilitate certain types of payments may be impaired. As a result, our business and operating results could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have identified material weaknesses in our internal controls over financial reporting, and management has determined that our disclosure controls and procedures were not effective as of the end of the period covered by this Annual Report on Form 10-K. Our business and share price may be adversely affected if we fail to implement and maintain effective disclosure controls and procedures and internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods ending March 31, 2023 and 2024, our management identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. The material weaknesses identified in our internal control over financial reporting as of March 31, 2024, as well as our remediation plans, are described in Part II, Item 9A, &#8220;Controls and Procedures.&#8221; While we believe these efforts will be sufficient to remediate the material weaknesses, we cannot provide assurance that we will be able to complete our evaluation, testing or any required remediation in a timely fashion, or at all. The effectiveness of our internal control over financial reporting is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the possibility of human error and the risk of fraud. Because of the inherent limitations in a cost-effective control system, misstatements in our financial statements due to error or fraud may occur and require restatement, such as those errors that resulted in the restatement of our previously issued audited consolidated financial statements described in Amendment No.1 on Form 10-K/A to our Annual Report on Form 10-K for the year ended March 31, 2023 (the &#8220;2023 Form 10-K/A&#8221;), and the restatement of our previously issued unaudited condensed consolidated financial statements described in Amendment No.1 on Form 10-Q/A to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the &#8220;2024 Q1 Form 10-Q/A&#8221;) and Amendment No.1 on Form 10-Q/A to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the &#8220;2024 Q2 Form 10-Q/A&#8221;, and together with the 2024 Q1 Form 10-Q/A and 2023 Form 10-K/A, the &#8220;Amended Reports&#8221;) as well as fiscal 2023 amounts restated in our Quarterly Report on Form 10-Q for the three and nine months ended December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material weaknesses in our internal control over financial reporting will not be considered remediated until the controls operate for a sufficient period and management has concluded through testing that these controls operate effectively.  If we are unable to remediate the material weaknesses or identify additional material weakness in the future, we may be unable to accurately report our financial results, which could cause our financial results to be materially misstated and require restatement.  In such case, we may be unable to maintain compliance with securities law </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements.  Ineffective disclosure controls and procedures and internal control over financial reporting could also result in litigation or regulatory actions by the SEC or other regulatory authorities, loss of investor confidence, harm to our reputation and financial condition, diversion of financial and management resources from the operation of our business, and the market price of our common stock may decline as a result.  We cannot assure you that the remediation measures we have taken to date, or any measures that we may take in the future, will be sufficient to avoid future material weaknesses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may face litigation and other risks as a result of the restatements described in the Amended Reports and material weaknesses in our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have identified material weaknesses in our internal control over financial reporting, including in connection with the restatements described in the Amended Reports. As a result of such material weaknesses and the restatement, we could face regulatory action by the SEC or other regulatory authorities, potential litigation, or other disputes, including claims invoking federal and state securities laws, contractual claims or other claims arising from the restatement and the material weaknesses in our internal control over financial reporting and the preparation of our financial statements.  Any such litigation or dispute, whether successful or not, could adversely affect our business, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As a result of our failure to timely file our Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, we are currently ineligible to file new short form registration statements on Form S-3, which may impair our ability to raise capital on terms favorable to us, in a timely manner or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form S-3 permits eligible issuers to conduct registered offerings using a short form registration statement that allows the issuer to incorporate by reference its past and future filings and reports made under the Exchange Act. In addition, Form S-3 enables eligible issuers to conduct primary offerings &#8220;off the shelf&#8221; under Rule 415 of the Securities Act. The shelf registration process, combined with the ability to forward incorporate information, allows issuers to avoid delays and interruptions in the offering process and to access the capital markets in a more expeditious and efficient manner than raising capital in a standard registered offering pursuant to a Registration Statement on Form S-1. The ability to register securities for resale may also be limited as a result of the loss of Form S-3 eligibility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our failure to timely file our Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, we are currently ineligible to file new short form registration statements on Form S-3 until March 2025. Our inability to use Form S-3 may impair our ability to raise necessary capital to fund our operations and execute our strategy. If we seek to access the capital markets through a registered offering during the period of time that we are unable to use Form S-3, we may be required to publicly disclose the proposed offering and the material terms thereof before the offering commences, we may experience delays in the offering process due to SEC review of a Form S-1 registration statement and we may incur increased offering and transaction costs and other considerations. Disclosing a public offering prior to the formal commencement of an offering may result in downward pressure on our share price. If we are unable to raise capital through a registered offering, we would be required to conduct our equity financing transactions on a private placement basis, which may be subject to pricing, size and other limitations imposed under the Nasdaq rules, or seek other sources of capital. The foregoing limitations on our financing approaches could have a material adverse effect on our results of operations, liquidity, and financial position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxing authorities may successfully assert that we should have collected, or in the future should collect, sales and use, value added, or similar taxes, and any such assessments could adversely affect our business, financial condition, and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the past several years, states have adopted laws that attempt to impose tax collection obligations on out-of-state companies. In 2018, the Supreme Court of the United States ("Supreme Court") ruled in South Dakota v. Wayfair, Inc. et al, or Wayfair, that online sellers can be required to collect sales and use tax despite not having a physical presence in the buyer&#8217;s state. In response to Wayfair, or otherwise, states or local governments may adopt, or begin to enforce, laws requiring us to register, calculate, collect, and remit taxes on sales in their jurisdictions. Additionally, states and some local tax jurisdictions have differing rules and regulations governing sales and use taxes, which are subject to varying interpretations that may change over time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">One or more taxing authorities could seek to impose additional sales and use, value added, or similar taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">on us or may determine that such taxes should have, but have not been, paid by us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any successful action by taxing authorities to compel us to collect and remit such taxes, either retroactively or prospectively, could have a material adverse effect on our business, financial condition and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The imposition by state governments or local governments of sales tax collection obligations on out-of-state sellers could also create additional administrative burdens for us, put us at a competitive disadvantage if they do not impose similar obligations on our competitors, and decrease our future sales, which could have a material adverse effect on our business and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we believe that we currently collect and remit applicable sales taxes to the extent required in all states in which we sell, a successful assertion by one or more states seeking to tax us on sales that occurred in prior tax years, or to collect more taxes in a jurisdiction in which we currently do collect some taxes, could result in substantial tax liabilities, including taxes on past sales, as well as penalties and interest. For example, during our 2023 fiscal year, we received a sales tax assessment relating to prior periods, following which, we evaluated, with the assistance of outside consultants, our sales tax positions in various jurisdictions, and related accounting matters, for potential additional sales tax exposure. As a result of that review, we recorded an accrual for additional sales tax liabilities as at March 31, 2023 (the &#8220;Additional Sales Tax Liabilities&#8217;). During the third quarter of our 2024 fiscal year, with the assistance of outside consultants, we again reviewed our accounting treatment for sales tax liabilities, including the Additional Sales Tax Liabilities, and determined that we should have accounted for sales tax liabilities using a legal liability approach, which required us to record a cumulative sales tax liability of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">approximately $26.0 million as of March 31, 2023 reflecting the total potential sales tax liability as of such date and resulted in the restatement of our consolidated financial statements described in our 2023 Form 10-K/A.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New legislation or regulations, the application of laws and regulations from jurisdictions, or the application of existing laws and regulations to the Internet and commercial online services could similarly result in significant additional taxes on our business. For instance, the Supreme Court&#8217;s decision and the enactment and enforcement of laws resulting therefrom could also impact where we are required to file state income taxes. As a result, our effective income tax rate as well as the cost and growth of our business could be materially and adversely affected, which could in turn have a material adverse effect on our financial condition and results of operations. In addition, because the Company&#8217;s products and services are available over the Internet, states may claim that the Company is required to do business as a foreign corporation in one or more of those jurisdictions. Failure to qualify as a foreign corporation in a jurisdiction where the Company is required to do so could subject it to taxes and penalties, and such jurisdictions may charge the Company with violations of local laws.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in tax laws or regulations in the various tax jurisdictions we are subject to could increase our cost of doing business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to additional tax liabilities and penalties resulting from new legislation or regulations; changes in taxing jurisdictions&#8217; administrative interpretations, decisions, policies and positions; results of tax audits, examinations, settlements or judicial decisions; changes in accounting principles, as well as the evaluation of new information that results in a change to a tax position taken in a prior period; and changes to our business operations, including acquisitions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any resulting increase in our tax obligation or cash taxes paid could adversely affect our cash flows and financial results. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Industry Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face significant competition from veterinarians and online and traditional retailers, as well as challenges from strategic alliances amongst our competitors, and may not be able to compete profitably with them.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete directly and indirectly with veterinarians for the sale of pet medications and other health products. Veterinarians hold a competitive advantage over us because many pet owners may find it more convenient or preferable to purchase these products directly from their veterinarians at the time of an office visit. We also compete directly and indirectly with both online and traditional retailers. Both online and traditional retailers may hold a competitive advantage over us because of longer operating histories, established brand names, greater resources, and/or an established customer base. Online retailers may have a competitive advantage over us because of established affiliate relationships to drive traffic to their website. Traditional retailers may hold a competitive advantage over us because pet owners may prefer to purchase these products from a store instead of online. In addition, we face growing competition from online and multichannel retailers, some of whom may have a lower cost structure than ours, as customers now routinely use computers, tablets, smartphones, and other mobile devices and mobile applications to shop online and compare prices and products in real time. In order to effectively compete in the future, we may be required to offer promotions and other incentives, which may result in lower operating margins and adversely affect the results of operations. We also face a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant challenge from our competitors forming alliances with each other, such as those between online and traditional retailers. These relationships may enable both their online and retail stores to negotiate better pricing and better terms from suppliers by aggregating the demand for products and negotiating volume discounts, which could be a competitive disadvantage to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Product recalls and concerns regarding the safety and quality of the pet products we sell could affect our business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations by various federal and state regulatory authorities regarding the safety and quality of the pet products that we sell. We purchase products from various suppliers, one or more of which might not adhere to product safety requirements or our quality control standards, and we may not be able to identify the deficiency before merchandise ships to our customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our suppliers are required to comply with applicable product safety laws, and we are dependent upon them to ensure such compliance.  Any issues of product safety or allegations that the products we sell are in violation of governmental regulations, including, but not limited to, issues involving products manufactured in foreign countries or issues of mislabeling or adulteration, could cause those products to be recalled. If our suppliers fail to manufacture or import merchandise that adheres to our quality control standards, product safety requirements, or applicable governmental regulations, our reputation and brands could be damaged, potentially leading to decreased sales or increases in customer litigation against us.  If consumers lose confidence in the safety and quality of the food or other products that we sell or in the suppliers that provide such products, then our sales could be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse publicity about these types of concerns, even if not valid, may discourage consumers from buying the products we offer, and such publicity cause disruptions with suppliers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The real or perceived sale of contaminated food products by us could result in product liability claims against our suppliers or us, expose us or our suppliers to governmental enforcement action or private litigation, or lead to costly recalls and a loss of consumer confidence, any of which could have an adverse effect on our business, financial condition, and results of operations. We may also in the future voluntarily recall or withdraw products that we consider do not meet our standards in order to protect our brands and reputation. While we carry product liability insurance, our insurance may not be adequate to cover all liabilities that we may incur in connection with product liability claims. In addition, we may be unable to continue to maintain our existing insurance coverage or obtain comparable insurance at a reasonable cost, if at all, or secure additional coverage, which may result in future product liability claims being uninsured. Any of these factors could negatively impact our business, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pandemics or other health crises, such as the possible resurgence of the COVID-19 pandemic, may adversely affect our results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak and global spread of the COVID-19 pandemic, including the spread of recent variants, and related containment efforts created, and may continue to contribute to, significant economic disruption in the United States and around the world. A resurgence of the COVID-19 pandemic, variations of the COVID-19 virus, or other pandemics could adversely affect our business operations. It is impossible to predict the effect and ultimate impact of the possible resurgence of the COVID-19 pandemic, a variation of the COVID-19 virus, or other pandemic. In response to the COVID-19 pandemic, we implemented working from home where possible and enhanced disinfection and social distancing within our workplace. Future COVID-19 surges or variants, as well as other pandemics, may result in us again encouraging employees to work from home, which could adversely impact costs, operations, and morale, as well as result in consumer privacy, IT security, and fraud concerns.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Governmental lockdowns and other restrictions at the onset of the COVID-19 pandemic negatively impacted, and in the event of a future resurgence or a different pandemic or health crisis may again negatively impact, the operations of and ability to ship from our fulfillment center. Our future results of operations and overall financial performance could be uncertain should a new virus strain of COVID-19, a new pandemic, or other health crisis occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Securities Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price fluctuates from time to time and may fall below expectations of securities analysts and investors, and could subject us to litigation, which may result in you suffering a loss on your investment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may fluctuate significantly in response to a number of factors, many of which are out of our control. These factors include: changes in accounting treatments or principles; announcements by our competitors of new products and services offerings; significant contracts, acquisitions, or strategic relationships; additions or departures of key personnel; any future sales of our common stock or other securities; stock market price and volume </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fluctuations of publicly traded companies; and general political, economic, and market conditions. In some future quarter our operating results may fall below the expectations of securities analysts and investors, which could result in a decrease in the trading price of our common stock. In addition, if the Company fails to meet expectations related to future growth, profitability, dividends, or other market expectations, the price of the Company&#8217;s common stock may decline significantly, which could have a material adverse impact on investor confidence and employee retention. In the past, securities class action litigation has often been brought against a company following periods of volatility in the market price of its securities. We may be the target of similar litigation in the future. Securities litigation could result in substantial costs and divert management's attention and resources, which could seriously harm our business and operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may issue additional shares of preferred stock that could defer a change of control or dilute the interests of our common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our charter documents could defer a takeover effort which could inhibit your ability to receive an acquisition premium for your shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our charter permits our Board of Directors to issue up to 5.0&#160;million shares of preferred stock without shareholder approval. Currently there are 2,500 shares of our Convertible Preferred Stock issued and outstanding. This leaves slightly less than 5.0&#160;million shares of preferred stock available for issuance at the discretion of our Board of Directors. These shares, if issued, could contain dividend, liquidation, conversion, voting, or other rights which could adversely affect the rights of our common shareholders and which could also be utilized, under some circumstances, as a method of discouraging, delaying, or preventing a change in control. Provisions of our articles of incorporation, bylaws and Florida law could make it more difficult for a third party to acquire us, even if many of our shareholders believe it is in their best interest.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our ability to pay regular dividends to our shareholders and the amounts of any such dividends are subject to the discretion of the Board and may be limited by our financial condition, or limitations under Florida law.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid regular dividends to our shareholders from 2009 to August 2023, and on February 1, 2024, our Board of Directors elected to suspend the quarterly dividend indefinitely. The Board of Directors determined to reserve and/or utilize cash resources that would otherwise be available for distributions in order to fund additional strategic transactions or investments in our business. The determination to pay dividends and the amounts thereof in the future will be at the discretion of the Board and will be dependent on then-existing conditions, including our financial condition, income, legal requirements, including limitations under Florida law, and other factors the Board deems relevant. For these reasons, shareholders should not rely on dividends to receive a return on investment. Accordingly, and for the foreseeable future, realization of any gain on shares of our common stock will depend solely on the appreciation of the price of our common stock, which may not occur.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i6c215bb864894b15adb92ac1022d7659_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_635"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C. CYBERSECURITY</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have an enterprise-wide information security program designed to assess, identify, and manage the Company&#8217;s information security risks and identify, evaluate, respond to and resolve information security incidents. To protect our information systems from information security incidents, we use various processes and tools to identify, prevent, detect, escalate, investigate, resolve and recover from identified vulnerabilities and threats. These include, but are not limited to, reporting, monitoring and detection tools that are widely used in the industry, and internal solutions. We have an enterprise-wide Incident Response Policy and Incident Response Procedure, which outlines the various points and detailed processes and procedures to be followed when a suspected incident is identified. The overall Incident Response Objectives are to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">Accurately investigate and validate the incident</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Minimize damage or loss of data and services for the Company, our clients, users,employees, and other potentially affected individual data subjects, as appropriate</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">Preserve and/or collect evidence pursuant to the incident in a legally sound manner</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Quickly restore data and services</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">Review evidence to determine next steps, including notifications where necessary or advisable</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.17pt">Document and implement post incident actionable recommendations to prevent incident reoccurrence and improve the incident response process</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We assess our cybersecurity maturity and readiness utilizing the CIS (Center for Internet Security) Critical Security Controls, and measure our ongoing progress against this framework to identify areas of opportunity for improvement to our overall cybersecurity readiness.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continually evaluate cybersecurity threats and our ability to monitor for or mitigate against these threats based on information from our vendors, partners, and our own internal research and exposures.  As we are undergoing multiple system upgrades and digital transformation efforts, we will be further evaluating and implementing security measures and best practices in our new systems as we phase out legacy systems.  We conduct regular scans, penetration, and vulnerability testing as part of our overall security practice, and as part of our Payment Card Industry Digital Security Standard (PCI-DSS) compliance. Our auditors perform an independent analysis on parts of our information security practices, predominantly in their assessment of our PCI compliance. We regularly conduct cybersecurity training for our employees, including training for some of the most common breach vectors seen in the industry.  For our key partners who help develop or key vendors who provide information systems or have access to our information systems, we require security training or review their information security practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We from time to time use our Incident Response Procedures to respond to potential cybersecurity incidents and threats, as our systems and users identify areas of potential incidents during the course of normal operations, none of which to date we believe have been material. We cannot provide assurance that there will not be future incidents that may materially impact us, our financials, our strategy, or our operations.  For more cybersecurity risks, see &#8220;Our failure or the failure of third-party service providers to protect our websites, networks, and systems against cybersecurity incidents, or otherwise to protect our confidential information, could damage our reputation and brands and substantially harm our business, financial condition, and results of operations&#8221; under Item 1A &#8220;Risk Factors.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s Board of Directors, as a whole, has oversight responsibility for our strategic and operational risks. The Audit Committee of the Board of Directors is responsible for board-level oversight of cybersecurity risk, and the Audit Committee regularly reports risks and compliance actions to the Board. As part of its&#8217; oversight role, the Audit Committee receives reporting about the Company&#8217;s strategy, programs, incidents and threats, and other developments and action items. These action items include receiving updates on the status of remediation efforts for any non-compliance or risk items related to cybersecurity regularly throughout the year, including through periodic updates from management.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_22"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own our principal executive offices and distribution center, which are located at 420 South Congress Avenue, Delray Beach, Florida 33445 (the &#8220;Delray Beach Property&#8221;). The Delray Beach Property consists of approximately 634,000 square feet of land or 14.6 acres with two building complexes totaling approximately 185,000 square feet, with additional land for future use. The first building complex consists of approximately 125,000 square feet and the second building complex consists of approximately 60,000 square feet each consisting of both office and warehouse space. The Company occupies approximately 97,000 square feet of the first building for its principal offices and distribution center. As of March&#160;31, 2024, 48% of the Delray Beach Property was leased to two tenants with a remaining weighted average lease term of 1 year, and we are currently in the process of renegotiating both leases.  We believe that our facilities are sufficient for our current needs and are in good condition in all material respects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our acquisition of PetCareRx, in April 2023 we assumed the leases of two buildings occupied by PetCareRx located in Lynbrook, New York.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These facilities, which aggregate approximately 32,000 square feet, are used by PetCareRx as a shipping and fulfillment center and as an executive office.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The leases expire in April 2027 and include the option to renew for an additional five years. We also assumed a PetCareRx lease for office space in Brooklyn, NY that PetCareRx did not occupy and was subleased. This lease expired in April 2024.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_25"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. LEGAL PROCEEDINGS</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are involved from time to time in various claims and lawsuits in the ordinary course of business, including claims related to products, product warranties, contracts, employment, intellectual property, consumer protection, pharmacy and other regulatory matters. We have settled complaints that had been filed with various states&#8217; pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against us in the future. We also initiate litigation to protect our trade or service marks. There can be no assurance that we will be successful in protecting our trade or service marks. In the opinion of management, none of the claims and suits, either individually or in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">aggregate, are reasonably likely to have a material adverse effect on our operations or consolidated financial statements. Legal costs related to the above matters are expensed as incurred.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 18, 2024, Plaintiff Timothy Fitchett (&#8220;Plaintiff&#8221;) filed an action in the Court of Common Pleas of Allegheny County, Pennsylvania, on behalf of himself and purportedly on behalf of a class of others similarly situated. Plaintiff alleges that the Company violated Pennsylvania&#8217;s Unfair Trade Practices and Consumer Protection Law by representing &#8220;reg.&#8221; prices for products which the Company allegedly never charged for those products. On May 13, 2024, the Company removed the matter to the U.S. District Court for the Western District of Pennsylvania in Pittsburgh, and Plaintiff moved to remand the case back to state court on June 11, 2024. The Company's deadline to respond to the motion to remand is June 25, 2024.  On the face of the Complaint, Plaintiff is seeking damages for himself in the amount of the allegedly illusory discounts he allegedly believed he was receiving when purchasing products from the Company or, in the alternative, a complete refund of amounts he paid to the Company, and he is also seeking a liability determination for members of the proposed class. The Company denies liability in this matter and intends to defend the action accordingly, and the Company cannot determine materiality or estimate a range of potential liability, if any, at this time if the Company were determined to be liable.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_31"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i6c215bb864894b15adb92ac1022d7659_34"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. MARKET FOR REGISTRANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the NASDAQ Global Select Market (&#8220;NASDAQ&#8221;) under the symbol &#8220;PETS.&#8221; </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 109 holders of record of our common stock on June&#160;12, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have paid cash dividends on a quarterly basis from August 2009 to August 2023. For the fiscal years ended March 31, 2024 and 2023, we declared and paid cash dividends totaling $12.7 million (an aggregate of $0.60 per share for the year ended March&#160;31, 2024) and $25.3 million (an aggregate of $1.20 per share for the year ended March&#160;31, 2023), respectively.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 26, 2023, our Board of Directors elected to suspend the quarterly dividend for the second quarter of fiscal year 2024, and on February 1, 2024, our Board of Directors elected to suspend the quarterly dividend indefinitely. This move is intended to focus use of the Company&#8217;s existing cash flow on growth initiatives and other higher return initiatives. The Board of Directors reviews and discusses the capital allocation needs of the Company, at a minimum, on a quarterly basis. The declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors. When considering whether to declare a dividend, our Board of Directors will take into account:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    General economic and business conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our financial condition and operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our available cash and current and anticipated cash needs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our capital requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Strategic uses of cash for growth initiatives;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Contractual, legal, tax and regulatory restrictions on the payment of dividends by us; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Such other factors as our Board of Directors may deem relevant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a line graph comparing the five-year cumulative performance of our common stock with the NASDAQ Composite, the Russell 2000, and S&amp;P 500 from March 31, 2019 to March 31, 2024. The graph assumes that $100 was invested on March 31, 2019, in each of our Common Stock, the NASDAQ Composite, the Russell 2000, and the S&amp;P 500. Because we have historically paid dividends on a quarterly basis, the graph assumes that dividends were reinvested. The performance graph and related information below shall not be deemed &#8220;filed&#8221; with the SEC, nor shall such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information be incorporated by reference into any future filing under the Securities Act or Exchange Act, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div style="margin-top:12pt;text-align:justify"><img src="pets-20240331_g1.jpg" alt="3591" style="height:421px;margin-bottom:5pt;vertical-align:text-bottom;width:633px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance graph data:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PetMed Express, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.44</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.99</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.10</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.52</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NASDAQ Composite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.62</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.38</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.98</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.91</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">S&amp;P 500</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.19</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.17</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.84</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.98</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.38</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Russell 2000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.89</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.45</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.06</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.98</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i6c215bb864894b15adb92ac1022d7659_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. [RESERVED]</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_40"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i6c215bb864894b15adb92ac1022d7659_43"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PetMed Express, Inc. and subsidiaries, d/b/a PetMeds&#174; (the "Company") is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies and vet services for dogs, cats, and horses. PetMeds markets and sells directly to consumers through its websites, toll-free numbers, and mobile application. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founded in 1996, the Company's executive headquarters offices are currently located at 420 South Congress Avenue, Delray Beach, Florida 33445, and our telephone number is (561) 526-4444. The Company has a March 31 fiscal year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently, our product line includes approximately 15,000 of the most popular pet medications, health products, and supplies for dogs, cats, and horses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our products through national advertising campaigns which aim to increase the recognition of the &#8220;PetMeds&#8221; brand name and "PetCareRx" brand name, increase traffic on our websites at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.petmeds.com </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.petcarerx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, acquire new customers, and maximize repeat purchases. Our sales consist of products sold mainly to retail consumers. The twelve-month average purchase remained at approximately $94 and $93 per order for the fiscal years ended March&#160;31, 2024, and March&#160;31, 2023, respectively.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in the Note 1 of &#8220;Notes to Condensed Consolidated Financial Statements,&#8221; we have restated our consolidated financial statements and Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the years ended March 31, 2023 and March 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and the results of our operations contained herein are based upon our consolidated financial statements and the data used to prepare them. Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, and income taxes. We base our estimates and judgments on our historical experience, knowledge of current conditions, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies. See Note (2) - Summary of Significant Accounting Policies, in the "Notes to Consolidated Financial Statements" included in Part II, Item 8, Financial Statements and Supplementary Data, of this 10-K Report for a description of our significant accounting policies as well as a description of recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of the date of this 10-K Report.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the estimates, assumptions and judgments involved in the accounting policies described below involve a significant level of estimation uncertainty and have the greatest potential impact on our financial condition and results of operations and, therefore, we consider these to be our critical accounting policies. Accordingly, we evaluate our estimates, assumptions, and judgments on an ongoing basis. Our actual results may differ from these estimates under different assumptions, judgments, and conditions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue under ASC Topic 606 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and generate revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on our website are drop shipped to customers. We consider ourself the principal in the arrangement because we control the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however this is not considered a key judgment. There are no amounts excluded from the variable </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration. Revenue is recognized when control transfers to the customer at the point in time in which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time where we have a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbound shipping and handling fees are an accounting policy election and are included in sales as we consider ourself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Membership fees represent the amounts recognized periodically from two membership models. The first is the PetPlus membership for PetCareRx customers, and the second is a partner membership provided through PetCareRx. These memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup which represent a single stand-ready performance obligation to provide these benefits. The PetPlus membership fee is an upfront annual charge and automatically renews one year from the initial enrollment date. The Company recognizes the revenue ratably over the term of the PetPlus membership which is generally one year</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We disaggregate sales in the following two categories: reorder sales vs new order sales vs membership sales. The following table illustrates sales by various classifications: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales (In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reorder sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New order sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Membership fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,485&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales (In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reorder sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New order sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,579&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,703)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we changed the definition of a new customer to include anyone who has not ordered over the past thirty-six months. The reorder and new order sales amounts for the years ended March&#160;31, 2022 reflect this revised  customer definition. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the previous definition of a new customer, reorder and new order sales were $249.4 million and $22.9 million, respectively, for year ended March&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virtually all of our sales are paid by credit cards and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We had no material contract asset or contract liability balances as of March&#160;31, 2024, or March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses that we estimate will arise from customers&#8217; inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. We determine our estimates of the uncollectability of accounts receivable by analyzing historical bad debts and current economic trends. The allowance for credit losses was approximately $273&#160;thousand and $35&#160;thousand at March&#160;31, 2024 and 2023, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business Combination</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification ("ASC") Topic 805 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Business Combinations"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The purchase price is allocated to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in our unaudited condensed consolidated financial statements from the date of acquisition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, we may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain obligations assumed. Acquisition-related transaction costs incurred by us are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. Goodwill is not amortized but instead is tested for impairment annually on January 1, or more frequently if events or changes in circumstances indicate goodwill might be impaired. When testing goodwill for impairment, we have the option to choose whether we will apply a qualitative assessment first and then a quantitative assessment, if necessary, or to apply the quantitative assessment directly. We have concluded that we have one reporting unit and have assigned the entire balance of goodwill to this reporting unit.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company performed its annual goodwill impairment testing as of January 1, 2024 using </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">quantitative</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> ass</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">essment and at that time concluded there was no impairment. Since then, the Company&#8217;s stock price decreased from $7.56 at December 31, 2023 to $4.79 at March 31, 2024.  The Company considered the decrease in its stock price to be indicative of a risk that the carrying amount of goodwill may not be recoverable.  Therefore, the Company performed a quantitative impairment assessment as of March 31, 2024.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Based on the assessment, the Company concluded that goodwill was not impaired because the estimated fair value of the reporting unit exceeded its carrying value by approximately 27%.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We estimated fair value using discounted cash flow and public company market approaches with a 70% and 30% weighting, respectively.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A key assumption under the cash flow approach was a 27% weighted average cost of capital.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A key assumption under the public company market approach was a 10% control premium.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for income taxes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the provisions of ASC Topic 740 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which generally requires recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in our consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by &#8220;Accounting for Uncertainty in Income Taxes&#8221; guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies &#8220;Accounting for Uncertainty in Income Taxes&#8221; guidance to all tax positions for which the statute of limitations remains open. The Company had no liabilities for uncertain tax positions for either fiscal 2024 or fiscal 2023. The Company files tax returns in the U.S. federal jurisdiction and Florida,  Arizona, California, Connecticut, Idaho, Maryland, Michigan, Oklahoma, South Carolina, Virginia, Wisconsin, New Jersey, Georgia, Indiana, New York and the District of Columbia. With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">examinations by tax authorities for years ending March 31, 2020, or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">COVID-19 and Other Macroeconomic Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic had a significant impact around the world and has created significant volatility, uncertainty, and economic disruption. It prompted governments and businesses to take unprecedented measures in response. While economies of various countries have rebounded from the global COVID-19 economic shutdown that began in the late first quarter and early second quarter 2020, the impact of the COVID-19 pandemic continued, to varying degrees, in 2022 and 2023, and continues, to varying degrees, in 2024 due to mounting inflationary cost pressures and potential recession indicators that have now negatively impacted the global economy. We continue to monitor the effects of the pandemic and macroeconomic environment and take appropriate steps to mitigate the impact on our business, employees and financial condition; however, the nature and extent of this impact in future periods remains difficult to predict due to numerous uncertainties outside our control.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following should be read in conjunction with our consolidated financial statements and the related notes thereto included elsewhere herein. The following table sets forth, as a percentage of sales, certain operating data appearing in our consolidated statements of income:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before provision for income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i6c215bb864894b15adb92ac1022d7659_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted EBITDA </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense; depreciation; income tax provision; interest income (expense); and other non-operational expenses. We have provided reconciliations below of adjusted EBITDA to net (loss) income, the most directly comparable GAAP financial measures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe it is useful to exclude non-cash charges, such as share-based compensation expense and depreciation from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s neither are components of our core business operations. We also believe that it is useful to exclude other expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and an estimated unremitted prior period state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although depreciation  is a non-cash charge, the assets being depreciated  may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;</span></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;</span></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;</span></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems; </span></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us; </span></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted EBITDA does not reflect non operating expenses (income) including sales tax expense (income) relating to recording a liability for sales tax we did not collect from our customers or recognizing a gain on settlement from settling a state liability for less than recorded.</span></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of these and other limitations, Adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of net (loss) income, the most directly comparable GAAP measure to Adjusted EBITDA  for each of the periods indicated:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Non-GAAP Measures<br/>PetMed Express, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($ in thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%<br/>Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add (subtract):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-based Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,630</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">669</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisition/Partnership Transactions and Other Items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,010</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Severance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">n/m</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,648</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(3,100)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(85)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($ in thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%<br/>Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA:</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(7,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,140</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">n/m</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add (subtract):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-based Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,617</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,056</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,510</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisition/Partnership Transactions and Other Items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,679</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Severance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">364</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales Tax Expense (Income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">-416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,525)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_55"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal 2024 Compared to Fiscal 2023</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales increased by approximately $24.5 million, or 9.5%, to $281.1 million for the fiscal year ended March&#160;31, 2024, from approximately $256.6 million for the fiscal year ended March&#160;31, 2023. The increase in sales for the fiscal year ended March&#160;31, 2024 was due to incremental sales and membership fees from the acquisition of PetCareRx, partially offset by declines in PetMeds new customer and reorder sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired approximately 302,000 new customers for the fiscal year ended March&#160;31, 2024, compared to approximately 274,000 new customers for the same period in the prior year. The following chart illustrates sales by various sales classifications:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales (In thousands)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reorder sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New order sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Membership fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,064&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,579&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,485&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 we launched AutoShip &amp; Save subscription program (&#8220;AutoShip&#8221;) on our website. AutoShip is a convenient way for our loyal customer base to have future pet medication orders delivered directly to them without the need to place an order each time. During the quarter ended June 30, 2022 we made a change to the methodology on how we calculate the percentage of our revenue that was generated by our AutoShip program. We now report AutoShip sales, as a percent of sales, net of discounts and credits for the entire quarter. Previously, we reported AutoShip sales as a percent of total sales on the last month in the quarter. This change to the calculation resulted in a decrease to the AutoShip percentage that was previously reported by only a few percentage points. We believe that this change reflects a more accurate representation of our subscription business for stakeholders to gauge our performance.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are encouraged by the adoption of our AutoShip program and have seen an increasingly positive trend  since we launched this program. For example, our quarterly AutoShip percentage was 53.5%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of net sales for the most recent quarter ended March&#160;31, 2024, up from 44.4% of net sales for the same period last year and up from 52.2% of net sales sequentially in the prior quarter.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going forward sales may be adversely affected due to increased competition and consumers giving more consideration to price. The changes in consumer behavior post pandemic makes future sales somewhat challenging to predict. No guarantees can be made that sales will continue to grow in the future. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Cost of sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased by approximately $16.6 million, or 8.9% to $202.4 million for the fiscal year ended March&#160;31, 2024, from $185.8 million for the fiscal year ended March&#160;31, 2023. The cost of sales increase can be directly related to the increase in sales during fiscal year 2024. As a percentage of sales, cost of sales was 72.0% in fiscal year 2024, as compared to 72.4% in fiscal 2023. The cost of sales percentage decrease was primarily due to higher profit margins driven by membership fees from the acquisition of PetCareRx.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Gross profit</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit increased by approximately $7.9 million, or 11.2%, to $78.6 million for the fiscal year ended March&#160;31, 2024, from $70.7 million for the fiscal year ended March&#160;31, 2023. The increase in gross profit can be directly related to the increase in sales and and higher profit margins during fiscal 2024. Gross profit as a percentage of sales for fiscal 2024 was 28.0% compared to 27.6% for fiscal 2023. The gross profit and gross profit percentage increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared to the previous fiscal year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General and administrative expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by approximately $13.5 million, or 32.4%, to $55.2 million for the fiscal year ended March&#160;31, 2024, from $41.7 million for the fiscal year ended March&#160;31, 2023. The increase in general and administrative expenses for the fiscal year ended March&#160;31, 2024 was due to a $8.4 million increase in payroll expenses, of which $0.3 million is from increased stock compensation and $0.1 million from accrued severance, as well as a $0.7 million increase of professional fees, a $1.0 million increase of software and systems expense, and a $4.9 million increase of variable and other overhead expenses. The expense increases were partially attributed to the combination of PetCareRx. These increases were offset by $1.4 million related to sales tax settlements with states.. General and administrative expenses as a percentage of sales was 19.7% for the fiscal year ended March&#160;31, 2024, compared to 16.3% for the fiscal year ended March&#160;31, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Advertising expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses, which is net of manufacturer funded advertising COOP, increased by approximately $5.1 million to $24.5 million for the fiscal year ended March&#160;31, 2024, from $19.4 million for the fiscal year ended March&#160;31, 2023. This increase for the fiscal year ended March&#160;31, 2024, can be mainly attributed </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to media spend related to PetCareRx, partially offset by increased advertising COOP. Advertising </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COOP increased by $1.5 million over the same period, of which $0.9 million of the increase can be attributed to the combination of PetCareRx. The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, was $81 for the fiscal year ended March&#160;31, 2024, compared to $71 for the fiscal year ended March&#160;31, 2023, per the new definition of new customers. The increase to customer acquisition costs for the fiscal year ended March&#160;31, 2024, the advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, spending, and price competition.  Historically, the advertising environment fluctuates due to supply and demand. A more favorable advertising environment may positively impact future sales, whereas a less favorable advertising environment may negatively impact future sales. As a percentage of sales, advertising expense was 8.7% and 7.6% for the fiscal years ended March&#160;31, 2024, and 2023, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Depreciation and amortization</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the fiscal year ended March&#160;31, 2024, increased to approximately $7.1 million from $3.5 million for the fiscal year ended March&#160;31, 2023. This increase to depreciation and amortization expense for the fiscal year ended March&#160;31, 2024 can be attributed to new property and equipment additions in fiscal 2024, as well as a $2.0 million amortization expense for the intangibles acquired from PetCareRx.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income increased by approximately $0.5 million, to $1.9 million for the fiscal year ended March&#160;31, 2024, from $1.4 million for the fiscal year ended March&#160;31, 2023. The increase was primarily related to additional interest income as a result of higher interest rates. Interest income may decrease in the future as we utilize our cash balances on future investments or partnerships, on our operating activities, enter a credit facility or if the current interest rate environment changes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Provision for income taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended March&#160;31, 2024 and 2023, we recorded an income tax provision of approximately $1.2 million and $2.3 million, respectively. The decrease to the income tax provision for fiscal 2024 is related to a decrease in operating income compared to fiscal 2023. The effective tax rate for the fiscal year ended March&#160;31, 2024 was approximately (19.0)%, compared to approximately 31.0% for the fiscal year ended March&#160;31, 2023. The pre-tax loss in fiscal 2024 caused unfavorable items to decrease the rate instead of increase it. The primary driver is related to the non-deductible executive compensation under Sec. 162(m).  This limits deductions for compensation of covered executives to $1&#160;million per individual. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Net income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income decreased by approximately $12.6 million, to a loss of approximately $7.5 million for the fiscal year ended March&#160;31, 2024, from income of approximately $5.1 million for the fiscal year ended March&#160;31, 2023. The decrease </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to net income was primarily related to increases in general and administrative expenses, and increased advertising expenses, partially offset by higher gross profit margins during the fiscal year.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our working capital at March&#160;31, 2024 and 2023 was approximately $21.5 million and approximately $72.9 million, respectively. The $51.4 million decrease in working capital was primarily attributable to $36 million paid in fiscal year 2024 to acquire PetCareRx along with a decrease in income generated by operations and the use of cash to fund both the   $5.3 million investments in the Vetster partnership and infrastructure and $4.5 million of property and equipment additions separate from the PetCareRx acquisition. Net cash provided by operating activities was $4.3 million and $27.8 million for the fiscal years ended March&#160;31, 2024 and 2023, respectively. This change is primarily due to the loss from operations, partially offset by higher non-cash expenses combined with a net increase in accounts payable, and an increase in inventory separate from inventory acquired in the PetCareRx acquisition in the fiscal year ended March&#160;31, 2024. Net cash used in investing activities was $40.7 million and $10.3 million for the fiscal years ended March&#160;31, 2024 and 2023, respectively. This change in investing activities is related to the acquisition of PetCareRx, partially offset by lower investments in the Vetster partnership year-over-year. Net cash used in financing activities was $12.4 million and $24.5 million for the fiscal years ended March&#160;31, 2024 and 2023, respectively, due to the payment of an aggregate $0.60 per share dividend in fiscal year 2024 and an aggregate $1.20 per share dividend in fiscal year 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid cash dividends quarterly from August 2009 to August 2023. On February 1, 2024, our Board of Directors elected to suspend the quarterly dividend indefinitely. This move is intended to focus use of the Company&#8217;s cash flow on growth initiatives and other higher return initiatives. The Board of Directors reviews and discusses the capital allocation needs of the Company, at a minimum, on a quarterly basis. The declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors. When considering whether to declare a dividend, our Board of Directors will take into account:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    General economic and business conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our financial condition and operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our available cash and current and anticipated cash needs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our capital requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Strategic uses of cash for growth initiatives;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Contractual, legal, tax and regulatory restrictions on the payment of dividends by us; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Such other factors as our Board of Directors may deem relevant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2023, we closed on our acquisition of PetCareRx for aggregate cash consideration of approximately $36.0 million.  At March&#160;31, 2024 we had no material outstanding purchase or lease commitments. We are not currently bound by any long- or short-term agreements for the purchase or lease of property and equipment. Any material amounts expended for property and equipment would be the result of an increase in the capacity needed to adequately provide for any future increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future. Our primary source of working capital is cash from operations. We presently have no need for alternative sources of working capital and have no commitments.</span></div><div><span><br/></span></div><div id="i6c215bb864894b15adb92ac1022d7659_64"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than disclosures included in Note 1 of the Consolidated Financial Statements, which are incorporated by reference as if fully set forth herein, we do not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on our consolidated financial position, results of operations, or cash flows.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_67"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk generally represents the risk that losses may occur in the value of financial instruments as a result of movements in interest rates, foreign currency exchange rates, and commodity prices. Our financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The book values of cash equivalents, accounts receivable, and accounts payable are considered to be representative of fair value because of the short maturity of these instruments. Interest rates affect our return on excess cash and cash equivalents. At March&#160;31, 2024, we had $55.3 million in cash and cash equivalents, and the majority of our cash and cash equivalents generate interest income based on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevailing interest rates. A significant change in interest rates would impact the amount of interest income generated from our excess cash and cash equivalents. It would also impact the market value of our cash and cash equivalents. Our cash and cash equivalents are subject to market risk, primarily interest rate and credit risk. Our cash and cash equivalents are managed by a limited number of outside professional managers within investment guidelines set by our Board of Directors. Such guidelines include security type, credit quality, and maturity, and are intended to limit market risk by maintaining cash in federally-insured bank deposit accounts and restricting cash equivalents to highly-liquid investments with a maturities of three months or less. We do not hold any derivative financial instruments that could expose us to significant market risk. At March&#160;31, 2024, we had no debt obligations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_70"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PETMED EXPRESS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Page</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_73">Report of Independent Registered Public Accounting Firm (PCAOB ID:</a><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-36">49</ix:nonNumeric><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_73">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_73">38</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_76">Consolidated Balance Sheets as of </a>March&#160;31, 2024<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_76"> and </a>2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_76">40</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_79">Consolidated Statements of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_79">Operations</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_79"> for each of the three years in the period ended </a>March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_79">41</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_82">Consolidated Statements of Changes in Shareholders&#8217; Equity for each of the three years in the period ended </a>March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_82">42</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_85">Consolidated Statements of Cash Flows for each of the three years in the period ended </a>March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_85">42</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_88">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_88">43</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_130">Report of Management on Internal Control Over Financial Reporting</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_130">71</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_133">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6c215bb864894b15adb92ac1022d7659_133">74</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_73"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Stockholders and the Board of Directors of PetMed Express, Inc. and subsidiaries</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of PetMed Express, Inc. and its subsidiaries (the Company) as of March 31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for each of the three years in the period ended March 31, 2024, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended March 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of March 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013. Our report dated June 13, 2024, expressed an opinion that the Company had not maintained effective internal control over financial reporting as of March 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Critical Audit Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matters communicated below are matters arising from the current-period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Valuation of Certain Identifiable Intangible Assets Acquired in a Business Combination</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 4 to the consolidated financial statements, on April 3, 2023, the Company acquired 100% of the issued and outstanding equity interests of PetCareRx for total consideration of $36.1 million. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair values of intangible assets acquired consisted primarily of a trade name, customer relationships, and developed technology, which were estimated by applying various discounted cash flow models such as the relief from royalty rate for the trade name, the multi-period excess earnings method for the customer relationships, and the cost to replace method for the developed technology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We identified valuation of certain identifiable intangible assets acquired in the business combination as a critical audit matter because of the significant assumptions management used in estimating their fair values. Auditing management&#8217;s assumptions used in the estimates of fair value, including projections of revenue and operating margins, and the selection of discount rates and a royalty rate, involved a high degree of auditor judgment and increased audit effort, including the use of our valuation specialists, due to the impact these assumptions have on the estimates of fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit procedures related to the Company&#8217;s identifiable intangible assets acquired in the business combination included the following, among others:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We tested the reasonableness of management&#8217;s projections of revenue and operating margins, by comparing them to current industry and market trends, historical results of the acquired business and to other relevant factors.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We utilized our valuation specialists to assist in the following procedures, among others:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Evaluating the reasonableness of the discount rates and royalty rate by comparing the inputs used by management to publicly available market data.</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Evaluating the appropriateness of the valuation models used by management and testing their mathematical accuracy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Goodwill Impairment Testing</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Notes 2 and 4 to the consolidated financial statements, the Company&#8217;s goodwill balance was $26.7 million as of March 31, 2024. The Company&#8217;s evaluation of goodwill for impairment involves the comparison of the fair value of its reporting unit to its carrying value. The Company determines the fair value of its reporting unit using a combination of an income (discounted cash flow) approach and the market approach. The determination of the fair value using the income approach requires management to make significant assumptions related to terminal value growth rates and weighted-average cost of capital. The determination of the fair value using the market approach requires management to make significant assumptions related to the selection of comparable publicly traded companies and cash flow multiples to determine the fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We identified the Company&#8217;s annual goodwill impairment test as a critical audit matter because of the significant assumptions management used in its annual impairment test This required a high degree of auditor judgment and an increased extent of effort, including the need to include our fair value specialists, when performing audit procedures to evaluate the reasonableness of management&#8217;s estimates and assumptions related to the terminal value growth rate, weighted-average cost of capital, comparable publicly traded companies, and cash flow multiples.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit procedures related to the Company&#8217;s annual goodwill impairment test included the following, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We evaluated the appropriateness of the model used by management to determine the market capitalization of the Company&#8217;s reporting unit and tested its mathematical accuracy.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We tested the underlying data, such as the number of shares and the quoted market prices used by management in its model for completeness and accuracy.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">With the assistance of our valuation specialists, we evaluated the reasonableness of the Company&#8217;s estimated fair value of its reporting unit by performing the following:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Tested the accuracy of the market data referenced by management in determining the selected control premium by agreeing such market data to independently sourced information.</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">We evaluated the terminal value growth rate and weighted-average cost of capital, including testing the underlying source information and the mathematical accuracy of the calculations, and developing ranges of independent estimates and comparing those to the terminal value growth rate and weighted-average cost of capital selected by management.</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">We evaluated the selected comparable publicly traded companies and cash flow multiples, including testing the underlying source information and mathematical accuracy of the calculations, and comparing the multiples selected by management to its comparable publicly traded companies.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-37">RSM US LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have served as the Company&#8217;s auditor since 2007.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-38">Fort Lauderdale, Florida</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 13, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_76"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PETMED EXPRESS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS (in thousands, except for share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">55,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-40">104,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, less allowance for credit losses of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-41">273</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-42">35</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">3,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-45">28,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-46">19,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">6,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">4,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidTaxes" scale="3" id="f-49">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidTaxes" scale="3" id="f-50">863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">93,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">130,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-53">26,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-54">26,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible and other assets, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-55">16,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-56">5,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-57">26,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-59">1,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-61">4,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-62">5,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">76,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">37,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-65">169,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-66">167,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">37,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">25,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">25,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">26,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-71">7,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">6,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-73">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">2,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">72,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">57,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-79">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-81">73,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-82">57,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-83"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-84"/></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-85"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-86">.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-88">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-89"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesIssued" scale="3" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesIssued" scale="3" id="f-91"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-92">3</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> convertible shares issued and outstanding with a liquidation preference of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="f-93"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="f-94">4</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="f-95">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="f-96">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-97"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-98">.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-100">40,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-102">21,149</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-104">21,084</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-105">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-106">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-107">25,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-108">18,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-109">71,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-110">91,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">96,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">109,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">169,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-114">167,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_79"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PETMED EXPRESS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-115">281,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-116">256,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-117">272,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-118">202,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-119">185,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-120">195,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-121">78,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-122">70,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-123">76,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">55,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-125">41,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">31,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">24,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">19,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">18,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-130">7,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-131">3,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-132">2,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-133">86,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">64,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-135">52,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">8,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">6,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">24,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestRevenueExpenseNet" scale="3" id="f-139">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestRevenueExpenseNet" scale="3" id="f-140">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:InterestRevenueExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-141">1,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-142">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-143">944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-144">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-145">1,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-146">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-147">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Income before provision for income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-148">6,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-149">7,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-150">24,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-151">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-152">2,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-153">5,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">7,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">5,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-156">18,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-157">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-158">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-159">0.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-160">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-161">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-162">0.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-163">20,395,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-164">20,274,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-165">20,175,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-166">20,395,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-167">20,339,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-168">20,357,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-169">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-170">1.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-171">1.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_82"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PETMED EXPRESS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended March&#160;31, 2022, March&#160;31, 2023, and March&#160;31, 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.056%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="f-172">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-173">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-174">20,269</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-175">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-176">7,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-177">117,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-178">124,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted stock, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-179">710</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-180">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-181">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-182">4,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-183">4,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-184">24,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-185">24,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">18,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">18,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="f-188">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-189">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-190">20,979</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-191">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">11,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">111,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">123,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted stock, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-195">105</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-196">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-197">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-198">6,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-199">6,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-200">25,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-201">25,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-202">5,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">5,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="f-204">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-205">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-206">21,084</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-207">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">18,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">91,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-210">109,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted stock, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-211">64</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-212">6,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-213">6,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-214">12,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-215">12,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">7,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">7,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="f-218">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-219">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-220">21,148</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-221">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-222">25,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-223">71,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">96,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_85"></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PETMED EXPRESS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-225">7,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-226">5,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-227">18,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-228">7,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-229">3,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-230">2,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-231">6,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-232">6,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-233">4,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-234">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-235">1,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-236">846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-237">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-238">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-239">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in operating assets and increase (decrease) in liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-240">1,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-241">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-242">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" format="ixt:num-dot-decimal" scale="3" id="f-243">6,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" format="ixt:num-dot-decimal" scale="3" id="f-244">13,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" format="ixt:num-dot-decimal" scale="3" id="f-245">1,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="3" id="f-246">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="3" id="f-247">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="3" id="f-248">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-249">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-250">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-251">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="pets:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="f-252">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="pets:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pets:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-255">6,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-256">2,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-257">12,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-258">1,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-259">1,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-260">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-261">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-262">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-263">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-264">766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-267">390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-270">4,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-271">27,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-272">18,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of minority interest investment in Vetster</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="3" id="f-273">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-274">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="f-275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of PetCareRx, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-276">35,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-279">4,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-280">5,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-281">1,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-282">40,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-283">10,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-284">1,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-285">12,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-286">24,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-287">24,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-288">12,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-289">24,537</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-290">24,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-291">48,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-292">6,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-293">7,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at beginning of fiscal year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-294">104,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-295">111,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-296">118,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at end of fiscal year</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-297">55,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-298">104,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-299">111,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-300">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-301">4,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-302">6,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable in accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="f-303">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="f-304">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAssumed1" scale="3" id="f-305">558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="i6c215bb864894b15adb92ac1022d7659_88"></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_532"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ErrorCorrectionTextBlock" id="f-306" continuedAt="f-306-1" escape="true">Restatement of Previously Issued Financial Statements</ix:nonNumeric></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="f-306-1"><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the third quarter of fiscal year 2024, we reviewed the accounting treatment related to previously reported sales tax accruals as well as the accounting treatment related to the valuation of the deferred tax asset associated with our acquisition of PetCareRx in April 2023. As a result of this review, management determined that we incorrectly applied United States Generally Accepted Accounting Principles (U.S. GAAP) as it relates to the sales tax liability and improperly valued the deferred tax asset and goodwill included in our consolidated financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We corrected the misstatements relating to sales tax accruals by recording sales tax accruals as of the end of each of the affected periods using a legal liability approach under Accounting Standards Codification Topic 405, Liabilities. The restated sales tax accrual amounts assume that (i) customers who have not yet provided certificates or other documentation of exemption from sales tax are taxable, (ii) total potential interest and penalty assessments may be imposed, and (iii) we will not receive waivers of interest and penalties or other benefits under agreements we may obtain with jurisdictions from our outreach with voluntary disclosures. We will continue to accrue interest on any outstanding liabilities until the voluntary disclosure agreements are settled. These accrual amounts have been, and will continue to be, adjusted in future periods as and if we obtain any waivers of interest and penalties or other benefits from our voluntary disclosures and as and if we obtain additional documentation from customers supporting exemption from sales tax.</span></div><div style="text-align:justify;text-indent:54pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we have corrected misstatements relating to the deferred tax asset we recognized in connection with our acquisition of PetCareRx on April 3, 2023. In the accounting for that acquisition, it was determined that we incorrectly valued deferred tax assets associated with loss carryforwards of PetCareRx under section 382 of the Internal Revenue Code. As a result of this error, we recorded a decrease in the amount of our deferred tax assets and a corresponding increase in the amount of goodwill in each of the affected periods.</span></div><div style="text-align:justify;text-indent:54pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The misstatements that appeared in our previously issued financial statements were material, and we also corrected other immaterial errors.</span></div><div style="text-align:justify;text-indent:54pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in additional detail in the Explanatory Note in our Amendment No. 1 on Form 10-K/A to our Annual Report on Form 10-K for the year ended March 31, 2023, originally filed with the SEC on May 23, 2023, we restated our audited consolidated financial statements as of and for the years ended March 31, 2023, 2022 and 2021, as well as our unaudited condensed consolidated quarterly financial information for the quarterly periods within the fiscal years ended March 31, 2023 and 2022, to reflect the correction of the misstatements relating to sales tax accruals and other immaterial adjustments, and to make corresponding disclosures. We also filed with the SEC (i) an Amendment No. 1 on Form 10-Q/A to our Quarterly Report on Form 10-Q for the three months ended June 30, 2023, originally filed with the SEC on August 2, 2023,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to restate our unaudited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">condensed consolidated financial statements as of and for the three months ended June 30, 2023 and 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and (ii) an Amendment No. 1 on Form 10-Q/A to our Quarterly Report on Form 10-Q for the three months ended September 30, 2023, originally filed with the SEC on October 31, 2023, to restate our unaudited condensed consolidated financial statements as of and for the three and six months ended September 30, 2023 and 2022, in each case to reflect the correction of the misstatements relating to sales tax accruals and the valuation of deferred tax assets associated with our acquisition of PetCareRx in April 2023.</span></div><div style="text-align:justify;text-indent:54pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The restated prior-year results are reflected in the consolidated financial results disclosed within this Annual Report on Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-307" continuedAt="f-307-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-307-1" continuedAt="f-307-2"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PetMed Express, Inc. and subsidiaries, d/b/a PetMeds&#174; (collectively, the "Company"), is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats, and horses. The Company markets and sells directly to consumers through its websites, toll-free numbers, and mobile application. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Founded in 1996, the Company's executive headquarters offices are currently located in Delray Beach, Florida. The Company has a March 31 fiscal year and references herein to fiscal 2024, 2023, or 2022 refer to the Company's fiscal years ended March&#160;31, 2024, 2023, and 2022, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-308" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include PetMed Express, Inc. and its  wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-309" escape="true"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification ("ASC") Topic 805 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Business Combinations"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The purchase price is allocated to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company&#8217;s unaudited condensed consolidated financial statements from the date of acquisition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">      Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain obligations assumed. Acquisition-related transaction costs incurred by the Company are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-310" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March&#160;31, 2024 and 2023 consisted of the Company&#8217;s cash accounts and money market accounts with a maturity of three months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times,  may exceed federally insured limits. The Company has not experienced any losses in such accounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-311" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</span></div></div><ix:continuation id="f-307-2" continuedAt="f-307-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-312" continuedAt="f-312-1" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-312-1">Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence.</ix:continuation> The inventory reserve was approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="f-313">72</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="f-314">48</ix:nonFraction> thousand at March&#160;31, 2024 and 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-315" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of <ix:nonNumeric contextRef="c-35" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-316">thirty years</ix:nonNumeric>. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from <span style="-sec-ix-hidden:f-317">three</span> to <ix:nonNumeric contextRef="c-37" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-318">ten years</ix:nonNumeric>.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-319" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-320" escape="true"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. Goodwill is not amortized but instead is tested for impairment annually on January 1, or more frequently if events or changes in circumstances indicate goodwill might be impaired. When testing goodwill for impairment, the Company has the option to choose whether it will apply a qualitative assessment first and then a quantitative assessment, if necessary, or to apply the quantitative assessment directly. The Company has concluded that it has <ix:nonFraction unitRef="reporting_unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-321">one</ix:nonFraction> reporting unit and has assigned the entire balance of goodwill to this reporting unit   </span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company performed its annual goodwill impairment testing as of January 1, 2024 using a </span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">quantitative </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">assessment and at that time concluded there was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt-sec:numwordsen" id="f-322">no</ix:nonFraction> impairment. Since then, the Company&#8217;s stock price decreased from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-38" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-323">7.56</ix:nonFraction> at December 31, 2023 to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-324">4.79</ix:nonFraction> at March 31, 2024.  The Company considered the decrease in its stock price to be indicative of a risk that the carrying amount of goodwill may not be recoverable.  Therefore, the Company performed a quantitative impairment assessment as of March 31, 2024.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Based on the assessment, the Company concluded that goodwill was not impaired because the estimated fair value of the reporting unit exceeded its carrying value by approximately <ix:nonFraction unitRef="number" contextRef="c-4" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="f-325">27</ix:nonFraction>%.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We estimated fair value using discounted cash flow and public company market approaches with a <ix:nonFraction unitRef="number" contextRef="c-39" decimals="2" name="pets:ReportingUnitMeasurementInput" scale="-2" id="f-326">70</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-40" decimals="2" name="pets:ReportingUnitMeasurementInput" scale="-2" id="f-327">30</ix:nonFraction>% weighting, respectively.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A key assumption under the cash flow approach was a <ix:nonFraction unitRef="number" contextRef="c-41" decimals="2" name="pets:ReportingUnitMeasurementInput" scale="-2" id="f-328">27</ix:nonFraction>% weighted average cost of capital.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A key assumption under the public company market approach was a <ix:nonFraction unitRef="number" contextRef="c-42" decimals="2" name="pets:ReportingUnitMeasurementInput" scale="-2" id="f-329">10</ix:nonFraction>% control premium.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-330" continuedAt="f-330-1" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div></ix:nonNumeric><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><ix:continuation id="f-330-1" continuedAt="f-330-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired definite-lived intangible assets in the acquisition (see Note 4) that will be amortized based on their estimated useful lives in accordance with ASC Topic 350 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-330-2">&#8221;). These definite-lived intangible assets are being amortized over periods ranging from <span style="-sec-ix-hidden:f-331">three</span> to <ix:nonNumeric contextRef="c-44" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-332">seven years</ix:nonNumeric>. Acquired trade name is not being amortized and is subject to an annual review for impairment consistent with the existing intangible assets in fiscal 2024.</ix:continuation> Following the Company's annual impairment testing in fiscal 2024, it concluded there was no impairment of its intangible assets.</span></div><ix:nonNumeric contextRef="c-1" name="pets:OtherAssetsPolicyTextBlock" id="f-333" continuedAt="f-333-1" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Assets</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-333-1">Other assets consist of the initial minority interest investment in Vetster.</ix:continuation> Details can be found in Note 16 below.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-334" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</span></div></div><ix:continuation id="f-307-3" continuedAt="f-307-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-335" continuedAt="f-335-1" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-335-1">The Company's advertising expense consists primarily of Internet marketing and direct mail/print, . Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-336" escape="true"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC Topic 842 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Leases")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are reported as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities and long-term lease liabilities on the unaudited Condensed Consolidated Balance Sheets.  The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#8217;s lease agreements do not contain any residual value guarantees.</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="number" contextRef="c-45" decimals="2" name="pets:PercentageOfPropertyLeasedToTenants" scale="-2" id="f-337">48</ix:nonFraction>% of our Delray Beach property, or approximately <ix:nonFraction unitRef="sqft" contextRef="c-46" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-338">88,000</ix:nonFraction> square feet was leased to <ix:nonFraction unitRef="tenant" contextRef="c-45" decimals="INF" name="pets:NumberOfTenants" format="ixt-sec:numwordsen" scale="0" id="f-339">two</ix:nonFraction> tenants. At</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the leases with these <ix:nonFraction unitRef="tenant" contextRef="c-45" decimals="INF" name="pets:NumberOfTenants" format="ixt-sec:numwordsen" scale="0" id="f-340">two</ix:nonFraction> tenants had a remaining weighted average lease term of <ix:nonNumeric contextRef="c-45" name="pets:LessorOperatingLeaseRemainingWeightedAverageLeaseTerm" format="ixt-sec:durwordsen" id="f-341">one year</ix:nonNumeric>. The Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:RentalIncomeNonoperating" format="ixt:num-dot-decimal" scale="6" id="f-342">1.2</ix:nonFraction> million , $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:RentalIncomeNonoperating" format="ixt:num-dot-decimal" scale="6" id="f-343">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:RentalIncomeNonoperating" format="ixt:num-dot-decimal" scale="6" id="f-344">0.7</ix:nonFraction> million in rental revenue in fiscal 2024, 2023 and 2022, respectively, which was included in other income. In 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:RentalIncomeNonoperating" format="ixt:num-dot-decimal" scale="6" id="f-345">0.5</ix:nonFraction> million of rental revenue associated with a PetCareRx lease which expired in April 2024. The Company expects to receive the following future lease payments, under the current lease agreements, over the next five years: $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="3" id="f-346">617</ix:nonFraction> thousand in fiscal 2025; $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="3" id="f-347">112</ix:nonFraction> thousand in fiscal 2026, and $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="3" id="f-348"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" scale="3" id="f-349"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" scale="3" id="f-350">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> thousand in fiscal 2027, 2028 and 2029. As of March 31, 2024, both leases were being negotiated.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-351" continuedAt="f-351-1" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Income</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><ix:continuation id="f-351-1" continuedAt="f-351-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC Topic 220 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting Comprehensive Income</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-351-2">&#8221;) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities.</ix:continuation> For the fiscal years ended March&#160;31, 2024, 2023 and 2022, the Company had no components of comprehensive income and therefore does not report comprehensive income or Consolidated Statements of Comprehensive Income. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-352" continuedAt="f-352-1" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the provisions of ASC Topic 740 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by &#8220;Accounting for Uncertainty in Income Taxes&#8221; guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</span></div></div><ix:continuation id="f-307-4"><ix:continuation id="f-352-1"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies &#8220;Accounting for Uncertainty in Income Taxes&#8221; guidance to all tax positions for which the statute of limitations remains open. The Company had <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt-sec:numwordsen" id="f-353"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt-sec:numwordsen" id="f-354">no</ix:nonFraction></ix:nonFraction> liabilities for uncertain tax positions for either fiscal 2024 or fiscal 2023. The Company files tax returns in the U.S. federal jurisdiction and Florida,  Arizona, California, Connecticut, Idaho, Maryland, Michigan, Oklahoma, South Carolina, Virginia, Wisconsin, New Jersey, Georgia, Indiana, New York and the District of Columbia. With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending March&#160;31, 2020, or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-355" continuedAt="f-355-1" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Concentrations</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-355-1">The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our product lines to obtain the lowest cost.</ix:continuation> There were seven and six suppliers from which we purchased approximately <ix:nonFraction unitRef="number" contextRef="c-50" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-356">78</ix:nonFraction>%  and <ix:nonFraction unitRef="number" contextRef="c-51" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-357">69</ix:nonFraction>% of all products in fiscal 2024 and 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-358" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for Share Based Compensation</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The compensation expense related to all of the Company&#8217;s stock-based compensation arrangements is recorded as a component of general and administrative expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-359" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company&#8217;s consolidated financial position, results of operations, or cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_593"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)  <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-360" continuedAt="f-360-1" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="f-360-1" continuedAt="f-360-2"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> ("Revenue from Contracts with Customers")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company generates revenue by selling prescription and non-prescription pet medication products, pet food, supplements, supplies, membership fees, and veterinary services. Certain pet supplies offered on the Company&#8217;s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain <ix:nonFraction unitRef="performanceobligation" contextRef="c-4" decimals="INF" name="pets:RevenueFromContractWithCustomerNumberOfPerformanceObligations" format="ixt-sec:numwordsen" id="f-361">one</ix:nonFraction> performance obligation, which is delivery of the product. Customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are based on historical patterns, however this is not considered a key judgment. Revenue is recognized when control transfers to the customer at the point in time at which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time when the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Virtually all the Company&#8217;s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales. Revenue is recorded net of sales tax, discounts and return allowances. Return allowances are estimated using historical experience and not material. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given its responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Membership fees represent the amounts recognized periodically from <ix:nonFraction unitRef="model" contextRef="c-4" decimals="INF" name="pets:RevenueFromContractWithCustomerNumberOfMembershipModels" format="ixt-sec:numwordsen" id="f-362">two</ix:nonFraction> membership models. The first is the PetPlus membership for PetCareRx customers, the second is a partner membership provided through PetCareRx. These memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup which represent a single stand-ready performance obligation to provide these benefits. The PetPlus membership fee is an upfront annual charge and automatically renews <ix:nonNumeric contextRef="c-52" name="pets:ContractWithCustomerRenewalPeriod" format="ixt-sec:durwordsen" id="f-363">one year</ix:nonNumeric> from the initial enrollment date. The Company recognizes the revenue ratably over the term of the PetPlus membership which is generally <ix:nonNumeric contextRef="c-52" name="pets:ContractWithCustomerRevenueRecognitionPeriod" format="ixt-sec:durwordsen" id="f-364">one year</ix:nonNumeric>. <ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-365" continuedAt="f-365-1" escape="true">As shown in the following table, under the PetPlus program, the Company recognized  $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-366">7.0</ix:nonFraction> million deferred annual membership fees in the twelve months ended March&#160;31, 2024, and had $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-367">2.6</ix:nonFraction> million of deferred revenue as of the year ended March&#160;31, 2024.</ix:nonNumeric></span></div><ix:continuation id="f-365-1"><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.878%"><tr><td style="width:1.0%"/><td style="width:68.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">( amounts in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-368">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue acquired with PetCareRx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" scale="6" id="f-369">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred memberships fees received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="pets:ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived" scale="6" id="f-370">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred membership fee revenue recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-371">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-372">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to annual membership fees earned under the PetPlus program, the Company also earns membership fees on a month-to-month basis under its PetCareRx partner membership program.  For the twelve months ended March&#160;31, 2024, membership fees earned under the partner program were $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-373">2.8</ix:nonFraction> million. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no material contract asset or liability balances at March&#160;31, 2024 and March&#160;31, 2023, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-360-2"><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates sales in the following <ix:nonFraction unitRef="category" contextRef="c-4" decimals="INF" name="pets:RevenueFromContractWithCustomerNumberOfSalesCategories" format="ixt-sec:numwordsen" id="f-374">two</ix:nonFraction> categories: reorder sales vs new order sales vs membership fees. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-375" continuedAt="f-375-1" escape="true">The following table illustrates sales by various classifications:</ix:nonNumeric></span></div><ix:continuation id="f-375-1"><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:29.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales (In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reorder sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-376">246,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-56" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-377">87.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-378">232,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-57" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-379">90.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="pets:RevenueFromContractWithCustomerVariance" format="ixt:num-dot-decimal" scale="3" id="f-380">14,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-56" decimals="3" name="pets:RevenueFromContractWithCustomerVariancePercentage" scale="-2" id="f-381">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New order sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-382">24,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-58" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-383">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-384">24,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-59" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-385">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="pets:RevenueFromContractWithCustomerVariance" scale="3" id="f-386">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-58" decimals="3" name="pets:RevenueFromContractWithCustomerVariancePercentage" scale="-2" id="f-387">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Membership fees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-388">9,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-60" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-389">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-61" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" format="ixt:fixed-zero" scale="-2" id="f-391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="pets:RevenueFromContractWithCustomerVariance" format="ixt:num-dot-decimal" scale="3" id="f-392">9,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-393">281,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-394">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-395">256,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-396">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pets:RevenueFromContractWithCustomerVariance" format="ixt:num-dot-decimal" scale="3" id="f-397">24,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="pets:RevenueFromContractWithCustomerVariancePercentage" scale="-2" id="f-398">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:29.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales (In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reorder sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-399">232,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-57" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-400">90.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-401">243,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-62" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-402">89.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="pets:RevenueFromContractWithCustomerVariance" format="ixt:num-dot-decimal" scale="3" id="f-403">11,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-57" decimals="3" sign="-" name="pets:RevenueFromContractWithCustomerVariancePercentage" scale="-2" id="f-404">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New order sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-405">24,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-59" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-406">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-407">28,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-408">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="pets:RevenueFromContractWithCustomerVariance" format="ixt:num-dot-decimal" scale="3" id="f-409">4,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-59" decimals="3" sign="-" name="pets:RevenueFromContractWithCustomerVariancePercentage" scale="-2" id="f-410">16.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-411">256,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-412">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-413">272,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="pets:RevenueFromContractWithCustomerPercentage" scale="-2" id="f-414">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="pets:RevenueFromContractWithCustomerVariance" format="ixt:num-dot-decimal" scale="3" id="f-415">15,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="pets:RevenueFromContractWithCustomerVariancePercentage" scale="-2" id="f-416">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company changed the definition of a new customer on April 1, 2022, to include anyone who has not ordered over the past thirty-six months. The reorder and new order sales amounts for the years ended March&#160;31, 2022 reflect this new customer definition change. Under the previous definition of a new customer, reorder and new order sales were $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-417">249.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-418">22.9</ix:nonFraction> million, respectively, for the  year ended March&#160;31, 2022. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses that the Company estimates will arise from customers&#8217; inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. The Company determines its estimates of the uncollectability of accounts receivable by analyzing historical bad debts and current economic trends in compliance with the provisions of ASC Topic 326 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses"). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses was approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-419">273</ix:nonFraction> thousand  and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-420">35</ix:nonFraction> thousand at March&#160;31, 2024 and March&#160;31, 2023, respectively.</span></div></ix:continuation><div id="i6c215bb864894b15adb92ac1022d7659_603"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(4)   <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-421" continuedAt="f-421-1" escape="true">Acquisition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-421-1" continuedAt="f-421-2"><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April&#160;3, 2023, the Company acquired <ix:nonFraction unitRef="number" contextRef="c-66" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-422">100</ix:nonFraction>% of the issued and outstanding equity interests of PetCareRx, a New York corporation and a leading supplier of pet food, pet medications, and supplies.  The acquisition was completed pursuant to an Agreement and Plan of Merger ("Merger Agreement") by and among the Company, Harry Merger Sub, Inc., a New York corporation and a wholly-owned subsidiary of the Company ("Merger Sub"), PetCareRx and Jeanette Loeb (as representative of the PetCareRx equity holders). The Merger Agreement provided for the Company&#8217;s acquisition of PetCareRx pursuant to the merger of Merger Sub with and into PetCareRx, with PetCareRx as the surviving corporation. The aggregate purchase price consideration was $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="f-423">36.1</ix:nonFraction> million and was funded from the Company's cash on hand.  </span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The acquisition of PetCareRx allowed the Company to significantly expand its product catalog, most notably in non-medication products, including food. In addition, PetCareRx brings increased distribution capability and experience, geographic diversity, technology enhancements, additional vendor relationships and a long-tenured and experienced staff.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognized goodwill of approximately $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-424">26.7</ix:nonFraction> million, which is calculated as the excess of the consideration exchanged and liabilities assumed as compared to the fair value of the identifiable assets acquired.  Goodwill recognized in the transaction represents synergies or scale achieved by significantly increasing the customer base without adding corresponding levels of additional overhead, the value of additional vendor relationships, including the food manufacturing relationships, a broader product catalog, and an assembled and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-421-2" continuedAt="f-421-3"><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">experienced workforce. These items represent intangible assets that do not qualify for separate recognition.  <ix:nonFraction unitRef="usd" contextRef="c-66" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt-sec:numwordsen" id="f-425">No</ix:nonFraction> goodwill is deductible for tax purposes. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The values assigned to the assets acquired and liabilities assumed are based on their estimates of fair value available as of April&#160;3, 2023, as calculated by an independent third-party firm. The selected rates of returns were chosen in consideration of the individual risk profiles of the assets, as well as the resulting weighted average return on assets. Intangible assets are considered to be riskier than the overall business, so the Company included a premium to the investment rate of return on the identified intangible discount rates. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair values of intangible assets acquired consist of a trade name, customer relationships, and developed technology, which were estimated by applying various discounted cash flow models such as the relief from royalty rate for the trade name, the multi-period excess earnings method for the customer relationships, and the cost to replace method for the developed technology. The fair value measurements were based on significant inputs that are not observable (Level 3). The assumptions made by management in determining the fair value of intangible assets included a discount rate of <ix:nonFraction unitRef="number" contextRef="c-66" decimals="2" name="pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate" scale="-2" id="f-426">12</ix:nonFraction>% based on the weighted average cost of capital.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As a result of the acquisition, the Company performed an Internal Revenue Code Section 382 analysis to determine if the net operating losses carried forward will have a utilization limitation. Refer to Note 9 for further discussion.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-427" escape="true"><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below outlines the purchase price allocation of the purchase for PetCareRx to the acquired identifiable assets, liabilities assumed and goodwill (in thousands):</span></div><div><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:76.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-428">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="f-429">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables" scale="3" id="f-430">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="f-431">3,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="f-432">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-433">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" scale="3" id="f-434">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-435">26,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-436">12,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="f-437">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="f-438">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-439">47,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-440">5,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" scale="3" id="f-441">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-442">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="3" id="f-443">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-444">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-445">11,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-446">36,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company incurred a total of $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" id="f-447">1.7</ix:nonFraction> million in acquisition related costs that were expensed as incurred and recorded in general and administrative expenses in the Company&#8217;s Condensed Consolidated Statements of Operations, of which $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-448">0.5</ix:nonFraction> million was recorded in fiscal year 2023, and $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-449">1.2</ix:nonFraction> million was recorded for the twelve months ended March&#160;31, 2024. These costs include banking, legal, accounting, and consulting fees related to the acquisition. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Supplemental Pro Forma Information (As Restated)</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The supplemental pro forma financial information presented below is for illustrative purposes only, does not include the pro forma adjustments that would be required under Regulation S-X of the Exchange Act for pro forma financial information, is not necessarily indicative of the financial position or results of operations that </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-421-3"><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">would have been realized if the PetCareRx acquisition had been completed on April 1, 2022, does not reflect synergies that might have been achieved, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that the Company believes are reasonable under the circumstances.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the PetCareRx acquisition had occurred on April 1, 2021 to give effect to certain events that the Company believes to be directly attributable to the acquisition. These pro forma adjustments primarily include:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">A decrease in depreciation expense that would have been recognized due to acquired identifiable fixed assets;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">A decrease in amortization expense that would have been recognized due to acquired identifiable intangible assets; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">A decrease in payroll costs and benefits.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="f-450" escape="true"><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The supplemental pro forma financial information for the prior period twelve months ended March&#160;31, 2023 and 2022 is as follows (in thousands):</span></div><div><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"/><td style="width:47.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-451">300,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-452">311,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="f-453">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-454">13,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-455" continuedAt="f-455-1" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="f-455-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-456" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major classifications of property and equipment consist of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:69.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-457">14,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-458">14,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-459">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-460">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building Improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-461">4,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-462">3,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-463">14,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-464">9,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-465">9,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-466">9,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-467">46,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-468">41,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-469">20,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-470">15,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-471">26,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-472">26,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-473">5.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-474">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-475">2.7</ix:nonFraction> million for the twelve months ended March&#160;31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its tangible property and equipment for indicators of impairment as of March&#160;31, 2024 and concluded that no impairment existed.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_657"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 6: <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-476" continuedAt="f-476-1" escape="true">Intangible and Other Assets, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-476-1" continuedAt="f-476-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-477" escape="true"><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets and other assets, net consisted of the following (in thousands):</span></div><div><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:35.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful Life (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toll-free telephone number</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-478">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-479">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internet domain names</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-480">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-481">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Names - PetCareRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-482">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-483">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships -PetCareRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-82" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-484">7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-485">6,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-486">957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-487">5,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-83" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-488">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology - PetCareRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-84" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-489">3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-490">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-491">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-492">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-85" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-493">2.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-494">13,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-495">1,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-496">11,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minority interest investment in Vetster</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-497">5,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-498">5,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:IntangibleAndOtherAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-499">18,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-500">1,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:IntangibleAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-501">16,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toll-free telephone number</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-502">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-503">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internet domain names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-504">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-505">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="f-506">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="f-507">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minority interest investment in Vetster</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-508">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-509">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:IntangibleAndOtherAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-510">5,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:IntangiblesAndOtherAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="3" id="f-511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:IntangibleAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-512">5,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluated its intangible assets for indicators of impairment as of March&#160;31, 2024 and concluded that no impairment existed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortization expense for intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-513">2.0</ix:nonFraction>&#160;million for the twelve months ended March&#160;31, 2024 and <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-514">zero</ix:nonFraction> for the twelve months ended March&#160;31, 2023 and 2022, respectively. The indefinite life intangibles are not </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-476-2" continuedAt="f-476-3"><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">being amortized and are subject to an annual review for impairment in accordance with the ASC Topic 350 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;).</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-515" escape="true"><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes expected amortization of our intangible assets at March 31, 2024 (in thousands):</span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.757%"><tr><td style="width:1.0%"/><td style="width:66.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-516">1,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-517">1,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="f-518">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-519">957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="f-520">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="f-521">957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-522">7,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;19, 2022, the Company engaged in a <ix:nonNumeric contextRef="c-88" name="pets:TermOfAgreement" format="ixt-sec:durwordsen" id="f-523">three-year</ix:nonNumeric> partnership agreement with Vetster Inc. (&#8220;Vetster&#8221;), a Canadian veterinary telehealth company. The Company also purchased a <ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-524">5</ix:nonFraction>% minority interest in Vetster in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-525">5.0</ix:nonFraction>&#160;million and received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, the Company became the exclusive e-commerce provider for Vetster, and Vetster became the exclusive provider of telehealth and telemedicine services to the Company. The minority interest investment is being valued on the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost basis and the investment will be evaluated periodically for any impairment. On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> October 3, 2023, the Company purchased additional shares in Vetster in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-526">0.3</ix:nonFraction>&#160;million. This increased the minority interest investment to $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-527">5.3</ix:nonFraction>&#160;million. Following this round, the Company&#8217;s minority ownership changed to approximately <ix:nonFraction unitRef="number" contextRef="c-91" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-528">4.8</ix:nonFraction>% of Vetster&#8217;s outstanding shares.  The minority interest investment is being valued on the cost basis.  At March&#160;31, 2024, we evaluated the investment in accordance with ASC Topic 321 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Equity Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and determined it was not impaired.   </span></div></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-476-3">Under the terms of the agreement, Vetster earns from <ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-529">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-530">20</ix:nonFraction>% of revenue generated from its customers on orders fulfilled by the Company.  For the years ended March 31, 2024 and 2023, the Company earned approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-531">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-532">0.4</ix:nonFraction>&#160;million in net sales for orders placed through Vetster and incurred fees to Vetster of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="f-533">153</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="f-534">80</ix:nonFraction>&#160;thousand, respectively.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-535" continuedAt="f-535-1" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-536" escape="true"><ix:continuation id="f-535-1"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major classifications of accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:69.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued credit card fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:AccruedCreditCardFeesCurrent" scale="3" id="f-537">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:AccruedCreditCardFeesCurrent" scale="3" id="f-538">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued salaries and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-539">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-540">1,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued merchandise credits / reward program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:AccruedMerchandiseCreditsAndRewardsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-541">1,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:AccruedMerchandiseCreditsAndRewardsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-542">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-543">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-544">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales return allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:AccruedSalesReturnsAndAllowancesCurrent" scale="3" id="f-545">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:AccruedSalesReturnsAndAllowancesCurrent" scale="3" id="f-546">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-547">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-548">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued real estate taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" scale="3" id="f-549">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" scale="3" id="f-550">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-551">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-552">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-553">7,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-554">6,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_620"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8) <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-555" continuedAt="f-555-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-555-1" continuedAt="f-555-2"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s leasing activities primarily consist of real estate leases acquired during the acquisition of PetCareRx for use in the business operations.  The leases had initial terms ranging from <ix:nonNumeric contextRef="c-43" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-556">5</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-44" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-557">10</ix:nonNumeric> years. Some of the initial lease terms have already matured and the remaining leases have maturity dates ranging from fiscal year 2024 to 2028. The Company assesses whether each lease is an operating lease or a finance lease at the lease commencement date. The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable Lease Costs</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s leases require payments for taxes, insurance, and other costs applicable to the property, in addition to the minimum lease payment. These costs are considered variable costs which are based on actual expenses incurred by the lessor. Therefore, these amounts are not included in the calculation of the right-of-use assets and lease liabilities. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements which provide for fixed and scheduled escalations, which are included in the calculation of the right-of-use assets and lease liabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options to Extend or Terminate Leases</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s leases may contain an option to extend the lease term for periods from <span style="-sec-ix-hidden:f-558">one</span> to <ix:nonNumeric contextRef="c-44" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-559">five years</ix:nonNumeric> The exercise of lease renewal options is at the Company&#8217;s sole discretion. If it is reasonably certain that the Company will exercise such options, the periods covered by such options are included in the lease term and are recognized as part of the Company&#8217;s right-of-use assets and lease liabilities. The Company&#8217;s leases do not generally contain options to early terminate.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Lease items</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities on the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discount Rate and Lease Term</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the weighted average remaining lease term and discount rate for the Company&#8217;s operating leases were <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-560">3</ix:nonNumeric> years and <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-561">3.6</ix:nonFraction>%, respectively. As the rate implicit in the lease is generally not readily determinable for the Company&#8217;s operating leases, the Company uses its estimated incremental borrowing rate based on the information available at the date of acquisition, April&#160;3, 2023, in determining the present value of future payments.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Costs and Activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-562" continuedAt="f-562-1" escape="true"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease costs as recorded in the general and administrative costs and activity for the twelve months ended March&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.636%"><tr><td style="width:1.0%"/><td style="width:69.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Twelve months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating lease cost - fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-563">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating lease costs - variable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-564">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-565">918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information for the twelve months ended March&#160;31, 2024 are as follows (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-555-2"><ix:continuation id="f-562-1"><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"><tr><td style="width:1.0%"/><td style="width:71.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.314%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Twelve months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash paid for the amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-566">832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Right-of-use assets obtained in exchange for new operating lease liabilities as a result of acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-567">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity of Lease Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-568" escape="true"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company&#8217;s lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating lease liabilities recognized on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.878%"><tr><td style="width:1.0%"/><td style="width:67.299%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-569">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-570">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-571">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-572">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-573">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less: Imputed Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-574">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-575">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-576" continuedAt="f-576-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></ix:nonNumeric></div><ix:continuation id="f-576-1" continuedAt="f-576-2"><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-577" continuedAt="f-577-1" escape="true">The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-577-1"><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:69.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales tax liability</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-578">5,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-579">5,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="3" id="f-580">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="3" id="f-582">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-583">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="f-584">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt and inventory reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="f-586">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="f-587">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="3" id="f-588">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:fixed-zero" scale="3" id="f-589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:DeferredTaxAssetsLeaseLiabilities" scale="3" id="f-590">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:DeferredTaxAssetsLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-592">3,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:fixed-zero" scale="3" id="f-593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-594">10,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-595">7,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax accounting method change</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:DeferredTaxLiabilitiesChangeInAccountingMethod" scale="3" id="f-596">541</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pets:DeferredTaxLiabilitiesChangeInAccountingMethod" format="ixt:fixed-zero" scale="3" id="f-597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-598">2,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-600">1,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-601">2,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="f-602">376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:fixed-zero" scale="3" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-604">4,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-605">2,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-606">624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="3" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-608">4,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-609">5,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-610">11.3</ix:nonFraction>&#160;million of federal net operating loss carryforwards which begin to expire in fiscal 2024. The Company also had $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-611">9.0</ix:nonFraction>&#160;million in state net operating loss carryforwards which begin to expire in fiscal 2026. In fiscal 2024 the Company acquired PetCareRx, a loss corporation. The tax attributes acquired are subject to Internal Revenue Code Section 382 which limits the utilization annually. The Company has determined the utilization of the state loss carryforwards is not likely to be realized. As a result, the Company has recorded a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-612">0.6</ix:nonFraction>&#160;million for the tax effected value of these state losses. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-613" continuedAt="f-613-1" escape="true">Outlined below are the tax attributes acquired and the balances remaining as of March 31, 2024 (in thousands).</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes (Continued)</span></div></div><ix:continuation id="f-576-2" continuedAt="f-576-3"><ix:continuation id="f-613-1"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"/><td style="width:29.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PetCareRx Tax Attributes Acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sec. 382 limited utilization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attributes for which a deferred tax asset is recorded</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - limited carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="pets:OperatingLossCarryforwardsSubjectToLimitations" format="ixt:num-dot-decimal" scale="3" id="f-614">85,454</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="pets:OperatingLossCarryforwardsSubjectToLimitations" format="ixt:num-dot-decimal" scale="3" id="f-615">83,300</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="pets:OperatingLossCarryforwardsSubjectToLimitations" format="ixt:num-dot-decimal" scale="3" id="f-616">2,154</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2024 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - unlimited carryover</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="pets:OperatingLossCarryforwardsNotSubjectToLimitations" format="ixt:num-dot-decimal" scale="3" id="f-617">10,501</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="pets:OperatingLossCarryforwardsNotSubjectToLimitations" format="ixt:num-dot-decimal" scale="3" id="f-618">10,501</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disallowed business interest expense carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="pets:DisallowedBusinessInterestExpenseCarryover" format="ixt:num-dot-decimal" scale="3" id="f-619">1,855</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="pets:DisallowedBusinessInterestExpenseCarryover" format="ixt:num-dot-decimal" scale="3" id="f-620">1,855</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-621">11,040</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-622">2,066</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-623">8,974</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2026 </span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"/><td style="width:29.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Attribute as of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sec. 382 limited utilization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attributes for which a deferred tax asset is recorded</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - limited carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="pets:OperatingLossCarryforwardsSubjectToLimitations" format="ixt:num-dot-decimal" scale="3" id="f-624">84,114</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="pets:OperatingLossCarryforwardsSubjectToLimitations" format="ixt:num-dot-decimal" scale="3" id="f-625">83,300</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="pets:OperatingLossCarryforwardsSubjectToLimitations" scale="3" id="f-626">814</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2025 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - unlimited carryover</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="pets:OperatingLossCarryforwardsNotSubjectToLimitations" format="ixt:num-dot-decimal" scale="3" id="f-627">10,501</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="pets:OperatingLossCarryforwardsNotSubjectToLimitations" format="ixt:num-dot-decimal" scale="3" id="f-628">10,501</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disallowed business interest expense carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pets:DisallowedBusinessInterestExpenseCarryover" format="ixt:fixed-zero" scale="3" id="f-629">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="pets:DisallowedBusinessInterestExpenseCarryover" scale="3" id="f-630">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-631">11,040</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-632">2,066</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-633">8,974</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2026 </span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-634" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax provision consist of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:54.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-635">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-636">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-637">5,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-638">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-639">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-640">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax provision</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-641">898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-642">3,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-643">6,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax provision (benefit)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-644">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-645">453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-646">778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-647">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-648">1,176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-649">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-650">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-651">1,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-652">847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-653">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-654">2,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-655">5,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes (Continued)</span></div></div><ix:continuation id="f-576-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-656" continuedAt="f-656-1" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income tax provision computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:54.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes at federal statutory rates</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-657">1,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-658">1,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-659">5,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-660">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-661">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-662">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-663">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="3" id="f-664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="3" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-666">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-667">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-668">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock shortfall adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="f-669">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="f-670">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="f-671">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="3" id="f-672">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" format="ixt:fixed-zero" scale="3" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="f-676">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="f-677">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-678">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-679">2,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-680">5,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal 2024, the Company recognized non-deductible executive stock compensation of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-681">1.8</ix:nonFraction>&#160;million. This includes adjusting the deferred tax assets by a cumulative $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="pets:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-682">1.0</ix:nonFraction>&#160;million to account for future limitations under Sec. 162(m). This limits deductions for compensation of covered executives to $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="pets:EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount" format="ixt:num-dot-decimal" scale="6" id="f-683">1.0</ix:nonFraction>&#160;million per individual.  In fiscal 2023, the Company recognized a stock compensation shortfall charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="f-684">171</ix:nonFraction> thousand, and recognized a one-time charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-685">124</ix:nonFraction> thousand, related to a return to provision true up from the fiscal 2022 income tax provision. In fiscal 2022, the Company recognized a stock compensation shortfall charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="f-686">31</ix:nonFraction> thousand, and recognized a one-time benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-687">184</ix:nonFraction>&#160;thousand, related to a return to provision true up from the fiscal 2021 income tax provision.</span></div><ix:continuation id="f-656-1"><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the effective income tax rate and the statutory U.S. federal income tax rate are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:54.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal rate on income before taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-688">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-689">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-690">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-691">4.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-692">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-693">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-694">28.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="f-695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="f-696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="pets:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="f-697">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="pets:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="f-698">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="pets:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="f-699">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock shortfall adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-700">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-701">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-702">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" id="f-703">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="f-705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-707">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-708">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Effective Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-709">19.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-710">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-711">22.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax loss in fiscal 2024 caused unfavorable items to decrease the rate instead of increase it. The primary driver is related to the non-deductible executive compensation. The primary drivers for the increase in effective tax rate for the fiscal 2023 is due to the recognition of permanent differences related to one-time acquisition costs and a non-deductible portion of restricted stock compensation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-712" continuedAt="f-712-1" escape="true">Shareholders</ix:nonNumeric></span><ix:continuation id="f-712-1" continuedAt="f-712-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span></ix:continuation></div><ix:continuation id="f-712-2"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 1998, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-713">250,000</ix:nonFraction> shares of its $<ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-714">.001</ix:nonFraction> par value preferred stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-715">4.00</ix:nonFraction> per share, less issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-716">112</ix:nonFraction> thousand. Each share of the preferred stock is convertible into approximately <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="2" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="f-717">4.05</ix:nonFraction> shares of common stock at the election of the shareholder. The shares have a liquidation value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="f-718">4.00</ix:nonFraction> per share and may pay dividends at the sole discretion of the Company. The Company does not anticipate paying dividends to the preferred shareholders in the foreseeable future. Each share of preferred stock is entitled to one vote on all matters submitted to a vote of shareholders of the Company. At March&#160;31, 2024 and 2023, <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-719"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-720">2,500</ix:nonFraction></ix:nonFraction> shares of the convertible preferred stock remained unconverted and outstanding.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company&#8217;s financial performance. <ix:nonNumeric contextRef="c-1" name="us-gaap:DividendsDeclaredTableTextBlock" id="f-721" continuedAt="f-721-1" escape="true">During fiscal 2024, our Board of Directors declared the following dividends:</ix:nonNumeric></span></div><ix:continuation id="f-721-1"><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.272%"><tr><td style="width:1.0%"/><td style="width:20.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Dividend</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Record Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Amount<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 22, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-119" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="f-722">0.30</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 6, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-723">6,352</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="f-724">0.30</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 14, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-725">6,344</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 18, 2023</span></td></tr></table></div></ix:continuation></ix:continuation><div id="i6c215bb864894b15adb92ac1022d7659_106"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-726" continuedAt="f-726-1" escape="true">Restricted Stock</ix:nonNumeric></span></div><ix:continuation id="f-726-1" continuedAt="f-726-2"><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, the Company&#8217;s 2015 Outside Director Equity Compensation Restricted Stock Plan (&#8220;2015 Director Plan&#8221;) became effective upon the approval of the plan by the Company&#8217;s shareholders. The 2015 Director Plan authorized <ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-727">400,000</ix:nonFraction> shares of the Company's common stock available for issuance under the plan and provides for an automatic increase every year in the amount of shares available for issuance under the plan of <ix:nonFraction unitRef="number" contextRef="c-122" decimals="2" name="pets:PercentageOfAutomaticIncreaseInSharesAvailableForIssuance" scale="-2" id="f-728">10</ix:nonFraction>% of the shares authorized under the plan. In July 2016, the Company&#8217;s 2016 Employee Equity Compensation Restricted Stock Plan (&#8220;2016 Employee Plan&#8221;) became effective upon the approval of the plan by the Company&#8217;s shareholders. The 2016 Employee Plan authorized <ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-729">1,000,000</ix:nonFraction> shares of the Company's Common stock available for issuance under the plan. In July 2022, the Company&#8217;s 2022 Employee Equity Compensation Restricted Stock Plan (&#8220;2022 Employee Plan&#8221;) became effective upon the approval of the plan by the Company&#8217;s shareholders. The 2022 Employee Plan replaced the 2016 Employee Plan, and as of April 2023 no further awards were granted, or will be granted, under the 2016 Employee Plan. The 2022 Employee Plan authorized <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-730">1,000,000</ix:nonFraction> shares of the Company's common stock available for issuance.The value of the restricted stock is determined based on the market value of the stock at the issuance date. The restriction period or forfeiture period is determined by the Company&#8217;s Compensation and Human Capital Committee and is to be no less than <ix:nonNumeric contextRef="c-125" name="pets:RestrictionPeriod" format="ixt-sec:duryear" id="f-731">1</ix:nonNumeric> year and no more than <ix:nonNumeric contextRef="c-126" name="pets:RestrictionPeriod" format="ixt-sec:durwordsen" id="f-732">ten years</ix:nonNumeric> unless otherwise specified by the Compensation and Human Capital Committee.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (ASU 2016-09). At March&#160;31, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-733">957,260</ix:nonFraction> common shares issued under the 2016 Employee Plan, <ix:nonFraction unitRef="shares" contextRef="c-128" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-734">255,251</ix:nonFraction> common shares issued under the 2015 Director Plan and <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-735">149,488</ix:nonFraction> common shares issued under the 2022 Employee Plan. As of March 31, 2024, all shares in the 2022 Employee Plan, 2016 Employee Plan and 2015 Director Plan were issued subject to a restriction or forfeiture or vesting period that lapses ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over a <span style="-sec-ix-hidden:f-736">one</span> to <ix:nonNumeric contextRef="c-131" name="pets:RestrictionPeriod" format="ixt-sec:durwordsen" id="f-737">three-year</ix:nonNumeric> restriction period, with the exception of performance restricted shares which were issued to the Company's former Chief Executive Officer and the Company's Chief Financial Officer.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-738">90,000</ix:nonFraction> restricted shares and <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-739">510,000</ix:nonFraction> performance restricted shares to the Company&#8217;s former CEO, in accordance with the former CEO&#8217;s employment agreement, under the 2016 Employee Plan.  The performance restricted shares were based on achieving absolute stock hurdles within the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;Restricted Stock (Continued)</span></div></div><ix:continuation id="f-726-2" continuedAt="f-726-3"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-133" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" format="ixt-sec:durwordsen" id="f-740">three-year</ix:nonNumeric> period from the grant date. If the shares met the absolute stock price hurdle, they would have only been released from restrictions on the third anniversary of the date of grant. As of March&#160;31, 2024, none of the performance stock hurdles were met, and subsequent to March 31, 2024 the performance restricted shares were forfeited and cancelled as a result of the former CEO's cessation of employment with the Company.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-134" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-741">13,000</ix:nonFraction> restricted shares and <ix:nonFraction unitRef="shares" contextRef="c-135" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-742">3,000</ix:nonFraction> performance restricted shares to the Company's CFO, in accordance with the CFO's employment agreement, under the 2016 Employee Plan. One-third of the restricted shares will vest on each of the first three anniversaries of the date of grant, subject to the CFO&#8217;s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company.</span><span style="color:#000000;font-family:'Lato',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance restricted shares were based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue, and on June 8, 2023 the Company determined that the performance criteria was not attained over the applicable performance period and the performance restricted shares were forfeited. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company granted the Company's CFO <ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-743">11,750</ix:nonFraction> RSUs under the 2022 Employee Plan, of which <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-744">3,750</ix:nonFraction> RSUs were awarded in recognition of the CFO&#8217;s contributions during fiscal year 2023 and the remaining <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-745">8,000</ix:nonFraction> awarded as a part of the equity award cycle for fiscal year 2024. One-third of the RSUs will vest on each of the first <span style="-sec-ix-hidden:f-746">three</span> anniversaries of the date of grant, subject to the CFO&#8217;s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company.</span><span style="color:#000000;font-family:'Lato',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in June 2023, the CFO was awarded <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-747">8,000</ix:nonFraction> PSUs with a market condition.  The CFO will earn shares of our common stock pursuant to the PSUs based on the Company&#8217;s total shareholder return (&#8220;TSR&#8221;) relative to the S&amp;P 600 Specialty Retail Index (&#8220;Index&#8221;) over an overall <ix:nonNumeric contextRef="c-139" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-748">three-year</ix:nonNumeric> performance period consisting of the 2024 through 2026 fiscal years, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-749">100</ix:nonFraction>% of the target number of shares, which is <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-750">8,000</ix:nonFraction> shares, will be earned if the Company&#8217;s TSR is equal to or greater than the 75th percentile of the Index (the &#8220;maximum target payout&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt"><ix:nonFraction unitRef="number" contextRef="c-141" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-751">50</ix:nonFraction>% of the target number of shares, which is <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-752">4,000</ix:nonFraction> shares, will be earned if the Company&#8217;s TSR is equal to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">at least the 50th percentile of the Index; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt"><ix:nonFraction unitRef="number" contextRef="c-142" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-753">25</ix:nonFraction>% of the target number of shares, which is <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-754">2,000</ix:nonFraction> shares, will be earned if the Company&#8217;s TSR is equal to at least the 25th percentile of the Index (the &#8220;minimum threshold&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt"><ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt-sec:numwordsen" scale="-2" id="f-755">No</ix:nonFraction> shares will be earned if the TSR is less than the 25th percentile of the Index, and the payout is capped at <ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-756">2,000</ix:nonFraction> shares if absolute TSR is negative, regardless of relative position to the Index; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">Linear scaling will be used to determine the number of shares earned for performance between the maximum target payout level and the minimum threshold payout level. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> Subsequent to March 31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-757">3,917</ix:nonFraction> of the RSUs granted in June 2023 and all PSUs granted granted in June 2023 were forfeited and cancelled in connection with the CFO's Transition and Separation Agreement - see Note 16, Subsequent Events.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended March&#160;31, 2024, 2023, and 2022, the Company recognized compensation expense related to the 2016 and 2022 Employee Plan and the 2015 Director Plan of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-758">6.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-759">6.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-760">4.5</ix:nonFraction> million, respectively. All stock-based compensation expense is recognized as a payroll-related expense and it is included within the general and administrative expenses line item within the Company&#8217;s Consolidated Statements of (Loss) Income, and the offset is included in the additional paid-in capital line item of the Company&#8217;s Consolidated Balance Sheets.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;Restricted Stock (Continued)</span></div></div><ix:continuation id="f-726-3" continuedAt="f-726-4"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="f-761" escape="true"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2024, restricted stock award ("RSA") activity under the Plans was as follows:</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:40.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2016 Employee<br/>Plan<br/>Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Employee Plan Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Plans<br/>Number of<br/>Shares</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-762">684,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-763">68,629</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="f-764">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-765">752,829</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted and issued</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-766">12,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-767">1,623</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-768">89,742</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-769">103,765</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-770">76,343</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-771">29,418</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-772">8,332</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-773">114,093</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-774">14,914</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-775">17,127</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-776">7,334</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-777">39,375</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-778">605,343</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-779">23,707</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-780">74,076</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-153" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-781">703,126</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024 and 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-782">703,126</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-783">752,829</ix:nonFraction>, restricted shares subject to restriction and forfeiture outstanding, respectively. During the fiscal years ended March&#160;31, 2024 and 2023, the Company released from restrictions, net of forfeitures, <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-784">64,390</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-157" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-785">99,390</ix:nonFraction> restricted shares, respectively. The weighted-average grant date fair value of restricted shares was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-156" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-786">14.75</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-787">21.57</ix:nonFraction> for fiscal years 2024 and 2023, respectively.  The total fair value of restricted shares released from restrictions was $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-788">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-789">2.4</ix:nonFraction> million for fiscal years 2024 and 2023, respectively.  At March&#160;31, 2024 and 2023, there were $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-790">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-791">9.1</ix:nonFraction> million of unrecognized compensation costs related to the restricted stock subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of <ix:nonNumeric contextRef="c-156" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="f-792">7</ix:nonNumeric> months and <ix:nonNumeric contextRef="c-157" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-793">1.6</ix:nonNumeric> years for fiscal 2024 and 2023, respectively.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company first granted restricted stock units ("RSUs") in the year ended March 31, 2024. The fair value assigned to RSUs is the market price of the Company&#8217;s stock on the grant date.  The vesting period for employees and members of the Board of Directors ranges from <span style="-sec-ix-hidden:f-794">one</span> to <ix:nonNumeric contextRef="c-159" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-795">three years</ix:nonNumeric>.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended March 31, 2024, <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-796" continuedAt="f-796-1" escape="true">RSU activity under the Plans was as follows:</ix:nonNumeric></span></div><ix:continuation id="f-796-1"><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.272%"><tr><td style="width:1.0%"/><td style="width:54.236%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>&#160;Grant Date<br/>&#160;Fair Value Per RSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding at March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-160" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-797">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-798">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-799">88,880</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-800">12.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="0" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="f-801">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-802">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-161" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-803">3,800</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-804">13.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-805">85,080</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" scale="0" id="f-806">12.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total grant-date fair value of RSUs granted during the twelve months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="f-807">1.1</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-808">zero</ix:nonFraction>, respectively.  For the twelve months ended March&#160;31, 2024 and 2023, the Company recorded stock-based compensation related to RSUs of $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-809">0.3</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="c-163" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-810">zero</ix:nonFraction>, respectively. At March&#160;31, 2024 and 2023, there were $0.8 million and <ix:nonFraction unitRef="usd" contextRef="c-160" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt-sec:numwordsen" id="f-811">zero</ix:nonFraction> of unrecognized compensation costs related to RSUs subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 2.3 years and <ix:nonNumeric contextRef="c-163" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-812">0</ix:nonNumeric> years for fiscal 2024 and 2023, respectively.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Performance Stock Units </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;Restricted Stock (Continued)</span></div></div><ix:continuation id="f-726-4"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company first granted performance stock units ("PSUs") in the year ended March 31, 2024.  The fair value assigned to PSUs is determined using the market price of the Company&#8217;s stock on the grant date for awards with a performance condition, and by using a Monte Carlo simulation for awards with a market condition. Existing PSUs with a performance condition vest over <ix:nonNumeric contextRef="c-164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-813">one year</ix:nonNumeric>.  Existing PSUs with a market condition vest over <ix:nonNumeric contextRef="c-165" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-814">three years</ix:nonNumeric>. Stock-based compensation costs associated with PSUs with a performance condition are re-assessed each reporting period based upon the estimated performance attainment on the reporting date until the performance conditions are met. The ultimate number of shares of common stock that are issued to an employee is the result of the actual performance of the Company at the end of the performance period compared to the performance targets and generally ranges from <ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-815">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-816">200</ix:nonFraction>% of the initial PSU grant. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="f-817" escape="true"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended March 31, 2024, PSU activity under the Plans was as follows:</span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"><tr><td style="width:1.0%"/><td style="width:53.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 37pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>&#160;Grant Date<br/>&#160;Fair Value Per PSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested PSUs outstanding at March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-166" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-818">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-166" decimals="2" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-819">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-820">12,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-167" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-821">10.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="f-822">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-167" decimals="2" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-823">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-824">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-167" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-825">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment" format="ixt:fixed-zero" scale="0" id="f-826">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-167" decimals="2" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-827">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-828">12,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" scale="0" id="f-829">10.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The total grant-date fair value of PSUs granted during the twelve months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" format="ixt:num-dot-decimal" scale="3" id="f-830">126</ix:nonFraction> thousand and <ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-831">zero</ix:nonFraction>, respectively. For the twelve months ended March&#160;31, 2024 and 2023, the Company recorded stock-based compensation related to PSUs of $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-832">64</ix:nonFraction> thousand and <ix:nonFraction unitRef="usd" contextRef="c-169" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-833">zero</ix:nonFraction>, respectively. At March&#160;31, 2024 and 2023, there were $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-834">62</ix:nonFraction> thousand and <ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt-sec:numwordsen" id="f-835">zero</ix:nonFraction> of unrecognized compensation costs related to PSUs subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of <ix:nonNumeric contextRef="c-167" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-836">1.6</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-169" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-837">0</ix:nonNumeric> years for fiscal 2024 and 2023, respectively</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i6c215bb864894b15adb92ac1022d7659_109"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-839" continuedAt="f-839-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-839-1"><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries cash and cash equivalents and investments at fair value in the Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Fair Value Measurements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs which are supported by little or no market activity.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At March&#160;31, 2024 and 2023 the Company had invested the majority of its $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-840">55.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-841">104.1</ix:nonFraction> million cash and cash equivalents balance in money market funds which are classified within Level 1.</span></div></ix:continuation><div id="i6c215bb864894b15adb92ac1022d7659_112"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-842" continuedAt="f-842-1" escape="true">Net (Loss) Income Per Share</ix:nonNumeric></span></div><ix:continuation id="f-842-1" continuedAt="f-842-2"><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC Topic 260 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) basic net (loss) income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net (loss) income per common share includes the dilutive </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12)&#160;&#160;&#160;&#160;Net Income Per Share (Continued)</span></div></div><ix:continuation id="f-842-2"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock, and convertible preferred shares issued by the Company represent the only dilutive effect reflected in diluted weighted average shares outstanding.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-843" continuedAt="f-843-1" escape="true">The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for per share amounts):</ix:nonNumeric></span></div><ix:continuation id="f-843-1"><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:54.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income (numerator):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-844">7,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-845">5,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-846">18,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (denominator)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding used in basic computation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-847">20,395,959</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-848">20,274,786</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-849">20,175,930</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon the vesting of restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="f-850">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="f-851">54,091</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="f-852">171,765</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon conversion of preferred shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" format="ixt:fixed-zero" scale="0" id="f-853">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" format="ixt:num-dot-decimal" scale="0" id="f-854">10,125</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" format="ixt:num-dot-decimal" scale="0" id="f-855">10,125</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted computation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-856">20,395,959</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-857">20,339,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-858">20,357,820</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-859">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-860">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-861">0.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-862">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-863">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-864">0.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024, 2023, and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-865">827,863</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-866">745,854</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-867">220,727</ix:nonFraction> shares of common restricted stock, respectively, were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted (net loss)/net income per common share.</span></div></ix:continuation><div id="i6c215bb864894b15adb92ac1022d7659_115"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-868" continuedAt="f-868-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-868-1" continuedAt="f-868-2"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal Matters and Routine Proceedings</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled complaints that had been filed with various states&#8217; pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company also intends to vigorously defend its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred. From time to time, the Company may be involved in and subject to disputes and legal proceedings, as well as demands, claims and threatened litigation that arise in the ordinary course of its business. These proceedings may include allegations involving business practices, infringement of intellectual property, employment or other matters. The ultimate outcome of any legal proceeding is often uncertain, there can be no assurance that the Company will be successful in any legal proceeding, and unfavorable outcomes could have a negative impact on our results of operations and financial condition. In accordance with ASC Topic 450-20 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), the Company records a liability in its financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews the status of each significant matter each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the financial statements not misleading. If the loss is not probable and cannot be reasonably estimated, a liability is </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14)&#160;&#160;&#160;&#160;Commitments and Contingencies (Continued)</span></div></div><ix:continuation id="f-868-2" continuedAt="f-868-3"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not recorded in the Company&#8217;s financial statements. Gain contingencies are not recorded until they are realized. Legal costs related to any legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employment Agreements</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Board of Directors appointed Mathew N. Hulett ("Mr. Hulett&#8221;) as Chief Executive Officer and President of the Company and as a member of the Board of Directors. These appointments and the employment agreement were effective as of August 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The employment agreement was for an initial term of three (<ix:nonNumeric contextRef="c-170" name="pets:EmploymentTermInitialPeriod" format="ixt-sec:duryear" id="f-869">3</ix:nonNumeric>) years commencing on August 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and automatically renewed for successive one (<ix:nonNumeric contextRef="c-170" name="pets:EmploymentTermSuccessiveRenewalPeriod" format="ixt-sec:duryear" id="f-870">1</ix:nonNumeric>) year terms, or for longer periods as mutually agreed upon by the parties, unless the employment agreement was expressly cancelled by either Mr. Hulett or the Company sixty (<ix:nonNumeric contextRef="c-170" name="pets:EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm" format="ixt-sec:durday" id="f-871">60</ix:nonNumeric>) days prior to the end of the then current term, or was otherwise terminated as provided in the agreement. The employment agreement provided that Mr. Hulett received an annual base salary of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:OfficersCompensation" scale="3" id="f-872">500</ix:nonFraction> thousand, subject to periodic review for increases with the approval of the Board of Directors, and was be eligible to participate in the standard employee benefit plans generally available to executives and employees of the Company, including health insurance, life and disability insurance, restricted stock under the Company&#8217;s equity compensation plan(s), 401(k) plan, and paid time off and paid holidays. The employment agreement also provided that the Company will reimburse Mr. Hulett for his documented business expenses incurred in connection with his employment pursuant to the Company's standard reimbursement expense policy and practices. The employment agreement contained certain rights of Mr. Hulett and the Company to terminate Mr. Hulett&#8217;s employment, including termination by the Company for &#8220;Cause&#8221; as defined in the employment agreement, and termination by Mr. Hulett for &#8220;Good Reason&#8221; as defined in the employment agreement within twelve (<ix:nonNumeric contextRef="c-170" name="pets:TerminationPeriodPeriodWithinChangeInControl" format="ixt-sec:durmonth" id="f-873">12</ix:nonNumeric>) months of a Change in Control as defined in the employment agreement. Mr. Hulett was also entitled to severance pay equal to twelve (<ix:nonNumeric contextRef="c-170" name="pets:SeverancePaymentBaseSalaryPeriod" format="ixt-sec:durmonth" id="f-874">12</ix:nonNumeric>) months of Mr. Hulett&#8217;s current base salary and eighteen (<ix:nonNumeric contextRef="c-170" name="pets:SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod" format="ixt-sec:durmonth" id="f-875">18</ix:nonNumeric>) months of health insurance benefits in the event of his termination by the Company without Cause, or termination by Mr. Hulett for Good Reason within twelve (<ix:nonNumeric contextRef="c-170" name="pets:SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod" format="ixt-sec:durmonth" id="f-876">12</ix:nonNumeric>) months of a Change in Control. The foregoing severance benefits are conditioned upon Mr. Hulett&#8217;s execution of a release of claims and compliance with certain restrictive covenants. The employment agreement contains customary non-disclosure and non-solicitation provisions as well as a one (<ix:nonNumeric contextRef="c-170" name="pets:NonCompeteAgreementPeriod" format="ixt-sec:duryear" id="f-877">1</ix:nonNumeric>) year non-compete following the termination of the agreement. Subsequent to March 31, 2024 the employment agreement with Mr. Hulett was terminated (See Note 16 - Subsequent Events, for a description of the Transition and Separation Agreement with Mr. Hulett).</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;30, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Hulett also received an award of <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-878">90,000</ix:nonFraction> shares of restricted stock under the Company&#8217;s 2016 Employee Plan, which stock restrictions will lapse pro rata on each of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 30, 2022,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 30, 2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 30, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which are subject to forfeiture in the event of termination of employment (except as provided in the restricted stock agreement). Mr. Hulett also received an award of <ix:nonFraction unitRef="shares" contextRef="c-172" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-879">510,000</ix:nonFraction> shares of performance restricted stock under the 2016 Employee Plan, which stock restrictions will lapse on the third anniversary of the date of grant based on (i) achieving absolute stock price hurdles within the <ix:nonNumeric contextRef="c-172" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" format="ixt-sec:durwordsen" id="f-880">three-year</ix:nonNumeric> period from the date of grant, and (ii) continued employment through the performance period of <ix:nonNumeric contextRef="c-172" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" format="ixt-sec:durwordsen" id="f-881">three years</ix:nonNumeric> from the date of grant, in accordance with the following schedule: <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-882">85,000</ix:nonFraction> shares at the stock hurdle price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-174" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-883">40</ix:nonFraction> per share, <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-884">107,000</ix:nonFraction> shares at the stock hurdle price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-885">45</ix:nonFraction> per share, <ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-886">106,000</ix:nonFraction> shares at the stock hurdle price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-178" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-887">50</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-888">106,000</ix:nonFraction> shares at the stock hurdle price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-889">55</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-890">106,000</ix:nonFraction> shares at the stock hurdle price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-891">60</ix:nonFraction>.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should none of the absolute stock price hurdles be met during the <ix:nonNumeric contextRef="c-172" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" format="ixt-sec:durwordsen" id="f-892">three-year</ix:nonNumeric> period from the date of grant, no shares would vest (as defined in the performance restricted stock agreement). Once the absolute stock price hurdle is achieved, it will be considered to have met the absolute stock price hurdle, regardless of the stock price on the third anniversary of the date of grant. The absolute stock price hurdle would be considered to have been met if the average closing stock price of the Company is at or above the absolute stock price hurdle for a period of ninety (<ix:nonNumeric contextRef="c-172" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod" format="ixt-sec:durday" id="f-893">90</ix:nonNumeric>) consecutive trading days. If the shares would be considered to have met the absolute stock price hurdle, they will only vest on the third anniversary of date of grant, subject to Mr. Hulett&#8217;s continued employment through the performance period of <ix:nonNumeric contextRef="c-172" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" format="ixt-sec:durwordsen" id="f-894">three years</ix:nonNumeric> from the date of grant (except as provided in the performance restricted stock agreement). As of March&#160;31, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-895">none</ix:nonFraction> of the performance restricted stock vested, as no performance stock price hurdles were met.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;14, 2022, the Board of Directors appointed Christine Chambers ("Ms. Chambers") to serve as the Company&#8217;s Chief Financial Officer and to assume the duties of principal financial officer and principal accounting officer effective August&#160;3, 2022 (&#8220;Effective Date&#8221;). The Company entered into an offer letter with Ms. Chambers </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14)&#160;&#160;&#160;&#160;Commitments and Contingencies (Continued)</span></div></div><ix:continuation id="f-868-3" continuedAt="f-868-4"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to set the terms and conditions of Ms. Chambers&#8217; employment as Chief Financial Officer of the Company. Ms. Chambers will receive an annual base salary of $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:OfficersCompensation" scale="3" id="f-896">375</ix:nonFraction> thousand and received a one-time sign-on bonus in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="pets:SalaryAndWageOfficerSignOnBonus" scale="3" id="f-897">50</ix:nonFraction> thousand, subject to pro rata repayment if Ms. Chambers terminated employment with the Company within the first <ix:nonNumeric contextRef="c-184" name="pets:SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" format="ixt-sec:durwordsen" id="f-898">twelve months</ix:nonNumeric> of employment. Ms. Chambers received an initial equity award  under the 2016 Employee Plan consisting of (i) an award of <ix:nonFraction unitRef="shares" contextRef="c-185" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-899">13,000</ix:nonFraction> restricted shares, and (ii) <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-900">3,000</ix:nonFraction> performance restricted shares, which performance restricted shares will be based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue as of the fiscal year ended March&#160;31, 2024. The shares for each grant will be released from restriction equally over a three (<ix:nonNumeric contextRef="c-186" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-901">3</ix:nonNumeric>) year period on the anniversary of the grant date, subject to the attainment of performance criteria in the case of the performance restricted shares. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Mr. Rosenbloom&#8217;s transition services and subsequent separation from employment with the Company, on August&#160;2, 2022 the Company and Mr. Rosenbloom entered into a CFO Transition and Separation Agreement (the "Separation Agreement&#8221;) pursuant to which Mr. Rosenbloom remained in his current position as CFO of the Company through and including August&#160;2, 2022, and following the termination of his status as CFO, Mr. Rosenbloom continued to serve as an employee of the Company to provide transition services to the Company through his date of termination. His employment ended on December&#160;31, 2022 ("Separation Date&#8221;). While Mr. Rosenbloom served as an employee of the Company, he continued to receive his current base salary and benefits as was in effect. The Separation Agreement provided that Mr. Rosenbloom would be paid <ix:nonFraction unitRef="payment" contextRef="c-187" decimals="INF" name="pets:NumberOfSeverancePayments" format="ixt-sec:numwordsen" scale="0" id="f-902">two</ix:nonFraction> lump-sum severance payments of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="pets:LumpSumSeverancePayments" scale="3" id="f-903"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="pets:ContingentLumpSumSeverancePayment" scale="3" id="f-904">182</ix:nonFraction></ix:nonFraction> thousand each, with the first such payment to be paid on the Company&#8217;s next payroll date following the Separation Date, and was paid January 13, 2023, and the second paid on the Company&#8217;s next payroll date six-months following the Separation Date, subject to his compliance with the terms and conditions of his then existing employment agreement, and the Separation Agreement. In exchange for the Company&#8217;s agreement to make the severance payments, Mr. Rosenbloom granted the Company a full release of any and all claims that he may have against the Company and its affiliates and related parties.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a part of the Separation Agreement, the Company confirmed that the <ix:nonFraction unitRef="shares" contextRef="c-190" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-905">13,275</ix:nonFraction> restricted shares held by Mr. Rosenbloom under the 2016 Employee Plan were released from restriction and forfeiture on December&#160;31, 2022, Under the Separation Agreement, Mr. Rosenbloom&#8217;s existing non-compete obligation was reduced to a period of twelve (<ix:nonNumeric contextRef="c-189" name="pets:NonCompeteAgreementPeriod" format="ixt-sec:durmonth" id="f-906">12</ix:nonNumeric>) months.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-868-4">In connection with the separation of the Company's former Chief Financial Officer, the Company paid the remaining $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="pets:AccruedSeveranceCosts" scale="3" id="f-907">182</ix:nonFraction> thousand payment with respect to the severance, pursuant to the Separation Agreement in fiscal year 2024.</ix:continuation> </span></div><div><span><br/></span></div><div id="i6c215bb864894b15adb92ac1022d7659_118"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-908" continuedAt="f-908-1" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="f-908-1"><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) Savings Plan for eligible employees. The plan is a defined contribution plan that is administered by the Company. All regular, full-time employees are eligible for voluntary participation upon completing <ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" format="ixt-sec:durday" id="f-909">90</ix:nonNumeric> days of service and having attained the age of <ix:nonNumeric contextRef="c-1" name="pets:DefinedContributionPlanWithIndividualAge" format="ixt-sec:duryear" id="f-910">21</ix:nonNumeric>. The plan provides for growth in savings through contributions and income from investments. It is subject to the provisions of the Employee Retirement Income Security Act of 1974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as amended. Plan participants are allowed to contribute a specified percentage of their base salary. The Company matches <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-911">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-912">4</ix:nonFraction>% of the employee's contribution. The matching contribution is funded subsequent to the calendar year. During the fiscal years ended March&#160;31, 2024, 2023, and 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="3" id="f-913">350</ix:nonFraction> thousand, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="3" id="f-914">289</ix:nonFraction> thousand, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="3" id="f-915">238</ix:nonFraction> thousand, respectively, of 401(k) matching contribution and administration expense to general and administrative expenses.</span></div></ix:continuation><div id="i6c215bb864894b15adb92ac1022d7659_124"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(16)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-916" continuedAt="f-916-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-916-1" continuedAt="f-916-2"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Transition and Separation Agreement with Matthew Hulett</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2024, the Company and Mathew Hulett entered into a Transition and Separation Agreement pursuant to which Mr. Hulett resigned as President and Chief Executive Officer, and also as a director, of the Company effective April 29, 2024 (the &#8220;Hulett Agreement&#8221;). Under the terms of the Hulett Agreement, Mr. Hulett remained employed by the Company through May 10, 2024 to assist the Company in transition matters, and the Company will pay Mr. Hulett severance compensation thereafter in the form of the continuation of his base salary </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><ix:continuation id="f-916-2" continuedAt="f-916-3"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reimbursement of COBRA premiums through August 30, 2024, which was the scheduled expiration date of his employment agreement. The Hulett Agreement also provided that the Company cancelled the <ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" format="ixt:num-dot-decimal" scale="0" id="f-917">510,000</ix:nonFraction> performance restricted shares granted in August 2021, and accelerated the vesting of Mr. Hulett&#8217;s remaining unvested shares of restricted common stock (consisting of <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-918">30,000</ix:nonFraction> shares) previously granted under a Restricted Stock Agreement between the Company and Mr. Hulett which would have otherwise vested on August 30, 2024. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appointment of Sandra Campos as Chief Executive Officer</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2024, the Company appointed Sandra Campos, an existing director of the Company, as the Company&#8217;s new Chief Executive Officer and President. On the same date, the Company and Ms. Campos entered into an Executive Employment Agreement setting forth the terms under which Ms. Campos was employed by the Company as Chief Executive Officer and President (the &#8220;Employment Agreement&#8221;). Ms. Campos will continue to serve as a director of the Company for so long as she remains Chief Executive Officer and President.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Campos&#8217; Employment Agreement provides for an initial employment term of <ix:nonNumeric contextRef="c-194" name="pets:EmploymentAgreementEmploymentTerm" format="ixt-sec:duryear" id="f-919">3</ix:nonNumeric> years and for automatic renewal for successive <ix:nonNumeric contextRef="c-194" name="pets:EmploymentAgreementRenewalTerm" format="ixt-sec:durwordsen" id="f-920">1-year</ix:nonNumeric> terms thereafter unless either party provides notice of non renewal at least <ix:nonNumeric contextRef="c-194" name="pets:EmploymentAgreementNonRenewalNoticePeriod" format="ixt-sec:durday" id="f-921">60</ix:nonNumeric> days prior to the end of the then-current term. As provided in the Employment Agreement, Ms. Campos will serve the Company on a full-time basis and will receive an annual base salary of $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-4" name="pets:SalaryAndWageOfficerAnnualBaseSalary" format="ixt:num-dot-decimal" scale="0" id="f-922">550,000</ix:nonFraction>, which may be increased in the discretion of the board of directors (but may not be decreased other than as part of a proportionate reduction in management salaries and wages applicable to all senior management). Ms. Campos will receive a signing bonus of $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="pets:SalaryAndWageOfficerSignOnBonus" format="ixt:num-dot-decimal" scale="0" id="f-923">120,000</ix:nonFraction>, which is subject to repayment if Ms. Campos leaves the Company within <ix:nonNumeric contextRef="c-192" name="pets:SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" format="ixt-sec:durwordsen" id="f-924">one year</ix:nonNumeric> under circumstances detailed in the Employment Agreement. Ms. Campos will also receive customary expense reimbursement (in accordance with the Company&#8217;s standard policies), and will receive the medical, health, and other benefits provided to Company employees generally, including participation in the Company&#8217;s 401(k) plan on the same basis as other employees generally. The Employment Agreement provides that Ms. Campos will be eligible to receive an annual performance bonus based on annual performance goals determined by the Company&#8217;s board of directors, with a target annual bonus of <ix:nonFraction unitRef="number" contextRef="c-194" decimals="2" name="pets:SalaryAndWageTargetAnnualBonusPercentage" scale="-2" id="f-925">100</ix:nonFraction>% of Ms. Campos&#8217; base salary and a maximum bonus of <ix:nonFraction unitRef="number" contextRef="c-194" decimals="2" name="pets:SalaryAndWageMaximumBonusPercentage" scale="-2" id="f-926">200</ix:nonFraction>% of base salary. The agreement includes customary restrictive covenants, including confidentiality and non-solicitation covenants and a one-year post-employment non-compete restriction.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Employment Agreement, Ms. Campos will be entitled to equity grants under the Company&#8217;s current or future equity plan, as follows: On April 29, 2024, Ms. Campos received a grant of restricted stock units (&#8220;RSUs&#8221;) under the Company&#8217;s 2022 Employee Equity Compensation Plan for a number of RSUs equal to $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount" format="ixt:num-dot-decimal" scale="6" id="f-927">2.0</ix:nonFraction>&#160;million divided by the closing price of the Company&#8217;s common stock on the Nasdaq Stock Market on the date of grant. Such RSUs will vest in one-third increments on each of the first <ix:nonNumeric contextRef="c-193" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-928">3</ix:nonNumeric> anniversaries of the date of grant so long as Ms. Campos continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. Thereafter, Ms. Campos will be entitled to annual grants of RSUs and performance stock units (&#8220;PSUs&#8221;) having an aggregate value per grant of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-4" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" format="ixt:num-dot-decimal" scale="0" id="f-929">750,000</ix:nonFraction> for the annual RSU grant and $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-4" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" format="ixt:num-dot-decimal" scale="0" id="f-930">750,000</ix:nonFraction> for the annual PSU grant, with such value being calculated based on the closing price of the Company&#8217;s common stock on the date of grant but subject to a floor of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-194" decimals="2" name="pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare" scale="0" id="f-931">4.00</ix:nonFraction> per share. The RSUs included in any such annual grants will vest in the same manner as the initial RSU grant, and the PSUs will have a <ix:nonNumeric contextRef="c-198" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-932">3-year</ix:nonNumeric> performance period and such performance goals and other terms as shall be determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appointment of Justin L. Mennen as a Director</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2024, the Board of Directors (the &#8220;Board&#8221;) of PetMed Express, Inc. (the &#8220;Company&#8221;), appointed Justin L. Mennen to serve as a director of the Company beginning June 3, 2024. Mr. Mennen will hold this position until the 2024 annual meeting of the Company&#8217;s stockholders or until his successor is elected and qualified, subject to his earlier resignation or removal. Mr. Mennen has been appointed to serve on the Board&#8217;s Audit Committee and Corporate Governance and Nominating Committee. In connection with his appointment to the Board, Mr. Mennen will receive compensation in accordance with the Company&#8217;s Non-Employee Director Compensation Program.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><ix:continuation id="f-916-3"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Transition and Separation Agreement with Christine Chambers</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 31, 2024, PetMed Express, Inc. (the &#8220;Company&#8221;) entered into a Transition and Separation Agreement (the &#8220;Chambers Agreement&#8221;) with Christine Chambers, the Company&#8217;s Chief Financial Officer, Treasurer, and Secretary, pursuant to which the Company and Ms. Chambers agreed to the mutual termination of Ms. Chambers&#8217; employment with the Company following a transition period.  Under the terms of the Agreement, the Company and Ms. Chambers mutually agreed to terminate the Executive Employment Agreement, dated August 3, 2022, between the Company and Ms. Chambers effective immediately (notwithstanding the scheduled expiration date of August 3, 2024), provided that Ms. Chambers will continue to serve as the Company&#8217;s Chief Financial Officer, Secretary, and Treasurer on a full-time basis for a transition period (the &#8220;Transition Period&#8221;) that will end on the fifth business day after the Company files its Quarterly Report on Form 10-Q for the Company&#8217;s fiscal quarter ending June 30, 2024, or, if earlier, upon the fifteenth day after written notice by the Company of the earlier termination of the Transition Period. Ms. Chambers will work with and cooperate with the Company in transitioning her duties and responsibilities to such successor.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chambers Agreement provides that, during the Transition Period, Ms. Chambers will continue to receive her current base salary and benefits, and upon the completion of the Transition Period and contingent on Ms. Chambers&#8217; complying with the terms of the Chambers Agreement, the Company will accelerate the vesting of all unvested restricted shares and restricted stock units that were originally scheduled to vest on or before August 3, 2025. Ms. Chambers has agreed to a customary general release and waiver of claims against the Company in exchange for the Company&#8217;s covenants and agreements set forth in the Chambers Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_130"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF MANAGEMENT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is responsible for the preparation and integrity of the Consolidated Financial Statements appearing in our Annual Report on Form 10-K. The financial statements were prepared in conformity with generally accepted accounting principles appropriate in the circumstances and, accordingly, include certain amounts based on our best judgments and estimates. Financial information in the Annual Report on Form 10-K is consistent with that in the financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) under the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;). The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Consolidated Financial Statements. Our internal control over financial reporting is supported by a team of consultants and appropriate reviews by management, written policies and guidelines, careful selection and training of qualified personnel, and a written Corporate Code of Business Conduct and Ethics adopted by our Company&#8217;s Board of Directors, applicable to all Company Directors and all officers and employees of our Company and subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements and even when determined to be effective, can only provide reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee (&#8220;Committee&#8221;) of our Company&#8217;s Board of Directors, comprised solely of Directors who are independent in accordance with the requirements of The NASDAQ Stock Market LLC listing standards, the Exchange Act and the Company&#8217;s Corporate Governance Guidelines, meets with the independent auditors and management periodically to discuss internal control over financial reporting, and auditing and financial reporting matters. The Committee reviews with the independent auditors the scope and results of the audit effort. The Committee also meets periodically with the independent auditors without management present to ensure that the independent auditors have free access to the Committee.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of March&#160;31, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Integrated Framework - 2013. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment, management believes that the Company did not maintain effective internal control over financial reporting as of March&#160;31, 2024 due to the material weaknesses described below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As identified in the Form 10-K/A filed on April 15, 2024, we identified the following material weaknesses;</span></div><div style="margin-top:12pt;padding-left:13.5pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A lack of segregation of duties over the preparation, approval and posting of certain journal entries. As mentioned below, this material weakness has been remediated at March 31, 2024; and</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.    A material weakness in the design of our controls over the review of appropriate application of GAAP relating to our sales tax liability in our consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time the 10-K/A was filed, we also identified a material weakness in the design of our controls over accurate valuation of our deferred tax asset and goodwill relating to our acquisition of PetCareRx. In April 2023, this</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">material weakness resulted in the restatement of our unaudited condensed consolidated financial statements included in our</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quarterly Reports on Form 10-Q for the quarters ended June 30, 2023 and September 30, 2023, as well as an additional tax</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">error in the year ending March 31, 2024 relating the misapplication of Internal Revenue Code 162(m) which limits the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">deductibility of executive compensation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material weakness due to a lack of segregation of duties over the preparation, approval and posting of certain journal entries has been remediated and the material weaknesses in the design of our controls over accurate recording of our sales tax liability and our controls over accurate valuation of our deferred tax asset and goodwill relating to our acquisition of PetCareRx remain unremediated as of March 31, 2024. Management is taking steps to remediate these material weaknesses (see &#8220;Remediation of Material Weaknesses&#8221; below for details).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ending March 31, 2024, we identified a new material weakness in internal controls relating to our information technology general controls (&#8220;ITGCs&#8221;) in the areas of user access, change management and service organizations over information technology (&#8220;IT&#8221;) systems that support the Company&#8217;s financial reporting processes. This material weakness may impact revenue and other business process controls and automated controls reliant opinion these ITGCs. We believe that these control deficiencies were a result of lack of documentation created and retained to evidence management's procedures. The individual deficiencies identified to preventative and detective controls resulted in an aggregate material weakness related to ITGCs. This material weakness did not result in any identified misstatements to the financial statements or any change in previously released financial results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:21.6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remediation of Material Weaknesses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned above, we have remediated the material weakness relating to segregation of duties. In response to the material weakness due to a lack of segregation of duties over the preparation, approval and posting of certain journal entries, we have increased resources and modified processes to eliminate the lack of segregation of duties over the preparation, approval and posting of journal entries.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While not yet remediated, in response to the material weakness due to the tax calculations, we have developed and are in the process of implementing a remediation plan. The key elements of the plan include:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. Enhancing the oversight and review of tax-related accounting estimates and calculations to ensure they are complete and accurate,</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. Providing additional training to personnel involved in tax accounting and financial reporting to enhance their understanding of the relevant accounting standards and requirements, and</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. Enhancing the documentation of tax positions and related accounting judgments to ensure they are adequately supported and can withstand external scrutiny.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our remediation plan related to the material weakness in internal controls relating to our information technology general controls (&#8220;ITGCs&#8221;) may evolve and expand, management has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated such that these controls are designed, implemented, and operating effectively. The remediation actions include: (i) developing and maintaining documentation underlying ITGCs; (ii) implementing an IT management review, bringing in new management and revising the testing plan to monitor ITGCs with a specific focus on systems supporting our financial reporting processes; and  (iii) enhanced quarterly reporting on the remediation measures to the Audit Committee of the Board of Directors.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the material weakness around segregation of duties has been remediated, the other material weaknesses described herein will not be remediated until our remediation plan has been fully developed and implemented, the applicable controls operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are operating effectively. We are continuing to work on the implementation of our remediation plan, following which we will continue to test and monitor the new and enhanced controls until management has concluded that they are designed and operating effectively. We may conclude that additional measures, including resources, are necessary to remediate the material weaknesses in our internal control over financial reporting, which may necessitate additional evaluation and implementation time. We may also modify certain of the remediation efforts described above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s auditors, RSM US LLP, an independent registered public accounting firm, are appointed by the Audit Committee of the Company&#8217;s Board of Directors, subject to ratification by our Company&#8217;s shareholders. RSM US LLP have audited and reported on the Consolidated Financial Statements of PetMed Express, Inc. and subsidiaries, and issued a report on the Company&#8217;s internal control over financial reporting. The reports of the independent auditors are contained in our Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandra Y. Campos</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandra Y. Campos</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer,President, Director</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;14, 2024</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Christine Chambers</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christine Chambers</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer, Treasurer and Secretary</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;14, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_133"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Shareholders and the Board of Directors of PetMed Express, Inc. and subsidiaries</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Internal Control Over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited PetMed Express, Inc. and its subsidiaries&#8217; (the Company) internal control over financial reporting as of March 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013. In our opinion, because of the effect of the material weaknesses described below, the Company has not maintained effective internal control over financial reporting as of March 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements of the Company and our report dated June 13, 2024, expressed an unqualified opinion on those consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Management&#8217;s Report on Internal Control Over Financial Reporting, management has excluded PetCareRx, Inc. from its assessment of internal control over financial reporting as of March 31, 2024, because it was acquired by the Company in a purchase business combination in the first quarter of 2024. We have also excluded PetCareRX, Inc. from our audit of internal control over financial reporting. PetCareRx, Inc. is a wholly owned subsidiary whose total assets and net loss represent approximately 26% and 50%, respectively, of the related consolidated financial statement amounts as of and for the year ended March 31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weaknesses have been identified and included in management&#8217;s assessment:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">There were deficiencies in the design and implementation of information technology general controls (ITGCs) in the areas of user access, change management and service organizations that are relevant to preparation of the financial statements and impacts all business processes including revenue. As a result, IT-dependent manual and automated controls that rely on the affected ITGCs, or information from the IT systems with affected ITGCs, were also ineffective.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">The Company did not have appropriate design and operating effectiveness in controls over the review of income taxes and the valuation of goodwill.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">The Company&#8217;s prior-year material weakness relating to the review of appropriate application of generally accepted accounting principles for the Company&#8217;s sales tax liability remained unremediated as of March 31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These material weaknesses were considered in determining the nature, timing and extent of audit tests applied in our audit of the 2024 consolidated financial statements, and this report does not affect our report dated June 13, 2024, on those consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ RSM US LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fort Lauderdale, Florida</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 13, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_136"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_139"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a&#8209;15(e) and 15d-15(e) promulgated under the Exchange Act) as of March&#160;31, 2024, the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of the Evaluation Date, that our disclosure controls and procedures were not effective as of March 31, 2024, due to the material weaknesses in internal control over financial reporting described below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s Report on Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of March&#160;31, 2024 based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Integrated Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Integrated Framework, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management concluded that our internal control over financial reporting was not effective, as of March&#160;31, 2024, as a result of the material weaknesses described below.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material Weaknesses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As identified in the Form 10-K/A filed on April 15, 2024, we identified the following material weaknesses;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A lack of segregation of duties over the preparation, approval and posting of certain journal entries. As mentioned below, this material weakness has been remediated at March 31, 2024; and</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.    A material weakness in the design of our controls over the review of appropriate application of GAAP relating to our sales tax liability in our consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time the 10-K/A was filed, we also identified a material weakness in the design of our controls over accurate valuation of our deferred tax asset and goodwill relating to our acquisition of PetCareRx. In April 2023, this</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">material weakness resulted in the restatement of our unaudited condensed consolidated financial statements included in our</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quarterly Reports on Form 10-Q for the quarters ended June 30, 2023 and September 30, 2023, as well as an additional tax</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">error in the year ending March 31, 2024 relating the misapplication of Internal Revenue Code 162(m) which limits the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">deductibility of executive compensation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material weakness due to a lack of segregation of duties over the preparation, approval and posting of certain journal entries has been remediated and the material weaknesses in the design of our controls over accurate recording of our sales tax liability and our controls over accurate valuation of our deferred tax asset and goodwill relating to our acquisition of PetCareRx remain unremediated as of March 31, 2024. Management is taking steps to remediate these material weaknesses (see &#8220;Remediation of Material Weaknesses&#8221; below for details).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ending March 31, 2024, we identified a new material weakness in internal controls relating to our information technology general controls (&#8220;ITGCs&#8221;) in the areas of user access, change management and service organizations over information technology (&#8220;IT&#8221;) systems that support the Company&#8217;s financial reporting processes. This material weakness may impact revenue and other business process controls and automated controls reliant opinion these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ITGCs. We believe that these control deficiencies were a result of lack of documentation created and retained to evidence management's procedures. The individual deficiencies identified to preventative and detective controls resulted in an aggregate material weakness related to ITGCs. This material weakness did not result in any identified misstatements to the financial statements or any change in previously released financial results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:21.6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remediation of Material Weaknesses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned above, we have remediated the material weakness relating to segregation of duties. In response to the material weakness due to a lack of segregation of duties over the preparation, approval and posting of certain journal entries, we have increased resources and modified processes to eliminate the lack of segregation of duties over the preparation, approval and posting of journal entries.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While not yet remediated, in response to the material weakness due to the tax calculations, we have developed and are in the process of implementing a remediation plan. The key elements of the plan include:</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. Enhancing the oversight and review of tax-related accounting estimates and calculations to ensure they are complete and accurate,</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. Providing additional training to personnel involved in tax accounting and financial reporting to enhance their understanding of the relevant accounting standards and requirements, and</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. Enhancing the documentation of tax positions and related accounting judgments to ensure they are adequately supported and can withstand external scrutiny.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our remediation plan related to the material weakness in internal controls relating to our information technology general controls (&#8220;ITGCs&#8221;) may evolve and expand, management has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated such that these controls are designed, implemented, and operating effectively. The remediation actions include: (i) developing and maintaining documentation underlying ITGCs; (ii) implementing an IT management review, bringing in new management and revising the testing plan to monitor ITGCs with a specific focus on systems supporting our financial reporting processes; and  (iii) enhanced quarterly reporting on the remediation measures to the Audit Committee of the Board of Directors.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the material weakness around segregation of duties has been remediated, the other material weaknesses described herein will not be remediated until our remediation plan has been fully developed and implemented, the applicable controls operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are operating effectively. We are continuing to work on the implementation of our remediation plan, following which we will continue to test and monitor the new and enhanced controls until management has concluded that they are designed and operating effectively. We may conclude that additional measures, including resources, are necessary to remediate the material weaknesses in our internal control over financial reporting, which may necessitate additional evaluation and implementation time. We may also modify certain of the remediation efforts described above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described above, there were no changes in our internal control over financial reporting during the fourth quarter ended March&#160;31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design and disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgement in evaluating the benefits of possible controls and procedures relative to the their cost.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_142"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. OTHER INFORMATION</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Trading Arrangements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fourth quarter ended March 31, 2024, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of the Company <ix:nonNumeric contextRef="c-202" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-937"><ix:nonNumeric contextRef="c-202" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-938">adopted</ix:nonNumeric></ix:nonNumeric>, modified, or <ix:nonNumeric contextRef="c-202" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-939"><ix:nonNumeric contextRef="c-202" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-940">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_145"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_148"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i6c215bb864894b15adb92ac1022d7659_151"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our proxy statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March&#160;31, 2024, relating to our 2024 Annual Meeting of Shareholders to be held on August&#160;8, 2024, and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Corporate Code of Business Conduct and Ethics ("Code") applicable to all officers, directors, and employees. The Code is available on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.petmeds.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under &#8220;Investors - Governance&#8221;. You may also obtain a copy of our Code free of charge by contacting Investor Relations at 1-800-738-6337. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of this Code by posting such information on the website address and location specified above.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_154"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our proxy statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March&#160;31, 2024, relating to our 2024 Annual Meeting of Shareholders to be held on August&#160;8, 2024, and is incorporated herein by reference.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_157"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item (other than information required by Item 201(d) of Regulation S-K with respect to equity compensation plans, which is set forth under Item 5 in this Annual Report on Form 10-K) will be set forth in our proxy statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March&#160;31, 2024, relating to our 2024 Annual Meeting of Shareholders to be held on August&#160;8, 2024, and is incorporated herein by reference.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_160"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our proxy statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March&#160;31, 2024, relating to our 2024 Annual Meeting of Shareholders to be held on August&#160;8, 2024, and is incorporated herein by reference.</span></div><div id="i6c215bb864894b15adb92ac1022d7659_163"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our proxy statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March&#160;31, 2024, relating to our 2024 Annual Meeting of Shareholders to be held on August&#160;8, 2024, and is incorporated herein by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_166"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i6c215bb864894b15adb92ac1022d7659_169"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">The following documents are filed as part of this Annual Report on Form</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10-K.</span></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Consolidated Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> See the Index to Consolidated Financial Statements in Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The following exhibits are filed as part of this Annual Report on Form 10-K or hereby incorporated by reference to exhibits previously filed with the SEC.</span></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Articles of Incorporation and By-Laws</span></div><div style="margin-top:12pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:6.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104291000000023/0001042910-00-000023.txt">Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form 10-SB, File No. 000-28827, filed January 10, 2000).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000157104915004580/t82385_ex3-2.htm">Articles of Amendment to the Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.2 to our Form 10-K for the year ended March 31, 2015, filed May 22, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774920006219/ex_179066.htm">Second Amended and Restated By-Laws of PetMed Express, Inc. (incorporated by reference to Exhibit 3.1 to our Form 8-K, filed March 26, 2020).</a></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Instruments Defining the Rights of Security Holders</span></div><div style="margin-top:12pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:6.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104291000000023/0001042910-00-000023.txt">Specimen common stock certificate (incorporated by reference to Exhibit 4.2 to our Registration Statement on Form 10-SB, File No. 000-28827, filed January 10, 2000).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pets-20240331xexx42.htm">Description of Securities.*</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="-sec-extract:summary;margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.34pt">Material Contracts</span></div><div style="margin-top:12pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:6.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000157104916015952/t1600385_def14a.htm">2016 Employee Equity Compensation Restricted Stock Plan, including form of Restricted Stock Agreement used for grants of restricted stock (incorporated by reference to Exhibit A to our definitive Proxy Statement for our 2016 Annual Meeting of Shareholders filed June 13, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2 +</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774919014942/ex_151991.htm">Form of Indemnification Agreement entered into with the Directors and Executive Officers of the Company (incorporated by reference to Exhibit 10.1 to our Form 10-Q for the quarter ended June 30, 2019, filed July 30, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3 +</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/ex_279895.htm">Executive Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/ex_279895.htm">,</a><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/ex_279895.htm"> </a><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/ex_279895.htm">dated August 25, 2021</a><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/ex_279895.htm">,</a><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/ex_279895.htm"> </a><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/ex_279895.htm">between the Company and</a><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/ex_279895.htm"> Mathew N. Hulett (incorporated by reference to Exhibit 10.1 to our Form 8-K filed August 30, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000143774922018636/ex_405957.htm">Executive Employment Agreement, dated August 3, 2022, between the Company and Christine Chambers (incorporated by reference to Exhibit 10.1 to our Form 8-K filed August 3, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.8+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex101.htm">2022 Employee Equity Compensation Plan (as amended and restated)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex101.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex101.htm">incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex101.htm"> 10.1 to our Form 8-K filed June 20, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.8.1+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k061523-ex103.htm">Form of Restricted Stock Unit Agreement under 2022 Employee Equity Compensation Plan (incorporated by reference to Exhibit 10.3 to our Form 8-K filed June 20, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.8.2+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k061523-ex104.htm">Form of Performance Stock Unit Agreement under 2022 Employee Equity Compensation Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k061523-ex104.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k061523-ex104.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k061523-ex104.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k061523-ex104.htm"> to our Form 8-K filed June 20, 2023)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k061523-ex104.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex105.htm">2015 Outside Director Equity Compensation Plan (as amended and restated)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex105.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex105.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex105.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex105.htm"> to our Form 8-K filed June 20, 2023)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex105.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9.1+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex107.htm">Form of Restricted Stock Unit Agreement under 2015 Outside Director Equity Compensation Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex107.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex107.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex107.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex107.htm"> to our Form 8-K filed June 20, 2023)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013023000040/a8k06152023-ex107.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9.2+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000157104917005258/t1700341_ex10-10z1.htm">Form of Restricted Stock Agreement </a><a style="-sec-extract:exhibit;color:#0000f1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000157104917005258/t1700341_ex10-10z1.htm">under the 2015 Outside Director Equity Compensation Plan (incorporated by reference to Exhibit 10.10.1 to our Form 10-K for the year ended March 31, 2017 filed May 23, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9.3+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm">Transition and Separation </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm">Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm">dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm"> April 29, 2024, between the Company and Mathew Hulett</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm">(inc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm">orporated by reference to Exhibit 10.1 to our Form 8-K filed on April 29, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm">2024)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx101.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9.4+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx102.htm">Executive Employment Agreement, dated April 29, 2024, between the Company and Sandra Campos</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx102.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx102.htm">(incorporated by reference to Exhibit 10.2 to our Form 8-K filed on April 29,2024</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/pets-20240429xexx102.htm">).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9.5+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1040130/000104013024000032/pets-20240531xexx101.htm">Transition and Separation Agreement, dated May 31, 2024, between the Company and Christine Chambers.</a></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19) &#160;&#160;&#160;&#160;Insider trading policies and procedures</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19.1&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-941"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pets-20240331xexx191.htm">Statement of Policy Regarding Insider Trading</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">*</span></ix:nonNumeric><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> </span></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.34pt">Subsidiaries of Registrant</span></div><div style="margin-top:12pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:6.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pets-20240331xexx211.htm">Subsidiaries of Registrant*</a></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(23)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.34pt">Consents of Experts and Counsel</span></div><div style="margin-top:12pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:6.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pets-20240331xexx231.htm">Consent of RSM US LLP*</a></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(31)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.34pt">Certifications</span></div><div style="margin-top:12pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:6.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pets-20240331xexx311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a)*</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pets-20240331xexx312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)*</a></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(32)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.34pt">Certifications</span></div><div style="margin-top:12pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:6.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pets-20240331xexx321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 1350**</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="-sec-extract:summary;margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(97)&#160;&#160;&#160;&#160;Policy Relating to Recovery of Erroneously Awarded Compensation</span></div><div><span><br/></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">97.1&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="pets-20240331xexx971.htm">Executive Compensation Recovery Policy</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">* </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition LInkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Filed herewith</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Furnished herewith</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ Indicates a management contract or compensatory plan or arrangement</span></div><div id="i6c215bb864894b15adb92ac1022d7659_172"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">K SUMMARY</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><div id="i6c215bb864894b15adb92ac1022d7659_175"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6c215bb864894b15adb92ac1022d7659_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: June&#160;14, 2024</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PETMED EXPRESS, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(the &#8220;registrant&#8221;)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By: </span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sandra Y. Campos</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Y. Campos</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on June&#160;14, 2024.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TITLE</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sandra Y. Campos</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and Director<br/>(principal executive officer)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Y. Campos</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christine Chambers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer<br/>(principal financial and accounting officer)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine Chambers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leslie C.G. Campbell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board and Director</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leslie C.G. Campbell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gian M. Fulgoni</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gian M. Fulgoni</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Diana Garvis Purcel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diana Garvis Purcel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Justin Mennen</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Justin Mennen</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>pets-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b431201b-f537-4396-8d13-986e96a3bf3a,g:5ff869d6-f8b6-477d-8b92-37fe9911b79a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pets="http://www.1800petmeds.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.1800petmeds.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pets-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pets-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pets-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pets-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.1800petmeds.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.1800petmeds.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.1800petmeds.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinShareholdersEquity" roleURI="http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestatementofPreviouslyIssuedFinancialStatements" roleURI="http://www.1800petmeds.com/role/RestatementofPreviouslyIssuedFinancialStatements">
        <link:definition>0000008 - Disclosure - Restatement of Previously Issued Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.1800petmeds.com/role/RevenueRecognition">
        <link:definition>0000010 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisition" roleURI="http://www.1800petmeds.com/role/Acquisition">
        <link:definition>0000011 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.1800petmeds.com/role/PropertyandEquipmentNet">
        <link:definition>0000012 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000013 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleandOtherAssetsNet" roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet">
        <link:definition>0000014 - Disclosure - Intangible and Other Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.1800petmeds.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.1800petmeds.com/role/IncomeTaxes">
        <link:definition>0000016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.1800petmeds.com/role/ShareholdersEquity">
        <link:definition>0000017 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedStock" roleURI="http://www.1800petmeds.com/role/RestrictedStock">
        <link:definition>0000018 - Disclosure - Restricted Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.1800petmeds.com/role/FairValueMeasurements">
        <link:definition>0000019 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShare" roleURI="http://www.1800petmeds.com/role/NetLossIncomePerShare">
        <link:definition>0000020 - Disclosure - Net (Loss) Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.1800petmeds.com/role/CommitmentsandContingencies">
        <link:definition>0000021 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.1800petmeds.com/role/EmployeeBenefitPlan">
        <link:definition>0000022 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.1800petmeds.com/role/SubsequentEvents">
        <link:definition>0000023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.1800petmeds.com/role/RevenueRecognitionTables">
        <link:definition>9954472 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionTables" roleURI="http://www.1800petmeds.com/role/AcquisitionTables">
        <link:definition>9954473 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.1800petmeds.com/role/PropertyandEquipmentNetTables">
        <link:definition>9954474 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9954475 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleandOtherAssetsNetTables" roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables">
        <link:definition>9954476 - Disclosure - Intangible and Other Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.1800petmeds.com/role/LeasesTables">
        <link:definition>9954477 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.1800petmeds.com/role/IncomeTaxesTables">
        <link:definition>9954478 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.1800petmeds.com/role/ShareholdersEquityTables">
        <link:definition>9954479 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedStockTables" roleURI="http://www.1800petmeds.com/role/RestrictedStockTables">
        <link:definition>9954480 - Disclosure - Restricted Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlLossIncomePerShareTables" roleURI="http://www.1800petmeds.com/role/NetlLossIncomePerShareTables">
        <link:definition>9954481 - Disclosure - Net (lLoss) Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>9954483 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails" roleURI="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails">
        <link:definition>9954484 - Disclosure - Revenue Recognition - Schedule of Rollforward of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofDisaggregationofRevenueDetails" roleURI="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails">
        <link:definition>9954485 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionNarrativeDetails" roleURI="http://www.1800petmeds.com/role/AcquisitionNarrativeDetails">
        <link:definition>9954486 - Disclosure - Acquisition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails" roleURI="http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails">
        <link:definition>9954487 - Disclosure - Acquisition - Schedule of Acquired Identifiable Assets, Liabilities Assumed and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionScheduleofProFormaInformationDetails" roleURI="http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails">
        <link:definition>9954488 - Disclosure - Acquisition - Schedule of Pro-Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails">
        <link:definition>9954489 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9954490 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleandOtherAssetsNetScheduleDetails" roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails">
        <link:definition>9954491 - Disclosure - Intangible and Other Assets, Net - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleandOtherAssetsNetScheduleDetails_1" roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails_1">
        <link:definition>9954491 - Disclosure - Intangible and Other Assets, Net - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleandOtherAssetsNetExpectedAmortizationDetails" roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails">
        <link:definition>9954492 - Disclosure - Intangible and Other Assets, Net - Expected Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleandOtherAssetsNetNarrativeDetails" roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails">
        <link:definition>9954493 - Disclosure - Intangible and Other Assets, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.1800petmeds.com/role/LeasesNarrativeDetails">
        <link:definition>9954494 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseCostsandActivityDetails" roleURI="http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails">
        <link:definition>9954495 - Disclosure - Leases - Schedule of Lease Costs and Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturityofLeaseLiabilitiesDetails" roleURI="http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails">
        <link:definition>9954496 - Disclosure - Leases - Schedule of Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>9954496 - Disclosure - Leases - Schedule of Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredIncomeTaxesDetails" roleURI="http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails">
        <link:definition>9954497 - Disclosure - Income Taxes - Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954498 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxAttributesDetails" roleURI="http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails">
        <link:definition>9954499 - Disclosure - Income Taxes - Tax Attributes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxProvisionDetails" roleURI="http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails">
        <link:definition>9954500 - Disclosure - Income Taxes - Components of Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxProvisionDetails" roleURI="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails">
        <link:definition>9954501 - Disclosure - Income Taxes - Reconciliation of Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails" roleURI="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails">
        <link:definition>9954502 - Disclosure - Income Taxes - Reconciliation of Total Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>9954503 - Disclosure - Shareholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDeclaredDividendsDetails" roleURI="http://www.1800petmeds.com/role/ShareholdersEquityDeclaredDividendsDetails">
        <link:definition>9954504 - Disclosure - Shareholder's Equity - Declared Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedStockNarrativeDetails" roleURI="http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails">
        <link:definition>9954505 - Disclosure - Restricted Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedStockNonvestedRestrictedStockDetails" roleURI="http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails">
        <link:definition>9954506 - Disclosure - Restricted Stock - Non-vested Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedStockRollforwardofRSUandPSUActivityDetails" roleURI="http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails">
        <link:definition>9954507 - Disclosure - Restricted Stock - Rollforward of RSU and PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.1800petmeds.com/role/FairValueMeasurementsDetails">
        <link:definition>9954508 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails">
        <link:definition>9954509 - Disclosure - Net (Loss) Income Per Share - Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlossIncomePerShareNarrativeDetails" roleURI="http://www.1800petmeds.com/role/NetlossIncomePerShareNarrativeDetails">
        <link:definition>9954510 - Disclosure - Net (loss) Income Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954511 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails">
        <link:definition>9954512 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.1800petmeds.com/role/SubsequentEventsDetails">
        <link:definition>9954513 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod" abstract="false" name="SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_IntangiblesAndOtherAssetsAccumulatedAmortization" abstract="false" name="IntangiblesAndOtherAssetsAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_DeferredTaxLiabilitiesChangeInAccountingMethod" abstract="false" name="DeferredTaxLiabilitiesChangeInAccountingMethod" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_OtherAssetsPolicyTextBlock" abstract="false" name="OtherAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pets_FiscalYear2023Member" abstract="true" name="FiscalYear2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_IntangibleAndOtherAssets" abstract="false" name="IntangibleAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pets_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pets_NewOrderMember" abstract="true" name="NewOrderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_SalaryAndWageOfficerAnnualBaseSalary" abstract="false" name="SalaryAndWageOfficerAnnualBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" abstract="false" name="DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_SalaryAndWageMaximumBonusPercentage" abstract="false" name="SalaryAndWageMaximumBonusPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pets_PercentageOfPropertyLeasedToTenants" abstract="false" name="PercentageOfPropertyLeasedToTenants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pets_IntangiblesAndOtherAssetsAbstract" abstract="true" name="IntangiblesAndOtherAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pets_DelrayBeachPropertyMember" abstract="true" name="DelrayBeachPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_AccruedCreditCardFeesCurrent" abstract="false" name="AccruedCreditCardFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_PerformanceRestrictedStockPriceHurdle1Member" abstract="true" name="PerformanceRestrictedStockPriceHurdle1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_FiscalYear2024Member" abstract="true" name="FiscalYear2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_EmploymentAgreementRenewalTerm" abstract="false" name="EmploymentAgreementRenewalTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pets_DisallowedBusinessInterestExpenseCarryover" abstract="false" name="DisallowedBusinessInterestExpenseCarryover" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_AccruedMerchandiseCreditsAndRewardsCurrent" abstract="false" name="AccruedMerchandiseCreditsAndRewardsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_SEC382LimitedUtilizationMember" abstract="true" name="SEC382LimitedUtilizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_EmploymentAgreementEmploymentTerm" abstract="false" name="EmploymentAgreementEmploymentTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_PerformanceRestrictedStockPriceHurdle5Member" abstract="true" name="PerformanceRestrictedStockPriceHurdle5Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_RevenueFromContractWithCustomerPercentage" abstract="false" name="RevenueFromContractWithCustomerPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pets_ContractWithCustomerLiabilityCurrentRollForward" abstract="true" name="ContractWithCustomerLiabilityCurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_PartnerProgramMember" abstract="true" name="PartnerProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_RevenueFromContractWithCustomerNumberOfSalesCategories" abstract="false" name="RevenueFromContractWithCustomerNumberOfSalesCategories" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pets_MembershipFeesMember" abstract="true" name="MembershipFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_VetsterIncMember" abstract="true" name="VetsterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember" abstract="true" name="The2022EmployeeEquityCompensationRestrictedStockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance" abstract="false" name="PercentageOfAutomaticIncreaseInSharesAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pets_TerminationPeriodPeriodWithinChangeInControl" abstract="false" name="TerminationPeriodPeriodWithinChangeInControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_DeferredTaxAssetIsRecordedMember" abstract="true" name="DeferredTaxAssetIsRecordedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_MembershipCustomersMember" abstract="true" name="MembershipCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm" abstract="false" name="LessorOperatingLeaseRemainingWeightedAverageLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_ContractWithCustomerRenewalPeriod" abstract="false" name="ContractWithCustomerRenewalPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_DefinedContributionPlanWithIndividualAge" abstract="false" name="DefinedContributionPlanWithIndividualAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_NonCompeteAgreementPeriod" abstract="false" name="NonCompeteAgreementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_SixSuppliersMember" abstract="true" name="SixSuppliersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_PerformanceRestrictedStockMember" abstract="true" name="PerformanceRestrictedStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_NumberOfSeverancePayments" abstract="false" name="NumberOfSeverancePayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pets_SeverancePaymentBaseSalaryPeriod" abstract="false" name="SeverancePaymentBaseSalaryPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_OperatingLossCarryforwardAxis" abstract="true" name="OperatingLossCarryforwardAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pets_RevenueFromContractWithCustomerVariancePercentage" abstract="false" name="RevenueFromContractWithCustomerVariancePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pets_SevenSuppliersMember" abstract="true" name="SevenSuppliersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_RevenueFromContractWithCustomerVariance" abstract="false" name="RevenueFromContractWithCustomerVariance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_NumberOfTenants" abstract="false" name="NumberOfTenants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_OperatingLossCarryforwardDomain" abstract="true" name="OperatingLossCarryforwardDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_ContingentLumpSumSeverancePayment" abstract="false" name="ContingentLumpSumSeverancePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations" abstract="false" name="RevenueFromContractWithCustomerNumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pets_RevenueFromContractWithCustomerNumberOfMembershipModels" abstract="false" name="RevenueFromContractWithCustomerNumberOfMembershipModels" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pets_EmploymentTermSuccessiveRenewalPeriod" abstract="false" name="EmploymentTermSuccessiveRenewalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" abstract="false" name="IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_A2022EmployeePlanMember" abstract="true" name="A2022EmployeePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_ShareBasedPaymentArrangementTrancheFourMember" abstract="true" name="ShareBasedPaymentArrangementTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod" abstract="false" name="SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_IntangibleAndOtherAssetsGross" abstract="false" name="IntangibleAndOtherAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_MeasurementInputWeightedAverageCostOfCapitalMember" abstract="true" name="MeasurementInputWeightedAverageCostOfCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_LumpSumSeverancePayments" abstract="false" name="LumpSumSeverancePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_PetCareRxIncMember" abstract="true" name="PetCareRxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_ContractWithCustomerRevenueRecognitionPeriod" abstract="false" name="ContractWithCustomerRevenueRecognitionPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_TollFreeTelephoneNumberMember" abstract="true" name="TollFreeTelephoneNumberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_SalaryAndWageOfficerSignOnBonus" abstract="false" name="SalaryAndWageOfficerSignOnBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_TermOfAgreement" abstract="false" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_FurnitureFixturesEquipmentAndComputerSoftwareMember" abstract="true" name="FurnitureFixturesEquipmentAndComputerSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pets_PerformanceRestrictedStockPriceHurdle2Member" abstract="true" name="PerformanceRestrictedStockPriceHurdle2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_EmploymentAgreementNonRenewalNoticePeriod" abstract="false" name="EmploymentAgreementNonRenewalNoticePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_EmployeeAndDirectorEquityCompensationPlanMember" abstract="true" name="EmployeeAndDirectorEquityCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" abstract="false" name="SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm" abstract="false" name="EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pets_PerformanceRestrictedStockPriceHurdle3Member" abstract="true" name="PerformanceRestrictedStockPriceHurdle3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_ReorderMember" abstract="true" name="ReorderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_ReportingUnitMeasurementInput" abstract="false" name="ReportingUnitMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="pets_AccruedSeveranceCosts" abstract="false" name="AccruedSeveranceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_RestrictionPeriod" abstract="false" name="RestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_AccruedSalesReturnsAndAllowancesCurrent" abstract="false" name="AccruedSalesReturnsAndAllowancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_SalaryAndWageTargetAnnualBonusPercentage" abstract="false" name="SalaryAndWageTargetAnnualBonusPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_NonvestedRestrictedStockMember" abstract="true" name="NonvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_OperatingLossCarryforwardsSubjectToLimitations" abstract="false" name="OperatingLossCarryforwardsSubjectToLimitations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived" abstract="false" name="ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_EmploymentTermInitialPeriod" abstract="false" name="EmploymentTermInitialPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pets_PerformanceRestrictedStockPriceHurdle4Member" abstract="true" name="PerformanceRestrictedStockPriceHurdle4Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_OperatingLossCarryforwardsNotSubjectToLimitations" abstract="false" name="OperatingLossCarryforwardsNotSubjectToLimitations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember" abstract="true" name="TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember" abstract="true" name="The2016EmployeeEquityCompensationRestrictedStockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>pets-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b431201b-f537-4396-8d13-986e96a3bf3a,g:5ff869d6-f8b6-477d-8b92-37fe9911b79a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pets-20240331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a9bf9d7f-1c0f-48e1-969f-d567a2afd84d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ce16b3e-4adf-4594-8804-0dbb2da4c345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a9bf9d7f-1c0f-48e1-969f-d567a2afd84d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ce16b3e-4adf-4594-8804-0dbb2da4c345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7f50fd9d-34f2-4fbf-9903-6c770278a774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a9bf9d7f-1c0f-48e1-969f-d567a2afd84d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7f50fd9d-34f2-4fbf-9903-6c770278a774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_ed43e464-5164-4e84-9a54-70715a7a1b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a9bf9d7f-1c0f-48e1-969f-d567a2afd84d" xlink:to="loc_us-gaap_InventoryFinishedGoods_ed43e464-5164-4e84-9a54-70715a7a1b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d68fe18f-1f89-497d-83c4-42f6aeb4aca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a9bf9d7f-1c0f-48e1-969f-d567a2afd84d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d68fe18f-1f89-497d-83c4-42f6aeb4aca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_9c374634-adea-4bc4-bb15-30eb7b8e391a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a9bf9d7f-1c0f-48e1-969f-d567a2afd84d" xlink:to="loc_us-gaap_PrepaidTaxes_9c374634-adea-4bc4-bb15-30eb7b8e391a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7432659f-232f-4828-ba41-1a8121d56519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fc10461d-9306-458d-a663-b25ef9c5c303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7432659f-232f-4828-ba41-1a8121d56519" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fc10461d-9306-458d-a663-b25ef9c5c303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e174f702-8839-4c59-917d-d54bfa681224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7432659f-232f-4828-ba41-1a8121d56519" xlink:to="loc_us-gaap_Liabilities_e174f702-8839-4c59-917d-d54bfa681224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_13796d3d-4e42-4cb8-942c-5cada546bb41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7432659f-232f-4828-ba41-1a8121d56519" xlink:to="loc_us-gaap_StockholdersEquity_13796d3d-4e42-4cb8-942c-5cada546bb41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_95395b67-18d6-47b6-9cd7-dd65c7391373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_15c4fbe2-a76a-4635-b372-36bf9974bb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_95395b67-18d6-47b6-9cd7-dd65c7391373" xlink:to="loc_us-gaap_CommonStockValue_15c4fbe2-a76a-4635-b372-36bf9974bb2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ff4d2b30-816c-471d-be5c-829b2e83790b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_95395b67-18d6-47b6-9cd7-dd65c7391373" xlink:to="loc_us-gaap_PreferredStockValue_ff4d2b30-816c-471d-be5c-829b2e83790b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e801b786-a915-4b12-b9fc-11ce28135d56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_95395b67-18d6-47b6-9cd7-dd65c7391373" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e801b786-a915-4b12-b9fc-11ce28135d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_df496a05-64de-4e8f-b9a5-2ccbc6b507ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_95395b67-18d6-47b6-9cd7-dd65c7391373" xlink:to="loc_us-gaap_AdditionalPaidInCapital_df496a05-64de-4e8f-b9a5-2ccbc6b507ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_94bbd706-59f7-4743-bb6c-2614984ebfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3f4ed620-e20e-4723-a21c-3b169eab183e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94bbd706-59f7-4743-bb6c-2614984ebfb3" xlink:to="loc_us-gaap_AssetsNoncurrent_3f4ed620-e20e-4723-a21c-3b169eab183e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_237c43d5-cb92-4fcd-850f-6fac65de3420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94bbd706-59f7-4743-bb6c-2614984ebfb3" xlink:to="loc_us-gaap_AssetsCurrent_237c43d5-cb92-4fcd-850f-6fac65de3420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cedee21a-d373-4576-b073-75bf1556ff60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f57e464e-a6e9-4503-a144-a4db69171a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cedee21a-d373-4576-b073-75bf1556ff60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f57e464e-a6e9-4503-a144-a4db69171a8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bf0b9593-2d7a-4144-a965-45359ffc4edd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cedee21a-d373-4576-b073-75bf1556ff60" xlink:to="loc_us-gaap_LiabilitiesCurrent_bf0b9593-2d7a-4144-a965-45359ffc4edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8736b2d0-b643-48e9-9af2-026669948ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_27f9257a-5778-4c20-abb8-05b817fe8ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8736b2d0-b643-48e9-9af2-026669948ad0" xlink:to="loc_us-gaap_AccountsPayableCurrent_27f9257a-5778-4c20-abb8-05b817fe8ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_fced4a03-8032-4148-9ee1-45e93a560cd3" xlink:href="pets-20240331.xsd#pets_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8736b2d0-b643-48e9-9af2-026669948ad0" xlink:to="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_fced4a03-8032-4148-9ee1-45e93a560cd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e0bea601-e6e2-4659-9f07-a69ae0a50144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8736b2d0-b643-48e9-9af2-026669948ad0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e0bea601-e6e2-4659-9f07-a69ae0a50144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_3cbf9792-ca80-4f3b-9b98-3de1650bfa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8736b2d0-b643-48e9-9af2-026669948ad0" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_3cbf9792-ca80-4f3b-9b98-3de1650bfa8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_801b311e-f392-4f38-8a3f-946f79bc1d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8736b2d0-b643-48e9-9af2-026669948ad0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_801b311e-f392-4f38-8a3f-946f79bc1d0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_df3e5370-be53-4e52-a465-a1e81acaaf69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_92aa8796-ff0e-47b1-aad6-fbcb7ddd0fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_df3e5370-be53-4e52-a465-a1e81acaaf69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_92aa8796-ff0e-47b1-aad6-fbcb7ddd0fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_32cdad1f-2deb-4593-aaa0-242a86e9950d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_df3e5370-be53-4e52-a465-a1e81acaaf69" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_32cdad1f-2deb-4593-aaa0-242a86e9950d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_bf4ed8b9-a209-4119-a431-0511df145878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_df3e5370-be53-4e52-a465-a1e81acaaf69" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_bf4ed8b9-a209-4119-a431-0511df145878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_533241f3-842b-46a6-9a2a-e94107daf0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_df3e5370-be53-4e52-a465-a1e81acaaf69" xlink:to="loc_us-gaap_Goodwill_533241f3-842b-46a6-9a2a-e94107daf0c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill_c03657ba-5a36-43c9-9265-f48448da0c8d" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_df3e5370-be53-4e52-a465-a1e81acaaf69" xlink:to="loc_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill_c03657ba-5a36-43c9-9265-f48448da0c8d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="pets-20240331.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_19665a50-8cbf-498d-9e77-f135692cb4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_457b0ea1-36e9-4551-b739-23cba1836999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_19665a50-8cbf-498d-9e77-f135692cb4f8" xlink:to="loc_us-gaap_AdvertisingExpense_457b0ea1-36e9-4551-b739-23cba1836999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_da6f61df-8f66-4657-a21a-c96714b5ad32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_19665a50-8cbf-498d-9e77-f135692cb4f8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_da6f61df-8f66-4657-a21a-c96714b5ad32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ef003bdd-1e75-412b-aa95-1a60c7c0b15a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_19665a50-8cbf-498d-9e77-f135692cb4f8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ef003bdd-1e75-412b-aa95-1a60c7c0b15a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8b5232f9-2090-46b7-bbe3-9293c2c25147" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c88b4d76-8211-457a-8d80-663fde950d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8b5232f9-2090-46b7-bbe3-9293c2c25147" xlink:to="loc_us-gaap_OperatingExpenses_c88b4d76-8211-457a-8d80-663fde950d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e6a91f99-9f58-4c55-854e-48ceee3ac132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8b5232f9-2090-46b7-bbe3-9293c2c25147" xlink:to="loc_us-gaap_GrossProfit_e6a91f99-9f58-4c55-854e-48ceee3ac132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_434283d6-08d7-4ed9-b69b-cfa450e05dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_84668672-e0cd-4db0-b8c1-dfb44ef8671c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_434283d6-08d7-4ed9-b69b-cfa450e05dc3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_84668672-e0cd-4db0-b8c1-dfb44ef8671c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8099191a-0de5-459b-a130-239009c03d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_434283d6-08d7-4ed9-b69b-cfa450e05dc3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8099191a-0de5-459b-a130-239009c03d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_73b0a110-8f74-41e8-8d7a-ec60c83d4d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_d5ba395b-4fb1-4920-945a-6c673a1735bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_73b0a110-8f74-41e8-8d7a-ec60c83d4d3e" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_d5ba395b-4fb1-4920-945a-6c673a1735bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6fc59383-0725-42cd-9533-5d82a1d7b0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_73b0a110-8f74-41e8-8d7a-ec60c83d4d3e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6fc59383-0725-42cd-9533-5d82a1d7b0d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96c8f7f3-48a7-4a2e-bd85-4677dbea123a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5455d200-b981-4fab-b42b-acd3e0ba3070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96c8f7f3-48a7-4a2e-bd85-4677dbea123a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5455d200-b981-4fab-b42b-acd3e0ba3070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5e6a22e6-faea-4d5c-af4a-cf88c0b23e49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96c8f7f3-48a7-4a2e-bd85-4677dbea123a" xlink:to="loc_us-gaap_OperatingIncomeLoss_5e6a22e6-faea-4d5c-af4a-cf88c0b23e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_75b94b9f-6763-4973-9659-2509c2f14ece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97325810-3051-48aa-8cf5-85bdc6780fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_75b94b9f-6763-4973-9659-2509c2f14ece" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97325810-3051-48aa-8cf5-85bdc6780fa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7c706cef-ef7d-4fa0-8ddc-2aa4b1679278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_75b94b9f-6763-4973-9659-2509c2f14ece" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7c706cef-ef7d-4fa0-8ddc-2aa4b1679278" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pets-20240331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_306edab2-2a6e-413a-9ca0-23fc33fdc447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38853ea3-1802-4f6d-a4a3-859156d1877b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_306edab2-2a6e-413a-9ca0-23fc33fdc447" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38853ea3-1802-4f6d-a4a3-859156d1877b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0714b5d-7089-4c86-992f-a350b8b9087f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_306edab2-2a6e-413a-9ca0-23fc33fdc447" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0714b5d-7089-4c86-992f-a350b8b9087f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0ad1605-b90a-4be5-b3d1-d7afac0f27a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_306edab2-2a6e-413a-9ca0-23fc33fdc447" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0ad1605-b90a-4be5-b3d1-d7afac0f27a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_cde5d457-86e5-4fc5-8957-8a6260ed2087" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_cde5d457-86e5-4fc5-8957-8a6260ed2087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4be36eb2-e80a-4741-a16d-68a4da5a2592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4be36eb2-e80a-4741-a16d-68a4da5a2592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_51c22cf6-795d-4633-a8e3-69df7dbd9e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_NetIncomeLoss_51c22cf6-795d-4633-a8e3-69df7dbd9e11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7f6382f1-43b5-4006-a1f4-56f920f5c6a5" xlink:href="pets-20240331.xsd#pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7f6382f1-43b5-4006-a1f4-56f920f5c6a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0a47b58f-4b2d-4923-8c45-b0de3e91227b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0a47b58f-4b2d-4923-8c45-b0de3e91227b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4dafefd7-ffad-49d2-be1c-2642d306cbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_ShareBasedCompensation_4dafefd7-ffad-49d2-be1c-2642d306cbc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_acd4960d-0b57-4767-9357-0b03333a4865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_acd4960d-0b57-4767-9357-0b03333a4865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_22307fb8-67d6-4350-85e3-a78650ba86a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_22307fb8-67d6-4350-85e3-a78650ba86a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_159c33ee-a027-4af2-95a5-227bf5742d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_159c33ee-a027-4af2-95a5-227bf5742d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b9378f46-01c6-416e-bd84-d6d1235d9b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b9378f46-01c6-416e-bd84-d6d1235d9b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_98fe2e9c-38a9-40f8-8fa7-2889afbab97e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_98fe2e9c-38a9-40f8-8fa7-2889afbab97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_1da2d5d0-ed24-4905-8e43-c70e65435956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_1da2d5d0-ed24-4905-8e43-c70e65435956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_d2163b73-57ce-409c-a350-308758204c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_d2163b73-57ce-409c-a350-308758204c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_bfe7939a-98f3-4afd-a176-cab91ab43530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_bfe7939a-98f3-4afd-a176-cab91ab43530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5c37bd77-351d-4cdc-938c-0472a07c2607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9874774a-63c1-48df-a4c4-a3166d70bcf6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5c37bd77-351d-4cdc-938c-0472a07c2607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7f78094-f0a8-4c67-b0f9-694c3a3e0ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_7b7b583a-24a4-4d5c-9f6c-66b22d509c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7f78094-f0a8-4c67-b0f9-694c3a3e0ea2" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_7b7b583a-24a4-4d5c-9f6c-66b22d509c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_780183f5-97ed-42c3-9845-0f1f0811c7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_81e7124d-5663-408d-a0ea-30118d0ddbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_780183f5-97ed-42c3-9845-0f1f0811c7d3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_81e7124d-5663-408d-a0ea-30118d0ddbeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_aef7d4e7-9ed9-46c8-90a3-814787ea47ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_780183f5-97ed-42c3-9845-0f1f0811c7d3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_aef7d4e7-9ed9-46c8-90a3-814787ea47ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_b949bc6c-3f53-4d03-a366-23b9c154b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_780183f5-97ed-42c3-9845-0f1f0811c7d3" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_b949bc6c-3f53-4d03-a366-23b9c154b1fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_59e34298-f150-48a5-b004-740cec694fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_83ef5efa-21b7-4db0-85fb-15139d0993c9" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_59e34298-f150-48a5-b004-740cec694fc1" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_83ef5efa-21b7-4db0-85fb-15139d0993c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_389b406f-e3ec-496b-8c38-c9a2fe9d7ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_59e34298-f150-48a5-b004-740cec694fc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_389b406f-e3ec-496b-8c38-c9a2fe9d7ce5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_a34a3f7d-6b7a-438e-a974-a06d9cbba665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_7e5d856e-3ea0-4c93-b7d9-48b54ccbdd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_a34a3f7d-6b7a-438e-a974-a06d9cbba665" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_7e5d856e-3ea0-4c93-b7d9-48b54ccbdd3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_7f18af47-032f-4203-8cfa-5fcfb60deceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_a34a3f7d-6b7a-438e-a974-a06d9cbba665" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_7f18af47-032f-4203-8cfa-5fcfb60deceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_8b6d8a59-681c-43b2-9d8a-8925ce76fa57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_a34a3f7d-6b7a-438e-a974-a06d9cbba665" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_8b6d8a59-681c-43b2-9d8a-8925ce76fa57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_69e0435c-9d55-4a5b-ad3b-41909b6dff22" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_a34a3f7d-6b7a-438e-a974-a06d9cbba665" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_69e0435c-9d55-4a5b-ad3b-41909b6dff22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_08a807f4-90e6-45bb-86fc-3aadf87401ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_a34a3f7d-6b7a-438e-a974-a06d9cbba665" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_08a807f4-90e6-45bb-86fc-3aadf87401ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets_d2318e84-4f98-4928-a3d9-45c6c52ae96a" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets_d2318e84-4f98-4928-a3d9-45c6c52ae96a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_cba1db78-6c4a-47c0-b2b0-c55de9edea2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_cba1db78-6c4a-47c0-b2b0-c55de9edea2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables_afc72464-977a-48ff-990f-c1071f537343" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables_afc72464-977a-48ff-990f-c1071f537343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_a67c9dfd-9a5d-4109-b0a5-6ad3da1b600e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_a67c9dfd-9a5d-4109-b0a5-6ad3da1b600e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d7b9bbf7-5441-427b-a332-392b2c36a5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d7b9bbf7-5441-427b-a332-392b2c36a5fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_34e627b0-70f4-4cbd-a1c0-5d0489ec2a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_34e627b0-70f4-4cbd-a1c0-5d0489ec2a8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_1bfe2c7f-93c0-48ee-9914-7e9b4235378a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_1bfe2c7f-93c0-48ee-9914-7e9b4235378a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6486ff05-357d-48bb-937f-dba2863f1509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_us-gaap_Goodwill_6486ff05-357d-48bb-937f-dba2863f1509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4e3b3298-6096-4b7c-80f9-aea0566e57c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4e3b3298-6096-4b7c-80f9-aea0566e57c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_d1270d36-ac49-473d-b5e4-cdcf6001dc16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_d1270d36-ac49-473d-b5e4-cdcf6001dc16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2ef1ac48-b2e2-405e-90b1-d2f9a5469b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_872ae907-8c10-475b-9140-58e396251991" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2ef1ac48-b2e2-405e-90b1-d2f9a5469b16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf23ffb1-7178-4607-a5ef-51a60f464a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fe855881-d6d7-4d27-bc6e-a9dcd7ed7541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bf23ffb1-7178-4607-a5ef-51a60f464a3e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fe855881-d6d7-4d27-bc6e-a9dcd7ed7541" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8db5299c-c79b-4743-ad31-d0b8ab5d5120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bf23ffb1-7178-4607-a5ef-51a60f464a3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8db5299c-c79b-4743-ad31-d0b8ab5d5120" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6e39c33f-531c-4fef-8398-96198f8769c0" xlink:href="pets-20240331.xsd#pets_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6201ee92-061e-4b04-bb18-889f78283310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6e39c33f-531c-4fef-8398-96198f8769c0" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6201ee92-061e-4b04-bb18-889f78283310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedMerchandiseCreditsAndRewardsCurrent_a2d266c5-a509-49a4-894d-fe0733634978" xlink:href="pets-20240331.xsd#pets_AccruedMerchandiseCreditsAndRewardsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6e39c33f-531c-4fef-8398-96198f8769c0" xlink:to="loc_pets_AccruedMerchandiseCreditsAndRewardsCurrent_a2d266c5-a509-49a4-894d-fe0733634978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4fe8ad7d-0f1f-4ed2-9bd8-b245cabb7f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6e39c33f-531c-4fef-8398-96198f8769c0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4fe8ad7d-0f1f-4ed2-9bd8-b245cabb7f0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_dc4ced14-b954-46af-a6be-24d291cd2028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6e39c33f-531c-4fef-8398-96198f8769c0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_dc4ced14-b954-46af-a6be-24d291cd2028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_cb8b3a89-5eda-4fa1-af79-1adcdd28431c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6e39c33f-531c-4fef-8398-96198f8769c0" xlink:to="loc_us-gaap_DividendsPayableCurrent_cb8b3a89-5eda-4fa1-af79-1adcdd28431c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_e72a7569-00cf-4327-af5b-be8ad66f92a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6e39c33f-531c-4fef-8398-96198f8769c0" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_e72a7569-00cf-4327-af5b-be8ad66f92a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedSalesReturnsAndAllowancesCurrent_876681f8-8bd4-4b28-a1f9-1d7f9a6ee7d5" xlink:href="pets-20240331.xsd#pets_AccruedSalesReturnsAndAllowancesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6e39c33f-531c-4fef-8398-96198f8769c0" xlink:to="loc_pets_AccruedSalesReturnsAndAllowancesCurrent_876681f8-8bd4-4b28-a1f9-1d7f9a6ee7d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedCreditCardFeesCurrent_61966b4d-d4ca-4d74-962c-a97481562302" xlink:href="pets-20240331.xsd#pets_AccruedCreditCardFeesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6e39c33f-531c-4fef-8398-96198f8769c0" xlink:to="loc_pets_AccruedCreditCardFeesCurrent_61966b4d-d4ca-4d74-962c-a97481562302" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNetScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4fb42a73-d2fb-4b2d-86e6-e4612cc70b44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c5fe7ee1-7eba-4f7a-9f91-c5f5595fd28b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4fb42a73-d2fb-4b2d-86e6-e4612cc70b44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c5fe7ee1-7eba-4f7a-9f91-c5f5595fd28b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_053ce47d-24ff-4419-870f-665aedd3216e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4fb42a73-d2fb-4b2d-86e6-e4612cc70b44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_053ce47d-24ff-4419-870f-665aedd3216e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssets_4b4c6fc1-2696-4def-91ff-e0ddf76acbcb" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssetsGross_2028ccd6-0dfa-4e2a-9cf9-450f343e609e" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_IntangibleAndOtherAssets_4b4c6fc1-2696-4def-91ff-e0ddf76acbcb" xlink:to="loc_pets_IntangibleAndOtherAssetsGross_2028ccd6-0dfa-4e2a-9cf9-450f343e609e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangiblesAndOtherAssetsAccumulatedAmortization_fe0d9979-c109-44b2-86bf-e4c075bdc907" xlink:href="pets-20240331.xsd#pets_IntangiblesAndOtherAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_IntangibleAndOtherAssets_4b4c6fc1-2696-4def-91ff-e0ddf76acbcb" xlink:to="loc_pets_IntangiblesAndOtherAssetsAccumulatedAmortization_fe0d9979-c109-44b2-86bf-e4c075bdc907" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssetsGross_23debf1d-1829-4659-9205-d3e4a7c7741e" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_cafe0348-b5a0-48c8-8873-aa825c16b5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_IntangibleAndOtherAssetsGross_23debf1d-1829-4659-9205-d3e4a7c7741e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_cafe0348-b5a0-48c8-8873-aa825c16b5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_33b96140-a152-4d71-9c2c-789e40213444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_IntangibleAndOtherAssetsGross_23debf1d-1829-4659-9205-d3e4a7c7741e" xlink:to="loc_us-gaap_Investments_33b96140-a152-4d71-9c2c-789e40213444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f2fa9f1-e3db-4281-bfe5-c60c44f55a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_486a1792-0f03-4a4b-a586-8f39319eef61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f2fa9f1-e3db-4281-bfe5-c60c44f55a5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_486a1792-0f03-4a4b-a586-8f39319eef61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e03bd75d-b129-4bf8-b5fe-853f7ce33dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f2fa9f1-e3db-4281-bfe5-c60c44f55a5b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e03bd75d-b129-4bf8-b5fe-853f7ce33dc1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails_1" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNetScheduleDetails_1"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssets_59ab4a9b-8932-47b1-bb47-51ddcefe5fab" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_ca4a7cec-7110-4764-8298-d251ef018ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_IntangibleAndOtherAssets_59ab4a9b-8932-47b1-bb47-51ddcefe5fab" xlink:to="loc_us-gaap_Investments_ca4a7cec-7110-4764-8298-d251ef018ad3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c3feab5a-13f3-4c64-a6bb-7a4bbbc97902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pets_IntangibleAndOtherAssets_59ab4a9b-8932-47b1-bb47-51ddcefe5fab" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c3feab5a-13f3-4c64-a6bb-7a4bbbc97902" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNetExpectedAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21d5f996-3eee-469d-a989-48aa78d5912b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e675e5e7-86b9-40e2-816c-20aa7fbb9856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21d5f996-3eee-469d-a989-48aa78d5912b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e675e5e7-86b9-40e2-816c-20aa7fbb9856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_22003f23-813e-4b9f-a742-955648c20f09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21d5f996-3eee-469d-a989-48aa78d5912b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_22003f23-813e-4b9f-a742-955648c20f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2b29a6ab-4a0d-4a3f-af76-1eba2369ad0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21d5f996-3eee-469d-a989-48aa78d5912b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2b29a6ab-4a0d-4a3f-af76-1eba2369ad0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_df11d559-4d61-4999-87f1-bce051c5458c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21d5f996-3eee-469d-a989-48aa78d5912b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_df11d559-4d61-4999-87f1-bce051c5458c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_afb4db0b-10b9-4eb3-9937-ed2f6afcab43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21d5f996-3eee-469d-a989-48aa78d5912b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_afb4db0b-10b9-4eb3-9937-ed2f6afcab43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_56e6d645-c183-4948-a7e8-c33c749fa5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21d5f996-3eee-469d-a989-48aa78d5912b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_56e6d645-c183-4948-a7e8-c33c749fa5e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#LeasesScheduleofLeaseCostsandActivityDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5a3b32e7-6f21-46d9-aab9-e4551ddc9dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5cc504d4-960e-4734-93d4-eb927b567abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5a3b32e7-6f21-46d9-aab9-e4551ddc9dc0" xlink:to="loc_us-gaap_OperatingLeaseCost_5cc504d4-960e-4734-93d4-eb927b567abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ad57ec52-28dd-4477-ba3a-916a31a16bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5a3b32e7-6f21-46d9-aab9-e4551ddc9dc0" xlink:to="loc_us-gaap_VariableLeaseCost_ad57ec52-28dd-4477-ba3a-916a31a16bc9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#LeasesScheduleofMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4244b2d3-612c-4c20-b06a-ab5aa02b986d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3e404dc4-843d-4983-b3c6-37b9e84961e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4244b2d3-612c-4c20-b06a-ab5aa02b986d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3e404dc4-843d-4983-b3c6-37b9e84961e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f7408b94-13dd-483d-9435-c00eb6053c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4244b2d3-612c-4c20-b06a-ab5aa02b986d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f7408b94-13dd-483d-9435-c00eb6053c0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8997dff5-e995-40c3-b6a3-b935d96bcf45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4244b2d3-612c-4c20-b06a-ab5aa02b986d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8997dff5-e995-40c3-b6a3-b935d96bcf45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1fdbc51d-afca-476e-ab7b-673e2345bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4244b2d3-612c-4c20-b06a-ab5aa02b986d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1fdbc51d-afca-476e-ab7b-673e2345bb3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="pets-20240331.xsd#LeasesScheduleofMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4bba52b-c864-4e5b-8c28-f0a8bcdfd34f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d30b0cf-eca4-44a8-aed7-acbd353f1da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4bba52b-c864-4e5b-8c28-f0a8bcdfd34f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d30b0cf-eca4-44a8-aed7-acbd353f1da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3e8a4097-71f1-4941-a56c-c24fe86d2d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4bba52b-c864-4e5b-8c28-f0a8bcdfd34f" xlink:to="loc_us-gaap_OperatingLeaseLiability_3e8a4097-71f1-4941-a56c-c24fe86d2d1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesDeferredIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_468f3b27-961f-4c4a-a023-7f90050953e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4473e724-df0a-46fc-bc13-c39ff81b132e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_468f3b27-961f-4c4a-a023-7f90050953e4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4473e724-df0a-46fc-bc13-c39ff81b132e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e2f9be8c-7496-4c5d-b1df-00aae68fd78c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_468f3b27-961f-4c4a-a023-7f90050953e4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e2f9be8c-7496-4c5d-b1df-00aae68fd78c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ce0ed206-002a-42f7-a418-52edbce104b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_468f3b27-961f-4c4a-a023-7f90050953e4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ce0ed206-002a-42f7-a418-52edbce104b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a8258cd6-da42-4ed2-9993-a1fbe0571841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b302fab-29a4-4930-9d7b-ce49992e5165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a8258cd6-da42-4ed2-9993-a1fbe0571841" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b302fab-29a4-4930-9d7b-ce49992e5165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetsLeaseLiabilities_009b2c87-53bb-455a-8ebc-20fe707fef53" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a8258cd6-da42-4ed2-9993-a1fbe0571841" xlink:to="loc_pets_DeferredTaxAssetsLeaseLiabilities_009b2c87-53bb-455a-8ebc-20fe707fef53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_6b477f45-0357-4919-baf1-23db486a6ca1" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a8258cd6-da42-4ed2-9993-a1fbe0571841" xlink:to="loc_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_6b477f45-0357-4919-baf1-23db486a6ca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_3fb4fa45-d625-4678-84f3-7fe72d53e529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a8258cd6-da42-4ed2-9993-a1fbe0571841" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_3fb4fa45-d625-4678-84f3-7fe72d53e529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3b070dcd-e394-40f3-9b94-41e45242c32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a8258cd6-da42-4ed2-9993-a1fbe0571841" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3b070dcd-e394-40f3-9b94-41e45242c32f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_beee222e-c573-4326-957c-cf09a2545b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a8258cd6-da42-4ed2-9993-a1fbe0571841" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_beee222e-c573-4326-957c-cf09a2545b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_0abd017e-3e79-452f-a25e-243d4e0de3be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a8258cd6-da42-4ed2-9993-a1fbe0571841" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_0abd017e-3e79-452f-a25e-243d4e0de3be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_e3b4bf0d-c336-438a-aacc-cb61878b18b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a8258cd6-da42-4ed2-9993-a1fbe0571841" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_e3b4bf0d-c336-438a-aacc-cb61878b18b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_97456d16-709a-4043-9b35-b1f1eff9ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f2cfa395-a4e7-4708-bc5c-b8b65bba6002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_97456d16-709a-4043-9b35-b1f1eff9ecfd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f2cfa395-a4e7-4708-bc5c-b8b65bba6002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_969e4c2e-90d8-40fb-a473-9ff96b3c85ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_97456d16-709a-4043-9b35-b1f1eff9ecfd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_969e4c2e-90d8-40fb-a473-9ff96b3c85ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxLiabilitiesChangeInAccountingMethod_4677110b-71c3-42d9-badb-59f566d62388" xlink:href="pets-20240331.xsd#pets_DeferredTaxLiabilitiesChangeInAccountingMethod"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_97456d16-709a-4043-9b35-b1f1eff9ecfd" xlink:to="loc_pets_DeferredTaxLiabilitiesChangeInAccountingMethod_4677110b-71c3-42d9-badb-59f566d62388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0eadb72b-0ad0-4d4a-b7b5-07653c17e9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_97456d16-709a-4043-9b35-b1f1eff9ecfd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0eadb72b-0ad0-4d4a-b7b5-07653c17e9e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesComponentsofIncomeTaxProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_87dc638c-ad13-46b6-98e3-de9756818f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a7b2e75c-ce93-4c50-ab02-a27ba234735a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_87dc638c-ad13-46b6-98e3-de9756818f17" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a7b2e75c-ce93-4c50-ab02-a27ba234735a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_95cba58d-7521-402c-aaca-dee8b87c1a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_87dc638c-ad13-46b6-98e3-de9756818f17" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_95cba58d-7521-402c-aaca-dee8b87c1a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_7623b66d-1a70-4db1-bb4c-853e9222a46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e2199147-d1c3-40ad-b189-25e0e6e17f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_7623b66d-1a70-4db1-bb4c-853e9222a46b" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e2199147-d1c3-40ad-b189-25e0e6e17f4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3fa43e38-ca6f-4efe-9e75-a1390910dd92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_7623b66d-1a70-4db1-bb4c-853e9222a46b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3fa43e38-ca6f-4efe-9e75-a1390910dd92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e312a746-e8d2-40ca-bfbb-36d64b887dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_2f227b33-9ec1-4bb1-b8f9-e23cbb8600c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e312a746-e8d2-40ca-bfbb-36d64b887dec" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_2f227b33-9ec1-4bb1-b8f9-e23cbb8600c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1c2a2d3b-02b6-4621-bb83-1389f0c2fcef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e312a746-e8d2-40ca-bfbb-36d64b887dec" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1c2a2d3b-02b6-4621-bb83-1389f0c2fcef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesReconciliationofIncomeTaxProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ea802501-4d2c-446d-b179-0e674a7bec30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_834635a3-d0c1-407a-b9ff-352219c358f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea802501-4d2c-446d-b179-0e674a7bec30" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_834635a3-d0c1-407a-b9ff-352219c358f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fe550815-0380-4796-8914-9fc756976431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea802501-4d2c-446d-b179-0e674a7bec30" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fe550815-0380-4796-8914-9fc756976431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8479ff6c-81a3-46c1-b66f-c1d5e759dac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea802501-4d2c-446d-b179-0e674a7bec30" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8479ff6c-81a3-46c1-b66f-c1d5e759dac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_69d9dda2-7b54-4bc8-932d-69aac7a31176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea802501-4d2c-446d-b179-0e674a7bec30" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_69d9dda2-7b54-4bc8-932d-69aac7a31176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2684825c-f02c-493e-9f56-2ddfdb7b752d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea802501-4d2c-446d-b179-0e674a7bec30" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2684825c-f02c-493e-9f56-2ddfdb7b752d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_c6f35c5a-6875-4fa0-847e-404da750fb67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea802501-4d2c-446d-b179-0e674a7bec30" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_c6f35c5a-6875-4fa0-847e-404da750fb67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_f16c1b1f-b5cb-4095-be70-9b19de0abcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea802501-4d2c-446d-b179-0e674a7bec30" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_f16c1b1f-b5cb-4095-be70-9b19de0abcf0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_593020e6-5744-4423-aaf8-a9d61180f5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_e5b245de-2da1-4112-a2b1-f8b9e7268090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_593020e6-5744-4423-aaf8-a9d61180f5a9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_e5b245de-2da1-4112-a2b1-f8b9e7268090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_8b580d9c-640b-416c-961d-80914f60bb87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_593020e6-5744-4423-aaf8-a9d61180f5a9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_8b580d9c-640b-416c-961d-80914f60bb87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_23ac4c38-231a-4244-b1be-07fb5a4dddec" xlink:href="pets-20240331.xsd#pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_593020e6-5744-4423-aaf8-a9d61180f5a9" xlink:to="loc_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_23ac4c38-231a-4244-b1be-07fb5a4dddec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a83f06fa-982e-4a29-83f0-70e744cd1785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_593020e6-5744-4423-aaf8-a9d61180f5a9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a83f06fa-982e-4a29-83f0-70e744cd1785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_55275055-910f-4cb6-a01a-0d2bec705fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_593020e6-5744-4423-aaf8-a9d61180f5a9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_55275055-910f-4cb6-a01a-0d2bec705fb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_21771196-eec7-4269-a44f-34926bed5dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_593020e6-5744-4423-aaf8-a9d61180f5a9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_21771196-eec7-4269-a44f-34926bed5dc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_02b6ce83-3076-40de-ae13-6f0708f96350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_593020e6-5744-4423-aaf8-a9d61180f5a9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_02b6ce83-3076-40de-ae13-6f0708f96350" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8b83efd1-c6a5-4e68-8493-f3536936e4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81034aed-a33a-43fe-a758-9142e0773510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8b83efd1-c6a5-4e68-8493-f3536936e4f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81034aed-a33a-43fe-a758-9142e0773510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_0c5d42f2-7a0c-4d5d-9ce3-c47b5a5e9212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8b83efd1-c6a5-4e68-8493-f3536936e4f9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_0c5d42f2-7a0c-4d5d-9ce3-c47b5a5e9212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b1a4d61e-574c-43c7-8eaa-760ab87393d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8b83efd1-c6a5-4e68-8493-f3536936e4f9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b1a4d61e-574c-43c7-8eaa-760ab87393d8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>pets-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b431201b-f537-4396-8d13-986e96a3bf3a,g:5ff869d6-f8b6-477d-8b92-37fe9911b79a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity" xlink:type="simple" xlink:href="pets-20240331.xsd#ConsolidatedStatementsofChangesinShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5f4c18a4-b858-4d2d-8d73-b3bddf9c593b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e41ff337-b362-425e-8ceb-84e7cf8f6e96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5f4c18a4-b858-4d2d-8d73-b3bddf9c593b" xlink:to="loc_us-gaap_StatementTable_e41ff337-b362-425e-8ceb-84e7cf8f6e96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8053dc0c-15cc-4ca3-b3b1-97685c7d6276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e41ff337-b362-425e-8ceb-84e7cf8f6e96" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8053dc0c-15cc-4ca3-b3b1-97685c7d6276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8053dc0c-15cc-4ca3-b3b1-97685c7d6276_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8053dc0c-15cc-4ca3-b3b1-97685c7d6276" xlink:to="loc_us-gaap_EquityComponentDomain_8053dc0c-15cc-4ca3-b3b1-97685c7d6276_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8053dc0c-15cc-4ca3-b3b1-97685c7d6276" xlink:to="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_6dbcf8fb-d576-45de-aa14-1e74f9231640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:to="loc_us-gaap_PreferredStockMember_6dbcf8fb-d576-45de-aa14-1e74f9231640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ef13c599-4acf-4b03-a005-dd16a2c919fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:to="loc_us-gaap_CommonStockMember_ef13c599-4acf-4b03-a005-dd16a2c919fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_16d3c897-0afc-4202-9258-0adf7d479a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_16d3c897-0afc-4202-9258-0adf7d479a8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ca92a6f6-2a9c-4b55-8c57-f275ce96c17e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:to="loc_us-gaap_RetainedEarningsMember_ca92a6f6-2a9c-4b55-8c57-f275ce96c17e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5f4c18a4-b858-4d2d-8d73-b3bddf9c593b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_31817e71-1666-43e0-ab9c-668336f0eff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_SharesOutstanding_31817e71-1666-43e0-ab9c-668336f0eff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a7f4736-55f7-479f-a3d5-9014c76dc2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_StockholdersEquity_1a7f4736-55f7-479f-a3d5-9014c76dc2de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2fb5b92d-6132-4219-8404-41c5f1d8b275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2fb5b92d-6132-4219-8404-41c5f1d8b275" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_4941894b-3dbf-4b34-aa3e-380af28218b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_4941894b-3dbf-4b34-aa3e-380af28218b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c73ac877-c8de-4496-b925-3b3f826d0c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c73ac877-c8de-4496-b925-3b3f826d0c3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_fcd25bf2-e1d9-4870-90d2-e84eb400ed6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_DividendsCommonStock_fcd25bf2-e1d9-4870-90d2-e84eb400ed6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb01dc6a-cb5d-47e4-acf2-08cfc2bec087" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_NetIncomeLoss_eb01dc6a-cb5d-47e4-acf2-08cfc2bec087" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9a7673c8-e4d3-49e9-aacd-b92047fc3155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1af4ec52-dd2e-4a19-8899-e3af145af492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48ad93a3-dc29-4e59-9352-8ee6f7ffa599" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_srt_RangeAxis_48ad93a3-dc29-4e59-9352-8ee6f7ffa599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48ad93a3-dc29-4e59-9352-8ee6f7ffa599_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_48ad93a3-dc29-4e59-9352-8ee6f7ffa599" xlink:to="loc_srt_RangeMember_48ad93a3-dc29-4e59-9352-8ee6f7ffa599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae28b4a7-18d1-4bed-b110-c72ecce203b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_48ad93a3-dc29-4e59-9352-8ee6f7ffa599" xlink:to="loc_srt_RangeMember_ae28b4a7-18d1-4bed-b110-c72ecce203b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7f70071-e084-48d0-96f5-2d480d2b5eaf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae28b4a7-18d1-4bed-b110-c72ecce203b2" xlink:to="loc_srt_MaximumMember_a7f70071-e084-48d0-96f5-2d480d2b5eaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ddbf753-e73d-4fdf-80e0-9f6d0f0155c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae28b4a7-18d1-4bed-b110-c72ecce203b2" xlink:to="loc_srt_MinimumMember_1ddbf753-e73d-4fdf-80e0-9f6d0f0155c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a6863a0-d5b7-4883-8ebb-933837b03d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a6863a0-d5b7-4883-8ebb-933837b03d2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a6863a0-d5b7-4883-8ebb-933837b03d2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a6863a0-d5b7-4883-8ebb-933837b03d2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a6863a0-d5b7-4883-8ebb-933837b03d2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35f4b12a-c542-4df6-97ac-0dced5f6cee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a6863a0-d5b7-4883-8ebb-933837b03d2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35f4b12a-c542-4df6-97ac-0dced5f6cee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember_c1df43f1-476a-4557-b5a7-bb4bc7dc88e0" xlink:href="pets-20240331.xsd#pets_FurnitureFixturesEquipmentAndComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35f4b12a-c542-4df6-97ac-0dced5f6cee2" xlink:to="loc_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember_c1df43f1-476a-4557-b5a7-bb4bc7dc88e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_aed1ad61-93ae-4196-b754-cd56868c1487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35f4b12a-c542-4df6-97ac-0dced5f6cee2" xlink:to="loc_us-gaap_BuildingMember_aed1ad61-93ae-4196-b754-cd56868c1487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_255d9ec2-dd21-4a56-8f4a-f8cf6d7a7170" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_255d9ec2-dd21-4a56-8f4a-f8cf6d7a7170" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_255d9ec2-dd21-4a56-8f4a-f8cf6d7a7170_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_255d9ec2-dd21-4a56-8f4a-f8cf6d7a7170" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_255d9ec2-dd21-4a56-8f4a-f8cf6d7a7170_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fe2e174e-36e8-4dcc-8473-bab18576dc53" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_255d9ec2-dd21-4a56-8f4a-f8cf6d7a7170" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fe2e174e-36e8-4dcc-8473-bab18576dc53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DelrayBeachPropertyMember_b5c1bd79-de41-4e05-9e30-a6293aa1383f" xlink:href="pets-20240331.xsd#pets_DelrayBeachPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fe2e174e-36e8-4dcc-8473-bab18576dc53" xlink:to="loc_pets_DelrayBeachPropertyMember_b5c1bd79-de41-4e05-9e30-a6293aa1383f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_14ed0b9f-18b7-458c-9abf-a6e3273d6fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_14ed0b9f-18b7-458c-9abf-a6e3273d6fb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14ed0b9f-18b7-458c-9abf-a6e3273d6fb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_14ed0b9f-18b7-458c-9abf-a6e3273d6fb7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14ed0b9f-18b7-458c-9abf-a6e3273d6fb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bf7d5351-ebad-40c8-addb-9b611fe8a02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_14ed0b9f-18b7-458c-9abf-a6e3273d6fb7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bf7d5351-ebad-40c8-addb-9b611fe8a02e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsTotalMember_63bca486-3836-4490-8962-28d0a03230c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bf7d5351-ebad-40c8-addb-9b611fe8a02e" xlink:to="loc_us-gaap_CostOfGoodsTotalMember_63bca486-3836-4490-8962-28d0a03230c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b8092f1c-dd24-4ae8-9a9f-76d3ce4995a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b8092f1c-dd24-4ae8-9a9f-76d3ce4995a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b8092f1c-dd24-4ae8-9a9f-76d3ce4995a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b8092f1c-dd24-4ae8-9a9f-76d3ce4995a9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b8092f1c-dd24-4ae8-9a9f-76d3ce4995a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fe595245-f7b2-42af-9c78-0f9235006e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b8092f1c-dd24-4ae8-9a9f-76d3ce4995a9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fe595245-f7b2-42af-9c78-0f9235006e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_a6114900-24aa-4fd6-b2c5-d3b5071e9c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fe595245-f7b2-42af-9c78-0f9235006e44" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_a6114900-24aa-4fd6-b2c5-d3b5071e9c7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_dff2627b-79fb-4867-9edb-ac5bcb426dad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_dff2627b-79fb-4867-9edb-ac5bcb426dad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_dff2627b-79fb-4867-9edb-ac5bcb426dad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_dff2627b-79fb-4867-9edb-ac5bcb426dad" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_dff2627b-79fb-4867-9edb-ac5bcb426dad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d27e4f22-59b0-4819-adbe-f37b7c1b1416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_dff2627b-79fb-4867-9edb-ac5bcb426dad" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d27e4f22-59b0-4819-adbe-f37b7c1b1416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SixSuppliersMember_443f4987-ef73-4e05-9c86-33149f3e83f0" xlink:href="pets-20240331.xsd#pets_SixSuppliersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d27e4f22-59b0-4819-adbe-f37b7c1b1416" xlink:to="loc_pets_SixSuppliersMember_443f4987-ef73-4e05-9c86-33149f3e83f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SevenSuppliersMember_40a8f7cd-81ae-485e-a162-be1cf6234f98" xlink:href="pets-20240331.xsd#pets_SevenSuppliersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d27e4f22-59b0-4819-adbe-f37b7c1b1416" xlink:to="loc_pets_SevenSuppliersMember_40a8f7cd-81ae-485e-a162-be1cf6234f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_c7f73093-6377-4998-8894-b7a2944ce2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_ValuationTechniqueAxis_c7f73093-6377-4998-8894-b7a2944ce2f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_c7f73093-6377-4998-8894-b7a2944ce2f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_c7f73093-6377-4998-8894-b7a2944ce2f8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_c7f73093-6377-4998-8894-b7a2944ce2f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_0d815b4b-3e64-44dd-b7ec-1de0078a5e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_c7f73093-6377-4998-8894-b7a2944ce2f8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_0d815b4b-3e64-44dd-b7ec-1de0078a5e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_a60179ee-cbe6-4a3d-b039-b88267d3c382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_0d815b4b-3e64-44dd-b7ec-1de0078a5e7e" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_a60179ee-cbe6-4a3d-b039-b88267d3c382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketApproachValuationTechniqueMember_bf1c314e-bbe2-4909-9cee-582523bbef72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketApproachValuationTechniqueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_0d815b4b-3e64-44dd-b7ec-1de0078a5e7e" xlink:to="loc_us-gaap_MarketApproachValuationTechniqueMember_bf1c314e-bbe2-4909-9cee-582523bbef72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a531dbbd-5795-4ddc-83a8-f5e559a3dfff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a531dbbd-5795-4ddc-83a8-f5e559a3dfff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a531dbbd-5795-4ddc-83a8-f5e559a3dfff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a531dbbd-5795-4ddc-83a8-f5e559a3dfff" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a531dbbd-5795-4ddc-83a8-f5e559a3dfff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_14dd757e-85b8-4fdf-9029-8e04b831a55d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a531dbbd-5795-4ddc-83a8-f5e559a3dfff" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_14dd757e-85b8-4fdf-9029-8e04b831a55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputControlPremiumMember_4e4153f0-da22-4314-85b9-9817870363d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputControlPremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_14dd757e-85b8-4fdf-9029-8e04b831a55d" xlink:to="loc_us-gaap_MeasurementInputControlPremiumMember_4e4153f0-da22-4314-85b9-9817870363d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MeasurementInputWeightedAverageCostOfCapitalMember_4c8e9987-bce5-4c5d-8d38-bfff7dc35cd6" xlink:href="pets-20240331.xsd#pets_MeasurementInputWeightedAverageCostOfCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_14dd757e-85b8-4fdf-9029-8e04b831a55d" xlink:to="loc_pets_MeasurementInputWeightedAverageCostOfCapitalMember_4c8e9987-bce5-4c5d-8d38-bfff7dc35cd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_173b1995-9cba-4b22-99b3-156c6e1262e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_InventoryValuationReserves_173b1995-9cba-4b22-99b3-156c6e1262e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a2b250e5-9994-4de7-8303-f8ca2d37f296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a2b250e5-9994-4de7-8303-f8ca2d37f296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_7ed52a1f-b4d2-4705-b8cf-8be52202f3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_NumberOfReportingUnits_7ed52a1f-b4d2-4705-b8cf-8be52202f3e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_01fba983-d43d-4c1a-91b0-c9b6b370cc44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_SharePrice_01fba983-d43d-4c1a-91b0-c9b6b370cc44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_28a54cfc-cc89-4a67-ae41-a34f93aa7905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_28a54cfc-cc89-4a67-ae41-a34f93aa7905" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_8cd57b62-4915-4326-97f2-02d191a0b5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_8cd57b62-4915-4326-97f2-02d191a0b5b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ReportingUnitMeasurementInput_f41e0a59-2293-4533-928d-921403308025" xlink:href="pets-20240331.xsd#pets_ReportingUnitMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_pets_ReportingUnitMeasurementInput_f41e0a59-2293-4533-928d-921403308025" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_26e55ce4-6063-4d86-ab7d-8cff82a4b830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_26e55ce4-6063-4d86-ab7d-8cff82a4b830" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PercentageOfPropertyLeasedToTenants_398aaf45-6710-46ad-a723-5bb2aeab0209" xlink:href="pets-20240331.xsd#pets_PercentageOfPropertyLeasedToTenants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_pets_PercentageOfPropertyLeasedToTenants_398aaf45-6710-46ad-a723-5bb2aeab0209" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_4c84048f-5b43-4a74-b63c-a741052d1f53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_4c84048f-5b43-4a74-b63c-a741052d1f53" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NumberOfTenants_f7ed5aed-6ea1-4b79-a20f-75141d35cd32" xlink:href="pets-20240331.xsd#pets_NumberOfTenants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_pets_NumberOfTenants_f7ed5aed-6ea1-4b79-a20f-75141d35cd32" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm_aff5e73e-f3e4-42c7-bf4d-cf819da8ac66" xlink:href="pets-20240331.xsd#pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm_aff5e73e-f3e4-42c7-bf4d-cf819da8ac66" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RentalIncomeNonoperating_325bbab9-387e-4b5f-80b3-4334c008d957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RentalIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_RentalIncomeNonoperating_325bbab9-387e-4b5f-80b3-4334c008d957" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e7b7fb5a-eb24-43af-b71a-9ed2ebd68216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e7b7fb5a-eb24-43af-b71a-9ed2ebd68216" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_00a8bc6a-bed7-4740-a2ea-86cf9b49b112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_00a8bc6a-bed7-4740-a2ea-86cf9b49b112" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_05f88383-3fcc-4e19-a38e-6e3f4bb13a93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_05f88383-3fcc-4e19-a38e-6e3f4bb13a93" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_52f2f360-1769-42ae-84d1-aeb5af5f960f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_52f2f360-1769-42ae-84d1-aeb5af5f960f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4dbbde2b-71f0-4f00-a3ea-6700bb2488fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4dbbde2b-71f0-4f00-a3ea-6700bb2488fc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_353cc76f-f4a5-4351-a470-4dbeb7dac079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_353cc76f-f4a5-4351-a470-4dbeb7dac079" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d735e970-0194-4452-993e-bcfaae724aff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d735e970-0194-4452-993e-bcfaae724aff" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ec1f7b5f-7271-4b7f-bfba-9832e590c27c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:to="loc_srt_MajorCustomersAxis_ec1f7b5f-7271-4b7f-bfba-9832e590c27c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ec1f7b5f-7271-4b7f-bfba-9832e590c27c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ec1f7b5f-7271-4b7f-bfba-9832e590c27c" xlink:to="loc_srt_NameOfMajorCustomerDomain_ec1f7b5f-7271-4b7f-bfba-9832e590c27c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ec1f7b5f-7271-4b7f-bfba-9832e590c27c" xlink:to="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipFeesMember_37108955-842e-4e97-8e2c-5263e4535ceb" xlink:href="pets-20240331.xsd#pets_MembershipFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:to="loc_pets_MembershipFeesMember_37108955-842e-4e97-8e2c-5263e4535ceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ReorderMember_53542cd9-81ee-40b6-a33a-ca5f756096a0" xlink:href="pets-20240331.xsd#pets_ReorderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:to="loc_pets_ReorderMember_53542cd9-81ee-40b6-a33a-ca5f756096a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NewOrderMember_1019989d-85a3-4892-aceb-938209429e1d" xlink:href="pets-20240331.xsd#pets_NewOrderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:to="loc_pets_NewOrderMember_1019989d-85a3-4892-aceb-938209429e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipCustomersMember_68c980d7-4bf4-4951-a2e6-a3181a1cc8c5" xlink:href="pets-20240331.xsd#pets_MembershipCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:to="loc_pets_MembershipCustomersMember_68c980d7-4bf4-4951-a2e6-a3181a1cc8c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c0ca5bf6-d626-4344-886b-622e6094a048" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:to="loc_srt_ProductOrServiceAxis_c0ca5bf6-d626-4344-886b-622e6094a048" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0ca5bf6-d626-4344-886b-622e6094a048_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c0ca5bf6-d626-4344-886b-622e6094a048" xlink:to="loc_srt_ProductsAndServicesDomain_c0ca5bf6-d626-4344-886b-622e6094a048_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53c593a0-1196-4cd5-8c1d-d51678ef8f1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c0ca5bf6-d626-4344-886b-622e6094a048" xlink:to="loc_srt_ProductsAndServicesDomain_53c593a0-1196-4cd5-8c1d-d51678ef8f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PartnerProgramMember_512d6495-7f68-4c10-9b8f-64a867db4d86" xlink:href="pets-20240331.xsd#pets_PartnerProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53c593a0-1196-4cd5-8c1d-d51678ef8f1e" xlink:to="loc_pets_PartnerProgramMember_512d6495-7f68-4c10-9b8f-64a867db4d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_1a5dcc77-979c-4bf5-b9d5-e1de833a64b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:to="loc_srt_RestatementAxis_1a5dcc77-979c-4bf5-b9d5-e1de833a64b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_1a5dcc77-979c-4bf5-b9d5-e1de833a64b9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1a5dcc77-979c-4bf5-b9d5-e1de833a64b9" xlink:to="loc_srt_RestatementDomain_1a5dcc77-979c-4bf5-b9d5-e1de833a64b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_2248993a-d7aa-45d9-b205-b356d6be9605" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1a5dcc77-979c-4bf5-b9d5-e1de833a64b9" xlink:to="loc_srt_RestatementDomain_2248993a-d7aa-45d9-b205-b356d6be9605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_9649fda0-db83-46b7-9227-422331cceb9e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2248993a-d7aa-45d9-b205-b356d6be9605" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_9649fda0-db83-46b7-9227-422331cceb9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations_5c46ba46-7ad2-4732-b3e4-60948b936ab6" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations_5c46ba46-7ad2-4732-b3e4-60948b936ab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerNumberOfMembershipModels_824ded6b-1c2c-42b0-9dfc-87a00ab470d6" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerNumberOfMembershipModels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_RevenueFromContractWithCustomerNumberOfMembershipModels_824ded6b-1c2c-42b0-9dfc-87a00ab470d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerRenewalPeriod_3b9abc92-e0ce-409f-adc1-8b6a8744708e" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerRenewalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_ContractWithCustomerRenewalPeriod_3b9abc92-e0ce-409f-adc1-8b6a8744708e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerRevenueRecognitionPeriod_45ead388-d735-4fad-9103-f5ae16e5ed2b" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerRevenueRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_ContractWithCustomerRevenueRecognitionPeriod_45ead388-d735-4fad-9103-f5ae16e5ed2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8a18c274-e6a9-4c49-a9cc-e7fe863f0240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8a18c274-e6a9-4c49-a9cc-e7fe863f0240" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8c91cdb2-7344-4e26-b91b-9c01e398fcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8c91cdb2-7344-4e26-b91b-9c01e398fcc2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerNumberOfSalesCategories_4a683105-79bd-4f35-95d0-c009933befd4" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerNumberOfSalesCategories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_RevenueFromContractWithCustomerNumberOfSalesCategories_4a683105-79bd-4f35-95d0-c009933befd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_fd3a9e44-f2ac-49f7-b393-94099221d025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_fd3a9e44-f2ac-49f7-b393-94099221d025" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bfc83512-5a91-4f33-bd70-dbce39ae642f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bfc83512-5a91-4f33-bd70-dbce39ae642f" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b162f540-44f4-49ce-b9fd-bcd471efc66f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b1c3493b-9606-4ba3-aadf-733998b99b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b162f540-44f4-49ce-b9fd-bcd471efc66f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b1c3493b-9606-4ba3-aadf-733998b99b92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_65671610-3424-4b63-b902-8beef8a004ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b1c3493b-9606-4ba3-aadf-733998b99b92" xlink:to="loc_srt_MajorCustomersAxis_65671610-3424-4b63-b902-8beef8a004ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_65671610-3424-4b63-b902-8beef8a004ab_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_65671610-3424-4b63-b902-8beef8a004ab" xlink:to="loc_srt_NameOfMajorCustomerDomain_65671610-3424-4b63-b902-8beef8a004ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2802a810-5974-4b41-b7c2-e19b83fe8b63" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_65671610-3424-4b63-b902-8beef8a004ab" xlink:to="loc_srt_NameOfMajorCustomerDomain_2802a810-5974-4b41-b7c2-e19b83fe8b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipFeesMember_8f0756bc-a789-4418-9f40-801921eaa416" xlink:href="pets-20240331.xsd#pets_MembershipFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2802a810-5974-4b41-b7c2-e19b83fe8b63" xlink:to="loc_pets_MembershipFeesMember_8f0756bc-a789-4418-9f40-801921eaa416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipCustomersMember_ede12d2e-a8ee-4ebd-8343-10d899d34591" xlink:href="pets-20240331.xsd#pets_MembershipCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2802a810-5974-4b41-b7c2-e19b83fe8b63" xlink:to="loc_pets_MembershipCustomersMember_ede12d2e-a8ee-4ebd-8343-10d899d34591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1f7643f2-16e5-4aa1-967e-b75814ea9ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b1c3493b-9606-4ba3-aadf-733998b99b92" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1f7643f2-16e5-4aa1-967e-b75814ea9ee3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f7643f2-16e5-4aa1-967e-b75814ea9ee3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1f7643f2-16e5-4aa1-967e-b75814ea9ee3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f7643f2-16e5-4aa1-967e-b75814ea9ee3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f34b3a4c-b673-47fc-81f2-f3561c2d1662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1f7643f2-16e5-4aa1-967e-b75814ea9ee3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f34b3a4c-b673-47fc-81f2-f3561c2d1662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_ae720b6a-309d-43f0-94c2-1827757e9b5a" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f34b3a4c-b673-47fc-81f2-f3561c2d1662" xlink:to="loc_pets_PetCareRxIncMember_ae720b6a-309d-43f0-94c2-1827757e9b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerLiabilityCurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b162f540-44f4-49ce-b9fd-bcd471efc66f" xlink:to="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a26fd34c-cdd7-4f57-a262-322db087c03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a26fd34c-cdd7-4f57-a262-322db087c03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_723bc7c5-266d-46c2-a15d-91176b3f3413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_723bc7c5-266d-46c2-a15d-91176b3f3413" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived_d61e3596-9146-4d0f-ac4f-6835a3c9c941" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:to="loc_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived_d61e3596-9146-4d0f-ac4f-6835a3c9c941" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f7fde755-edf6-4464-bc87-9ff6ef490acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f7fde755-edf6-4464-bc87-9ff6ef490acf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4cc964ec-a6ac-4fd7-aebf-23642ef28ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RevenueRecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f8153b52-96f6-473b-a39b-2f2d5c0c44c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f8153b52-96f6-473b-a39b-2f2d5c0c44c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2e3ce27d-43c9-4db3-be43-eeb563e63c2e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f8153b52-96f6-473b-a39b-2f2d5c0c44c8" xlink:to="loc_srt_MajorCustomersAxis_2e3ce27d-43c9-4db3-be43-eeb563e63c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2e3ce27d-43c9-4db3-be43-eeb563e63c2e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2e3ce27d-43c9-4db3-be43-eeb563e63c2e" xlink:to="loc_srt_NameOfMajorCustomerDomain_2e3ce27d-43c9-4db3-be43-eeb563e63c2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2e3ce27d-43c9-4db3-be43-eeb563e63c2e" xlink:to="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ReorderMember_ad80385e-3658-44f6-bab0-776aa2e9a1b2" xlink:href="pets-20240331.xsd#pets_ReorderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:to="loc_pets_ReorderMember_ad80385e-3658-44f6-bab0-776aa2e9a1b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NewOrderMember_7e7e85e5-b383-4634-bf74-a170ec7569b4" xlink:href="pets-20240331.xsd#pets_NewOrderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:to="loc_pets_NewOrderMember_7e7e85e5-b383-4634-bf74-a170ec7569b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipFeesMember_87a57d03-9798-427c-99aa-2c6d425d6c10" xlink:href="pets-20240331.xsd#pets_MembershipFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:to="loc_pets_MembershipFeesMember_87a57d03-9798-427c-99aa-2c6d425d6c10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d4715c83-6db3-4c20-aa47-d2ad9c7aa7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d4715c83-6db3-4c20-aa47-d2ad9c7aa7dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerPercentage_cfaa850a-0964-47c1-93ee-2b353e8f95e7" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:to="loc_pets_RevenueFromContractWithCustomerPercentage_cfaa850a-0964-47c1-93ee-2b353e8f95e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerVariance_4d545b87-4f84-4b96-b59c-2c57704d3a9d" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerVariance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:to="loc_pets_RevenueFromContractWithCustomerVariance_4d545b87-4f84-4b96-b59c-2c57704d3a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerVariancePercentage_8cfcd3dc-ea55-4ee2-93a5-59a993e911b1" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerVariancePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:to="loc_pets_RevenueFromContractWithCustomerVariancePercentage_8cfcd3dc-ea55-4ee2-93a5-59a993e911b1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AcquisitionNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#AcquisitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/AcquisitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db40cfa5-5e49-49a6-8ba2-6705bc6706cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db40cfa5-5e49-49a6-8ba2-6705bc6706cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_269965b7-c245-4e27-a7f9-5544f0b8400e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db40cfa5-5e49-49a6-8ba2-6705bc6706cd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_269965b7-c245-4e27-a7f9-5544f0b8400e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_269965b7-c245-4e27-a7f9-5544f0b8400e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_269965b7-c245-4e27-a7f9-5544f0b8400e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_269965b7-c245-4e27-a7f9-5544f0b8400e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a67f7ee-a8a3-4018-b976-98ae0666da37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_269965b7-c245-4e27-a7f9-5544f0b8400e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a67f7ee-a8a3-4018-b976-98ae0666da37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_35c3c58f-a3c0-4eac-8afc-72e3adf516f7" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a67f7ee-a8a3-4018-b976-98ae0666da37" xlink:to="loc_pets_PetCareRxIncMember_35c3c58f-a3c0-4eac-8afc-72e3adf516f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_347746b8-912d-49e5-a559-28b2121abf06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_347746b8-912d-49e5-a559-28b2121abf06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f696100b-d381-4e8b-992b-a6a2068ba0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f696100b-d381-4e8b-992b-a6a2068ba0dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_947078c7-b381-489d-8b31-910e5418b32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_Goodwill_947078c7-b381-489d-8b31-910e5418b32c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_069479ad-8cb5-46ea-99bd-a28cf83b02d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_069479ad-8cb5-46ea-99bd-a28cf83b02d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate_22c1364e-06ee-4702-93e4-825d121c3a11" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate_22c1364e-06ee-4702-93e4-825d121c3a11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_ee50d040-8548-4938-add4-63b309aefdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_ee50d040-8548-4938-add4-63b309aefdfc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5fadb724-7a1a-4471-8b98-cfbd92c160e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5fadb724-7a1a-4471-8b98-cfbd92c160e9" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cfe281c-414f-4033-8ae0-c65b21262fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cfe281c-414f-4033-8ae0-c65b21262fed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_13a352f1-22df-4494-87dc-dca7dd2e857d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cfe281c-414f-4033-8ae0-c65b21262fed" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_13a352f1-22df-4494-87dc-dca7dd2e857d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13a352f1-22df-4494-87dc-dca7dd2e857d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_13a352f1-22df-4494-87dc-dca7dd2e857d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13a352f1-22df-4494-87dc-dca7dd2e857d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_931336b0-ec7d-4881-8d1f-58743b8e34de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_13a352f1-22df-4494-87dc-dca7dd2e857d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_931336b0-ec7d-4881-8d1f-58743b8e34de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_b5c6ccd5-bbc2-4309-a724-7485231efdf4" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_931336b0-ec7d-4881-8d1f-58743b8e34de" xlink:to="loc_pets_PetCareRxIncMember_b5c6ccd5-bbc2-4309-a724-7485231efdf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e9676282-a622-4d04-95d6-4bbefdd1db86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e9676282-a622-4d04-95d6-4bbefdd1db86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8d08f7ec-50a4-494f-97e0-988866fc4f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8d08f7ec-50a4-494f-97e0-988866fc4f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables_f9b79357-6536-4a2f-adde-c50442fac9aa" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables_f9b79357-6536-4a2f-adde-c50442fac9aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_95902ff8-dca2-4290-b419-9f7e1455e8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_95902ff8-dca2-4290-b419-9f7e1455e8ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_5dfcd95e-26e3-483e-856c-7ae32ceb843e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_5dfcd95e-26e3-483e-856c-7ae32ceb843e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d086e891-ffb2-4792-8d7d-2804d958b586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d086e891-ffb2-4792-8d7d-2804d958b586" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_df6089ab-bc9d-4003-ac9f-35b5921eda23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_df6089ab-bc9d-4003-ac9f-35b5921eda23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1f358d2b-a72d-409c-87ee-2da96695c908" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_Goodwill_1f358d2b-a72d-409c-87ee-2da96695c908" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5127684b-2fde-4e44-86b8-d37dc99972b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5127684b-2fde-4e44-86b8-d37dc99972b2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets_09748ed6-9c0d-4fda-adfc-25e20552f969" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets_09748ed6-9c0d-4fda-adfc-25e20552f969" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_aaa9a376-299c-4c82-bf33-1e893e1c020d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_aaa9a376-299c-4c82-bf33-1e893e1c020d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_fe0afcb4-519c-4118-ac9b-bb5562f8e6dd" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_fe0afcb4-519c-4118-ac9b-bb5562f8e6dd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6144661c-dd75-4818-801b-924369c915b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6144661c-dd75-4818-801b-924369c915b0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_04a30640-d8f9-410f-96ba-e38d4a3b3605" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_04a30640-d8f9-410f-96ba-e38d4a3b3605" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_8d025976-e14d-4523-a103-d15012afa51f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_8d025976-e14d-4523-a103-d15012afa51f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_ec6c0447-051e-4e6b-9a8c-e2e7d6da029b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_ec6c0447-051e-4e6b-9a8c-e2e7d6da029b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_efafe41a-5890-4c08-be36-f9372b441d01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_efafe41a-5890-4c08-be36-f9372b441d01" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1916fb10-24d6-456c-acb6-96370568ef1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1916fb10-24d6-456c-acb6-96370568ef1d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5f593023-2070-495c-97be-dfc429e6ddf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5f593023-2070-495c-97be-dfc429e6ddf1" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#AcquisitionScheduleofProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_efe8cec1-00f7-418a-80d9-9206ce40a551" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_40313a9b-bd1d-4327-914a-cae5be23815b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_efe8cec1-00f7-418a-80d9-9206ce40a551" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_40313a9b-bd1d-4327-914a-cae5be23815b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_67689cc5-9e3b-42c3-bf07-cb35498a1aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_40313a9b-bd1d-4327-914a-cae5be23815b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_67689cc5-9e3b-42c3-bf07-cb35498a1aa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_67689cc5-9e3b-42c3-bf07-cb35498a1aa0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_67689cc5-9e3b-42c3-bf07-cb35498a1aa0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_67689cc5-9e3b-42c3-bf07-cb35498a1aa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5dc9be26-11f9-43eb-be36-292e6f376e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_67689cc5-9e3b-42c3-bf07-cb35498a1aa0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5dc9be26-11f9-43eb-be36-292e6f376e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_3ee72758-edbe-4e84-ad42-ce50a4a03c82" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5dc9be26-11f9-43eb-be36-292e6f376e8d" xlink:to="loc_pets_PetCareRxIncMember_3ee72758-edbe-4e84-ad42-ce50a4a03c82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c556290c-780e-49f8-928e-a2dd869547ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_efe8cec1-00f7-418a-80d9-9206ce40a551" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c556290c-780e-49f8-928e-a2dd869547ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_a15c0719-2187-433e-b8d1-3777bc946e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_efe8cec1-00f7-418a-80d9-9206ce40a551" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_a15c0719-2187-433e-b8d1-3777bc946e1c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d029573a-be0b-4f5c-bcbd-8b601f88d76b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d029573a-be0b-4f5c-bcbd-8b601f88d76b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb4a7ac6-90b4-419e-b764-ff7c0eb966cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d029573a-be0b-4f5c-bcbd-8b601f88d76b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb4a7ac6-90b4-419e-b764-ff7c0eb966cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb4a7ac6-90b4-419e-b764-ff7c0eb966cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb4a7ac6-90b4-419e-b764-ff7c0eb966cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb4a7ac6-90b4-419e-b764-ff7c0eb966cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb4a7ac6-90b4-419e-b764-ff7c0eb966cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_c2a4eacb-3021-4561-bf21-af9bb3ffd671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_BuildingMember_c2a4eacb-3021-4561-bf21-af9bb3ffd671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_18e8ab7e-498e-4922-a8f1-f0381c00f271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_LandMember_18e8ab7e-498e-4922-a8f1-f0381c00f271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember_8b5827cc-0edf-4a23-9f69-cf1213f9fdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_BuildingImprovementsMember_8b5827cc-0edf-4a23-9f69-cf1213f9fdf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_39135436-ef07-49ff-9208-f192c55f0c30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_39135436-ef07-49ff-9208-f192c55f0c30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_80f97d45-401f-4876-8760-419863722ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_80f97d45-401f-4876-8760-419863722ced" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_790d8f7c-2bd8-43eb-b368-a55daab7b009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_790d8f7c-2bd8-43eb-b368-a55daab7b009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f0a3e44-b067-4a3e-90fd-ac4154bddcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f0a3e44-b067-4a3e-90fd-ac4154bddcf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e175847d-f190-4280-9c11-fb588e4b8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e175847d-f190-4280-9c11-fb588e4b8c4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_98b0c65b-9b64-403d-b6ee-566cca7de021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:to="loc_us-gaap_Depreciation_98b0c65b-9b64-403d-b6ee-566cca7de021" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNetScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be437517-32d0-4c98-bf59-4c4c24ee4872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be437517-32d0-4c98-bf59-4c4c24ee4872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_be437517-32d0-4c98-bf59-4c4c24ee4872_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be437517-32d0-4c98-bf59-4c4c24ee4872" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_be437517-32d0-4c98-bf59-4c4c24ee4872_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be437517-32d0-4c98-bf59-4c4c24ee4872" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TollFreeTelephoneNumberMember_3a339d04-eb7b-453b-b5d0-bb81b488f757" xlink:href="pets-20240331.xsd#pets_TollFreeTelephoneNumberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:to="loc_pets_TollFreeTelephoneNumberMember_3a339d04-eb7b-453b-b5d0-bb81b488f757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternetDomainNamesMember_d10d2530-f9d1-4611-9750-e5a1069af37c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternetDomainNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:to="loc_us-gaap_InternetDomainNamesMember_d10d2530-f9d1-4611-9750-e5a1069af37c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_58618f9f-c95d-4748-b884-6899600ad7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:to="loc_us-gaap_TradeNamesMember_58618f9f-c95d-4748-b884-6899600ad7b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45214400-e10a-4cec-9f6c-7ffa87484cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45214400-e10a-4cec-9f6c-7ffa87484cc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_45214400-e10a-4cec-9f6c-7ffa87484cc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45214400-e10a-4cec-9f6c-7ffa87484cc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_45214400-e10a-4cec-9f6c-7ffa87484cc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_522ff5f0-e678-40c0-9805-807415e4f484" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45214400-e10a-4cec-9f6c-7ffa87484cc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_522ff5f0-e678-40c0-9805-807415e4f484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2974da5e-1553-4fcb-b5e4-1ebe503202a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_522ff5f0-e678-40c0-9805-807415e4f484" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2974da5e-1553-4fcb-b5e4-1ebe503202a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0363af92-f9bf-431f-b8d0-a229beb0828e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_522ff5f0-e678-40c0-9805-807415e4f484" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0363af92-f9bf-431f-b8d0-a229beb0828e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_816f5e3b-acbf-420e-9421-fe7b9f2656cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_816f5e3b-acbf-420e-9421-fe7b9f2656cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_816f5e3b-acbf-420e-9421-fe7b9f2656cd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_816f5e3b-acbf-420e-9421-fe7b9f2656cd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_816f5e3b-acbf-420e-9421-fe7b9f2656cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ecbd1670-bfb2-4643-8f34-3d6835153660" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_816f5e3b-acbf-420e-9421-fe7b9f2656cd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ecbd1670-bfb2-4643-8f34-3d6835153660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_VetsterIncMember_57ba3cd2-67c3-4638-b62f-93f4052aa576" xlink:href="pets-20240331.xsd#pets_VetsterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ecbd1670-bfb2-4643-8f34-3d6835153660" xlink:to="loc_pets_VetsterIncMember_57ba3cd2-67c3-4638-b62f-93f4052aa576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_49f26c7c-c389-46b1-84cd-d3fd7a5e13cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_49f26c7c-c389-46b1-84cd-d3fd7a5e13cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4b544ddd-6f4c-41e9-bf35-19a9a46230f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4b544ddd-6f4c-41e9-bf35-19a9a46230f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a93a73d-ccb6-439f-8b8a-388d98a60a91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a93a73d-ccb6-439f-8b8a-388d98a60a91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0e70902d-f12f-47db-a415-d03331e32998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0e70902d-f12f-47db-a415-d03331e32998" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f777e90-8887-4e13-829f-1416212ed34f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f777e90-8887-4e13-829f-1416212ed34f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ab9169b8-4668-409e-a777-5e11011a5122" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ab9169b8-4668-409e-a777-5e11011a5122" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c4f4d482-c216-457d-bc1a-55464224a124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_141d2819-b2db-43da-bf11-8e143a835d87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ab9169b8-4668-409e-a777-5e11011a5122" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_141d2819-b2db-43da-bf11-8e143a835d87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f960de0b-2c7d-4bdf-970a-effc48705bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ab9169b8-4668-409e-a777-5e11011a5122" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f960de0b-2c7d-4bdf-970a-effc48705bc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_82d0a2dd-ee2b-4556-beb6-6d54c9729b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_82d0a2dd-ee2b-4556-beb6-6d54c9729b94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsAbstract_249d4c7f-e156-472d-904d-a62e17099bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_OtherAssetsAbstract_249d4c7f-e156-472d-904d-a62e17099bb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_3887c216-d073-4fad-a5be-bb60e8530e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherAssetsAbstract_249d4c7f-e156-472d-904d-a62e17099bb5" xlink:to="loc_us-gaap_Investments_3887c216-d073-4fad-a5be-bb60e8530e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_087094a7-3a15-4687-af6e-44082b337d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherAssetsAbstract_249d4c7f-e156-472d-904d-a62e17099bb5" xlink:to="loc_us-gaap_EquityMethodInvestments_087094a7-3a15-4687-af6e-44082b337d72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:href="pets-20240331.xsd#pets_IntangiblesAndOtherAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssetsGross_fbfaa27d-1bd6-47cd-b3ac-b874a28ef2a2" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:to="loc_pets_IntangibleAndOtherAssetsGross_fbfaa27d-1bd6-47cd-b3ac-b874a28ef2a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangiblesAndOtherAssetsAccumulatedAmortization_8094474a-9191-48c6-ad16-b2a129ab5d4b" xlink:href="pets-20240331.xsd#pets_IntangiblesAndOtherAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:to="loc_pets_IntangiblesAndOtherAssetsAccumulatedAmortization_8094474a-9191-48c6-ad16-b2a129ab5d4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssets_4835f505-845b-4030-a83e-b969f8735f35" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:to="loc_pets_IntangibleAndOtherAssets_4835f505-845b-4030-a83e-b969f8735f35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_22a3fb28-903f-4c9b-8c32-38b14abd8250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_22a3fb28-903f-4c9b-8c32-38b14abd8250" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TermOfAgreement_be8169b8-9bda-4273-93c1-2e1c36289110" xlink:href="pets-20240331.xsd#pets_TermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_pets_TermOfAgreement_be8169b8-9bda-4273-93c1-2e1c36289110" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e8cbd90a-b48f-483d-b771-e4d63e2908b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e8cbd90a-b48f-483d-b771-e4d63e2908b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9506d900-538c-4533-bd54-6eadc9efed95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9506d900-538c-4533-bd54-6eadc9efed95" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7792cb64-7772-42a2-b635-95a75a426fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7792cb64-7772-42a2-b635-95a75a426fbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_297a4151-4e8a-4e9a-bb82-8bea4c62dd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7792cb64-7772-42a2-b635-95a75a426fbc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_297a4151-4e8a-4e9a-bb82-8bea4c62dd3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_297a4151-4e8a-4e9a-bb82-8bea4c62dd3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_297a4151-4e8a-4e9a-bb82-8bea4c62dd3f" xlink:to="loc_us-gaap_RelatedPartyDomain_297a4151-4e8a-4e9a-bb82-8bea4c62dd3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6daf3e28-3c70-4920-9f57-31423a11bf04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_297a4151-4e8a-4e9a-bb82-8bea4c62dd3f" xlink:to="loc_us-gaap_RelatedPartyDomain_6daf3e28-3c70-4920-9f57-31423a11bf04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_2fecb046-3263-4d74-988f-a46b3494189c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6daf3e28-3c70-4920-9f57-31423a11bf04" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_2fecb046-3263-4d74-988f-a46b3494189c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5cfe0cd-e62d-428a-aa29-3a3dcc870ca3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7792cb64-7772-42a2-b635-95a75a426fbc" xlink:to="loc_srt_RangeAxis_a5cfe0cd-e62d-428a-aa29-3a3dcc870ca3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5cfe0cd-e62d-428a-aa29-3a3dcc870ca3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a5cfe0cd-e62d-428a-aa29-3a3dcc870ca3" xlink:to="loc_srt_RangeMember_a5cfe0cd-e62d-428a-aa29-3a3dcc870ca3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eaee01fc-315a-4a59-a494-09076f29fb74" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a5cfe0cd-e62d-428a-aa29-3a3dcc870ca3" xlink:to="loc_srt_RangeMember_eaee01fc-315a-4a59-a494-09076f29fb74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b05a6f59-3aad-4fdf-ba4e-2ef9c20791df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eaee01fc-315a-4a59-a494-09076f29fb74" xlink:to="loc_srt_MinimumMember_b05a6f59-3aad-4fdf-ba4e-2ef9c20791df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26a567e9-c662-4c71-914b-69efa9cfea5d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eaee01fc-315a-4a59-a494-09076f29fb74" xlink:to="loc_srt_MaximumMember_26a567e9-c662-4c71-914b-69efa9cfea5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_4daefed7-347a-4edd-b130-e44d4885b148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_4daefed7-347a-4edd-b130-e44d4885b148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b9d46175-14c1-474c-a74c-6b43b05d88b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b9d46175-14c1-474c-a74c-6b43b05d88b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_93675663-8343-4f81-8519-9475d36006db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_93675663-8343-4f81-8519-9475d36006db" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_da86f11c-ceaa-4567-a0fe-2113ea93eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_da86f11c-ceaa-4567-a0fe-2113ea93eb5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_276707b1-f3aa-49e5-b04d-94eabcded9b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_da86f11c-ceaa-4567-a0fe-2113ea93eb5d" xlink:to="loc_srt_RangeAxis_276707b1-f3aa-49e5-b04d-94eabcded9b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_276707b1-f3aa-49e5-b04d-94eabcded9b6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_276707b1-f3aa-49e5-b04d-94eabcded9b6" xlink:to="loc_srt_RangeMember_276707b1-f3aa-49e5-b04d-94eabcded9b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5b3f0a2-6f3b-41cd-b6dc-f7045e7cc412" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_276707b1-f3aa-49e5-b04d-94eabcded9b6" xlink:to="loc_srt_RangeMember_d5b3f0a2-6f3b-41cd-b6dc-f7045e7cc412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0448969c-3aa8-46c9-a621-07188976b4db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d5b3f0a2-6f3b-41cd-b6dc-f7045e7cc412" xlink:to="loc_srt_MinimumMember_0448969c-3aa8-46c9-a621-07188976b4db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c45402b2-3a3c-4d5b-a42b-d5febe33a8b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d5b3f0a2-6f3b-41cd-b6dc-f7045e7cc412" xlink:to="loc_srt_MaximumMember_c45402b2-3a3c-4d5b-a42b-d5febe33a8b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_321c761c-893b-44c2-8edb-461fd094a060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_321c761c-893b-44c2-8edb-461fd094a060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a527610f-9ede-4468-97c8-26f414b5e2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a527610f-9ede-4468-97c8-26f414b5e2c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a9573e00-085a-46f9-b859-ca6ccbab2351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a9573e00-085a-46f9-b859-ca6ccbab2351" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_8f57a229-8d24-47d6-a324-94af0962b712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_8f57a229-8d24-47d6-a324-94af0962b712" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_2c13171e-c797-48ac-bab5-5412cd0588a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_2c13171e-c797-48ac-bab5-5412cd0588a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_97a28359-f3c1-4c32-9f3d-87859db54251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2c13171e-c797-48ac-bab5-5412cd0588a9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_97a28359-f3c1-4c32-9f3d-87859db54251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_97a28359-f3c1-4c32-9f3d-87859db54251_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_97a28359-f3c1-4c32-9f3d-87859db54251" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_97a28359-f3c1-4c32-9f3d-87859db54251_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0bfb9b64-5d4b-48b1-9260-13d74da03a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_97a28359-f3c1-4c32-9f3d-87859db54251" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0bfb9b64-5d4b-48b1-9260-13d74da03a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3372339e-88af-4682-89ad-33c6350ba48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0bfb9b64-5d4b-48b1-9260-13d74da03a39" xlink:to="loc_us-gaap_DomesticCountryMember_3372339e-88af-4682-89ad-33c6350ba48b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e6684f57-14a2-41cb-ab0a-04dd07a62da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0bfb9b64-5d4b-48b1-9260-13d74da03a39" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e6684f57-14a2-41cb-ab0a-04dd07a62da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6f4adf7d-1b06-43ed-b82c-3b8b5108085b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6f4adf7d-1b06-43ed-b82c-3b8b5108085b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a9da51f0-5e18-4733-a344-2d0fbc503b01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a9da51f0-5e18-4733-a344-2d0fbc503b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9cab9b7b-4799-48e9-83ec-f3f7a05c58c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9cab9b7b-4799-48e9-83ec-f3f7a05c58c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment_f8a8fc8c-bade-4adf-83a0-632b5ec81fc0" xlink:href="pets-20240331.xsd#pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment_f8a8fc8c-bade-4adf-83a0-632b5ec81fc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount_3f8cde88-e138-4f4c-b931-4b7add4daf74" xlink:href="pets-20240331.xsd#pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount_3f8cde88-e138-4f4c-b931-4b7add4daf74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_b3420488-141e-4545-9b1d-5f73c884e51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_b3420488-141e-4545-9b1d-5f73c884e51c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_217167f0-3b46-4fdd-9052-4709f07f1cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_217167f0-3b46-4fdd-9052-4709f07f1cd0" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesTaxAttributesDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a15f57f8-6321-4643-846d-75b5004cb05e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a15f57f8-6321-4643-846d-75b5004cb05e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a15f57f8-6321-4643-846d-75b5004cb05e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a15f57f8-6321-4643-846d-75b5004cb05e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a15f57f8-6321-4643-846d-75b5004cb05e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63472c99-dc6a-48aa-8b8a-7ea821afa96c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a15f57f8-6321-4643-846d-75b5004cb05e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63472c99-dc6a-48aa-8b8a-7ea821afa96c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_72adcf92-6cac-4521-86cf-b3fa28cf655d" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63472c99-dc6a-48aa-8b8a-7ea821afa96c" xlink:to="loc_pets_PetCareRxIncMember_72adcf92-6cac-4521-86cf-b3fa28cf655d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_babc60f6-454a-419c-bea1-2d899aaad3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_babc60f6-454a-419c-bea1-2d899aaad3c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_babc60f6-454a-419c-bea1-2d899aaad3c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_babc60f6-454a-419c-bea1-2d899aaad3c0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_babc60f6-454a-419c-bea1-2d899aaad3c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_64205353-9dfc-4f02-bec1-584772bd6cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_babc60f6-454a-419c-bea1-2d899aaad3c0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_64205353-9dfc-4f02-bec1-584772bd6cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_db7c5d53-311a-4fb7-a361-8533b0cccc01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_64205353-9dfc-4f02-bec1-584772bd6cd8" xlink:to="loc_us-gaap_DomesticCountryMember_db7c5d53-311a-4fb7-a361-8533b0cccc01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_94532d52-f784-4698-b167-82ab54f0cab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_64205353-9dfc-4f02-bec1-584772bd6cd8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_94532d52-f784-4698-b167-82ab54f0cab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardAxis_4ea223b4-e904-4e73-a107-21b5c8272b82" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:to="loc_pets_OperatingLossCarryforwardAxis_4ea223b4-e904-4e73-a107-21b5c8272b82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardDomain_4ea223b4-e904-4e73-a107-21b5c8272b82_default" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pets_OperatingLossCarryforwardAxis_4ea223b4-e904-4e73-a107-21b5c8272b82" xlink:to="loc_pets_OperatingLossCarryforwardDomain_4ea223b4-e904-4e73-a107-21b5c8272b82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardDomain_794e9cc6-5978-47a2-a3ad-6500f8860b8a" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pets_OperatingLossCarryforwardAxis_4ea223b4-e904-4e73-a107-21b5c8272b82" xlink:to="loc_pets_OperatingLossCarryforwardDomain_794e9cc6-5978-47a2-a3ad-6500f8860b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SEC382LimitedUtilizationMember_e769e81c-025d-48cb-8371-caac025587ec" xlink:href="pets-20240331.xsd#pets_SEC382LimitedUtilizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pets_OperatingLossCarryforwardDomain_794e9cc6-5978-47a2-a3ad-6500f8860b8a" xlink:to="loc_pets_SEC382LimitedUtilizationMember_e769e81c-025d-48cb-8371-caac025587ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetIsRecordedMember_2688131a-4f82-4d45-99ba-eca2ef2f13a3" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetIsRecordedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pets_OperatingLossCarryforwardDomain_794e9cc6-5978-47a2-a3ad-6500f8860b8a" xlink:to="loc_pets_DeferredTaxAssetIsRecordedMember_2688131a-4f82-4d45-99ba-eca2ef2f13a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardsSubjectToLimitations_006fcfcd-3fa7-4636-af7e-407c37470302" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardsSubjectToLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:to="loc_pets_OperatingLossCarryforwardsSubjectToLimitations_006fcfcd-3fa7-4636-af7e-407c37470302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardsNotSubjectToLimitations_f70fffad-e6f1-4d9e-96e9-a0460611d549" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardsNotSubjectToLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:to="loc_pets_OperatingLossCarryforwardsNotSubjectToLimitations_f70fffad-e6f1-4d9e-96e9-a0460611d549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DisallowedBusinessInterestExpenseCarryover_8dd38ed1-d13d-4831-b6df-d1f7cce884d9" xlink:href="pets-20240331.xsd#pets_DisallowedBusinessInterestExpenseCarryover"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:to="loc_pets_DisallowedBusinessInterestExpenseCarryover_8dd38ed1-d13d-4831-b6df-d1f7cce884d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_47fdb30f-7dc4-407b-b352-e29322a8b747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_47fdb30f-7dc4-407b-b352-e29322a8b747" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bcf95668-dbcb-4081-bbdf-409722669629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bcf95668-dbcb-4081-bbdf-409722669629" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c2277204-eeab-489c-bb0e-6d1d2a07177b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bcf95668-dbcb-4081-bbdf-409722669629" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c2277204-eeab-489c-bb0e-6d1d2a07177b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c2277204-eeab-489c-bb0e-6d1d2a07177b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2277204-eeab-489c-bb0e-6d1d2a07177b" xlink:to="loc_us-gaap_ClassOfStockDomain_c2277204-eeab-489c-bb0e-6d1d2a07177b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_86d219ba-b3b1-4d77-ba37-e0156d31b3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2277204-eeab-489c-bb0e-6d1d2a07177b" xlink:to="loc_us-gaap_ClassOfStockDomain_86d219ba-b3b1-4d77-ba37-e0156d31b3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_791d167a-b7b0-4a48-ba28-b11603d9ee40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_86d219ba-b3b1-4d77-ba37-e0156d31b3e1" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_791d167a-b7b0-4a48-ba28-b11603d9ee40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_23866fb3-d041-43aa-9e17-e3dec8f4e299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PreferredStockSharesIssued_23866fb3-d041-43aa-9e17-e3dec8f4e299" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0b484396-4ffa-4d55-9cf3-7f0ab7176ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0b484396-4ffa-4d55-9cf3-7f0ab7176ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_aaa51d80-865d-4cb1-89c6-e969e576bdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_aaa51d80-865d-4cb1-89c6-e969e576bdf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a124679e-c23c-42dd-8d1e-e4c55607f88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a124679e-c23c-42dd-8d1e-e4c55607f88a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_430587c8-0220-4e80-9927-4e228ef3c6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_430587c8-0220-4e80-9927-4e228ef3c6a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_3425b045-c098-4536-bfbe-bbfabcee5b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_3425b045-c098-4536-bfbe-bbfabcee5b5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d435dc3f-272f-43bb-a0ed-a078fbb304d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d435dc3f-272f-43bb-a0ed-a078fbb304d2" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RestrictedStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c3e51427-abb3-4393-83ba-652524c7349c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_PlanNameAxis_c3e51427-abb3-4393-83ba-652524c7349c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c3e51427-abb3-4393-83ba-652524c7349c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c3e51427-abb3-4393-83ba-652524c7349c" xlink:to="loc_us-gaap_PlanNameDomain_c3e51427-abb3-4393-83ba-652524c7349c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c3e51427-abb3-4393-83ba-652524c7349c" xlink:to="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_0cb6168b-4a44-40ce-9898-54725c4d8d58" xlink:href="pets-20240331.xsd#pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_0cb6168b-4a44-40ce-9898-54725c4d8d58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_e1e9504b-48a2-4c0e-a429-f51410cb641e" xlink:href="pets-20240331.xsd#pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_e1e9504b-48a2-4c0e-a429-f51410cb641e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_22de78fa-bf16-4164-8003-b2c042654e73" xlink:href="pets-20240331.xsd#pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_22de78fa-bf16-4164-8003-b2c042654e73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmployeeAndDirectorEquityCompensationPlanMember_4e766617-cd4c-4416-8d4b-b141b26f90f5" xlink:href="pets-20240331.xsd#pets_EmployeeAndDirectorEquityCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_EmployeeAndDirectorEquityCompensationPlanMember_4e766617-cd4c-4416-8d4b-b141b26f90f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_A2022EmployeePlanMember_2e95157f-401b-4f09-9ee5-6b47793dd762" xlink:href="pets-20240331.xsd#pets_A2022EmployeePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_A2022EmployeePlanMember_2e95157f-401b-4f09-9ee5-6b47793dd762" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d86827c2-b350-4cb7-ab10-ba5356aae424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_AwardTypeAxis_d86827c2-b350-4cb7-ab10-ba5356aae424" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d86827c2-b350-4cb7-ab10-ba5356aae424_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d86827c2-b350-4cb7-ab10-ba5356aae424" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d86827c2-b350-4cb7-ab10-ba5356aae424_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d86827c2-b350-4cb7-ab10-ba5356aae424" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f2044b89-7029-4698-b6df-49937ee86841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_us-gaap_RestrictedStockMember_f2044b89-7029-4698-b6df-49937ee86841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockMember_275dcaa7-d4f3-43ba-9d67-3911aec372c2" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_pets_PerformanceRestrictedStockMember_275dcaa7-d4f3-43ba-9d67-3911aec372c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ba3eafe6-165e-4686-9d7c-51ab1c13a671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_us-gaap_CommonStockMember_ba3eafe6-165e-4686-9d7c-51ab1c13a671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NonvestedRestrictedStockMember_4e6358e7-9c51-416a-b156-7ef210c2c723" xlink:href="pets-20240331.xsd#pets_NonvestedRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_pets_NonvestedRestrictedStockMember_4e6358e7-9c51-416a-b156-7ef210c2c723" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_dc564b3d-a4d3-40b1-91d1-84c0d37b4439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_us-gaap_PerformanceSharesMember_dc564b3d-a4d3-40b1-91d1-84c0d37b4439" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cec73ea3-6260-43f6-82c9-7d37f986edf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cec73ea3-6260-43f6-82c9-7d37f986edf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e51e0d30-d333-40a4-b570-bce2bdc0281e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_srt_RangeAxis_e51e0d30-d333-40a4-b570-bce2bdc0281e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e51e0d30-d333-40a4-b570-bce2bdc0281e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e51e0d30-d333-40a4-b570-bce2bdc0281e" xlink:to="loc_srt_RangeMember_e51e0d30-d333-40a4-b570-bce2bdc0281e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68dd5261-5040-4df7-8ac2-1d333e81cabc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e51e0d30-d333-40a4-b570-bce2bdc0281e" xlink:to="loc_srt_RangeMember_68dd5261-5040-4df7-8ac2-1d333e81cabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f57f9269-70a4-4f6f-aa90-afc63d5128a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68dd5261-5040-4df7-8ac2-1d333e81cabc" xlink:to="loc_srt_MinimumMember_f57f9269-70a4-4f6f-aa90-afc63d5128a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ecd37fd7-48ce-4bd5-881d-ede97e9aaf32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68dd5261-5040-4df7-8ac2-1d333e81cabc" xlink:to="loc_srt_MaximumMember_ecd37fd7-48ce-4bd5-881d-ede97e9aaf32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_aef2317b-3a4e-45ae-9393-0313cc280adc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_srt_TitleOfIndividualAxis_aef2317b-3a4e-45ae-9393-0313cc280adc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aef2317b-3a4e-45ae-9393-0313cc280adc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_aef2317b-3a4e-45ae-9393-0313cc280adc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aef2317b-3a4e-45ae-9393-0313cc280adc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdf47b7-f6f9-45f2-96bc-9659656e3158" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_aef2317b-3a4e-45ae-9393-0313cc280adc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdf47b7-f6f9-45f2-96bc-9659656e3158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_c813e5af-a088-43ee-b83d-04b29b9cc4e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdf47b7-f6f9-45f2-96bc-9659656e3158" xlink:to="loc_srt_ChiefExecutiveOfficerMember_c813e5af-a088-43ee-b83d-04b29b9cc4e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_8c634e18-f7e4-4f5f-b79e-f0211c0818be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdf47b7-f6f9-45f2-96bc-9659656e3158" xlink:to="loc_srt_ChiefFinancialOfficerMember_8c634e18-f7e4-4f5f-b79e-f0211c0818be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_84315637-7de0-47fa-a546-b7983cae9328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_VestingAxis_84315637-7de0-47fa-a546-b7983cae9328" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_84315637-7de0-47fa-a546-b7983cae9328_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_84315637-7de0-47fa-a546-b7983cae9328" xlink:to="loc_us-gaap_VestingDomain_84315637-7de0-47fa-a546-b7983cae9328_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_84315637-7de0-47fa-a546-b7983cae9328" xlink:to="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_df7f48e6-2d64-467c-aa88-84c55c236cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_df7f48e6-2d64-467c-aa88-84c55c236cef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7120d1a8-f1bb-4a32-93e4-e01044afe938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7120d1a8-f1bb-4a32-93e4-e01044afe938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2d31d444-7a26-45ed-bd88-701693c8b67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2d31d444-7a26-45ed-bd88-701693c8b67d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedPaymentArrangementTrancheFourMember_926a9862-e73f-4db7-8426-61ca45eabb8a" xlink:href="pets-20240331.xsd#pets_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:to="loc_pets_ShareBasedPaymentArrangementTrancheFourMember_926a9862-e73f-4db7-8426-61ca45eabb8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_133de437-1d71-4fc1-bd46-c873ed3970f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_AwardDateAxis_133de437-1d71-4fc1-bd46-c873ed3970f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_133de437-1d71-4fc1-bd46-c873ed3970f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_133de437-1d71-4fc1-bd46-c873ed3970f2" xlink:to="loc_us-gaap_AwardDateDomain_133de437-1d71-4fc1-bd46-c873ed3970f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_0d94fee2-ac91-4e46-8177-2a50996c061b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_133de437-1d71-4fc1-bd46-c873ed3970f2" xlink:to="loc_us-gaap_AwardDateDomain_0d94fee2-ac91-4e46-8177-2a50996c061b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_FiscalYear2023Member_c45a993f-cf2f-447e-ad43-8d67802d3a7d" xlink:href="pets-20240331.xsd#pets_FiscalYear2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_0d94fee2-ac91-4e46-8177-2a50996c061b" xlink:to="loc_pets_FiscalYear2023Member_c45a993f-cf2f-447e-ad43-8d67802d3a7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_FiscalYear2024Member_bcbd81c0-1bae-48dd-9f14-1f96ee5903b1" xlink:href="pets-20240331.xsd#pets_FiscalYear2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_0d94fee2-ac91-4e46-8177-2a50996c061b" xlink:to="loc_pets_FiscalYear2024Member_bcbd81c0-1bae-48dd-9f14-1f96ee5903b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4a8cf8a7-f59a-4363-8426-720521a227d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4a8cf8a7-f59a-4363-8426-720521a227d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4a8cf8a7-f59a-4363-8426-720521a227d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4a8cf8a7-f59a-4363-8426-720521a227d6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4a8cf8a7-f59a-4363-8426-720521a227d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8ab84278-02b6-4acc-a6bf-b52ce3b90a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4a8cf8a7-f59a-4363-8426-720521a227d6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8ab84278-02b6-4acc-a6bf-b52ce3b90a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1513ebd7-258d-41ef-b54b-2e55962f437d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ab84278-02b6-4acc-a6bf-b52ce3b90a6e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1513ebd7-258d-41ef-b54b-2e55962f437d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_b835806e-78fe-4f8c-b4da-9ff051d507b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_b835806e-78fe-4f8c-b4da-9ff051d507b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_b835806e-78fe-4f8c-b4da-9ff051d507b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_b835806e-78fe-4f8c-b4da-9ff051d507b6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_b835806e-78fe-4f8c-b4da-9ff051d507b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_358117b0-6087-4129-8aa3-de84c95df515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_b835806e-78fe-4f8c-b4da-9ff051d507b6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_358117b0-6087-4129-8aa3-de84c95df515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetIsRecordedMember_799ec6cd-9df6-423d-a4a6-fda53a19daab" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetIsRecordedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_358117b0-6087-4129-8aa3-de84c95df515" xlink:to="loc_pets_DeferredTaxAssetIsRecordedMember_799ec6cd-9df6-423d-a4a6-fda53a19daab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a4039f68-7435-44d2-943a-b31393feaa68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a4039f68-7435-44d2-943a-b31393feaa68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance_33969e56-81e6-4d5c-967f-e790b3be4f8e" xlink:href="pets-20240331.xsd#pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance_33969e56-81e6-4d5c-967f-e790b3be4f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RestrictionPeriod_7da17757-12d8-4578-a95f-291b7a37b774" xlink:href="pets-20240331.xsd#pets_RestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_pets_RestrictionPeriod_7da17757-12d8-4578-a95f-291b7a37b774" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9ab8f0b-5302-4ac3-8362-b7f6d376e71e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9ab8f0b-5302-4ac3-8362-b7f6d376e71e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_d5b7f63e-eae9-4abc-bf51-887aff706975" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_d5b7f63e-eae9-4abc-bf51-887aff706975" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_69f60bf9-fefa-45e9-b000-73a2fe9cd979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_69f60bf9-fefa-45e9-b000-73a2fe9cd979" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b790953d-1386-432b-8403-b6a66ab3184a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensation_b790953d-1386-432b-8403-b6a66ab3184a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2977d83-75ef-425b-bdd1-dac334672714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2977d83-75ef-425b-bdd1-dac334672714" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5c2e2003-fb1f-4020-ba13-a15edf65519a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5c2e2003-fb1f-4020-ba13-a15edf65519a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30722eb1-bb50-4ac9-acc2-cd04b0a27b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30722eb1-bb50-4ac9-acc2-cd04b0a27b4f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_63edd825-48bb-4ada-b17f-0edb1c4997e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_63edd825-48bb-4ada-b17f-0edb1c4997e4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b3e1295e-a065-496c-8894-bc7dbbaf762c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b3e1295e-a065-496c-8894-bc7dbbaf762c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2a6664e1-b8db-4680-9daf-bf5745314883" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2a6664e1-b8db-4680-9daf-bf5745314883" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a0eb3b5c-7601-49bb-856f-757e75ef7021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a0eb3b5c-7601-49bb-856f-757e75ef7021" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue_74ab3e7f-da3b-469b-a865-544e9f16ee0f" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue_74ab3e7f-da3b-469b-a865-544e9f16ee0f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18e0d2b8-b997-4a1a-9b76-88e24b2f4254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18e0d2b8-b997-4a1a-9b76-88e24b2f4254" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ebc18337-4f2b-444e-84f8-966ba41797ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ebc18337-4f2b-444e-84f8-966ba41797ae" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a335215f-33ca-45b6-abb1-cf70b0e55888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a335215f-33ca-45b6-abb1-cf70b0e55888" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RestrictedStockNonvestedRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_601a27c3-c0a6-4065-bd92-d636ce8d9e35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef26fb1-80d9-477d-b968-347d101ae352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_601a27c3-c0a6-4065-bd92-d636ce8d9e35" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef26fb1-80d9-477d-b968-347d101ae352" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e760bb5e-caf1-4ce3-9beb-0333acf410a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef26fb1-80d9-477d-b968-347d101ae352" xlink:to="loc_us-gaap_PlanNameAxis_e760bb5e-caf1-4ce3-9beb-0333acf410a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e760bb5e-caf1-4ce3-9beb-0333acf410a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e760bb5e-caf1-4ce3-9beb-0333acf410a2" xlink:to="loc_us-gaap_PlanNameDomain_e760bb5e-caf1-4ce3-9beb-0333acf410a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e760bb5e-caf1-4ce3-9beb-0333acf410a2" xlink:to="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_288edaca-9a61-4daa-afa3-9d1aa439c25c" xlink:href="pets-20240331.xsd#pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:to="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_288edaca-9a61-4daa-afa3-9d1aa439c25c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_9dc0e4e5-9eb1-4891-a3cc-ffc7e3db7389" xlink:href="pets-20240331.xsd#pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:to="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_9dc0e4e5-9eb1-4891-a3cc-ffc7e3db7389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_f1d401f8-d572-4a84-ab26-0c16f9cb2d9e" xlink:href="pets-20240331.xsd#pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:to="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_f1d401f8-d572-4a84-ab26-0c16f9cb2d9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e285a122-147b-4198-b368-7a416746115b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef26fb1-80d9-477d-b968-347d101ae352" xlink:to="loc_us-gaap_AwardTypeAxis_e285a122-147b-4198-b368-7a416746115b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e285a122-147b-4198-b368-7a416746115b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e285a122-147b-4198-b368-7a416746115b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e285a122-147b-4198-b368-7a416746115b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98a52932-2862-449e-82ef-c79e61e15bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e285a122-147b-4198-b368-7a416746115b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98a52932-2862-449e-82ef-c79e61e15bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_12490abe-9b8d-4dae-bf39-c2a1e3016d10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98a52932-2862-449e-82ef-c79e61e15bc5" xlink:to="loc_us-gaap_RestrictedStockMember_12490abe-9b8d-4dae-bf39-c2a1e3016d10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_601a27c3-c0a6-4065-bd92-d636ce8d9e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e1fd0256-6cc2-4828-80a4-85e00e5560cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e1fd0256-6cc2-4828-80a4-85e00e5560cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5ec4ddea-09bc-42f1-9bb6-d90e0cd5f820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5ec4ddea-09bc-42f1-9bb6-d90e0cd5f820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_223d197f-d71c-4507-ada6-4c1807d576de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_223d197f-d71c-4507-ada6-4c1807d576de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d14f6aad-bde1-4459-8f62-94636122fa55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d14f6aad-bde1-4459-8f62-94636122fa55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04e9cf44-e198-41d6-8295-65582548c609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RestrictedStockRollforwardofRSUandPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d98a9a-6fe5-40f9-a1e2-c76a548eb8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4772f058-9d5c-4c6e-8b99-f5e09b8f9d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d98a9a-6fe5-40f9-a1e2-c76a548eb8d3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4772f058-9d5c-4c6e-8b99-f5e09b8f9d7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc75955b-20b5-415d-a8ce-f6addab38ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4772f058-9d5c-4c6e-8b99-f5e09b8f9d7f" xlink:to="loc_us-gaap_AwardTypeAxis_cc75955b-20b5-415d-a8ce-f6addab38ba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc75955b-20b5-415d-a8ce-f6addab38ba4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc75955b-20b5-415d-a8ce-f6addab38ba4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc75955b-20b5-415d-a8ce-f6addab38ba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f982eeb3-3208-47c4-b8e1-d75a696c8fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc75955b-20b5-415d-a8ce-f6addab38ba4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f982eeb3-3208-47c4-b8e1-d75a696c8fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8c1fb13a-d9e2-45f8-9e51-8669941f25c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f982eeb3-3208-47c4-b8e1-d75a696c8fed" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8c1fb13a-d9e2-45f8-9e51-8669941f25c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_832c61d8-be19-40d6-acbb-41eb721a340a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f982eeb3-3208-47c4-b8e1-d75a696c8fed" xlink:to="loc_us-gaap_PerformanceSharesMember_832c61d8-be19-40d6-acbb-41eb721a340a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d98a9a-6fe5-40f9-a1e2-c76a548eb8d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_dcdbf2f0-7e29-4a8a-b1d9-7782ee93c756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_dcdbf2f0-7e29-4a8a-b1d9-7782ee93c756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5a6a8fc7-9a98-457f-b4e4-c92b094dcc45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5a6a8fc7-9a98-457f-b4e4-c92b094dcc45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_f85ff265-036b-41d5-93b0-38635e248d11" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_f85ff265-036b-41d5-93b0-38635e248d11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a486625c-3a29-4d28-a770-79feb106d32b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a486625c-3a29-4d28-a770-79feb106d32b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment_a14c17a7-398a-45af-8143-6eb18da1b961" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment_a14c17a7-398a-45af-8143-6eb18da1b961" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_74090ed6-cece-4afc-a772-3f9984b1b373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d98a9a-6fe5-40f9-a1e2-c76a548eb8d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_5dd2a371-906c-4770-8fc9-8952c2d6f253" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_5dd2a371-906c-4770-8fc9-8952c2d6f253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d234874-9cfa-49ed-adfe-cc91b46ee2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d234874-9cfa-49ed-adfe-cc91b46ee2a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_f163f6ff-cda2-4673-b8ec-42af78059ae1" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_f163f6ff-cda2-4673-b8ec-42af78059ae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0e3b72a6-ff0b-4576-a7c7-3a6679546981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0e3b72a6-ff0b-4576-a7c7-3a6679546981" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue_5abe3283-6d13-40cb-9e62-287e907a9bf2" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue_5abe3283-6d13-40cb-9e62-287e907a9bf2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_9c1b2816-f4b2-4478-b87c-ca24c6f5729d" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_76f0b29c-9cad-4c9a-95ce-8d02dc93ee87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:to="loc_srt_TitleOfIndividualAxis_76f0b29c-9cad-4c9a-95ce-8d02dc93ee87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76f0b29c-9cad-4c9a-95ce-8d02dc93ee87_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_76f0b29c-9cad-4c9a-95ce-8d02dc93ee87" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76f0b29c-9cad-4c9a-95ce-8d02dc93ee87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b0f6e1e-73b9-461c-936b-611b003b0f0a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_76f0b29c-9cad-4c9a-95ce-8d02dc93ee87" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b0f6e1e-73b9-461c-936b-611b003b0f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_a5513b28-218a-4e1e-ad5d-794b93eb88df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b0f6e1e-73b9-461c-936b-611b003b0f0a" xlink:to="loc_srt_ChiefExecutiveOfficerMember_a5513b28-218a-4e1e-ad5d-794b93eb88df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_d396d1c7-f73c-4923-8f88-4f84bf0cfb4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b0f6e1e-73b9-461c-936b-611b003b0f0a" xlink:to="loc_srt_ChiefFinancialOfficerMember_d396d1c7-f73c-4923-8f88-4f84bf0cfb4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_14dcd187-10ee-4c18-a9b8-16397c7b5b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:to="loc_us-gaap_PlanNameAxis_14dcd187-10ee-4c18-a9b8-16397c7b5b3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_14dcd187-10ee-4c18-a9b8-16397c7b5b3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_14dcd187-10ee-4c18-a9b8-16397c7b5b3c" xlink:to="loc_us-gaap_PlanNameDomain_14dcd187-10ee-4c18-a9b8-16397c7b5b3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aa64b9e6-aba9-4588-9db0-ae5e81231fac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_14dcd187-10ee-4c18-a9b8-16397c7b5b3c" xlink:to="loc_us-gaap_PlanNameDomain_aa64b9e6-aba9-4588-9db0-ae5e81231fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_dd7d9cd3-e737-4adc-9a68-9889edc05ed2" xlink:href="pets-20240331.xsd#pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_aa64b9e6-aba9-4588-9db0-ae5e81231fac" xlink:to="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_dd7d9cd3-e737-4adc-9a68-9889edc05ed2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e2ff391-1b30-4746-b7e8-7206ae4ae77c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:to="loc_us-gaap_AwardTypeAxis_4e2ff391-1b30-4746-b7e8-7206ae4ae77c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2ff391-1b30-4746-b7e8-7206ae4ae77c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4e2ff391-1b30-4746-b7e8-7206ae4ae77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2ff391-1b30-4746-b7e8-7206ae4ae77c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4e2ff391-1b30-4746-b7e8-7206ae4ae77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2de03164-cb82-4898-84f2-90d5a80094ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_us-gaap_RestrictedStockMember_2de03164-cb82-4898-84f2-90d5a80094ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockMember_2acdd294-cca4-47e8-aa07-ff74eb5f8fd1" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockMember_2acdd294-cca4-47e8-aa07-ff74eb5f8fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle1Member_5e3c9656-1f78-4e63-962d-04996d5f7856" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle1Member_5e3c9656-1f78-4e63-962d-04996d5f7856" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle2Member_561f720e-bcfb-45a4-897e-3b0abda81b8e" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle2Member_561f720e-bcfb-45a4-897e-3b0abda81b8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle3Member_3d0933d6-a3cc-4b75-93b9-fe922e6aa256" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle3Member_3d0933d6-a3cc-4b75-93b9-fe922e6aa256" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle4Member_a653ff95-7365-41eb-941a-2f0cccfee073" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle4Member_a653ff95-7365-41eb-941a-2f0cccfee073" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle5Member_a778d773-569f-4ab5-9ca6-30ce90f88dad" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle5Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle5Member_a778d773-569f-4ab5-9ca6-30ce90f88dad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NumberOfSeverancePayments_ee46769e-73a8-4bb8-afad-5e5875439683" xlink:href="pets-20240331.xsd#pets_NumberOfSeverancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_NumberOfSeverancePayments_ee46769e-73a8-4bb8-afad-5e5875439683" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_LumpSumSeverancePayments_a43b4678-0696-4700-bd1e-17eac6658921" xlink:href="pets-20240331.xsd#pets_LumpSumSeverancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_LumpSumSeverancePayments_a43b4678-0696-4700-bd1e-17eac6658921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_a45e6d7f-8283-44b9-a179-d355082002ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_a45e6d7f-8283-44b9-a179-d355082002ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentTermInitialPeriod_a8667112-e1f4-4a01-b518-69df55b22ef0" xlink:href="pets-20240331.xsd#pets_EmploymentTermInitialPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_EmploymentTermInitialPeriod_a8667112-e1f4-4a01-b518-69df55b22ef0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentTermSuccessiveRenewalPeriod_94c096aa-381f-46a5-8c72-b0d4cc070496" xlink:href="pets-20240331.xsd#pets_EmploymentTermSuccessiveRenewalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_EmploymentTermSuccessiveRenewalPeriod_94c096aa-381f-46a5-8c72-b0d4cc070496" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm_349f70d4-64e9-490c-8f4c-868dcb4b679a" xlink:href="pets-20240331.xsd#pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm_349f70d4-64e9-490c-8f4c-868dcb4b679a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficersCompensation_0b2eda4e-dc41-4f85-b3fc-b677c24f1c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_OfficersCompensation_0b2eda4e-dc41-4f85-b3fc-b677c24f1c98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TerminationPeriodPeriodWithinChangeInControl_892557d8-d4bc-40ea-bdde-f9c77839c105" xlink:href="pets-20240331.xsd#pets_TerminationPeriodPeriodWithinChangeInControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_TerminationPeriodPeriodWithinChangeInControl_892557d8-d4bc-40ea-bdde-f9c77839c105" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SeverancePaymentBaseSalaryPeriod_8f655d21-2bb1-4e22-95c2-d849ac913bea" xlink:href="pets-20240331.xsd#pets_SeverancePaymentBaseSalaryPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SeverancePaymentBaseSalaryPeriod_8f655d21-2bb1-4e22-95c2-d849ac913bea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod_92bb246b-7853-4a79-8eef-5f486fc9be70" xlink:href="pets-20240331.xsd#pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod_92bb246b-7853-4a79-8eef-5f486fc9be70" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod_7f363c27-6d4e-42cf-8525-c9b9e2f34029" xlink:href="pets-20240331.xsd#pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod_7f363c27-6d4e-42cf-8525-c9b9e2f34029" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NonCompeteAgreementPeriod_9b08e47c-0341-427a-842b-f61874d401d0" xlink:href="pets-20240331.xsd#pets_NonCompeteAgreementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_NonCompeteAgreementPeriod_9b08e47c-0341-427a-842b-f61874d401d0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a5d9103b-532e-41e7-8d50-72e6c8417adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a5d9103b-532e-41e7-8d50-72e6c8417adf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_ff5e01d1-e3dc-4a21-be5c-d253aa86ff7d" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_ff5e01d1-e3dc-4a21-be5c-d253aa86ff7d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod_c92265d9-7ca0-4c61-ae33-a6627610f8f1" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod_c92265d9-7ca0-4c61-ae33-a6627610f8f1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b109c06a-2239-45d1-a1a6-baf90422e87b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b109c06a-2239-45d1-a1a6-baf90422e87b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod_8bd90abf-1701-4a96-85ef-788aede9ea51" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod_8bd90abf-1701-4a96-85ef-788aede9ea51" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d90a8d83-ad7d-48a3-a8ba-7ab3ae059a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d90a8d83-ad7d-48a3-a8ba-7ab3ae059a35" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOnBonus_9bc5ed72-ff65-4b88-b2ba-9701001166cb" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOnBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SalaryAndWageOfficerSignOnBonus_9bc5ed72-ff65-4b88-b2ba-9701001166cb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_138c8529-13f5-4c24-9447-3b47f278e21f" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_138c8529-13f5-4c24-9447-3b47f278e21f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c203536-c262-42bc-8dd1-2dd4426b9185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c203536-c262-42bc-8dd1-2dd4426b9185" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContingentLumpSumSeverancePayment_7e76437a-8da4-44ce-86fa-f0c1f90c3289" xlink:href="pets-20240331.xsd#pets_ContingentLumpSumSeverancePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_ContingentLumpSumSeverancePayment_7e76437a-8da4-44ce-86fa-f0c1f90c3289" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedSeveranceCosts_095d3cd3-25bb-400d-856c-bffe4b0a50b0" xlink:href="pets-20240331.xsd#pets_AccruedSeveranceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_AccruedSeveranceCosts_095d3cd3-25bb-400d-856c-bffe4b0a50b0" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.1800petmeds.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a7615ba1-9997-46f8-a088-81a121f44d13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:to="loc_us-gaap_AwardTypeAxis_a7615ba1-9997-46f8-a088-81a121f44d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7615ba1-9997-46f8-a088-81a121f44d13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a7615ba1-9997-46f8-a088-81a121f44d13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7615ba1-9997-46f8-a088-81a121f44d13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1be96721-9d7f-49c3-858a-398e4bb14c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a7615ba1-9997-46f8-a088-81a121f44d13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1be96721-9d7f-49c3-858a-398e4bb14c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f5547f46-5618-419d-890f-2f581ab294a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1be96721-9d7f-49c3-858a-398e4bb14c95" xlink:to="loc_us-gaap_RestrictedStockMember_f5547f46-5618-419d-890f-2f581ab294a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_01dced81-2471-48fa-b747-6ae3299fee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1be96721-9d7f-49c3-858a-398e4bb14c95" xlink:to="loc_us-gaap_PerformanceSharesMember_01dced81-2471-48fa-b747-6ae3299fee6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ec519dd2-28c6-45fc-8496-7e0ab40171e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:to="loc_us-gaap_PlanNameAxis_ec519dd2-28c6-45fc-8496-7e0ab40171e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ec519dd2-28c6-45fc-8496-7e0ab40171e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ec519dd2-28c6-45fc-8496-7e0ab40171e8" xlink:to="loc_us-gaap_PlanNameDomain_ec519dd2-28c6-45fc-8496-7e0ab40171e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e6100952-3ac7-4104-a2de-4508b549a4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ec519dd2-28c6-45fc-8496-7e0ab40171e8" xlink:to="loc_us-gaap_PlanNameDomain_e6100952-3ac7-4104-a2de-4508b549a4f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_7aa39b83-f383-4f6c-9ae1-e20a6ea00e94" xlink:href="pets-20240331.xsd#pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e6100952-3ac7-4104-a2de-4508b549a4f6" xlink:to="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_7aa39b83-f383-4f6c-9ae1-e20a6ea00e94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c6fe379b-e199-48ac-8ac5-ecd2dac707a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c6fe379b-e199-48ac-8ac5-ecd2dac707a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c6fe379b-e199-48ac-8ac5-ecd2dac707a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c6fe379b-e199-48ac-8ac5-ecd2dac707a1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c6fe379b-e199-48ac-8ac5-ecd2dac707a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a9509e5f-5e5c-4275-99c9-c56647fe119e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c6fe379b-e199-48ac-8ac5-ecd2dac707a1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a9509e5f-5e5c-4275-99c9-c56647fe119e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_58d0de76-30a1-4b8c-b663-ba05b0b7424f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a9509e5f-5e5c-4275-99c9-c56647fe119e" xlink:to="loc_us-gaap_SubsequentEventMember_58d0de76-30a1-4b8c-b663-ba05b0b7424f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c25dca1d-6a66-4f41-8ad6-73812a98c82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:to="loc_us-gaap_VestingAxis_c25dca1d-6a66-4f41-8ad6-73812a98c82d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c25dca1d-6a66-4f41-8ad6-73812a98c82d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_c25dca1d-6a66-4f41-8ad6-73812a98c82d" xlink:to="loc_us-gaap_VestingDomain_c25dca1d-6a66-4f41-8ad6-73812a98c82d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_c25dca1d-6a66-4f41-8ad6-73812a98c82d" xlink:to="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_cb99f4b5-821d-4bc1-84d4-2f74ccba818c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_cb99f4b5-821d-4bc1-84d4-2f74ccba818c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1721b63d-5bcb-4674-aca2-87720eb77d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1721b63d-5bcb-4674-aca2-87720eb77d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_91f85f14-dc1f-44b2-8af9-e66f65d3f4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_91f85f14-dc1f-44b2-8af9-e66f65d3f4ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_79d59528-2e81-4d8e-bb2d-60ff12392e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_79d59528-2e81-4d8e-bb2d-60ff12392e9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentAgreementEmploymentTerm_2b72f246-4ddb-465e-b287-2cecdd4bc760" xlink:href="pets-20240331.xsd#pets_EmploymentAgreementEmploymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_EmploymentAgreementEmploymentTerm_2b72f246-4ddb-465e-b287-2cecdd4bc760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentAgreementRenewalTerm_064a6214-a08d-43c8-840d-2cb9e67f935e" xlink:href="pets-20240331.xsd#pets_EmploymentAgreementRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_EmploymentAgreementRenewalTerm_064a6214-a08d-43c8-840d-2cb9e67f935e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentAgreementNonRenewalNoticePeriod_5520db4f-faa1-459a-ad2e-261cc8771ba5" xlink:href="pets-20240331.xsd#pets_EmploymentAgreementNonRenewalNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_EmploymentAgreementNonRenewalNoticePeriod_5520db4f-faa1-459a-ad2e-261cc8771ba5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerAnnualBaseSalary_2b86d8a3-7261-43ad-b40c-b56b08a2e90f" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerAnnualBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageOfficerAnnualBaseSalary_2b86d8a3-7261-43ad-b40c-b56b08a2e90f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOnBonus_000b19c0-2fd0-4a8e-9971-7c9c81a1de84" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOnBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageOfficerSignOnBonus_000b19c0-2fd0-4a8e-9971-7c9c81a1de84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_b916d035-6213-4c9f-9497-699b249a3322" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_b916d035-6213-4c9f-9497-699b249a3322" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageTargetAnnualBonusPercentage_8eb9b04a-0af9-4d15-85a2-281d579c0caa" xlink:href="pets-20240331.xsd#pets_SalaryAndWageTargetAnnualBonusPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageTargetAnnualBonusPercentage_8eb9b04a-0af9-4d15-85a2-281d579c0caa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageMaximumBonusPercentage_17f2e2fb-8d85-4201-a277-abc9ce4e7043" xlink:href="pets-20240331.xsd#pets_SalaryAndWageMaximumBonusPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageMaximumBonusPercentage_17f2e2fb-8d85-4201-a277-abc9ce4e7043" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount_5fc421a5-72f5-4951-a860-aba5b9d57755" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount_5fc421a5-72f5-4951-a860-aba5b9d57755" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_47f47c73-352f-4e69-ae87-1fb9dcf7b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_47f47c73-352f-4e69-ae87-1fb9dcf7b9db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount_4c4d7899-0c2e-446b-95d2-0693e472e3f4" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount_4c4d7899-0c2e-446b-95d2-0693e472e3f4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare_8f8e03c9-0fc9-4c7a-af1b-7cc10acd826f" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare_8f8e03c9-0fc9-4c7a-af1b-7cc10acd826f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d30dae16-bef5-4c08-86f6-a185130c2d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d30dae16-bef5-4c08-86f6-a185130c2d4c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_61f4d68b-a1ed-4302-a471-010be8793f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_61f4d68b-a1ed-4302-a471-010be8793f50" xlink:type="arc" order="14"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pets-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b431201b-f537-4396-8d13-986e96a3bf3a,g:5ff869d6-f8b6-477d-8b92-37fe9911b79a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_c0b468d1-0466-4665-807a-0c5bad5cff07_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations_2ea683fe-dc30-4727-8783-4b0d5ee7b7bc_terseLabel_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations_label_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Number Of Performance Obligations</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations" xlink:to="lab_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_2bee685c-d8c5-45e9-ad78-4231a80fd8aa_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_FiscalYear2023Member_b0e40bcf-ebc1-4065-9e52-d01ba3b6c8f3_terseLabel_en-US" xlink:label="lab_pets_FiscalYear2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Year 2023</link:label>
    <link:label id="lab_pets_FiscalYear2023Member_label_en-US" xlink:label="lab_pets_FiscalYear2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Year 2023 [Member]</link:label>
    <link:label id="lab_pets_FiscalYear2023Member_documentation_en-US" xlink:label="lab_pets_FiscalYear2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fiscal Year 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_FiscalYear2023Member" xlink:href="pets-20240331.xsd#pets_FiscalYear2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_FiscalYear2023Member" xlink:to="lab_pets_FiscalYear2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_84cf3f97-1369-4ad8-8276-3fa313147eea_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_7caa4026-3e3d-4733-ae7d-a0a0f72dd8f9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f9e7dd4-190b-4145-840a-f12eb1a1ab66_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in operating assets and increase (decrease) in liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_772160a1-f5cf-4289-9522-6448f14cb202_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, requisite service period</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_06b0ecda-3450-450a-80be-ab216293fff4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_RestrictionPeriod_b331c01c-c402-4376-8e0a-06c74bbf8c40_terseLabel_en-US" xlink:label="lab_pets_RestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restriction period</link:label>
    <link:label id="lab_pets_RestrictionPeriod_label_en-US" xlink:label="lab_pets_RestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restriction Period</link:label>
    <link:label id="lab_pets_RestrictionPeriod_documentation_en-US" xlink:label="lab_pets_RestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of restriction of forfeiture.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RestrictionPeriod" xlink:href="pets-20240331.xsd#pets_RestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_RestrictionPeriod" xlink:to="lab_pets_RestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_a0f3c622-e542-4fcd-aca3-61605d8678d5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e6ff7e1e-661f-4202-af1e-076e9d6d65ab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_c995e143-27bf-4ee8-8fcd-df909ad639b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, liquidation preference (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreference" xlink:to="lab_us-gaap_PreferredStockLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_259881b8-40b3-4b63-a110-70268b592abc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_1896183b-8fbc-4f3e-bb24-9428de985eaf_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_70022e2a-ee94-441d-8a8e-9e9c13733f5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-vested restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06483e54-6dd1-471e-a903-26249a5d13fe_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested restricted stock outstanding at March 31, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8507bc8e-9560-4870-8262-fa6976585b6f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested restricted stock outstanding at March 31, 2024 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f493ddc5-69da-4c9e-beba-27977234de86_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5d4a9e20-52a1-4e73-adeb-45b34a9ef285_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Identifiable Assets, Liabilities Assumed and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EmploymentTermSuccessiveRenewalPeriod_1947f2ac-b0d3-416a-a356-64cf051b76ed_terseLabel_en-US" xlink:label="lab_pets_EmploymentTermSuccessiveRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Successive renewal employment term</link:label>
    <link:label id="lab_pets_EmploymentTermSuccessiveRenewalPeriod_label_en-US" xlink:label="lab_pets_EmploymentTermSuccessiveRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Term, Successive Renewal Period</link:label>
    <link:label id="lab_pets_EmploymentTermSuccessiveRenewalPeriod_documentation_en-US" xlink:label="lab_pets_EmploymentTermSuccessiveRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Term, Successive Renewal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentTermSuccessiveRenewalPeriod" xlink:href="pets-20240331.xsd#pets_EmploymentTermSuccessiveRenewalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EmploymentTermSuccessiveRenewalPeriod" xlink:to="lab_pets_EmploymentTermSuccessiveRenewalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1d8aed0b-18ba-4260-8ced-04715db6d72e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_2c4e1423-5058-45d4-94c4-5f55fd989b0f_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5b9f6572-4471-463b-af3d-fc4809e29e93_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1fe1c3ab-a409-4a50-9ded-d8c3dc670240_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingImprovementsMember_39c58f87-c801-4028-a658-25a1c73c3c0d_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building Improvements</link:label>
    <link:label id="lab_us-gaap_BuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_000cf6a9-7b18-4a23-aef4-af55ec10ec9d_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_838e4c00-5438-4e05-a8e6-eb571265611d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible compensation (as percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_085a4a14-7cde-40ad-b81c-48fe5a8653a1_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22e67c7d-22b1-4b8a-b58c-1c273afe1aa6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal rate on income before taxes (as percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_32c1dba0-4c6f-4b74-8ab2-6f751de64add_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_c85c8650-2035-4962-b0ad-87fc46d0e915_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_13388cfc-2cd7-4b2a-9492-3920c8f916ff_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_IntangiblesAndOtherAssetsAbstract_23b5a060-870a-4bfe-8c62-977821e47187_terseLabel_en-US" xlink:label="lab_pets_IntangiblesAndOtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles and Other Assets</link:label>
    <link:label id="lab_pets_IntangiblesAndOtherAssetsAbstract_label_en-US" xlink:label="lab_pets_IntangiblesAndOtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangibles and Other Assets [Abstract]</link:label>
    <link:label id="lab_pets_IntangiblesAndOtherAssetsAbstract_documentation_en-US" xlink:label="lab_pets_IntangiblesAndOtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangibles and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangiblesAndOtherAssetsAbstract" xlink:href="pets-20240331.xsd#pets_IntangiblesAndOtherAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_IntangiblesAndOtherAssetsAbstract" xlink:to="lab_pets_IntangiblesAndOtherAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_174e9b48-365f-4d26-8234-c1ff7d577341_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_faa44317-9f28-4599-92a0-85ba609ccebf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7597b7e8-c044-4fb1-ab16-e26fac5c2639_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables_5eb47624-930e-474a-b229-6320ef0335ec_terseLabel_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables_label_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Other Receivables</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables_documentation_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables" xlink:to="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment_443abf6d-eeca-4610-838c-fb8eea34ce62_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance adjustment (in shares)</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_59ea1e23-6d3d-4e64-b97b-cfc945e13904_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fa9ca400-885e-4272-8600-8f4fd154b56b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ae386f8b-8c37-4263-bca8-adf3942776c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of restricted stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_a3b85d29-5969-4baf-b86d-288a5371182f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax adjustments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm_a65a39ee-5784-4fa2-924b-c1190e618bc8_terseLabel_en-US" xlink:label="lab_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm_label_en-US" xlink:label="lab_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease Remaining Weighted Average Lease Term</link:label>
    <link:label id="lab_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm_documentation_en-US" xlink:label="lab_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm" xlink:href="pets-20240331.xsd#pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm" xlink:to="lab_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_74ea19a3-261a-4ab3-885b-885b9979666a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_8eaa3ccb-b4d5-4998-88b1-cb59e7e715a5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_ca8e09f6-c2d8-474c-9b4b-597afdf503b6_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Absolute stock price hurdle period</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Hurdle Period</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Hurdle Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b09f6695-f8c3-4dbe-811e-90686567f237_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_27c2c700-3fab-41e0-9788-36d394f6f886_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod_4dfb343c-c936-4028-beba-f9898913fd8e_terseLabel_en-US" xlink:label="lab_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance pay health insurance benefits, without cause termination, period</link:label>
    <link:label id="lab_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod_label_en-US" xlink:label="lab_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Payment, Termination Without Cause, Health Insurance Benefits, Period</link:label>
    <link:label id="lab_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod_documentation_en-US" xlink:label="lab_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Severance Payment, Termination Without Cause, Health Insurance Benefits, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod" xlink:href="pets-20240331.xsd#pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod" xlink:to="lab_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7ed69ccc-ac5f-4893-b3e9-2e05c5c8d446_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3e8cb2d5-37eb-4520-99ec-043507036ebb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d1e2d224-036d-4892-bf6e-abcfb8cffa8c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_aa334321-13b2-4f10-b4a6-a03c421d013a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_484a4adc-ae95-4c57-a148-ad290275a9b5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e77d6017-1e07-485f-9ad0-d54911761c2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_05341f31-9231-498a-adde-1a035e17bef2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cbea97a6-5c3e-4c01-89bb-dbbc842d22dd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d71823c-9df3-43bd-8af7-bc245ffec44c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d3d3e025-b21b-41cd-94dd-89dca40a0cf5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, less allowance for credit losses of $273 and $35, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_NonCompeteAgreementPeriod_f760ca9d-f6ac-4a13-9344-0c73b64a0980_terseLabel_en-US" xlink:label="lab_pets_NonCompeteAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-compete term</link:label>
    <link:label id="lab_pets_NonCompeteAgreementPeriod_label_en-US" xlink:label="lab_pets_NonCompeteAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Compete Agreement, Period</link:label>
    <link:label id="lab_pets_NonCompeteAgreementPeriod_documentation_en-US" xlink:label="lab_pets_NonCompeteAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Compete Agreement, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NonCompeteAgreementPeriod" xlink:href="pets-20240331.xsd#pets_NonCompeteAgreementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_NonCompeteAgreementPeriod" xlink:to="lab_pets_NonCompeteAgreementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_AccruedSalesReturnsAndAllowancesCurrent_c0969e4f-3cc9-40bb-8df4-62cec6254fbc_terseLabel_en-US" xlink:label="lab_pets_AccruedSalesReturnsAndAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued sales return allowance</link:label>
    <link:label id="lab_pets_AccruedSalesReturnsAndAllowancesCurrent_label_en-US" xlink:label="lab_pets_AccruedSalesReturnsAndAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued sales return allowance</link:label>
    <link:label id="lab_pets_AccruedSalesReturnsAndAllowancesCurrent_documentation_en-US" xlink:label="lab_pets_AccruedSalesReturnsAndAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued sales returns and allowances. Used to reflect the current portion (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedSalesReturnsAndAllowancesCurrent" xlink:href="pets-20240331.xsd#pets_AccruedSalesReturnsAndAllowancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_AccruedSalesReturnsAndAllowancesCurrent" xlink:to="lab_pets_AccruedSalesReturnsAndAllowancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_AccruedMerchandiseCreditsAndRewardsCurrent_596fb2ea-35ac-466f-80d8-2892406f7ed9_terseLabel_en-US" xlink:label="lab_pets_AccruedMerchandiseCreditsAndRewardsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued merchandise credits / reward program</link:label>
    <link:label id="lab_pets_AccruedMerchandiseCreditsAndRewardsCurrent_label_en-US" xlink:label="lab_pets_AccruedMerchandiseCreditsAndRewardsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued merchandise credits / reward program</link:label>
    <link:label id="lab_pets_AccruedMerchandiseCreditsAndRewardsCurrent_documentation_en-US" xlink:label="lab_pets_AccruedMerchandiseCreditsAndRewardsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of accrued merchandise credits and rewards classified as current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedMerchandiseCreditsAndRewardsCurrent" xlink:href="pets-20240331.xsd#pets_AccruedMerchandiseCreditsAndRewardsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_AccruedMerchandiseCreditsAndRewardsCurrent" xlink:to="lab_pets_AccruedMerchandiseCreditsAndRewardsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_7a5470b1-b34f-4a24-a5af-48d1d3b5c6c5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued salaries and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_b7a00214-104e-4580-9fe7-9918c57669cc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_33fae30f-1b49-4d01-ba05-64d7283dd159_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment_3466b38f-4968-4636-82af-fd5421db38f8_terseLabel_en-US" xlink:label="lab_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset adjustment</link:label>
    <link:label id="lab_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment_label_en-US" xlink:label="lab_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Asset Adjustment</link:label>
    <link:label id="lab_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment_documentation_en-US" xlink:label="lab_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Asset Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment" xlink:href="pets-20240331.xsd#pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment" xlink:to="lab_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_465f7cf1-242a-4077-983d-cdddb34728cf_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketApproachValuationTechniqueMember_60376adb-db34-48bc-b6e3-8714c86e7413_terseLabel_en-US" xlink:label="lab_us-gaap_MarketApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation, Market Approach</link:label>
    <link:label id="lab_us-gaap_MarketApproachValuationTechniqueMember_label_en-US" xlink:label="lab_us-gaap_MarketApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation, Market Approach [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketApproachValuationTechniqueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketApproachValuationTechniqueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketApproachValuationTechniqueMember" xlink:to="lab_us-gaap_MarketApproachValuationTechniqueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_674246d3-5cb1-4da4-9767-18b125654a1f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d2b6eea1-0e4e-4bda-98ac-e3ed65cf884c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5e67f37b-23b3-44b3-9723-86f689648731_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_11773484-ad6c-4717-82d4-a5ae7ded1458_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0e62bc2d-0110-4fcb-b25c-21322146812e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ContingentLumpSumSeverancePayment_b6a743fc-ea04-41e2-9985-18af57148cdb_terseLabel_en-US" xlink:label="lab_pets_ContingentLumpSumSeverancePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent lump sum severance payment</link:label>
    <link:label id="lab_pets_ContingentLumpSumSeverancePayment_label_en-US" xlink:label="lab_pets_ContingentLumpSumSeverancePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Lump Sum Severance Payment</link:label>
    <link:label id="lab_pets_ContingentLumpSumSeverancePayment_documentation_en-US" xlink:label="lab_pets_ContingentLumpSumSeverancePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Lump Sum Severance Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContingentLumpSumSeverancePayment" xlink:href="pets-20240331.xsd#pets_ContingentLumpSumSeverancePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ContingentLumpSumSeverancePayment" xlink:to="lab_pets_ContingentLumpSumSeverancePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e800ece-2552-402e-9f98-ff465ccdae6d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9cea6d10-a97e-408d-b206-a98a1b11c0c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5856086c-97a8-482d-953b-fc0bfdb9f268_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_OperatingLossCarryforwardsNotSubjectToLimitations_48d955ac-2c4d-4f75-9aa8-4cd2bc6f58da_terseLabel_en-US" xlink:label="lab_pets_OperatingLossCarryforwardsNotSubjectToLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating losses - unlimited carryover</link:label>
    <link:label id="lab_pets_OperatingLossCarryforwardsNotSubjectToLimitations_label_en-US" xlink:label="lab_pets_OperatingLossCarryforwardsNotSubjectToLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Limitations</link:label>
    <link:label id="lab_pets_OperatingLossCarryforwardsNotSubjectToLimitations_documentation_en-US" xlink:label="lab_pets_OperatingLossCarryforwardsNotSubjectToLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardsNotSubjectToLimitations" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardsNotSubjectToLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_OperatingLossCarryforwardsNotSubjectToLimitations" xlink:to="lab_pets_OperatingLossCarryforwardsNotSubjectToLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2b9ccf1a-d033-405a-9eca-3109a05e85a2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0d2955ee-88fc-4500-8cfd-b2b4cf79db78_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_IntangibleAndOtherAssetsGross_97b35b24-19ce-4c51-846d-0e4bb3041fd3_totalLabel_en-US" xlink:label="lab_pets_IntangibleAndOtherAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible and other assets, Gross Value</link:label>
    <link:label id="lab_pets_IntangibleAndOtherAssetsGross_label_en-US" xlink:label="lab_pets_IntangibleAndOtherAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible And Other Assets, Gross</link:label>
    <link:label id="lab_pets_IntangibleAndOtherAssetsGross_documentation_en-US" xlink:label="lab_pets_IntangibleAndOtherAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible And Other Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssetsGross" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_IntangibleAndOtherAssetsGross" xlink:to="lab_pets_IntangibleAndOtherAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_323b5610-0671-4235-95d2-6765c947f1a7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_c0df397a-c6eb-4787-bdba-3563bdd865e7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid income taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_RevenueFromContractWithCustomerNumberOfSalesCategories_acae87a2-e547-4cd5-8afc-46a49103ff96_terseLabel_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerNumberOfSalesCategories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of sales categories</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerNumberOfSalesCategories_label_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerNumberOfSalesCategories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Number Of Sales Categories</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerNumberOfSalesCategories_documentation_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerNumberOfSalesCategories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Number Of Sales Categories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerNumberOfSalesCategories" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerNumberOfSalesCategories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_RevenueFromContractWithCustomerNumberOfSalesCategories" xlink:to="lab_pets_RevenueFromContractWithCustomerNumberOfSalesCategories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e864e766-0724-4530-aac3-cf639952e4ae_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_db982ad9-e019-404d-b989-54b9b0fd1320_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_NumberOfTenants_9f120443-859f-444e-9dfb-5f644b13058a_terseLabel_en-US" xlink:label="lab_pets_NumberOfTenants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tenants</link:label>
    <link:label id="lab_pets_NumberOfTenants_label_en-US" xlink:label="lab_pets_NumberOfTenants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Tenants</link:label>
    <link:label id="lab_pets_NumberOfTenants_documentation_en-US" xlink:label="lab_pets_NumberOfTenants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of tenants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NumberOfTenants" xlink:href="pets-20240331.xsd#pets_NumberOfTenants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_NumberOfTenants" xlink:to="lab_pets_NumberOfTenants" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SalaryAndWageTargetAnnualBonusPercentage_ba606bc5-56fe-4860-8fbe-ba7517b0e44b_terseLabel_en-US" xlink:label="lab_pets_SalaryAndWageTargetAnnualBonusPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Target annual bonus percentage</link:label>
    <link:label id="lab_pets_SalaryAndWageTargetAnnualBonusPercentage_label_en-US" xlink:label="lab_pets_SalaryAndWageTargetAnnualBonusPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary And Wage, Target Annual Bonus Percentage</link:label>
    <link:label id="lab_pets_SalaryAndWageTargetAnnualBonusPercentage_documentation_en-US" xlink:label="lab_pets_SalaryAndWageTargetAnnualBonusPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Salary And Wage, Target Annual Bonus Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageTargetAnnualBonusPercentage" xlink:href="pets-20240331.xsd#pets_SalaryAndWageTargetAnnualBonusPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SalaryAndWageTargetAnnualBonusPercentage" xlink:to="lab_pets_SalaryAndWageTargetAnnualBonusPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_DisallowedBusinessInterestExpenseCarryover_8edae8b0-13ec-4226-a319-12794dc56d6f_terseLabel_en-US" xlink:label="lab_pets_DisallowedBusinessInterestExpenseCarryover" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disallowed business interest expense carryover</link:label>
    <link:label id="lab_pets_DisallowedBusinessInterestExpenseCarryover_label_en-US" xlink:label="lab_pets_DisallowedBusinessInterestExpenseCarryover" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disallowed Business Interest Expense Carryover</link:label>
    <link:label id="lab_pets_DisallowedBusinessInterestExpenseCarryover_documentation_en-US" xlink:label="lab_pets_DisallowedBusinessInterestExpenseCarryover" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disallowed Business Interest Expense Carryover</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DisallowedBusinessInterestExpenseCarryover" xlink:href="pets-20240331.xsd#pets_DisallowedBusinessInterestExpenseCarryover"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_DisallowedBusinessInterestExpenseCarryover" xlink:to="lab_pets_DisallowedBusinessInterestExpenseCarryover" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsAbstract_5bcae3b2-ade8-48a1-8eb8-121410d16ff0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract" xlink:to="lab_us-gaap_OtherAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_073e9b64-dc2b-47d8-94a4-10abd39acc02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_52f6a641-3102-477a-b3b1-83d27c26b774_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_931f1795-f526-4a56-9e6c-92872e4dc0d6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction amount</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c246c8a6-cb22-49dc-990c-e9d0636bc0e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted shares, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_411bac42-1fb9-4acc-abbb-f0c79941f3cc_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Useful Life (Years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8c3b10dc-858d-4f37-bc11-3e0946e621e6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b552af1d-992b-4397-a8f5-bd8e9d56bdd3_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, 2028</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_OtherAssetsPolicyTextBlock_f938e3e8-be48-4321-8a25-d79fde93a1dd_terseLabel_en-US" xlink:label="lab_pets_OtherAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_pets_OtherAssetsPolicyTextBlock_label_en-US" xlink:label="lab_pets_OtherAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Policy Text Block]</link:label>
    <link:label id="lab_pets_OtherAssetsPolicyTextBlock_documentation_en-US" xlink:label="lab_pets_OtherAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OtherAssetsPolicyTextBlock" xlink:href="pets-20240331.xsd#pets_OtherAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_OtherAssetsPolicyTextBlock" xlink:to="lab_pets_OtherAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fbc5f8d3-07df-49c5-a744-ddb5ffe2eb75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_b0d7bd66-d723-4ff3-9f2b-c3036efe784b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_1bfd5119-65a2-4c9d-8c95-d70b5e653bcb_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_cb7d2ab6-8981-45ca-8fbb-c5e5b5ca7b4d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d6f480bf-dacd-4e5b-8e90-90b1b1b74b28_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_73e1a50f-9b2d-4347-8331-4be80f2e5354_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_12c07457-2018-4972-946b-9ecf3bdc700a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e9accdd3-c07d-4ea3-9fca-94d23753671b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_548982cf-4f6a-4c95-aa11-bad8209021a0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_22fcb2a0-5257-4385-885c-14e929096c3f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_038d4122-5d82-49f8-8406-413b60917b5b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_92860147-cd3f-4bdc-a98f-fbe3241300dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends declared per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_ddd50936-d54f-418f-93ed-c03a5c5b54bd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock (windfall) shortfall adjustment (as percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d2213a57-2fee-4ac4-8f57-702c06dc82c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_9b4524f5-71c2-4529-93de-32744c938148_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_587312f5-2e76-489f-976e-9aae8a1547ce_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_e72fe8fe-475a-4369-ac62-bd548ed103ed_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_4eecedee-3185-4182-94bc-e55940ee72af_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_da4339c3-97f5-4c3d-8c38-1ff0f0f322c2_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_5bc9eec7-22c8-416f-b4b0-675af3548fa3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible executive compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_DeferredTaxAssetIsRecordedMember_b4bdfcea-12dc-409a-a5e0-4aefb35f0f25_terseLabel_en-US" xlink:label="lab_pets_DeferredTaxAssetIsRecordedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributes for which a deferred tax asset is recorded</link:label>
    <link:label id="lab_pets_DeferredTaxAssetIsRecordedMember_label_en-US" xlink:label="lab_pets_DeferredTaxAssetIsRecordedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset Is Recorded [Member]</link:label>
    <link:label id="lab_pets_DeferredTaxAssetIsRecordedMember_documentation_en-US" xlink:label="lab_pets_DeferredTaxAssetIsRecordedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset Is Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetIsRecordedMember" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetIsRecordedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_DeferredTaxAssetIsRecordedMember" xlink:to="lab_pets_DeferredTaxAssetIsRecordedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EmploymentTermInitialPeriod_3bece9f1-eed8-4239-9dc6-7e94da162d96_terseLabel_en-US" xlink:label="lab_pets_EmploymentTermInitialPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial employment term</link:label>
    <link:label id="lab_pets_EmploymentTermInitialPeriod_label_en-US" xlink:label="lab_pets_EmploymentTermInitialPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Term, Initial Period</link:label>
    <link:label id="lab_pets_EmploymentTermInitialPeriod_documentation_en-US" xlink:label="lab_pets_EmploymentTermInitialPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Term, Initial Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentTermInitialPeriod" xlink:href="pets-20240331.xsd#pets_EmploymentTermInitialPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EmploymentTermInitialPeriod" xlink:to="lab_pets_EmploymentTermInitialPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e4fc921a-e8c3-4835-862e-53a9b457643a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_582b20dc-01a9-4190-9bd6-de27b905e1e9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_9587f887-ee81-4246-a561-9f1ceb5c00c6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, matching contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SevenSuppliersMember_7c767a51-a56b-4fb8-870d-f609a46a80cc_terseLabel_en-US" xlink:label="lab_pets_SevenSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seven Suppliers</link:label>
    <link:label id="lab_pets_SevenSuppliersMember_label_en-US" xlink:label="lab_pets_SevenSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seven Suppliers [Member]</link:label>
    <link:label id="lab_pets_SevenSuppliersMember_documentation_en-US" xlink:label="lab_pets_SevenSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seven Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SevenSuppliersMember" xlink:href="pets-20240331.xsd#pets_SevenSuppliersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SevenSuppliersMember" xlink:to="lab_pets_SevenSuppliersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4d77ae7f-b5ff-4380-9211-1076b107f693_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_2212cf1f-337d-4482-a2c1-0b858d7b9333_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_80a0e2e6-4cec-438b-9e96-bad52e510944_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bad debt and inventory reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_38025e94-adb0-4ca3-bfb7-dce09295c239_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Costs and Activity</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9ea421d-cec6-42ca-aca2-2a57a5b5e016_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_27f586e7-96ed-4f5a-8aa6-02ccec13ebbc_negatedTerseLabel_en-US" xlink:label="lab_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="pets-20240331.xsd#pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_cd24569d-79f2-4259-b35a-967035c66d03_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_c38f575e-84ca-4af9-ab5d-84004eacf01b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_886ecaeb-bc4b-443f-b3a4-54ddde1a0f22_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue acquired with PetCareRx</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1958983c-9fc0-409e-ba39-ce56b83a6bf2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0cbbb50b-5009-46a6-a6ea-8679b384ed2b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_974b225e-f622-4946-b6d6-551659ad6317_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2363de8f-f895-4a57-a929-2f0c6105af30_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_fa47e013-261e-45ba-ba7e-b6c253084209_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_fa35fc6c-e154-4dff-b92c-e6b250d5d7d0_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_4ffbf443-76fc-442a-bc26-413250facd9f_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount_1d978174-935b-4e9c-afda-c89dacaf355f_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual grant amount</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Annual Grant Amount</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Annual Grant Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_60739374-6da4-4022-ad6d-ed4a91f085ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_OperatingLossCarryforwardDomain_3f056c5f-4fdd-4a60-b7a8-9cd04340e085_terseLabel_en-US" xlink:label="lab_pets_OperatingLossCarryforwardDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward [Domain]</link:label>
    <link:label id="lab_pets_OperatingLossCarryforwardDomain_label_en-US" xlink:label="lab_pets_OperatingLossCarryforwardDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward [Domain]</link:label>
    <link:label id="lab_pets_OperatingLossCarryforwardDomain_documentation_en-US" xlink:label="lab_pets_OperatingLossCarryforwardDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardDomain" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_OperatingLossCarryforwardDomain" xlink:to="lab_pets_OperatingLossCarryforwardDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7becce03-4095-4e9e-8fdf-3b31dc723413_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities as a result of acquisition</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_83bd8871-ccfc-44a6-98d1-22ba1caa4253_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Dividend Declaration</link:label>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:to="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_06da5124-5e49-4f0e-bf55-2417153704f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6789c754-c1f5-414b-8f36-664775449c34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_130a6972-749d-46f6-bce9-53597fdcfb61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Outstanding Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ccde59a3-41d1-436f-b93c-9b1d58a0b0b9_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7ae1c2e1-d182-4163-b98d-a35e7a873463_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SalaryAndWageMaximumBonusPercentage_4aee9bb0-8f7e-4414-8bfb-0f2a748f5e24_terseLabel_en-US" xlink:label="lab_pets_SalaryAndWageMaximumBonusPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum bonus percentage</link:label>
    <link:label id="lab_pets_SalaryAndWageMaximumBonusPercentage_label_en-US" xlink:label="lab_pets_SalaryAndWageMaximumBonusPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary And Wage, Maximum Bonus Percentage</link:label>
    <link:label id="lab_pets_SalaryAndWageMaximumBonusPercentage_documentation_en-US" xlink:label="lab_pets_SalaryAndWageMaximumBonusPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Salary And Wage, Maximum Bonus Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageMaximumBonusPercentage" xlink:href="pets-20240331.xsd#pets_SalaryAndWageMaximumBonusPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SalaryAndWageMaximumBonusPercentage" xlink:to="lab_pets_SalaryAndWageMaximumBonusPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_0228dbeb-cb54-47e5-b3e3-77b5ace2285e_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of fair value in excess of carrying amount</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dcb11fb8-5a3e-49fc-ab0a-05bc05bf563c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_95d23633-b20e-482c-a0ba-37b2daf426e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_TollFreeTelephoneNumberMember_4660a4ce-d626-4bc8-9382-7685fa2c18dc_terseLabel_en-US" xlink:label="lab_pets_TollFreeTelephoneNumberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toll-free telephone number</link:label>
    <link:label id="lab_pets_TollFreeTelephoneNumberMember_label_en-US" xlink:label="lab_pets_TollFreeTelephoneNumberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toll-free telephone number [Member]</link:label>
    <link:label id="lab_pets_TollFreeTelephoneNumberMember_documentation_en-US" xlink:label="lab_pets_TollFreeTelephoneNumberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Toll-free telephone number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TollFreeTelephoneNumberMember" xlink:href="pets-20240331.xsd#pets_TollFreeTelephoneNumberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_TollFreeTelephoneNumberMember" xlink:to="lab_pets_TollFreeTelephoneNumberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_492a23a5-50b4-40c6-be74-1c7131d95da1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_654873cd-5b7e-49ec-9d6f-8892adda5c16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_5e390835-9cb5-49ec-8dc0-eafd4dd1f204_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0b0cf9f6-f5d1-48e6-ba7b-e69baab062d0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_dc72181e-be2b-4c2a-97d7-5e441e713969_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87ef93cb-3a9e-47dc-b407-23dff37a2db7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_94c6b126-c522-473f-aced-ca1df853cd8c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8ea2df9a-b0dd-4345-b0b4-dd361bda49f1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_d644beae-099b-4547-b3da-55b61dd39f34_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d93143e1-659a-47de-931d-02d78eb5870f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_26315d22-a103-4d2e-a5cd-c08afb54d2fd_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_cbfaffb3-a650-4ba9-bc5d-c5de6cd49830_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_54221586-48b6-4e53-b28c-50a6a6b5f5ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ed1efb9f-6bfd-4b5c-a7e3-16f64408964d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_ec0e8096-03cb-4356-8a0e-5c6496c6c749_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_50aced7a-3f2d-4aa4-8b07-766754bcfa74_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs - variable</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ada17dd2-998f-446c-b5e7-40e19ef1563a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost - fixed</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_6b17208d-4c81-45b8-940e-fe0ec1956532_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3939f0cb-9c21-4ec7-a4a8-a24976aa544d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_916b6d4f-2208-4ff6-b379-165b2e260f2a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted stock vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dc9448d1-bf7c-443c-937c-17f44b31612c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance restricted stock vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_79f65de7-64b2-405b-81ad-f28c10c98274_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_253ba641-76b8-4f8e-84e1-26ee2672fe66_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e1078a25-3589-4834-b627-e8695f7661a7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_51f50592-4b3c-4161-af11-9018d1b1722a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_760b5b57-1cdb-4ad7-8cd8-9b056e6700eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_32eaa98a-8ce9-4322-8c14-5c23762dc2ee_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_9bee6a15-8bc1-43c0-b565-6e0c404d59d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_06e7098b-21e7-432e-b166-e21b035f814e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_409819d8-3361-46a6-aed1-0b80650ae832_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer match contribution percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_DeferredTaxLiabilitiesChangeInAccountingMethod_75e5cf1a-8382-44f8-94a3-867560c1e72a_negatedTerseLabel_en-US" xlink:label="lab_pets_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax accounting method change</link:label>
    <link:label id="lab_pets_DeferredTaxLiabilitiesChangeInAccountingMethod_label_en-US" xlink:label="lab_pets_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Change In Accounting Method</link:label>
    <link:label id="lab_pets_DeferredTaxLiabilitiesChangeInAccountingMethod_documentation_en-US" xlink:label="lab_pets_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Change In Accounting Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:href="pets-20240331.xsd#pets_DeferredTaxLiabilitiesChangeInAccountingMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:to="lab_pets_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_76ff6453-3363-4832-a5ab-1b4e11ebc41f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average restriction and forfeiture period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle2Member_5ccd70a1-2101-4c39-bd27-58908a8c20d4_terseLabel_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 2</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle2Member_label_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 2 [Member]</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle2Member_documentation_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Performance Restricted Stock Price Hurdle 2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle2Member" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PerformanceRestrictedStockPriceHurdle2Member" xlink:to="lab_pets_PerformanceRestrictedStockPriceHurdle2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c1b8f9b8-2f08-433a-8115-8e91056b80e3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_5023f010-8357-4eb9-b642-163ae7ed0738_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1a0f365f-1e8f-4966-adb5-13fb63d80918_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation costs related to restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3d6724e2-c4b0-41b1-83b7-78c212de1edb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_ef73604b-7869-4a6a-9a5f-ed2fde055cc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e6e93fb2-26c4-4c16-977b-8d562710b464_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionTextBlock_5ae6d207-8c64-44e6-97c5-93cb99d7b7a4_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement of Previously Issued Financial Statements</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionTextBlock_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Error Correction [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionTextBlock" xlink:to="lab_us-gaap_ErrorCorrectionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_e3145788-93c6-43c3-8c9b-813da6a516cd_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EmploymentAgreementRenewalTerm_6848fd02-a329-4c6e-b6ea-4610e26e8f05_terseLabel_en-US" xlink:label="lab_pets_EmploymentAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_pets_EmploymentAgreementRenewalTerm_label_en-US" xlink:label="lab_pets_EmploymentAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Agreement, Renewal Term</link:label>
    <link:label id="lab_pets_EmploymentAgreementRenewalTerm_documentation_en-US" xlink:label="lab_pets_EmploymentAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Agreement, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentAgreementRenewalTerm" xlink:href="pets-20240331.xsd#pets_EmploymentAgreementRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EmploymentAgreementRenewalTerm" xlink:to="lab_pets_EmploymentAgreementRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_61c6e637-5856-48db-8968-45f47bc4c795_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_7d19f989-f865-4e62-ae96-2350584963fe_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_TerminationPeriodPeriodWithinChangeInControl_41a08f9c-c37c-4be8-b2da-6f1b29b4075c_terseLabel_en-US" xlink:label="lab_pets_TerminationPeriodPeriodWithinChangeInControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">"Good Reason" termination period</link:label>
    <link:label id="lab_pets_TerminationPeriodPeriodWithinChangeInControl_label_en-US" xlink:label="lab_pets_TerminationPeriodPeriodWithinChangeInControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Termination Period, Period Within Change In Control</link:label>
    <link:label id="lab_pets_TerminationPeriodPeriodWithinChangeInControl_documentation_en-US" xlink:label="lab_pets_TerminationPeriodPeriodWithinChangeInControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Termination Period, Period Within Change In Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TerminationPeriodPeriodWithinChangeInControl" xlink:href="pets-20240331.xsd#pets_TerminationPeriodPeriodWithinChangeInControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_TerminationPeriodPeriodWithinChangeInControl" xlink:to="lab_pets_TerminationPeriodPeriodWithinChangeInControl" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EarningsPerShareBasicAndDilutedEPSAbstract_24a10938-b085-4fcb-9066-66247733d43c_terseLabel_en-US" xlink:label="lab_pets_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per common share:</link:label>
    <link:label id="lab_pets_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_pets_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_pets_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_pets_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="pets-20240331.xsd#pets_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_pets_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_fb58c5fd-9c32-480c-aee8-fad6fb06cc2d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_ccea8252-9fd9-4f29-93b8-30c590ae67c9_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8e92e2d0-6a36-4513-8a0c-ebf03d0ed7f2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3a89ce84-ecc3-412c-a344-d372dab93310_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_DefinedContributionPlanWithIndividualAge_f156b115-63dd-4cc1-90be-0a9aa6483ac7_terseLabel_en-US" xlink:label="lab_pets_DefinedContributionPlanWithIndividualAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, requisite age</link:label>
    <link:label id="lab_pets_DefinedContributionPlanWithIndividualAge_label_en-US" xlink:label="lab_pets_DefinedContributionPlanWithIndividualAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan With Individual Age</link:label>
    <link:label id="lab_pets_DefinedContributionPlanWithIndividualAge_documentation_en-US" xlink:label="lab_pets_DefinedContributionPlanWithIndividualAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum age that the individual is required in order to participate in the defined contribution plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DefinedContributionPlanWithIndividualAge" xlink:href="pets-20240331.xsd#pets_DefinedContributionPlanWithIndividualAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_DefinedContributionPlanWithIndividualAge" xlink:to="lab_pets_DefinedContributionPlanWithIndividualAge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_52c5c833-4dd1-4cea-81bd-77fdfc74c8f7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2c10dae1-5e9e-4a5f-9bd8-ae84c4a9cf09_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_af488bcc-6926-412d-b1d8-78081498ef92_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_ea7a82b2-a118-4d8e-b740-1c835bbce568_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of revenue generated</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate" xlink:to="lab_us-gaap_RelatedPartyTransactionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle1Member_745e4a08-2657-4710-ade6-2cc750fd3e65_terseLabel_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 1</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle1Member_label_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 1 [Member]</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle1Member_documentation_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Performance Restricted Stock Price Hurdle 1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle1Member" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PerformanceRestrictedStockPriceHurdle1Member" xlink:to="lab_pets_PerformanceRestrictedStockPriceHurdle1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_3571e0e8-fce7-4952-b574-adcabad1f8ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_e9492b3e-6d8b-4ca3-bfc4-6492ef1960ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_025d3398-715e-4e87-961e-9134ceacc7ec_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_MembershipCustomersMember_f33a5905-4a44-4cfc-a04e-da93720b0ff6_terseLabel_en-US" xlink:label="lab_pets_MembershipCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Membership Customers</link:label>
    <link:label id="lab_pets_MembershipCustomersMember_label_en-US" xlink:label="lab_pets_MembershipCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Membership Customers [Member]</link:label>
    <link:label id="lab_pets_MembershipCustomersMember_documentation_en-US" xlink:label="lab_pets_MembershipCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Membership Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipCustomersMember" xlink:href="pets-20240331.xsd#pets_MembershipCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_MembershipCustomersMember" xlink:to="lab_pets_MembershipCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6150c3ee-394b-446a-bc1f-8209c133751e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_57275d85-2a41-4c1c-82ad-cfac1ae95c0d_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, 2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7881b342-a005-479f-a32e-9a6d1d805e51_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_04957aee-8d15-4aab-bc8b-2d06fa5ba9a2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f6cee7a2-b6a7-452a-afeb-57b47ab86acc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_4c645c17-49ad-4e87-b2c4-4514a0b4307c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ffb3585d-4680-4771-a5d1-9c8ebe0508f4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_cb27e4a1-9097-49ed-a528-0c1f8f6595c9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_6d0219b2-aeee-4dd3-bbdb-96b5f979560a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued sales tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a69b908-2fca-4ab1-b667-785541055829_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ab5fb639-000b-4f66-a805-f3f36a49dd2c_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_RevenueFromContractWithCustomerNumberOfMembershipModels_a93162d9-29f0-4dab-87ac-ed8f784bc577_terseLabel_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerNumberOfMembershipModels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of membership models</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerNumberOfMembershipModels_label_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerNumberOfMembershipModels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Number Of Membership Models</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerNumberOfMembershipModels_documentation_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerNumberOfMembershipModels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Number Of Membership Models</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerNumberOfMembershipModels" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerNumberOfMembershipModels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_RevenueFromContractWithCustomerNumberOfMembershipModels" xlink:to="lab_pets_RevenueFromContractWithCustomerNumberOfMembershipModels" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f68fb246-e37a-4a0d-a5a2-04f8561d6cff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e06b9098-3162-4a93-93b1-3aa9e0cf2cc8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock hurdle price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_93721c0f-40da-4c32-8e60-06dd19991fec_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income (numerator):</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_357acd13-62f4-48f7-8566-24728430f7b4_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and issued (in dollars per share)</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_cc9117c0-50db-4790-92a2-752161b72960_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_da08c6db-19c2-48f5-9c5d-db543186c69c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedPaymentArrangementTrancheFourMember_c9c9a9e4-c3c7-4225-8224-a06111b63dc2_terseLabel_en-US" xlink:label="lab_pets_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Four</link:label>
    <link:label id="lab_pets_ShareBasedPaymentArrangementTrancheFourMember_label_en-US" xlink:label="lab_pets_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Four [Member]</link:label>
    <link:label id="lab_pets_ShareBasedPaymentArrangementTrancheFourMember_documentation_en-US" xlink:label="lab_pets_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedPaymentArrangementTrancheFourMember" xlink:href="pets-20240331.xsd#pets_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedPaymentArrangementTrancheFourMember" xlink:to="lab_pets_ShareBasedPaymentArrangementTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e303224d-d0d5-4071-b141-c5ba1b299f04_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes at federal statutory rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_0e37cb5a-1f62-495c-b33e-21d87d07a788_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends payable in accrued expenses</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_AccruedSeveranceCosts_42cddb65-c7d7-4e52-a467-7bd53f989a26_terseLabel_en-US" xlink:label="lab_pets_AccruedSeveranceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued severance costs</link:label>
    <link:label id="lab_pets_AccruedSeveranceCosts_label_en-US" xlink:label="lab_pets_AccruedSeveranceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Severance Costs</link:label>
    <link:label id="lab_pets_AccruedSeveranceCosts_documentation_en-US" xlink:label="lab_pets_AccruedSeveranceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedSeveranceCosts" xlink:href="pets-20240331.xsd#pets_AccruedSeveranceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_AccruedSeveranceCosts" xlink:to="lab_pets_AccruedSeveranceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_92d12bd2-8270-46d7-b382-18b484e867ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares issuable upon conversion of preferred shares (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d1e6631f-38ee-4e9c-bc6b-2f4f99009407_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_44b9d107-7cad-4b17-a83f-bd7a9b531049_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minority interest investment in Vetster</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_a7e1bcb8-1f85-4251-99c7-3f4d12eb9d6a_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_3baf6a14-af4e-4d11-a1bd-8cd271ad65ce_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_419f8c0a-db54-43d9-8f5d-7c99107e0c67_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f6d8ae2d-3165-476d-afec-c5a5e5d4fd24_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_8521ad9c-f5ce-43d9-807d-d1ebae6202d5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod_0ed0996b-439b-4ce1-b0a9-e36645de087e_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment performance period</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Performance Period</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_5cd7b46e-27d7-4494-931b-32969ebaf79a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_57425d54-b314-4cd0-b81f-777db3ae73a6_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2e2cfa8c-7ca0-4066-a676-d80957451416_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SEC382LimitedUtilizationMember_1cf735a2-bf78-47cf-95f5-0f90d97720b9_terseLabel_en-US" xlink:label="lab_pets_SEC382LimitedUtilizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec. 382 limited utilization</link:label>
    <link:label id="lab_pets_SEC382LimitedUtilizationMember_label_en-US" xlink:label="lab_pets_SEC382LimitedUtilizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC 382 Limited Utilization [Member]</link:label>
    <link:label id="lab_pets_SEC382LimitedUtilizationMember_documentation_en-US" xlink:label="lab_pets_SEC382LimitedUtilizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SEC 382 Limited Utilization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SEC382LimitedUtilizationMember" xlink:href="pets-20240331.xsd#pets_SEC382LimitedUtilizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SEC382LimitedUtilizationMember" xlink:to="lab_pets_SEC382LimitedUtilizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_45da180d-0040-4330-ad1b-be761f54e1be_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_38a531da-1483-4be2-ae97-3a248d8374a0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d741a0-0620-4bbb-bc08-60be1cc6df5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_85907748-1527-4a89-b836-5d1a2e90f155_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales tax payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Property and Other Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_7fa14255-46aa-416e-b0ce-c26c5a760223_terseLabel_en-US" xlink:label="lab_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Employee Plan</link:label>
    <link:label id="lab_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_label_en-US" xlink:label="lab_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2022 Employee Equity Compensation Restricted Stock Plan [Member]</link:label>
    <link:label id="lab_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_documentation_en-US" xlink:label="lab_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The 2022 Employee Equity Compensation Restricted Stock Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember" xlink:href="pets-20240331.xsd#pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember" xlink:to="lab_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_127682d8-838b-4809-950a-64aa3bec6106_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7055388c-85b4-48b0-a928-1db391a325da_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock, released in period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6b10b80-8034-495f-8ef0-e7f3e21ee5b9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_55a3a330-61eb-43d2-b63b-f7e570af9384_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount_c7a6ba56-877d-463f-baf2-61d035aca488_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant issued amount</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted Stock Amount</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted Stock Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_619ac59e-b9eb-469e-a87b-24ebc04a20a5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1c296c21-5121-4a5b-bb0a-61a1359c63eb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_3f544ab7-bf81-4be3-9808-40e9028717e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_c1d59453-22ac-48df-ad6d-e65357b034db_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6194afbb-ad90-4b71-8791-3e1e48a4e12b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_744ab69e-12f6-40b2-8359-b96727d8f2b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7193887-7dc6-4468-a6a8-9b69743f2118_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0d5ff53-a2eb-462e-9974-2d155f423851_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_13041908-cac7-4715-bf4b-d826689c2d71_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a4a7dc00-0550-4a24-af6c-eae963b4b73a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for the amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fd8319da-c441-4ff8-a2ef-e2319dbe1696_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6a096e91-776c-4899-a23d-6188a8065333_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_db314ebb-0b53-404d-845f-b3a8e8263e88_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_FiscalYear2024Member_8407989b-810f-4c34-884d-18fcd06cf68a_terseLabel_en-US" xlink:label="lab_pets_FiscalYear2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Year 2024</link:label>
    <link:label id="lab_pets_FiscalYear2024Member_label_en-US" xlink:label="lab_pets_FiscalYear2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Year 2024 [Member]</link:label>
    <link:label id="lab_pets_FiscalYear2024Member_documentation_en-US" xlink:label="lab_pets_FiscalYear2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fiscal Year 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_FiscalYear2024Member" xlink:href="pets-20240331.xsd#pets_FiscalYear2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_FiscalYear2024Member" xlink:to="lab_pets_FiscalYear2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_b150555d-8f3c-467e-8a1f-0ecc8a7d23f3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_16ffd429-b682-4c29-9248-59c70962cdaf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_06bbf120-e35d-44ec-a38b-60adf3d744dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_4d6cd126-61d9-4f59-a485-b4015ec2d717_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_a82faf6b-3d54-4eab-adb4-aba2e171f703_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_bc12e2e0-727c-447f-bbcf-3432b3228ecf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0ce0e1c3-4e98-4834-87fb-f8fc92caf766_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (as percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_30e6e638-1d65-4782-b32b-2bf3bbac6964_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_614fefbf-c8c7-43b1-8e9c-d0e35c63d340_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_d5b729fb-cd34-4e1c-a600-57890c3a071b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_c00d0392-760e-4069-8fce-3bde8c967ae7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_97100d82-1a65-45e2-b750-6aad1a038d62_negatedTerseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested and issued (in shares)</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_e6de35f2-b95d-4d88-a21d-666348cc4f0c_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5647f101-8c64-4915-afef-5bcda01e8a63_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Effective Tax Rate (as percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_b1963dd3-4690-438d-b08a-f213d6308738_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_023f740f-68e4-4cde-85b3-8634f52e89d9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6f5ea912-ac73-4b36-b0dd-4ecac9ab0106_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle4Member_358ee612-c46e-4f22-8251-0039da1a9d1b_terseLabel_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle4Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 4</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle4Member_label_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 4 [Member]</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle4Member_documentation_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle4Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Performance Restricted Stock Price Hurdle 4.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle4Member" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle4Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PerformanceRestrictedStockPriceHurdle4Member" xlink:to="lab_pets_PerformanceRestrictedStockPriceHurdle4Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c6597632-5345-4932-a23e-81007b18cb01_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_8653e8ae-c5ae-4f17-8b57-a4fbf462c52a_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current income tax provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ec7a0541-dfd5-405d-8e12-f1d091d7de4e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_d8cec595-29c9-43b6-a5ee-d0ae0d474d3e_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fbb6ce7d-43e6-4ed5-b7e3-317be22e071a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_52d5fe43-663f-4754-b153-12692af2c9e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_88623e12-465f-4e95-b297-70541769c8d2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount_4e104af2-e45d-4eef-a1e2-162e810fc873_terseLabel_en-US" xlink:label="lab_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation of covered executives</link:label>
    <link:label id="lab_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount_label_en-US" xlink:label="lab_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Compensation Of Covered People Limit Deduction Amount</link:label>
    <link:label id="lab_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount_documentation_en-US" xlink:label="lab_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Compensation Of Covered People Limit Deduction Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount" xlink:href="pets-20240331.xsd#pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount" xlink:to="lab_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_OperatingLossCarryforwardsSubjectToLimitations_e00f1c7e-51e5-479b-a0bb-7b73fe867b54_terseLabel_en-US" xlink:label="lab_pets_OperatingLossCarryforwardsSubjectToLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating losses - limited carryover</link:label>
    <link:label id="lab_pets_OperatingLossCarryforwardsSubjectToLimitations_label_en-US" xlink:label="lab_pets_OperatingLossCarryforwardsSubjectToLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Limitations</link:label>
    <link:label id="lab_pets_OperatingLossCarryforwardsSubjectToLimitations_documentation_en-US" xlink:label="lab_pets_OperatingLossCarryforwardsSubjectToLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardsSubjectToLimitations" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardsSubjectToLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_OperatingLossCarryforwardsSubjectToLimitations" xlink:to="lab_pets_OperatingLossCarryforwardsSubjectToLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_df6f8946-98de-4af1-9a41-734b0c05ca9e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_82bd8d1b-454d-4ffb-bd43-e0a49b78d7a8_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, 2027</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_cd4138be-a009-420b-8d34-ca0e66645b43_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets_2ddbeb7b-8b2c-49cf-8971-d82d9d6e67a5_terseLabel_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets_label_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Lease Assets</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets_documentation_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets" xlink:to="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_60269e08-a314-4e10-beac-f2f4a5019014_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle3Member_abd9c727-e082-4e3f-b2e7-463de6dd86c9_terseLabel_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 3</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle3Member_label_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 3 [Member]</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle3Member_documentation_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Performance Restricted Stock Price Hurdle 3.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle3Member" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PerformanceRestrictedStockPriceHurdle3Member" xlink:to="lab_pets_PerformanceRestrictedStockPriceHurdle3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a5239106-d13a-4d70-80c7-62c372285371_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_565f9087-3384-4b4c-9c21-54a9926573f0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b9291aa4-b53b-452a-b041-c8e5c32716b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $.001 par value, 40,000 shares authorized; 21,149 and 21,084 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_13b14e41-e005-4127-8e11-31d16564db74_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_2fe6b5d3-ba09-4c8c-8f13-7fe6312363a9_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Names - PetCareRx</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_0ecf4bd3-7577-4b7d-b4cd-735a85589601_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f1585147-2dbc-4bee-9735-5859bf333a6e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PartnerProgramMember_90426f7c-5f99-478e-8c84-67f813c833e4_terseLabel_en-US" xlink:label="lab_pets_PartnerProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partner Program</link:label>
    <link:label id="lab_pets_PartnerProgramMember_label_en-US" xlink:label="lab_pets_PartnerProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partner Program [Member]</link:label>
    <link:label id="lab_pets_PartnerProgramMember_documentation_en-US" xlink:label="lab_pets_PartnerProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Partner Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PartnerProgramMember" xlink:href="pets-20240331.xsd#pets_PartnerProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PartnerProgramMember" xlink:to="lab_pets_PartnerProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SalaryAndWageOfficerAnnualBaseSalary_1e013838-2161-40d4-8671-abe7e0249d9f_terseLabel_en-US" xlink:label="lab_pets_SalaryAndWageOfficerAnnualBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual base salary</link:label>
    <link:label id="lab_pets_SalaryAndWageOfficerAnnualBaseSalary_label_en-US" xlink:label="lab_pets_SalaryAndWageOfficerAnnualBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary And Wage, Officer, Annual Base Salary</link:label>
    <link:label id="lab_pets_SalaryAndWageOfficerAnnualBaseSalary_documentation_en-US" xlink:label="lab_pets_SalaryAndWageOfficerAnnualBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Salary And Wage, Officer, Annual Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerAnnualBaseSalary" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerAnnualBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SalaryAndWageOfficerAnnualBaseSalary" xlink:to="lab_pets_SalaryAndWageOfficerAnnualBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2c090588-a2fe-439e-98bc-1ef12b8dc8fb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived_89cddf9b-3601-4d7a-bd0b-ecae6c6e72ff_terseLabel_en-US" xlink:label="lab_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred memberships fees received</link:label>
    <link:label id="lab_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived_label_en-US" xlink:label="lab_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability, Increase For Deferred Fees Received</link:label>
    <link:label id="lab_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived_documentation_en-US" xlink:label="lab_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability, Increase For Deferred Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived" xlink:to="lab_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_ae54a4fc-e6bc-4339-9917-64d13b5d8e86_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_a45bd64d-fec8-40bb-9e18-eb18962d48c4_terseLabel_en-US" xlink:label="lab_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Director Plan</link:label>
    <link:label id="lab_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_label_en-US" xlink:label="lab_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 Outside Director Equity Compensation Restricted Stock Plan [Member]</link:label>
    <link:label id="lab_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_documentation_en-US" xlink:label="lab_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the 2015 Outside Director Equity Compensation Restricted Stock Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember" xlink:href="pets-20240331.xsd#pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember" xlink:to="lab_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c19f9e15-3284-46dc-b95c-f6cde6fd0553_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_262f7063-e0c5-44b6-9ab3-813b41a2ddd1_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, 2029</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill_085d50b0-d3be-4d04-9f7e-b476f7075aa3_terseLabel_en-US" xlink:label="lab_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible and other assets, net</link:label>
    <link:label id="lab_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible And Other Noncurrent Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill_documentation_en-US" xlink:label="lab_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible And Other Noncurrent Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" xlink:to="lab_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ContractWithCustomerLiabilityCurrentRollForward_fd5ae838-0879-470b-9e03-040ea6cff3c0_terseLabel_en-US" xlink:label="lab_pets_ContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current [Roll Forward]</link:label>
    <link:label id="lab_pets_ContractWithCustomerLiabilityCurrentRollForward_label_en-US" xlink:label="lab_pets_ContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current [Roll Forward]</link:label>
    <link:label id="lab_pets_ContractWithCustomerLiabilityCurrentRollForward_documentation_en-US" xlink:label="lab_pets_ContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerLiabilityCurrentRollForward" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerLiabilityCurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward" xlink:to="lab_pets_ContractWithCustomerLiabilityCurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_ff52dae8-ac7c-4582-a33e-459cdc45632b_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued real estate taxes</link:label>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for Taxes Other than Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e7bacf11-eeb6-4e3f-8088-35cc53604ac6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d5015725-29b3-4c17-b2ab-397f1229aea7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_b7d6fe3d-f473-498d-bb73-0f19ad9dbeb4_terseLabel_en-US" xlink:label="lab_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Requisite service period</link:label>
    <link:label id="lab_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_label_en-US" xlink:label="lab_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary And Wage, Officer, Sign Of Bonus, Requisite Service Period</link:label>
    <link:label id="lab_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_documentation_en-US" xlink:label="lab_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Salary And Wage, Officer, Sign Of Bonus, Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" xlink:to="lab_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_24a27a9a-3d91-4466-84d8-d2fdbb74ac5e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_eec91505-2fac-4c58-b2fa-d9e95b11ff25_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_MembershipFeesMember_e10d3919-f614-4554-b671-e0628127700d_terseLabel_en-US" xlink:label="lab_pets_MembershipFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Membership fees</link:label>
    <link:label id="lab_pets_MembershipFeesMember_label_en-US" xlink:label="lab_pets_MembershipFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Membership Fees [Member]</link:label>
    <link:label id="lab_pets_MembershipFeesMember_documentation_en-US" xlink:label="lab_pets_MembershipFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Membership Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipFeesMember" xlink:href="pets-20240331.xsd#pets_MembershipFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_MembershipFeesMember" xlink:to="lab_pets_MembershipFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_ebd1fb8b-fe57-4765-8f27-aa22bbcac628_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales tax payable</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_20bd1283-130d-4c09-8196-3cc6cfd01828_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c12ce8b9-0457-43eb-8f03-2968927ec3d0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities for uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle5Member_df1aca27-a4be-49d3-ada5-a1c21f7cf38f_terseLabel_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle5Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 5</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle5Member_label_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle5Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Price Hurdle 5 [Member]</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockPriceHurdle5Member_documentation_en-US" xlink:label="lab_pets_PerformanceRestrictedStockPriceHurdle5Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Performance Restricted Stock Price Hurdle 5.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle5Member" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle5Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PerformanceRestrictedStockPriceHurdle5Member" xlink:to="lab_pets_PerformanceRestrictedStockPriceHurdle5Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_e469538f-ffd4-4359-aca4-16ae90552956_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock shortfall adjustment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_f107f23b-5ac6-4116-9dfa-80f7689b0659_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_b1174a70-de01-4a92-8a83-14a27482069b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of all products purchased</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aabbdb76-a0bc-40fa-93bd-7e97f64b9770_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f99dc6ea-f853-4640-9b4a-f926732e1f83_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9e04977d-c51f-4c2e-bbf1-076ef7a76417_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal tax benefit (as percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_32f55223-8891-421a-aa5e-5a508000de62_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minority interest purchased, amount</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_AccruedCreditCardFeesCurrent_1319bfb9-a295-46e2-b8e2-3ff1b9847d11_terseLabel_en-US" xlink:label="lab_pets_AccruedCreditCardFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued credit card fees</link:label>
    <link:label id="lab_pets_AccruedCreditCardFeesCurrent_label_en-US" xlink:label="lab_pets_AccruedCreditCardFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued credit card fees</link:label>
    <link:label id="lab_pets_AccruedCreditCardFeesCurrent_documentation_en-US" xlink:label="lab_pets_AccruedCreditCardFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for credit card fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedCreditCardFeesCurrent" xlink:href="pets-20240331.xsd#pets_AccruedCreditCardFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_AccruedCreditCardFeesCurrent" xlink:to="lab_pets_AccruedCreditCardFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c02ec523-2dfb-42fe-9090-8469c041f34a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d8ec7c38-7ca1-4c3a-8016-5d5b4a15f856_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_7176df07-c716-4faa-bbc7-4ce15b956596_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c0d6a823-1d8d-4d9b-a1fc-94a99143f300_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6af8e139-ecae-4dd8-bd74-b5425920c1e0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0ef7d68e-93ca-40b7-9607-55dfa21e3c5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7a6eac9a-59dd-4a70-8aee-4119681bd024_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_e6a77faf-a7cb-42f1-bcf2-06e6841a4675_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_DeferredTaxAssetsLeaseLiabilities_2853559d-726a-451d-a62f-84c30a6feb5f_terseLabel_en-US" xlink:label="lab_pets_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_pets_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_pets_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_pets_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_pets_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetsLeaseLiabilities" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_pets_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_bfaddf9c-48ce-4ce1-a34f-7657b98c1ad7_terseLabel_en-US" xlink:label="lab_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences (as percent)</link:label>
    <link:label id="lab_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_label_en-US" xlink:label="lab_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</link:label>
    <link:label id="lab_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_documentation_en-US" xlink:label="lab_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:href="pets-20240331.xsd#pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="lab_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_fb5c4722-a5f4-42b6-8e36-ac82b37951b1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ad25dd31-6a0c-4f00-b631-5de6e8894b93_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_1e750591-a200-4e1a-beaa-cae82bac7897_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a7efbdc4-2abd-49bb-8d72-7cb60ba3d91f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_4458f828-e19c-40d7-9a06-fcc49eea529b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ContractWithCustomerRenewalPeriod_0b9e697e-dfa8-45da-8cc8-e737179be754_terseLabel_en-US" xlink:label="lab_pets_ContractWithCustomerRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual membership fees renewal period</link:label>
    <link:label id="lab_pets_ContractWithCustomerRenewalPeriod_label_en-US" xlink:label="lab_pets_ContractWithCustomerRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Renewal Period</link:label>
    <link:label id="lab_pets_ContractWithCustomerRenewalPeriod_documentation_en-US" xlink:label="lab_pets_ContractWithCustomerRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Renewal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerRenewalPeriod" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerRenewalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ContractWithCustomerRenewalPeriod" xlink:to="lab_pets_ContractWithCustomerRenewalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f2280266-7b00-4346-ab1e-19c4ab3becd7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e4bc077d-22b3-4ec9-a297-b31d10f6b154_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8c500173-1449-46c1-9054-6ba01dd56f7b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_8e080ef4-be57-4cd9-9e77-602f5d89afb9_totalLabel_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_label_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_documentation_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:to="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare_9cba6c77-13c4-4e57-ac72-3b71ac4e5fe4_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subject to floor (in dollars per share)</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Subject To Floor Per Share</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Subject To Floor Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c56697ef-00bf-4bfb-9e05-57df808eac75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_734753d7-00b2-4cfa-8fc2-dbb3ad197b0a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_ea302427-10be-4cc6-93ba-799806f87fbe_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_3b292d9c-e8b6-477c-a8e0-8515042d02cf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_f8e37322-2f77-4404-8d46-f7db02f10f94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_95e79f2f-fea4-4ab5-b2aa-e929ee042fb2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c8350101-945c-475c-b19c-c350fb5aa92a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance_c4432958-9278-4452-8cce-7c5aea8254d2_terseLabel_en-US" xlink:label="lab_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for issuance, automatic annual increase, percent</link:label>
    <link:label id="lab_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance_label_en-US" xlink:label="lab_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Automatic Increase In Shares Available For Issuance</link:label>
    <link:label id="lab_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of automatic increase in the amount of shares available for issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance" xlink:href="pets-20240331.xsd#pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance" xlink:to="lab_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d54a664-a482-4919-afb3-98e26fd66d14_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred membership fee revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d5c121e0-7b45-4ad3-bbac-216448fd4c00_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred membership fee revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e4fa0800-dbe3-496f-a50e-201117f72993_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7d0e65d9-a41b-4c45-a717-8e29e6b00c9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternetDomainNamesMember_fe9dda83-beab-4f74-8a98-fa05b11b65b9_terseLabel_en-US" xlink:label="lab_us-gaap_InternetDomainNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internet domain names</link:label>
    <link:label id="lab_us-gaap_InternetDomainNamesMember_label_en-US" xlink:label="lab_us-gaap_InternetDomainNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internet Domain Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternetDomainNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternetDomainNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternetDomainNamesMember" xlink:to="lab_us-gaap_InternetDomainNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_820ba023-2a54-499a-8851-98622f211187_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_d547ad2d-d5f2-4042-b90f-d5bf69eab367_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dd3ccb33-cde2-4ec6-9a5d-a9f3cf999c3f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue_3a220dcf-7c44-4cc9-af69-0bad97a16073_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, total grant date fair value</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Total Grant Date Fair Value</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Total Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_NonvestedRestrictedStockMember_421d5ca1-4f33-4aed-a197-9d32a1ff341e_terseLabel_en-US" xlink:label="lab_pets_NonvestedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-vested Restricted Stock</link:label>
    <link:label id="lab_pets_NonvestedRestrictedStockMember_label_en-US" xlink:label="lab_pets_NonvestedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-vested Restricted Stock [Member]</link:label>
    <link:label id="lab_pets_NonvestedRestrictedStockMember_documentation_en-US" xlink:label="lab_pets_NonvestedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to non-vested restricted stock awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NonvestedRestrictedStockMember" xlink:href="pets-20240331.xsd#pets_NonvestedRestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_NonvestedRestrictedStockMember" xlink:to="lab_pets_NonvestedRestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fe5a39d-50d8-490b-be59-c342de6f2d60_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_74fbc0af-c479-4e4e-8abd-64a87747f137_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4bdce4da-f28b-4d77-a134-32162d27aa1f_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_A2022EmployeePlanMember_19d875c9-6369-4870-ba0d-fd0aac53f7c7_terseLabel_en-US" xlink:label="lab_pets_A2022EmployeePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Employee Plan</link:label>
    <link:label id="lab_pets_A2022EmployeePlanMember_label_en-US" xlink:label="lab_pets_A2022EmployeePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Employee Plan [Member]</link:label>
    <link:label id="lab_pets_A2022EmployeePlanMember_documentation_en-US" xlink:label="lab_pets_A2022EmployeePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Employee Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_A2022EmployeePlanMember" xlink:href="pets-20240331.xsd#pets_A2022EmployeePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_A2022EmployeePlanMember" xlink:to="lab_pets_A2022EmployeePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_744e24bf-c768-40cc-9283-db429ff58dac_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod_fe3ea4f4-0353-474b-b771-ded283dc322f_terseLabel_en-US" xlink:label="lab_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance pay health insurance benefits, change in control, period</link:label>
    <link:label id="lab_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod_label_en-US" xlink:label="lab_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Payment, Change In Control, Health Insurance Benefits, Period</link:label>
    <link:label id="lab_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod_documentation_en-US" xlink:label="lab_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Severance Payment, Change In Control, Health Insurance Benefits, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod" xlink:href="pets-20240331.xsd#pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod" xlink:to="lab_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PercentageOfPropertyLeasedToTenants_5a4f2cdf-f706-4fc2-908e-da8f3937fdfb_terseLabel_en-US" xlink:label="lab_pets_PercentageOfPropertyLeasedToTenants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of property leased to tenants</link:label>
    <link:label id="lab_pets_PercentageOfPropertyLeasedToTenants_label_en-US" xlink:label="lab_pets_PercentageOfPropertyLeasedToTenants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Property Leased To Tenants</link:label>
    <link:label id="lab_pets_PercentageOfPropertyLeasedToTenants_documentation_en-US" xlink:label="lab_pets_PercentageOfPropertyLeasedToTenants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage amount of property that was leased to tenants of the property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PercentageOfPropertyLeasedToTenants" xlink:href="pets-20240331.xsd#pets_PercentageOfPropertyLeasedToTenants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PercentageOfPropertyLeasedToTenants" xlink:to="lab_pets_PercentageOfPropertyLeasedToTenants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_02626d46-7ef4-4fe3-a5f5-44ed12a1dd04_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_37e0485f-4e7e-42df-97d0-1985f2eb9b0f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_b62c298d-b2e3-4649-ac7c-d853e51cecdf_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_TermOfAgreement_57978231-0338-4cf3-906f-2e70c9d33d76_terseLabel_en-US" xlink:label="lab_pets_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_pets_TermOfAgreement_label_en-US" xlink:label="lab_pets_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Agreement</link:label>
    <link:label id="lab_pets_TermOfAgreement_documentation_en-US" xlink:label="lab_pets_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TermOfAgreement" xlink:href="pets-20240331.xsd#pets_TermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_TermOfAgreement" xlink:to="lab_pets_TermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e06cc311-b9e6-442d-aa93-ec93ad599b5c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fd6b7f9a-b3de-49cd-82f4-4c5c7dab3ed9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_84d98693-0fff-4250-8019-fdaf1f48d856_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per Share Dividend (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_label_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableAmountPerShare" xlink:to="lab_us-gaap_DividendsPayableAmountPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_497df1f6-8d92-4ac2-9c73-c86b6b9ceec4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7f043631-932f-496b-bfb6-11617f379db2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definite-lived intangible assets useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_DelrayBeachPropertyMember_2567cadb-d577-401f-bb3f-54f08a4fc675_terseLabel_en-US" xlink:label="lab_pets_DelrayBeachPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Delray Beach Property</link:label>
    <link:label id="lab_pets_DelrayBeachPropertyMember_label_en-US" xlink:label="lab_pets_DelrayBeachPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Delray Beach Property [Member]</link:label>
    <link:label id="lab_pets_DelrayBeachPropertyMember_documentation_en-US" xlink:label="lab_pets_DelrayBeachPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the Delray Beach Property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DelrayBeachPropertyMember" xlink:href="pets-20240331.xsd#pets_DelrayBeachPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_DelrayBeachPropertyMember" xlink:to="lab_pets_DelrayBeachPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f341213c-474b-4df7-bc5b-c9eb50b95d2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4a2409b8-88f3-4729-859b-ac3df5eafddf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bede4cc5-14e0-4ea1-a791-7530b683a86e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_4fdc6b75-e86d-46d4-89b2-0cd4c2dae1c3_terseLabel_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:to="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1c050ff3-834d-4cca-94bc-64b580eb961c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_NumberOfSeverancePayments_7a9aabff-1522-47b2-8550-d00441f5125d_terseLabel_en-US" xlink:label="lab_pets_NumberOfSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of severance payments</link:label>
    <link:label id="lab_pets_NumberOfSeverancePayments_label_en-US" xlink:label="lab_pets_NumberOfSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Severance Payments</link:label>
    <link:label id="lab_pets_NumberOfSeverancePayments_documentation_en-US" xlink:label="lab_pets_NumberOfSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Severance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NumberOfSeverancePayments" xlink:href="pets-20240331.xsd#pets_NumberOfSeverancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_NumberOfSeverancePayments" xlink:to="lab_pets_NumberOfSeverancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_80ba12a3-e46c-4854-81f4-3c0ae2c6ba4d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6e5ae641-70c0-4149-8f1c-b27b323ceb07_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_08568b78-0046-4c81-b89e-e72647d25c67_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_224c433c-c87b-4586-8208-90be31372839_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1581b955-93a3-495b-919a-db9c62a50738_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Share Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_0bfb3130-da5e-44be-9f7d-947d2bcfda49_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_215b8ad9-2a36-41b2-a354-03590a121351_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_66139701-01ce-4fe0-97f1-6a14459987b6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_b5914cd7-4efe-48c5-8cb1-eb03db56fbf7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_81a0f187-55f3-4464-b3b2-ef9e6ee81f08_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_f1138620-fbad-4870-a2c5-4a6945e889ef_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for Share Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_27c8e759-d55d-4286-b358-882a2ce5b0fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ac63d92a-9969-4bae-bf98-2d0a960b8797_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a186d8d2-0d86-4cfa-8459-1152b9d6b379_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae92f5bd-e0ed-4021-a32d-6adc6b3fdc65_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares (denominator)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9f0bbde0-6384-4d03-b5c0-587bbefe8ff3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_086dc62d-1832-4536-983d-04665e473aa4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_304abcd9-f6f4-4e74-9992-329d31eab680_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1a0c94f3-537b-4d7b-9988-ca3eb55defc8_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of real estate property (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm_d1c62cc6-c674-488b-b2f9-a882a0693639_terseLabel_en-US" xlink:label="lab_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment term cancellation period</link:label>
    <link:label id="lab_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm_label_en-US" xlink:label="lab_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Term, Cancellation Period Prior To End Of Current Term</link:label>
    <link:label id="lab_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm_documentation_en-US" xlink:label="lab_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Term, Cancellation Period Prior To End Of Current Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm" xlink:href="pets-20240331.xsd#pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm" xlink:to="lab_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_79ae8c73-1a8d-4445-a7af-e881fd542eb1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d29fa5d8-efe9-4617-99d9-3c09896c41f0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_VetsterIncMember_d0513a0c-e9d4-4476-ac97-e5cb99e4fda4_terseLabel_en-US" xlink:label="lab_pets_VetsterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vetster Inc</link:label>
    <link:label id="lab_pets_VetsterIncMember_label_en-US" xlink:label="lab_pets_VetsterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vetster Inc [Member]</link:label>
    <link:label id="lab_pets_VetsterIncMember_documentation_en-US" xlink:label="lab_pets_VetsterIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vetster Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_VetsterIncMember" xlink:href="pets-20240331.xsd#pets_VetsterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_VetsterIncMember" xlink:to="lab_pets_VetsterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_165f0328-61d1-45df-9088-5f698eba087c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Finished Goods and Work in Process Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dc920e74-2c41-4bff-9b43-9353a639d0ca_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_905469a5-47d8-40cd-8263-d463afbafe4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_a693604a-7d24-46ff-88f7-25c3e8093432_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ReportingUnitMeasurementInput_6375e745-b307-4649-8b2a-31ebfa48cea3_terseLabel_en-US" xlink:label="lab_pets_ReportingUnitMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting unit measurement type</link:label>
    <link:label id="lab_pets_ReportingUnitMeasurementInput_label_en-US" xlink:label="lab_pets_ReportingUnitMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit, Measurement Input</link:label>
    <link:label id="lab_pets_ReportingUnitMeasurementInput_documentation_en-US" xlink:label="lab_pets_ReportingUnitMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reporting Unit, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ReportingUnitMeasurementInput" xlink:href="pets-20240331.xsd#pets_ReportingUnitMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ReportingUnitMeasurementInput" xlink:to="lab_pets_ReportingUnitMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_4e34a5cd-8a9b-4220-9d41-3017a62f0d2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d5a96f19-049b-4d60-bf79-940798414f34_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_e105f629-bfc3-4f64-9e9f-24857c0106f9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_589369c1-34c0-4b1c-af20-21b1baf94c49_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_81bd8de5-abc0-42db-96ff-ccba95481b7a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_2d4cf002-917d-4af0-8477-2e8fb49bcfcd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of minority interest investment in Vetster</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_8f5c1e9c-dbbe-4dec-bd28-2b3491312632_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Technology - PetCareRx</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_d763d769-76f2-43c6-8f62-48566dd46ec7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of equity interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c62ae8f8-d4c6-4d24-aeb8-e24cacb35ebc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e7243a62-81da-4908-a1d8-e5251e752b64_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill deductible for tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_23275021-e70a-4cde-a0d1-0b43d0cafead_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_51acda74-2887-45d3-9710-26b9e7b1fd93_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_9d1c103b-6548-4734-a190-689d5058120f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a32579dc-b1a3-439a-a7ca-82aff78a13f7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_936e4ce0-2a3b-4667-aab0-b018d0438c12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_395b0155-0fd4-4873-9ecc-abc5e2ec9d74_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Revenue (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueExpenseNet" xlink:to="lab_us-gaap_InterestRevenueExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ContractWithCustomerRevenueRecognitionPeriod_35b1ae09-c2d6-462b-8120-8f44fbfa15a2_terseLabel_en-US" xlink:label="lab_pets_ContractWithCustomerRevenueRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition period</link:label>
    <link:label id="lab_pets_ContractWithCustomerRevenueRecognitionPeriod_label_en-US" xlink:label="lab_pets_ContractWithCustomerRevenueRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Revenue Recognition, Period</link:label>
    <link:label id="lab_pets_ContractWithCustomerRevenueRecognitionPeriod_documentation_en-US" xlink:label="lab_pets_ContractWithCustomerRevenueRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Revenue Recognition, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerRevenueRecognitionPeriod" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerRevenueRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ContractWithCustomerRevenueRecognitionPeriod" xlink:to="lab_pets_ContractWithCustomerRevenueRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_33668592-f9a8-490b-bd4c-0ba5dc308939_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_927736e1-726d-48bd-afe8-c7fac7a2345e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_bfcd65c6-05db-4742-8343-df39db09a2f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2a63ed62-5a8f-43d3-93bb-69675021918d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EmployeeAndDirectorEquityCompensationPlanMember_d44445da-e683-4896-906d-c8236f17902f_terseLabel_en-US" xlink:label="lab_pets_EmployeeAndDirectorEquityCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee and Director Equity Compensation Plan</link:label>
    <link:label id="lab_pets_EmployeeAndDirectorEquityCompensationPlanMember_label_en-US" xlink:label="lab_pets_EmployeeAndDirectorEquityCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee and Director Equity Compensation Plan [Member]</link:label>
    <link:label id="lab_pets_EmployeeAndDirectorEquityCompensationPlanMember_documentation_en-US" xlink:label="lab_pets_EmployeeAndDirectorEquityCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to both the employee and director equity compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmployeeAndDirectorEquityCompensationPlanMember" xlink:href="pets-20240331.xsd#pets_EmployeeAndDirectorEquityCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EmployeeAndDirectorEquityCompensationPlanMember" xlink:to="lab_pets_EmployeeAndDirectorEquityCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SixSuppliersMember_82db6d40-2218-41c2-828c-34c46916d1a6_terseLabel_en-US" xlink:label="lab_pets_SixSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Six Suppliers</link:label>
    <link:label id="lab_pets_SixSuppliersMember_label_en-US" xlink:label="lab_pets_SixSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Six Suppliers [Member]</link:label>
    <link:label id="lab_pets_SixSuppliersMember_documentation_en-US" xlink:label="lab_pets_SixSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Six Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SixSuppliersMember" xlink:href="pets-20240331.xsd#pets_SixSuppliersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SixSuppliersMember" xlink:to="lab_pets_SixSuppliersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e440f7bc-cee0-40af-9efa-145e9d51d431_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SeverancePaymentBaseSalaryPeriod_262fcae1-6f47-46ae-a096-5a0860b99d68_terseLabel_en-US" xlink:label="lab_pets_SeverancePaymentBaseSalaryPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance pay equal to based salary for number of periods</link:label>
    <link:label id="lab_pets_SeverancePaymentBaseSalaryPeriod_label_en-US" xlink:label="lab_pets_SeverancePaymentBaseSalaryPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Payment, Base Salary, Period</link:label>
    <link:label id="lab_pets_SeverancePaymentBaseSalaryPeriod_documentation_en-US" xlink:label="lab_pets_SeverancePaymentBaseSalaryPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Severance Payment, Base Salary, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SeverancePaymentBaseSalaryPeriod" xlink:href="pets-20240331.xsd#pets_SeverancePaymentBaseSalaryPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SeverancePaymentBaseSalaryPeriod" xlink:to="lab_pets_SeverancePaymentBaseSalaryPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_MeasurementInputWeightedAverageCostOfCapitalMember_dffc9206-95eb-4455-a607-2c0834b60389_terseLabel_en-US" xlink:label="lab_pets_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Weighted Average Cost Of Capital</link:label>
    <link:label id="lab_pets_MeasurementInputWeightedAverageCostOfCapitalMember_label_en-US" xlink:label="lab_pets_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Weighted Average Cost Of Capital [Member]</link:label>
    <link:label id="lab_pets_MeasurementInputWeightedAverageCostOfCapitalMember_documentation_en-US" xlink:label="lab_pets_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Weighted Average Cost Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:href="pets-20240331.xsd#pets_MeasurementInputWeightedAverageCostOfCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:to="lab_pets_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3c56ca5b-f26a-4e40-9a70-0413f6dfd1ce_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17b5562c-88ab-4226-a5de-68dbcefa9840_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_e1691157-0dc8-4bca-95e0-62f4b97dd19d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember_f7f10417-b5e3-4950-be05-95c1f0dc8bab_terseLabel_en-US" xlink:label="lab_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, Fixtures, Equipment and Computer Software</link:label>
    <link:label id="lab_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember_label_en-US" xlink:label="lab_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture, Fixtures, Equipment and Computer Software [Member]</link:label>
    <link:label id="lab_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember_documentation_en-US" xlink:label="lab_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding furniture, fixtures, equipment and computer software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember" xlink:href="pets-20240331.xsd#pets_FurnitureFixturesEquipmentAndComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember" xlink:to="lab_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_ea007b09-4ec2-4e58-a191-1e92faa05d2a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related costs incurred</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsTotalMember_0e9ce82c-e493-4363-a77f-24bf43671338_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsTotalMember_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsTotalMember" xlink:to="lab_us-gaap_CostOfGoodsTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9b134304-8f51-4979-852a-82721e015767_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_65e26968-311b-4ca9-baa7-ee719e4c093b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_460ac3a2-32f5-4799-b078-7aec8eee3a72_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_db420c3a-1f4e-409f-b01a-ad10873e4576_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_AccruedExpensesAndOtherCurrentLiabilities_d709f7f7-81bf-4a4b-8e6d-1a31db755b3d_terseLabel_en-US" xlink:label="lab_pets_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_pets_AccruedExpensesAndOtherCurrentLiabilities_bf74683b-32ac-4e2b-82b6-63077be0d397_totalLabel_en-US" xlink:label="lab_pets_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_pets_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_pets_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_pets_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_pets_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="pets-20240331.xsd#pets_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_pets_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_2b538639-bfe2-4067-95df-84a3cb57f429_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_03218ec5-0a58-47b2-a3ca-cf22dc264c75_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_IntangiblesAndOtherAssetsAccumulatedAmortization_7fb63237-e3fd-4ccc-8cc4-dcdea0f94c0b_negatedTerseLabel_en-US" xlink:label="lab_pets_IntangiblesAndOtherAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_pets_IntangiblesAndOtherAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_pets_IntangiblesAndOtherAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangibles And Other Assets, Accumulated Amortization</link:label>
    <link:label id="lab_pets_IntangiblesAndOtherAssetsAccumulatedAmortization_documentation_en-US" xlink:label="lab_pets_IntangiblesAndOtherAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangibles And Other Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangiblesAndOtherAssetsAccumulatedAmortization" xlink:href="pets-20240331.xsd#pets_IntangiblesAndOtherAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_IntangiblesAndOtherAssetsAccumulatedAmortization" xlink:to="lab_pets_IntangiblesAndOtherAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bcaad99b-d50e-47bb-b018-34f82ab87097_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ReorderMember_166bbae3-a333-49e6-9479-e9339db149f0_terseLabel_en-US" xlink:label="lab_pets_ReorderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reorder sales</link:label>
    <link:label id="lab_pets_ReorderMember_label_en-US" xlink:label="lab_pets_ReorderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reorder Customer [Member]</link:label>
    <link:label id="lab_pets_ReorderMember_documentation_en-US" xlink:label="lab_pets_ReorderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disaggregate of revenue in reorder sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ReorderMember" xlink:href="pets-20240331.xsd#pets_ReorderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ReorderMember" xlink:to="lab_pets_ReorderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_RevenueFromContractWithCustomerVariancePercentage_f5303993-d0bc-424f-90a0-5d204f5997bb_terseLabel_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerVariancePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues, variance, percentage</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerVariancePercentage_label_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerVariancePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer Variance Percentage</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerVariancePercentage_documentation_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerVariancePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of changes in revenue in current period comparing to the same period in the previous year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerVariancePercentage" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerVariancePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_RevenueFromContractWithCustomerVariancePercentage" xlink:to="lab_pets_RevenueFromContractWithCustomerVariancePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0ffd5677-5bd1-460c-8355-0acdc4d0e8c6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_aefc3100-1963-4795-ac5f-0abd473dbd47_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_3329ee57-0aad-43f6-ba91-53b65dbc50a8_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_e5e661ba-49e9-4128-bc29-04b5b8400155_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Amount</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_AuditInformationAbstract_label_en-US" xlink:label="lab_pets_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_pets_AuditInformationAbstract_documentation_en-US" xlink:label="lab_pets_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AuditInformationAbstract" xlink:href="pets-20240331.xsd#pets_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_AuditInformationAbstract" xlink:to="lab_pets_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_862127fb-e548-4b69-8855-810f9fa38bdd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_9731a46e-8e53-4784-9c02-3b72cc3d432b_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_61f54540-c955-43b4-91be-090cd2b696c6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bd83a18a-7986-4e92-877a-a57727040371_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2442fa76-c1bf-4ff0-b3a9-e3373ec9101e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d30a8036-292b-420c-986c-bc2d7e6d6156_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_9b3675e8-426d-4aa7-b63f-3def583b0aa6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_f8ee238d-20f5-4a5f-8881-f13e90d75443_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_916b370b-148c-45de-b6d3-90148b845e9c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d0114dbc-130c-45bc-9701-27a8939a2834_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_88cc38c8-0fc5-40cd-a6e3-92dfb5aa79e6_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fee46285-fa0b-468a-acd1-ee7df43e0382_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_332c3e94-d75e-4c83-b057-6f84684d839a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6da9336d-b479-40bc-93da-d52c065c9990_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted stock forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_989bd0af-35f0-41ca-b672-29311a5b1843_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of employees gross compensation eligible for match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_6babb998-3979-4d65-9daf-d70fe97ff5c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_96d3c428-d911-4fa3-92d1-b35f878d7fa4_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfd82075-ad5e-48f7-9082-147db6738111_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_56291d64-3b5a-4dd3-abfa-2463202a1a14_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_28abaafa-579c-496c-9723-1bd2031d184b_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares issuable upon the vesting of restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e1d9e95e-fcd5-4ea1-9d96-1d7266abf3f4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fcea0db6-9ed6-4991-adc8-ce0016941f8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_f2510b09-ff39-4414-8d67-b4f9a6918184_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_c8242b6e-8f00-4fe7-b01e-0411e77f41f4_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_5ad1b269-60e3-4b37-9dc9-97271cc8bd82_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EmploymentAgreementEmploymentTerm_f00472e9-4c45-4576-b9bd-e277e0519d8b_terseLabel_en-US" xlink:label="lab_pets_EmploymentAgreementEmploymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment term</link:label>
    <link:label id="lab_pets_EmploymentAgreementEmploymentTerm_label_en-US" xlink:label="lab_pets_EmploymentAgreementEmploymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Agreement, Employment Term</link:label>
    <link:label id="lab_pets_EmploymentAgreementEmploymentTerm_documentation_en-US" xlink:label="lab_pets_EmploymentAgreementEmploymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Agreement, Employment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentAgreementEmploymentTerm" xlink:href="pets-20240331.xsd#pets_EmploymentAgreementEmploymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EmploymentAgreementEmploymentTerm" xlink:to="lab_pets_EmploymentAgreementEmploymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7a12d253-fbf4-4f1d-a4ad-1485663af47c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_c6ba2d71-a987-49f1-a623-765ab3d3e4c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_554f8f46-5150-4ace-bc30-a938d9829f51_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_434662f1-ad93-487e-a03d-906f32998796_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of restricted stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_1e5bdfd3-4550-4260-8e12-f480de96aa6a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Pro-Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4a89a4b9-9015-4a0a-8be7-e2b1613584f5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ce94e866-3493-4187-80ef-853372f378a8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_747b2d5b-afc4-447d-bff2-f1ac4a9b267e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_25c7cae8-5103-4da5-b726-d2dbd209afc3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_be3ade87-38dd-4d95-bf02-1b1f6eb78da0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_54a62de4-bd2e-4d55-b026-8e450af6814f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_b2c71514-3cce-46a5-8bee-07a722a3c5a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_3701d3b6-af55-449a-9ebc-14f9d644465f_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_bf04bdd1-6b50-492f-9d99-1ff16e436a23_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0e8b8154-fc0d-40bc-b7bd-f82a4b6169aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PetCareRxIncMember_86925330-244f-4c6b-990f-b7aeee5756dc_terseLabel_en-US" xlink:label="lab_pets_PetCareRxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PetCareRx</link:label>
    <link:label id="lab_pets_PetCareRxIncMember_label_en-US" xlink:label="lab_pets_PetCareRxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PetCareRx, Inc. [Member]</link:label>
    <link:label id="lab_pets_PetCareRxIncMember_documentation_en-US" xlink:label="lab_pets_PetCareRxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PetCareRx, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PetCareRxIncMember" xlink:to="lab_pets_PetCareRxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue_0a71cc11-40df-4efd-83fa-9540d24f1c49_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance adjustment (in dollars per share)</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_7f158844-b614-4c26-9f06-743652265796_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1d4ee2ca-c271-4e06-a871-02cc47e24cd4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d6c7806a-08bf-4783-9e98-878df26a3615_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4ba5f2b6-f179-4378-b939-79cd4bb2efef_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1c6d6ce0-8c93-41bc-8aae-e58abd86f96e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_8dea98c2-7ac0-45b6-8184-599a5a69ef89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_NewOrderMember_10538433-e4f1-45c9-8df8-73ca530fc61d_terseLabel_en-US" xlink:label="lab_pets_NewOrderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New order sales</link:label>
    <link:label id="lab_pets_NewOrderMember_label_en-US" xlink:label="lab_pets_NewOrderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Order Customer [Member]</link:label>
    <link:label id="lab_pets_NewOrderMember_documentation_en-US" xlink:label="lab_pets_NewOrderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disaggregate of revenue in new order sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NewOrderMember" xlink:href="pets-20240331.xsd#pets_NewOrderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_NewOrderMember" xlink:to="lab_pets_NewOrderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_067302fc-3578-4323-99a8-83a701190106_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible and Other Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_IntangibleAndOtherAssets_64bc7b2c-2363-44ce-8534-58296cbf956d_totalLabel_en-US" xlink:label="lab_pets_IntangibleAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible and Other Assets, Net Carrying Value</link:label>
    <link:label id="lab_pets_IntangibleAndOtherAssets_label_en-US" xlink:label="lab_pets_IntangibleAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible And Other Assets</link:label>
    <link:label id="lab_pets_IntangibleAndOtherAssets_documentation_en-US" xlink:label="lab_pets_IntangibleAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssets" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_IntangibleAndOtherAssets" xlink:to="lab_pets_IntangibleAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_f43f8e6d-43e1-40c5-81fa-5c02b1e901c6_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, 2026</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6aabb7f-e6f7-4810-a6ec-1d261a4fef8b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_980b02b2-8706-4194-83d9-76a01d259481_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of PetCareRx, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_EmploymentAgreementNonRenewalNoticePeriod_87aa24a5-570b-461b-a10c-631d641f5ff5_terseLabel_en-US" xlink:label="lab_pets_EmploymentAgreementNonRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non renewal notice period</link:label>
    <link:label id="lab_pets_EmploymentAgreementNonRenewalNoticePeriod_label_en-US" xlink:label="lab_pets_EmploymentAgreementNonRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Agreement, Non Renewal Notice Period</link:label>
    <link:label id="lab_pets_EmploymentAgreementNonRenewalNoticePeriod_documentation_en-US" xlink:label="lab_pets_EmploymentAgreementNonRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Agreement, Non Renewal Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentAgreementNonRenewalNoticePeriod" xlink:href="pets-20240331.xsd#pets_EmploymentAgreementNonRenewalNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_EmploymentAgreementNonRenewalNoticePeriod" xlink:to="lab_pets_EmploymentAgreementNonRenewalNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputControlPremiumMember_26c13c6e-6bf2-4928-b108-e870f6f968de_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputControlPremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Control Premium</link:label>
    <link:label id="lab_us-gaap_MeasurementInputControlPremiumMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputControlPremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Control Premium [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputControlPremiumMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputControlPremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputControlPremiumMember" xlink:to="lab_us-gaap_MeasurementInputControlPremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_774b2f6e-6328-44e5-9c2b-d55cbd0a7fc3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ad54486d-c832-4896-a917-54ec646227e4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_7fbb2966-7738-4cfd-8c79-36d0d6cfe629_terseLabel_en-US" xlink:label="lab_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:label id="lab_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:label id="lab_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b85bbb92-96bd-49f0-abba-1a726d8b7f08_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d7ff704b-a6c7-45ed-a564-ef802418cb9b_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in diluted computation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_RevenueFromContractWithCustomerPercentage_92e62446-9591-4b94-ba9b-491ed1437732_terseLabel_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales, percentage</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerPercentage_label_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer Percentage</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerPercentage_documentation_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of revenue from the specified category to the total revenue during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerPercentage" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_RevenueFromContractWithCustomerPercentage" xlink:to="lab_pets_RevenueFromContractWithCustomerPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b1b2f3e9-aa77-4245-8bba-cd650840ba50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod_7f3985a4-63dc-4f9b-a6cc-b8322abc6580_terseLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of absolute stock price hurdle period, consecutive days</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Absolute Stock Price Hurdle Period</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Absolute Stock Price Hurdle Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_10ad1f12-b0a2-47e9-be76-8882314d6465_periodStartLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_19d5e7a3-66cd-4637-bcf6-1c77f1cb530f_periodEndLabel_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="lab_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_fdaea9c3-4d8e-4eca-b2a2-533c10ea3ceb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Rollforward of Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c66d5559-c847-4f30-a380-69948b37f08d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_15030c6e-1873-4087-b697-65ee3c28535e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1af7a9dc-6f61-49c4-a3b5-46ff591c2049_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_97369fc6-369c-4506-900f-9d0456f56a07_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8329e7af-dfd4-4a96-9255-055f3ac157dc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_ebb52be7-68be-45a5-8ef4-5f4761612a38_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficersCompensation_a3dfe6fa-7c8d-4b9d-bb2c-ec8f7eddc893_terseLabel_en-US" xlink:label="lab_us-gaap_OfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual base salary</link:label>
    <link:label id="lab_us-gaap_OfficersCompensation_label_en-US" xlink:label="lab_us-gaap_OfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation" xlink:to="lab_us-gaap_OfficersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_PerformanceRestrictedStockMember_b30457c0-3a38-483b-aab0-abd505001400_terseLabel_en-US" xlink:label="lab_pets_PerformanceRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockMember_label_en-US" xlink:label="lab_pets_PerformanceRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock [Member]</link:label>
    <link:label id="lab_pets_PerformanceRestrictedStockMember_documentation_en-US" xlink:label="lab_pets_PerformanceRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents performance restricted stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockMember" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_PerformanceRestrictedStockMember" xlink:to="lab_pets_PerformanceRestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_RevenueFromContractWithCustomerVariance_7d5d39e0-ea68-46bc-b910-e70dd875a431_terseLabel_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerVariance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues, variance</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerVariance_label_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerVariance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer Variance</link:label>
    <link:label id="lab_pets_RevenueFromContractWithCustomerVariance_documentation_en-US" xlink:label="lab_pets_RevenueFromContractWithCustomerVariance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of changes in revenue in current period comparing to the same period in the previous year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerVariance" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerVariance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_RevenueFromContractWithCustomerVariance" xlink:to="lab_pets_RevenueFromContractWithCustomerVariance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b5929e88-ede9-4895-8f27-ebce25adb3a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, at beginning of fiscal year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_cca192d3-9c9d-4bbf-a0e1-ab22cadc140d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, at end of fiscal year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bfa7b0a9-b89b-4b8f-8739-cf8331aa1a3b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_4dd37030-e159-4ac2-ae58-b0e38cbbb354_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4cb1e317-0eea-4195-8815-e4eb818f6679_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_4e6798d8-64bd-4f3b-b157-414c66ef9ebe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4cb65f3f-264f-4663-a620-25a72214a76d_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_1623a257-5f51-4d5b-924e-3e664b8795ff_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d1f700c1-cbc9-4c9e-9b95-1a093254725d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate_baa824c4-06c7-4cb4-bbec-0b2ed016b5eb_terseLabel_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate applied to intangible assets acquired</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate_label_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill, Fair Value Disclosure, Discount Rate</link:label>
    <link:label id="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate_documentation_en-US" xlink:label="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill, Fair Value Disclosure, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate" xlink:to="lab_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_f8630477-0dfa-437e-b51b-99d6db0198c5_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_45109e38-7548-4c42-91c4-730fee2b6597_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b913bf1d-e4f9-4523-8c90-d429f56c7233_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_SalaryAndWageOfficerSignOnBonus_8f1ef12c-5427-4f3b-bec0-0860809064a9_terseLabel_en-US" xlink:label="lab_pets_SalaryAndWageOfficerSignOnBonus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sign on bonus</link:label>
    <link:label id="lab_pets_SalaryAndWageOfficerSignOnBonus_label_en-US" xlink:label="lab_pets_SalaryAndWageOfficerSignOnBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary And Wage, Officer, Sign On Bonus</link:label>
    <link:label id="lab_pets_SalaryAndWageOfficerSignOnBonus_documentation_en-US" xlink:label="lab_pets_SalaryAndWageOfficerSignOnBonus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Salary And Wage, Officer, Sign On Bonus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOnBonus" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOnBonus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_SalaryAndWageOfficerSignOnBonus" xlink:to="lab_pets_SalaryAndWageOfficerSignOnBonus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1f36f70f-c30e-42fc-ba47-a7a31940fc4f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_3e9720bc-f124-48bf-9df7-2351028266cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease option to extend period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c1b2de4d-dcd3-4268-973b-a265531dacb5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_OperatingLossCarryforwardAxis_4552ce96-2603-4e5f-b06e-1050224b8cd5_terseLabel_en-US" xlink:label="lab_pets_OperatingLossCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward [Axis]</link:label>
    <link:label id="lab_pets_OperatingLossCarryforwardAxis_label_en-US" xlink:label="lab_pets_OperatingLossCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward [Axis]</link:label>
    <link:label id="lab_pets_OperatingLossCarryforwardAxis_documentation_en-US" xlink:label="lab_pets_OperatingLossCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardAxis" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_OperatingLossCarryforwardAxis" xlink:to="lab_pets_OperatingLossCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5529d1ff-6bf6-4753-be6b-f4519bf87df5_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b5c4a210-5e74-4d82-9013-9833a7f68324_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b79172b4-0666-493f-8991-3738db85d1c9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_814961d1-425f-4cc6-a7a5-f065fa5575f2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding used in basic computation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cd3e92cb-b316-4758-b0b1-b55571259f83_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_3fcde979-7f2a-4c16-af35-4b621c0b767d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3622c8fe-f791-4c48-b7d6-5db4dd6e5467_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3a013dc8-96aa-4e6f-a45d-e97b77f89781_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_5c121141-934d-46ce-8391-a814b61ae6ac_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_55852925-7109-4e52-b26c-31614784261f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0d895d02-216f-4dcf-8891-e41c8d455a51_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2409161a-6980-4658-b2ea-d06c3d76f88c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_3d5fb4b1-da81-43bd-9bdb-55192d53a793_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RentalIncomeNonoperating_0a9150ff-e94d-47bf-b748-1520e90625c9_terseLabel_en-US" xlink:label="lab_us-gaap_RentalIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rental revenue</link:label>
    <link:label id="lab_us-gaap_RentalIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RentalIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rental Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RentalIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RentalIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RentalIncomeNonoperating" xlink:to="lab_us-gaap_RentalIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_2b447189-6151-42f6-a827-15ff1a09d52b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Relationships -PetCareRx</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2cf23362-3b63-44fd-bbcc-acf7f8bac4b7_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_db8b9d39-72c1-4c6d-a727-4c8a788e6753_terseLabel_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Financial Officer</link:label>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_label_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember" xlink:to="lab_srt_ChiefFinancialOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_LumpSumSeverancePayments_3303722a-326d-4d7b-8f3a-f644b66b0bad_terseLabel_en-US" xlink:label="lab_pets_LumpSumSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lump-sum severance payments</link:label>
    <link:label id="lab_pets_LumpSumSeverancePayments_label_en-US" xlink:label="lab_pets_LumpSumSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lump Sum Severance Payments</link:label>
    <link:label id="lab_pets_LumpSumSeverancePayments_documentation_en-US" xlink:label="lab_pets_LumpSumSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents lump-sum severance payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_LumpSumSeverancePayments" xlink:href="pets-20240331.xsd#pets_LumpSumSeverancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_LumpSumSeverancePayments" xlink:to="lab_pets_LumpSumSeverancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_89a0df66-1886-4991-8bfb-8f84a8aa8366_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_397cfd83-1ac7-44e1-b4f0-60e23c0cd345_terseLabel_en-US" xlink:label="lab_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Employee Plan</link:label>
    <link:label id="lab_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_label_en-US" xlink:label="lab_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2016 Employee Equity Compensation Restricted Stock Plan [Member]</link:label>
    <link:label id="lab_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_documentation_en-US" xlink:label="lab_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">represents the 2016 Employee Equity Compensation Restricted Stock Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember" xlink:href="pets-20240331.xsd#pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember" xlink:to="lab_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_86ba9ade-72f7-4739-970f-7bf7ff6fba19_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax adjustments (as percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_344d7c42-8382-47f3-a32b-1e11ccbd1c24_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pets-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b431201b-f537-4396-8d13-986e96a3bf3a,g:5ff869d6-f8b6-477d-8b92-37fe9911b79a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.1800petmeds.com/role/Cover" xlink:type="simple" xlink:href="pets-20240331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b4af4bae-b4fc-43b8-a5dc-fe5361cc2381" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_DocumentType_b4af4bae-b4fc-43b8-a5dc-fe5361cc2381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_943c6f24-531b-40be-84f6-bdb647ad1ef1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_DocumentAnnualReport_943c6f24-531b-40be-84f6-bdb647ad1ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ff1a3938-6a24-4516-a885-7efd7630fba1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_CurrentFiscalYearEndDate_ff1a3938-6a24-4516-a885-7efd7630fba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_aa66d869-1067-4e48-b14a-aa218e0687d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_DocumentPeriodEndDate_aa66d869-1067-4e48-b14a-aa218e0687d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_becc8da1-4ec0-4fc1-b0b0-8ccfb2f63440" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_DocumentTransitionReport_becc8da1-4ec0-4fc1-b0b0-8ccfb2f63440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8bd7a4ad-e1cb-47c4-8d62-ecd03a5109fe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityFileNumber_8bd7a4ad-e1cb-47c4-8d62-ecd03a5109fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cf4b75c5-ce5c-4aad-ba5f-31c975b13054" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityRegistrantName_cf4b75c5-ce5c-4aad-ba5f-31c975b13054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9a6c6b1a-c416-4045-b357-0a6379d29c7a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9a6c6b1a-c416-4045-b357-0a6379d29c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_94134c6f-dc97-44b5-b865-b3b952ba5b54" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityTaxIdentificationNumber_94134c6f-dc97-44b5-b865-b3b952ba5b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d3ce9180-94d0-4088-9b0e-370fff20fc52" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityAddressAddressLine1_d3ce9180-94d0-4088-9b0e-370fff20fc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fe6ae7e9-17a4-4e15-a920-28ef80996f07" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityAddressCityOrTown_fe6ae7e9-17a4-4e15-a920-28ef80996f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e31ccda4-2cd9-4043-a81c-e78f18693deb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityAddressStateOrProvince_e31ccda4-2cd9-4043-a81c-e78f18693deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_120ef999-90c9-406a-a850-4a9f2bae1abe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityAddressPostalZipCode_120ef999-90c9-406a-a850-4a9f2bae1abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f87d64f1-eb6c-4c81-9e88-e25cccf474b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_CityAreaCode_f87d64f1-eb6c-4c81-9e88-e25cccf474b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4f5efa66-73d9-4063-8f45-d9f999c62a9d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_LocalPhoneNumber_4f5efa66-73d9-4063-8f45-d9f999c62a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f8809906-cf75-4e26-9acb-a524aa1ed22b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_Security12bTitle_f8809906-cf75-4e26-9acb-a524aa1ed22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_901e79ef-7460-4f54-a386-9f665abd85d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_TradingSymbol_901e79ef-7460-4f54-a386-9f665abd85d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cc8235cc-efbc-4c61-9fd3-05cde047f0c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_SecurityExchangeName_cc8235cc-efbc-4c61-9fd3-05cde047f0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1c3b0248-d1cf-4d4e-a192-97414f5c4c47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1c3b0248-d1cf-4d4e-a192-97414f5c4c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_5bda8609-92ac-4ef2-8592-2dcb82afe548" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityVoluntaryFilers_5bda8609-92ac-4ef2-8592-2dcb82afe548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_52ad93e4-d71c-4a5d-83e2-6a75094de96a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityCurrentReportingStatus_52ad93e4-d71c-4a5d-83e2-6a75094de96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8f724784-50f0-4b86-93dc-c83de3375178" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityInteractiveDataCurrent_8f724784-50f0-4b86-93dc-c83de3375178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_393873c4-ca41-43fa-aa2e-f4cedf048361" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityFilerCategory_393873c4-ca41-43fa-aa2e-f4cedf048361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f596eff0-8d2a-4b84-8ef7-4d689e18a260" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntitySmallBusiness_f596eff0-8d2a-4b84-8ef7-4d689e18a260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_69d33f8b-c4bf-4d24-b3ba-9d54fc88e848" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityEmergingGrowthCompany_69d33f8b-c4bf-4d24-b3ba-9d54fc88e848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1ef35443-c086-4b1f-a67f-640d36780672" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1ef35443-c086-4b1f-a67f-640d36780672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_b7275d64-807c-4986-a247-06ae173062e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_b7275d64-807c-4986-a247-06ae173062e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e2cb5c63-dce7-4cd2-b291-3c306c8305b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityShellCompany_e2cb5c63-dce7-4cd2-b291-3c306c8305b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_28f7b7eb-46c2-41b9-9057-5b216547d958" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityPublicFloat_28f7b7eb-46c2-41b9-9057-5b216547d958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fad31404-5709-4404-ac11-32b65a89b036" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fad31404-5709-4404-ac11-32b65a89b036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fae91c37-5208-423a-a812-d4b05ee6e58d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fae91c37-5208-423a-a812-d4b05ee6e58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9032f793-df17-478b-8244-af7925de65aa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_EntityCentralIndexKey_9032f793-df17-478b-8244-af7925de65aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8f49bfea-c7fc-4638-b381-b9d5b503e1e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_AmendmentFlag_8f49bfea-c7fc-4638-b381-b9d5b503e1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9d92b59b-557f-41d3-8298-8bde446e9af1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_DocumentFiscalYearFocus_9d92b59b-557f-41d3-8298-8bde446e9af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_141d182b-1101-46c0-bce7-57a7cb016b96" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57680b1d-f49d-41fc-b696-14c7d413d01d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_141d182b-1101-46c0-bce7-57a7cb016b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AuditInformation" xlink:type="simple" xlink:href="pets-20240331.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pets_AuditInformationAbstract_b97efb13-8531-43d2-a0ba-0cf2466d9ebe" xlink:href="pets-20240331.xsd#pets_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_1b11c0b4-6ed2-4409-ae0e-0951ebbba3e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_AuditInformationAbstract_b97efb13-8531-43d2-a0ba-0cf2466d9ebe" xlink:to="loc_dei_AuditorFirmId_1b11c0b4-6ed2-4409-ae0e-0951ebbba3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_dda9737b-76ef-4e06-b65f-9b4a7fceee3a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_AuditInformationAbstract_b97efb13-8531-43d2-a0ba-0cf2466d9ebe" xlink:to="loc_dei_AuditorName_dda9737b-76ef-4e06-b65f-9b4a7fceee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_7f31fa40-cc81-4bb3-8081-bbde90b540d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_AuditInformationAbstract_b97efb13-8531-43d2-a0ba-0cf2466d9ebe" xlink:to="loc_dei_AuditorLocation_7f31fa40-cc81-4bb3-8081-bbde90b540d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pets-20240331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d5ff3f2c-1e47-491c-ab18-46dfb67d12fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4d5bcad7-daef-45c9-a6d7-635ff90239d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d5ff3f2c-1e47-491c-ab18-46dfb67d12fc" xlink:to="loc_us-gaap_AssetsAbstract_4d5bcad7-daef-45c9-a6d7-635ff90239d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bd1b3ae4-6df6-48d0-9187-43caf9df2b80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d5bcad7-daef-45c9-a6d7-635ff90239d9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bd1b3ae4-6df6-48d0-9187-43caf9df2b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3f834aaf-ad9c-4c5e-8038-efec7ef67a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd1b3ae4-6df6-48d0-9187-43caf9df2b80" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3f834aaf-ad9c-4c5e-8038-efec7ef67a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_48f7828c-bb25-4d90-8c0d-96c0c169d994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd1b3ae4-6df6-48d0-9187-43caf9df2b80" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_48f7828c-bb25-4d90-8c0d-96c0c169d994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_ef142dc7-3400-4896-9e83-cd410ec760a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd1b3ae4-6df6-48d0-9187-43caf9df2b80" xlink:to="loc_us-gaap_InventoryFinishedGoods_ef142dc7-3400-4896-9e83-cd410ec760a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a92d5d29-b4bf-4f9d-8356-3b8dcaababa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd1b3ae4-6df6-48d0-9187-43caf9df2b80" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a92d5d29-b4bf-4f9d-8356-3b8dcaababa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_0b9c2c87-3ee5-4908-a6e6-9baba4a36084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd1b3ae4-6df6-48d0-9187-43caf9df2b80" xlink:to="loc_us-gaap_PrepaidTaxes_0b9c2c87-3ee5-4908-a6e6-9baba4a36084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9d7bc18d-c7d5-41de-8563-9b999acee85e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd1b3ae4-6df6-48d0-9187-43caf9df2b80" xlink:to="loc_us-gaap_AssetsCurrent_9d7bc18d-c7d5-41de-8563-9b999acee85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_8c56c015-d191-439e-8791-9b0518830a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d5bcad7-daef-45c9-a6d7-635ff90239d9" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_8c56c015-d191-439e-8791-9b0518830a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_265c509f-ca57-4d1b-a762-d4d99b5f22cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8c56c015-d191-439e-8791-9b0518830a53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_265c509f-ca57-4d1b-a762-d4d99b5f22cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill_b7085496-ba83-4ca4-acf0-b7d6ddeaec78" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8c56c015-d191-439e-8791-9b0518830a53" xlink:to="loc_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill_b7085496-ba83-4ca4-acf0-b7d6ddeaec78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_660863a7-e536-4fa4-9a06-5f2354465254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8c56c015-d191-439e-8791-9b0518830a53" xlink:to="loc_us-gaap_Goodwill_660863a7-e536-4fa4-9a06-5f2354465254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f5104d2d-1daf-4e28-a082-3cecf240a6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8c56c015-d191-439e-8791-9b0518830a53" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f5104d2d-1daf-4e28-a082-3cecf240a6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_e2a5a052-143e-4d79-89a3-9770c2e20291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8c56c015-d191-439e-8791-9b0518830a53" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_e2a5a052-143e-4d79-89a3-9770c2e20291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_c7f6e8a3-8a38-4e27-983f-d34e067aaab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8c56c015-d191-439e-8791-9b0518830a53" xlink:to="loc_us-gaap_AssetsNoncurrent_c7f6e8a3-8a38-4e27-983f-d34e067aaab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2b6c7609-5084-4302-8be4-badee9e29a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d5bcad7-daef-45c9-a6d7-635ff90239d9" xlink:to="loc_us-gaap_Assets_2b6c7609-5084-4302-8be4-badee9e29a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c2601244-9859-4130-8799-8d062aa6ec2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d5ff3f2c-1e47-491c-ab18-46dfb67d12fc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c2601244-9859-4130-8799-8d062aa6ec2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_eaf64851-6433-4f8c-92b1-7c46cfef5502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c2601244-9859-4130-8799-8d062aa6ec2f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_eaf64851-6433-4f8c-92b1-7c46cfef5502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_16b000dd-42e6-47f8-a46f-3775c3d82214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eaf64851-6433-4f8c-92b1-7c46cfef5502" xlink:to="loc_us-gaap_AccountsPayableCurrent_16b000dd-42e6-47f8-a46f-3775c3d82214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_a577fb72-6c4d-43ad-bdbc-128879ccab58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eaf64851-6433-4f8c-92b1-7c46cfef5502" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_a577fb72-6c4d-43ad-bdbc-128879ccab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_b1dca0ff-75d5-4d89-b2c3-95a35c702687" xlink:href="pets-20240331.xsd#pets_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eaf64851-6433-4f8c-92b1-7c46cfef5502" xlink:to="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_b1dca0ff-75d5-4d89-b2c3-95a35c702687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_28dbe233-40e3-4f38-8ec8-dd74b4be7001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eaf64851-6433-4f8c-92b1-7c46cfef5502" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_28dbe233-40e3-4f38-8ec8-dd74b4be7001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7276ee66-3cb7-4549-81af-72b115e660bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eaf64851-6433-4f8c-92b1-7c46cfef5502" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7276ee66-3cb7-4549-81af-72b115e660bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_06b79012-3a61-4b11-8aeb-93c1d476ea6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eaf64851-6433-4f8c-92b1-7c46cfef5502" xlink:to="loc_us-gaap_LiabilitiesCurrent_06b79012-3a61-4b11-8aeb-93c1d476ea6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_baf1d8ce-285d-4356-8d07-30b2522784eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c2601244-9859-4130-8799-8d062aa6ec2f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_baf1d8ce-285d-4356-8d07-30b2522784eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b200dc5-4a49-4582-a627-a0551e4ecb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c2601244-9859-4130-8799-8d062aa6ec2f" xlink:to="loc_us-gaap_Liabilities_6b200dc5-4a49-4582-a627-a0551e4ecb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0a9feef7-130d-4513-8de9-944176ca95d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c2601244-9859-4130-8799-8d062aa6ec2f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0a9feef7-130d-4513-8de9-944176ca95d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c0f399c3-6504-4663-bfb6-c0acdeea3ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c2601244-9859-4130-8799-8d062aa6ec2f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c0f399c3-6504-4663-bfb6-c0acdeea3ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_466d902d-edd3-4fc2-8abe-52da0541403b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c0f399c3-6504-4663-bfb6-c0acdeea3ee7" xlink:to="loc_us-gaap_PreferredStockValue_466d902d-edd3-4fc2-8abe-52da0541403b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a08301f1-9a4b-4142-9c40-462ef4d81203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c0f399c3-6504-4663-bfb6-c0acdeea3ee7" xlink:to="loc_us-gaap_CommonStockValue_a08301f1-9a4b-4142-9c40-462ef4d81203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1998f613-d43f-437d-ac94-1ad1655fc5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c0f399c3-6504-4663-bfb6-c0acdeea3ee7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1998f613-d43f-437d-ac94-1ad1655fc5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ddb140bb-6573-48fd-9b0b-750fbe6898d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c0f399c3-6504-4663-bfb6-c0acdeea3ee7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ddb140bb-6573-48fd-9b0b-750fbe6898d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bcc2d822-66da-47ca-915a-75f95ec7cee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c0f399c3-6504-4663-bfb6-c0acdeea3ee7" xlink:to="loc_us-gaap_StockholdersEquity_bcc2d822-66da-47ca-915a-75f95ec7cee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fed82af4-565b-42cb-9ae0-42a84b9eca5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c2601244-9859-4130-8799-8d062aa6ec2f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fed82af4-565b-42cb-9ae0-42a84b9eca5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pets-20240331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_75aaaec3-b8d7-4214-aa29-4bb88e8a2388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_75aaaec3-b8d7-4214-aa29-4bb88e8a2388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a5ca756e-c038-4a2a-9899-d0c290a820b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a5ca756e-c038-4a2a-9899-d0c290a820b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3c2b9a03-9d25-4b77-a23f-901883d20526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3c2b9a03-9d25-4b77-a23f-901883d20526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_eb10fe91-6164-41e9-adaf-c05193056c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_eb10fe91-6164-41e9-adaf-c05193056c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d5668ab3-9cd2-4a54-9f88-69ba9999aa23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d5668ab3-9cd2-4a54-9f88-69ba9999aa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_d355095c-eae8-4a30-a29a-2dd685295ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_d355095c-eae8-4a30-a29a-2dd685295ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a77d9c4e-13e4-4485-bdf6-4bcadd0df1db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a77d9c4e-13e4-4485-bdf6-4bcadd0df1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8c892e4e-f0c9-4b80-9c70-de0d71f5224f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8c892e4e-f0c9-4b80-9c70-de0d71f5224f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b0f50644-2036-4548-9395-3d7aab6f4440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_CommonStockSharesIssued_b0f50644-2036-4548-9395-3d7aab6f4440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4ce4fd2a-2ef7-4eed-85f0-fa36d3876fad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6da3830-161b-4344-a0f6-95e5d8a420f2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4ce4fd2a-2ef7-4eed-85f0-fa36d3876fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="pets-20240331.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a9386e82-0367-45c5-8d91-54c5782ef3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a9386e82-0367-45c5-8d91-54c5782ef3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_819b14ee-c270-4e1f-9c45-a64faac6705f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_819b14ee-c270-4e1f-9c45-a64faac6705f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_401a45fe-0493-408e-bce6-c6e3ddea7d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_GrossProfit_401a45fe-0493-408e-bce6-c6e3ddea7d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_35dd9b1f-2b80-495c-ac75-6eaeee1ed465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_OperatingExpensesAbstract_35dd9b1f-2b80-495c-ac75-6eaeee1ed465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_27f2b193-47e6-47c2-8640-5f5ee248c1be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35dd9b1f-2b80-495c-ac75-6eaeee1ed465" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_27f2b193-47e6-47c2-8640-5f5ee248c1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_cc2d5a6d-c667-4fa4-becb-37b629e7d29c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35dd9b1f-2b80-495c-ac75-6eaeee1ed465" xlink:to="loc_us-gaap_AdvertisingExpense_cc2d5a6d-c667-4fa4-becb-37b629e7d29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7687dae4-7674-4e87-8ba8-67c6f1515528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35dd9b1f-2b80-495c-ac75-6eaeee1ed465" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7687dae4-7674-4e87-8ba8-67c6f1515528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a7912931-fbf9-459a-ae90-1b0c6b6daa07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35dd9b1f-2b80-495c-ac75-6eaeee1ed465" xlink:to="loc_us-gaap_OperatingExpenses_a7912931-fbf9-459a-ae90-1b0c6b6daa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fe3bc73c-470a-4680-b433-baf20c5075e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_OperatingIncomeLoss_fe3bc73c-470a-4680-b433-baf20c5075e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac7e12e1-d33f-4d45-a154-adb90fa494c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac7e12e1-d33f-4d45-a154-adb90fa494c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_398328e5-a90b-44a3-bd2a-3310dbdde54a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac7e12e1-d33f-4d45-a154-adb90fa494c4" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_398328e5-a90b-44a3-bd2a-3310dbdde54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_694a386b-1a12-462e-ae27-b166901675e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac7e12e1-d33f-4d45-a154-adb90fa494c4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_694a386b-1a12-462e-ae27-b166901675e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_01015cdb-2c4c-4ce0-a828-4a0df819315b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac7e12e1-d33f-4d45-a154-adb90fa494c4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_01015cdb-2c4c-4ce0-a828-4a0df819315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c17a1192-96a9-4f3e-a84b-8f01ac5ab9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c17a1192-96a9-4f3e-a84b-8f01ac5ab9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_721f2505-3dc5-4eae-9fbc-9b1bb40f77b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_721f2505-3dc5-4eae-9fbc-9b1bb40f77b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab7d4dff-83ed-4035-aebb-7d9bc1e32d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_NetIncomeLoss_ab7d4dff-83ed-4035-aebb-7d9bc1e32d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_38a0d1d7-0465-4542-807c-251264051e54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_EarningsPerShareAbstract_38a0d1d7-0465-4542-807c-251264051e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_635d7867-f7a8-47d0-a790-200f3b347ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38a0d1d7-0465-4542-807c-251264051e54" xlink:to="loc_us-gaap_EarningsPerShareBasic_635d7867-f7a8-47d0-a790-200f3b347ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f1cfa678-092d-4a78-a9ac-9b9d98176a76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38a0d1d7-0465-4542-807c-251264051e54" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f1cfa678-092d-4a78-a9ac-9b9d98176a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_d2f91bc5-98bf-4d25-845d-aaabba79abbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_d2f91bc5-98bf-4d25-845d-aaabba79abbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9b602bd9-e720-42ee-a2b8-033be48f9a50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_d2f91bc5-98bf-4d25-845d-aaabba79abbb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9b602bd9-e720-42ee-a2b8-033be48f9a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7aacffcf-9541-4df8-b354-99dc1b49cdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_d2f91bc5-98bf-4d25-845d-aaabba79abbb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7aacffcf-9541-4df8-b354-99dc1b49cdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_682351c7-81e4-4365-a1a5-296e0d9fe13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5f94259-c06f-45f5-96a3-e56e13957a89" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_682351c7-81e4-4365-a1a5-296e0d9fe13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity" xlink:type="simple" xlink:href="pets-20240331.xsd#ConsolidatedStatementsofChangesinShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_015ef866-10c0-4ecb-92e7-1d954d052575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e41ff337-b362-425e-8ceb-84e7cf8f6e96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_015ef866-10c0-4ecb-92e7-1d954d052575" xlink:to="loc_us-gaap_StatementTable_e41ff337-b362-425e-8ceb-84e7cf8f6e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8053dc0c-15cc-4ca3-b3b1-97685c7d6276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e41ff337-b362-425e-8ceb-84e7cf8f6e96" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8053dc0c-15cc-4ca3-b3b1-97685c7d6276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8053dc0c-15cc-4ca3-b3b1-97685c7d6276" xlink:to="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_6dbcf8fb-d576-45de-aa14-1e74f9231640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:to="loc_us-gaap_PreferredStockMember_6dbcf8fb-d576-45de-aa14-1e74f9231640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ef13c599-4acf-4b03-a005-dd16a2c919fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:to="loc_us-gaap_CommonStockMember_ef13c599-4acf-4b03-a005-dd16a2c919fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_16d3c897-0afc-4202-9258-0adf7d479a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_16d3c897-0afc-4202-9258-0adf7d479a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ca92a6f6-2a9c-4b55-8c57-f275ce96c17e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8edf07f6-4fdc-4e0a-9c73-878b37f27de2" xlink:to="loc_us-gaap_RetainedEarningsMember_ca92a6f6-2a9c-4b55-8c57-f275ce96c17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5f4c18a4-b858-4d2d-8d73-b3bddf9c593b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e41ff337-b362-425e-8ceb-84e7cf8f6e96" xlink:to="loc_us-gaap_StatementLineItems_5f4c18a4-b858-4d2d-8d73-b3bddf9c593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5f4c18a4-b858-4d2d-8d73-b3bddf9c593b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_31817e71-1666-43e0-ab9c-668336f0eff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_SharesOutstanding_31817e71-1666-43e0-ab9c-668336f0eff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a7f4736-55f7-479f-a3d5-9014c76dc2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_StockholdersEquity_1a7f4736-55f7-479f-a3d5-9014c76dc2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2fb5b92d-6132-4219-8404-41c5f1d8b275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2fb5b92d-6132-4219-8404-41c5f1d8b275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_4941894b-3dbf-4b34-aa3e-380af28218b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_4941894b-3dbf-4b34-aa3e-380af28218b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c73ac877-c8de-4496-b925-3b3f826d0c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c73ac877-c8de-4496-b925-3b3f826d0c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_fcd25bf2-e1d9-4870-90d2-e84eb400ed6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_DividendsCommonStock_fcd25bf2-e1d9-4870-90d2-e84eb400ed6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb01dc6a-cb5d-47e4-acf2-08cfc2bec087" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_NetIncomeLoss_eb01dc6a-cb5d-47e4-acf2-08cfc2bec087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9a7673c8-e4d3-49e9-aacd-b92047fc3155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_SharesOutstanding_9a7673c8-e4d3-49e9-aacd-b92047fc3155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1af4ec52-dd2e-4a19-8899-e3af145af492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d75b4d39-f71a-4b29-abe2-6e4c5157ff2b" xlink:to="loc_us-gaap_StockholdersEquity_1af4ec52-dd2e-4a19-8899-e3af145af492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pets-20240331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f82d14b3-f45e-400a-9474-42cb66375cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dec01f0e-8dec-4875-9a0c-a76dc1d04baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f82d14b3-f45e-400a-9474-42cb66375cad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dec01f0e-8dec-4875-9a0c-a76dc1d04baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5087c644-20d7-4143-98ab-821d295f605c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dec01f0e-8dec-4875-9a0c-a76dc1d04baf" xlink:to="loc_us-gaap_NetIncomeLoss_5087c644-20d7-4143-98ab-821d295f605c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5a53d509-0e0b-4107-8239-1d2281b27ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dec01f0e-8dec-4875-9a0c-a76dc1d04baf" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5a53d509-0e0b-4107-8239-1d2281b27ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7161855e-eccf-4a3f-a30c-52728cf8d6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5a53d509-0e0b-4107-8239-1d2281b27ddd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7161855e-eccf-4a3f-a30c-52728cf8d6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_82bb8b55-cedd-45dd-b1ef-3c0b42bae2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5a53d509-0e0b-4107-8239-1d2281b27ddd" xlink:to="loc_us-gaap_ShareBasedCompensation_82bb8b55-cedd-45dd-b1ef-3c0b42bae2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c60797bc-709d-4c84-ad5c-9072b3f49280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5a53d509-0e0b-4107-8239-1d2281b27ddd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c60797bc-709d-4c84-ad5c-9072b3f49280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_bdd9dc8b-4452-44bb-bf2d-3633e057cadb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5a53d509-0e0b-4107-8239-1d2281b27ddd" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_bdd9dc8b-4452-44bb-bf2d-3633e057cadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5a53d509-0e0b-4107-8239-1d2281b27ddd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7188fcfb-b47e-4c42-8d7e-82ecd3e57fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7188fcfb-b47e-4c42-8d7e-82ecd3e57fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_5dd66677-b934-417e-ae2c-2ad9a690ed6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_5dd66677-b934-417e-ae2c-2ad9a690ed6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_1bf5a0b4-047a-460f-bbe6-019b7f3898d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_1bf5a0b4-047a-460f-bbe6-019b7f3898d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_89155810-ea14-4377-93d2-da422887c757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_89155810-ea14-4377-93d2-da422887c757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_8acfcbbc-912f-4ac4-b8d4-117f8ff61323" xlink:href="pets-20240331.xsd#pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_8acfcbbc-912f-4ac4-b8d4-117f8ff61323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2d91638b-733f-43d4-bb5c-94fc89c29e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2d91638b-733f-43d4-bb5c-94fc89c29e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_c7565fae-614a-42d2-9dc7-d7743b1e3403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_c7565fae-614a-42d2-9dc7-d7743b1e3403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c38a7ae3-aad0-4991-9a20-86bfca4ada24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c38a7ae3-aad0-4991-9a20-86bfca4ada24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5d3c16e9-f9ef-4641-8ea2-d7bc11b168de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5d3c16e9-f9ef-4641-8ea2-d7bc11b168de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_13f7ea92-1f00-415f-8207-fdc61c947ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50342629-d6fa-4715-ad88-3e7f84fc0899" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_13f7ea92-1f00-415f-8207-fdc61c947ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f84a4938-97a5-4cb8-8e79-dd83c2a6cd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dec01f0e-8dec-4875-9a0c-a76dc1d04baf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f84a4938-97a5-4cb8-8e79-dd83c2a6cd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1ea0d3b6-c95a-4723-9b8a-822ef1bee668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f82d14b3-f45e-400a-9474-42cb66375cad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1ea0d3b6-c95a-4723-9b8a-822ef1bee668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_d4d7ada2-9b34-493a-a788-1edd970dca3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1ea0d3b6-c95a-4723-9b8a-822ef1bee668" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_d4d7ada2-9b34-493a-a788-1edd970dca3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e455941f-c266-46af-a174-068c40eb6e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1ea0d3b6-c95a-4723-9b8a-822ef1bee668" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e455941f-c266-46af-a174-068c40eb6e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fca3af53-4b47-4df0-a92f-f7003bf15e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1ea0d3b6-c95a-4723-9b8a-822ef1bee668" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fca3af53-4b47-4df0-a92f-f7003bf15e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e68b8a37-9b9b-4dad-b1dc-adc8f715b650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1ea0d3b6-c95a-4723-9b8a-822ef1bee668" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e68b8a37-9b9b-4dad-b1dc-adc8f715b650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee8df674-6e97-4705-b3e0-d047f99f8bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f82d14b3-f45e-400a-9474-42cb66375cad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee8df674-6e97-4705-b3e0-d047f99f8bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_a7a90b0c-a0c4-4971-be41-92683efe43f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee8df674-6e97-4705-b3e0-d047f99f8bdc" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_a7a90b0c-a0c4-4971-be41-92683efe43f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2947b8f5-87f1-47e3-8130-9a3fd015f5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee8df674-6e97-4705-b3e0-d047f99f8bdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2947b8f5-87f1-47e3-8130-9a3fd015f5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b49268e0-b7dc-4325-bdbe-14ccf5403788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f82d14b3-f45e-400a-9474-42cb66375cad" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b49268e0-b7dc-4325-bdbe-14ccf5403788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c25a76d7-a2d4-4aad-83c6-1bf72c0acaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f82d14b3-f45e-400a-9474-42cb66375cad" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c25a76d7-a2d4-4aad-83c6-1bf72c0acaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_fff22f53-d4b6-4a3a-bfd1-0939431546f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f82d14b3-f45e-400a-9474-42cb66375cad" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_fff22f53-d4b6-4a3a-bfd1-0939431546f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_73c1529f-3360-420e-a12c-ed5f50014a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f82d14b3-f45e-400a-9474-42cb66375cad" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_73c1529f-3360-420e-a12c-ed5f50014a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_d24855c9-a58e-46c6-aa12-81eae07c39ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_73c1529f-3360-420e-a12c-ed5f50014a78" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_d24855c9-a58e-46c6-aa12-81eae07c39ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_8dcc21e1-66bf-48a0-a846-8b1f971b08e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_73c1529f-3360-420e-a12c-ed5f50014a78" xlink:to="loc_us-gaap_LiabilitiesAssumed1_8dcc21e1-66bf-48a0-a846-8b1f971b08e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RestatementofPreviouslyIssuedFinancialStatements" xlink:type="simple" xlink:href="pets-20240331.xsd#RestatementofPreviouslyIssuedFinancialStatements"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RestatementofPreviouslyIssuedFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_b2e40833-5862-4417-bfb1-02c655e8c04e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionTextBlock_c438c7bd-7dc5-4382-9e84-99141a5fe738" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_b2e40833-5862-4417-bfb1-02c655e8c04e" xlink:to="loc_us-gaap_ErrorCorrectionTextBlock_c438c7bd-7dc5-4382-9e84-99141a5fe738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="pets-20240331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a432ed98-bbd8-4fba-b0d0-cd7d0bdb1574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_58f6ad3a-1fad-4abe-bbfd-de4ed69b9110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a432ed98-bbd8-4fba-b0d0-cd7d0bdb1574" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_58f6ad3a-1fad-4abe-bbfd-de4ed69b9110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RevenueRecognition" xlink:type="simple" xlink:href="pets-20240331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa14335-d65d-470d-86e8-3cd69a438b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5250e008-1a01-409b-a14a-443ebe81fb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa14335-d65d-470d-86e8-3cd69a438b78" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5250e008-1a01-409b-a14a-443ebe81fb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/Acquisition" xlink:type="simple" xlink:href="pets-20240331.xsd#Acquisition"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/Acquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_156ea758-a253-446b-b2b2-ee3e1ea274d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8faac810-4ab2-4fc8-9f17-c9a3d0c3e5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_156ea758-a253-446b-b2b2-ee3e1ea274d2" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8faac810-4ab2-4fc8-9f17-c9a3d0c3e5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="pets-20240331.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9c557b22-ae08-41b2-a81f-5f53ff6d67ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_495ac66d-a168-45a8-ade1-e40cb4569737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9c557b22-ae08-41b2-a81f-5f53ff6d67ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_495ac66d-a168-45a8-ade1-e40cb4569737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="pets-20240331.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_309bdc5b-0c2f-4403-9449-b4ac0ed6352a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_8964f51a-92b7-48af-bfe7-8b17f066198f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_309bdc5b-0c2f-4403-9449-b4ac0ed6352a" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_8964f51a-92b7-48af-bfe7-8b17f066198f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNet"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3995aa9e-94c2-4870-aedd-908222594fba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_ca6c6836-f9be-4930-b9aa-c97f7d92cdee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3995aa9e-94c2-4870-aedd-908222594fba" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_ca6c6836-f9be-4930-b9aa-c97f7d92cdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/Leases" xlink:type="simple" xlink:href="pets-20240331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9bef5a7b-35f3-4ed4-9535-a74dc9bee2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_40b964d7-8c15-4714-b967-7a02ac691850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9bef5a7b-35f3-4ed4-9535-a74dc9bee2ba" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_40b964d7-8c15-4714-b967-7a02ac691850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fa8643a7-ea7b-4ded-8fcd-1dafbed5e7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c19dc577-23ee-4428-a256-583f8b93bc30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa8643a7-ea7b-4ded-8fcd-1dafbed5e7e9" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c19dc577-23ee-4428-a256-583f8b93bc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="pets-20240331.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_17e95837-4b52-40ec-a555-c42d8ad7d758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_aafd8406-a1b9-4e95-a59e-10fc223a9d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_17e95837-4b52-40ec-a555-c42d8ad7d758" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_aafd8406-a1b9-4e95-a59e-10fc223a9d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RestrictedStock" xlink:type="simple" xlink:href="pets-20240331.xsd#RestrictedStock"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RestrictedStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5057e8e4-2f16-4519-9548-ea36c8e36b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_08b33916-4d54-4c07-8f53-f126c91901aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5057e8e4-2f16-4519-9548-ea36c8e36b70" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_08b33916-4d54-4c07-8f53-f126c91901aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="pets-20240331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d15c0494-76bd-4353-af31-8c64ca78011e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_94023f57-8e7b-4a5b-b9bd-da3f4503a1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d15c0494-76bd-4353-af31-8c64ca78011e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_94023f57-8e7b-4a5b-b9bd-da3f4503a1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/NetLossIncomePerShare" xlink:type="simple" xlink:href="pets-20240331.xsd#NetLossIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/NetLossIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ea364b04-2b6b-412d-989d-c9d37c58cafd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_94beb6c8-b7bf-4186-9565-74282344cffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea364b04-2b6b-412d-989d-c9d37c58cafd" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_94beb6c8-b7bf-4186-9565-74282344cffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="pets-20240331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d3b64aff-92cb-4323-b3ab-ef34705c06b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a3035ed4-46d4-4bca-847b-7c28d76527ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d3b64aff-92cb-4323-b3ab-ef34705c06b6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a3035ed4-46d4-4bca-847b-7c28d76527ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="pets-20240331.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c2907c03-ec65-4287-b2e0-acbaa0e92588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_15f569b9-326a-44e1-a7b3-b1d17ea79abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c2907c03-ec65-4287-b2e0-acbaa0e92588" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_15f569b9-326a-44e1-a7b3-b1d17ea79abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/SubsequentEvents" xlink:type="simple" xlink:href="pets-20240331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_86a0f284-0d2f-4ad5-8441-782b625802c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_e3572971-bc50-4702-af5e-16e92a9c31de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_86a0f284-0d2f-4ad5-8441-782b625802c8" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_e3572971-bc50-4702-af5e-16e92a9c31de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pets-20240331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_c7e7821c-95e4-4fd6-afde-ba7fc2c4c62b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_c7e7821c-95e4-4fd6-afde-ba7fc2c4c62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_117d2515-6dcb-4066-8ca7-f3d0bbe93656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_117d2515-6dcb-4066-8ca7-f3d0bbe93656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_287c1b1f-53b7-4516-a6a7-4d06859b0ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_287c1b1f-53b7-4516-a6a7-4d06859b0ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_33078852-f449-4e56-bde2-8cab040c7adb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_UseOfEstimates_33078852-f449-4e56-bde2-8cab040c7adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_fef6a2c5-fa3e-47d8-b64d-1f64786956d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_fef6a2c5-fa3e-47d8-b64d-1f64786956d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d3c61314-c55a-4b85-85e5-da98ec187d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d3c61314-c55a-4b85-85e5-da98ec187d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c4ca312c-500d-46af-9d5f-4648e1bea787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c4ca312c-500d-46af-9d5f-4648e1bea787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1f886d16-cdcb-44f6-aeb7-74fe52bd47a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1f886d16-cdcb-44f6-aeb7-74fe52bd47a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7c4ee1cd-a2fb-4745-b363-030eb00d2a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7c4ee1cd-a2fb-4745-b363-030eb00d2a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OtherAssetsPolicyTextBlock_e1d8dd7d-3cea-40a3-b088-67e30821d9c0" xlink:href="pets-20240331.xsd#pets_OtherAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_pets_OtherAssetsPolicyTextBlock_e1d8dd7d-3cea-40a3-b088-67e30821d9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11195a7f-75e0-4aac-83aa-f177742dab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11195a7f-75e0-4aac-83aa-f177742dab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_aa0fda86-eecb-4703-8b9f-7b2119fd579f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_aa0fda86-eecb-4703-8b9f-7b2119fd579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_eddabdde-85de-47cb-b8cd-e54863118809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_eddabdde-85de-47cb-b8cd-e54863118809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c0e86402-e767-4ef8-998a-1eb6324d4ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c0e86402-e767-4ef8-998a-1eb6324d4ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_24a7a015-cb81-4302-9566-97ae6c51922c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_24a7a015-cb81-4302-9566-97ae6c51922c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_ba70ed86-41b7-4ede-9f78-52c9147b352a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_ba70ed86-41b7-4ede-9f78-52c9147b352a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_98812223-0416-45de-85b0-617c84a686b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_98812223-0416-45de-85b0-617c84a686b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_45e25a1a-37aa-4da1-ac8b-b36734548ace" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f311e7fc-31b3-47a8-9390-af8fbfbe468c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_45e25a1a-37aa-4da1-ac8b-b36734548ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="pets-20240331.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_dbebfd2a-94a7-4c6e-90c2-22e3498fb0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_bff7dde5-ac72-4040-86d6-09bb009399e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_dbebfd2a-94a7-4c6e-90c2-22e3498fb0b6" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_bff7dde5-ac72-4040-86d6-09bb009399e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2c946af1-23a4-4ebb-984d-8d5ea98f8486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_dbebfd2a-94a7-4c6e-90c2-22e3498fb0b6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2c946af1-23a4-4ebb-984d-8d5ea98f8486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AcquisitionTables" xlink:type="simple" xlink:href="pets-20240331.xsd#AcquisitionTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/AcquisitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7d7c4766-d8af-4b9f-8ce5-d6e713246ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4df93325-83a5-46ea-a4d3-a4d24ea8d1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7d7c4766-d8af-4b9f-8ce5-d6e713246ada" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4df93325-83a5-46ea-a4d3-a4d24ea8d1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_44d630b1-3432-4ddd-b277-a1e16cce1c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7d7c4766-d8af-4b9f-8ce5-d6e713246ada" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_44d630b1-3432-4ddd-b277-a1e16cce1c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="pets-20240331.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_edb3de5d-bd41-43b3-99d1-aa2881acc95b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_495a452d-ca60-4594-ac68-bb396d38724d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_edb3de5d-bd41-43b3-99d1-aa2881acc95b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_495a452d-ca60-4594-ac68-bb396d38724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="pets-20240331.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d4cecd01-6822-4a6d-a2ae-61a154eca47c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1b032e04-0edc-4457-ad98-9a457e7eb635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d4cecd01-6822-4a6d-a2ae-61a154eca47c" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1b032e04-0edc-4457-ad98-9a457e7eb635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_532c5fad-32fe-43d9-8c5d-9472119ff75c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_db0d2030-44ba-40ac-88e6-eab3fb251dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_532c5fad-32fe-43d9-8c5d-9472119ff75c" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_db0d2030-44ba-40ac-88e6-eab3fb251dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c807a518-ab58-4816-beb1-a3c32ba566bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_532c5fad-32fe-43d9-8c5d-9472119ff75c" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c807a518-ab58-4816-beb1-a3c32ba566bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/LeasesTables" xlink:type="simple" xlink:href="pets-20240331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cf2f56eb-7093-46c5-95c7-825efb688e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c6f39bb5-5f0b-4a60-a263-87fa78140db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf2f56eb-7093-46c5-95c7-825efb688e5f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c6f39bb5-5f0b-4a60-a263-87fa78140db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d8a6572c-54ed-40df-9b63-ca7c3619048f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf2f56eb-7093-46c5-95c7-825efb688e5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d8a6572c-54ed-40df-9b63-ca7c3619048f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_80b30363-d3a6-4ff3-8925-8ab2f94fe2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_976ccb01-7834-49b3-acea-b0ea0b612266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80b30363-d3a6-4ff3-8925-8ab2f94fe2f6" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_976ccb01-7834-49b3-acea-b0ea0b612266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_adebeb0e-5160-43e0-901e-f006f293fcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80b30363-d3a6-4ff3-8925-8ab2f94fe2f6" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_adebeb0e-5160-43e0-901e-f006f293fcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_df3ea859-a407-47de-aa18-d31b5709c23e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80b30363-d3a6-4ff3-8925-8ab2f94fe2f6" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_df3ea859-a407-47de-aa18-d31b5709c23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_89e79fec-343e-4ab9-a101-19df39ff5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80b30363-d3a6-4ff3-8925-8ab2f94fe2f6" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_89e79fec-343e-4ab9-a101-19df39ff5fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="pets-20240331.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5ceb0378-7ac6-4aba-a1a5-3355bd1c06ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_7a504f25-a7ef-4799-b58d-d3c40fbd02a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5ceb0378-7ac6-4aba-a1a5-3355bd1c06ce" xlink:to="loc_us-gaap_DividendsDeclaredTableTextBlock_7a504f25-a7ef-4799-b58d-d3c40fbd02a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RestrictedStockTables" xlink:type="simple" xlink:href="pets-20240331.xsd#RestrictedStockTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RestrictedStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc75fbda-0b06-42c4-aaef-816021f93b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_12b14bc8-78f1-40f7-be78-fe3bfffb5f61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc75fbda-0b06-42c4-aaef-816021f93b24" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_12b14bc8-78f1-40f7-be78-fe3bfffb5f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9900dfc7-5619-4ad8-9bac-c42fa3d2fcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc75fbda-0b06-42c4-aaef-816021f93b24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9900dfc7-5619-4ad8-9bac-c42fa3d2fcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_f0a715af-c4f9-40bd-a8e2-86007d8e75e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc75fbda-0b06-42c4-aaef-816021f93b24" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_f0a715af-c4f9-40bd-a8e2-86007d8e75e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/NetlLossIncomePerShareTables" xlink:type="simple" xlink:href="pets-20240331.xsd#NetlLossIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/NetlLossIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ba8d49e8-fc63-4e0c-8b03-d19c650d6a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7e601a7e-3ae0-424a-9f18-96dad92dea9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ba8d49e8-fc63-4e0c-8b03-d19c650d6a56" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7e601a7e-3ae0-424a-9f18-96dad92dea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6e04d82a-6af1-4042-ae28-e5bc8f975c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e04d82a-6af1-4042-ae28-e5bc8f975c2d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48ad93a3-dc29-4e59-9352-8ee6f7ffa599" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_srt_RangeAxis_48ad93a3-dc29-4e59-9352-8ee6f7ffa599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae28b4a7-18d1-4bed-b110-c72ecce203b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_48ad93a3-dc29-4e59-9352-8ee6f7ffa599" xlink:to="loc_srt_RangeMember_ae28b4a7-18d1-4bed-b110-c72ecce203b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7f70071-e084-48d0-96f5-2d480d2b5eaf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae28b4a7-18d1-4bed-b110-c72ecce203b2" xlink:to="loc_srt_MaximumMember_a7f70071-e084-48d0-96f5-2d480d2b5eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ddbf753-e73d-4fdf-80e0-9f6d0f0155c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae28b4a7-18d1-4bed-b110-c72ecce203b2" xlink:to="loc_srt_MinimumMember_1ddbf753-e73d-4fdf-80e0-9f6d0f0155c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a6863a0-d5b7-4883-8ebb-933837b03d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a6863a0-d5b7-4883-8ebb-933837b03d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35f4b12a-c542-4df6-97ac-0dced5f6cee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a6863a0-d5b7-4883-8ebb-933837b03d2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35f4b12a-c542-4df6-97ac-0dced5f6cee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember_c1df43f1-476a-4557-b5a7-bb4bc7dc88e0" xlink:href="pets-20240331.xsd#pets_FurnitureFixturesEquipmentAndComputerSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35f4b12a-c542-4df6-97ac-0dced5f6cee2" xlink:to="loc_pets_FurnitureFixturesEquipmentAndComputerSoftwareMember_c1df43f1-476a-4557-b5a7-bb4bc7dc88e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_aed1ad61-93ae-4196-b754-cd56868c1487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35f4b12a-c542-4df6-97ac-0dced5f6cee2" xlink:to="loc_us-gaap_BuildingMember_aed1ad61-93ae-4196-b754-cd56868c1487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_255d9ec2-dd21-4a56-8f4a-f8cf6d7a7170" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_255d9ec2-dd21-4a56-8f4a-f8cf6d7a7170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fe2e174e-36e8-4dcc-8473-bab18576dc53" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_255d9ec2-dd21-4a56-8f4a-f8cf6d7a7170" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fe2e174e-36e8-4dcc-8473-bab18576dc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DelrayBeachPropertyMember_b5c1bd79-de41-4e05-9e30-a6293aa1383f" xlink:href="pets-20240331.xsd#pets_DelrayBeachPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fe2e174e-36e8-4dcc-8473-bab18576dc53" xlink:to="loc_pets_DelrayBeachPropertyMember_b5c1bd79-de41-4e05-9e30-a6293aa1383f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_14ed0b9f-18b7-458c-9abf-a6e3273d6fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_14ed0b9f-18b7-458c-9abf-a6e3273d6fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bf7d5351-ebad-40c8-addb-9b611fe8a02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_14ed0b9f-18b7-458c-9abf-a6e3273d6fb7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bf7d5351-ebad-40c8-addb-9b611fe8a02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsTotalMember_63bca486-3836-4490-8962-28d0a03230c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bf7d5351-ebad-40c8-addb-9b611fe8a02e" xlink:to="loc_us-gaap_CostOfGoodsTotalMember_63bca486-3836-4490-8962-28d0a03230c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b8092f1c-dd24-4ae8-9a9f-76d3ce4995a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b8092f1c-dd24-4ae8-9a9f-76d3ce4995a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fe595245-f7b2-42af-9c78-0f9235006e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b8092f1c-dd24-4ae8-9a9f-76d3ce4995a9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fe595245-f7b2-42af-9c78-0f9235006e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_a6114900-24aa-4fd6-b2c5-d3b5071e9c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fe595245-f7b2-42af-9c78-0f9235006e44" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_a6114900-24aa-4fd6-b2c5-d3b5071e9c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_dff2627b-79fb-4867-9edb-ac5bcb426dad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_dff2627b-79fb-4867-9edb-ac5bcb426dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d27e4f22-59b0-4819-adbe-f37b7c1b1416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_dff2627b-79fb-4867-9edb-ac5bcb426dad" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d27e4f22-59b0-4819-adbe-f37b7c1b1416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SixSuppliersMember_443f4987-ef73-4e05-9c86-33149f3e83f0" xlink:href="pets-20240331.xsd#pets_SixSuppliersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d27e4f22-59b0-4819-adbe-f37b7c1b1416" xlink:to="loc_pets_SixSuppliersMember_443f4987-ef73-4e05-9c86-33149f3e83f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SevenSuppliersMember_40a8f7cd-81ae-485e-a162-be1cf6234f98" xlink:href="pets-20240331.xsd#pets_SevenSuppliersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d27e4f22-59b0-4819-adbe-f37b7c1b1416" xlink:to="loc_pets_SevenSuppliersMember_40a8f7cd-81ae-485e-a162-be1cf6234f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_c7f73093-6377-4998-8894-b7a2944ce2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_ValuationTechniqueAxis_c7f73093-6377-4998-8894-b7a2944ce2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_0d815b4b-3e64-44dd-b7ec-1de0078a5e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_c7f73093-6377-4998-8894-b7a2944ce2f8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_0d815b4b-3e64-44dd-b7ec-1de0078a5e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_a60179ee-cbe6-4a3d-b039-b88267d3c382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_0d815b4b-3e64-44dd-b7ec-1de0078a5e7e" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_a60179ee-cbe6-4a3d-b039-b88267d3c382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketApproachValuationTechniqueMember_bf1c314e-bbe2-4909-9cee-582523bbef72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketApproachValuationTechniqueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_0d815b4b-3e64-44dd-b7ec-1de0078a5e7e" xlink:to="loc_us-gaap_MarketApproachValuationTechniqueMember_bf1c314e-bbe2-4909-9cee-582523bbef72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a531dbbd-5795-4ddc-83a8-f5e559a3dfff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a531dbbd-5795-4ddc-83a8-f5e559a3dfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_14dd757e-85b8-4fdf-9029-8e04b831a55d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a531dbbd-5795-4ddc-83a8-f5e559a3dfff" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_14dd757e-85b8-4fdf-9029-8e04b831a55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputControlPremiumMember_4e4153f0-da22-4314-85b9-9817870363d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputControlPremiumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_14dd757e-85b8-4fdf-9029-8e04b831a55d" xlink:to="loc_us-gaap_MeasurementInputControlPremiumMember_4e4153f0-da22-4314-85b9-9817870363d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MeasurementInputWeightedAverageCostOfCapitalMember_4c8e9987-bce5-4c5d-8d38-bfff7dc35cd6" xlink:href="pets-20240331.xsd#pets_MeasurementInputWeightedAverageCostOfCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_14dd757e-85b8-4fdf-9029-8e04b831a55d" xlink:to="loc_pets_MeasurementInputWeightedAverageCostOfCapitalMember_4c8e9987-bce5-4c5d-8d38-bfff7dc35cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_77488c41-7472-47d4-8c80-cdc59314a002" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_173b1995-9cba-4b22-99b3-156c6e1262e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_InventoryValuationReserves_173b1995-9cba-4b22-99b3-156c6e1262e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a2b250e5-9994-4de7-8303-f8ca2d37f296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a2b250e5-9994-4de7-8303-f8ca2d37f296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_7ed52a1f-b4d2-4705-b8cf-8be52202f3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_NumberOfReportingUnits_7ed52a1f-b4d2-4705-b8cf-8be52202f3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_01fba983-d43d-4c1a-91b0-c9b6b370cc44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_SharePrice_01fba983-d43d-4c1a-91b0-c9b6b370cc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_28a54cfc-cc89-4a67-ae41-a34f93aa7905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_28a54cfc-cc89-4a67-ae41-a34f93aa7905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_8cd57b62-4915-4326-97f2-02d191a0b5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_8cd57b62-4915-4326-97f2-02d191a0b5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ReportingUnitMeasurementInput_f41e0a59-2293-4533-928d-921403308025" xlink:href="pets-20240331.xsd#pets_ReportingUnitMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_pets_ReportingUnitMeasurementInput_f41e0a59-2293-4533-928d-921403308025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_26e55ce4-6063-4d86-ab7d-8cff82a4b830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_26e55ce4-6063-4d86-ab7d-8cff82a4b830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PercentageOfPropertyLeasedToTenants_398aaf45-6710-46ad-a723-5bb2aeab0209" xlink:href="pets-20240331.xsd#pets_PercentageOfPropertyLeasedToTenants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_pets_PercentageOfPropertyLeasedToTenants_398aaf45-6710-46ad-a723-5bb2aeab0209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_4c84048f-5b43-4a74-b63c-a741052d1f53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_4c84048f-5b43-4a74-b63c-a741052d1f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NumberOfTenants_f7ed5aed-6ea1-4b79-a20f-75141d35cd32" xlink:href="pets-20240331.xsd#pets_NumberOfTenants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_pets_NumberOfTenants_f7ed5aed-6ea1-4b79-a20f-75141d35cd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm_aff5e73e-f3e4-42c7-bf4d-cf819da8ac66" xlink:href="pets-20240331.xsd#pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm_aff5e73e-f3e4-42c7-bf4d-cf819da8ac66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RentalIncomeNonoperating_325bbab9-387e-4b5f-80b3-4334c008d957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RentalIncomeNonoperating"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_RentalIncomeNonoperating_325bbab9-387e-4b5f-80b3-4334c008d957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e7b7fb5a-eb24-43af-b71a-9ed2ebd68216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e7b7fb5a-eb24-43af-b71a-9ed2ebd68216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_00a8bc6a-bed7-4740-a2ea-86cf9b49b112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_00a8bc6a-bed7-4740-a2ea-86cf9b49b112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_05f88383-3fcc-4e19-a38e-6e3f4bb13a93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_05f88383-3fcc-4e19-a38e-6e3f4bb13a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_52f2f360-1769-42ae-84d1-aeb5af5f960f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_52f2f360-1769-42ae-84d1-aeb5af5f960f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4dbbde2b-71f0-4f00-a3ea-6700bb2488fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4dbbde2b-71f0-4f00-a3ea-6700bb2488fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_353cc76f-f4a5-4351-a470-4dbeb7dac079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_353cc76f-f4a5-4351-a470-4dbeb7dac079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d735e970-0194-4452-993e-bcfaae724aff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab6fed76-50de-41b0-ab91-e749ead7dcd0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d735e970-0194-4452-993e-bcfaae724aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2967178f-e54b-49eb-9f13-c1671cb02d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2967178f-e54b-49eb-9f13-c1671cb02d72" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ec1f7b5f-7271-4b7f-bfba-9832e590c27c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:to="loc_srt_MajorCustomersAxis_ec1f7b5f-7271-4b7f-bfba-9832e590c27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ec1f7b5f-7271-4b7f-bfba-9832e590c27c" xlink:to="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipFeesMember_37108955-842e-4e97-8e2c-5263e4535ceb" xlink:href="pets-20240331.xsd#pets_MembershipFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:to="loc_pets_MembershipFeesMember_37108955-842e-4e97-8e2c-5263e4535ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ReorderMember_53542cd9-81ee-40b6-a33a-ca5f756096a0" xlink:href="pets-20240331.xsd#pets_ReorderMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:to="loc_pets_ReorderMember_53542cd9-81ee-40b6-a33a-ca5f756096a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NewOrderMember_1019989d-85a3-4892-aceb-938209429e1d" xlink:href="pets-20240331.xsd#pets_NewOrderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:to="loc_pets_NewOrderMember_1019989d-85a3-4892-aceb-938209429e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipCustomersMember_68c980d7-4bf4-4951-a2e6-a3181a1cc8c5" xlink:href="pets-20240331.xsd#pets_MembershipCustomersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f4733ff6-39d5-41be-96a0-287fd09e648d" xlink:to="loc_pets_MembershipCustomersMember_68c980d7-4bf4-4951-a2e6-a3181a1cc8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c0ca5bf6-d626-4344-886b-622e6094a048" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:to="loc_srt_ProductOrServiceAxis_c0ca5bf6-d626-4344-886b-622e6094a048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53c593a0-1196-4cd5-8c1d-d51678ef8f1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c0ca5bf6-d626-4344-886b-622e6094a048" xlink:to="loc_srt_ProductsAndServicesDomain_53c593a0-1196-4cd5-8c1d-d51678ef8f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PartnerProgramMember_512d6495-7f68-4c10-9b8f-64a867db4d86" xlink:href="pets-20240331.xsd#pets_PartnerProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53c593a0-1196-4cd5-8c1d-d51678ef8f1e" xlink:to="loc_pets_PartnerProgramMember_512d6495-7f68-4c10-9b8f-64a867db4d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_1a5dcc77-979c-4bf5-b9d5-e1de833a64b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:to="loc_srt_RestatementAxis_1a5dcc77-979c-4bf5-b9d5-e1de833a64b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_2248993a-d7aa-45d9-b205-b356d6be9605" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1a5dcc77-979c-4bf5-b9d5-e1de833a64b9" xlink:to="loc_srt_RestatementDomain_2248993a-d7aa-45d9-b205-b356d6be9605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_9649fda0-db83-46b7-9227-422331cceb9e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2248993a-d7aa-45d9-b205-b356d6be9605" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_9649fda0-db83-46b7-9227-422331cceb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1da283c7-a4b5-489a-9a36-132ba0cb7941" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations_5c46ba46-7ad2-4732-b3e4-60948b936ab6" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations_5c46ba46-7ad2-4732-b3e4-60948b936ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerNumberOfMembershipModels_824ded6b-1c2c-42b0-9dfc-87a00ab470d6" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerNumberOfMembershipModels"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_RevenueFromContractWithCustomerNumberOfMembershipModels_824ded6b-1c2c-42b0-9dfc-87a00ab470d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerRenewalPeriod_3b9abc92-e0ce-409f-adc1-8b6a8744708e" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerRenewalPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_ContractWithCustomerRenewalPeriod_3b9abc92-e0ce-409f-adc1-8b6a8744708e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerRevenueRecognitionPeriod_45ead388-d735-4fad-9103-f5ae16e5ed2b" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerRevenueRecognitionPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_ContractWithCustomerRevenueRecognitionPeriod_45ead388-d735-4fad-9103-f5ae16e5ed2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8a18c274-e6a9-4c49-a9cc-e7fe863f0240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8a18c274-e6a9-4c49-a9cc-e7fe863f0240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8c91cdb2-7344-4e26-b91b-9c01e398fcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8c91cdb2-7344-4e26-b91b-9c01e398fcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerNumberOfSalesCategories_4a683105-79bd-4f35-95d0-c009933befd4" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerNumberOfSalesCategories"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_pets_RevenueFromContractWithCustomerNumberOfSalesCategories_4a683105-79bd-4f35-95d0-c009933befd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_fd3a9e44-f2ac-49f7-b393-94099221d025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_fd3a9e44-f2ac-49f7-b393-94099221d025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bfc83512-5a91-4f33-bd70-dbce39ae642f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9e3e1422-2c4a-4364-ba87-9d6ffe43a4a1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bfc83512-5a91-4f33-bd70-dbce39ae642f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3a683773-dea9-4624-9c1e-5059dbbc1ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b1c3493b-9606-4ba3-aadf-733998b99b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3a683773-dea9-4624-9c1e-5059dbbc1ea3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b1c3493b-9606-4ba3-aadf-733998b99b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_65671610-3424-4b63-b902-8beef8a004ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b1c3493b-9606-4ba3-aadf-733998b99b92" xlink:to="loc_srt_MajorCustomersAxis_65671610-3424-4b63-b902-8beef8a004ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2802a810-5974-4b41-b7c2-e19b83fe8b63" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_65671610-3424-4b63-b902-8beef8a004ab" xlink:to="loc_srt_NameOfMajorCustomerDomain_2802a810-5974-4b41-b7c2-e19b83fe8b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipFeesMember_8f0756bc-a789-4418-9f40-801921eaa416" xlink:href="pets-20240331.xsd#pets_MembershipFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2802a810-5974-4b41-b7c2-e19b83fe8b63" xlink:to="loc_pets_MembershipFeesMember_8f0756bc-a789-4418-9f40-801921eaa416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipCustomersMember_ede12d2e-a8ee-4ebd-8343-10d899d34591" xlink:href="pets-20240331.xsd#pets_MembershipCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2802a810-5974-4b41-b7c2-e19b83fe8b63" xlink:to="loc_pets_MembershipCustomersMember_ede12d2e-a8ee-4ebd-8343-10d899d34591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1f7643f2-16e5-4aa1-967e-b75814ea9ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b1c3493b-9606-4ba3-aadf-733998b99b92" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1f7643f2-16e5-4aa1-967e-b75814ea9ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f34b3a4c-b673-47fc-81f2-f3561c2d1662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1f7643f2-16e5-4aa1-967e-b75814ea9ee3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f34b3a4c-b673-47fc-81f2-f3561c2d1662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_ae720b6a-309d-43f0-94c2-1827757e9b5a" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f34b3a4c-b673-47fc-81f2-f3561c2d1662" xlink:to="loc_pets_PetCareRxIncMember_ae720b6a-309d-43f0-94c2-1827757e9b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b162f540-44f4-49ce-b9fd-bcd471efc66f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b1c3493b-9606-4ba3-aadf-733998b99b92" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b162f540-44f4-49ce-b9fd-bcd471efc66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerLiabilityCurrentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b162f540-44f4-49ce-b9fd-bcd471efc66f" xlink:to="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a26fd34c-cdd7-4f57-a262-322db087c03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a26fd34c-cdd7-4f57-a262-322db087c03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_723bc7c5-266d-46c2-a15d-91176b3f3413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_723bc7c5-266d-46c2-a15d-91176b3f3413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived_d61e3596-9146-4d0f-ac4f-6835a3c9c941" xlink:href="pets-20240331.xsd#pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:to="loc_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived_d61e3596-9146-4d0f-ac4f-6835a3c9c941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f7fde755-edf6-4464-bc87-9ff6ef490acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f7fde755-edf6-4464-bc87-9ff6ef490acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4cc964ec-a6ac-4fd7-aebf-23642ef28ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_ContractWithCustomerLiabilityCurrentRollForward_4e3d5a8b-73a3-47c6-af23-34e37f68c381" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4cc964ec-a6ac-4fd7-aebf-23642ef28ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RevenueRecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_416be6c0-1674-4196-9d6b-35c92290a96d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f8153b52-96f6-473b-a39b-2f2d5c0c44c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_416be6c0-1674-4196-9d6b-35c92290a96d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f8153b52-96f6-473b-a39b-2f2d5c0c44c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2e3ce27d-43c9-4db3-be43-eeb563e63c2e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f8153b52-96f6-473b-a39b-2f2d5c0c44c8" xlink:to="loc_srt_MajorCustomersAxis_2e3ce27d-43c9-4db3-be43-eeb563e63c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2e3ce27d-43c9-4db3-be43-eeb563e63c2e" xlink:to="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ReorderMember_ad80385e-3658-44f6-bab0-776aa2e9a1b2" xlink:href="pets-20240331.xsd#pets_ReorderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:to="loc_pets_ReorderMember_ad80385e-3658-44f6-bab0-776aa2e9a1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NewOrderMember_7e7e85e5-b383-4634-bf74-a170ec7569b4" xlink:href="pets-20240331.xsd#pets_NewOrderMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:to="loc_pets_NewOrderMember_7e7e85e5-b383-4634-bf74-a170ec7569b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_MembershipFeesMember_87a57d03-9798-427c-99aa-2c6d425d6c10" xlink:href="pets-20240331.xsd#pets_MembershipFeesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbae3e5e-ad73-4af5-89db-f8b5e7648f98" xlink:to="loc_pets_MembershipFeesMember_87a57d03-9798-427c-99aa-2c6d425d6c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f8153b52-96f6-473b-a39b-2f2d5c0c44c8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d4715c83-6db3-4c20-aa47-d2ad9c7aa7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d4715c83-6db3-4c20-aa47-d2ad9c7aa7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerPercentage_cfaa850a-0964-47c1-93ee-2b353e8f95e7" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:to="loc_pets_RevenueFromContractWithCustomerPercentage_cfaa850a-0964-47c1-93ee-2b353e8f95e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerVariance_4d545b87-4f84-4b96-b59c-2c57704d3a9d" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerVariance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:to="loc_pets_RevenueFromContractWithCustomerVariance_4d545b87-4f84-4b96-b59c-2c57704d3a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RevenueFromContractWithCustomerVariancePercentage_8cfcd3dc-ea55-4ee2-93a5-59a993e911b1" xlink:href="pets-20240331.xsd#pets_RevenueFromContractWithCustomerVariancePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa161aa9-e87a-478d-a237-ad2151736776" xlink:to="loc_pets_RevenueFromContractWithCustomerVariancePercentage_8cfcd3dc-ea55-4ee2-93a5-59a993e911b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AcquisitionNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#AcquisitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/AcquisitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d8a83454-aa3d-487f-b8ab-88466eae287c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db40cfa5-5e49-49a6-8ba2-6705bc6706cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d8a83454-aa3d-487f-b8ab-88466eae287c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db40cfa5-5e49-49a6-8ba2-6705bc6706cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_269965b7-c245-4e27-a7f9-5544f0b8400e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db40cfa5-5e49-49a6-8ba2-6705bc6706cd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_269965b7-c245-4e27-a7f9-5544f0b8400e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a67f7ee-a8a3-4018-b976-98ae0666da37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_269965b7-c245-4e27-a7f9-5544f0b8400e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a67f7ee-a8a3-4018-b976-98ae0666da37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_35c3c58f-a3c0-4eac-8afc-72e3adf516f7" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a67f7ee-a8a3-4018-b976-98ae0666da37" xlink:to="loc_pets_PetCareRxIncMember_35c3c58f-a3c0-4eac-8afc-72e3adf516f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db40cfa5-5e49-49a6-8ba2-6705bc6706cd" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_347746b8-912d-49e5-a559-28b2121abf06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_347746b8-912d-49e5-a559-28b2121abf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f696100b-d381-4e8b-992b-a6a2068ba0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f696100b-d381-4e8b-992b-a6a2068ba0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_947078c7-b381-489d-8b31-910e5418b32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_Goodwill_947078c7-b381-489d-8b31-910e5418b32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_069479ad-8cb5-46ea-99bd-a28cf83b02d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_069479ad-8cb5-46ea-99bd-a28cf83b02d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate_22c1364e-06ee-4702-93e4-825d121c3a11" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate_22c1364e-06ee-4702-93e4-825d121c3a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_ee50d040-8548-4938-add4-63b309aefdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_ee50d040-8548-4938-add4-63b309aefdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5fadb724-7a1a-4471-8b98-cfbd92c160e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8464d03-5880-4cd1-9677-441713c8baa9" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5fadb724-7a1a-4471-8b98-cfbd92c160e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4905ced6-3647-46f6-bb71-4ebdfe92a8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cfe281c-414f-4033-8ae0-c65b21262fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4905ced6-3647-46f6-bb71-4ebdfe92a8ad" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cfe281c-414f-4033-8ae0-c65b21262fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_13a352f1-22df-4494-87dc-dca7dd2e857d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cfe281c-414f-4033-8ae0-c65b21262fed" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_13a352f1-22df-4494-87dc-dca7dd2e857d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_931336b0-ec7d-4881-8d1f-58743b8e34de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_13a352f1-22df-4494-87dc-dca7dd2e857d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_931336b0-ec7d-4881-8d1f-58743b8e34de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_b5c6ccd5-bbc2-4309-a724-7485231efdf4" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_931336b0-ec7d-4881-8d1f-58743b8e34de" xlink:to="loc_pets_PetCareRxIncMember_b5c6ccd5-bbc2-4309-a724-7485231efdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cfe281c-414f-4033-8ae0-c65b21262fed" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e9676282-a622-4d04-95d6-4bbefdd1db86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e9676282-a622-4d04-95d6-4bbefdd1db86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8d08f7ec-50a4-494f-97e0-988866fc4f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8d08f7ec-50a4-494f-97e0-988866fc4f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables_f9b79357-6536-4a2f-adde-c50442fac9aa" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables_f9b79357-6536-4a2f-adde-c50442fac9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_95902ff8-dca2-4290-b419-9f7e1455e8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_95902ff8-dca2-4290-b419-9f7e1455e8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_5dfcd95e-26e3-483e-856c-7ae32ceb843e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_5dfcd95e-26e3-483e-856c-7ae32ceb843e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d086e891-ffb2-4792-8d7d-2804d958b586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d086e891-ffb2-4792-8d7d-2804d958b586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_df6089ab-bc9d-4003-ac9f-35b5921eda23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_df6089ab-bc9d-4003-ac9f-35b5921eda23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1f358d2b-a72d-409c-87ee-2da96695c908" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_Goodwill_1f358d2b-a72d-409c-87ee-2da96695c908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5127684b-2fde-4e44-86b8-d37dc99972b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5127684b-2fde-4e44-86b8-d37dc99972b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets_09748ed6-9c0d-4fda-adfc-25e20552f969" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets_09748ed6-9c0d-4fda-adfc-25e20552f969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_aaa9a376-299c-4c82-bf33-1e893e1c020d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_aaa9a376-299c-4c82-bf33-1e893e1c020d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_fe0afcb4-519c-4118-ac9b-bb5562f8e6dd" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_fe0afcb4-519c-4118-ac9b-bb5562f8e6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6144661c-dd75-4818-801b-924369c915b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6144661c-dd75-4818-801b-924369c915b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_04a30640-d8f9-410f-96ba-e38d4a3b3605" xlink:href="pets-20240331.xsd#pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_04a30640-d8f9-410f-96ba-e38d4a3b3605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_8d025976-e14d-4523-a103-d15012afa51f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_8d025976-e14d-4523-a103-d15012afa51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_ec6c0447-051e-4e6b-9a8c-e2e7d6da029b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_ec6c0447-051e-4e6b-9a8c-e2e7d6da029b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_efafe41a-5890-4c08-be36-f9372b441d01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_efafe41a-5890-4c08-be36-f9372b441d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1916fb10-24d6-456c-acb6-96370568ef1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1916fb10-24d6-456c-acb6-96370568ef1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5f593023-2070-495c-97be-dfc429e6ddf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_040442c6-af88-4a00-9d38-1400ac3b3d1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5f593023-2070-495c-97be-dfc429e6ddf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#AcquisitionScheduleofProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_57513d98-3ec5-4ccf-b3c2-2069a630cb94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_40313a9b-bd1d-4327-914a-cae5be23815b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_57513d98-3ec5-4ccf-b3c2-2069a630cb94" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_40313a9b-bd1d-4327-914a-cae5be23815b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_67689cc5-9e3b-42c3-bf07-cb35498a1aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_40313a9b-bd1d-4327-914a-cae5be23815b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_67689cc5-9e3b-42c3-bf07-cb35498a1aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5dc9be26-11f9-43eb-be36-292e6f376e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_67689cc5-9e3b-42c3-bf07-cb35498a1aa0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5dc9be26-11f9-43eb-be36-292e6f376e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_3ee72758-edbe-4e84-ad42-ce50a4a03c82" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5dc9be26-11f9-43eb-be36-292e6f376e8d" xlink:to="loc_pets_PetCareRxIncMember_3ee72758-edbe-4e84-ad42-ce50a4a03c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_efe8cec1-00f7-418a-80d9-9206ce40a551" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_40313a9b-bd1d-4327-914a-cae5be23815b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_efe8cec1-00f7-418a-80d9-9206ce40a551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c556290c-780e-49f8-928e-a2dd869547ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_efe8cec1-00f7-418a-80d9-9206ce40a551" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c556290c-780e-49f8-928e-a2dd869547ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_a15c0719-2187-433e-b8d1-3777bc946e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_efe8cec1-00f7-418a-80d9-9206ce40a551" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_a15c0719-2187-433e-b8d1-3777bc946e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ff299aa6-4838-407e-9240-9d885d988813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d029573a-be0b-4f5c-bcbd-8b601f88d76b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ff299aa6-4838-407e-9240-9d885d988813" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d029573a-be0b-4f5c-bcbd-8b601f88d76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb4a7ac6-90b4-419e-b764-ff7c0eb966cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d029573a-be0b-4f5c-bcbd-8b601f88d76b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb4a7ac6-90b4-419e-b764-ff7c0eb966cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb4a7ac6-90b4-419e-b764-ff7c0eb966cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_c2a4eacb-3021-4561-bf21-af9bb3ffd671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_BuildingMember_c2a4eacb-3021-4561-bf21-af9bb3ffd671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_18e8ab7e-498e-4922-a8f1-f0381c00f271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_LandMember_18e8ab7e-498e-4922-a8f1-f0381c00f271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember_8b5827cc-0edf-4a23-9f69-cf1213f9fdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_BuildingImprovementsMember_8b5827cc-0edf-4a23-9f69-cf1213f9fdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_39135436-ef07-49ff-9208-f192c55f0c30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_39135436-ef07-49ff-9208-f192c55f0c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_80f97d45-401f-4876-8760-419863722ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_130407bc-776c-4453-9a23-8be9329dd6d8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_80f97d45-401f-4876-8760-419863722ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d029573a-be0b-4f5c-bcbd-8b601f88d76b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_790d8f7c-2bd8-43eb-b368-a55daab7b009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_790d8f7c-2bd8-43eb-b368-a55daab7b009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f0a3e44-b067-4a3e-90fd-ac4154bddcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f0a3e44-b067-4a3e-90fd-ac4154bddcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e175847d-f190-4280-9c11-fb588e4b8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e175847d-f190-4280-9c11-fb588e4b8c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_98b0c65b-9b64-403d-b6ee-566cca7de021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fba85e42-0133-4562-85ad-1b08e1dbad09" xlink:to="loc_us-gaap_Depreciation_98b0c65b-9b64-403d-b6ee-566cca7de021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedCreditCardFeesCurrent_5092e96d-5b20-4e37-b8f4-ac8990a35566" xlink:href="pets-20240331.xsd#pets_AccruedCreditCardFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:to="loc_pets_AccruedCreditCardFeesCurrent_5092e96d-5b20-4e37-b8f4-ac8990a35566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_23e2bafb-c136-4063-953a-199ebb2282a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_23e2bafb-c136-4063-953a-199ebb2282a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedMerchandiseCreditsAndRewardsCurrent_f117355b-df97-418e-abaa-8bc6383f2cac" xlink:href="pets-20240331.xsd#pets_AccruedMerchandiseCreditsAndRewardsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:to="loc_pets_AccruedMerchandiseCreditsAndRewardsCurrent_f117355b-df97-418e-abaa-8bc6383f2cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_76020667-fb63-4684-86bb-3ea38f60cebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_76020667-fb63-4684-86bb-3ea38f60cebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedSalesReturnsAndAllowancesCurrent_8179f734-7597-46bd-b4ae-a0504a8eff75" xlink:href="pets-20240331.xsd#pets_AccruedSalesReturnsAndAllowancesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:to="loc_pets_AccruedSalesReturnsAndAllowancesCurrent_8179f734-7597-46bd-b4ae-a0504a8eff75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_2d85faca-03c4-4f67-a48e-16788221ada1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:to="loc_us-gaap_DividendsPayableCurrent_2d85faca-03c4-4f67-a48e-16788221ada1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_f65e2fa0-6cc5-4654-9c98-ff9218f0ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_f65e2fa0-6cc5-4654-9c98-ff9218f0ddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7e499474-e89d-4213-8369-97152b28e830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7e499474-e89d-4213-8369-97152b28e830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6bc1d33d-c8e2-4f73-8bd8-7443f396bb41" xlink:href="pets-20240331.xsd#pets_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51a40bd5-e788-49fc-ac43-5ed897fb8465" xlink:to="loc_pets_AccruedExpensesAndOtherCurrentLiabilities_6bc1d33d-c8e2-4f73-8bd8-7443f396bb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNetScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44d49198-3c43-4564-957a-ac5f9a5ec913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44d49198-3c43-4564-957a-ac5f9a5ec913" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be437517-32d0-4c98-bf59-4c4c24ee4872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be437517-32d0-4c98-bf59-4c4c24ee4872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be437517-32d0-4c98-bf59-4c4c24ee4872" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TollFreeTelephoneNumberMember_3a339d04-eb7b-453b-b5d0-bb81b488f757" xlink:href="pets-20240331.xsd#pets_TollFreeTelephoneNumberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:to="loc_pets_TollFreeTelephoneNumberMember_3a339d04-eb7b-453b-b5d0-bb81b488f757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternetDomainNamesMember_d10d2530-f9d1-4611-9750-e5a1069af37c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternetDomainNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:to="loc_us-gaap_InternetDomainNamesMember_d10d2530-f9d1-4611-9750-e5a1069af37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_58618f9f-c95d-4748-b884-6899600ad7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198a4f0c-b729-44a6-973b-32fe41bafafa" xlink:to="loc_us-gaap_TradeNamesMember_58618f9f-c95d-4748-b884-6899600ad7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45214400-e10a-4cec-9f6c-7ffa87484cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45214400-e10a-4cec-9f6c-7ffa87484cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_522ff5f0-e678-40c0-9805-807415e4f484" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45214400-e10a-4cec-9f6c-7ffa87484cc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_522ff5f0-e678-40c0-9805-807415e4f484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2974da5e-1553-4fcb-b5e4-1ebe503202a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_522ff5f0-e678-40c0-9805-807415e4f484" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2974da5e-1553-4fcb-b5e4-1ebe503202a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0363af92-f9bf-431f-b8d0-a229beb0828e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_522ff5f0-e678-40c0-9805-807415e4f484" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0363af92-f9bf-431f-b8d0-a229beb0828e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_816f5e3b-acbf-420e-9421-fe7b9f2656cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_816f5e3b-acbf-420e-9421-fe7b9f2656cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ecbd1670-bfb2-4643-8f34-3d6835153660" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_816f5e3b-acbf-420e-9421-fe7b9f2656cd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ecbd1670-bfb2-4643-8f34-3d6835153660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_VetsterIncMember_57ba3cd2-67c3-4638-b62f-93f4052aa576" xlink:href="pets-20240331.xsd#pets_VetsterIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ecbd1670-bfb2-4643-8f34-3d6835153660" xlink:to="loc_pets_VetsterIncMember_57ba3cd2-67c3-4638-b62f-93f4052aa576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33cb7138-ff1a-40e4-a529-27e001dc5cc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_49f26c7c-c389-46b1-84cd-d3fd7a5e13cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_49f26c7c-c389-46b1-84cd-d3fd7a5e13cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4b544ddd-6f4c-41e9-bf35-19a9a46230f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4b544ddd-6f4c-41e9-bf35-19a9a46230f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a93a73d-ccb6-439f-8b8a-388d98a60a91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a93a73d-ccb6-439f-8b8a-388d98a60a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0e70902d-f12f-47db-a415-d03331e32998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract_d175ce8c-e539-49ce-8d26-c405a75fbecf" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0e70902d-f12f-47db-a415-d03331e32998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f777e90-8887-4e13-829f-1416212ed34f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f777e90-8887-4e13-829f-1416212ed34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ab9169b8-4668-409e-a777-5e11011a5122" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ab9169b8-4668-409e-a777-5e11011a5122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c4f4d482-c216-457d-bc1a-55464224a124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ab9169b8-4668-409e-a777-5e11011a5122" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c4f4d482-c216-457d-bc1a-55464224a124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_141d2819-b2db-43da-bf11-8e143a835d87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ab9169b8-4668-409e-a777-5e11011a5122" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_141d2819-b2db-43da-bf11-8e143a835d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f960de0b-2c7d-4bdf-970a-effc48705bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ab9169b8-4668-409e-a777-5e11011a5122" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f960de0b-2c7d-4bdf-970a-effc48705bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_82d0a2dd-ee2b-4556-beb6-6d54c9729b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_82d0a2dd-ee2b-4556-beb6-6d54c9729b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsAbstract_249d4c7f-e156-472d-904d-a62e17099bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_OtherAssetsAbstract_249d4c7f-e156-472d-904d-a62e17099bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_3887c216-d073-4fad-a5be-bb60e8530e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_249d4c7f-e156-472d-904d-a62e17099bb5" xlink:to="loc_us-gaap_Investments_3887c216-d073-4fad-a5be-bb60e8530e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_087094a7-3a15-4687-af6e-44082b337d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_249d4c7f-e156-472d-904d-a62e17099bb5" xlink:to="loc_us-gaap_EquityMethodInvestments_087094a7-3a15-4687-af6e-44082b337d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:href="pets-20240331.xsd#pets_IntangiblesAndOtherAssetsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssetsGross_fbfaa27d-1bd6-47cd-b3ac-b874a28ef2a2" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:to="loc_pets_IntangibleAndOtherAssetsGross_fbfaa27d-1bd6-47cd-b3ac-b874a28ef2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangiblesAndOtherAssetsAccumulatedAmortization_8094474a-9191-48c6-ad16-b2a129ab5d4b" xlink:href="pets-20240331.xsd#pets_IntangiblesAndOtherAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:to="loc_pets_IntangiblesAndOtherAssetsAccumulatedAmortization_8094474a-9191-48c6-ad16-b2a129ab5d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_IntangibleAndOtherAssets_4835f505-845b-4030-a83e-b969f8735f35" xlink:href="pets-20240331.xsd#pets_IntangibleAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_IntangiblesAndOtherAssetsAbstract_56ae249c-ef6d-4a30-813b-2d231ff9f2fc" xlink:to="loc_pets_IntangibleAndOtherAssets_4835f505-845b-4030-a83e-b969f8735f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_22a3fb28-903f-4c9b-8c32-38b14abd8250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_22a3fb28-903f-4c9b-8c32-38b14abd8250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TermOfAgreement_be8169b8-9bda-4273-93c1-2e1c36289110" xlink:href="pets-20240331.xsd#pets_TermOfAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_pets_TermOfAgreement_be8169b8-9bda-4273-93c1-2e1c36289110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e8cbd90a-b48f-483d-b771-e4d63e2908b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e8cbd90a-b48f-483d-b771-e4d63e2908b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9506d900-538c-4533-bd54-6eadc9efed95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_30d23268-09e6-4653-a09d-58a80fc91f17" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9506d900-538c-4533-bd54-6eadc9efed95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNetExpectedAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f13270c4-f6ba-43a0-b914-d839dc707dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_682cf5d4-af02-4b86-a248-424aa6a10574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f13270c4-f6ba-43a0-b914-d839dc707dd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_682cf5d4-af02-4b86-a248-424aa6a10574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d7b536f0-6229-47f8-8712-be4e8643b425" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f13270c4-f6ba-43a0-b914-d839dc707dd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d7b536f0-6229-47f8-8712-be4e8643b425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f0af881d-6fc8-464a-9dcc-a4d5130a1647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f13270c4-f6ba-43a0-b914-d839dc707dd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f0af881d-6fc8-464a-9dcc-a4d5130a1647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ced18e3e-9224-4a2e-b7cc-718b68ec63cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f13270c4-f6ba-43a0-b914-d839dc707dd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ced18e3e-9224-4a2e-b7cc-718b68ec63cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_16dec842-8c19-4054-bc02-ac2ba6b5219f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f13270c4-f6ba-43a0-b914-d839dc707dd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_16dec842-8c19-4054-bc02-ac2ba6b5219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4bfd95e8-2bdb-4304-9f64-0e736ff7fce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f13270c4-f6ba-43a0-b914-d839dc707dd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4bfd95e8-2bdb-4304-9f64-0e736ff7fce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fa750886-9baa-4a91-b4de-dc5a1b7f8e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f13270c4-f6ba-43a0-b914-d839dc707dd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fa750886-9baa-4a91-b4de-dc5a1b7f8e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IntangibleandOtherAssetsNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_79ee5fb9-2adc-4e47-adc6-edbe4adb3bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7792cb64-7772-42a2-b635-95a75a426fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_79ee5fb9-2adc-4e47-adc6-edbe4adb3bc1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7792cb64-7772-42a2-b635-95a75a426fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_297a4151-4e8a-4e9a-bb82-8bea4c62dd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7792cb64-7772-42a2-b635-95a75a426fbc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_297a4151-4e8a-4e9a-bb82-8bea4c62dd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6daf3e28-3c70-4920-9f57-31423a11bf04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_297a4151-4e8a-4e9a-bb82-8bea4c62dd3f" xlink:to="loc_us-gaap_RelatedPartyDomain_6daf3e28-3c70-4920-9f57-31423a11bf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_2fecb046-3263-4d74-988f-a46b3494189c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6daf3e28-3c70-4920-9f57-31423a11bf04" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_2fecb046-3263-4d74-988f-a46b3494189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5cfe0cd-e62d-428a-aa29-3a3dcc870ca3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7792cb64-7772-42a2-b635-95a75a426fbc" xlink:to="loc_srt_RangeAxis_a5cfe0cd-e62d-428a-aa29-3a3dcc870ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eaee01fc-315a-4a59-a494-09076f29fb74" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a5cfe0cd-e62d-428a-aa29-3a3dcc870ca3" xlink:to="loc_srt_RangeMember_eaee01fc-315a-4a59-a494-09076f29fb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b05a6f59-3aad-4fdf-ba4e-2ef9c20791df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eaee01fc-315a-4a59-a494-09076f29fb74" xlink:to="loc_srt_MinimumMember_b05a6f59-3aad-4fdf-ba4e-2ef9c20791df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26a567e9-c662-4c71-914b-69efa9cfea5d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eaee01fc-315a-4a59-a494-09076f29fb74" xlink:to="loc_srt_MaximumMember_26a567e9-c662-4c71-914b-69efa9cfea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7792cb64-7772-42a2-b635-95a75a426fbc" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_4daefed7-347a-4edd-b130-e44d4885b148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_4daefed7-347a-4edd-b130-e44d4885b148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b9d46175-14c1-474c-a74c-6b43b05d88b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b9d46175-14c1-474c-a74c-6b43b05d88b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_93675663-8343-4f81-8519-9475d36006db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b34215da-a913-4869-809c-98a93fe4575f" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_93675663-8343-4f81-8519-9475d36006db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6193b9b7-2cea-44c8-a5a7-bdf9af5a11f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_da86f11c-ceaa-4567-a0fe-2113ea93eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6193b9b7-2cea-44c8-a5a7-bdf9af5a11f8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_da86f11c-ceaa-4567-a0fe-2113ea93eb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_276707b1-f3aa-49e5-b04d-94eabcded9b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_da86f11c-ceaa-4567-a0fe-2113ea93eb5d" xlink:to="loc_srt_RangeAxis_276707b1-f3aa-49e5-b04d-94eabcded9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5b3f0a2-6f3b-41cd-b6dc-f7045e7cc412" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_276707b1-f3aa-49e5-b04d-94eabcded9b6" xlink:to="loc_srt_RangeMember_d5b3f0a2-6f3b-41cd-b6dc-f7045e7cc412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0448969c-3aa8-46c9-a621-07188976b4db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d5b3f0a2-6f3b-41cd-b6dc-f7045e7cc412" xlink:to="loc_srt_MinimumMember_0448969c-3aa8-46c9-a621-07188976b4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c45402b2-3a3c-4d5b-a42b-d5febe33a8b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d5b3f0a2-6f3b-41cd-b6dc-f7045e7cc412" xlink:to="loc_srt_MaximumMember_c45402b2-3a3c-4d5b-a42b-d5febe33a8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_da86f11c-ceaa-4567-a0fe-2113ea93eb5d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_321c761c-893b-44c2-8edb-461fd094a060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_321c761c-893b-44c2-8edb-461fd094a060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a527610f-9ede-4468-97c8-26f414b5e2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a527610f-9ede-4468-97c8-26f414b5e2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a9573e00-085a-46f9-b859-ca6ccbab2351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a9573e00-085a-46f9-b859-ca6ccbab2351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_8f57a229-8d24-47d6-a324-94af0962b712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_31d6f124-1a3a-498b-898a-56eefc7f271d" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_8f57a229-8d24-47d6-a324-94af0962b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#LeasesScheduleofLeaseCostsandActivityDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cd8ab7aa-3b8b-45e6-ae88-f1aedec6b45e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ea0cc5f7-6ff2-4e1e-835c-8ea86f7f1920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd8ab7aa-3b8b-45e6-ae88-f1aedec6b45e" xlink:to="loc_us-gaap_OperatingLeaseCost_ea0cc5f7-6ff2-4e1e-835c-8ea86f7f1920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_eea9bb09-6f63-4e04-bf11-0f61666d0a22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd8ab7aa-3b8b-45e6-ae88-f1aedec6b45e" xlink:to="loc_us-gaap_VariableLeaseCost_eea9bb09-6f63-4e04-bf11-0f61666d0a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_e9bd8f7f-fa90-4591-aee7-c918f5760a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd8ab7aa-3b8b-45e6-ae88-f1aedec6b45e" xlink:to="loc_us-gaap_LeaseCost_e9bd8f7f-fa90-4591-aee7-c918f5760a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_be7c7e16-e423-4628-9832-aaf5059d9723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd8ab7aa-3b8b-45e6-ae88-f1aedec6b45e" xlink:to="loc_us-gaap_OperatingLeasePayments_be7c7e16-e423-4628-9832-aaf5059d9723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_294e5c8b-739c-4327-b9ab-b8402d29723b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd8ab7aa-3b8b-45e6-ae88-f1aedec6b45e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_294e5c8b-739c-4327-b9ab-b8402d29723b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#LeasesScheduleofMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6ff573e4-6f50-4609-879b-982939c5f114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bce8e205-0fb6-44e0-8581-d84fc20445a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff573e4-6f50-4609-879b-982939c5f114" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bce8e205-0fb6-44e0-8581-d84fc20445a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c21bf099-c243-4158-85c9-f2900b262362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff573e4-6f50-4609-879b-982939c5f114" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c21bf099-c243-4158-85c9-f2900b262362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7d0bc34c-23d4-4d24-99e7-b0265d7bfc98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff573e4-6f50-4609-879b-982939c5f114" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7d0bc34c-23d4-4d24-99e7-b0265d7bfc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2ccb4952-331b-4216-8671-7f163e92a4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff573e4-6f50-4609-879b-982939c5f114" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2ccb4952-331b-4216-8671-7f163e92a4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c154b733-1f25-4f2e-8ee8-b4453900fb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff573e4-6f50-4609-879b-982939c5f114" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c154b733-1f25-4f2e-8ee8-b4453900fb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_60b5cbc6-cf5d-47a7-9216-1bd75c97c680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff573e4-6f50-4609-879b-982939c5f114" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_60b5cbc6-cf5d-47a7-9216-1bd75c97c680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4c9a0bda-2492-4070-88a4-7be7222c2ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff573e4-6f50-4609-879b-982939c5f114" xlink:to="loc_us-gaap_OperatingLeaseLiability_4c9a0bda-2492-4070-88a4-7be7222c2ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesDeferredIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3c93211d-0ce6-4a22-8989-c1e3192cd973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c93211d-0ce6-4a22-8989-c1e3192cd973" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_faf991ba-9f11-4a7f-b0a4-ce00946c4359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_faf991ba-9f11-4a7f-b0a4-ce00946c4359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_6b321aa0-42bf-454f-ba39-5a8d392d7ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_6b321aa0-42bf-454f-ba39-5a8d392d7ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_8383aeb9-72c4-41c1-9ebf-3f8100f8af3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_8383aeb9-72c4-41c1-9ebf-3f8100f8af3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_62c13ec2-b77d-40e6-ab4c-d4d90395c03e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_62c13ec2-b77d-40e6-ab4c-d4d90395c03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_865a358b-ad81-402d-ae21-0bb50baf70b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_865a358b-ad81-402d-ae21-0bb50baf70b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_12bf4fa9-4257-4f00-a21c-f1f0ea7c883b" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:to="loc_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_12bf4fa9-4257-4f00-a21c-f1f0ea7c883b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetsLeaseLiabilities_84cdfa83-bf9e-4728-b483-cf392aae51b9" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:to="loc_pets_DeferredTaxAssetsLeaseLiabilities_84cdfa83-bf9e-4728-b483-cf392aae51b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_285f8899-fd35-4c03-9d4a-bb49f447af4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_285f8899-fd35-4c03-9d4a-bb49f447af4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a66155d5-76c7-4803-8989-b76e9dbc0bff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec1d9439-8e96-4abc-abde-d34686ef5327" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a66155d5-76c7-4803-8989-b76e9dbc0bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dcdd3d62-375e-4499-9c7a-6fb2f5894a66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c93211d-0ce6-4a22-8989-c1e3192cd973" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dcdd3d62-375e-4499-9c7a-6fb2f5894a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxLiabilitiesChangeInAccountingMethod_b9c6fc21-f110-4476-b425-b011642fa2ad" xlink:href="pets-20240331.xsd#pets_DeferredTaxLiabilitiesChangeInAccountingMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dcdd3d62-375e-4499-9c7a-6fb2f5894a66" xlink:to="loc_pets_DeferredTaxLiabilitiesChangeInAccountingMethod_b9c6fc21-f110-4476-b425-b011642fa2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f56b13e3-2b0d-4d63-95c4-445858d27d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dcdd3d62-375e-4499-9c7a-6fb2f5894a66" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f56b13e3-2b0d-4d63-95c4-445858d27d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3f59b4df-f914-4213-9e4d-9a95f9fa881c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dcdd3d62-375e-4499-9c7a-6fb2f5894a66" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3f59b4df-f914-4213-9e4d-9a95f9fa881c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_581b989d-4d3b-40a5-b6ae-92864c284e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dcdd3d62-375e-4499-9c7a-6fb2f5894a66" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_581b989d-4d3b-40a5-b6ae-92864c284e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4d8ab519-03c6-4d79-a8c6-2e4086fc2572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dcdd3d62-375e-4499-9c7a-6fb2f5894a66" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4d8ab519-03c6-4d79-a8c6-2e4086fc2572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ae5837b5-e559-4a6b-ad10-491aecba82a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c93211d-0ce6-4a22-8989-c1e3192cd973" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ae5837b5-e559-4a6b-ad10-491aecba82a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_df632604-91fa-4223-8e14-5c3d0cc50a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c93211d-0ce6-4a22-8989-c1e3192cd973" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_df632604-91fa-4223-8e14-5c3d0cc50a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_48cde2c1-ff4a-4c68-aedb-83777d9b2c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_2c13171e-c797-48ac-bab5-5412cd0588a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48cde2c1-ff4a-4c68-aedb-83777d9b2c0d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_2c13171e-c797-48ac-bab5-5412cd0588a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_97a28359-f3c1-4c32-9f3d-87859db54251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2c13171e-c797-48ac-bab5-5412cd0588a9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_97a28359-f3c1-4c32-9f3d-87859db54251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0bfb9b64-5d4b-48b1-9260-13d74da03a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_97a28359-f3c1-4c32-9f3d-87859db54251" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0bfb9b64-5d4b-48b1-9260-13d74da03a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3372339e-88af-4682-89ad-33c6350ba48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0bfb9b64-5d4b-48b1-9260-13d74da03a39" xlink:to="loc_us-gaap_DomesticCountryMember_3372339e-88af-4682-89ad-33c6350ba48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e6684f57-14a2-41cb-ab0a-04dd07a62da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0bfb9b64-5d4b-48b1-9260-13d74da03a39" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e6684f57-14a2-41cb-ab0a-04dd07a62da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2c13171e-c797-48ac-bab5-5412cd0588a9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6f4adf7d-1b06-43ed-b82c-3b8b5108085b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6f4adf7d-1b06-43ed-b82c-3b8b5108085b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a9da51f0-5e18-4733-a344-2d0fbc503b01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a9da51f0-5e18-4733-a344-2d0fbc503b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9cab9b7b-4799-48e9-83ec-f3f7a05c58c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9cab9b7b-4799-48e9-83ec-f3f7a05c58c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment_f8a8fc8c-bade-4adf-83a0-632b5ec81fc0" xlink:href="pets-20240331.xsd#pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment_f8a8fc8c-bade-4adf-83a0-632b5ec81fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount_3f8cde88-e138-4f4c-b931-4b7add4daf74" xlink:href="pets-20240331.xsd#pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount_3f8cde88-e138-4f4c-b931-4b7add4daf74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_b3420488-141e-4545-9b1d-5f73c884e51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_b3420488-141e-4545-9b1d-5f73c884e51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_217167f0-3b46-4fdd-9052-4709f07f1cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42733654-3ed7-4e96-939c-c83718687201" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_217167f0-3b46-4fdd-9052-4709f07f1cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesTaxAttributesDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a8347469-5a45-4837-856e-baa119ed6ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a8347469-5a45-4837-856e-baa119ed6ca1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a15f57f8-6321-4643-846d-75b5004cb05e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a15f57f8-6321-4643-846d-75b5004cb05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63472c99-dc6a-48aa-8b8a-7ea821afa96c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a15f57f8-6321-4643-846d-75b5004cb05e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63472c99-dc6a-48aa-8b8a-7ea821afa96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PetCareRxIncMember_72adcf92-6cac-4521-86cf-b3fa28cf655d" xlink:href="pets-20240331.xsd#pets_PetCareRxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63472c99-dc6a-48aa-8b8a-7ea821afa96c" xlink:to="loc_pets_PetCareRxIncMember_72adcf92-6cac-4521-86cf-b3fa28cf655d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_babc60f6-454a-419c-bea1-2d899aaad3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_babc60f6-454a-419c-bea1-2d899aaad3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_64205353-9dfc-4f02-bec1-584772bd6cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_babc60f6-454a-419c-bea1-2d899aaad3c0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_64205353-9dfc-4f02-bec1-584772bd6cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_db7c5d53-311a-4fb7-a361-8533b0cccc01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_64205353-9dfc-4f02-bec1-584772bd6cd8" xlink:to="loc_us-gaap_DomesticCountryMember_db7c5d53-311a-4fb7-a361-8533b0cccc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_94532d52-f784-4698-b167-82ab54f0cab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_64205353-9dfc-4f02-bec1-584772bd6cd8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_94532d52-f784-4698-b167-82ab54f0cab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardAxis_4ea223b4-e904-4e73-a107-21b5c8272b82" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:to="loc_pets_OperatingLossCarryforwardAxis_4ea223b4-e904-4e73-a107-21b5c8272b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardDomain_794e9cc6-5978-47a2-a3ad-6500f8860b8a" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_OperatingLossCarryforwardAxis_4ea223b4-e904-4e73-a107-21b5c8272b82" xlink:to="loc_pets_OperatingLossCarryforwardDomain_794e9cc6-5978-47a2-a3ad-6500f8860b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SEC382LimitedUtilizationMember_e769e81c-025d-48cb-8371-caac025587ec" xlink:href="pets-20240331.xsd#pets_SEC382LimitedUtilizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_OperatingLossCarryforwardDomain_794e9cc6-5978-47a2-a3ad-6500f8860b8a" xlink:to="loc_pets_SEC382LimitedUtilizationMember_e769e81c-025d-48cb-8371-caac025587ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetIsRecordedMember_2688131a-4f82-4d45-99ba-eca2ef2f13a3" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetIsRecordedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_OperatingLossCarryforwardDomain_794e9cc6-5978-47a2-a3ad-6500f8860b8a" xlink:to="loc_pets_DeferredTaxAssetIsRecordedMember_2688131a-4f82-4d45-99ba-eca2ef2f13a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5c243cc-f1bc-4626-948d-f3ff28dffa81" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardsSubjectToLimitations_006fcfcd-3fa7-4636-af7e-407c37470302" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardsSubjectToLimitations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:to="loc_pets_OperatingLossCarryforwardsSubjectToLimitations_006fcfcd-3fa7-4636-af7e-407c37470302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_OperatingLossCarryforwardsNotSubjectToLimitations_f70fffad-e6f1-4d9e-96e9-a0460611d549" xlink:href="pets-20240331.xsd#pets_OperatingLossCarryforwardsNotSubjectToLimitations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:to="loc_pets_OperatingLossCarryforwardsNotSubjectToLimitations_f70fffad-e6f1-4d9e-96e9-a0460611d549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DisallowedBusinessInterestExpenseCarryover_8dd38ed1-d13d-4831-b6df-d1f7cce884d9" xlink:href="pets-20240331.xsd#pets_DisallowedBusinessInterestExpenseCarryover"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:to="loc_pets_DisallowedBusinessInterestExpenseCarryover_8dd38ed1-d13d-4831-b6df-d1f7cce884d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_47fdb30f-7dc4-407b-b352-e29322a8b747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_66dd89d3-7828-47a7-ac20-7b8f5b3bf9d1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_47fdb30f-7dc4-407b-b352-e29322a8b747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesComponentsofIncomeTaxProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6cdcd28e-5b16-41bc-af2a-bcfa2e59e3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_437958af-806d-4f0b-86b6-31c689aa592a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cdcd28e-5b16-41bc-af2a-bcfa2e59e3ef" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_437958af-806d-4f0b-86b6-31c689aa592a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d112fd4a-38a8-4693-82fb-2ce05171c583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_437958af-806d-4f0b-86b6-31c689aa592a" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d112fd4a-38a8-4693-82fb-2ce05171c583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fd908808-ace7-4047-947f-7dc7f2d37cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_437958af-806d-4f0b-86b6-31c689aa592a" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fd908808-ace7-4047-947f-7dc7f2d37cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b04a35df-bc5c-4268-b65d-e15c24cfdaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_437958af-806d-4f0b-86b6-31c689aa592a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b04a35df-bc5c-4268-b65d-e15c24cfdaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ca7ea79c-b308-44c4-96d0-d23b81b66fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cdcd28e-5b16-41bc-af2a-bcfa2e59e3ef" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ca7ea79c-b308-44c4-96d0-d23b81b66fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f2ea7f67-337b-4e63-9219-6d0e7a04fb72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ca7ea79c-b308-44c4-96d0-d23b81b66fbf" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f2ea7f67-337b-4e63-9219-6d0e7a04fb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_bc15dc6d-381f-4ca0-8b14-5baac3db4a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ca7ea79c-b308-44c4-96d0-d23b81b66fbf" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_bc15dc6d-381f-4ca0-8b14-5baac3db4a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_bb5e87fa-b483-4d91-b42a-118c1e14840d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ca7ea79c-b308-44c4-96d0-d23b81b66fbf" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_bb5e87fa-b483-4d91-b42a-118c1e14840d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b170e0f8-81fc-40c9-ab6f-0cf8a780f571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cdcd28e-5b16-41bc-af2a-bcfa2e59e3ef" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b170e0f8-81fc-40c9-ab6f-0cf8a780f571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesReconciliationofIncomeTaxProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_48313c05-9dfc-4d59-8658-e8b010548e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_853fc2e3-acf2-4255-a462-53fc5308cbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48313c05-9dfc-4d59-8658-e8b010548e92" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_853fc2e3-acf2-4255-a462-53fc5308cbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_216d23a7-5364-4ffe-bbbc-7c416f829a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48313c05-9dfc-4d59-8658-e8b010548e92" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_216d23a7-5364-4ffe-bbbc-7c416f829a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c7d90033-d37f-4bc5-83b4-c0890be57834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48313c05-9dfc-4d59-8658-e8b010548e92" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c7d90033-d37f-4bc5-83b4-c0890be57834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_4daa921d-f566-4a48-b6a2-825df3dc88f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48313c05-9dfc-4d59-8658-e8b010548e92" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_4daa921d-f566-4a48-b6a2-825df3dc88f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_c736b0a1-dfd9-49ec-8931-13a2a357fa75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48313c05-9dfc-4d59-8658-e8b010548e92" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_c736b0a1-dfd9-49ec-8931-13a2a357fa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_ef0dd1cd-1b79-437a-b894-0f50cf37cf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48313c05-9dfc-4d59-8658-e8b010548e92" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_ef0dd1cd-1b79-437a-b894-0f50cf37cf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_e2dd7191-c538-4ce3-ac12-3fe6b9652c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48313c05-9dfc-4d59-8658-e8b010548e92" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_e2dd7191-c538-4ce3-ac12-3fe6b9652c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_48119f2b-1009-4e48-b071-6b55696cc158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48313c05-9dfc-4d59-8658-e8b010548e92" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_48119f2b-1009-4e48-b071-6b55696cc158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_58b8dd62-bd9b-43be-9e20-4657911fbaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dbe5e860-c9e4-4c59-9a92-844ac184d146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_58b8dd62-bd9b-43be-9e20-4657911fbaf4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dbe5e860-c9e4-4c59-9a92-844ac184d146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2ab2e39e-a4f7-4105-9b45-121b3b8df7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_58b8dd62-bd9b-43be-9e20-4657911fbaf4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2ab2e39e-a4f7-4105-9b45-121b3b8df7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_275a140a-412e-4122-866f-92128d9e8459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_58b8dd62-bd9b-43be-9e20-4657911fbaf4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_275a140a-412e-4122-866f-92128d9e8459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_afc35214-a47f-46e7-9f79-e837aff82527" xlink:href="pets-20240331.xsd#pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_58b8dd62-bd9b-43be-9e20-4657911fbaf4" xlink:to="loc_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_afc35214-a47f-46e7-9f79-e837aff82527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_cbb9f5b1-f529-4492-ad28-64c542d70fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_58b8dd62-bd9b-43be-9e20-4657911fbaf4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_cbb9f5b1-f529-4492-ad28-64c542d70fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_cd64e5ff-a732-4d51-b960-5eed2b285c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_58b8dd62-bd9b-43be-9e20-4657911fbaf4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_cd64e5ff-a732-4d51-b960-5eed2b285c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_77617a74-7985-46ed-bf59-956df1667d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_58b8dd62-bd9b-43be-9e20-4657911fbaf4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_77617a74-7985-46ed-bf59-956df1667d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_163702d1-aac6-48ba-81fa-ffa083d61cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_58b8dd62-bd9b-43be-9e20-4657911fbaf4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_163702d1-aac6-48ba-81fa-ffa083d61cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7a83d05c-9315-4004-9e58-d6d1bd101d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bcf95668-dbcb-4081-bbdf-409722669629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7a83d05c-9315-4004-9e58-d6d1bd101d51" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bcf95668-dbcb-4081-bbdf-409722669629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c2277204-eeab-489c-bb0e-6d1d2a07177b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bcf95668-dbcb-4081-bbdf-409722669629" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c2277204-eeab-489c-bb0e-6d1d2a07177b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_86d219ba-b3b1-4d77-ba37-e0156d31b3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2277204-eeab-489c-bb0e-6d1d2a07177b" xlink:to="loc_us-gaap_ClassOfStockDomain_86d219ba-b3b1-4d77-ba37-e0156d31b3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_791d167a-b7b0-4a48-ba28-b11603d9ee40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_86d219ba-b3b1-4d77-ba37-e0156d31b3e1" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_791d167a-b7b0-4a48-ba28-b11603d9ee40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bcf95668-dbcb-4081-bbdf-409722669629" xlink:to="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_23866fb3-d041-43aa-9e17-e3dec8f4e299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PreferredStockSharesIssued_23866fb3-d041-43aa-9e17-e3dec8f4e299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0b484396-4ffa-4d55-9cf3-7f0ab7176ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0b484396-4ffa-4d55-9cf3-7f0ab7176ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_aaa51d80-865d-4cb1-89c6-e969e576bdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_aaa51d80-865d-4cb1-89c6-e969e576bdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a124679e-c23c-42dd-8d1e-e4c55607f88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a124679e-c23c-42dd-8d1e-e4c55607f88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_430587c8-0220-4e80-9927-4e228ef3c6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_430587c8-0220-4e80-9927-4e228ef3c6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_3425b045-c098-4536-bfbe-bbfabcee5b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_3425b045-c098-4536-bfbe-bbfabcee5b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d435dc3f-272f-43bb-a0ed-a078fbb304d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_908de298-a53e-4bcb-9912-b484946f4ffe" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d435dc3f-272f-43bb-a0ed-a078fbb304d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/ShareholdersEquityDeclaredDividendsDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#ShareholdersEquityDeclaredDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/ShareholdersEquityDeclaredDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0f41c3ae-adbc-47bd-add5-7c778900f51d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_64a7a3d0-5927-4f01-bee7-dd035783304a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0f41c3ae-adbc-47bd-add5-7c778900f51d" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_64a7a3d0-5927-4f01-bee7-dd035783304a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_e542abe0-099f-46b1-a2ff-0038f060d102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0f41c3ae-adbc-47bd-add5-7c778900f51d" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_e542abe0-099f-46b1-a2ff-0038f060d102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RestrictedStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9330a46e-b039-406d-a722-7457ac722697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9330a46e-b039-406d-a722-7457ac722697" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c3e51427-abb3-4393-83ba-652524c7349c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_PlanNameAxis_c3e51427-abb3-4393-83ba-652524c7349c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c3e51427-abb3-4393-83ba-652524c7349c" xlink:to="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_0cb6168b-4a44-40ce-9898-54725c4d8d58" xlink:href="pets-20240331.xsd#pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_0cb6168b-4a44-40ce-9898-54725c4d8d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_e1e9504b-48a2-4c0e-a429-f51410cb641e" xlink:href="pets-20240331.xsd#pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_e1e9504b-48a2-4c0e-a429-f51410cb641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_22de78fa-bf16-4164-8003-b2c042654e73" xlink:href="pets-20240331.xsd#pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_22de78fa-bf16-4164-8003-b2c042654e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmployeeAndDirectorEquityCompensationPlanMember_4e766617-cd4c-4416-8d4b-b141b26f90f5" xlink:href="pets-20240331.xsd#pets_EmployeeAndDirectorEquityCompensationPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_EmployeeAndDirectorEquityCompensationPlanMember_4e766617-cd4c-4416-8d4b-b141b26f90f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_A2022EmployeePlanMember_2e95157f-401b-4f09-9ee5-6b47793dd762" xlink:href="pets-20240331.xsd#pets_A2022EmployeePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e8d89acc-6fb0-44f1-ba09-68cf224aefd5" xlink:to="loc_pets_A2022EmployeePlanMember_2e95157f-401b-4f09-9ee5-6b47793dd762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d86827c2-b350-4cb7-ab10-ba5356aae424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_AwardTypeAxis_d86827c2-b350-4cb7-ab10-ba5356aae424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d86827c2-b350-4cb7-ab10-ba5356aae424" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f2044b89-7029-4698-b6df-49937ee86841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_us-gaap_RestrictedStockMember_f2044b89-7029-4698-b6df-49937ee86841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockMember_275dcaa7-d4f3-43ba-9d67-3911aec372c2" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_pets_PerformanceRestrictedStockMember_275dcaa7-d4f3-43ba-9d67-3911aec372c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ba3eafe6-165e-4686-9d7c-51ab1c13a671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_us-gaap_CommonStockMember_ba3eafe6-165e-4686-9d7c-51ab1c13a671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NonvestedRestrictedStockMember_4e6358e7-9c51-416a-b156-7ef210c2c723" xlink:href="pets-20240331.xsd#pets_NonvestedRestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_pets_NonvestedRestrictedStockMember_4e6358e7-9c51-416a-b156-7ef210c2c723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_dc564b3d-a4d3-40b1-91d1-84c0d37b4439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_us-gaap_PerformanceSharesMember_dc564b3d-a4d3-40b1-91d1-84c0d37b4439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cec73ea3-6260-43f6-82c9-7d37f986edf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfa84976-c76c-4aa7-bb8a-062707c6907f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cec73ea3-6260-43f6-82c9-7d37f986edf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e51e0d30-d333-40a4-b570-bce2bdc0281e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_srt_RangeAxis_e51e0d30-d333-40a4-b570-bce2bdc0281e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68dd5261-5040-4df7-8ac2-1d333e81cabc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e51e0d30-d333-40a4-b570-bce2bdc0281e" xlink:to="loc_srt_RangeMember_68dd5261-5040-4df7-8ac2-1d333e81cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f57f9269-70a4-4f6f-aa90-afc63d5128a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_68dd5261-5040-4df7-8ac2-1d333e81cabc" xlink:to="loc_srt_MinimumMember_f57f9269-70a4-4f6f-aa90-afc63d5128a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ecd37fd7-48ce-4bd5-881d-ede97e9aaf32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_68dd5261-5040-4df7-8ac2-1d333e81cabc" xlink:to="loc_srt_MaximumMember_ecd37fd7-48ce-4bd5-881d-ede97e9aaf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_aef2317b-3a4e-45ae-9393-0313cc280adc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_srt_TitleOfIndividualAxis_aef2317b-3a4e-45ae-9393-0313cc280adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdf47b7-f6f9-45f2-96bc-9659656e3158" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_aef2317b-3a4e-45ae-9393-0313cc280adc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdf47b7-f6f9-45f2-96bc-9659656e3158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_c813e5af-a088-43ee-b83d-04b29b9cc4e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdf47b7-f6f9-45f2-96bc-9659656e3158" xlink:to="loc_srt_ChiefExecutiveOfficerMember_c813e5af-a088-43ee-b83d-04b29b9cc4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_8c634e18-f7e4-4f5f-b79e-f0211c0818be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdf47b7-f6f9-45f2-96bc-9659656e3158" xlink:to="loc_srt_ChiefFinancialOfficerMember_8c634e18-f7e4-4f5f-b79e-f0211c0818be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_84315637-7de0-47fa-a546-b7983cae9328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_VestingAxis_84315637-7de0-47fa-a546-b7983cae9328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_84315637-7de0-47fa-a546-b7983cae9328" xlink:to="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_df7f48e6-2d64-467c-aa88-84c55c236cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_df7f48e6-2d64-467c-aa88-84c55c236cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7120d1a8-f1bb-4a32-93e4-e01044afe938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7120d1a8-f1bb-4a32-93e4-e01044afe938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2d31d444-7a26-45ed-bd88-701693c8b67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2d31d444-7a26-45ed-bd88-701693c8b67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedPaymentArrangementTrancheFourMember_926a9862-e73f-4db7-8426-61ca45eabb8a" xlink:href="pets-20240331.xsd#pets_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a4bea8bb-0ad5-4970-ad41-87615f6fd4ea" xlink:to="loc_pets_ShareBasedPaymentArrangementTrancheFourMember_926a9862-e73f-4db7-8426-61ca45eabb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_133de437-1d71-4fc1-bd46-c873ed3970f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_AwardDateAxis_133de437-1d71-4fc1-bd46-c873ed3970f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_0d94fee2-ac91-4e46-8177-2a50996c061b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_133de437-1d71-4fc1-bd46-c873ed3970f2" xlink:to="loc_us-gaap_AwardDateDomain_0d94fee2-ac91-4e46-8177-2a50996c061b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_FiscalYear2023Member_c45a993f-cf2f-447e-ad43-8d67802d3a7d" xlink:href="pets-20240331.xsd#pets_FiscalYear2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_0d94fee2-ac91-4e46-8177-2a50996c061b" xlink:to="loc_pets_FiscalYear2023Member_c45a993f-cf2f-447e-ad43-8d67802d3a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_FiscalYear2024Member_bcbd81c0-1bae-48dd-9f14-1f96ee5903b1" xlink:href="pets-20240331.xsd#pets_FiscalYear2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_0d94fee2-ac91-4e46-8177-2a50996c061b" xlink:to="loc_pets_FiscalYear2024Member_bcbd81c0-1bae-48dd-9f14-1f96ee5903b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4a8cf8a7-f59a-4363-8426-720521a227d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4a8cf8a7-f59a-4363-8426-720521a227d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8ab84278-02b6-4acc-a6bf-b52ce3b90a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4a8cf8a7-f59a-4363-8426-720521a227d6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8ab84278-02b6-4acc-a6bf-b52ce3b90a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1513ebd7-258d-41ef-b54b-2e55962f437d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ab84278-02b6-4acc-a6bf-b52ce3b90a6e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1513ebd7-258d-41ef-b54b-2e55962f437d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_b835806e-78fe-4f8c-b4da-9ff051d507b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_b835806e-78fe-4f8c-b4da-9ff051d507b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_358117b0-6087-4129-8aa3-de84c95df515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_b835806e-78fe-4f8c-b4da-9ff051d507b6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_358117b0-6087-4129-8aa3-de84c95df515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DeferredTaxAssetIsRecordedMember_799ec6cd-9df6-423d-a4a6-fda53a19daab" xlink:href="pets-20240331.xsd#pets_DeferredTaxAssetIsRecordedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_358117b0-6087-4129-8aa3-de84c95df515" xlink:to="loc_pets_DeferredTaxAssetIsRecordedMember_799ec6cd-9df6-423d-a4a6-fda53a19daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09642e1-c13a-42de-b4c1-2ecc78d8444a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a4039f68-7435-44d2-943a-b31393feaa68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a4039f68-7435-44d2-943a-b31393feaa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance_33969e56-81e6-4d5c-967f-e790b3be4f8e" xlink:href="pets-20240331.xsd#pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance_33969e56-81e6-4d5c-967f-e790b3be4f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_RestrictionPeriod_7da17757-12d8-4578-a95f-291b7a37b774" xlink:href="pets-20240331.xsd#pets_RestrictionPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_pets_RestrictionPeriod_7da17757-12d8-4578-a95f-291b7a37b774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9ab8f0b-5302-4ac3-8362-b7f6d376e71e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9ab8f0b-5302-4ac3-8362-b7f6d376e71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_d5b7f63e-eae9-4abc-bf51-887aff706975" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_d5b7f63e-eae9-4abc-bf51-887aff706975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_69f60bf9-fefa-45e9-b000-73a2fe9cd979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_69f60bf9-fefa-45e9-b000-73a2fe9cd979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b790953d-1386-432b-8403-b6a66ab3184a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensation_b790953d-1386-432b-8403-b6a66ab3184a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2977d83-75ef-425b-bdd1-dac334672714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2977d83-75ef-425b-bdd1-dac334672714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5c2e2003-fb1f-4020-ba13-a15edf65519a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5c2e2003-fb1f-4020-ba13-a15edf65519a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30722eb1-bb50-4ac9-acc2-cd04b0a27b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30722eb1-bb50-4ac9-acc2-cd04b0a27b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_63edd825-48bb-4ada-b17f-0edb1c4997e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_63edd825-48bb-4ada-b17f-0edb1c4997e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b3e1295e-a065-496c-8894-bc7dbbaf762c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b3e1295e-a065-496c-8894-bc7dbbaf762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2a6664e1-b8db-4680-9daf-bf5745314883" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2a6664e1-b8db-4680-9daf-bf5745314883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a0eb3b5c-7601-49bb-856f-757e75ef7021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a0eb3b5c-7601-49bb-856f-757e75ef7021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue_74ab3e7f-da3b-469b-a865-544e9f16ee0f" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue_74ab3e7f-da3b-469b-a865-544e9f16ee0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18e0d2b8-b997-4a1a-9b76-88e24b2f4254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18e0d2b8-b997-4a1a-9b76-88e24b2f4254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ebc18337-4f2b-444e-84f8-966ba41797ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ebc18337-4f2b-444e-84f8-966ba41797ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a335215f-33ca-45b6-abb1-cf70b0e55888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a7e7396-6878-4ee7-a824-251ac1f34162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a335215f-33ca-45b6-abb1-cf70b0e55888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RestrictedStockNonvestedRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34305256-8595-4c87-94f7-d6342afb6453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef26fb1-80d9-477d-b968-347d101ae352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34305256-8595-4c87-94f7-d6342afb6453" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef26fb1-80d9-477d-b968-347d101ae352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e760bb5e-caf1-4ce3-9beb-0333acf410a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef26fb1-80d9-477d-b968-347d101ae352" xlink:to="loc_us-gaap_PlanNameAxis_e760bb5e-caf1-4ce3-9beb-0333acf410a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e760bb5e-caf1-4ce3-9beb-0333acf410a2" xlink:to="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_288edaca-9a61-4daa-afa3-9d1aa439c25c" xlink:href="pets-20240331.xsd#pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:to="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_288edaca-9a61-4daa-afa3-9d1aa439c25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_9dc0e4e5-9eb1-4891-a3cc-ffc7e3db7389" xlink:href="pets-20240331.xsd#pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:to="loc_pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember_9dc0e4e5-9eb1-4891-a3cc-ffc7e3db7389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_f1d401f8-d572-4a84-ab26-0c16f9cb2d9e" xlink:href="pets-20240331.xsd#pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7ed48231-0b9e-4d13-9faa-b8f63d426e1d" xlink:to="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_f1d401f8-d572-4a84-ab26-0c16f9cb2d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e285a122-147b-4198-b368-7a416746115b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef26fb1-80d9-477d-b968-347d101ae352" xlink:to="loc_us-gaap_AwardTypeAxis_e285a122-147b-4198-b368-7a416746115b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98a52932-2862-449e-82ef-c79e61e15bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e285a122-147b-4198-b368-7a416746115b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98a52932-2862-449e-82ef-c79e61e15bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_12490abe-9b8d-4dae-bf39-c2a1e3016d10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98a52932-2862-449e-82ef-c79e61e15bc5" xlink:to="loc_us-gaap_RestrictedStockMember_12490abe-9b8d-4dae-bf39-c2a1e3016d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_601a27c3-c0a6-4065-bd92-d636ce8d9e35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef26fb1-80d9-477d-b968-347d101ae352" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_601a27c3-c0a6-4065-bd92-d636ce8d9e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_601a27c3-c0a6-4065-bd92-d636ce8d9e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e1fd0256-6cc2-4828-80a4-85e00e5560cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e1fd0256-6cc2-4828-80a4-85e00e5560cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5ec4ddea-09bc-42f1-9bb6-d90e0cd5f820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5ec4ddea-09bc-42f1-9bb6-d90e0cd5f820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_223d197f-d71c-4507-ada6-4c1807d576de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_223d197f-d71c-4507-ada6-4c1807d576de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d14f6aad-bde1-4459-8f62-94636122fa55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d14f6aad-bde1-4459-8f62-94636122fa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04e9cf44-e198-41d6-8295-65582548c609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_db71cd18-da71-41df-8274-fcac3cff4949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04e9cf44-e198-41d6-8295-65582548c609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#RestrictedStockRollforwardofRSUandPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaf79732-b495-4b9c-8e14-557ed788593e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4772f058-9d5c-4c6e-8b99-f5e09b8f9d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaf79732-b495-4b9c-8e14-557ed788593e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4772f058-9d5c-4c6e-8b99-f5e09b8f9d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc75955b-20b5-415d-a8ce-f6addab38ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4772f058-9d5c-4c6e-8b99-f5e09b8f9d7f" xlink:to="loc_us-gaap_AwardTypeAxis_cc75955b-20b5-415d-a8ce-f6addab38ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f982eeb3-3208-47c4-b8e1-d75a696c8fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc75955b-20b5-415d-a8ce-f6addab38ba4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f982eeb3-3208-47c4-b8e1-d75a696c8fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8c1fb13a-d9e2-45f8-9e51-8669941f25c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f982eeb3-3208-47c4-b8e1-d75a696c8fed" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8c1fb13a-d9e2-45f8-9e51-8669941f25c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_832c61d8-be19-40d6-acbb-41eb721a340a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f982eeb3-3208-47c4-b8e1-d75a696c8fed" xlink:to="loc_us-gaap_PerformanceSharesMember_832c61d8-be19-40d6-acbb-41eb721a340a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d98a9a-6fe5-40f9-a1e2-c76a548eb8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4772f058-9d5c-4c6e-8b99-f5e09b8f9d7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d98a9a-6fe5-40f9-a1e2-c76a548eb8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d98a9a-6fe5-40f9-a1e2-c76a548eb8d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_dcdbf2f0-7e29-4a8a-b1d9-7782ee93c756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_dcdbf2f0-7e29-4a8a-b1d9-7782ee93c756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5a6a8fc7-9a98-457f-b4e4-c92b094dcc45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5a6a8fc7-9a98-457f-b4e4-c92b094dcc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_f85ff265-036b-41d5-93b0-38635e248d11" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_f85ff265-036b-41d5-93b0-38635e248d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a486625c-3a29-4d28-a770-79feb106d32b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a486625c-3a29-4d28-a770-79feb106d32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment_a14c17a7-398a-45af-8143-6eb18da1b961" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment_a14c17a7-398a-45af-8143-6eb18da1b961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_74090ed6-cece-4afc-a772-3f9984b1b373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84c2cf7e-561e-4114-87b5-fbb8f612388e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_74090ed6-cece-4afc-a772-3f9984b1b373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d98a9a-6fe5-40f9-a1e2-c76a548eb8d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_5dd2a371-906c-4770-8fc9-8952c2d6f253" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_5dd2a371-906c-4770-8fc9-8952c2d6f253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d234874-9cfa-49ed-adfe-cc91b46ee2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d234874-9cfa-49ed-adfe-cc91b46ee2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_f163f6ff-cda2-4673-b8ec-42af78059ae1" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_f163f6ff-cda2-4673-b8ec-42af78059ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0e3b72a6-ff0b-4576-a7c7-3a6679546981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0e3b72a6-ff0b-4576-a7c7-3a6679546981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue_5abe3283-6d13-40cb-9e62-287e907a9bf2" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue_5abe3283-6d13-40cb-9e62-287e907a9bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_9c1b2816-f4b2-4478-b87c-ca24c6f5729d" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b5532e2-e2e8-4c46-9913-e1848af8efe6" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_9c1b2816-f4b2-4478-b87c-ca24c6f5729d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d397c989-9f93-4cec-9b2e-ee06e59fe4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5fc29e75-30a2-4ea0-b9b4-ffb3bdb4f4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d397c989-9f93-4cec-9b2e-ee06e59fe4d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5fc29e75-30a2-4ea0-b9b4-ffb3bdb4f4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3115ce3f-6254-4156-8b77-01f3949572a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_e45706b3-df3d-45c9-a019-55f70e1071e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3115ce3f-6254-4156-8b77-01f3949572a5" xlink:to="loc_us-gaap_NetIncomeLossAbstract_e45706b3-df3d-45c9-a019-55f70e1071e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_63826c1c-8f37-4be4-b8ea-5853acd55b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_e45706b3-df3d-45c9-a019-55f70e1071e3" xlink:to="loc_us-gaap_NetIncomeLoss_63826c1c-8f37-4be4-b8ea-5853acd55b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b32cf83a-817d-47bd-95d7-793d4caa8dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3115ce3f-6254-4156-8b77-01f3949572a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b32cf83a-817d-47bd-95d7-793d4caa8dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_384c2281-a525-4ade-9acf-459cdabf6c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b32cf83a-817d-47bd-95d7-793d4caa8dbe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_384c2281-a525-4ade-9acf-459cdabf6c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_566538e6-457b-40e2-be1c-f2f49cd4ce25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b32cf83a-817d-47bd-95d7-793d4caa8dbe" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_566538e6-457b-40e2-be1c-f2f49cd4ce25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_e9165b5c-fef7-4f58-86c7-c32ebe80e487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b32cf83a-817d-47bd-95d7-793d4caa8dbe" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_e9165b5c-fef7-4f58-86c7-c32ebe80e487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e0b0707-ce80-4e8d-98f9-2228d5224729" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b32cf83a-817d-47bd-95d7-793d4caa8dbe" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e0b0707-ce80-4e8d-98f9-2228d5224729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EarningsPerShareBasicAndDilutedEPSAbstract_9d207213-832f-48be-96e7-0826ac75101d" xlink:href="pets-20240331.xsd#pets_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3115ce3f-6254-4156-8b77-01f3949572a5" xlink:to="loc_pets_EarningsPerShareBasicAndDilutedEPSAbstract_9d207213-832f-48be-96e7-0826ac75101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bc5bc23e-18d6-4552-8aac-cfa242204107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_EarningsPerShareBasicAndDilutedEPSAbstract_9d207213-832f-48be-96e7-0826ac75101d" xlink:to="loc_us-gaap_EarningsPerShareBasic_bc5bc23e-18d6-4552-8aac-cfa242204107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cb4b2123-0cc5-463a-a0c3-aecb577d775d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pets_EarningsPerShareBasicAndDilutedEPSAbstract_9d207213-832f-48be-96e7-0826ac75101d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cb4b2123-0cc5-463a-a0c3-aecb577d775d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/NetlossIncomePerShareNarrativeDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#NetlossIncomePerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/NetlossIncomePerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_af612785-05b0-498a-9009-66fa5c67b59c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79a70214-d4c3-4dfd-b0cf-36ffd25d0aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af612785-05b0-498a-9009-66fa5c67b59c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79a70214-d4c3-4dfd-b0cf-36ffd25d0aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db0a11e1-8d53-42b9-bfc9-ccb736f7eabf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db0a11e1-8d53-42b9-bfc9-ccb736f7eabf" xlink:to="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_76f0b29c-9cad-4c9a-95ce-8d02dc93ee87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:to="loc_srt_TitleOfIndividualAxis_76f0b29c-9cad-4c9a-95ce-8d02dc93ee87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b0f6e1e-73b9-461c-936b-611b003b0f0a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_76f0b29c-9cad-4c9a-95ce-8d02dc93ee87" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b0f6e1e-73b9-461c-936b-611b003b0f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_a5513b28-218a-4e1e-ad5d-794b93eb88df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b0f6e1e-73b9-461c-936b-611b003b0f0a" xlink:to="loc_srt_ChiefExecutiveOfficerMember_a5513b28-218a-4e1e-ad5d-794b93eb88df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_d396d1c7-f73c-4923-8f88-4f84bf0cfb4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b0f6e1e-73b9-461c-936b-611b003b0f0a" xlink:to="loc_srt_ChiefFinancialOfficerMember_d396d1c7-f73c-4923-8f88-4f84bf0cfb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_14dcd187-10ee-4c18-a9b8-16397c7b5b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:to="loc_us-gaap_PlanNameAxis_14dcd187-10ee-4c18-a9b8-16397c7b5b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aa64b9e6-aba9-4588-9db0-ae5e81231fac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_14dcd187-10ee-4c18-a9b8-16397c7b5b3c" xlink:to="loc_us-gaap_PlanNameDomain_aa64b9e6-aba9-4588-9db0-ae5e81231fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_dd7d9cd3-e737-4adc-9a68-9889edc05ed2" xlink:href="pets-20240331.xsd#pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_aa64b9e6-aba9-4588-9db0-ae5e81231fac" xlink:to="loc_pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember_dd7d9cd3-e737-4adc-9a68-9889edc05ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e2ff391-1b30-4746-b7e8-7206ae4ae77c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:to="loc_us-gaap_AwardTypeAxis_4e2ff391-1b30-4746-b7e8-7206ae4ae77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4e2ff391-1b30-4746-b7e8-7206ae4ae77c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2de03164-cb82-4898-84f2-90d5a80094ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_us-gaap_RestrictedStockMember_2de03164-cb82-4898-84f2-90d5a80094ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockMember_2acdd294-cca4-47e8-aa07-ff74eb5f8fd1" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockMember_2acdd294-cca4-47e8-aa07-ff74eb5f8fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle1Member_5e3c9656-1f78-4e63-962d-04996d5f7856" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle1Member_5e3c9656-1f78-4e63-962d-04996d5f7856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle2Member_561f720e-bcfb-45a4-897e-3b0abda81b8e" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle2Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle2Member_561f720e-bcfb-45a4-897e-3b0abda81b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle3Member_3d0933d6-a3cc-4b75-93b9-fe922e6aa256" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle3Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle3Member_3d0933d6-a3cc-4b75-93b9-fe922e6aa256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle4Member_a653ff95-7365-41eb-941a-2f0cccfee073" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle4Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle4Member_a653ff95-7365-41eb-941a-2f0cccfee073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_PerformanceRestrictedStockPriceHurdle5Member_a778d773-569f-4ab5-9ca6-30ce90f88dad" xlink:href="pets-20240331.xsd#pets_PerformanceRestrictedStockPriceHurdle5Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f408f604-e9f1-418d-ac10-dc43f9c5182b" xlink:to="loc_pets_PerformanceRestrictedStockPriceHurdle5Member_a778d773-569f-4ab5-9ca6-30ce90f88dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_7a07dffd-2cc3-4022-a6ed-19f890e43139" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NumberOfSeverancePayments_ee46769e-73a8-4bb8-afad-5e5875439683" xlink:href="pets-20240331.xsd#pets_NumberOfSeverancePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_NumberOfSeverancePayments_ee46769e-73a8-4bb8-afad-5e5875439683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_LumpSumSeverancePayments_a43b4678-0696-4700-bd1e-17eac6658921" xlink:href="pets-20240331.xsd#pets_LumpSumSeverancePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_LumpSumSeverancePayments_a43b4678-0696-4700-bd1e-17eac6658921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_a45e6d7f-8283-44b9-a179-d355082002ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_a45e6d7f-8283-44b9-a179-d355082002ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentTermInitialPeriod_a8667112-e1f4-4a01-b518-69df55b22ef0" xlink:href="pets-20240331.xsd#pets_EmploymentTermInitialPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_EmploymentTermInitialPeriod_a8667112-e1f4-4a01-b518-69df55b22ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentTermSuccessiveRenewalPeriod_94c096aa-381f-46a5-8c72-b0d4cc070496" xlink:href="pets-20240331.xsd#pets_EmploymentTermSuccessiveRenewalPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_EmploymentTermSuccessiveRenewalPeriod_94c096aa-381f-46a5-8c72-b0d4cc070496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm_349f70d4-64e9-490c-8f4c-868dcb4b679a" xlink:href="pets-20240331.xsd#pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm_349f70d4-64e9-490c-8f4c-868dcb4b679a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficersCompensation_0b2eda4e-dc41-4f85-b3fc-b677c24f1c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_OfficersCompensation_0b2eda4e-dc41-4f85-b3fc-b677c24f1c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_TerminationPeriodPeriodWithinChangeInControl_892557d8-d4bc-40ea-bdde-f9c77839c105" xlink:href="pets-20240331.xsd#pets_TerminationPeriodPeriodWithinChangeInControl"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_TerminationPeriodPeriodWithinChangeInControl_892557d8-d4bc-40ea-bdde-f9c77839c105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SeverancePaymentBaseSalaryPeriod_8f655d21-2bb1-4e22-95c2-d849ac913bea" xlink:href="pets-20240331.xsd#pets_SeverancePaymentBaseSalaryPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SeverancePaymentBaseSalaryPeriod_8f655d21-2bb1-4e22-95c2-d849ac913bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod_92bb246b-7853-4a79-8eef-5f486fc9be70" xlink:href="pets-20240331.xsd#pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod_92bb246b-7853-4a79-8eef-5f486fc9be70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod_7f363c27-6d4e-42cf-8525-c9b9e2f34029" xlink:href="pets-20240331.xsd#pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod_7f363c27-6d4e-42cf-8525-c9b9e2f34029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_NonCompeteAgreementPeriod_9b08e47c-0341-427a-842b-f61874d401d0" xlink:href="pets-20240331.xsd#pets_NonCompeteAgreementPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_NonCompeteAgreementPeriod_9b08e47c-0341-427a-842b-f61874d401d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a5d9103b-532e-41e7-8d50-72e6c8417adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a5d9103b-532e-41e7-8d50-72e6c8417adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_ff5e01d1-e3dc-4a21-be5c-d253aa86ff7d" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod_ff5e01d1-e3dc-4a21-be5c-d253aa86ff7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod_c92265d9-7ca0-4c61-ae33-a6627610f8f1" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod_c92265d9-7ca0-4c61-ae33-a6627610f8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b109c06a-2239-45d1-a1a6-baf90422e87b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b109c06a-2239-45d1-a1a6-baf90422e87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod_8bd90abf-1701-4a96-85ef-788aede9ea51" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod_8bd90abf-1701-4a96-85ef-788aede9ea51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d90a8d83-ad7d-48a3-a8ba-7ab3ae059a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d90a8d83-ad7d-48a3-a8ba-7ab3ae059a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOnBonus_9bc5ed72-ff65-4b88-b2ba-9701001166cb" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOnBonus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SalaryAndWageOfficerSignOnBonus_9bc5ed72-ff65-4b88-b2ba-9701001166cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_138c8529-13f5-4c24-9447-3b47f278e21f" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_138c8529-13f5-4c24-9447-3b47f278e21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c203536-c262-42bc-8dd1-2dd4426b9185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c203536-c262-42bc-8dd1-2dd4426b9185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ContingentLumpSumSeverancePayment_7e76437a-8da4-44ce-86fa-f0c1f90c3289" xlink:href="pets-20240331.xsd#pets_ContingentLumpSumSeverancePayment"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_ContingentLumpSumSeverancePayment_7e76437a-8da4-44ce-86fa-f0c1f90c3289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_AccruedSeveranceCosts_095d3cd3-25bb-400d-856c-bffe4b0a50b0" xlink:href="pets-20240331.xsd#pets_AccruedSeveranceCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_17a1c367-e761-47d2-9477-2cffcf0d3847" xlink:to="loc_pets_AccruedSeveranceCosts_095d3cd3-25bb-400d-856c-bffe4b0a50b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e762f88-6885-4f56-85bf-a962cb306c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_deff3868-07cc-4e2a-ac25-cdda14f3fcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e762f88-6885-4f56-85bf-a962cb306c66" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_deff3868-07cc-4e2a-ac25-cdda14f3fcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_DefinedContributionPlanWithIndividualAge_3e402dbd-dad2-456c-b51b-63a1b82d27e4" xlink:href="pets-20240331.xsd#pets_DefinedContributionPlanWithIndividualAge"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e762f88-6885-4f56-85bf-a962cb306c66" xlink:to="loc_pets_DefinedContributionPlanWithIndividualAge_3e402dbd-dad2-456c-b51b-63a1b82d27e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_83b03d4a-adfd-46d6-880b-e776cfb15947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e762f88-6885-4f56-85bf-a962cb306c66" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_83b03d4a-adfd-46d6-880b-e776cfb15947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_8bf49e95-65a1-4d3a-bf21-e7986712278f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e762f88-6885-4f56-85bf-a962cb306c66" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_8bf49e95-65a1-4d3a-bf21-e7986712278f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_f0c2ad72-4c0c-4563-a9a3-a636001adf85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e762f88-6885-4f56-85bf-a962cb306c66" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_f0c2ad72-4c0c-4563-a9a3-a636001adf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.1800petmeds.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="pets-20240331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c81d700b-170e-4b4e-b7d8-acc38140e1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c81d700b-170e-4b4e-b7d8-acc38140e1fd" xlink:to="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a7615ba1-9997-46f8-a088-81a121f44d13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:to="loc_us-gaap_AwardTypeAxis_a7615ba1-9997-46f8-a088-81a121f44d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1be96721-9d7f-49c3-858a-398e4bb14c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a7615ba1-9997-46f8-a088-81a121f44d13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1be96721-9d7f-49c3-858a-398e4bb14c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f5547f46-5618-419d-890f-2f581ab294a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1be96721-9d7f-49c3-858a-398e4bb14c95" xlink:to="loc_us-gaap_RestrictedStockMember_f5547f46-5618-419d-890f-2f581ab294a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_01dced81-2471-48fa-b747-6ae3299fee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1be96721-9d7f-49c3-858a-398e4bb14c95" xlink:to="loc_us-gaap_PerformanceSharesMember_01dced81-2471-48fa-b747-6ae3299fee6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ec519dd2-28c6-45fc-8496-7e0ab40171e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:to="loc_us-gaap_PlanNameAxis_ec519dd2-28c6-45fc-8496-7e0ab40171e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e6100952-3ac7-4104-a2de-4508b549a4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ec519dd2-28c6-45fc-8496-7e0ab40171e8" xlink:to="loc_us-gaap_PlanNameDomain_e6100952-3ac7-4104-a2de-4508b549a4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_7aa39b83-f383-4f6c-9ae1-e20a6ea00e94" xlink:href="pets-20240331.xsd#pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e6100952-3ac7-4104-a2de-4508b549a4f6" xlink:to="loc_pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember_7aa39b83-f383-4f6c-9ae1-e20a6ea00e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c6fe379b-e199-48ac-8ac5-ecd2dac707a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c6fe379b-e199-48ac-8ac5-ecd2dac707a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a9509e5f-5e5c-4275-99c9-c56647fe119e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c6fe379b-e199-48ac-8ac5-ecd2dac707a1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a9509e5f-5e5c-4275-99c9-c56647fe119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_58d0de76-30a1-4b8c-b663-ba05b0b7424f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a9509e5f-5e5c-4275-99c9-c56647fe119e" xlink:to="loc_us-gaap_SubsequentEventMember_58d0de76-30a1-4b8c-b663-ba05b0b7424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c25dca1d-6a66-4f41-8ad6-73812a98c82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:to="loc_us-gaap_VestingAxis_c25dca1d-6a66-4f41-8ad6-73812a98c82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_c25dca1d-6a66-4f41-8ad6-73812a98c82d" xlink:to="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_cb99f4b5-821d-4bc1-84d4-2f74ccba818c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_cb99f4b5-821d-4bc1-84d4-2f74ccba818c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1721b63d-5bcb-4674-aca2-87720eb77d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1721b63d-5bcb-4674-aca2-87720eb77d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_91f85f14-dc1f-44b2-8af9-e66f65d3f4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d8d07074-75a5-40ef-97a8-585692c78bc9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_91f85f14-dc1f-44b2-8af9-e66f65d3f4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8dbf8a6e-afe1-41c8-af3a-59f973e11c03" xlink:to="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_79d59528-2e81-4d8e-bb2d-60ff12392e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_79d59528-2e81-4d8e-bb2d-60ff12392e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentAgreementEmploymentTerm_2b72f246-4ddb-465e-b287-2cecdd4bc760" xlink:href="pets-20240331.xsd#pets_EmploymentAgreementEmploymentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_EmploymentAgreementEmploymentTerm_2b72f246-4ddb-465e-b287-2cecdd4bc760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentAgreementRenewalTerm_064a6214-a08d-43c8-840d-2cb9e67f935e" xlink:href="pets-20240331.xsd#pets_EmploymentAgreementRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_EmploymentAgreementRenewalTerm_064a6214-a08d-43c8-840d-2cb9e67f935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_EmploymentAgreementNonRenewalNoticePeriod_5520db4f-faa1-459a-ad2e-261cc8771ba5" xlink:href="pets-20240331.xsd#pets_EmploymentAgreementNonRenewalNoticePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_EmploymentAgreementNonRenewalNoticePeriod_5520db4f-faa1-459a-ad2e-261cc8771ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerAnnualBaseSalary_2b86d8a3-7261-43ad-b40c-b56b08a2e90f" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerAnnualBaseSalary"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageOfficerAnnualBaseSalary_2b86d8a3-7261-43ad-b40c-b56b08a2e90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOnBonus_000b19c0-2fd0-4a8e-9971-7c9c81a1de84" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOnBonus"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageOfficerSignOnBonus_000b19c0-2fd0-4a8e-9971-7c9c81a1de84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_b916d035-6213-4c9f-9497-699b249a3322" xlink:href="pets-20240331.xsd#pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod_b916d035-6213-4c9f-9497-699b249a3322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageTargetAnnualBonusPercentage_8eb9b04a-0af9-4d15-85a2-281d579c0caa" xlink:href="pets-20240331.xsd#pets_SalaryAndWageTargetAnnualBonusPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageTargetAnnualBonusPercentage_8eb9b04a-0af9-4d15-85a2-281d579c0caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_SalaryAndWageMaximumBonusPercentage_17f2e2fb-8d85-4201-a277-abc9ce4e7043" xlink:href="pets-20240331.xsd#pets_SalaryAndWageMaximumBonusPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_SalaryAndWageMaximumBonusPercentage_17f2e2fb-8d85-4201-a277-abc9ce4e7043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount_5fc421a5-72f5-4951-a860-aba5b9d57755" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount_5fc421a5-72f5-4951-a860-aba5b9d57755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_47f47c73-352f-4e69-ae87-1fb9dcf7b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_47f47c73-352f-4e69-ae87-1fb9dcf7b9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount_4c4d7899-0c2e-446b-95d2-0693e472e3f4" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount_4c4d7899-0c2e-446b-95d2-0693e472e3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare_8f8e03c9-0fc9-4c7a-af1b-7cc10acd826f" xlink:href="pets-20240331.xsd#pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare_8f8e03c9-0fc9-4c7a-af1b-7cc10acd826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d30dae16-bef5-4c08-86f6-a185130c2d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d30dae16-bef5-4c08-86f6-a185130c2d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_61f4d68b-a1ed-4302-a471-010be8793f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c9fcc4b1-003d-43d1-b5e0-2951c163abef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_61f4d68b-a1ed-4302-a471-010be8793f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>7
<FILENAME>pets-20240331xexx191.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i68b24bc28b2545eeb8625cd0cfb4e929_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 19.1</font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Statement of Policy Regarding Insider Trading</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Amended and Restated Effective July 28, 2022)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;&#160;&#160;&#160;&#160;All directors, officers and employees of and consultants to PetMed Express, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221;)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Introduction</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of this memorandum is to remind you of your obligation as a director, officer or employee of, or consultant to, the Company to treat and keep material non-public information about the Company as confidential, and to not purchase or sell securities of PetMed Express, Inc. while you have knowledge of such material non-public information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the policy of the Company to prohibit all employees, officers, and members of the board of directors (&#8220;Directors&#8221;) from purchasing or selling Company securities (e.g., stocks, bonds, options, etc.) based upon material non-public information about the Company.  In addition, all employees, officers, directors, and consultants to the Company are prohibited from disclosing material non-public information about the Company to another person who may in turn trade in the Company&#8217;s securities.  It is also the policy of the Company to prohibit purchases or sales of the securities of any publicly-traded company based on material non-public information about such company that was obtained in the course of service with the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Restrictions on Trading Securities Based on Insider Information</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Your Relationship With the Company</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the course of your employment with, or consultancy to, the Company or because of your relationship as a director, officer or employee, you may come into possession of confidential information concerning the Company.  Much of this information has a potential for affecting the market price of shares of PetMed Express, Inc.  Under some circumstances, federal securities law would impose potentially onerous civil and criminal penalties on persons who improperly obtain or use material non-public information about the Company in connection with a purchase or sale of its securities.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liability of the Company for Insider Trading Violations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to creating criminal and civil penalties for employees, officers, directors and consultants who purchase or sell PetMed Express, Inc. securities based upon material, non-public information, federal law empowers the Securities and Exchange Commission (&#8220;SEC&#8221;) to seek substantial civil penalties from any person who, at the time of an insider trading violation, &#8220;directly or indirectly controlled the person who committed such violation&#8221; i.e., the Company.  Thus, the Company may also be subject to civil penalties for insider trading violations committed by employees, officers or directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Application of the Law&#59; Material Non-Public Information</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal and state securities laws prohibit insider trading.  Insider trading is the buying or selling of PetMed Express, Inc. securities (i.e., stocks, bonds, options, etc.) based upon &#8220;material non-public information&#8221; about the Company.  These laws also prohibit you from &#8220;tipping&#8221; or disclosing such information to others, such as a friend or relative, who may then trade in Company securities on the basis of that information.  These rules also apply to buying or selling securities of any other public company based on important information that is not known to the public and that was obtained in the course of service at the Company.  To be clear, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">any</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> violation of these laws could subject you, the Company, and the Company&#8217;s management to civil and criminal liability and penalties, including imprisonment.  There is no exception for &#8220;minor&#8221; trades--state and federal law enforcement have successfully prosecuted insider </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 19.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trading involving only a small number of shares, modest profits or even where the insider trading avoided losses.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Non-public&#8221; information consists of information that is not generally known or available to the public.  Information is generally not considered to be known or generally available to the public until it has been released broadly to the marketplace (such as by a press release or a SEC filing), and enough time has elapsed to permit the investment market to absorb and evaluate the information.  Once information is broadly released to the public, it will normally be regarded as absorbed and evaluated within two business days after the information has been broadly released.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Material&#8221; information is information that a reasonable investor would consider important in deciding to buy, sell, hold, or short, PetMed Express, Inc. securities. Information may be important for this purpose even if it would not alone determine an investor&#8217;s decision. Material information can be favorable or unfavorable.  Examples that could be considered material include (but are not limited to) unannounced or unexpected results of operations&#59; news of a significant pending transaction such as a proposed merger, acquisition, tender offer, exchange offer, major sales, or other commercial agreement&#59; establishment of new line of business&#59; an intended or actual sale of significant assets or the disposition of all or substantially all of a subsidiary&#59; changes in dividend policies, the declaration of a stock split or the offering of additional securities&#59; changes in management&#59; significant joint ventures&#59; introductions of significant new products or services&#59; impending bankruptcy or financial liquidity problems&#59; or the gain or loss of a substantial customer or supplier.  Of course, there are numerous other examples of material information and the determination will necessarily depend on the circumstances existing at the time including but not limited to unusually high or low sales of a certain product, overall sales data, financial results, forecasts, changes in senior management, strategic decisions, new contracts or transactions with other companies, and actual or threatened litigation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Material non-public information&#8221; is information that is both material and non-public.  It is also sometimes referred to as &#8220;Inside Information&#8221; or &#8220;Insider Information.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Statement of Company Policy</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Outright Restriction Against Trading When in Possession of Material Non-Public Information</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All employees, officers, directors, and consultants to the Company are prohibited from purchasing or selling PetMed Express, Inc. securities (e.g., stocks, bonds, options, etc.) based on material non-public information about the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">No Tipping</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees, officers, directors, and consultants to the Company are prohibited from (i) &#8220;tipping&#8221; or disclosing material non-public information about PetMed Express, Inc. to another person so that they or others can buy or sell PetMed Express, Inc. securities, and (ii) recommending trading in PetMed Express, Inc. securities to another person based upon material non-public information. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees, officers, directors, and consultants to the Company are also prohibited from (i) &#8220;tipping&#8221; or disclosing material non-public information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">about any other publicly-traded company with whom PetMed Express, Inc. has a business relationship to another person so that they or others can buy or sell securities of such company, and (ii) recommending the trading in such company&#8217;s securities to another person based on material non-public information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that you know about such company that was obtained in the course of your service with PetMed Express, Inc. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Blackout Period</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 19.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Employees, officers and directors are prohibited from buying and selling the Company&#8217;s securities except during the specified trading &#8220;window&#8221; period for each quarter.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 19.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading window will open on the second business day after the public release by the Company of any financial or other material information.  Trading windows open due to the public release of financial information shall close on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day of the last month of the fiscal current quarter.  The Company can announce a new blackout period at any time.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two exceptions are hereby created to the requirements of the blackout period&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">to allow for the selling of the Company&#8217;s securities only to independent institutional investors and only with the express authorization of the following individuals&#58; either the Chairman of the Board or Chief Executive Officer of the Company (depending on the identity of the seller), and two (2) independent board members.  Additionally, either of the two (2) independent board members may require that legal counsel be contacted in order to discuss the propriety of the sale.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        (2) to allow for the selling of the Company&#8217;s securities pursuant to a previously filed 10b5-1 plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hedging of Company Stock&#59; Short Sales</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees, directors, officers, and consultants to the Company are prohibited from entering into any transaction designed to hedge, or having the effect of hedging, the economic risk of owning the Company&#8217;s stock.  Examples of transactions that fall within this prohibition include trading in options, puts, calls and other similar instruments related to Company stock.  In addition, employees, directors, officers and consultants to the Company are prohibited from engaging in short sales (i.e. selling securities you do not own) of PetMed Express, Inc. securities.  Regardless of any other provision of this Policy, the prohibitions set forth in this section are not eligible for the granting of an exception.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Margin Accounts and Pledges</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities held in a margin account or pledged as collateral for a loan may be sold without your consent by the broker if you fail to meet a margin call or be foreclosed upon by the lender if you default on the loan. A margin or foreclosure sale that occurs when you are aware of material non-public information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may result in unlawful insider trading. As a result, directors, officers, and employees are prohibited from holding PetMed Express, Inc. securities in a margin account that can be sold without your consent and from pledging PetMed Express, Inc. securities as collateral for a loan. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Family Members</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No director, officer, employee or consultant may permit any member of his or her immediate family or anyone on his or her behalf (&#8220;Related Persons&#8221;), or anyone to whom he or she has disclosed material, non-public information, to purchase or sell such securities in violation of the insider trading laws or the policies of the Company.  It must be stressed that it is the personal responsibility of each such person to ensure his or her compliance with the laws and regulations applicable to his or her sales and purchases of securities, and that the Company has no obligation to any such person to ensure such compliance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Companies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the acquisition nature of our business, you may become privy to material non-public information of other companies, such as companies with which we may be negotiating transactions.  All employees, officers, directors, and consultants to the Company are also prohibited from purchasing or selling the securities of any other publicly-traded company with whom PetMed Express, Inc. has a business relationship based on material non-public information about such company that was obtained in the course of your service with PetMed Express, Inc. or the related company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Restrictions for Directors, Officers, and Members of the Management Committee</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Standing Orders&#47;10b5-1 Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A standing order placed with a broker to purchase or sell PetMed Express, Inc. securities at a specified price leaves you with no control over the timing of the transaction. A standing order transaction executed by the broker when you are aware of material non-public information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may result in unlawful insider trading even if you were not aware of the material non-public information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when you placed the order. As a result, directors, officers, and members of the management committee are prohibited from placing standing orders that are longer than one day for PetMed Express, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An exception to this prohibition are plans created consistent with Rule 10b5-1 of the Securities Exchange Act of 1934, which provides a &#8220;safe harbor&#8221; (i.e. an affirmative defense) from insider trading liability under the federal securities laws for trading plans that meet certain requirements. The Company requires that all 10b5-1 plans in PetMed Express, Inc. securities for directors and officers be approved in advance by Chief Financial Officer.  Trades in PetMed Express, Inc. securities that are executed pursuant to an approved 10b5-1 plan are not subject to the prohibitions on trading contained in this policy.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Short Swing Transactions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Directors and those senior officers who are subject to Section 16 of the Securities Exchange Act of 1934 (&#8220;Reporting Persons&#8221;) must refrain from engaging in &#34;short swing&#34; transactions in PetMed Express, Inc. securities prohibited under Section 16. As a general rule, this requirement means that a Reporting Person may not purchase any PetMed Express, Inc. securities if the Reporting Person sold similar securities within the prior six (6) months&#59; and a Reporting Person may not sell any PetMed Express, Inc. securities if the Reporting Person purchased similar securities within the last six (6) months.  However, the exercise of a stock option or sale of stock previously granted under PetMed Express, Inc.&#8217;s Board-approved equity plans shall not be treated as either a &#8220;purchase&#8221; or &#8220;sale&#8221; for purposes of the short swing transaction restrictions nor would the granting or purchase of stock under any Board-approved Company equity plan or stock purchase plan, respectively, be considered a &#34;purchase&#34; for purposes of short swing transaction restrictions.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Reporting Requirements</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16 Reports</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Reporting Persons must file certain reports with the SEC when they engage in transactions involving PetMed Express, Inc. securities. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rule 144 Reports</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If required, directors, officers and employees must notify the SEC of their intention to sell PetMed Express, Inc. securities in the open market by filing a SEC Form 144</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with the existing rules regarding Form 144 filings. This form is generally prepared and filed by your broker and is in addition to any required Section 16 reports.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corrective Action</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any violation of this Company policy may serve as grounds for immediate termination of employment for cause of the person violating the policy, and may result in the Company seeking reimbursement from such person for any consequential damages or other injury suffered by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Further Assistance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person who has a question concerning the propriety of a proposed transaction or about the Company&#8217;s policy may obtain additional guidance from the Company&#8217;s Chief Financial Officer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>8
<FILENAME>pets-20240331xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if29f639ef7da44d0abafcadf4c014e6b_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Exhibit 21.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SUBSIDIARIES OF THE REGISTRANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">PETMED EXPRESS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(as of March&#160;31, 2024)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Subsidiaries Wholly-Owned by PetMed Express, Inc.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:74.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Entity Name</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">State of Incorporation or Organization</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Southeastern Veterinary Exports, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Florida</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Global Veterinary Supply, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Florida</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">420 South Congress Avenue, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Florida</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PetCareRx, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New York</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PetMeds Insurance Services, LLC</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Florida</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Indirectly Owned Subsidiaries  </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:74.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Entity Name</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">State of Incorporation or Organization</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Congress Park South Owners Association, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Florida</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1) Each of the named subsidiaries is not necessarily a &#8220;significant subsidiary&#8221; as defined in Rule 1-02(w) of Regulation S-X.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) A not-for-profit corporation&#59; 420 South Congress Avenue, LLC holds a majority of the voting power.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>pets-20240331xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i50a7fb5eb0774f0b9054b9cf6dc34cba_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:396pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 23.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in these Registration Statements (No. 333-269661 and No. 333-218917) on Form S-8 and related Reoffer Prospectus of PetMed Express, Inc. of our reports dated June 13, 2024, relating to the consolidated financial statements of PetMed Express, Inc. and the effectiveness of internal control over financial reporting (which report expresses an adverse opinion on the effectiveness of the Company&#8217;s internal control over financial reporting because of material weaknesses) of PetMed Express, Inc., appearing in this Annual Report on Form 10-K of PetMed Express, Inc. for the year ended March 31, 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also consent to the reference to our firm under the heading &#8220;Experts&#8221; in such Reoffer Prospectus.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; RSM US LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Palm Beach, Florida</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;14, 2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>pets-20240331xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6fa316aedb0243b29f77afde12ed107c_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sandra Y. Campos, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of PetMed Express, Inc. for the fiscal year ended March&#160;31, 2024&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June&#160;14, 2024</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sandra Y. Campos </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Y. Campos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>pets-20240331xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3dcf6a1705f64c8ebbc2366bd47b6a4c_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christine Chambers, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of PetMed Express, Inc. for the fiscal year ended March&#160;31, 2024&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June&#160;14, 2024</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Christine Chambers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine Chambers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>pets-20240331xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0fd92bf7dcb74982b08ad03cd6af04ad_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sandra Y. Campos, and I, Christine Chambers, each certify to the best of our knowledge, based upon a review of the Annual Report on Form 10-K for the year ended March&#160;31, 2024 (the &#8220;Report&#8221;) of PetMed Express, Inc. (the &#8220;Registrant&#8221;), that&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; June&#160;14, 2024</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#47;s&#47; Sandra Y. Campos </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Y. Campos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#47;s&#47; Christine Chambers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine Chambers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>13
<FILENAME>pets-20240331xexx42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic27cd81803174c3381bf0eb64179a578_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 4.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF THE COMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">S SECURITIES REGISTERED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following is a brief description of the common stock, $0.001 par value per share (the &#8220;Common Stock&#8221;), of PetMed Express, Inc., a Florida corporation (the &#8220;Company&#8221;), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Common Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following descriptions of our Common Stock and of certain provisions of Florida law do not purport to be complete and are subject to and qualified in their entirety by reference to our amended and restated articles of incorporation, our amended and restated&#160;bylaws&#160;and the Florida Business Corporation Act, as amended (the &#8220;Florida Act&#8221;). The Company has authorized 40,000,000 shares of Common Stock of which as of June&#160;14, 2024, 20,606,692 shares of Common Stock are issued and outstanding. All of our outstanding shares of Common Stock are fully paid and&#160;non-assessable. Our Common Stock is listed on the NASDAQ Global Select Market under the symbol &#8220;PETS.&#8221;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of the Common Stock have no pre-emptive, redemption, subscription or conversion rights. Each outstanding share of Common Stock is entitled to one vote on all matters submitted to a vote of the Company's shareholders. Subject to the dividend rights of the holders of any outstanding preferred stock, each share of Common Stock is entitled to participate equally with respect to dividends as may be declared by the board of directors out of funds legally available therefor. In the case of voluntary or involuntary liquidation, distribution or sale of assets, dissolution, or winding up of the Company, holders of our Common Stock are entitled to receive a pro rata share of the amount distributed after provisions for payment of all debts, other liabilities and any liquidation preferences of outstanding preferred stock. The Florida Act also may affect the terms of these securities.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Limitations on Rights of Holders of Common Stock&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Preferred Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rights of holders of Common Stock may be materially limited or qualified by the rights of holders of preferred stock that we may issue in the future. Set forth below is a description of the Company&#8217;s authority to issue preferred stock and the possible terms of that stock.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our amended and restated articles of incorporation authorizes our board of directors, without further shareholder action, to provide for the issuance of up to 5,000,000 shares of preferred stock, with a par value of $0.001 per share, in one or more series, and to fix the designations, preferences, conversion rights, cumulative, relative, participating, optional or other rights, including voting rights, qualifications, limitations or restrictions, redemption and liquidation preferences of each of these series. Of the preferred stock, 250,000 shares have been designated Convertible Preferred Stock of which as of June&#160;14, 2024, 2,500 shares of Convertible Preferred Stock are issued and outstanding. We may amend from time to time our amended and restated articles of incorporation to increase the number of authorized shares of preferred stock. Any such amendment would require the approval of the holders of a majority of our shares of Common Stock entitled to vote.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholder Action by Written Consent and Special Meeting</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our amended and restated bylaws provide for action by our shareholders without a meeting with the written consent of shareholders holding the number of shares necessary to approve such action if it were taken at a meeting at which all shares entitled to vote thereon were present. Our amended and restated bylaws also provide that shareholder action can be taken at an annual meeting of the shareholders or at a special meeting which may be called, for any purpose or purposes, by the board of directors or the person or persons authorized to do so by the board of directors and must be called by the Secretary if the holders of not less than ten percent of all votes entitled to be cast on any issue proposed to be considered at such special meeting sign, date and deliver to the Secretary one or more written demands for a special meeting, describing the purpose or purposes for which it is to be held.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:1440px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Authorized but Unissued Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our authorized but unissued shares of Common Stock and preferred stock are available for future issuance without shareholder approval, subject to the requirements of applicable law or regulation, including any listing requirement of the principal stock exchange on which our Common Stock is then listed. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of Common Stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our Common Stock by means of a proxy contest, tender offer, merger or otherwise.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board Authority to Amend Bylaws</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under our amended and restated bylaws, our board of directors has the authority to adopt, amend or repeal the bylaws without the approval of our shareholders unless the Florida Act reserves the power to amend a particular bylaw provision exclusively to the shareholders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Anti-Takeover provisions of Florida Law and our Bylaws</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Florida Business Corporation Act</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to certain anti-takeover provisions that apply to public corporations under Florida law. Pursuant to Section 607.0901 of the Florida Act, a publicly held Florida corporation may not engage in a broad range of business combinations or other extraordinary corporate transactions with an &#8220;interested shareholder&#8221; without the approval of the holders of two-thirds of the voting shares of such corporation (excluding shares held by the interested shareholder), unless&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9679;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the transaction is approved by a majority of disinterested directors before the shareholder becomes an </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">interested shareholder&#59;</font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9679;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the interested shareholder has owned at least 80% of the corporation&#8217;s outstanding voting shares for at least </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">five years preceding the announcement date of any such business combination&#59;</font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9679;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the interested shareholder is the beneficial owner of at least 90% of the outstanding voting shares of the </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">corporation, exclusive of shares acquired directly from the corporation in a transaction not approved by a </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">majority of the disinterested directors&#59; or</font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9679;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the consideration paid to the holders of the corporation&#8217;s voting stock is at least equal to certain fair price </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">criteria.</font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">An &#8220;interested shareholder&#8221; is defined as a person who together with affiliates and associates beneficially owns more than 10% of a corporation&#8217;s outstanding voting shares. We have not made an election in our amended and restated articles of incorporation to opt out of Section 607.0901.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, we are subject to Section 607.0902 of the Florida Act which prohibits the voting of shares in a publicly held Florida corporation that are acquired in a &#8220;control share acquisition&#8221; unless (i) our board of directors approved such acquisition prior to its consummation or (ii) after such acquisition, in lieu of prior approval by our board of directors, the holders of a majority of the corporation&#8217;s voting shares, exclusive of shares owned by officers of the corporation, employee directors or the acquiring party, approve the granting of voting rights as to the shares acquired in the control share acquisition. A &#8220;control share acquisition&#8221; is defined as an acquisition that immediately thereafter entitles the acquiring party to 20% or more of the total voting power in an election of directors.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These statutory provisions may prevent takeover attempts that might result in a premium over the market price for shares of our common stock.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:1440px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Advance Notice of Shareholder Proposals or Nominations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our amended and restated bylaws provide that shareholders at an annual meeting may only consider proposals or nominations (i) specified in the notice of meeting given by or at the direction of the Board, (ii) properly brought before the meeting by or at the direction of the Board or (iii) otherwise properly brought before the meeting by a shareholder of the Company who was a shareholder of record on (a) the date of the giving of timely notice to our Corporate Secretary and (b) the record date for the meeting, who is entitled to vote at the meeting and who has given our Corporate Secretary timely written notice, in proper form. In addition to certain other applicable requirements, for business to be properly brought before an annual meeting by a shareholder, such shareholder generally must have given notice thereof in proper written form to our Corporate Secretary not less than 90 days nor more than 120 days prior to the anniversary date of the immediately preceding annual meeting of shareholders. Our amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or defer a potential acquiror from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Proxy Access</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our By-Laws permit a shareholder (or a group of up to 20 shareholders) owning three percent (3%) or more of our common stock continuously for at least three years to nominate and include in our proxy statement candidates for up to the greater of 2 of 20% of our Board. To be timely, a notice of a nomination under our proxy access bylaw provisions must be delivered to or mailed and received at the principal executive offices of the Company not less than one-hundred twenty (120) days nor more than one-hundred fifty (150) days prior to the anniversary of the date that the Company first distributed its proxy statement to shareholders for the immediately preceding annual meeting of shareholders. The notice must contain certain information specified in our amended and restated bylaws.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transfer Agent and Registrar</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The transfer agent and registrar for the Company's common stock is Continental Stock Transfer &#38; Trust Company.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>14
<FILENAME>pets-20240331xexx971.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5b3de584dc93482a8c7e6e43f184b5af_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 97.1</font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PetMed Express, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION RECOVERY POLICY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Effective October 25, 2023)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Executive Compensation Recovery Policy (&#8220;Policy&#8221;) covers  Covered Officers of PetMed Express, Inc. (collectively with its subsidiaries, &#8220;PetMeds&#8221;) and explains when PetMeds will be required or authorized, as applicable, to seek recovery of Incentive Compensation awarded or paid to Covered Officers. Please refer to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions Exhibit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for the definitions of capitalized terms used throughout this Policy. Included in this Policy is Annex A &#8220;Attestation and Acknowledgement of Executive Compensation Recovery Policy.&#8221;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">Miscalculation of Financial Performance Measure Results. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a Restatement, PetMeds will seek to recover, reasonably promptly, all Recoverable Incentive Compensation from a Covered Officer during the Applicable Period. Such recovery, in the case of a Restatement, will be made without regard to any individual knowledge or responsibility related to the Restatement or the Recoverable Incentive Compensation. Notwithstanding the foregoing, if PetMeds is required to undertake a Restatement, PetMeds will not be required to recover the Recoverable Incentive Compensation if the Compensation Committee determines it Impracticable to do so, after exercising a normal due process review of all the relevant facts and circumstances. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PetMeds will seek to recover all Recoverable Incentive Compensation that was awarded or paid in accordance with the definition of &#8220;Recoverable Incentive Compensation&#8221; set forth on the Definitions Exhibit. If such Recoverable Incentive Compensation was not awarded or paid on a formulaic basis, PetMeds will seek to recover the amount that the Compensation Committee determines in good faith should be recouped.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">Legal and Compliance Violations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Compliance with the law and PetMeds&#8217; Code of Business Conduct and Ethics and other corporate policies is a pre-condition to earning Incentive Compensation. If PetMeds in its sole discretion concludes that a Covered Officer (1) committed a significant legal or compliance violation in connection with the Covered Officer&#8217;s employment, including a violation of PetMeds&#8217; corporate policies or PetMeds&#8217; Code of Business Conduct and Ethics (each, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Misconduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or (2) was aware of or willfully blind to Misconduct that occurred in an area over which the Covered Officer had supervisory authority, PetMeds may, at the direction of the Compensation Committee, seek recovery of all or a portion of the Recoverable Incentive Compensation awarded or paid to the Covered Officer for the Applicable Period in which the violation occurred. In addition, PetMeds may, at the direction of the Compensation Committee, conclude that any unpaid or unvested Incentive Compensation has not been earned and must be forfeited.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of Misconduct, PetMeds may seek recovery of Recoverable Incentive Compensation even if the Misconduct did not result in an award or payment greater than would have been awarded or paid absent the Misconduct.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of Misconduct, in determining whether to seek recovery and the amount, if any, by which the payment or award should be reduced, the Compensation Committee may consider&#8212; among other things&#8212; the seriousness of the Misconduct, whether the Covered Officer was unjustly enriched, whether seeking the recovery would prejudice PetMeds&#8217; interests in any way, including in a proceeding or investigation, and any other factors it deems relevant to the determination.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">Other Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Compensation Committee may, subject to applicable law, seek recovery in the manner it chooses, including by seeking reimbursement from the Covered Officer of all or part of the compensation awarded or paid, by electing to withhold unpaid compensation, by set-off, or by rescinding or canceling  unvested equity and restricted stock awards. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 97.1</font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the reasonable exercise of its business judgment under this Policy, the Compensation Committee may in its sole discretion determine whether and to what extent additional action is appropriate to address the circumstances surrounding a Restatement or Misconduct to minimize the likelihood of any recurrence and to impose such other discipline as it deems appropriate.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">No Indemnification or Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the terms of any other policy, program, agreement or arrangement, in no event will PetMeds or any of its affiliates indemnify or reimburse a Covered Officer for any loss under this Policy and in no event will PetMeds or any of its affiliates pay premiums on any insurance policy that would cover a Covered Officer&#8217;s potential obligations with respect to Recoverable Incentive Compensation under this Policy.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">Administration of Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Compensation Committee will have full authority to administer this Policy. Actions of the Compensation Committee pursuant to this Policy will be taken by the vote of a majority of its members. The Compensation Committee will, subject to the provisions of this Policy and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and PetMeds&#8217; applicable exchange listing standards, make such determinations and interpretations and take such actions in connection with this Policy as it deems necessary, appropriate or advisable. All  determinations and interpretations made by the Compensation Committee will be final, binding and conclusive.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">Other Claims and Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The remedies under this Policy are in addition to, and not in lieu of, any legal and equitable claims PetMeds or any of its affiliates may have or any actions that may be imposed by law enforcement agencies, regulators, administrative bodies, or other authorities. Further, the exercise by the Compensation Committee of any rights pursuant to this Policy will not impact any other rights that PetMeds or any of its affiliates may have with respect to any Covered Officer subject to this Policy.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">Condition to Eligibility for Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All Incentive Compensation will be subject to this Policy, even if already paid, until the Policy ceases to apply to such Incentive Compensation and any other vesting conditions applicable to such Incentive Compensation are satisfied.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">Amendment&#59; Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Board or the Compensation Committee may amend or terminate this Policy at any time.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as otherwise determined in writing by the Compensation Committee, this Policy will apply to any Incentive Compensation that (a) in the case of any Restatement, is Received by Covered Officers prior to, on or following the Effective Date, and (b) in the case of Misconduct, is awarded or paid to a Covered Officer on or after the Effective Date. This Policy will survive and continue notwithstanding any termination of a Covered Officer&#8217;s employment with PetMeds and its affiliates.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.21pt">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Policy shall be binding and enforceable against all Covered Officers and their successors, beneficiaries, heirs, executors, administrators, or other legal representatives.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.21pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent not preempted by U.S. federal law, this Policy will be governed by and construed in accordance with the laws of the State of Florida, without reference to principles of conflict of laws.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.21pt">Disclosure Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. PetMeds shall file all disclosures with respect to this Policy required by applicable Securities and Exchange Commission filings and rules.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 97.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEFINITIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a) in the case of any Restatement, the three completed fiscal years of PetMeds immediately preceding the earlier of (i) the date the Board, a committee of the Board, or the officer or officers of PetMeds authorized to take such action if Board action is not required, concludes (or reasonably should have concluded) that a Restatement is required or (ii) the date a regulator, court or other legally authorized entity directs PetMeds to undertake a Restatement, and (b) in the case of any Misconduct, such period as the Compensation Committee or Board determines to be appropriate in light of the scope and nature of the Misconduct. The &#8220;Applicable Period&#8221; also includes any transition period (that results from a change in PetMeds&#8217; fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of PetMeds.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means PetMeds&#8217; committee of independent directors responsible for executive compensation decisions, or in the absence of such a committee, a majority of the independent directors serving on the Board.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a) in the case of any Restatement, any person who is, or was at any time, during the Applicable Period, an Executive Officer of PetMeds or an SLT Member, and (b) in the case of any Misconduct, any person who was an Executive Officer or an SLT Member at the time of the Misconduct. For the avoidance of doubt, a Covered Officer may include a former Executive Officer or SLT Member that left PetMeds, retired, or transitioned to an employee role (including after serving as an Executive Officer in an interim capacity) during the Applicable Period.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means October 25, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means PetMeds&#8217; president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person (including an officer of PetMeds&#8217; parent(s) or subsidiaries) who performs similar policy-making functions for PetMeds.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Performance Measure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a measure that is determined and presented in accordance with the accounting principles used in preparing PetMeds&#8217; financial statements (including &#8220;non-GAAP&#8221; financial measures, such as those appearing in PetMeds&#8217; earnings releases or Management Discussion and Analysis), and any measure that is derived wholly or in part from such measure. Stock price and total shareholder return (and any measures derived wholly or in part therefrom) shall be considered Financial Performance Measures.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impracticable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; The Compensation Committee may determine in good faith that recovery of Recoverable Incentive Compensation is &#8220;Impracticable&#8221; (a) in the case of any Restatement, if&#58; (i) pursuing such recovery would violate home country law of the jurisdiction of incorporation of PetMeds where that law was adopted prior to November 28, 2022 and PetMeds provides an opinion of counsel to that effect acceptable to PetMeds&#8217; listing exchange&#59; (ii) the direct expense paid to a third party to assist in enforcing this Policy would exceed the Recoverable Incentive Compensation and PetMeds has (A) made a reasonable attempt to recover such amounts and (B) provided documentation of such attempts to recover to PetMeds&#8217; applicable listing exchange&#59; or (iii) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of PetMeds, to fail to meet the requirements of the Internal Revenue Code of 1986, as amended, and (b) in the case of any Misconduct, in its sole discretion, in light of the scope and nature of the Misconduct.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Performance Measure. Incentive Compensation does not include any base salaries (except with respect to any salary increases earned wholly or in part based on the attainment of a Financial Performance Measure performance goal)&#59; bonuses paid solely at the discretion of the Compensation Committee or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 97.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board that are not paid from a &#8220;bonus pool&#8221; that is determined by satisfying a Financial Performance Measure performance goal&#59; bonuses paid solely upon satisfying one or more subjective standards and&#47;or completion of a specified employment period&#59; nonequity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures&#59; and equity awards that vest solely based on the passage of time and&#47;or attaining one or more non-Financial Performance Measures. Notwithstanding the foregoing, in the case of any Misconduct, Incentive Compensation will include all forms of cash and equity incentive compensation, including, without limitation, cash bonuses and equity awards that are received or vest solely based on the passage of time and&#47;or attaining one or more non-Financial Performance Measures.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; Incentive Compensation is deemed &#8220;Received&#8221; in PetMeds&#8217; fiscal period during which the Financial Performance Measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recoverable Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a) in the case of any Restatement, the amount of any Incentive Compensation (calculated on a pre-tax basis) Received by a Covered Officer during the Applicable Period that is in excess of the amount that otherwise would have been Received if the calculation were based on the Restatement, and (b) in the case of any Misconduct, the amount of any Incentive Compensation (calculated on a pre-tax basis) awarded or paid to a Covered Officer during the Applicable Period that the Compensation Committee determines, in its sole discretion, to be appropriate in light of the scope and nature of the Misconduct. For the avoidance of doubt, in the case of any Restatement, Recoverable Incentive Compensation does not include any Incentive Compensation Received by a person (i) before such person began service as a Covered Officer and (ii) who did not serve as a Covered Officer at any time during the performance period for that Incentive Compensation. For the avoidance of doubt, in the case of any Restatement, Recoverable Incentive Compensation may include Incentive Compensation Received by a person while serving as an employee if such person previously served as a Covered Officer and then transitioned to an employee role. For Incentive Compensation based on (or derived from) stock price or total shareholder return where the amount of Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in the applicable Restatement, the amount will be determined by the Compensation Committee based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the Incentive Compensation was Received (in which case, PetMeds will maintain documentation of such determination of that reasonable estimate and provide such documentation to PetMeds&#8217; applicable listing exchange).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an accounting restatement of any of PetMeds&#8217; financial statements filed with the Securities and Exchange Commission under the Exchange Act, or the Securities Act of 1933, as amended, due to PetMeds&#8217; material noncompliance with any financial reporting requirement under U.S. securities laws, regardless of whether PetMeds or Covered Officer misconduct was the cause for such restatement. Restatement includes any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (commonly referred to as &#8220;Big R&#8221; restatements), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as &#8220;little r&#8221; restatements).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SLT Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any person who has been designated as a member of PetMeds&#8217; Senior Leadership Team, other than an Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 97.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNEX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATTESTATION AND ACKNOWLEDGEMENT OF EXECUTIVE COMPENSATION RECOVERY POLICY</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By my signature below, I acknowledge and agree that&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">I have received and read the attached PetMed Express, Inc. (&#8220;PetMeds&#8221;) Executive Compensation Recovery Policy (the &#8220;Policy&#8221;).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">I hereby agree to abide by all of the terms of the Policy both during and after my employment with PetMeds, including, without limitation, by promptly repaying or returning any Incentive Compensation (as defined in the Policy) to PetMeds as determined recoverable in accordance with the Policy.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signature&#58; ________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Printed Name&#58; _____________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; ____________________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  '4P    +" (    _RG5D   !2DE$051X7NW;
ML0W# !#$,.^_=-RK3/'& >0:@IX'                    OO8#      #8
MU.P!                    ]WK# P      C&CV
M@'N]X0$      $8T>P                   ,"]WO         CFCT
M              #@7F]X      " $<T>                    <*\W/
M    P(AF#P                   +C7&QX      &!$LP<
M      #<ZPT/       PHMD#                    [O6&!P      &-'L
M 0                   /=ZPP,      (S0.0
;     .!/+[(EK+CB\\@      $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pets-20240331_g1.jpg
<TEXT>
begin 644 pets-20240331_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA:ZTK4?BA(]P'THR(Q0Q,TIGE/G;)))&D#2>6@ 3!S[K_P $P_\ @FM\,/\
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M#DG[3HH _)C_ (*D?\$>?V^M(_X*5Z3_ ,%@_P#@D=XO\,+\1GTY+3Q=X/\
M%4R0Q7[I9_8O.C,F(98Y+41QR1NT;*T2R(Y9ODZ/_@BE_P $>/VM_@+^UY\2
M_P#@J/\ \%,?&V@ZM\9_B+!-:6>C>'YEF@TB":2)II'=5$8D*P0PQQQ;ECA1
M@78OA/U$HH _%OX[_P#!'K_@KM^P/_P4/^)G[;/_  17\6>"M2T7XRFZE\1^
M%?%<\$4FDW-U<?:9B([G;#)&EP7EA=7#(LC1&-E&9/IW_@W^_P""._CS_@EO
M\)O&WCC]HWQQI_B3XN_%?6(=0\8WNERO-;V441E:*V25U5II#)<3RRR!55FD
M50&$8=OT'HH **** "O"_P!K#_DMGP/_ .Q[E_\ 29J]TKPO]K#_ )+9\#_^
MQ[E_])FH ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5_/3^QW<?\$NK#]KGXZ#_@MK;ZF?B=_PL6\-
MB_B2/5'T_;YTGF<6.3O+8(\X>5Y7E^7WK^A:OR$_X*R_\%%_^"&6M?M&ZA\(
M?VEOV0M2^*_B?PY<?V=XE\6>%+=+*6SEB.UK07D=U;S7+Q$%2F[RT(*ALA@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -CW+_Z3-7NE>%_M8?\ );/@?_V/<O\ Z3-0![I1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_@F/X/UV2#X:^(M2TJ5[73-0:2*ZAO=0M]*M)1(6;S#%;K<".0DG%PYR<YH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY(V*NCZG$"I'!!!;@U=TC7]!\01//H.MVE\D;;9'M+E90I]"5)P: +=>+_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?#W_!Q'XP^-W@G_ ()<>,=5^"-_J-F\VJ:?;>)[W2I&
M2>#2))MLQ#)\RHSF&-R.L<C@_*37W#7Y"?$3_@W&_;4\>ZGKDNI?\%8M>.E:
MS<7+3Z5=6>I20>1*S$PNIO\ :R;6VD$8([8H K?"_P#X-0?V6_%_PWT'Q9??
MM@^+M2EU32+>\;4-#L;(6=QYL:N)(-RN?+(;*DL<C!K[K_X)D?\ !,7X:?\
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MEL^!_P#V/<O_ *3-7NE>%_M8?\EL^!__ &/<O_I,U 'NE%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M _C+]G;]K2*P^/WP6\.W&BW7C+4M3N8TUJTGSN3[1Y<D@\L%D19$*NDK!B,
MU[/_ ,$;O^";WQ+_ ."?'PE\7WGQ]^*%OXM^(OQ'\3'6_%VIV-Q--"L@#;5\
MZ95DGD+232/*RKN:7&#MW-^*'P%^!W_!'OXQF&Q\8_\ !2GXL?#N_EPOV?QE
M\/E\K?W GL[B>-5_VI"GOCI7[4_\$7/V1_V=?V3O@AXFT_\ 9L_;"LOC+HWB
M/7X[Z?6[&\MIELY5@5/()@ED"M@!BK$,,\B@#[+HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\+_ &L/^2V? _\ ['N7_P!)FKW2O"_VL/\ DMGP/_['
MN7_TF:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$GNU:]DCA,D4!E=%9CF14^5OND ]^HK^;[]J[_@C#^V%^Q'_ ,$P+S_@J_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHK@?VD?VIOV=?V0/AG=?&']IOXQZ#X*\.6F0^I:[>B(2O@D10IR\\I .(HU
M9V[*: .^KQ;]M3_@H9^QU_P3U^'I^(_[6OQQTCPM;2QL=-TR60S:CJ;+_!:V
MD8::<YP"57:N0691S7Y!?M@_\'3_ .TW^U_\1W_9+_X(<_LUZ_K&M:D7A@\<
M:EX?-YJ,JYVM/::?AH[:->&^T798!3EXHR,U>_8K_P"#4;XR_M%?$,?M7_\
M!;K]HO7/%?B35)%N;WP-IGB*2[NINXBO]4+':HY7R;3Y5&-DX VT <5\??\
M@X:_X*E_\%<?B5>_LK?\$2OV:O$7AK293Y5]XQ\B*765MV)4337+'['HT9&1
MN+O)D I,K?+7Y!?\%&OV6_CO^QC^V7XQ_9T_:=\>6_B?Q]HW]G7?BC7+;5)[
MU;FYOM.MM0.;B=5DF=5NE1G8?,R,02,$_P!JWP#_ &=/@3^RS\-K+X/_ +.G
MPFT+P9X9T\?Z-H_A_3TMXMV #(^T9DD; +2.6=CRQ)YKM* /X!Z*_OXHH ^
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M8_\ !&']G-= UJVN/^$K\;Z%KNB^5*#]HLD\.WVZ5,=5'VR#D<?O%]17BO\
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M\:D#Q1X_\5,GVJ>(2&3R(D7/E1M)^\?+.\C@%G(5 H!^='_!I%&OPO\ V_\
M]L_X#>+)1;^([36K826,QQ*18:KJEO<G:><+)<1 ^A<>M._X-?K8_$O_ (+%
M?MM?'_PG(+KPW/KFI)!?P'=%)]O\0W5S;D,.#NCMI&'M7UM_P4)_X-G_ -G?
M]L[]I?5/VNO@W^T9XV^"GC?Q/$T?C.Y\&[7M=8WJ$ED,8>)XI)4 $FV0QR$;
MFC+%V;Z<_P""8/\ P2Y_9L_X)1_L_P GP)_9YAU&]?4K_P#M#Q-XGUR1'O\
M6+O8$#R%%54C11MCB0!4&3\S,[L ?2%%%% 'E_Q6\*?M9ZOXN>\^#_Q7\+Z1
MHI@0)9:MH3W$PD ^=BX(X)Z"O%?BGX:_:;T;X]_!N3XT?$OPYK-N_C<BRCTC
M1FMFC80DN6))R"F0/0\U]=5X7^UA_P EL^!__8]R_P#I,U 'NE%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@'_B*+_P""%7_1\O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (.W/VCN/A'_ ,$XF\%PS_\ 'M<+\(;VQ&T]&\S6[AD;_>QCVH _H HK^?\
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M8$ST.=?G<#ZM7[_HB1H(XT"JHPJ@8 'I2T ?P#T5]_?\0NG_  75_P"C&O\
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MM^!+^_NL?9]$U;5?[*U&0GLMI?"&9R.AVH?UKZ75E=0Z,"",@@\$4 +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M7B?[;/\ P43_ &-_^">/P^/Q$_:U^..D^%X9HV;2])>0SZEJC+_!:VD>99N<
M L%V+D%V4<U^+GQX_P"#@[_@JM_P5\^)%[^RS_P1/_9L\1>%=%E;RK_QBL44
MFLK Y($T]VQ^R:-&1D9WM)D#9,#\M 'ZV_\ !1#_ (+%_L%?\$QO#TEQ^TI\
M88&\2/;^;IO@'PZ%O=;O01E2+<,! C<XEG:*,X(#$\5^._CO_@J/_P %UO\
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MXS@=;7[7"4I03DK-K;MY::?<?T33E*=.,I1Y6TKK33RTTT\M HHHJRPHHHH
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MHQ?D@KZ!^&W_  3,_P""=/P>\M_AC^PG\(M%FCQMN[+X>:<MP?K,83(WXL:
M/QXU;_@\^^//Q1OY-"_9<_X);RZA= [8FN_%UUJLC$],P6EC&5^F\_6JW_#Z
M#_@ZN_:,^3X)?\$P3X6M)O\ CUOD^#NKQ @]#Y^J7!A?ZA0/:OWWTG1M(T"P
MCTK0M*MK*UB&(K:T@6.-!Z!5  JS0!_/_P#\*F_X/7?VDN?%7Q*D\"6,_P#J
MC_;7A?2?+4_]@Y7N1_P/YOTH_P"(;O\ X.!?V@/WO[4__!715MKC_66;_$SQ
M'K!C!ZKY+QPPK]%;%?T 44 ?A#X#_P"#(CP9/=_VM\<?^"BVO:Q/,V^Z30?
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M ,%$/^$GT6S.;/PW8^+;G2#-C[N[3;\R:>?^!3'&<=.:_H,HH _GS'_!>_\
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MWUKB7-/X%-8>#^U/WI_*.R])'D_7.+\ZTPU)86F_M5/>J?*&R?E+[S\^]_\
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MBB@ HHHH **** "O"_VL/^2V? __ +'N7_TF:O=*\+_:P_Y+9\#_ /L>Y?\
MTF:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBO&/VC/^"A7[''[*BS6WQG^.VBV6I0@YT&QF-YJ!/8&W@#R)GH&<*ON,&L:^
M)P^%INI6FHQ75M)?B>EE.39OGV,CA,MP\Z]5[0IQE.3^44V>STCND:&21PJJ
M,LS'  ]:_+7XM?\ !PWXY^)/B _#C]@W]E;5-=U6Y)6ROM?M9+JXE[92PLB6
M/J"9?3*]J_)G_@H__P %B/VV_BWXVG^ FN_&'5O%_B>\O18OX4\.W*MIUI<N
MP5+?[+8_NKFX#'9Y?SNK@JYW J?GEQ/AL76]CEU.5:7=*T%ZS?Z)^1^PS\"\
MYX?R[^T.,L91RRE:ZA.2J8F?;V>'IN[?^*<+?:LKM?O+^W__ ,%Y_P#@G!_P
M3T\+WEQ\0_C7:>*O%$<;#3_!'@>5+^^NI1QL9U;R;< _>,LBD#. QPI_E$_X
M*2?MN^)?^"CG[;/CO]L[Q;X'LO#5YXTN[1ET+3[EYH[."ULK>R@0R. 9'\FV
MC+OA0SEB%0$*/V(_X)"?\&I_B[XGZM8_M:_\%?&O6-V4N]+^$?VQEN)P>4;5
M9HR#"H&"+.(AAP)&3#0G]Y/AY\-OAW\(O"%G\/OA3X#T;PSH.G1"/3]%T#3(
MK.TMD' 6.*)51![ "OH:/M^1>UM?K:]EZ7W]=/1'X[F3REXF2P"FJ:TCS\KE
M)=Y<ME&^_*N:VW/*UW_!%17]8G_!1S_@@W_PN_XQ6'Q<_9'N=)\/?\)#JRKX
MTT6\/E6MIO.7U"W51]2\ QEB"N,L*^W/V-_V-O@[^Q%\';3X1_"/2O[LVM:U
M<(/M6K76,-/,P_)4'RHO [D^;A,;FE;'5*-;#*$([3Y[\W:RY5\]=#[7B+AG
M@3+.%<)F66YU+$XFM\6'^K^S=*WQ>TG[>:6OP6B^=:Z(_'__ (-ZO^"VOP9_
M9;_X)Z?#?]ECX\?#;6;33M!DU<6?B[1I%NE<7&L7MR3-;$*Z!6F9=T9D) 'R
MCFOV:^ _[4O[._[3NA?\)%\!?C!H?B:!4#SPZ?>#[1;@]/.@?$L)]G534?Q\
M_90_9Q_:AT3^POCW\'=$\2QK&4@N;VTVW5N#U\JX3;+#_P  <5\"_'?_ (-W
ME\.Z[_PLG]A/]H?5?"FLVKF:PTS7[N11"_;R;^V FA Z#<DAYY>N#$5.)\OK
MSG",<12;;27NSBK[=G9:=V?891@O SB[*</A<17K91CXPA&522=?"U9J*4IM
M*U2FZDDY-:4X7ZI'Z>45^1%K_P % ?\ @L/_ ,$V[F/0_P!LKX+S^.O"ENXC
M77-2C#;DS@!-5M0R;FZXN%>3U Q7UM^S!_P7 _86_:+^SZ+KWC>7X?Z]-A3I
MGC,+! S]_+NU)@(SP-[1L?[M:X/BC*L34]C5;I5/Y:BY7^.C^^_D>=Q'X$\>
MY)@O[1P-.&88/I7PDE7A;NU'WXV6[<;+N?8-%16-_8ZI91:EIEY%<6\\8D@G
M@D#I(A&0RL."".XJ6OHMS\;:<79[A1110(**** "BBB@ HHHH **** "BBB@
M HHHH **** "LG_A//!O_"=_\*Q_X22T_P"$A_LG^U/['\T>?]C\WRO/V]=G
MF?+GUXJWK^O:-X6T*]\3^(]2ALM/TVTDNK^\N'VQP0QJ7>1CV55!)/H*_ 7_
M (>O>,O^'J__  W7YUW_ ,(]_:W]E_V/DY_X1G/E>1MZ;_+_ '^.GG_-7@9Y
MG^&R1T54UYY6](]9?+0^8XCXGPG#CH*KK[223\H_:E\KKU/Z!:*J:!KVC>*=
M"LO$_AS4H;W3]2M([JPO+=]T<\,BATD4]U92"#Z&K=>\FFKH^F34E=!1113&
M%%%% !1110 4444 %%%% $5[96>I6<NGZC:17%O/&4F@GC#I(I&"K*>"".QK
MY/\ VEO^"%'_  28_:P^T7?Q5_8B\&VVHW.6DUKPC:-H5XTA_P"6CR:>T/FM
M_P!= X/<$<5]:T4 ?B/^T1_P95?LZ:K>/XF_8[_;&\9^!]0BD\ZSL?%NG0ZM
M!'(#E5CFMS:RP@'&&/FL/>O*O^&"?^#N'_@FO^]_9N_:@N/B[X;L.8].M/%\
M.MQK /X!9:\BR1\?P6V2"?E/>OZ#:* /P!\-_P#!V#_P4I_8]UNW\#_\%/?^
M"8TMI,'\DWUM8:CX7NI .L@CO8YXK@XY_=F-3U! K[,_9I_X.SO^"0OQY^SZ
M=X\^('BCX6ZG-A?LWCKPU(8#)W N;$W$2KZ/*8QCJ >*_23Q)X8\->,M$N/#
M7B_P]8ZKIMVFRZT_4K1)X)E_NO&X*L/8BOC/]I;_ (-V/^"/?[4/VB^\4_L:
MZ#X8U.?)&K_#V230I(W/5_)M&2W=CUS)$_//6@#Z@^!_[4'[-O[3.A_\))^S
MK\??!OCFQ"!Y+CPGXDMM0$0/9_)=BA[$-@@\$9KNJ_"WXX_\&6V@^&];_P"$
M[_8._;W\3>%=4LW,FF6GC/31-)&_;;J%@T#Q8]1 Y_KPO_"EO^#Q'_@FISX%
M^)=[\;O#%AP\<6LVWBM)D7[JK'J*QZF!@<"(#'3TH _H,HK\#_AY_P 'A/[4
M?[/OB6+X<?\ !2W_ ()I7^A:LG%Y/H)O-#NXP#AB-.U-'+G_ +;H ?KQ]P_L
MU?\ !TC_ ,$<_P!HS[/8:E^T!?\ PYU2XQMTSXD:#+8A2>NZZA\ZT7'^U,/Y
MT ?H?17XN_\ !S#_ ,%K/VB_V2?#?P#\9?\ !,#]LCPW'H_C?_A*/^$BU7PO
M:Z)XAMK[[(-(-MB6XAN5CV_:I_\ 5E=V_P";.U<?E/\ \11?_!=7_H^7_P Q
MGX8_^5E ']?5%?R"_P#$47_P75_Z/E_\QGX8_P#E97T__P $_P#_ (.]OVG_
M (*_#/XH:K^WKK&K?&?Q;>?V0GPHT>UT+2-$LK)@+[[?)=W%E;1-L.;+"^7*
MQ*$+Y8+-0!_2AK^OZ#X4T2[\2^*-;M--TVPMWGOM0O[E88+:)1EI))'(5% !
M)8D  5^2'_!2?_@[:_9:_9^U"Y^#/_!/[PLOQK\>R3?9(-9A,B^'K6X)VJ$>
M/$NI-NP D&V-LC;/GBOD30/V0/\ @O\ ?\'(^MVGCW]K7QU/\&O@5<W"7.GZ
M5=V$UCI\D.=RO9Z2'$^H. 0R7%VX0ACLEQ\M?K?_ ,$V/^"%O_!/S_@F)I]M
MK?P<^&"^(/'20[;KXC^+U2[U5F(PWD':([-#DC; J$K@.SD9H _*7X6?\$7/
M^"T__!=3QWIW[0W_  5P^/.M_#?P%YPN=(\)WUL([Z.%OX;+1UVPZ?E?D,UR
M!/PI9)NM?LM^P)_P2H_8:_X)I>#_ /A&_P!E7X*V6FZE/;B+5O%^IXN]:U,<
M9\^[<;MI(SY4>R('E46OHJB@ HHHH ***\F_:4_;F_91_9'T]KKX]_&K1]%N
MO+WPZ,LQN-0G&."EK$&E(/3<5"C/)%95J]'#TW4JR48KJW9?>S'$8G#X2DZM
M>:C%;MM)?>SUFJ'B;Q3X8\%:%<^*/&7B.PTG3+./S+O4=3O$@@@3^\\CD*H]
MR:_+;XP?\' WQG^-_BAOA-_P3G_9>U75=3N24MM6UG3GOKQES@R1V-L2L8'7
M?)(ZX/S(.:PO#/\ P1__ ."EG[>NNVWQ"_X*)_M*76@Z>9/.BT*6Z6^NH0>2
M(K2!EL[3(.,J2P[IQBOFY\30Q,W3RRC*O+NO=@O63_I]SY&IQC#%S=+)Z$L3
M+;F7NTUZSE^BUZ,^AOVIO^#@C]C'X&_:= ^#WV[XFZY%E5&B-]GTU''9KR13
MO'3!A253ZBOFK_A;/_!<W_@JA^Y^&6@3?"SP#?\ "W]J9-&M9(3T8W;[KNZ!
M'!\@%#SE1TK[O_99_P""27[#7[)GV;5?!7PC@UW7[?!7Q/XN*W]X''1XPRB*
M!O>*-#SR37TK4_V3G>9ZYAB.2/\ )2T^^3U?FMNQ']A\19QKFF*]G!_\NZ/N
MKT<W[S\UMV9^<W[,/_!N?^SKX"N(O%O[4WC[4_B+K+/YL^FVSO8:;YA.3OVL
M9YSG^(R(&YRG-??'PS^$WPP^#'A>+P3\)/A]HWAK2(.8].T33H[:+.,;BL8&
MYCW8Y)[DUT-%>U@,HRW+(VPU)1\]V_5O5_>?0Y7D649-#EP=%1\]Y/UD[M_>
M%%%%>B>L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?CO_P %M?\ @M%^V;\!-8\8_LE>!OV;]=^&VI:7K-I-HOQ?
MT?Q:US#?:>6$D;I$VGHBF9#L9/.8QN'3+%<G]B*^9O\ @KG\>/V;/V</V(O$
M/Q/_ &I/@KI_Q%T""^M(=.\%:G#&T6J:B\G^CH3(K+&%(:0OM8JL;$*QPI /
M@+P;_P '0WQZTOP5I6EZA_P2X\4:Q=V^EP13ZR_C>X'VZ18U!N"HT@XWD%\!
MC][KWKZ4_P"" 7Q2_;A^./PQ^*/Q@_; C\70Z;KOC@3> K+Q@\YDM;4QLTL5
MOYZJYMTW1(K !69'QR&KYJ\$?\%^O^"GNL^$M.OOA3_P1YU>Z\-FSC71)=(\
M/:W<6WV4*!$(Y(K?8RA-N"O&,8K[R_X)8_MG_M1_MI?#7Q/XO_:E_92U'X3Z
MEHVN1V>F:9J.F7UJU] T(<S 7<:,P#$KE01QZT ?4M%%% !17P#^UM_P<%_L
MV?LW?\%'_AC_ ,$UO _@YOB!XI\;^+M+\/\ BG5=&\01Q6_A.ZO[Z&TBBF'E
MOY\RB1I'A#(4 0$Y?Y?JW]M;]JWP-^P[^RKXX_:R^)&EW=]HW@?16U"[L+!D
M$]T=ZQQPQER%#O(Z*,G&6H ]1HK\4?\ B-P_8N_Z,X^*'_@=IW_QVOO_ /;\
M_P""P?[+_P#P3H_8_P##7[6OQRMM6G'C6TM6\'^#M)2-]2U.>:W6?RQN941(
MT8&25CM7@#<SHC 'U?17YK_\$\/^#E;X ?MJ?M-Z=^Q]\8_V;O&WP3\=^([<
M3^#[/QD0]MK *&2.,2&.)XI)(P6C#1^7)M*K(6**_P"E% !17PA_P56_X+W?
ML^?\$R/B?X?_ &<;#X2>*?BM\5_$MHEW9>!/!JJ)+>W=F6)II-KLKRE'V11Q
MR.0I9@H*%^A_X),?\%MOV;_^"L4/B?PAX*\&Z_X%^(7@HAO%/P_\5*GVJ"(R
M&,SPNN/-C63]V^51XW(#( R%@#[.HK\T_P#@H7_P<N? #]C']IW5/V0/@S^S
M9XW^-GCCPQ 9O&=MX.(2VT<*@DDC,@CE>62)&#28C$<9(5I P=4^F_\ @F!_
MP5'_ &;/^"KO[/\ )\=?V>9M1LI-,O\ ^S_$_AC7(T2_T>[V!PD@1F5XW4[H
MY5)5QD?*ZNB@'TC1110 5X7^UA_R6SX'_P#8]R_^DS5[I7A?[6'_ "6SX'_]
MCW+_ .DS4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5_N[?(^BX<XMXFX0QOUO)<94P]3JX2<;^4EM)>4DUY'Y%7W_  3B_P""NO\
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M?20A"E!1@K)=%HCZZG3IT8*%-));):)?(****HL**** "BBB@ HHHH ****
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M6EF\'G'(:/2+?:1<,,$F[D'E*%9D5UQ*OSS\2_VF?^"MW_!U-\7[WX%?LO\
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ME?Q>UZ/^RA^U?\<?V*OCCHW[0/[/WC*?1]>T>=6(5V\B_@W R6MS&"!-!(
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M&J6IZ7.G7B3QG_@2$BOA#QY_P;B?L&>)]\WA+Q'X]\-2'/EQV.N0W$(/NMQ
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M#R*A@*LJ,W[9+W82C).^RW5K)ZO78^M?@/\ \&[7_!OQ^T1\&_#7QO\ A_\
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ML_S/7&U_90_DI;_.;U^[0Z_[)XHSG7,<3["F_P#EW1W^=1Z^MKIGYC_L\_\
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MHH **** "BBB@ HHHH *\+_:P_Y+9\#_ /L>Y?\ TF:O=*\+_:P_Y+9\#_\
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MUM%"V8V=-LCR(X#!!\_X^'XJ?$\^+/\ A/3\1]>_MWS?-_MK^V)_M?F9SO\
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M6RZYX!^(WACP+IIF)M]$T+P=974:QYX5Y+^.>1CC&6!4$\@+TKZQ_P""8/\
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M,WPKUC2]<CM=&TR;0KZP-[;&$.TVV\8LV')7*\<>M 'U+1110 4444 %%%%
M!1110 4444 %%%% !1110 5X7^UA_P EL^!__8]R_P#I,U>Z5X7^UA_R6SX'
M_P#8]R_^DS4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%<C\7OC]\$?@#H?_  DGQK^*^@>%[,J3%)K6J1P&;':-6.Z1O]E
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M"(@.*]J\-^&_#O@WP_9>$_"&@66E:5IMK';:=IFFVJ06]K BA4BCC0!415
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M/6CZEX%^%5U<?9O[!T^9C?ZXK'"_;YHN7W<8M(LIDX;S2H<>L_L]_P#!$O\
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M;\S])IP=.G&+;=DE=[OS=K*[ZZ(****LL**** "BBB@ HHHH **** "BBB@
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MV?61C&$5&.R"BBBN4H**** "BBB@ HHHH **** "BBB@ HHHH *_&G_@N?\
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MU^(>),^XLS268YQB)5Z\DDYS=W:*LEV22Z+S>[84445TGB!1110 445\+_\
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M&X^&/PTU"?P7X+U[3+O3UU/5X-*>WM[.WCN$\YHVS<2M*%8+)*H7)P!]7?\
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M9K5-;I]T?"'[5O\ P0!_9#^.'VGQ'\%)KKX9Z]+EPNDQ_:-+D<_WK1V'ECH
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M?T;?\'7_ .R!XU^._P"Q?X7_ &AO 6CS:A/\)-;N;C6[6WC+/'I-['$EQ<
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M<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]OJ5M-_8R_9UD\(>'[IBL6MV.G"7"GJ&U*_"V^0/^>:(X[<XK8\ _P#! /\
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MC'7GI7I%,N+:WNXC!=6Z2H2"4D0,"0<C@^A /X4 ?S#_ !Q_;U_X*&_MJ_\
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M7'B.[UI@EE"<RJ+[6-.M[=B!R SV\P!_V&]#7[IW?BCPS8:O#X>OO$5A#?W
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M$+U.D:/+> ?C'#+7FOB7_@C[XG\'%AXL^&7Q4TG:2&_M/07AQCKG?:BOFO\
M6[*X?Q8U(?XH2_2Y^7?Z]Y+'^/"K3_Q4Y?I<_KP_X6S\*_\ HI?A_P#\','_
M ,75FQ^(/@+5 S:9XWT>X"$;S!J43[<^N&XK^.32?^">OP*%XUMXM\?>,K *
MV&%I96L[CZJYB_G78:5_P35_8"U QKK'[6'Q>THD?O##\)=+OES]?[:A('X&
MM:?%O#M3;$+YJ2_-(VI<=<*5=L4EZJ2_.*/Z\O\ A+/"O_0S:?\ ^!J?XT?\
M)9X5_P"AFT__ ,#4_P :_E$\-_\ !(#_ ();ZX5&I_\ !57QWHV3S_:7[/;-
MM^OV?59?TKOO#?\ P0._X)0>*0O]G_\ !=1("1RNI? R]M,>Q,UXH_6NZGGN
M2U?AQ,/_  )?JSTJ7$O#U;X,73_\#BOS9_4+8ZQI.J%ETS5+:X* ;Q!.K[<^
MN#Q5BOYJ=*_X-=O^"??C 1IX1_X+\_#Y)&./*OO!]BKOZ!4?6XV_0UVWAS_@
MS*^$/C':?"/_  67\-ZKO&4_LWX7V\^X>VS73FNZGBL+5^":?HTST:6-P=?^
M'4C+T:?Y,_H@HK\ _P#B!F_ZRA_^83_^_5'_ ! ^>(M(_?\ AO\ X*D;)6^6
M0_\ "H'@^7ZKK#$\XXK<ZC]_**_ /_B";^*G_25#_P QE/\ _+6C_B";^*G_
M $E0_P#,93__ "UH _?RBOP#_P"(*[XX:5_I7A[_ (*J;;C[I/\ PKVYA^7O
M\RZFQ].,4?\ $&C^U/\ ])7/_+2OO_EA0!^_E%?@'_Q!H_M3_P#25S_RTK[_
M .6%'_$'!^U]IO\ I>A_\%8-MRO"'_A&M0BX/7YEOR1Q[4 ?OY17X"?\0@W[
M?7_26H_^ .J__)='_$(-^WU_TEJ/_@#JO_R70!]^_P#!T7_R@J^.7_<L_P#J
M3Z37\@M?K[_P5&_X-Q/VN_V"_P!A3QS^UA\4/^"A_P#PG6A>%/[,^W>%?LFH
M+]N^U:G:6:<S7#H-CW"2<J?]7Q@X(_(*@ KZ"_X)7_L/VW_!1[]OKX>?L8WW
MCY_"]KXRO+TWNN160N)+>WL]/N;^4)&64%WCM6C4DX5G#$$ @^#:EHVJZ-]G
M_M6PE@^U6R7%MYJX\R)L[7'J#@\^U?>O_!KI_P IU?@;_P!S-_ZC&K4HRC)7
M3NB8RC.-XNZ/ZC/V#_\ @GA^R?\ \$W?@U#\%/V5/AG;Z+9,$?6-8N,3:EK5
MPHQ]HO+@@-,_)P.$0,51$7Y:]NK@OV@/VH/@!^RSX1/C?X_?%32?#5B0WV<7
MT^9[HCJL$" R3M_LHK&OS?\ CG_P7?\ V@_VDO&+_ S_ ()C? '5KO4+K*1>
M(M0TK[9?%<X,L5HNZ*W0'!\V=G4 _,B8KR<QSS+LK]VM.\WM&.LG\E^MD>)F
MW$F4Y-:%>=ZCVA'WIOTBN_G9>9^DWQW_ &D?@3^S)X/?QW\>OBCI/AG30&\J
M34;G$ERP&2D,2YDG?'\,:LWM7YP?'W_@O=\9OCUXO;X&_P#!,KX":MJFJWA:
M.W\1ZEI)N[QQT,L%DFY(U'!\V<LH!^:-:C^!'_!!KX[_ +0_C!/CG_P4X^/N
MK7^I7962;PYIVK?:[UESD137C;HX4!R/*@#KM/RNE?I!\ _V9?@)^R]X07P-
M\ _A9I/AG3\+YXL+?]]<L. \TS9DG;_:D9C[UY5^(\Y_ZA:3^=1K\H_FO,\.
M_%G$&W^QT7_V]6:_*'_I2\S\V?@E_P $*OVE/VH/&,?QS_X*=_'_ %::]N<.
M_AVPU07E^4SGRI+D[H;5 >/+@5Q@X#(:_1_]GG]E;]GO]E/PF/!GP ^%6E>&
M[-E47,MI#NN;LCHT\[DRS-[NQQVP*]!KEOC1\;OA'^SK\-]3^+_QR^(6E^%_
M#6CP^9J&L:O="**,=E&>7=CPJ*"SL0J@D@5[63<-X7#8B-/!TG4K3:2=G.I*
M3T26[;;Z):OH>UE7#F49)>I1A>;WG)\TWW;D]O.UD=37YV_\%8?^#A?]G7]@
M3^T/@S\$4LOB/\6TW0-HUI<EM-T*;H/MTT9RT@/_ "[1GS."':'*D_'G[77_
M  6L_;D_X*U_%FY_8@_X([?#GQ#I7A^\W0ZQXSB7[-J5Y:YVM.\Y(72;/G[Q
M83/\HW(6,)^P/^"3W_!O-^SO^P0=/^-'QTDLOB1\6TVSKJ]W;E]-T*;J?L,,
M@R\@/_+S(-_ *+%E@?Z>P'AQPIX98.GF_B+)SQ$DI4LNIR_>S[2Q$E_!IO\
ME^)^JE WGC*^-DZ>#VZS>WR[O^O,^/?V1_\ @BQ^W/\ \%<?BQ;?MO?\%AOB
M-XATCP[=[9M&\&RG[-J5Y:D[E@CM\!=)LSG[NT3/\QVJ7$Q_:WX*? [X0_LY
M?#;3?@_\"_AYI?A;PSI$/EV&D:1;".*/U8]W=CRTC$NY)+$DDUU5%?G/'WB?
MQ)X@584L2XT<)2THX:DN2C2BM$HP6CE;>3N]TK1T79A,%1PB;CK)[M[L****
M_.3L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "OF+]JW_ ()#_L2?M9?:=:\1?#1/#/B.XRQ\3>#]EE<.Y_BE
MC"F&<DXRSH7QP&%?3M%<V+P6$QU+V>(@IQ[-7_X8]SA_B;B'A7'K&Y/BJF'J
MK[5.3BVNSMI)=T[I]4?D3K'_  3;_P""KW_!-G5;CQE^PM\;+KQGX9CE,T^A
M:>0LDB]3YNF7!>&9L?+NA9I3R0%KT']G7_@X<TC3-<_X5E^WA\#M2\&:W:2B
M"_UC1;&8Q0R=_M%C-^_@QWVF4G/W17Z:UYK^T3^Q[^S1^U?H?]A_'WX/Z1X@
MV1E+:_F@,=[;#_IE<QE98QGG"L >X-?-OA[&Y:^;*<0X+_GW/WH?+K'Y79^U
M1\8^&>-(JCXA91#$S>GUO#6H8I><DK4ZK71248KLS:^#'[0'P3_:)\++XT^!
M_P 4-%\3Z<<>9/I-ZLC0,>0LJ??A?_9<*WM785^6'QG_ ."!/Q@^"?BEOB]_
MP3F_:2U32=3M27MM&U?4GL[M!U,<5];@*X/39*BJ0/F<UB^"/^"R?[??[$'B
M6V^%O_!1[]G"_P!5MU;RX]=6S6QOI5'!>.6,&TO@!_<V9.<R$TX\25\!)0S:
M@Z7]^/O4W\UJO1W\R:O@GEG%E*6)\/<VIX]6O]6JM4,7%=5R3:C4MUE%Q3^R
MF?K317A7[+'_  4E_8Z_;"AAM/A!\7+-=:E4%O"VMXL]20XR5$+G]]CNT)D4
M>M>ZU]+A\5AL7252A-2B^J=T?B&<Y'G/#N/E@LTP\Z%:.\*D7&7K9I:/H]GT
M"BBBMSR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4_ ]M6T3QG=:"WA[68_%.E6^([/0;"TDS#<74<@_?Q3J0RC(12#C!/Q!X_\
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M_P#@@9\6OC?XN7XX_P#!3+X]:KK&K7A62Y\.Z;JS75TXZB.XOGW!%'(\N $
M'Y9%K]'_ (&?LZ? W]FCP<G@+X$?##2/#&EKCS(=-M@KW# 8#S2G,DSX_CD9
MF]Z[2BOTC+LDR[*]:$/>>\GK)^K?Z61^N93P[E.2IRP]/WWO.7O3?K)ZZ]E9
M>0450\4>*?#/@CPY?>,/&?B&QTC2=,M7N=1U/4[M(+>UA09:221R%10 26)
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MU'3?B4GQ"NX;31O$>MW6FV!B261) ;B':5:-E6)8FD14C1 JL,[0#];/"?\
MP6W_ ."4_C36(]#T?]MCPE#/*P5'U5;FPA!/K+<Q1QK]2PKZ=T+7M#\4:-:^
M(_#.LVFHZ=?0+/97]A<+-#<1,,JZ.A*NI'(()!K\C/B5^R#_ ,&I=KX0N[M/
MC!X3TGR[8@WGAKXK:G?WB'!^>.$W%QO?V$;#('R]J[G_ (-:_$'C*]_9N^*G
MA6QUK5]2^&VA_$F2#X<WNL(5<Q-&7G51T3Y3;R,B_*))I#C+'(!^HM%%% !1
M110 4444 %%%% !1110 4444 %%%% !7A?[6'_);/@?_ -CW+_Z3-7NE>%_M
M8?\ );/@?_V/<O\ Z3-0![I1110 4444 %%%% !1110 4RZM;:]MI+.]MXYH
M94*2Q2H&5U(P00>"".U/HIIM.Z ^9/V@_P#@C5_P3%_:<\^Y^*/[&_@]+ZXR
M9-6\-V;:/=LY_C:6Q:)I&_W]P[$$<5\-_'S_ (-"/V:/$$\FM_LO_M0^,?!5
MXK^;;V?B.RAU>VC<'*JCQFVEC&<?,S2,.O/2OU_HK])X;\8?$_A.T<MS6M&"
MVA*7M(+TA4YX+Y(XJV78+$?'37Y/[T?A;_P[S_X.>?\ @G_^_P#V8OVJIOB5
MH5GS;Z7:^+X]01(1_#]BUQ D?'\$!8\\'-3Z7_P<F?\ !43]CO48?#7_  47
M_P""=),:2"(ZE_95_P"&YY_]L/,D]O.>X\M44] 1UK]RZ@U32M,UO3YM(UK3
MH+RTN(REQ:W4*R1RJ>JLK AA[&OMO^(W91GWN\6\.8/&7WJ4HRPM9^;J4[W?
M_;J.;^S*E+_=ZTH^3]Y?<S\X?V?/^#I[_@F!\7_(L/B;JGB[X:7\F%D_X2?P
M^US:;SV6:Q,YV_[4B1CUP.:^X?@9^US^RW^TU8KJ'[/?[0W@WQFICWO#X=\1
M6]U-$/\ II$CEXS[.H(]*\6_:#_X(@_\$L_VE?/NO'G['GA?3=0GR3JO@^)]
M$G#G_EH?L31I(W_717![@U\/?'/_ (-!_@W-?-XE_9)_:^\5^$KZ"3SK.S\5
MZ=%J*)(.0$N+8VTD(!Z,5D88[]:/[.^CIQ/_ +OC,7E-1]*M-8FBGY.G:K;S
MD'/F]#>,:B\GRO\ '0_8ZBOPM_X8X_X.G/\ @GW^\^!G[0MQ\5?#]E]VSM_%
M$.MH(1T06VM(DR>FRWR1V/>KGA[_ (.>?^"@'[+&L0>#O^"C'_!.>2TFW^4U
MW;65_P"'+EP.L@BO$FCG..?D:-3U! J9?1\S[-8NIPKF6$S..ZC1KQC5M_>I
MU.7E?ES-C_M:E3TKPE#U6GWH_<:BOSM_9\_X.@O^"5_QJ\BP\;>-_$OPWU";
M"^1XS\.NT)?N!<61GC5?]J0Q\=<=*^V_@Q^TM^SO^T9I']N_ /XY^$?&=H$#
M/+X8\0V][Y8_VQ$[%#V(8 @\&OR[B+@+C7A*36<9=6H)?:G3DHOTG;E?R;.V
MCBL-B/X<T_F=O1117R1T')?'C7OBGX9^#?B76_@?X'_X23QA!I$O_"-:*;N"
M!;B](VQ;Y)W2-45B';+#*J0,D@'\&]?_ ."*'_!6;Q5KU[XG\1_LWS7NH:E=
MR75_>7'CG1&DGFD8N\C'[;RS,22?4U_0C17S^=<.8//I0>(G-*-[*+26N[UB
M]3Y;B+A/ <33IRQ52:4+V47%+7=ZQ>NW4_GC_P"'&7_!4W_HUW_R]M#_ /DV
MONS_ ((@?LJ?\%$OV)_B/XC^'GQ^^!,VE_#_ ,4V@NC?#Q3I=TNGZG",))Y4
M%T\A66,F-BJDY2(G 4D?IA3998X8VFFD5$12SNQP% ZDGM7!EW!>6Y9C88FA
M4J<T>[C9]+/W=F>9E7A[E&39A#&8>M5YX=W&SZ-/W%HUYCJ^?/\ @H'_ ,%-
M_P!D_P#X)M?#?_A-_P!H;QPHU2\A9O#W@[2BLVJZPXXQ%"2-L8/#32%8UZ%M
MQ"GXE_X*C?\ !R9X*^$>O3_LN_\ !-W28?B9\3;VY_L[_A([&V:]TS3KISL6
M.U2/)U*YW'"A,PABN3*0T=><?\$_/^#=SXQ_M*_$?_AMS_@L_P"-]7\1:_K$
MR7T?P^O-3:2YN.Z?VE.A_=1J,!;. @*NU69 &AK^J^'?"7+<BRFGQ'XA5Y8/
M!RUI8>/^]8FW2$'_  X/K.=M+?"I*9]/6Q\ZM1T<(N:75_9CZOJ_(\;DN?\
M@K#_ ,'-_P 23!:H_P +/V=].U/YB?-.EQ[&[GY'UB]4#I\L,;8_U&[+?L!_
MP3V_X)?_ +)W_!-;X=?\(?\ L_>"0^L7L"IXA\::L%EU75V&#^\E &R($96&
M,+&O7!8EC[QX3\)>%? 7AFP\%^!_#5AHVCZ7:I;:;I6EVB6]O:0H,+''&@"H
MH' 4  5H5\_QWXMYEQ1@(Y'E-". RFG\&&I;2_O5I[U9O1MRTOK;FO)ZX7 0
MH3]K4?/4>\G^G9!1117Y&>@%%%% !1110 4444 %%%% !1110 4444 %%%%
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MC\MH+C#/XKN ;0*#U8:;=F<K[ 9XZ5^Z_P"QEKG[)VO_ +.'AN]_8CG\./\
M#9;9DT!/"\7EVT8#'S%9" Z2[RQD$@$F\DO\Q-?FK\3_ /@J?_P;3:GX2N[2
M;]C_ ,.Z]O@<+9Z/\$+.UN6..D<SI#Y3'LP=2,=17>?\&NOP^\<Z!^S=\4/B
M4?"6H^'_ (?^,OB&UY\.]'U&9W*6T<9221&;F1<>3#YO\;6S?W: /T_HHHH
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M.GQY\-37O[-OQ;\)>+-(T:1+*>3P?K%O=V]DP0%(3Y#%8SLQA>.,<5\50?\
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MDOS"BBBOYA/;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'/A'79="\=^&07V6M[&H;S(Q)\ZQN"?D?YD=)$);:';\^['_ ((>>!?V,?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY&(&Y6K\TO'?[%7_  4C_P""//BR]^,7[&?CJ]\<?#LRF?5M*2U:;$0Z_;K
M'YL*,?:8"& !),0.*\+ZQGG#VF(3Q%!?;7\2*_O+[27??JWT/U?^QO"SQA][
M)90R?-I?\P]1_P"R5I?].:F]&4GM!KEO:,4]9'["45\8_L&_\%K/V:OVOOL7
M@3Q[<1> ?'<VV-='U:['V/4).G^BW)PK$G&(GVODX7S,;J^SJ^EP.88+,J"K
M8::E'RZ>36Z?DS\1XJX/XEX)S6679WA94*JZ26DE_-&2O&<?[T6UYA11178?
M-A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5RW@?XY?!7XF>%Y_''PY^+WAC7]&M;Y[*ZU;1M>M[FVANDV[X
M'DC<JDJ[ERA(8;AD<UU-?S:_MN_L=_\ !57_ ()X_L@>//V8?B#X9TR]_9\N
MOB)%JT?BJWNK"5[J[=XX[>5<2_:HC((8MT;QX5E..#N(!_23')'-&LL4BLC*
M"K*<@@]"#2U^,7PU^-O_  =16WPZT"V\#_LV>&9M$CT2U71YGCT/=):B%1$Q
MW7P.2FT\@'U%??'_  2Q\8_\%,?&7PU\3W?_  4U^'FG>'?$4.N1IX;M].6R
M"RV7D@LQ^R32KGS,CYB#[8H ^I:*** "OFW_ (*\_MC^)OV O^"<7Q2_:Q\#
MFQ_M_P +Z+"OA]=2@\V W]S=P6D&^,$%U$DZDKD9 -?25?&__!=/_@GG\=_^
M"GW["LW[*?[/_P 1O#GAG4KWQ98:EJ5UXI:X6UN;2V69_(W6\<CJQG-N^=I&
M(SWQ0!^=GP(_;P_X/!_VF/@]X=^/GP4_9%^&6L>$_%FF1ZAX?U5YM#M#=VS_
M ')/*N=7CE0$#(#HIQ@XP17UK_P6Z_X+(_'?_@F3^SA\)_ 'PO\ ASI6M?M!
M?%Y(K/3]+O8_/M-,GCCMTNY?*BDQ,YN+B.&%-^QF9F+.(RC_  #_ ,%!_P#@
MG'_P4=_X('_LL>!?VX_@+_P5F^('B>Z\':GI.@ZYX0OY;F/1H+8QF."&"UEN
M98IK2-HUA^SR1XVN'&PKMK._X*R_M&3_ +7O_!3'_@F?^T]KFBKINF^/=!\$
M:W=:;N)AM+FX\0PR7<2EOO*I*J">2H4GK0!]*_L]?\%??^"N/["7_!1[X;?L
M)_\ !:;PYX*U/2?C*MK'X8\6>%+>")],NKJ<V\"F2W"PR1K<[8949 R"1)1(
MR#$G[05^#O\ P=T_:#^W5^Q@/#F?[8_MR]^S^5]_=_:>D^3CO]_=CWS7[Q4
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M>"=,T3X,BYB\1^*O%5O!*^JW5M/]GF427(:*-'N \,*(FYQ&TK2*IQ']-_\
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M6A*D+L)Y4'<<]A0!]=4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X_P#M<?L)
M_LU?ML>$_P#A'/CGX!BN;R"(IIGB*PQ!J6GYS_JIP"=N3GRW#1D\E3@5[!16
M-?#T,52=*M%2B]TU='HY3F^:9%F%/'9=7E1K0=XSA)QDGY-:^JV:T>A^.WC#
M]E+_ (*7_P#!&+Q->?%/]ECQE<>/?ACYQN-5T]+1YH5C'4WMB&+1D*.;F!N
MN69 =E?9/[!W_!9C]F7]LL6?@GQ#>)X&\=S;8QX<UF[7R+Z3_ITN2%64D](V
M"2=<*P&ZOL"OB3]O'_@B!^SE^U6UY\0?A(D'P\\=2EI6O=,M1_9VHR]?](ME
MP%8GK+%M;)+,LAP*^5>49ID<O:95+GI]:,WI_P!N2>WH].]S]^I>(G GBE3C
MA/$"A]7QMK1S##P2DWT^LT8V51=Y07-:RBHJ[/MNBOR ^'/[??\ P44_X))>
M,++X(_MV_#W4?&?@?S/)TK67NC--Y*][*_/RW"A>?L\^'4;5S$.*_3']E_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#29J]TKPO]K#_DMGP/_P"Q[E_])FH ]THHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1H7=MB N=S,6=I'8X!"J ?5-%%% !1110 4444 %%%% !1110 4444 %%%%
M!7A?[6'_ "6SX'_]CW+_ .DS5[I7A?[6'_);/@?_ -CW+_Z3-0![I1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>*+.\UZTM9B@N9=0U6'3(I#_ +<40N@A[?:']: /U=_9+_X*=_L!_MU:Y?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X4_P#!USX;UK]G
MW]OW]D+_ (*,ZGH=W<^$O"7B:SM==O+6 N+:73]6@U..)O1Y8FN2@_B^SOZ5
M^ZU<O\9O@E\(/VB?ASJ/PA^.WPTT7Q=X8U>,)J.A>(-.CNK:< AE)1P0&5@&
M5AAE8 @@@&@#\#?^"T'[2/P&_P""R?\ P5Y_8_\ V<?V&_B+:?$&RTC4HY]>
MUK08Y'M[2*YO[:XN=Q90<P6=BTT@Q\H(4_,&4?LO\7O^"H/[''P+_;2\'?\
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MWO\ !/\ Z&WQW_X65S_C7NE% 'A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\
MH;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\ "RN?\:/^'>_P3_Z&WQW_ .%E
M<_XU[I10!X7_ ,.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C7NE%
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M_P"AM\=_^%E<_P"->Z44 >%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\
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M#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\
M"RN?\:/^'>_P3_Z&WQW_ .%E<_XU[I10!X7_ ,.]_@G_ -#;X[_\+*Y_QH_X
M=[_!/_H;?'?_ (65S_C7NE% 'A?_  [W^"?_ $-OCO\ \+*Y_P :/^'>_P $
M_P#H;?'?_A97/^->Z44 >%_\.]_@G_T-OCO_ ,+*Y_QH_P"'>_P3_P"AM\=_
M^%E<_P"->Z44 >%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\ X65S_C7N
ME% 'A?\ P[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/^->Z44 >%_\
M#O?X)_\ 0V^._P#PLKG_ !KROPG^R'\.-4_:[\7?"JZ\5>,/[+TKPK87MJ4\
M4W F\V5V#;I,Y9>.!VK[(KS[PY\&=3T3]I+Q)\<9=:@>TUSP]9Z=%8K&PDB:
M%B2Y/0@YH XS_AWO\$_^AM\=_P#A97/^-'_#O?X)_P#0V^.__"RN?\:]THH
M\+_X=[_!/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\ &O=** /"_P#A
MWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&O=** /"_\ AWO\$_\
MH;?'?_A97/\ C1_P[W^"?_0V^.__  LKG_&O=** /"_^'>_P3_Z&WQW_ .%E
M<_XT?\.]_@G_ -#;X[_\+*Y_QKW2B@#PO_AWO\$_^AM\=_\ A97/^-'_  [W
M^"?_ $-OCO\ \+*Y_P :]THH \+_ .'>_P $_P#H;?'?_A97/^-'_#O?X)_]
M#;X[_P#"RN?\:]THH \+_P"'>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\
M"RN?\:]THH \+_X=[_!/_H;?'?\ X65S_C1_P[W^"?\ T-OCO_PLKG_&O=**
M /"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X)_\ 0V^._P#PLKG_ !KW2B@#PO\
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M*Y_QKW2B@#PO_AWO\$_^AM\=_P#A97/^-'_#O?X)_P#0V^.__"RN?\:]THH
M\+_X=[_!/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\ &O=** /"_P#A
MWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&O=** /"_\ AWO\$_\
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M>Z9:Z-XIL0\>K>()8E']JW]PI=F-JPWX1LI%)-"B8Q6'_P ' 'Q/_:<\'?\
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MX?5#=V]O(R^<B"0%2)(P\3 ]4E;!!P:_GX_X+8?L;_\ !([_ ()O_L<>'_\
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M+--UO0M5LTN],UG2;Z.XM+NW<;EEBEC)21".0RD@CO7XQ_$3_@@U_P $O?\
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M#KFUSVH ^T_VH/\ @K3_ ,$WOV,?'J?"S]IG]L#PAX6\2LB/+H,UT]S=VRN
M4:>*W21K<,I# R!05.1QS7L_PF^+WPL^/'P]TSXL_!7XAZ-XJ\,ZS!YVE:]H
M&HQW5K<IDJ2DD9*DA@5(ZJRD$ @BOR(_:T_X)?\ _!'K_@DUI?Q9_;Q_X*D:
MWKWQPNOC+XGFMM$@\1Z&9[ZVU*YCO;R6"T-NZHDDNPXN7\L0B%%5UW'=J_\
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MR_\ !.+]L[XA3?";]F7]KWPCXK\30QR2+H5M=2075PB EV@CG1#<*H!8F+<
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M &Q_CP/B-\3_ !+"WB3QEXBC>1XQ=W6DZD/L\<D@4R1Q)$B*0D:@ *J*JJ*
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M^SI;^%_A[J^APW=K\5O%>J+=:1JD<MNLL6^Q-H0(#.LMNTK2E4E@^8!267X
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M&/V7OV4/V>?V+OA);? K]F#X867A'PG:7D]U!H]C/-*HFF??(Y>9W=BQ]6.
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M[MIO[,O[/>D_ 6/]EJT^#/AP_#B+2?[+7P3<:5'-IOV+KY!@D!1DSS@@\\T
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M]1U*W>.\MHRVXQ)<PLDHC+<F/?M)YQF@#\+O^"&'[,?[._Q5_P"#C#7OB_\
M\$]?#VHR? 3X(:!=KI?B2^DGF_M&XFTDZ5YTDTP#-+=7,][<H"%_=QG:JJH4
M?T>UP?[.G[+O[._[(WPZB^$O[,OP:\/^"/#L4QF.E^'M.2!)9B #+*P&Z:0@
M &1RS$* 3P*[R@ HHHH **** "BBB@ HHHH \9_X*#?M5>)_V(/V._''[5OA
M3X(7_P 1)_!&FIJ%SX4TS4A:37%J)HUGF$IBEVK#$SSO\A^2)J_(3_@I=_P6
M"_X(X_\ !1[_ ((S>+_BIXW\+^#--^.GB?18K;2O!$EBEWXDT76XKA5A9;W[
M/&[P1H"_G_)&\+-&1N8Q5^[\T,-Q"]O<1+)'(I5T=<A@>""#U%?*R_\ !#O_
M ()&I\5_^%U+_P $_P#X<#7OM?VH'^Q?]"\[=NW_ &'=]ESGG_5=: /QO^)4
MG[1WC_\ X( ?L0?\$X/BIJ&JP^)OVA/C3;V&BP:DS&Z3PI#J$GV;<&Y\M?MF
MGRQD_*L B'  Q^L'_!8#_@JQ_P .7/@W\//'>F_LCZAXZ\&ZOJQT"^O-+\0C
M3X?#@CBC-NC V\WF&2)9]BY09MMI8;@1]'?$W]C?]F?XR?&OP'^T3\3?A/9:
MOXR^&+3MX#UBXNIU_L=I@!(T<22"(DA5Y9&(VKC&!CKOBA\*_AI\;? 6I_"S
MXP^ -'\4>&M9M_(U70=?TZ.[M+N/(.V2*0%6P0",C@@$8(!H _G=_P"#DK]J
MO_@F!^UIX3^!TG_!+Z\\-Z_\:]0\<B_M-5^&.@M::E';SJ2D%PT,4<GVN2^>
M!XXVS,CI*<*7^;^B#X1VWCNS^%'ABT^*-RD_B:+P]9)XBFC(VR7X@07##;Q@
MR[SQQ7B'[-O_  2$_P""9_[(?Q('Q?\ V=?V-/!OAOQ1&7-KKL=F]S<V9888
MV[W#R&V)4E28MG!(Z$BOI"@#\+O^#4K_ )2._MR?]C;%_P"GC5Z]W_8!7_AK
MW_@Y5_:O_:JD_P!*T3X)>$--^&WAYI.1;WDC*+G:?[RS66H@@=!<<\D&OT*^
M!'[%?[*'[,/C'Q/\0?V?/@%X;\(:WXTN!/XKU/1-/$,VJ2"220-,P^^=\LC?
M5SZU+^SQ^QY^S9^RA?\ C#5?V??A9:>'+KQ_XDEU_P 8W4%W<3R:KJ4I8O<2
M-/(YR2S'"D*"Q( R: /PP_X.0/\ @MK?_';]IJ[_ ."2GP8^.L'PU^&>F:TF
MC?&OXEO:7=R;B8,!=68BLXY+A[6W^9)8XUWSRJT9Q&I+_=/_  0@_:4_X(5_
M#7PAI_\ P3U_X)F_']O%WBN[T^;5_$=]?^"-9LK[Q#-$BB>\N)[NRAB 4$!(
M0X"+\J@G<3])^+_^"+?_  2D\?\ BS5/'?C7]@GX<:GK.MZC/?ZMJ5YH*O-=
MW,TC22S.Q.6=G9F)[DFNG_9\_P""8/\ P3X_91^(B?%O]F_]D3P1X,\2Q6<M
MK'K>@Z0L-PL,@ DC##^%L#(]J /Q*_X-S_VPOV<_^",OQ[_:Q_9&_;[^)4'@
M#4=(UBT?3)=9@D OSICW\4\<6U3YDDD<UM)"J\RJY*9XSZ)_P:@WUC\*/A5^
MUW_P52^."3:!X"U'4EN$U*XC./)LA?:AJ!0?\M"@NK=!MSN?<HR1BOUH_:H_
MX)6_\$\/VVO&=K\1OVI/V2O"7B[Q!:0I#'KEY:O#>21)]R.6:!T>9%[)(649
M. ,FN_NOV4/V:KO]GEOV3#\#O#,7PS?31I[>!K72HX=--KO#^5Y$8"[2XW'^
M\22<DF@#^9;QY_P4M_9F_P""U_\ P4./Q2_X*X_M4WGPE_9Y\#3F;P1\+=,T
M75K^;48BY @+Z=;3".:15#7-TY5]K"*# PT7Z??\%2OB)^R)_P %2?\ @WJ^
M*MK_ ,$L]:@\2^%/A3/ID=CI>B>%;_3(K%-*DL[FXMHK>[MX7VQ:?*9 40J=
MN <@X^O?^'%W_!'[_I';\+__  G4_P :]J_9M_9'_9G_ &/O!5]\.?V8/@EX
M?\#Z%J6I-J%_I7AZQ$$,]TT<<33,HZL4BC7/H@H _G[^,O\ P5N_9 \5_P#!
MJ/H7[%FD?%>RD^+5SI^E^%;GP2J.;RT%EK<5VUTXVX\AK6V4K)G!:94^\&4?
MLI_P0F_9\\7_ ++O_!(WX&?!SQ]I,VGZS;>$&U/4=/N8RDMK)J-W/J)AD4\J
MZ?:]K*>0RD'I6OHW_!%O_@E/X>^-B?M#Z)^P?\/+;Q9%?B^AO8]&'V>&Y#;A
M,EIG[,D@;Y@RQ@A@&!!&:^GJ "BBB@ HHHH **** "BBB@ K\Y?VMO\ @N]^
MSU^S=_P4JN/^"9/[=_[.EOX7^'NKZ'#=VOQ6\5ZHMUI&J1RVZRQ;[$VA @,Z
MRV[2M*526#Y@%)9?T:KR?]JW]A7]D#]N/PU9^$_VM/V>?#7CJTTYV?3'UJQS
M<61;&_R+A"LL.["[@CJ&VC.<"@#\/OV8?''P5^-W_!V7I'C[_@DK:V<7PVAT
M"4_$G4?!VGFUT2]A73)5O9O+153R7N#:(&VA7NE65<DAS]?_ /!M\I_:6_:!
M_;)_X*<78^T6_P 3OC9+H/A.[DY*Z3IP>2((>ZF&[M$)Z$V_'0BOOO\ 9I_8
M%_8U_8Y\!ZK\-?V7OV=O#G@C2M=C*:T-"M3%<WZ[64>=<EC/+M#,%+.2FX[<
M9K<_9>_90_9Y_8N^$EM\"OV8/AA9>$?"=I>3W4&CV,\TJB:9]\CEYG=V+'U8
MX  &  * /SG^#W_!PQ_P3I_:O\>_$[]G'_@J9^S_ .%O@WJOPQU2:U@T#XJS
M1Z[%J3)YT%X(P]BJQ3)MV>2 S2I,-A8;@/ O^#01?$^M?M(?M5>-_@CI>K:;
M^SY?>)5_X0[3KX.+>.Y:\N7M8XPY(\Z.P:-9L'=AH-Y/R5^J/[47_!)K_@G#
M^VCXZC^)_P"TW^R#X0\5>)$1$?7I[1[>\N$0 (LTUN\;SJH  $A8 <#CBO8/
M@Y\%/A#^SS\.].^$GP*^&FB>$?#&DQE-.T+P]IL=K;09.6(2, ;F)+,Q^9F)
M))))H _'7_@]R_Y,V^#/_93;G_TW2U]&?\'$W[0-S\"/^"$.O:1HL[KK'Q%T
MW0?!NCQQ9+3->&-[B, <L6LX+L8'K7VW^TO^QS^RY^V3X<T[PC^U-\"_#OCO
M3-(O6O-,L?$=@)X[:<H4,B ]&*DC/H:@_:%_8M_9@_:LT+PIX7_:#^$=EXET
MWP/K]MK?A:PNKJ>.&QO[=2D,P2*1 Y1690KAEPQ&.30!\W_'']I/X8_\$"?^
M",WA#6/&FBIJ-]\/_ VC^%_#^@13",ZYXA-H%\LN/NJTJ3W$K#)$<<K*"0%/
MXI?\$U_VP/\ @FO^T=^V%JO_  5$_P""\/[;\>K?$*UUD/X(^%[^!=<OM.TU
M83O@FD^RV4T MXF/[BT1R-RF28NS$'^D?]I7]D/]F7]L?PG8>!/VI/@EH'CK
M1M,U$7^GZ;XBLA/#!<B-XQ,JG@/L=USZ,?6O%_\ AQ=_P1^_Z1V_"_\ \)U/
M\: /S&_X.U-2T#]JK]C;]F+_ (*8?LT7\WB;P!HOB#4!#KD6G7%NK0:D+.2V
MFDBGC26%#)IKQYD1<-(B]64'SW_@Y!_;O_9T_P""PUS^RW^RE^P!\0X/'?B/
MQ1XBEN[JRTV"0OI4U\MK;VMO< J-DH+3F1.L:PEFP""?WQTW]F7]GO2?@+'^
MRU:?!GPX?AQ%I/\ 9:^";C2HYM-^Q=?(,$@*,F><$'GFO,OV8?\ @D]_P3C_
M &,_B'-\6?V9?V0O"'A3Q--&\:Z[:VCS75NC@AU@DG=S;JP)5A%M!!P<CB@#
MX+_X.4O^"V'B/_@F7\)M _85_9(UIK+XG^*?"Z27GB9"#)X8T4;K=)8NPNYC
M%(J-_P LEC9\!FB8>._\&^/[07_! []A&;1=)M?VW8OB#^TK\6]0M-)UGQ+/
M\//$@'VR]N(U32[.:XTY5CA:X=/,GD93,X$DA151(_UB^/\ _P $N_\ @GI^
MU3\1Y_B]^T9^R%X(\9>)[FVBMY];U[2%GN'BB7;&A8G[JC@"N=\$_P#!&'_@
ME3\./&>D?$/P)^P7\.-*US0=3M]1T;5+/0%2:SNX)%EAF1L\.CJK ]B!0!Z%
M^WU_R8I\:O\ LDOB/_TUW%?G#_P99_\ **OQK_V7G5O_ $SZ+7ZT^*_"WAWQ
MSX7U+P3XOT>#4=)UBPFL=4T^Z3=%<V\J&.2)QW5D9E(]#7&_LW?LI_LX_L?>
M!;GX8_LP?!K0O WA^\U634KK2/#UD(();MXXXGF*CJY2&)2?1%]* /0:***
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M^.[:B&GNM1G\'Q:J6\^/0FN6-H/G^;RS^\:+/'DO%M^3;7QK^V)_RN<? O\
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M-$V(+N4VMA);L4P/LUO$QB@4*YS)@1?KQ_P4A_X+\?#C]@/P5\"/C[H?[/\
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MKGUH ]-HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,"YO_C='_#_ (_X(V_])"?A_P#^!<W_ ,;KP#_B$._X(V_]"5\0/_"[F_\
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M_P#X?\?\$;?^DA/P_P#_  +F_P#C='_#_C_@C;_TD)^'_P#X%S?_ !NO /\
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M$#_PNYO_ (B@#W__ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\
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M^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;KP#_B$._P""-O\
MT)7Q _\ "[F_^(H_XA#O^"-O_0E?$#_PNYO_ (B@#W__ (?\?\$;?^DA/P__
M / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;KP#_B$._X(V_\ 0E?$#_PNYO\
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M0/\ PNYO_B*/^(0[_@C;_P!"5\0/_"[F_P#B* /?_P#A_P ?\$;?^DA/P_\
M_ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;KP#_B$._P""-O\ T)7Q _\
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M._X(V_\ 0E?$#_PNYO\ XBC_ (A#O^"-O_0E?$#_ ,+N;_XB@#W_ /X?\?\
M!&W_ *2$_#__ ,"YO_C='_#_ (_X(V_])"?A_P#^!<W_ ,;KP#_B$._X(V_]
M"5\0/_"[F_\ B*/^(0[_ ((V_P#0E?$#_P +N;_XB@#W_P#X?\?\$;?^DA/P
M_P#_  +F_P#C='_#_C_@C;_TD)^'_P#X%S?_ !NO /\ B$._X(V_]"5\0/\
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M?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;KP#_B$._X(V_\
M0E?$#_PNYO\ XBC_ (A#O^"-O_0E?$#_ ,+N;_XB@#W_ /X?\?\ !&W_ *2$
M_#__ ,"YO_C='_#_ (_X(V_])"?A_P#^!<W_ ,;KP#_B$._X(V_]"5\0/_"[
MF_\ B*/^(0[_ ((V_P#0E?$#_P +N;_XB@#W_P#X?\?\$;?^DA/P_P#_  +F
M_P#C='_#_C_@C;_TD)^'_P#X%S?_ !NO /\ B$._X(V_]"5\0/\ PNYO_B*/
M^(0[_@C;_P!"5\0/_"[F_P#B* /?_P#A_P ?\$;?^DA/P_\ _ N;_P"-T?\
M#_C_ ((V_P#20GX?_P#@7-_\;KP#_B$._P""-O\ T)7Q _\ "[F_^(H_XA#O
M^"-O_0E?$#_PNYO_ (B@#W__ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\
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M ,"YO_C='_#_ (_X(V_])"?A_P#^!<W_ ,;KP#_B$._X(V_]"5\0/_"[F_\
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MA7]H/X!^._&-S\._!'QO\(:SX@LRXN]"TKQ+:W%Y!M^]OACD+KCOD<5\D_\
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M&1G('6M_Q3XM\*^!M!N/%7C;Q-I^CZ7:)NN]2U6]CM[>%<XR\DA"J,D#D]Z
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M_*RC_B*+_P""ZO\ T?+_ .8S\,?_ "LH _KZHHHH **_"7_@HW_P<A?M<?\
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M:QHEXO\ RVM+F%9HG]B4=>.W2@#HJ*_%C]MK_@NY_P %$OVKOV_=;_X)G?\
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MV3/B+\+;R'P5<6<.N'7?#VG615KI9FBV!HSOX@DSZ8'K7DFA_1-17X6^#_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\
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MXA?L&?#SX>^%/%HBM/$NJ:'?V=D\EJ)%=DDDN]8NG$1*KO$,9<J"HR&(+/\
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M88U5V4#=L3/W%Q]G_P#!M-_P2C_:L_X)4_!_XH>"/VJ8_#:WOB[Q+87VD?\
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MW8*FOU&_X*7_ /!&C_@IA^UY_P $Z/V3O^">/PHN_!FFZ+\,?">E)\4[V_\
M$C*DFJVMA#8Q&!5B)GCA1KQ\G;O,J8 *U]Y>#O\ @BK_ ,$G_!_A'2O"*_\
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M95T7P;9_LY>.8[NTU?PW;ZO]EN=/L[N&.X:&"T$7EJMOJ$:F-58 0#8NW)%
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M@%P0=#X7?\$AO^"\/_!'#XG^.?#G_!(?XG> ?'?PH\<:D;NUT3QQ<11W6EN
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M2."0&Q6-_P *"^!/_1%?"7_A.6O_ ,;KJK>W@M($M;6!(HHD"1QQJ%5% P
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M\OOV:OV?_"'_  09_P""KOA3PW_P6=^#Q\6>'=#\,/JOPX\0Z1>W-[H]C?\
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M/^"C7_!3KP#\&OA/9_##4+#4[7PU\)XLW>NWEE=&[MC.ZRSAOW^TR2R3LVQ
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M_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\
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MOB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\
MA16/^% '[=W-O'=VTEK+G9(A1L'G!&#7S;_P3:_X)1_LI_\ !*KPAXG\$_LK
M1^)%LO%VI07VK_\ "1ZP+Q_-AC:--A$:;1M8Y'-?FM_Q&\_LL_\ 1CWQ _\
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M_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\
M_P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#P
MC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (
MVQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_
M .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^
M-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4
M?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\
M,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G
M_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_L
ML_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_
M]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\
M1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?
M#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P
M_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\
M\(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_
M  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ
M_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;
M'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C
M5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU
M7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_1
M0!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4
M <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'
M_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_
MPR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_
M[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^
MRS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_
M $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T
M;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5
M\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/
M_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\
M_P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#P
MC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (
MVQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_
M .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^
M-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4
M?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\
M,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G
M_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_L
ML_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_
M]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\
M1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?
M#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P
M_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\
M\(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_
M  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ
M_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;
M'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C
M5=_10!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU
M7?T4 <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_1
M0!P'_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4
M <!_PR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'
M_#)_[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_
MPR?^RS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_
M[+/_ $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^
MRS_T;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_
M $;5\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T
M;5\/_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5
M\/\ _P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/
M_P#PC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\
M_P (VQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#P
MC;'_ .-4?\,G_LL_]&U?#_\ \(VQ_P#C5=_10!P'_#)_[+/_ $;5\/\ _P (
MVQ_^-4?\,G_LL_\ 1M7P_P#_  C;'_XU7?T4 <!_PR?^RS_T;5\/_P#PC;'_
M .-5U?A#P1X+^'VC+X<\!>$-+T/3UD:1;#2-/CMH0[?>8)&H7)[G'-:E% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223560466384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 13, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-28827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PETMED EXPRESS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0680967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">420 South Congress Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Delray Beach<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">526-4444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, PETS $.001 Par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PETS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,606,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information to be set forth in our proxy statement relating to our 2024 Annual Meeting of Shareholders is incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of our fiscal year ended March 31, 2024.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001040130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223469301152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">RSM US LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Fort Lauderdale, Florida<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468635104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,296<span></span>
</td>
<td class="nump">$ 104,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, less allowance for credit losses of $273 and $35, respectively</a></td>
<td class="nump">3,283<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventories</a></td>
<td class="nump">28,556<span></span>
</td>
<td class="nump">19,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,325<span></span>
</td>
<td class="nump">4,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income taxes</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">93,648<span></span>
</td>
<td class="nump">130,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">26,657<span></span>
</td>
<td class="nump">26,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill', window );">Intangible and other assets, net</a></td>
<td class="nump">16,503<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">26,658<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">1,432<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">4,986<span></span>
</td>
<td class="nump">5,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">76,236<span></span>
</td>
<td class="nump">37,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">169,884<span></span>
</td>
<td class="nump">167,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">37,024<span></span>
</td>
<td class="nump">25,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales tax payable</a></td>
<td class="nump">25,012<span></span>
</td>
<td class="nump">26,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,060<span></span>
</td>
<td class="nump">6,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,603<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">72,158<span></span>
</td>
<td class="nump">57,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">995<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">73,153<span></span>
</td>
<td class="nump">57,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value, 40,000 shares authorized; 21,149 and 21,084 shares issued and outstanding, respectively</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">25,146<span></span>
</td>
<td class="nump">18,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">71,555<span></span>
</td>
<td class="nump">91,659<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">96,731<span></span>
</td>
<td class="nump">109,966<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 169,884<span></span>
</td>
<td class="nump">$ 167,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible And Other Noncurrent Assets, Net (Excluding Goodwill)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223469273952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference (in dollars per share)</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">21,149,000<span></span>
</td>
<td class="nump">21,084,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">21,149,000<span></span>
</td>
<td class="nump">21,084,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223558606944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 281,064<span></span>
</td>
<td class="nump">$ 256,579<span></span>
</td>
<td class="nump">$ 272,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">202,416<span></span>
</td>
<td class="nump">185,844<span></span>
</td>
<td class="nump">195,341<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">78,648<span></span>
</td>
<td class="nump">70,735<span></span>
</td>
<td class="nump">76,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">55,246<span></span>
</td>
<td class="nump">41,714<span></span>
</td>
<td class="nump">31,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising</a></td>
<td class="nump">24,508<span></span>
</td>
<td class="nump">19,424<span></span>
</td>
<td class="nump">18,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,056<span></span>
</td>
<td class="nump">3,546<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">86,810<span></span>
</td>
<td class="nump">64,684<span></span>
</td>
<td class="nump">52,651<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(8,162)<span></span>
</td>
<td class="nump">6,051<span></span>
</td>
<td class="nump">24,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="num">(1,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">1,889<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) Income before provision for income taxes</a></td>
<td class="num">(6,273)<span></span>
</td>
<td class="nump">7,445<span></span>
</td>
<td class="nump">24,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (7,464)<span></span>
</td>
<td class="nump">$ 5,140<span></span>
</td>
<td class="nump">$ 18,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (loss) income per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">20,395,959<span></span>
</td>
<td class="nump">20,274,786<span></span>
</td>
<td class="nump">20,175,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">20,395,959<span></span>
</td>
<td class="nump">20,339,002<span></span>
</td>
<td class="nump">20,357,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share (in dollars per share)</a></td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468263136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">20,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 124,929<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 7,111<span></span>
</td>
<td class="nump">$ 117,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">4,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared</a></td>
<td class="num">(24,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">18,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,716<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">20,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">123,450<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">11,660<span></span>
</td>
<td class="nump">111,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">6,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared</a></td>
<td class="num">(25,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">5,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,140<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">21,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">109,966<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">18,277<span></span>
</td>
<td class="nump">91,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">6,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared</a></td>
<td class="num">(12,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(7,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,464)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">21,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 96,731<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 25,146<span></span>
</td>
<td class="nump">$ 71,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223472602384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (7,464)<span></span>
</td>
<td class="nump">$ 5,140<span></span>
</td>
<td class="nump">$ 18,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,056<span></span>
</td>
<td class="nump">3,546<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">6,869<span></span>
</td>
<td class="nump">6,617<span></span>
</td>
<td class="nump">4,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">292<span></span>
</td>
<td class="num">(1,630)<span></span>
</td>
<td class="num">(846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>(Increase) decrease in operating assets and increase (decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,742)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories', window );">Inventories</a></td>
<td class="num">(6,417)<span></span>
</td>
<td class="nump">13,432<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidTaxes', window );">Prepaid income taxes</a></td>
<td class="nump">675<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(185)<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">788<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,102<span></span>
</td>
<td class="num">(2,292)<span></span>
</td>
<td class="num">(12,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable', window );">Sales tax payable</a></td>
<td class="num">(1,101)<span></span>
</td>
<td class="nump">1,956<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">896<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(766)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(390)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,317<span></span>
</td>
<td class="nump">27,803<span></span>
</td>
<td class="nump">18,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of minority interest investment in Vetster</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of PetCareRx, net of cash acquired</a></td>
<td class="num">(35,859)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,511)<span></span>
</td>
<td class="num">(5,260)<span></span>
</td>
<td class="num">(1,752)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(40,670)<span></span>
</td>
<td class="num">(10,260)<span></span>
</td>
<td class="num">(1,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(12,437)<span></span>
</td>
<td class="num">(24,537)<span></span>
</td>
<td class="num">(24,384)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(12,437)<span></span>
</td>
<td class="num">(24,537)<span></span>
</td>
<td class="num">(24,384)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(48,790)<span></span>
</td>
<td class="num">(6,994)<span></span>
</td>
<td class="num">(7,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, at beginning of fiscal year</a></td>
<td class="nump">104,086<span></span>
</td>
<td class="nump">111,080<span></span>
</td>
<td class="nump">118,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, at end of fiscal year</a></td>
<td class="nump">55,296<span></span>
</td>
<td class="nump">104,086<span></span>
</td>
<td class="nump">111,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">4,312<span></span>
</td>
<td class="nump">6,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Dividends payable in accrued expenses</a></td>
<td class="nump">$ 1,466<span></span>
</td>
<td class="nump">$ 1,262<span></span>
</td>
<td class="nump">$ 558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223469136112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionTextBlock', window );">Restatement of Previously Issued Financial Statements</a></td>
<td class="text">Restatement of Previously Issued Financial Statements<div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the third quarter of fiscal year 2024, we reviewed the accounting treatment related to previously reported sales tax accruals as well as the accounting treatment related to the valuation of the deferred tax asset associated with our acquisition of PetCareRx in April 2023. As a result of this review, management determined that we incorrectly applied United States Generally Accepted Accounting Principles (U.S. GAAP) as it relates to the sales tax liability and improperly valued the deferred tax asset and goodwill included in our consolidated financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We corrected the misstatements relating to sales tax accruals by recording sales tax accruals as of the end of each of the affected periods using a legal liability approach under Accounting Standards Codification Topic 405, Liabilities. The restated sales tax accrual amounts assume that (i) customers who have not yet provided certificates or other documentation of exemption from sales tax are taxable, (ii) total potential interest and penalty assessments may be imposed, and (iii) we will not receive waivers of interest and penalties or other benefits under agreements we may obtain with jurisdictions from our outreach with voluntary disclosures. We will continue to accrue interest on any outstanding liabilities until the voluntary disclosure agreements are settled. These accrual amounts have been, and will continue to be, adjusted in future periods as and if we obtain any waivers of interest and penalties or other benefits from our voluntary disclosures and as and if we obtain additional documentation from customers supporting exemption from sales tax.</span></div><div style="text-align:justify;text-indent:54pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we have corrected misstatements relating to the deferred tax asset we recognized in connection with our acquisition of PetCareRx on April 3, 2023. In the accounting for that acquisition, it was determined that we incorrectly valued deferred tax assets associated with loss carryforwards of PetCareRx under section 382 of the Internal Revenue Code. As a result of this error, we recorded a decrease in the amount of our deferred tax assets and a corresponding increase in the amount of goodwill in each of the affected periods.</span></div><div style="text-align:justify;text-indent:54pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The misstatements that appeared in our previously issued financial statements were material, and we also corrected other immaterial errors.</span></div><div style="text-align:justify;text-indent:54pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in additional detail in the Explanatory Note in our Amendment No. 1 on Form 10-K/A to our Annual Report on Form 10-K for the year ended March 31, 2023, originally filed with the SEC on May 23, 2023, we restated our audited consolidated financial statements as of and for the years ended March 31, 2023, 2022 and 2021, as well as our unaudited condensed consolidated quarterly financial information for the quarterly periods within the fiscal years ended March 31, 2023 and 2022, to reflect the correction of the misstatements relating to sales tax accruals and other immaterial adjustments, and to make corresponding disclosures. We also filed with the SEC (i) an Amendment No. 1 on Form 10-Q/A to our Quarterly Report on Form 10-Q for the three months ended June 30, 2023, originally filed with the SEC on August 2, 2023,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to restate our unaudited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">condensed consolidated financial statements as of and for the three months ended June 30, 2023 and 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and (ii) an Amendment No. 1 on Form 10-Q/A to our Quarterly Report on Form 10-Q for the three months ended September 30, 2023, originally filed with the SEC on October 31, 2023, to restate our unaudited condensed consolidated financial statements as of and for the three and six months ended September 30, 2023 and 2022, in each case to reflect the correction of the misstatements relating to sales tax accruals and the valuation of deferred tax assets associated with our acquisition of PetCareRx in April 2023.</span></div><div style="text-align:justify;text-indent:54pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The restated prior-year results are reflected in the consolidated financial results disclosed within this Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223472728448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PetMed Express, Inc. and subsidiaries, d/b/a PetMeds&#174; (collectively, the "Company"), is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats, and horses. The Company markets and sells directly to consumers through its websites, toll-free numbers, and mobile application. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Founded in 1996, the Company's executive headquarters offices are currently located in Delray Beach, Florida. The Company has a March 31 fiscal year and references herein to fiscal 2024, 2023, or 2022 refer to the Company's fiscal years ended March&#160;31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include PetMed Express, Inc. and its  wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification ("ASC") Topic 805 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Business Combinations"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The purchase price is allocated to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company&#8217;s unaudited condensed consolidated financial statements from the date of acquisition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">      Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain obligations assumed. Acquisition-related transaction costs incurred by the Company are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March&#160;31, 2024 and 2023 consisted of the Company&#8217;s cash accounts and money market accounts with a maturity of three months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times,  may exceed federally insured limits. The Company has not experienced any losses in such accounts.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $72 thousand and $48 thousand at March&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of thirty years. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from <span style="-sec-ix-hidden:f-317">three</span> to ten years.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. Goodwill is not amortized but instead is tested for impairment annually on January 1, or more frequently if events or changes in circumstances indicate goodwill might be impaired. When testing goodwill for impairment, the Company has the option to choose whether it will apply a qualitative assessment first and then a quantitative assessment, if necessary, or to apply the quantitative assessment directly. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit   </span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company performed its annual goodwill impairment testing as of January 1, 2024 using a </span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">quantitative </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">assessment and at that time concluded there was no impairment. Since then, the Company&#8217;s stock price decreased from $7.56 at December 31, 2023 to $4.79 at March 31, 2024.  The Company considered the decrease in its stock price to be indicative of a risk that the carrying amount of goodwill may not be recoverable.  Therefore, the Company performed a quantitative impairment assessment as of March 31, 2024.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Based on the assessment, the Company concluded that goodwill was not impaired because the estimated fair value of the reporting unit exceeded its carrying value by approximately 27%.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We estimated fair value using discounted cash flow and public company market approaches with a 70% and 30% weighting, respectively.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A key assumption under the cash flow approach was a 27% weighted average cost of capital.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A key assumption under the public company market approach was a 10% control premium.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired definite-lived intangible assets in the acquisition (see Note 4) that will be amortized based on their estimated useful lives in accordance with ASC Topic 350 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). These definite-lived intangible assets are being amortized over periods ranging from <span style="-sec-ix-hidden:f-331">three</span> to seven years. Acquired trade name is not being amortized and is subject to an annual review for impairment consistent with the existing intangible assets in fiscal 2024. Following the Company's annual impairment testing in fiscal 2024, it concluded there was no impairment of its intangible assets.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets consist of the initial minority interest investment in Vetster. Details can be found in Note 16 below.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's advertising expense consists primarily of Internet marketing and direct mail/print, . Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC Topic 842 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Leases")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are reported as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities and long-term lease liabilities on the unaudited Condensed Consolidated Balance Sheets.  The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#8217;s lease agreements do not contain any residual value guarantees.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 48% of our Delray Beach property, or approximately 88,000 square feet was leased to two tenants. At</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the leases with these two tenants had a remaining weighted average lease term of one year. The Company recorded approximately $1.2 million , $0.7 million and $0.7 million in rental revenue in fiscal 2024, 2023 and 2022, respectively, which was included in other income. In 2024, the Company recorded $0.5 million of rental revenue associated with a PetCareRx lease which expired in April 2024. The Company expects to receive the following future lease payments, under the current lease agreements, over the next five years: $617 thousand in fiscal 2025; $112 thousand in fiscal 2026, and $0 thousand in fiscal 2027, 2028 and 2029. As of March 31, 2024, both leases were being negotiated.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC Topic 220 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. For the fiscal years ended March&#160;31, 2024, 2023 and 2022, the Company had no components of comprehensive income and therefore does not report comprehensive income or Consolidated Statements of Comprehensive Income. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the provisions of ASC Topic 740 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by &#8220;Accounting for Uncertainty in Income Taxes&#8221; guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies &#8220;Accounting for Uncertainty in Income Taxes&#8221; guidance to all tax positions for which the statute of limitations remains open. The Company had no liabilities for uncertain tax positions for either fiscal 2024 or fiscal 2023. The Company files tax returns in the U.S. federal jurisdiction and Florida,  Arizona, California, Connecticut, Idaho, Maryland, Michigan, Oklahoma, South Carolina, Virginia, Wisconsin, New Jersey, Georgia, Indiana, New York and the District of Columbia. With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending March&#160;31, 2020, or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Concentrations</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our product lines to obtain the lowest cost. There were seven and six suppliers from which we purchased approximately 78%  and 69% of all products in fiscal 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for Share Based Compensation</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The compensation expense related to all of the Company&#8217;s stock-based compensation arrangements is recorded as a component of general and administrative expenses.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company&#8217;s consolidated financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468503104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> ("Revenue from Contracts with Customers")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company generates revenue by selling prescription and non-prescription pet medication products, pet food, supplements, supplies, membership fees, and veterinary services. Certain pet supplies offered on the Company&#8217;s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product. Customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are based on historical patterns, however this is not considered a key judgment. Revenue is recognized when control transfers to the customer at the point in time at which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time when the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Virtually all the Company&#8217;s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales. Revenue is recorded net of sales tax, discounts and return allowances. Return allowances are estimated using historical experience and not material. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given its responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Membership fees represent the amounts recognized periodically from two membership models. The first is the PetPlus membership for PetCareRx customers, the second is a partner membership provided through PetCareRx. These memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup which represent a single stand-ready performance obligation to provide these benefits. The PetPlus membership fee is an upfront annual charge and automatically renews one year from the initial enrollment date. The Company recognizes the revenue ratably over the term of the PetPlus membership which is generally one year. As shown in the following table, under the PetPlus program, the Company recognized  $7.0 million deferred annual membership fees in the twelve months ended March&#160;31, 2024, and had $2.6 million of deferred revenue as of the year ended March&#160;31, 2024.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.878%"><tr><td style="width:1.0%"></td><td style="width:68.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">( amounts in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue acquired with PetCareRx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred memberships fees received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred membership fee revenue recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to annual membership fees earned under the PetPlus program, the Company also earns membership fees on a month-to-month basis under its PetCareRx partner membership program.  For the twelve months ended March&#160;31, 2024, membership fees earned under the partner program were $2.8 million. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no material contract asset or liability balances at March&#160;31, 2024 and March&#160;31, 2023, respectively. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates sales in the following two categories: reorder sales vs new order sales vs membership fees. The following table illustrates sales by various classifications:</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:29.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales (In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reorder sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New order sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Membership fees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,485&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:29.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales (In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reorder sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New order sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,579&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,703)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company changed the definition of a new customer on April 1, 2022, to include anyone who has not ordered over the past thirty-six months. The reorder and new order sales amounts for the years ended March&#160;31, 2022 reflect this new customer definition change. Under the previous definition of a new customer, reorder and new order sales were $249.4 million and $22.9 million, respectively, for the  year ended March&#160;31, 2022. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses that the Company estimates will arise from customers&#8217; inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. The Company determines its estimates of the uncollectability of accounts receivable by analyzing historical bad debts and current economic trends in compliance with the provisions of ASC Topic 326 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses"). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses was approximately $273 thousand  and $35 thousand at March&#160;31, 2024 and March&#160;31, 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223466407776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition</a></td>
<td class="text">Acquisition<div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April&#160;3, 2023, the Company acquired 100% of the issued and outstanding equity interests of PetCareRx, a New York corporation and a leading supplier of pet food, pet medications, and supplies.  The acquisition was completed pursuant to an Agreement and Plan of Merger ("Merger Agreement") by and among the Company, Harry Merger Sub, Inc., a New York corporation and a wholly-owned subsidiary of the Company ("Merger Sub"), PetCareRx and Jeanette Loeb (as representative of the PetCareRx equity holders). The Merger Agreement provided for the Company&#8217;s acquisition of PetCareRx pursuant to the merger of Merger Sub with and into PetCareRx, with PetCareRx as the surviving corporation. The aggregate purchase price consideration was $36.1 million and was funded from the Company's cash on hand.  </span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The acquisition of PetCareRx allowed the Company to significantly expand its product catalog, most notably in non-medication products, including food. In addition, PetCareRx brings increased distribution capability and experience, geographic diversity, technology enhancements, additional vendor relationships and a long-tenured and experienced staff.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognized goodwill of approximately $26.7 million, which is calculated as the excess of the consideration exchanged and liabilities assumed as compared to the fair value of the identifiable assets acquired.  Goodwill recognized in the transaction represents synergies or scale achieved by significantly increasing the customer base without adding corresponding levels of additional overhead, the value of additional vendor relationships, including the food manufacturing relationships, a broader product catalog, and an assembled and </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">experienced workforce. These items represent intangible assets that do not qualify for separate recognition.  No goodwill is deductible for tax purposes. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The values assigned to the assets acquired and liabilities assumed are based on their estimates of fair value available as of April&#160;3, 2023, as calculated by an independent third-party firm. The selected rates of returns were chosen in consideration of the individual risk profiles of the assets, as well as the resulting weighted average return on assets. Intangible assets are considered to be riskier than the overall business, so the Company included a premium to the investment rate of return on the identified intangible discount rates. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair values of intangible assets acquired consist of a trade name, customer relationships, and developed technology, which were estimated by applying various discounted cash flow models such as the relief from royalty rate for the trade name, the multi-period excess earnings method for the customer relationships, and the cost to replace method for the developed technology. The fair value measurements were based on significant inputs that are not observable (Level 3). The assumptions made by management in determining the fair value of intangible assets included a discount rate of 12% based on the weighted average cost of capital.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As a result of the acquisition, the Company performed an Internal Revenue Code Section 382 analysis to determine if the net operating losses carried forward will have a utilization limitation. Refer to Note 9 for further discussion.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below outlines the purchase price allocation of the purchase for PetCareRx to the acquired identifiable assets, liabilities assumed and goodwill (in thousands):</span></div><div><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company incurred a total of $1.7 million in acquisition related costs that were expensed as incurred and recorded in general and administrative expenses in the Company&#8217;s Condensed Consolidated Statements of Operations, of which $0.5 million was recorded in fiscal year 2023, and $1.2 million was recorded for the twelve months ended March&#160;31, 2024. These costs include banking, legal, accounting, and consulting fees related to the acquisition. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Supplemental Pro Forma Information (As Restated)</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The supplemental pro forma financial information presented below is for illustrative purposes only, does not include the pro forma adjustments that would be required under Regulation S-X of the Exchange Act for pro forma financial information, is not necessarily indicative of the financial position or results of operations that </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">would have been realized if the PetCareRx acquisition had been completed on April 1, 2022, does not reflect synergies that might have been achieved, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that the Company believes are reasonable under the circumstances.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the PetCareRx acquisition had occurred on April 1, 2021 to give effect to certain events that the Company believes to be directly attributable to the acquisition. These pro forma adjustments primarily include:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">A decrease in depreciation expense that would have been recognized due to acquired identifiable fixed assets;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">A decrease in amortization expense that would have been recognized due to acquired identifiable intangible assets; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">A decrease in payroll costs and benefits.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The supplemental pro forma financial information for the prior period twelve months ended March&#160;31, 2023 and 2022 is as follows (in thousands):</span></div><div><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:47.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223469135856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major classifications of property and equipment consist of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building Improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,785&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $5.1 million, $3.5 million and $2.7 million for the twelve months ended March&#160;31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its tangible property and equipment for indicators of impairment as of March&#160;31, 2024 and concluded that no impairment existed.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223467266912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major classifications of accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued credit card fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued salaries and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued merchandise credits / reward program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales return allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued real estate taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223466427600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible and Other Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible and Other Assets, Net</a></td>
<td class="text">Intangible and Other Assets, Net<div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets and other assets, net consisted of the following (in thousands):</span></div><div><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:35.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful Life (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toll-free telephone number</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internet domain names</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Names - PetCareRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships -PetCareRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology - PetCareRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,957)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minority interest investment in Vetster</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,957)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,503&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toll-free telephone number</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internet domain names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minority interest investment in Vetster</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluated its intangible assets for indicators of impairment as of March&#160;31, 2024 and concluded that no impairment existed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortization expense for intangible assets was $2.0&#160;million for the twelve months ended March&#160;31, 2024 and zero for the twelve months ended March&#160;31, 2023 and 2022, respectively. The indefinite life intangibles are not </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">being amortized and are subject to an annual review for impairment in accordance with the ASC Topic 350 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;).</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes expected amortization of our intangible assets at March 31, 2024 (in thousands):</span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.757%"><tr><td style="width:1.0%"></td><td style="width:66.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;19, 2022, the Company engaged in a three-year partnership agreement with Vetster Inc. (&#8220;Vetster&#8221;), a Canadian veterinary telehealth company. The Company also purchased a 5% minority interest in Vetster in the amount of $5.0&#160;million and received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, the Company became the exclusive e-commerce provider for Vetster, and Vetster became the exclusive provider of telehealth and telemedicine services to the Company. The minority interest investment is being valued on the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost basis and the investment will be evaluated periodically for any impairment. On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> October 3, 2023, the Company purchased additional shares in Vetster in the amount of $0.3&#160;million. This increased the minority interest investment to $5.3&#160;million. Following this round, the Company&#8217;s minority ownership changed to approximately 4.8% of Vetster&#8217;s outstanding shares.  The minority interest investment is being valued on the cost basis.  At March&#160;31, 2024, we evaluated the investment in accordance with ASC Topic 321 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Equity Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and determined it was not impaired.   </span></div>Under the terms of the agreement, Vetster earns from 10% to 20% of revenue generated from its customers on orders fulfilled by the Company.  For the years ended March 31, 2024 and 2023, the Company earned approximately $0.8&#160;million and $0.4&#160;million in net sales for orders placed through Vetster and incurred fees to Vetster of approximately $153&#160;thousand and $80&#160;thousand, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223466354032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s leasing activities primarily consist of real estate leases acquired during the acquisition of PetCareRx for use in the business operations.  The leases had initial terms ranging from 5 years to 10 years. Some of the initial lease terms have already matured and the remaining leases have maturity dates ranging from fiscal year 2024 to 2028. The Company assesses whether each lease is an operating lease or a finance lease at the lease commencement date. The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable Lease Costs</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s leases require payments for taxes, insurance, and other costs applicable to the property, in addition to the minimum lease payment. These costs are considered variable costs which are based on actual expenses incurred by the lessor. Therefore, these amounts are not included in the calculation of the right-of-use assets and lease liabilities. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements which provide for fixed and scheduled escalations, which are included in the calculation of the right-of-use assets and lease liabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options to Extend or Terminate Leases</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s leases may contain an option to extend the lease term for periods from <span style="-sec-ix-hidden:f-558">one</span> to five years The exercise of lease renewal options is at the Company&#8217;s sole discretion. If it is reasonably certain that the Company will exercise such options, the periods covered by such options are included in the lease term and are recognized as part of the Company&#8217;s right-of-use assets and lease liabilities. The Company&#8217;s leases do not generally contain options to early terminate.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Lease items</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities on the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discount Rate and Lease Term</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the weighted average remaining lease term and discount rate for the Company&#8217;s operating leases were 3 years and 3.6%, respectively. As the rate implicit in the lease is generally not readily determinable for the Company&#8217;s operating leases, the Company uses its estimated incremental borrowing rate based on the information available at the date of acquisition, April&#160;3, 2023, in determining the present value of future payments.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Costs and Activity</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease costs as recorded in the general and administrative costs and activity for the twelve months ended March&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.636%"><tr><td style="width:1.0%"></td><td style="width:69.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Twelve months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating lease cost - fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating lease costs - variable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information for the twelve months ended March&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"><tr><td style="width:1.0%"></td><td style="width:71.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Twelve months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash paid for the amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Right-of-use assets obtained in exchange for new operating lease liabilities as a result of acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity of Lease Liabilities</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company&#8217;s lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating lease liabilities recognized on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.878%"><tr><td style="width:1.0%"></td><td style="width:67.299%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less: Imputed Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223469432624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales tax liability</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt and inventory reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax accounting method change</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,627)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,585)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,527)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, the Company had $11.3&#160;million of federal net operating loss carryforwards which begin to expire in fiscal 2024. The Company also had $9.0&#160;million in state net operating loss carryforwards which begin to expire in fiscal 2026. In fiscal 2024 the Company acquired PetCareRx, a loss corporation. The tax attributes acquired are subject to Internal Revenue Code Section 382 which limits the utilization annually. The Company has determined the utilization of the state loss carryforwards is not likely to be realized. As a result, the Company has recorded a valuation allowance of $0.6&#160;million for the tax effected value of these state losses. Outlined below are the tax attributes acquired and the balances remaining as of March 31, 2024 (in thousands).</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:29.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PetCareRx Tax Attributes Acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sec. 382 limited utilization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attributes for which a deferred tax asset is recorded</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - limited carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,454</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,154</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2024 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - unlimited carryover</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,501</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,501</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disallowed business interest expense carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2026 </span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:29.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Attribute as of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sec. 382 limited utilization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attributes for which a deferred tax asset is recorded</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - limited carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,114</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2025 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - unlimited carryover</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,501</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,501</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disallowed business interest expense carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2026 </span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax provision consist of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:54.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax provision</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax provision (benefit)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,629)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income tax provision computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:54.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes at federal statutory rates</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock shortfall adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal 2024, the Company recognized non-deductible executive stock compensation of approximately $1.8&#160;million. This includes adjusting the deferred tax assets by a cumulative $1.0&#160;million to account for future limitations under Sec. 162(m). This limits deductions for compensation of covered executives to $1.0&#160;million per individual.  In fiscal 2023, the Company recognized a stock compensation shortfall charge of approximately $171 thousand, and recognized a one-time charge of approximately $124 thousand, related to a return to provision true up from the fiscal 2022 income tax provision. In fiscal 2022, the Company recognized a stock compensation shortfall charge of approximately $31 thousand, and recognized a one-time benefit of approximately $184&#160;thousand, related to a return to provision true up from the fiscal 2021 income tax provision.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the effective income tax rate and the statutory U.S. federal income tax rate are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:54.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal rate on income before taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock shortfall adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Effective Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223469158416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 1998, the Company issued 250,000 shares of its $.001 par value preferred stock at a price of $4.00 per share, less issuance costs of $112 thousand. Each share of the preferred stock is convertible into approximately 4.05 shares of common stock at the election of the shareholder. The shares have a liquidation value of $4.00 per share and may pay dividends at the sole discretion of the Company. The Company does not anticipate paying dividends to the preferred shareholders in the foreseeable future. Each share of preferred stock is entitled to one vote on all matters submitted to a vote of shareholders of the Company. At March&#160;31, 2024 and 2023, 2,500 shares of the convertible preferred stock remained unconverted and outstanding.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company&#8217;s financial performance. During fiscal 2024, our Board of Directors declared the following dividends:</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.272%"><tr><td style="width:1.0%"></td><td style="width:20.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Dividend</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Record Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Amount<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 22, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 6, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,352</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 14, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,344</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 18, 2023</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223571231664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Restricted Stock</a></td>
<td class="text">Restricted Stock<div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, the Company&#8217;s 2015 Outside Director Equity Compensation Restricted Stock Plan (&#8220;2015 Director Plan&#8221;) became effective upon the approval of the plan by the Company&#8217;s shareholders. The 2015 Director Plan authorized 400,000 shares of the Company's common stock available for issuance under the plan and provides for an automatic increase every year in the amount of shares available for issuance under the plan of 10% of the shares authorized under the plan. In July 2016, the Company&#8217;s 2016 Employee Equity Compensation Restricted Stock Plan (&#8220;2016 Employee Plan&#8221;) became effective upon the approval of the plan by the Company&#8217;s shareholders. The 2016 Employee Plan authorized 1,000,000 shares of the Company's Common stock available for issuance under the plan. In July 2022, the Company&#8217;s 2022 Employee Equity Compensation Restricted Stock Plan (&#8220;2022 Employee Plan&#8221;) became effective upon the approval of the plan by the Company&#8217;s shareholders. The 2022 Employee Plan replaced the 2016 Employee Plan, and as of April 2023 no further awards were granted, or will be granted, under the 2016 Employee Plan. The 2022 Employee Plan authorized 1,000,000 shares of the Company's common stock available for issuance.The value of the restricted stock is determined based on the market value of the stock at the issuance date. The restriction period or forfeiture period is determined by the Company&#8217;s Compensation and Human Capital Committee and is to be no less than 1 year and no more than ten years unless otherwise specified by the Compensation and Human Capital Committee.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (ASU 2016-09). At March&#160;31, 2024, the Company had 957,260 common shares issued under the 2016 Employee Plan, 255,251 common shares issued under the 2015 Director Plan and 149,488 common shares issued under the 2022 Employee Plan. As of March 31, 2024, all shares in the 2022 Employee Plan, 2016 Employee Plan and 2015 Director Plan were issued subject to a restriction or forfeiture or vesting period that lapses ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over a <span style="-sec-ix-hidden:f-736">one</span> to three-year restriction period, with the exception of performance restricted shares which were issued to the Company's former Chief Executive Officer and the Company's Chief Financial Officer.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company issued 90,000 restricted shares and 510,000 performance restricted shares to the Company&#8217;s former CEO, in accordance with the former CEO&#8217;s employment agreement, under the 2016 Employee Plan.  The performance restricted shares were based on achieving absolute stock hurdles within the </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three-year period from the grant date. If the shares met the absolute stock price hurdle, they would have only been released from restrictions on the third anniversary of the date of grant. As of March&#160;31, 2024, none of the performance stock hurdles were met, and subsequent to March 31, 2024 the performance restricted shares were forfeited and cancelled as a result of the former CEO's cessation of employment with the Company.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company issued 13,000 restricted shares and 3,000 performance restricted shares to the Company's CFO, in accordance with the CFO's employment agreement, under the 2016 Employee Plan. One-third of the restricted shares will vest on each of the first three anniversaries of the date of grant, subject to the CFO&#8217;s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company.</span><span style="color:#000000;font-family:'Lato',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance restricted shares were based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue, and on June 8, 2023 the Company determined that the performance criteria was not attained over the applicable performance period and the performance restricted shares were forfeited. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company granted the Company's CFO 11,750 RSUs under the 2022 Employee Plan, of which 3,750 RSUs were awarded in recognition of the CFO&#8217;s contributions during fiscal year 2023 and the remaining 8,000 awarded as a part of the equity award cycle for fiscal year 2024. One-third of the RSUs will vest on each of the first <span style="-sec-ix-hidden:f-746">three</span> anniversaries of the date of grant, subject to the CFO&#8217;s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company.</span><span style="color:#000000;font-family:'Lato',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in June 2023, the CFO was awarded 8,000 PSUs with a market condition.  The CFO will earn shares of our common stock pursuant to the PSUs based on the Company&#8217;s total shareholder return (&#8220;TSR&#8221;) relative to the S&amp;P 600 Specialty Retail Index (&#8220;Index&#8221;) over an overall three-year performance period consisting of the 2024 through 2026 fiscal years, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">100% of the target number of shares, which is 8,000 shares, will be earned if the Company&#8217;s TSR is equal to or greater than the 75th percentile of the Index (the &#8220;maximum target payout&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">50% of the target number of shares, which is 4,000 shares, will be earned if the Company&#8217;s TSR is equal to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">at least the 50th percentile of the Index; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">25% of the target number of shares, which is 2,000 shares, will be earned if the Company&#8217;s TSR is equal to at least the 25th percentile of the Index (the &#8220;minimum threshold&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">No shares will be earned if the TSR is less than the 25th percentile of the Index, and the payout is capped at 2,000 shares if absolute TSR is negative, regardless of relative position to the Index; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">Linear scaling will be used to determine the number of shares earned for performance between the maximum target payout level and the minimum threshold payout level. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> Subsequent to March 31, 2024, 3,917 of the RSUs granted in June 2023 and all PSUs granted granted in June 2023 were forfeited and cancelled in connection with the CFO's Transition and Separation Agreement - see Note 16, Subsequent Events.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended March&#160;31, 2024, 2023, and 2022, the Company recognized compensation expense related to the 2016 and 2022 Employee Plan and the 2015 Director Plan of $6.9 million, $6.6 million, and $4.5 million, respectively. All stock-based compensation expense is recognized as a payroll-related expense and it is included within the general and administrative expenses line item within the Company&#8217;s Consolidated Statements of (Loss) Income, and the offset is included in the additional paid-in capital line item of the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2024, restricted stock award ("RSA") activity under the Plans was as follows:</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:40.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2016 Employee<br/>Plan<br/>Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Employee Plan Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Plans<br/>Number of<br/>Shares</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,829</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted and issued</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,742</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,765</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,343)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,418)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,332)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,093)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,914)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,127)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,334)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,375)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,343</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,707</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,076</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,126</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024 and 2023, there were 703,126 and 752,829, restricted shares subject to restriction and forfeiture outstanding, respectively. During the fiscal years ended March&#160;31, 2024 and 2023, the Company released from restrictions, net of forfeitures, 64,390 and 99,390 restricted shares, respectively. The weighted-average grant date fair value of restricted shares was $14.75 and $21.57 for fiscal years 2024 and 2023, respectively.  The total fair value of restricted shares released from restrictions was $1.4 million and $2.4 million for fiscal years 2024 and 2023, respectively.  At March&#160;31, 2024 and 2023, there were $3.2 million and $9.1 million of unrecognized compensation costs related to the restricted stock subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 7 months and 1.6 years for fiscal 2024 and 2023, respectively.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company first granted restricted stock units ("RSUs") in the year ended March 31, 2024. The fair value assigned to RSUs is the market price of the Company&#8217;s stock on the grant date.  The vesting period for employees and members of the Board of Directors ranges from <span style="-sec-ix-hidden:f-794">one</span> to three years.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended March 31, 2024, RSU activity under the Plans was as follows:</span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.272%"><tr><td style="width:1.0%"></td><td style="width:54.236%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>&#160;Grant Date<br/>&#160;Fair Value Per RSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding at March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,880</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,800)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,080</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.75&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total grant-date fair value of RSUs granted during the twelve months ended March&#160;31, 2024 and 2023 was $1.1 million and zero, respectively.  For the twelve months ended March&#160;31, 2024 and 2023, the Company recorded stock-based compensation related to RSUs of $0.3 million and zero, respectively. At March&#160;31, 2024 and 2023, there were $0.8 million and zero of unrecognized compensation costs related to RSUs subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 2.3 years and 0 years for fiscal 2024 and 2023, respectively.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Performance Stock Units </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company first granted performance stock units ("PSUs") in the year ended March 31, 2024.  The fair value assigned to PSUs is determined using the market price of the Company&#8217;s stock on the grant date for awards with a performance condition, and by using a Monte Carlo simulation for awards with a market condition. Existing PSUs with a performance condition vest over one year.  Existing PSUs with a market condition vest over three years. Stock-based compensation costs associated with PSUs with a performance condition are re-assessed each reporting period based upon the estimated performance attainment on the reporting date until the performance conditions are met. The ultimate number of shares of common stock that are issued to an employee is the result of the actual performance of the Company at the end of the performance period compared to the performance targets and generally ranges from 0% to 200% of the initial PSU grant. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended March 31, 2024, PSU activity under the Plans was as follows:</span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"><tr><td style="width:1.0%"></td><td style="width:53.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 37pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>&#160;Grant Date<br/>&#160;Fair Value Per PSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested PSUs outstanding at March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The total grant-date fair value of PSUs granted during the twelve months ended March&#160;31, 2024 and 2023 was $126 thousand and zero, respectively. For the twelve months ended March&#160;31, 2024 and 2023, the Company recorded stock-based compensation related to PSUs of $64 thousand and zero, respectively. At March&#160;31, 2024 and 2023, there were $62 thousand and zero of unrecognized compensation costs related to PSUs subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 1.6 years and 0 years for fiscal 2024 and 2023, respectively</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223469524704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries cash and cash equivalents and investments at fair value in the Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Fair Value Measurements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs which are supported by little or no market activity.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At March&#160;31, 2024 and 2023 the Company had invested the majority of its $55.3 million and $104.1 million cash and cash equivalents balance in money market funds which are classified within Level 1.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223466446464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text">Net (Loss) Income Per Share<div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC Topic 260 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) basic net (loss) income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net (loss) income per common share includes the dilutive </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock, and convertible preferred shares issued by the Company represent the only dilutive effect reflected in diluted weighted average shares outstanding.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for per share amounts):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:54.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income (numerator):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (denominator)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding used in basic computation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,395,959</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,274,786</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,175,930</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon the vesting of restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,091</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,765</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon conversion of preferred shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,125</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,125</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted computation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,395,959</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,357,820</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024, 2023, and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 827,863, 745,854, and 220,727 shares of common restricted stock, respectively, were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted (net loss)/net income per common share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468503984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal Matters and Routine Proceedings</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled complaints that had been filed with various states&#8217; pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company also intends to vigorously defend its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred. From time to time, the Company may be involved in and subject to disputes and legal proceedings, as well as demands, claims and threatened litigation that arise in the ordinary course of its business. These proceedings may include allegations involving business practices, infringement of intellectual property, employment or other matters. The ultimate outcome of any legal proceeding is often uncertain, there can be no assurance that the Company will be successful in any legal proceeding, and unfavorable outcomes could have a negative impact on our results of operations and financial condition. In accordance with ASC Topic 450-20 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), the Company records a liability in its financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews the status of each significant matter each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the financial statements not misleading. If the loss is not probable and cannot be reasonably estimated, a liability is </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not recorded in the Company&#8217;s financial statements. Gain contingencies are not recorded until they are realized. Legal costs related to any legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employment Agreements</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Board of Directors appointed Mathew N. Hulett ("Mr. Hulett&#8221;) as Chief Executive Officer and President of the Company and as a member of the Board of Directors. These appointments and the employment agreement were effective as of August 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The employment agreement was for an initial term of three (3) years commencing on August 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and automatically renewed for successive one (1) year terms, or for longer periods as mutually agreed upon by the parties, unless the employment agreement was expressly cancelled by either Mr. Hulett or the Company sixty (60) days prior to the end of the then current term, or was otherwise terminated as provided in the agreement. The employment agreement provided that Mr. Hulett received an annual base salary of $500 thousand, subject to periodic review for increases with the approval of the Board of Directors, and was be eligible to participate in the standard employee benefit plans generally available to executives and employees of the Company, including health insurance, life and disability insurance, restricted stock under the Company&#8217;s equity compensation plan(s), 401(k) plan, and paid time off and paid holidays. The employment agreement also provided that the Company will reimburse Mr. Hulett for his documented business expenses incurred in connection with his employment pursuant to the Company's standard reimbursement expense policy and practices. The employment agreement contained certain rights of Mr. Hulett and the Company to terminate Mr. Hulett&#8217;s employment, including termination by the Company for &#8220;Cause&#8221; as defined in the employment agreement, and termination by Mr. Hulett for &#8220;Good Reason&#8221; as defined in the employment agreement within twelve (12) months of a Change in Control as defined in the employment agreement. Mr. Hulett was also entitled to severance pay equal to twelve (12) months of Mr. Hulett&#8217;s current base salary and eighteen (18) months of health insurance benefits in the event of his termination by the Company without Cause, or termination by Mr. Hulett for Good Reason within twelve (12) months of a Change in Control. The foregoing severance benefits are conditioned upon Mr. Hulett&#8217;s execution of a release of claims and compliance with certain restrictive covenants. The employment agreement contains customary non-disclosure and non-solicitation provisions as well as a one (1) year non-compete following the termination of the agreement. Subsequent to March 31, 2024 the employment agreement with Mr. Hulett was terminated (See Note 16 - Subsequent Events, for a description of the Transition and Separation Agreement with Mr. Hulett).</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;30, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Hulett also received an award of 90,000 shares of restricted stock under the Company&#8217;s 2016 Employee Plan, which stock restrictions will lapse pro rata on each of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 30, 2022,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 30, 2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 30, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which are subject to forfeiture in the event of termination of employment (except as provided in the restricted stock agreement). Mr. Hulett also received an award of 510,000 shares of performance restricted stock under the 2016 Employee Plan, which stock restrictions will lapse on the third anniversary of the date of grant based on (i) achieving absolute stock price hurdles within the three-year period from the date of grant, and (ii) continued employment through the performance period of three years from the date of grant, in accordance with the following schedule: 85,000 shares at the stock hurdle price of $40 per share, 107,000 shares at the stock hurdle price of $45 per share, 106,000 shares at the stock hurdle price of $50, 106,000 shares at the stock hurdle price of $55, and 106,000 shares at the stock hurdle price of $60.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should none of the absolute stock price hurdles be met during the three-year period from the date of grant, no shares would vest (as defined in the performance restricted stock agreement). Once the absolute stock price hurdle is achieved, it will be considered to have met the absolute stock price hurdle, regardless of the stock price on the third anniversary of the date of grant. The absolute stock price hurdle would be considered to have been met if the average closing stock price of the Company is at or above the absolute stock price hurdle for a period of ninety (90) consecutive trading days. If the shares would be considered to have met the absolute stock price hurdle, they will only vest on the third anniversary of date of grant, subject to Mr. Hulett&#8217;s continued employment through the performance period of three years from the date of grant (except as provided in the performance restricted stock agreement). As of March&#160;31, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">none of the performance restricted stock vested, as no performance stock price hurdles were met.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;14, 2022, the Board of Directors appointed Christine Chambers ("Ms. Chambers") to serve as the Company&#8217;s Chief Financial Officer and to assume the duties of principal financial officer and principal accounting officer effective August&#160;3, 2022 (&#8220;Effective Date&#8221;). The Company entered into an offer letter with Ms. Chambers </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to set the terms and conditions of Ms. Chambers&#8217; employment as Chief Financial Officer of the Company. Ms. Chambers will receive an annual base salary of $375 thousand and received a one-time sign-on bonus in the amount of $50 thousand, subject to pro rata repayment if Ms. Chambers terminated employment with the Company within the first twelve months of employment. Ms. Chambers received an initial equity award  under the 2016 Employee Plan consisting of (i) an award of 13,000 restricted shares, and (ii) 3,000 performance restricted shares, which performance restricted shares will be based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue as of the fiscal year ended March&#160;31, 2024. The shares for each grant will be released from restriction equally over a three (3) year period on the anniversary of the grant date, subject to the attainment of performance criteria in the case of the performance restricted shares. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Mr. Rosenbloom&#8217;s transition services and subsequent separation from employment with the Company, on August&#160;2, 2022 the Company and Mr. Rosenbloom entered into a CFO Transition and Separation Agreement (the "Separation Agreement&#8221;) pursuant to which Mr. Rosenbloom remained in his current position as CFO of the Company through and including August&#160;2, 2022, and following the termination of his status as CFO, Mr. Rosenbloom continued to serve as an employee of the Company to provide transition services to the Company through his date of termination. His employment ended on December&#160;31, 2022 ("Separation Date&#8221;). While Mr. Rosenbloom served as an employee of the Company, he continued to receive his current base salary and benefits as was in effect. The Separation Agreement provided that Mr. Rosenbloom would be paid two lump-sum severance payments of $182 thousand each, with the first such payment to be paid on the Company&#8217;s next payroll date following the Separation Date, and was paid January 13, 2023, and the second paid on the Company&#8217;s next payroll date six-months following the Separation Date, subject to his compliance with the terms and conditions of his then existing employment agreement, and the Separation Agreement. In exchange for the Company&#8217;s agreement to make the severance payments, Mr. Rosenbloom granted the Company a full release of any and all claims that he may have against the Company and its affiliates and related parties.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a part of the Separation Agreement, the Company confirmed that the 13,275 restricted shares held by Mr. Rosenbloom under the 2016 Employee Plan were released from restriction and forfeiture on December&#160;31, 2022, Under the Separation Agreement, Mr. Rosenbloom&#8217;s existing non-compete obligation was reduced to a period of twelve (12) months.</span></div>In connection with the separation of the Company's former Chief Financial Officer, the Company paid the remaining $182 thousand payment with respect to the severance, pursuant to the Separation Agreement in fiscal year 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223466472192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) Savings Plan for eligible employees. The plan is a defined contribution plan that is administered by the Company. All regular, full-time employees are eligible for voluntary participation upon completing 90 days of service and having attained the age of 21. The plan provides for growth in savings through contributions and income from investments. It is subject to the provisions of the Employee Retirement Income Security Act of 1974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as amended. Plan participants are allowed to contribute a specified percentage of their base salary. The Company matches 100% of the first 4% of the employee's contribution. The matching contribution is funded subsequent to the calendar year. During the fiscal years ended March&#160;31, 2024, 2023, and 2022, the Company recorded $350 thousand, $289 thousand, and $238 thousand, respectively, of 401(k) matching contribution and administration expense to general and administrative expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223466456352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Transition and Separation Agreement with Matthew Hulett</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2024, the Company and Mathew Hulett entered into a Transition and Separation Agreement pursuant to which Mr. Hulett resigned as President and Chief Executive Officer, and also as a director, of the Company effective April 29, 2024 (the &#8220;Hulett Agreement&#8221;). Under the terms of the Hulett Agreement, Mr. Hulett remained employed by the Company through May 10, 2024 to assist the Company in transition matters, and the Company will pay Mr. Hulett severance compensation thereafter in the form of the continuation of his base salary </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reimbursement of COBRA premiums through August 30, 2024, which was the scheduled expiration date of his employment agreement. The Hulett Agreement also provided that the Company cancelled the 510,000 performance restricted shares granted in August 2021, and accelerated the vesting of Mr. Hulett&#8217;s remaining unvested shares of restricted common stock (consisting of 30,000 shares) previously granted under a Restricted Stock Agreement between the Company and Mr. Hulett which would have otherwise vested on August 30, 2024. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appointment of Sandra Campos as Chief Executive Officer</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2024, the Company appointed Sandra Campos, an existing director of the Company, as the Company&#8217;s new Chief Executive Officer and President. On the same date, the Company and Ms. Campos entered into an Executive Employment Agreement setting forth the terms under which Ms. Campos was employed by the Company as Chief Executive Officer and President (the &#8220;Employment Agreement&#8221;). Ms. Campos will continue to serve as a director of the Company for so long as she remains Chief Executive Officer and President.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Campos&#8217; Employment Agreement provides for an initial employment term of 3 years and for automatic renewal for successive 1-year terms thereafter unless either party provides notice of non renewal at least 60 days prior to the end of the then-current term. As provided in the Employment Agreement, Ms. Campos will serve the Company on a full-time basis and will receive an annual base salary of $550,000, which may be increased in the discretion of the board of directors (but may not be decreased other than as part of a proportionate reduction in management salaries and wages applicable to all senior management). Ms. Campos will receive a signing bonus of $120,000, which is subject to repayment if Ms. Campos leaves the Company within one year under circumstances detailed in the Employment Agreement. Ms. Campos will also receive customary expense reimbursement (in accordance with the Company&#8217;s standard policies), and will receive the medical, health, and other benefits provided to Company employees generally, including participation in the Company&#8217;s 401(k) plan on the same basis as other employees generally. The Employment Agreement provides that Ms. Campos will be eligible to receive an annual performance bonus based on annual performance goals determined by the Company&#8217;s board of directors, with a target annual bonus of 100% of Ms. Campos&#8217; base salary and a maximum bonus of 200% of base salary. The agreement includes customary restrictive covenants, including confidentiality and non-solicitation covenants and a one-year post-employment non-compete restriction.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Employment Agreement, Ms. Campos will be entitled to equity grants under the Company&#8217;s current or future equity plan, as follows: On April 29, 2024, Ms. Campos received a grant of restricted stock units (&#8220;RSUs&#8221;) under the Company&#8217;s 2022 Employee Equity Compensation Plan for a number of RSUs equal to $2.0&#160;million divided by the closing price of the Company&#8217;s common stock on the Nasdaq Stock Market on the date of grant. Such RSUs will vest in one-third increments on each of the first 3 anniversaries of the date of grant so long as Ms. Campos continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. Thereafter, Ms. Campos will be entitled to annual grants of RSUs and performance stock units (&#8220;PSUs&#8221;) having an aggregate value per grant of $750,000 for the annual RSU grant and $750,000 for the annual PSU grant, with such value being calculated based on the closing price of the Company&#8217;s common stock on the date of grant but subject to a floor of $4.00 per share. The RSUs included in any such annual grants will vest in the same manner as the initial RSU grant, and the PSUs will have a 3-year performance period and such performance goals and other terms as shall be determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appointment of Justin L. Mennen as a Director</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2024, the Board of Directors (the &#8220;Board&#8221;) of PetMed Express, Inc. (the &#8220;Company&#8221;), appointed Justin L. Mennen to serve as a director of the Company beginning June 3, 2024. Mr. Mennen will hold this position until the 2024 annual meeting of the Company&#8217;s stockholders or until his successor is elected and qualified, subject to his earlier resignation or removal. Mr. Mennen has been appointed to serve on the Board&#8217;s Audit Committee and Corporate Governance and Nominating Committee. In connection with his appointment to the Board, Mr. Mennen will receive compensation in accordance with the Company&#8217;s Non-Employee Director Compensation Program.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Transition and Separation Agreement with Christine Chambers</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 31, 2024, PetMed Express, Inc. (the &#8220;Company&#8221;) entered into a Transition and Separation Agreement (the &#8220;Chambers Agreement&#8221;) with Christine Chambers, the Company&#8217;s Chief Financial Officer, Treasurer, and Secretary, pursuant to which the Company and Ms. Chambers agreed to the mutual termination of Ms. Chambers&#8217; employment with the Company following a transition period.  Under the terms of the Agreement, the Company and Ms. Chambers mutually agreed to terminate the Executive Employment Agreement, dated August 3, 2022, between the Company and Ms. Chambers effective immediately (notwithstanding the scheduled expiration date of August 3, 2024), provided that Ms. Chambers will continue to serve as the Company&#8217;s Chief Financial Officer, Secretary, and Treasurer on a full-time basis for a transition period (the &#8220;Transition Period&#8221;) that will end on the fifth business day after the Company files its Quarterly Report on Form 10-Q for the Company&#8217;s fiscal quarter ending June 30, 2024, or, if earlier, upon the fifteenth day after written notice by the Company of the earlier termination of the Transition Period. Ms. Chambers will work with and cooperate with the Company in transitioning her duties and responsibilities to such successor.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chambers Agreement provides that, during the Transition Period, Ms. Chambers will continue to receive her current base salary and benefits, and upon the completion of the Transition Period and contingent on Ms. Chambers&#8217; complying with the terms of the Chambers Agreement, the Company will accelerate the vesting of all unvested restricted shares and restricted stock units that were originally scheduled to vest on or before August 3, 2025. Ms. Chambers has agreed to a customary general release and waiver of claims against the Company in exchange for the Company&#8217;s covenants and agreements set forth in the Chambers Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223466324336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">$ (7,464)<span></span>
</td>
<td class="nump">$ 5,140<span></span>
</td>
<td class="nump">$ 18,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468647232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223472649616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223571039568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include PetMed Express, Inc. and its  wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification ("ASC") Topic 805 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Business Combinations"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The purchase price is allocated to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company&#8217;s unaudited condensed consolidated financial statements from the date of acquisition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">      Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain obligations assumed. Acquisition-related transaction costs incurred by the Company are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March&#160;31, 2024 and 2023 consisted of the Company&#8217;s cash accounts and money market accounts with a maturity of three months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times,  may exceed federally insured limits. The Company has not experienced any losses in such accounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div>Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of thirty years. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from <span style="-sec-ix-hidden:f-317">three</span> to ten years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. Goodwill is not amortized but instead is tested for impairment annually on January 1, or more frequently if events or changes in circumstances indicate goodwill might be impaired. When testing goodwill for impairment, the Company has the option to choose whether it will apply a qualitative assessment first and then a quantitative assessment, if necessary, or to apply the quantitative assessment directly. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit   </span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company performed its annual goodwill impairment testing as of January 1, 2024 using a </span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">quantitative </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">assessment and at that time concluded there was no impairment. Since then, the Company&#8217;s stock price decreased from $7.56 at December 31, 2023 to $4.79 at March 31, 2024.  The Company considered the decrease in its stock price to be indicative of a risk that the carrying amount of goodwill may not be recoverable.  Therefore, the Company performed a quantitative impairment assessment as of March 31, 2024.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Based on the assessment, the Company concluded that goodwill was not impaired because the estimated fair value of the reporting unit exceeded its carrying value by approximately 27%.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We estimated fair value using discounted cash flow and public company market approaches with a 70% and 30% weighting, respectively.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A key assumption under the cash flow approach was a 27% weighted average cost of capital.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">  </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A key assumption under the public company market approach was a 10% control premium.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired definite-lived intangible assets in the acquisition (see Note 4) that will be amortized based on their estimated useful lives in accordance with ASC Topic 350 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span>&#8221;). These definite-lived intangible assets are being amortized over periods ranging from <span style="-sec-ix-hidden:f-331">three</span> to seven years. Acquired trade name is not being amortized and is subject to an annual review for impairment consistent with the existing intangible assets in fiscal 2024.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OtherAssetsPolicyTextBlock', window );">Other Assets</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Assets</span></div>Other assets consist of the initial minority interest investment in Vetster.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div>The Company's advertising expense consists primarily of Internet marketing and direct mail/print, . Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC Topic 842 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Leases")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are reported as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities and long-term lease liabilities on the unaudited Condensed Consolidated Balance Sheets.  The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#8217;s lease agreements do not contain any residual value guarantees.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Income</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC Topic 220 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting Comprehensive Income</span>&#8221;) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the provisions of ASC Topic 740 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by &#8220;Accounting for Uncertainty in Income Taxes&#8221; guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies &#8220;Accounting for Uncertainty in Income Taxes&#8221; guidance to all tax positions for which the statute of limitations remains open. The Company had no liabilities for uncertain tax positions for either fiscal 2024 or fiscal 2023. The Company files tax returns in the U.S. federal jurisdiction and Florida,  Arizona, California, Connecticut, Idaho, Maryland, Michigan, Oklahoma, South Carolina, Virginia, Wisconsin, New Jersey, Georgia, Indiana, New York and the District of Columbia. With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending March&#160;31, 2020, or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Business Concentrations</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Concentrations</span></div>The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our product lines to obtain the lowest cost.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accounting for Share Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for Share Based Compensation</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The compensation expense related to all of the Company&#8217;s stock-based compensation arrangements is recorded as a component of general and administrative expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company&#8217;s consolidated financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_OtherAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_OtherAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223471195376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Rollforward of Deferred Revenue</a></td>
<td class="text">As shown in the following table, under the PetPlus program, the Company recognized  $7.0 million deferred annual membership fees in the twelve months ended March&#160;31, 2024, and had $2.6 million of deferred revenue as of the year ended March&#160;31, 2024.<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.878%"><tr><td style="width:1.0%"></td><td style="width:68.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">( amounts in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue acquired with PetCareRx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred memberships fees received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred membership fee revenue recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text">The following table illustrates sales by various classifications:<div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:29.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales (In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reorder sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New order sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Membership fees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,485&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:29.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales (In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reorder sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New order sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,579&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,703)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468234496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Acquired Identifiable Assets, Liabilities Assumed and Goodwill</a></td>
<td class="text"><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below outlines the purchase price allocation of the purchase for PetCareRx to the acquired identifiable assets, liabilities assumed and goodwill (in thousands):</span></div><div><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro-Forma Information</a></td>
<td class="text"><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The supplemental pro forma financial information for the prior period twelve months ended March&#160;31, 2023 and 2022 is as follows (in thousands):</span></div><div><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:47.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223557898384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major classifications of property and equipment consist of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building Improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,785&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223570305696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major classifications of accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued credit card fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued salaries and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued merchandise credits / reward program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales return allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued real estate taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468044560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible and Other Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Other Assets</a></td>
<td class="text"><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets and other assets, net consisted of the following (in thousands):</span></div><div><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:35.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful Life (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toll-free telephone number</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internet domain names</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Names - PetCareRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships -PetCareRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology - PetCareRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,957)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minority interest investment in Vetster</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,957)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,503&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toll-free telephone number</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internet domain names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minority interest investment in Vetster</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes expected amortization of our intangible assets at March 31, 2024 (in thousands):</span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.757%"><tr><td style="width:1.0%"></td><td style="width:66.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223466513424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs and Activity</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease costs as recorded in the general and administrative costs and activity for the twelve months ended March&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.636%"><tr><td style="width:1.0%"></td><td style="width:69.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Twelve months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating lease cost - fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating lease costs - variable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information for the twelve months ended March&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"><tr><td style="width:1.0%"></td><td style="width:71.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Twelve months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash paid for the amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Right-of-use assets obtained in exchange for new operating lease liabilities as a result of acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company&#8217;s lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating lease liabilities recognized on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.878%"><tr><td style="width:1.0%"></td><td style="width:67.299%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less: Imputed Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468835392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are as follows (in thousands):<div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales tax liability</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt and inventory reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax accounting method change</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,627)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,585)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,527)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text">Outlined below are the tax attributes acquired and the balances remaining as of March 31, 2024 (in thousands).<div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:29.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PetCareRx Tax Attributes Acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sec. 382 limited utilization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attributes for which a deferred tax asset is recorded</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - limited carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,454</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,154</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2024 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - unlimited carryover</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,501</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,501</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disallowed business interest expense carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2026 </span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:29.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Attribute as of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sec. 382 limited utilization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attributes for which a deferred tax asset is recorded</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - limited carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,114</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2025 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating losses - unlimited carryover</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,501</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,501</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disallowed business interest expense carryover</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;None </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Beginning in FY 2026 </span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Provision</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax provision consist of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:54.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax provision</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax provision (benefit)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,629)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income tax provision computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:54.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes at federal statutory rates</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock shortfall adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the effective income tax rate and the statutory U.S. federal income tax rate are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:54.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal rate on income before taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock shortfall adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Effective Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223472890000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Schedule of Dividend Declaration</a></td>
<td class="text">During fiscal 2024, our Board of Directors declared the following dividends:<div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.272%"><tr><td style="width:1.0%"></td><td style="width:20.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Dividend</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Record Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Amount<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 22, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 6, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,352</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 14, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,344</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 18, 2023</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223469013872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2024, restricted stock award ("RSA") activity under the Plans was as follows:</span></div><div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:40.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2016 Employee<br/>Plan<br/>Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Employee Plan Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Plans<br/>Number of<br/>Shares</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,829</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted and issued</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,742</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,765</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,343)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,418)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,332)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,093)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,914)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,127)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,334)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,375)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,343</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,707</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,076</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,126</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Share-Based Payment Arrangement, Restricted Stock Unit, Activity</a></td>
<td class="text">RSU activity under the Plans was as follows:<div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.272%"><tr><td style="width:1.0%"></td><td style="width:54.236%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>&#160;Grant Date<br/>&#160;Fair Value Per RSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding at March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,880</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,800)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,080</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.75&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">Share-Based Payment Arrangement, Performance Shares, Outstanding Activity</a></td>
<td class="text"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended March 31, 2024, PSU activity under the Plans was as follows:</span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"><tr><td style="width:1.0%"></td><td style="width:53.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 37pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>&#160;Grant Date<br/>&#160;Fair Value Per PSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested PSUs outstanding at March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223568974432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (lLoss) Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net (Loss) Income Per Share</a></td>
<td class="text">The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for per share amounts):<div style="margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:54.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income (numerator):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (denominator)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding used in basic computation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,395,959</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,274,786</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,175,930</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon the vesting of restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,091</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,765</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon conversion of preferred shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,125</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,125</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted computation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,395,959</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,357,820</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223461057104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ / shares in Units, ft&#178; in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>tenant </div>
<div>reporting_unit </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percent of fair value in excess of carrying amount</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Liabilities for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Valuation Technique, Discounted Cash Flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ReportingUnitMeasurementInput', window );">Reporting unit measurement type</a></td>
<td class="nump">0.70<span></span>
</td>
<td class="nump">0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Valuation Technique, Discounted Cash Flow | Measurement Input, Weighted Average Cost Of Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ReportingUnitMeasurementInput', window );">Reporting unit measurement type</a></td>
<td class="nump">0.27<span></span>
</td>
<td class="nump">0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember', window );">Valuation, Market Approach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ReportingUnitMeasurementInput', window );">Reporting unit measurement type</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember', window );">Valuation, Market Approach | Measurement Input, Control Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ReportingUnitMeasurementInput', window );">Reporting unit measurement type</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember', window );">Cost of Goods and Service Benchmark | Supplier Concentration Risk | Six Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all products purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember', window );">Cost of Goods and Service Benchmark | Supplier Concentration Risk | Seven Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all products purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=pets_DelrayBeachPropertyMember', window );">Delray Beach Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_PercentageOfPropertyLeasedToTenants', window );">Percentage of property leased to tenants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property (in square feet) | ft&#178;</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_NumberOfTenants', window );">Number of tenants | tenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RentalIncomeNonoperating', window );">Rental revenue</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">Lessor, operating lease, payment to be received, 2025</a></td>
<td class="nump">617,000<span></span>
</td>
<td class="nump">617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">Lessor, operating lease, payment to be received, 2026</a></td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">Lessor, operating lease, payment to be received, 2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">Lessor, operating lease, payment to be received, 2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">Lessor, operating lease, payment to be received, 2028</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment useful life</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Definite-lived intangible assets useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture, Fixtures, Equipment and Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Definite-lived intangible assets useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture, Fixtures, Equipment and Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_NumberOfTenants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_NumberOfTenants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_PercentageOfPropertyLeasedToTenants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage amount of property that was leased to tenants of the property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_PercentageOfPropertyLeasedToTenants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ReportingUnitMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ReportingUnitMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RentalIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RentalIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=pets_MeasurementInputWeightedAverageCostOfCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=pets_MeasurementInputWeightedAverageCostOfCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputControlPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputControlPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=pets_SixSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=pets_SixSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=pets_SevenSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=pets_SevenSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=pets_DelrayBeachPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=pets_DelrayBeachPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pets_FurnitureFixturesEquipmentAndComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pets_FurnitureFixturesEquipmentAndComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468060016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>model </div>
<div>category </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerNumberOfMembershipModels', window );">Number of membership models | model</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 2,603<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerNumberOfSalesCategories', window );">Number of sales categories | category</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 281,064<span></span>
</td>
<td class="nump">256,579<span></span>
</td>
<td class="nump">$ 272,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_MembershipFeesMember', window );">Membership fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">9,783<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_ReorderMember', window );">Reorder sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">246,977<span></span>
</td>
<td class="nump">232,380<span></span>
</td>
<td class="nump">243,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_ReorderMember', window );">Reorder sales | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_NewOrderMember', window );">New order sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 24,304<span></span>
</td>
<td class="nump">$ 24,199<span></span>
</td>
<td class="nump">28,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_NewOrderMember', window );">New order sales | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_MembershipCustomersMember', window );">Membership Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ContractWithCustomerRenewalPeriod', window );">Annual membership fees renewal period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ContractWithCustomerRevenueRecognitionPeriod', window );">Revenue recognition period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred membership fee revenue recognized</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_MembershipCustomersMember', window );">Membership Customers | Partner Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ContractWithCustomerRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Renewal Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ContractWithCustomerRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ContractWithCustomerRevenueRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Revenue Recognition, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ContractWithCustomerRevenueRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_RevenueFromContractWithCustomerNumberOfMembershipModels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Number Of Membership Models</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_RevenueFromContractWithCustomerNumberOfMembershipModels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_RevenueFromContractWithCustomerNumberOfSalesCategories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Number Of Sales Categories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_RevenueFromContractWithCustomerNumberOfSalesCategories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pets_MembershipFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pets_MembershipFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pets_ReorderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pets_ReorderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pets_NewOrderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pets_NewOrderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pets_MembershipCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pets_MembershipCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pets_PartnerProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pets_PartnerProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223473082240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Rollforward of Deferred Revenue (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Contract With Customer, Liability, Current [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, ending balance</a></td>
<td class="nump">2,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Contract With Customer, Liability, Current [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Deferred revenue acquired with PetCareRx</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_MembershipCustomersMember', window );">Membership Customers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Contract With Customer, Liability, Current [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived', window );">Deferred memberships fees received</a></td>
<td class="nump">6,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred membership fee revenue recognized</a></td>
<td class="num">(7,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, ending balance</a></td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ContractWithCustomerLiabilityCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ContractWithCustomerLiabilityCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Liability, Increase For Deferred Fees Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pets_MembershipCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pets_MembershipCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223473183328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 281,064<span></span>
</td>
<td class="nump">$ 256,579<span></span>
</td>
<td class="nump">$ 272,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerPercentage', window );">Sales, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerVariance', window );">Revenues, variance</a></td>
<td class="nump">$ 24,485<span></span>
</td>
<td class="num">$ (15,703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerVariancePercentage', window );">Revenues, variance, percentage</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_ReorderMember', window );">Reorder sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 246,977<span></span>
</td>
<td class="nump">$ 232,380<span></span>
</td>
<td class="nump">$ 243,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerPercentage', window );">Sales, percentage</a></td>
<td class="nump">87.90%<span></span>
</td>
<td class="nump">90.60%<span></span>
</td>
<td class="nump">89.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerVariance', window );">Revenues, variance</a></td>
<td class="nump">$ 14,597<span></span>
</td>
<td class="num">$ (11,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerVariancePercentage', window );">Revenues, variance, percentage</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_NewOrderMember', window );">New order sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 24,304<span></span>
</td>
<td class="nump">$ 24,199<span></span>
</td>
<td class="nump">$ 28,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerPercentage', window );">Sales, percentage</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerVariance', window );">Revenues, variance</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="num">$ (4,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerVariancePercentage', window );">Revenues, variance, percentage</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pets_MembershipFeesMember', window );">Membership fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 9,783<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerPercentage', window );">Sales, percentage</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RevenueFromContractWithCustomerVariance', window );">Revenues, variance</a></td>
<td class="nump">$ 9,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_RevenueFromContractWithCustomerPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue from the specified category to the total revenue during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_RevenueFromContractWithCustomerPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_RevenueFromContractWithCustomerVariance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of changes in revenue in current period comparing to the same period in the previous year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_RevenueFromContractWithCustomerVariance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_RevenueFromContractWithCustomerVariancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of changes in revenue in current period comparing to the same period in the previous year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_RevenueFromContractWithCustomerVariancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pets_ReorderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pets_ReorderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pets_NewOrderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pets_NewOrderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pets_MembershipFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pets_MembershipFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468469616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,658,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of equity interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Aggregate consideration</a></td>
<td class="nump">$ 36,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">26,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate', window );">Discount rate applied to intangible assets acquired</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Acquisition related costs incurred</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill, Fair Value Disclosure, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223472514816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition - Schedule of Acquired Identifiable Assets, Liabilities Assumed and Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 26,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets', window );">Right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Other Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223557852048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Schedule of Pro-Forma Information (Details) - PetCareRx - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">$ 300,230<span></span>
</td>
<td class="nump">$ 311,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (261)<span></span>
</td>
<td class="nump">$ 13,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223461842480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 46,785<span></span>
</td>
<td class="nump">$ 41,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(20,128)<span></span>
</td>
<td class="num">(15,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">26,657<span></span>
</td>
<td class="nump">26,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,999<span></span>
</td>
<td class="nump">14,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,511<span></span>
</td>
<td class="nump">3,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,246<span></span>
</td>
<td class="nump">9,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 9,329<span></span>
</td>
<td class="nump">$ 9,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223471198096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_AccruedCreditCardFeesCurrent', window );">Accrued credit card fees</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">$ 401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued salaries and benefits</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_AccruedMerchandiseCreditsAndRewardsCurrent', window );">Accrued merchandise credits / reward program</a></td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional expenses</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_AccruedSalesReturnsAndAllowancesCurrent', window );">Accrued sales return allowance</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Accrued dividends payable</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent', window );">Accrued real estate taxes</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">1,136<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,060<span></span>
</td>
<td class="nump">$ 6,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_AccruedCreditCardFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for credit card fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_AccruedCreditCardFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_AccruedMerchandiseCreditsAndRewardsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued merchandise credits and rewards classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_AccruedMerchandiseCreditsAndRewardsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_AccruedSalesReturnsAndAllowancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents accrued sales returns and allowances. Used to reflect the current portion (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_AccruedSalesReturnsAndAllowancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223558519664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible and Other Assets, Net - Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract', window );"><strong>Gross Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,160<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Net Carrying Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,203<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Minority interest purchased, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Minority interest investment in Vetster</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_IntangiblesAndOtherAssetsAbstract', window );"><strong>Intangibles and Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_IntangibleAndOtherAssetsGross', window );">Intangible and other assets, Gross Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,460<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_IntangiblesAndOtherAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_IntangibleAndOtherAssets', window );">Intangible and Other Assets, Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,503<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire investments</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pets_VetsterIncMember', window );">Vetster Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_IntangiblesAndOtherAssetsAbstract', window );"><strong>Intangibles and Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships -PetCareRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Definite-lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract', window );"><strong>Gross Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Net Carrying Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Remaining Useful Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology - PetCareRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Definite-lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract', window );"><strong>Gross Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Net Carrying Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Remaining Useful Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pets_TollFreeTelephoneNumberMember', window );">Toll-free telephone number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract', window );"><strong>Gross Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Net Carrying Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Internet domain names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract', window );"><strong>Gross Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Net Carrying Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names - PetCareRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract', window );"><strong>Gross Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Net Carrying Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_IntangibleAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_IntangibleAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_IntangibleAndOtherAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible And Other Assets, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_IntangibleAndOtherAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_IntangiblesAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangibles and Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_IntangiblesAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_IntangiblesAndOtherAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangibles And Other Assets, Accumulated Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_IntangiblesAndOtherAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pets_VetsterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pets_VetsterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pets_TollFreeTelephoneNumberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pets_TollFreeTelephoneNumberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468424176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible and Other Assets, Net - Expected Amortization (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">1,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 7,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223473175472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible and Other Assets, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 281,064<span></span>
</td>
<td class="nump">$ 256,579<span></span>
</td>
<td class="nump">$ 272,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount</a></td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Percent of revenue generated</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Percent of revenue generated</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223558640032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease option to extend period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease option to extend period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223558656720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Costs and Activity (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost - fixed</a></td>
<td class="nump">$ 853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Operating lease costs - variable</a></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for the amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities as a result of acquisition</a></td>
<td class="nump">$ 2,220<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223472616464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturity of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest</a></td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223471283808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued sales tax liability</a></td>
<td class="nump">$ 5,126<span></span>
</td>
<td class="nump">$ 5,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other accrued expenses</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Deferred stock compensation</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Bad debt and inventory reserves</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development costs</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">3,001<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">10,195<span></span>
</td>
<td class="nump">7,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_DeferredTaxLiabilitiesChangeInAccountingMethod', window );">Tax accounting method change</a></td>
<td class="num">(541)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(2,627)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(1,041)<span></span>
</td>
<td class="num">(2,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use assets</a></td>
<td class="num">(376)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Total deferred tax liabilities</a></td>
<td class="num">(4,585)<span></span>
</td>
<td class="num">(2,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(624)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets</a></td>
<td class="nump">$ 4,986<span></span>
</td>
<td class="nump">$ 5,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_DeferredTaxLiabilitiesChangeInAccountingMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Change In Accounting Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_DeferredTaxLiabilitiesChangeInAccountingMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468348288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible executive compensation</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment', window );">Deferred tax asset adjustment</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount', window );">Compensation of covered executives</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Restricted stock shortfall adjustment</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="num">$ (184)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Compensation Of Covered People Limit Deduction Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deferred Tax Asset Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223461833424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax Attributes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_DisallowedBusinessInterestExpenseCarryover', window );">Disallowed business interest expense carryover</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardAxis=pets_DeferredTaxAssetIsRecordedMember', window );">Attributes for which a deferred tax asset is recorded</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_DisallowedBusinessInterestExpenseCarryover', window );">Disallowed business interest expense carryover</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsSubjectToLimitations', window );">Federal net operating losses - limited carryover</a></td>
<td class="nump">84,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsNotSubjectToLimitations', window );">Federal net operating losses - unlimited carryover</a></td>
<td class="nump">10,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Sec. 382 limited utilization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsSubjectToLimitations', window );">Federal net operating losses - limited carryover</a></td>
<td class="nump">83,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Attributes for which a deferred tax asset is recorded</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsSubjectToLimitations', window );">Federal net operating losses - limited carryover</a></td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsNotSubjectToLimitations', window );">Federal net operating losses - unlimited carryover</a></td>
<td class="nump">10,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Sec. 382 limited utilization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Attributes for which a deferred tax asset is recorded</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">8,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_DisallowedBusinessInterestExpenseCarryover', window );">Disallowed business interest expense carryover</a></td>
<td class="nump">1,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx | Attributes for which a deferred tax asset is recorded</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_DisallowedBusinessInterestExpenseCarryover', window );">Disallowed business interest expense carryover</a></td>
<td class="nump">1,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsSubjectToLimitations', window );">Federal net operating losses - limited carryover</a></td>
<td class="nump">85,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsNotSubjectToLimitations', window );">Federal net operating losses - unlimited carryover</a></td>
<td class="nump">10,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx | Federal | Sec. 382 limited utilization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsSubjectToLimitations', window );">Federal net operating losses - limited carryover</a></td>
<td class="nump">83,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx | Federal | Attributes for which a deferred tax asset is recorded</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsSubjectToLimitations', window );">Federal net operating losses - limited carryover</a></td>
<td class="nump">2,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_OperatingLossCarryforwardsNotSubjectToLimitations', window );">Federal net operating losses - unlimited carryover</a></td>
<td class="nump">10,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx | State | Sec. 382 limited utilization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember', window );">PetCareRx | State | Attributes for which a deferred tax asset is recorded</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 8,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_DisallowedBusinessInterestExpenseCarryover">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disallowed Business Interest Expense Carryover</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_DisallowedBusinessInterestExpenseCarryover</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_OperatingLossCarryforwardsNotSubjectToLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_OperatingLossCarryforwardsNotSubjectToLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_OperatingLossCarryforwardsSubjectToLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_OperatingLossCarryforwardsSubjectToLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_OperatingLossCarryforwardAxis=pets_DeferredTaxAssetIsRecordedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_OperatingLossCarryforwardAxis=pets_DeferredTaxAssetIsRecordedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_OperatingLossCarryforwardAxis=pets_SEC382LimitedUtilizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_OperatingLossCarryforwardAxis=pets_SEC382LimitedUtilizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223560505248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 2,623<span></span>
</td>
<td class="nump">$ 5,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax provision</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">6,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax provision (benefit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">412<span></span>
</td>
<td class="num">(453)<span></span>
</td>
<td class="num">(778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(1,176)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Total deferred taxes</a></td>
<td class="nump">293<span></span>
</td>
<td class="num">(1,629)<span></span>
</td>
<td class="num">(847)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 1,191<span></span>
</td>
<td class="nump">$ 2,305<span></span>
</td>
<td class="nump">$ 5,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468680576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes at federal statutory rates</a></td>
<td class="num">$ (1,317)<span></span>
</td>
<td class="nump">$ 1,564<span></span>
</td>
<td class="nump">$ 5,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible executive compensation</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other permanent differences</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Restricted stock shortfall adjustment</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Deferred tax adjustments</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 1,191<span></span>
</td>
<td class="nump">$ 2,305<span></span>
</td>
<td class="nump">$ 5,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223558624000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Total Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal rate on income before taxes (as percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit (as percent)</a></td>
<td class="num">(4.90%)<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible compensation (as percent)</a></td>
<td class="num">(28.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences (as percent)</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Restricted stock (windfall) shortfall adjustment (as percent)</a></td>
<td class="num">(4.50%)<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Deferred tax adjustments (as percent)</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (as percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total Effective Tax Rate (as percent)</a></td>
<td class="num">(19.00%)<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">22.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223557837968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 1998</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock, shares issued, price per share (in dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares)</a></td>
<td class="nump">4.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference (in dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223469524208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholder's Equity - Declared Dividends (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>May 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Per Share Dividend (in dollars per share)</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Total Amount</a></td>
<td class="nump">$ 6,344<span></span>
</td>
<td class="nump">$ 6,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480191/946-405-45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223454948080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Stock - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 03, 2022</div></th>
<th class="th"><div>Aug. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,617,000<span></span>
</td>
<td class="nump">$ 4,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average restriction and forfeiture period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue', window );">Granted, total grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average restriction and forfeiture period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue', window );">Granted, total grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,800)<span></span>
</td>
<td class="num">(3,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember', window );">2015 Director Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">255,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance', window );">Common stock available for issuance, automatic annual increase, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember', window );">2015 Director Plan | Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RestrictionPeriod', window );">Restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember', window );">2015 Director Plan | Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RestrictionPeriod', window );">Restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember', window );">2016 Employee Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember', window );">2016 Employee Plan | Restricted Stock | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember', window );">2016 Employee Plan | Restricted Stock | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember', window );">2016 Employee Plan | Performance Restricted Stock | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod', window );">Absolute stock price hurdle period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember', window );">2016 Employee Plan | Performance Restricted Stock | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember', window );">2022 Employee Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember', window );">2022 Employee Plan | Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RestrictionPeriod', window );">Restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember', window );">2022 Employee Plan | Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_RestrictionPeriod', window );">Restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_EmployeeAndDirectorEquityCompensationPlanMember', window );">Employee and Director Equity Compensation Plan | Non-vested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average restriction and forfeiture period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember', window );">2022 Employee Plan | PSUs | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember', window );">2022 Employee Plan | PSUs | Chief Financial Officer | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember', window );">2022 Employee Plan | PSUs | Chief Financial Officer | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember', window );">2022 Employee Plan | PSUs | Chief Financial Officer | Share-Based Payment Arrangement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember', window );">2022 Employee Plan | PSUs | Chief Financial Officer | Share-Based Payment Arrangement, Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember', window );">2022 Employee Plan | RSUs | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember', window );">2022 Employee Plan | RSUs | Chief Financial Officer | Fiscal Year 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember', window );">2022 Employee Plan | RSUs | Chief Financial Officer | Fiscal Year 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of automatic increase in the amount of shares available for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_RestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of restriction of forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_RestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Total Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Hurdle Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_EmployeeAndDirectorEquityCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_EmployeeAndDirectorEquityCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pets_NonvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pets_NonvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=pets_ShareBasedPaymentArrangementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=pets_ShareBasedPaymentArrangementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pets_FiscalYear2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pets_FiscalYear2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pets_FiscalYear2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pets_FiscalYear2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223471283552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Stock - Non-vested Restricted Stock (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock outstanding at March 31, 2023 (in shares)</a></td>
<td class="nump">752,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="nump">103,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares)</a></td>
<td class="num">(114,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock forfeited or expired (in shares)</a></td>
<td class="num">(39,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock outstanding at March 31, 2024 (in shares)</a></td>
<td class="nump">703,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember', window );">2016 Employee Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock outstanding at March 31, 2023 (in shares)</a></td>
<td class="nump">684,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="nump">12,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares)</a></td>
<td class="num">(76,343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock forfeited or expired (in shares)</a></td>
<td class="num">(14,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock outstanding at March 31, 2024 (in shares)</a></td>
<td class="nump">605,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember', window );">2015 Director Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock outstanding at March 31, 2023 (in shares)</a></td>
<td class="nump">68,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="nump">1,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares)</a></td>
<td class="num">(29,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock forfeited or expired (in shares)</a></td>
<td class="num">(17,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock outstanding at March 31, 2024 (in shares)</a></td>
<td class="nump">23,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember', window );">2022 Employee Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock outstanding at March 31, 2023 (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="nump">89,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares)</a></td>
<td class="num">(8,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock forfeited or expired (in shares)</a></td>
<td class="num">(7,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested restricted stock outstanding at March 31, 2024 (in shares)</a></td>
<td class="nump">74,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468530208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Stock - Rollforward of RSU and PSU Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">85,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">88,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod', window );">Vested and issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(3,800)<span></span>
</td>
<td class="num">(3,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">85,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">12.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and issued (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">13.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 12.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod', window );">Vested and issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment', window );">Performance adjustment (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and issued (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue', window );">Performance adjustment (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223466494432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,296<span></span>
</td>
<td class="nump">$ 104,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223559074448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net (loss) income (numerator):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (7,464)<span></span>
</td>
<td class="nump">$ 5,140<span></span>
</td>
<td class="nump">$ 18,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares (denominator)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding used in basic computation (in shares)</a></td>
<td class="nump">20,395,959<span></span>
</td>
<td class="nump">20,274,786<span></span>
</td>
<td class="nump">20,175,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Common shares issuable upon the vesting of restricted stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,091<span></span>
</td>
<td class="nump">171,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Common shares issuable upon conversion of preferred shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,125<span></span>
</td>
<td class="nump">10,125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted computation (in shares)</a></td>
<td class="nump">20,395,959<span></span>
</td>
<td class="nump">20,339,002<span></span>
</td>
<td class="nump">20,357,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net (loss) income per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223467636640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (loss) Income Per Share - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">827,863<span></span>
</td>
<td class="nump">745,854<span></span>
</td>
<td class="nump">220,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223461066448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 13, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Aug. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember', window );">2016 Employee Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EmploymentTermInitialPeriod', window );">Initial employment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EmploymentTermSuccessiveRenewalPeriod', window );">Successive renewal employment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm', window );">Employment term cancellation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual base salary | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_TerminationPeriodPeriodWithinChangeInControl', window );">"Good Reason" termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SeverancePaymentBaseSalaryPeriod', window );">Severance pay equal to based salary for number of periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod', window );">Severance pay health insurance benefits, without cause termination, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod', window );">Severance pay health insurance benefits, change in control, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_NonCompeteAgreementPeriod', window );">Non-compete term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | 2016 Employee Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | 2016 Employee Plan | Performance Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod', window );">Absolute stock price hurdle period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod', window );">Employment performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod', window );">Achievement of absolute stock price hurdle period, consecutive days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | 2016 Employee Plan | Performance Restricted Stock Price Hurdle 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Stock hurdle price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | 2016 Employee Plan | Performance Restricted Stock Price Hurdle 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Stock hurdle price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | 2016 Employee Plan | Performance Restricted Stock Price Hurdle 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Stock hurdle price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | 2016 Employee Plan | Performance Restricted Stock Price Hurdle 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Stock hurdle price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | 2016 Employee Plan | Performance Restricted Stock Price Hurdle 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Stock hurdle price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_NumberOfSeverancePayments', window );">Number of severance payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_LumpSumSeverancePayments', window );">Lump-sum severance payments | $</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock, released in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual base salary | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_NonCompeteAgreementPeriod', window );">Non-compete term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SalaryAndWageOfficerSignOnBonus', window );">Sign on bonus | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod', window );">Requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ContingentLumpSumSeverancePayment', window );">Contingent lump sum severance payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_AccruedSeveranceCosts', window );">Accrued severance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer | 2016 Employee Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer | 2016 Employee Plan | Performance Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_AccruedSeveranceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Severance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_AccruedSeveranceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ContingentLumpSumSeverancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Lump Sum Severance Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ContingentLumpSumSeverancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Term, Cancellation Period Prior To End Of Current Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EmploymentTermInitialPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Term, Initial Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EmploymentTermInitialPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EmploymentTermSuccessiveRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Term, Successive Renewal Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EmploymentTermSuccessiveRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_LumpSumSeverancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents lump-sum severance payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_LumpSumSeverancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_NonCompeteAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Compete Agreement, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_NonCompeteAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_NumberOfSeverancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Severance Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_NumberOfSeverancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary And Wage, Officer, Sign Of Bonus, Requisite Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SalaryAndWageOfficerSignOnBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary And Wage, Officer, Sign On Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SalaryAndWageOfficerSignOnBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SeverancePaymentBaseSalaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance Payment, Base Salary, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SeverancePaymentBaseSalaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance Payment, Change In Control, Health Insurance Benefits, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance Payment, Termination Without Cause, Health Insurance Benefits, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Absolute Stock Price Hurdle Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Hurdle Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_TerminationPeriodPeriodWithinChangeInControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination Period, Period Within Change In Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_TerminationPeriodPeriodWithinChangeInControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockPriceHurdle5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223467837808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1', window );">Defined contribution plan, requisite service period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_DefinedContributionPlanWithIndividualAge', window );">Defined contribution plan, requisite age</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer match contribution percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employees gross compensation eligible for match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined contribution plan, matching contribution</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_DefinedContributionPlanWithIndividualAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum age that the individual is required in order to participate in the defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_DefinedContributionPlanWithIndividualAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482943/710-10-55-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140223468459728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EmploymentAgreementEmploymentTerm', window );">Employment term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EmploymentAgreementRenewalTerm', window );">Renewal term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_EmploymentAgreementNonRenewalNoticePeriod', window );">Non renewal notice period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SalaryAndWageOfficerAnnualBaseSalary', window );">Annual base salary</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SalaryAndWageOfficerSignOnBonus', window );">Sign on bonus</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod', window );">Requisite service period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SalaryAndWageTargetAnnualBonusPercentage', window );">Target annual bonus percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_SalaryAndWageMaximumBonusPercentage', window );">Maximum bonus percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare', window );">Subject to floor (in dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</a></td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Share-Based Payment Arrangement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance restricted stock vested (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount', window );">Annual grant amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | 2022 Employee Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | 2022 Employee Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount', window );">Grant issued amount</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount', window );">Annual grant amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted shares, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EmploymentAgreementEmploymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Agreement, Employment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EmploymentAgreementEmploymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EmploymentAgreementNonRenewalNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Agreement, Non Renewal Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EmploymentAgreementNonRenewalNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_EmploymentAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Agreement, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_EmploymentAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SalaryAndWageMaximumBonusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary And Wage, Maximum Bonus Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SalaryAndWageMaximumBonusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SalaryAndWageOfficerAnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary And Wage, Officer, Annual Base Salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SalaryAndWageOfficerAnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary And Wage, Officer, Sign Of Bonus, Requisite Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SalaryAndWageOfficerSignOnBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary And Wage, Officer, Sign On Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SalaryAndWageOfficerSignOnBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_SalaryAndWageTargetAnnualBonusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary And Wage, Target Annual Bonus Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_SalaryAndWageTargetAnnualBonusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Annual Grant Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted Stock Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Subject To Floor Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pets_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1^;O5IF_JT_<RU=6]U&*4S\"+YJO"N7[YHSER^/P4"@J=OZ0*-4%#/K+-/9
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M2V/+W$\+VU=!.0>[?Y#2G QW0->IT[]02P,$%     @ SD/.6!Y0+]93!@
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MB-Q-"7Y4;A4#&0AM[9:P1OD&9A5H-DT4B ]L<^O('+9V+#R13)UXEE$Z\-;
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M'P+(N9B;'9&G2?;@\\<O2=FC]HU33U/@[!0K*DIG6 9WWT=_V'<,;KJ.P:!
M\2X&6[<T2;)55"J=$>_(O3DQUCB.%%,(&W.H<&_+&%W[SK3.Y][,L1@D5!3C
M<<&;+;NT*(Q V.&5 A>2[>G2C+TQ$_,P]1AT=#"5& ?.?TA2N*C <)E-S+0=
M5CU^3E]#[JI/ @+&(I9SO.A)ESA%TC)2]A\L8E&X><U6.A5!>!W<XY+*$!)P
MDR'*W4_F?!+N772RA5V7@/5\&-YRR[J$E3U,R++GDW'34^>]6Q-]?@<+6\MT
M&->(NB+/5^B B)1;/:<=&F([)Q$A"+M#H@(U#BY5Y ,+:KO";72*TS%CJ4L3
M*VMQ<15#X8*2C_NH6,G-1;LX[ @,N->)2<_=P%%P:IR[5)=T.+,Q-7=!4R?%
M9(QBDVH;Z2YJ)/G@Y:9O=Z3HNRMI4>!@'HPO;(A5!Q?-#]N\SJ>0&A"KE^UR
MFQNQD1G%C^YPJU"$R[8')"C:Z!AMLG;AWD[/MCL$J5_2=4RCZ*0DCR?8'F.I
MAB6)==/2,:AH?I48\L#6)XK.'*D<T@C#HP>#F/OBZCM"T+5^,!-"'HFK:^R$
MAF'ZU=7XY.1$!9HV 1]I4I*"T\JD7D>SQC\#<\:>?CL)&_<\"UUOB_C7[X)A
MI=0'NA9';W8"Z\QX$?:X$RJF;3NSU(P>EB5/)[@-B EIYU@].9E<=E^Y2ID_
ML#1IR?J>6JAXLC/E<F X91P[4VL9#>A:V$Z*%C5L@.&^8L^6'=R!S?,.&ZZ#
M#["!GKM8]HLB]\DT-[B7SP^=_A *D/I42[I&)%/M28>E\,4:*8%@;-RZJA([
M%XW/4%G&>6XT\,J]@(Y[5:FA[.#?O=Q7^%X]>7%ZV1>%!\Q]_@IW=7IVX.V+
M<;RM ^\O^6JNTM6\A"3N29,1E^$V.FDT79)0F[EKF+$3YI W"YJ\!>(?^-Z&
M45BL[/=A%@*7/J'YW.7$>R%UT8U<5=??D3X!U6@:L\S:!IEM$MYGK:70#=UP
MU2EV7T/JY?=GB_1)02(&8%QGW#,I$6M6-!<35I7>)%GC>%\O.7JER)#,%I4B
M6+KW35S$U@%30UK+"_>BU=':;%;4L*\VB2VI+MOCPD;(>5B(.DI@L9%#QIV!
M7\6IZ11EX,K*W]O8TQ5!:FMIJ #B7()8CB2Y34C=[^AP\EXP>^QITS4@ #:8
M@IJI/";Q/@9:WSCBEAF18?&3>DS?<I>QL"D%I3Y(E?O=OP48#J+>K!G'?<Y=
M:9UT\J\?'LM%TD7RJJS(01.H@3T_M30[?;F\R/0E&R(C4(,#MY2E[Y]F:M.I
M2&K8EB8.&@"=0QW+%!9W]?]H[FC+%*?,;).2G,!E\4):0;$LSA+;S^IM3RQ]
M?1J)CL=1WN#4FAK1D6?<[J"^U/B;R"!MZ'*UK#8C?4_!>FJ:M8F):H]+7[D;
MUNGZOBRS@@WEX\WBP1";5/DD 8%WE]8*$=JUJ2N][MF/5QPLB[9DPQU4[\^)
M2'EWZM601_247ER'WE;@\"A46S+UI8X*S;6:@8A%"4/,9#F#3EX<"9NG?"T,
MQ7;7;[-M#EO<[:UI%"8I(1,G>.B!);6F[L6,6GS#3$"GGGUE[FE<C.^_!4^X
MUK3FQC9W;"I[9[A)@<2/=#_ QNDT+Y..Z3TZ33Y3&AQM588+"9V45*0TXJFP
M1K"/"/81P:8265BXJA0.Q*IWYIRZ8;VO3DL(L\#?.97,$H.B2E%RC%"",FPA
M[/D)U>P*CC0()[MPTE85S]V9\79%]=5*DC=8YJ:1T?7>>^UGZ&2O;_^OY8A[
M2-2R&;"9@/3S2R0EK8Q,\#1+'"&00#A0IE=O-Y?8.VP;LK;NY\&V3S,V.N@N
MB"7;TW\]'YXPLS2GDIFF;D"%!J+C%([Z'5XOE+;HQB+B2/E877O[)Y*VL;K!
MM>#\VM+G.$A7M,U8?2CUPHW))VZ0^T"<?@8[[%S78_7QKL*[)7;<.EP/8'B(
M$D'[U?JY95B_44L +@K+_V76ZA]D!1!Z_V0<5F@:R2ZMIBWT]G^<O^OLV0]<
M:RL:\755NYQ:/0$\'#3#6NI=K-+X8,81[K5RD8EZ\>WT=YZI<0.&C$7A.=US
MQ-C>'P*N7G;CUC1&EPE?NL N6"!!&T0+)YR1X36D$@G/=9T5FV74I-95K-]4
M:41ZX(U3!;_+,; @3TG4TS1?\VPP5\ZU +]GLCRUMJ5<(K7,-%^KX42\-=+!
M#T@SB^%<:Y+3I:Y;FN2$SZ!9SA)X!,A'7P]UZ?<=-%5O:%B&9B=^,^)TEZ3G
M*_B-.&7CHZQ3*AO3VXB7JKB(231/.]M( S9!"AJQ*2>Y0"#O+F.Q]B&'3:3%
MY,YD@W[#3//R2GI-+UYRCDW*WS%GF$8>G'W9,C>W"W)[TMDC[N.6\E\ZY+FC
MA/_=@E3VV$X826Y(!VC<G!N>CU:/+T^O^C M1^93JIT,^C+[4<CDDEAR8(J1
ML3F2^&4 )JL[A^V9\ZV)TQ@=2E!2DCL-+,#W71DH\*")V?IEEW>U:V-Q+NPO
M_4[A=\Q]RE3H9T6L09Z!T<!$""V5\&D.@]9O3*,,C]_A]/'>E(W'#OI?Z^C2
MK;@+P/HJI>:^T"RP4M5H9P1T?[B9',$X'\>/Y4,V<Q3?=J,PDWT_T3O.?EJY
M-'#8-_R[+:9&?F79/>U^HWHM/\WLE\L/7&'6YN35*C/#UI/)Y?.15*_3E\:M
M^(>:2-$;M^2/]"LGXVD!WL^<:](7.J#[Y>[;?P-02P,$%     @ SD/.6 FD
MDR0\"@  *QH  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULK5EK;]NX
M$OTKA#==I(#BA^S$3IL$2-,MML#M;M'N Q<7]P,MT18WDJ@EJ3C>7W_/\"'+
MKI.VP 6*QJ;(X<R9F3,S\M5&Z7M3"&'98U76YGI06-N\&HU,5HB*FZ%J1(TG
M*Z4K;O%5KT>FT8+G[E!5CM+Q^&)4<5D/;J[<VD=]<Z5:6\I:?-3,M%7%]?:-
M*-7F>C 9Q(5/<EU86AC=7#5\+3X+^WOS4>/;J).2RTK41JJ::;&Z'MQ.7KV9
MT7ZWX0\I-J;WF9$E2Z7NZ<O[_'HP)H5$*3)+$CC^/(@[498D"&K\'60.NBOI
M8/]SE/[.V0Y;EMR(.U7^*7-;7 \6 Y:+%6]+^TEM?A;!GG.2EZG2N/_9QN^=
MS0<L:XU553@,#2I9^[_\,>#0.[ 8/W$@#0=2I[>_R&GYEEM^<Z75AFG:#6GT
MP9GJ3D,Y69-3/EN-IQ+G[,TG\2#J5K!/(E/K6A)25R,+P?1XE 4A;[R0] DA
MDY1]4+4M#/NISD6^+V $C3JUTJC6F_19B1^X'K+I)&'I.)T](V_:F3EU\J9?
M,7.E5<7NH*M&. !J6[ [![+0[#^W2^/6_WL, 2]_=EP^I<XKT_!,7 ^0&T;H
M!S&X^?&'R<7X]3/:SSKM9\])_U8G?;<0]I[2(E,ZYW4F/!RWG^_8;ZJ1&;L8
M7[#3P5'DS#YT9O"2)<P6 ANJAM=;MA:UT-P*@\3UYY=;AER$4FM&"&5:-CXM
MZYS5JC[;6VS 1I7(9<;]5ZWR%K<F[L%*J3P!BS1-*4 /M.R^2(%/E:B64*B0
M#5L)6B#Y#\(*+6N0#B/7R$R8(;L3VH*TG,AXGJG52FB1,US:,^?''Q;I9/X:
M5HNED58PK@7+M6H87=1@OU4A67'WD/W60R)3(+ <RTQ: +!R<AMHD\F&ETSZ
MB[C6O%X[<]A29+PU8@_/C(!'JKM%TXA,KB2N70,*[ <W"XAG$L\AQ\ &[96B
M[5&Q(8N^S#HWTB<"0=502FA'\A0*:EG*M0,_89M"9@7)SD4)!@6(*EKAW#+<
MI5!&P!#B!*C2UI^"6>1C2PHM\1S\1?Z ]9HXL],S:.7Q<X;P+/@?+B-9//\+
M5T$:M^Y(#D&DC>$E(E1I1EAQ\F7&EUBB=6@@3:9:!(I3C==,&"NK<#08@3BU
MK:Y--)<,(;9WH5!(V <=H''#+72G?87: $X-/: 8_I&!T=FD(;L76_97FZ_)
MJ3OL):6$R\!_L&M3B#HZM_.=.?1<-+=1$O%!(8.Z2(M>5Q<3"$07/?N^82K+
M6A^2N+BOD7<-;$%1(75-)Z9Q.4I713"T<*1&"'ZIAC.A'ZL%9'$63NQ<W/ M
MW0N>D!:NH5W/!*M/W#T0G%R#[D'X!UJ:>^]2+39<YY2]3&UJG_Y#]H?4MN5E
MB8@HRZ/I[,.#7-UPF1-%95 %B90Y<5&#:%AKO#CX3R 1/!@9-P58Q5I/1@Z6
MC?+F:$%!5-\3H#G?$NGLY(?; ;^L$ N>!K(0J/X*%\-+7E)*TEK)J84AV>[L
M%T&E<THT86-*0$/^F!S$OP]TPD1MG& 2<[#D,(E9DL-PLJ"7!>(19"$%,87G
M;]OE])#]VMHEKLMWP41["OSGV)]HF7F>B/;Z@$/2;MFN7:-4)5JKL[(ENP!L
M\)<YI,;O)-@U0*QI-[ P#1U?RE+:K6.04 HT,WNJ$(9 CKXJRGJB)*@]9)^C
MD9DRU@6HRJ1#S95(%<%8:=<@,KZR1)0AY9TLWF7KD:3@/1;X9M#"%DAPI&C8
MJBU7LBR=^4'1(_C2DRYVANS#?BW=T8!'M.I"-;(9!86BJDU9XAH&2H5>2:X4
M:D@HD"NIC2]9^/(1_7[9FKWR#<VQ? <E/SWNJJOO,PPNA0'2,0W7%DG?/PL\
M'V3N>$*K=EWL!+F[45QWFTW<W>4)6>+=FY#;<)L%6BYE@[.3?DMA 7\A>&F+
MKKMPZ):*4H6NQ;ASSSX6',45WMKO=&1VWS:'/ NK*.7*</49C5O;)PJTX]9@
M@76V+=%\K1#>'N=CT I?36O6-G 3W5?7X#:60<>USVG> F]<D 7*JS$.N39A
M*[@.SBTH?-!)$B/4"&<?7U24]WN@+D2\LV-+B 81#+?U24 /J!K% G9$[:X1
M\=TEZ145&K);T#E*<AT3?J6(S2A)Z!*1,"1AN":*!FIKS:O]SK47SB?SX1C\
MC*85*&/2\SD9H#IH-..U=B-*4'3EQR%!XQ##, .]XS23!#J$_'1XT<F'V=T5
M$2!N(AH.]&/2ANRTRT2H$*29E^SM@;!D_^"4G3!7!R>OO]@*^OB[E3I2V"X)
MI\"CV]S/H$ /KBSF[ )F'=GFPJ[S_0[F4\#\57UGC,"B>27/90S[)UP!K*BE
M^4:'\](H=^0P12C<J5DE5YY9=>8^4%.("/2RJ83LT#G.0W3AD+U3^IO#XZOF
MQ(N"=$PEX'$$TR*Z?S_[J*C4:M=TQSZ;:A7U"IJ5DH<*V#4;:"X/\*>HW0^A
MQ-5/X=ZKE-O]2\&E?+W68NV&0%^XO\Q,5 >,>&*-MD*85Q!'+8P.VQ^@MMBP
M@Z4#=$(MV4]V!AA:FN5W=Z.W>^"H3HB"K(3AF)_\<(EK_TW)]=.!+][7J/<8
M -CI6^$_O62_ *[/3MSI>[(%TH *DLT!],+GU0MDU@NT5'V]3U@ZNT@NYW.V
MF \OW99TFB;3Q9A=CA'7M#"9)>>7<R0/B?CEP' 2D$S',[8(N_%U<GG)+H<S
M?WA\SL;N\V'1/F&7R7PQ1>Z>NYTNZ=/7W=\7W8YZ5&'RMX@0:B&[>Q>39'PQ
MPPUC9+^[^OPB.9]?]E=FR6QQ#F7HBO\+FE./9OH4FH?@I;-I,KL<LT4$Y'0R
M2283\,KI;'CQ\BE$^Q"FBV1^F<*J(/*4_#&%@,D%\=.+8]A\B<0\3=)%VELY
MG9PG\S').1\NG)A^[UI04^JG#+"_#*]E0/K<Q7[7^F'Q%CU)R7SJI0G17VC=
M:.BE.K@I5,AUZRVEX?6AXPQ#;1M&HNV9D8^!@7SVQ+1SK?P!3+&VK *!42$Z
M2EPIO:*E/M0/Q'O:]TSS%@_9[SLV ^&[O'P.@.19)0,!SLB5L9[2OI,T1;:%
ME7VV2O8L.FK0/J'1"VYZ5>+:IFY2<E+"T%@J\"EU.&%:CR?C'$4OS3"(@H5,
M>)W6-;5A(H5'(Q%;(NQ[\DTHQ6%\IC=:$. &*1(A4*&%[L^MH8E;\@S3,;2#
MRNT*;">I-UNABH !"X&'!X0=WP6X.:JG=.A VCH#R0*^J"'YZ-BXBHI:\W+[
MS\'(N$3#DXMEF#RR%K4>^E ;KRJ98>H1I)D;0BH,8+L7DN%MQH.DWP&<.KM7
ME-.47E&R=\ -XQYN>5^#]EL'%#N+T_:_G&,&+[W!S_EN0Z\8&MSVZ(Q'@WF2
MSJ<=-_F@FI[W%KZ_3!Y['SSJO<!'/*S=SQ3T=@[H^G?YW6KW2\BM_P%@M]W_
MC(*[UQ2EI5CAZ'@X/Q_X=S#QBU6-^SE@J2R"SWW$]()DH@UXOE+*QB]T0??[
MT,W_ %!+ P04    " #.0\Y87S#48#\+  !T'   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6RM66ESX[@1_2LHK7=C5]&V1/F:RU6>V4UV4SM'C3=7
MI?(!(D$)&1+@ *!D[:_/ZP8OR1J[DLH7FZ)P]/'Z]0/T>F/=%[]2*HB'JC3^
MS6050OWR_-QG*U5)?V9K9?!-85TE SZZY;FOG9(Y3ZK*\W0ZO3JOI#:3V]?\
M[I.[?6V;4&JC/CGAFZJ2;OM6E7;S9C*;="\^Z^4JT(OSV]>U7*I[%?Y2?W+X
M=-ZODNM*&:^M$4X5;R9WLY=O+V@\#_BK5AL_>A;DR<+:+_3AE_S-9$H&J5)E
M@5:0^+=6[U19TD(PXVN[YJ3?DB:.G[O5_\B^PY>%].J=+?^F\[!Z,[F9B%P5
MLBG#9[OY6;7^7-)ZF2T]_Q6;./;R8B*RQ@=;M9-A0:5-_"\?VCB,)MQ,OS$A
M;2>D;'?<B*W\409Y^]K9C7 T&JO1 [O*LV&<-I24^^#PK<:\<'N7?6VTUQ2A
MU^<!"]+K\ZR=_#9.3K\Q>9:*]]:$E1<_F5SENPN<PY+>G+0SYVWZY(KOI3L3
M\UDBTFEZ\<1Z\]Z].:\W_\9Z;QN/-]Z+=[9::",C$DPN[KP'XD?>BW_>+7QP
M0,F_#@4B;G-Q>!NJG)>^EIEZ,T%I>.76:G+[PW>SJ^FK)YRXZ)VX>&KUYW+T
MY.3#IHW]_FC$7>UT*>8<=?P-*T7QJJ79HFHPTJE<S*;3[X4M^$OM?8-7%$?4
MN0]XT&8I%(:&K= F*.P4/ W_I,([Z=3GAT1(\0%%^@\4J<BLJZT;LB%%"4*A
M-7Q3UZ56CN;6R%!A;9[P4Z5RG?$4G_"D=J@_$[_!)CER:2,]MJCJ4@6863?.
M-]($$2SFB;NE4PJT$GB13R5>8:_WRBVQZ_&D?>A'34[$8AN-K"P,' 4G$3]+
MY[;=W/MFD8A?3';VC*N;E2W+[:G=&$5.++S.-?BP"VX7^=X4K#LY289(\C)_
M5M*H$)3XU:J%.(;#3G%^39#$<]UJPZPV.]@\5\Z?Q*CM>RMJ9]<:M8S N[$Y
M/WQWD\ZN7_F=.(_SNQ-FFEC%I8?8P@^06UBQ_0")'8.#OQBYZ'D-W[BU7A,N
M1F%L\[V$S4N)"&#C; 5BANTZ4QB)C@$790^%H_G5V0SD699=$NAMT1CVT]EJ
M[.@? !WI5P(C5QCZ&%P[3LL270VKC!,'Q[Q>&ET KB:46Z$>:G89%8'PYDT6
ML$60I5TFHK(^"&.#7)14.7@TIP/2N_% O#99V7")4$F< 6A"YCF;-,;&PF&(
MI]%HT1Z6Y1JLIA<-+Y?)6BYT23@@BV"8<EJ93"5BJ>S2R7JE,TQ9 R$8!"I0
MV<I86 HO#.*1,4JH -N]92G6RN0 BU-EK,Z5KGU7U:B8TZ!,XUJZ&'8$](,L
MBAC?+G1.91:1^QW?+N'E!BFC>,L:<7C0Z,$*43I*K\ZNNW0".3!Y!4J"<V76
MP ;:*L)'/63$_6TI[ (#W\&?96M7J6-<0">8#(42%R$2D61[B^E":B?6LFSZ
M^L*")B#5R)^BF2KXGC//Q)\Z)T:.(<DT$:W&>!FE25^Z7OBM0;60&0BIATL$
MOI56:\P$#^T"J\VR;FDIR@4590I7%-B9,Q4+"'O4-E)UB05+CLPHD19I7X&'
M8P?HW7PFU6-H<HS@,Q2*:0IXUQ <]\=+H-1*9.)Q.3!L# >R0D0?@X8T'J@I
M4PP<N*F#JD;D1\2"M.I1.L)*!I%;JC+QM9&E+K;,;EXAMT0@;7(BMWRP _0
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M=\K22O9D16\@:J= YZ52]L(X!_VKNOX;4$L#!!0    ( ,Y#SEA1)MS,!P,
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MVH"+:1RBH]!?(H#O,VO#9B(;;/^[XOJ_4$L#!!0    ( ,Y#SEA\#_6OI 8
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M!GQER^4:Q*\="^#]TMK0W+"#]H>2\_\ 4$L#!!0    ( ,Y#SEB+#X,'CP@
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M[NWNX1&NG81%Y_=]^8D+WUBV@(,SK0C:E/L4PM@+ROG@Y7$A,![TBIQ.N0!
M^QZY?]J_A;^P+Y]WR^TK?+0(F!YP4*PAZLX6T835]K6XO='5UKR*7E5:5X7Y
MNA$<I:8%^'U=5;J[(0/]?Q/G_P502P,$%     @ SD/.6-2Z3J@K!   =PD
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M(]1.@<ZWBAJBW3@'_;?6\A=02P,$%     @ SD/.6/8_MDFU#0  5S   !D
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MVK=RZ )%0LE3'OC>+]\552CD*JI/=I;\\CN:[N\69 Q2++'<I@EH]AT#]TW
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ME/K94>,_F0-A\(D%4SIJU1!OTT(MC).)K(6WV=3TE1"NHG17.5Q&D(K6@LZ
M4R03!%&E4'@703AVG0@Q&WJ"6"Q>3)RKC3[*E BPS9QRZ J0%=@^0JXPNLF+
M9VY;;T!61(*H&EW2^HC6<>51W&Y\-&QS^(>>)7#:F_9FK%<F!GPR)FY2MC<=
MYCTFC9&NA1T!D/CB\L,*9B#(,(E1\\V[S(V!(;L^@$+1"\S.ZB?"= JVQD1F
MDFYJ- E9ZB-!/&3WY)'#E)IV_DWE.)H0%A91]/U .Y/&.EB-^R&#/]IG,>J
M/ "GX5G54'2RAMW@(%G\VK#K?9P2H<A#8:!%?AT^4AQ(O3-LZ=*?6_!1 'I
MDF)\0?SW<N:30ZMX-JU *KY$&U8Z6YY'=*,;2X(S.(LO+B=;5CZ+EQ>3(VK]
M&OUD4>V,W>Z;Z&7G&&#H!--5+#[2?*40DXLY-:DA+[Z5.N(@9><OO2WAY/DO
MT>1^R''$J46Z23">CG-TUXV/)_%N"%/0<GX,%&:D&LT_G =@NL'6;9RN_3 Y
M:$>CR2\+^B^ A@7H/M/:#1LV,/Z[V/X+4$L#!!0    ( ,Y#SECZ=T1PKPL
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M2%%JA_BW^-TN![JKY5(Q(^S<4!S1JN^_^VD^G[Y(6K3*\L^S%S],Q"= W;%
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ME,YHJJ2,MV+7&I)5YO-?,ZG$Q"QS]7\ K@/4_H8QN3=T@OZ/$_\%4$L#!!0
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M970R-RYX;6RM6VUSVS:V_BL8;7<WF9%E2W;BM$T\XZ1-;W:VFTS<M'/GSGZ
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MDO#=M #?%\;X](,.:/^\[.K_ 5!+ P04    " #.0\Y8&OE9"BT$   '"@
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M[]%^J=::M*!CR7B)TG E06.^\*ZBV2IQ^ ;PE>/.',G@,MDH]<LI-]G""UU
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M;"]W;W)K<VAE971S+W-H965T,S$N>&ULE57;;MLP#/T5PBN&#@CJ2QRWZ9(
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M5Z0AV][^[8,W=;AQU\;3_1V6)7TPH64#VB^,\?L'#M!]@BW^!5!+ P04
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MIZJ9BIE\8&J(7>J'<S'WHQ*O06\0'I!+0%,TH"O/-]V=N]1W'3^4Y0??<UG
MA7.SF#J7;5.1;]B1=0LVKWBC8,\5T-]*5-3VZIK0@@3>UMM*/"":50QO2DFM
M22$8"WB_JY>$0/G9K)3QS[Y9G->95M7!'UW*U>%6'H5,;Y'2O"G*9@U<?Y]B
M"$D6N?2$T==-V!!\2&/F9B3]1L0P(&0)I5([$@/F1J0:D&8(V=!-(P:!'[II
M$L/'UOM%FKAA%%["!1NZ49"1D+EAR.@;!)'K#^F([GV%I=6FK6$0F</4#5A*
M0DK:9B,<NF$:7_[OS")(_-B$ HP"]%-(R7N:0$KQ!BSI(67<D3+N)V5_.[GP
MZ'&Y;4K:[B-LK\?S37:SN/UQ'I*R@D_VK<;B:GJ/DGYZ3N_8*O0SYN6+C 7!
M*_BEDXY4R3(WRWPZ"-@@S8Z4."'08],3+H1NYON7QCH<A/&S@HH@BUV_<QU#
M3WF3KKS)SY5WCM).!4V.AX9TX<-)D'UU[G5]OLX_\%K-GT.%^7]18?XS5*"G
MPO=M/?Q!]%PJ/#X[O6M>_$.#@:W'8\7GL>9?49YCC7<R7-0HUW:$4I"+7:/;
M.:/;[::T:3N<?%-O1SQROBZI$A6NR-0GGCH@V[&I76BQM:/*4F@:?*RXH4D3
MI5&@\Y40^K@P#KK9=?(54$L#!!0    ( ,Y#SECG+$_$>P,  -D'   9
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;'U5VX[;-A#]E8%2!#8@6'?+=FP#
MZTV*!FB*139M4!1]H*6Q1:Q$JB2UWOY]AY2L>%&O7WB=.7/F1JY/4CWI"M'
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M+RHK0/<'*<UY8PV,O_GV/U!+ P04    " #.0\Y8L1]\4Y *   V9   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RUG?]OXC@:QO\5BUN==J1N(2%
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MHMLU4>N6NMT]NA.%R55!H5LB$S0ITP2\@[X0O" ID8\=-:FB1"7ZKN.'KJH
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M")J5ATN"Y:M!82#OSRD5NY-B@&;K;/(?4$L#!!0    ( ,Y#SEA:GGU\P0,
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M2S SZ8S-\K@4YTAY)S\P=]:7FH97OYC52&Y=5H=JW!VL4,^SZD4T:AU>NW6
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MJ9QM0K7I=?6FMYB;7N)BU/VZ??>+8;SIKI5,)6V#J=VOJW>_!9A#QH.]JIR
MI2(*\VIBZ2 CHQZX5&ONW'F^,UMT&1GUP';C,YCZ:/F%\%V4"GAWMB#OG,_
M5_+B.V!Q(MDA_S)VSZ1D27ZXIP0HJ0?@_I8Q^72B/K957V/7_P%02P,$%
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M:TRLDP<I'^UDD@^]P H"#IFQ#!1?*Q@#YY8(93RUG%ZWI05NCS?LGYUW]/)
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M1'EAH+XO&9,OC:*#YI)M]A]02P,$%     @ SD/.6(+-XC=, P  A0H  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULK9;?;],P$,?_%2L@!!(L/YNV
MHZVT=2"00$P;@P?$@YM<&VM.'&RWW?Y[SDD6TM2%//#2Q,G=MY\[.W<WVPMY
MKS( 31YR7JBYDVE=GKNN2C+(J3H3)13X9BUD3C4NY<95I02:5DXY=P//B]V<
MLL)9S*IGUW(Q$UO-60'7DJAMGE/Y> E<[.>.[SP]N&&;3)L'[F)6T@W<@KXK
MKR6NW%8E93D4BHF"2%C/G0O_?.E7#I7%-P9[U;DG)I25$/=F\3&=.YXA @Z)
M-A(4+SM8 N=&"3E^-:).^Y_&L7O_I/Z^"AZ#65$%2\&_LU1G<V?BD!36=,OU
MC=A_@":@D=%+!%?5+]DWMIY#DJW2(F^<D2!G17VE#TTB.@Y^=,(A:!R"H0YA
MXQ!6@=9D55A75-/%3(H]D<8:U<Q-E9O*&Z-AA=G&6RWQ+4,_O;A($KF%E+Q[
MP(.A0!%:I.2+SD"2Y59**#3YQ.B*<:89OGUY!9HRKEZ1-^3N]HJ\?/Z*/">L
M(%\SL57HJV:N1BPC[B8-PF6-$)Q ^$SE&0G]UR3P@LCBOASN'AZZNYB,-B-!
MFY&@T@M/Z%W31[KB32:J]%"NR(^+E=(2#]U/6X"U8F17-%_BN2II G,'/S4%
M<@?.XL4S/_;>VL+]3V('P8=M\.'?U-OCD$A(F28)E2E9 UAWM58:5TJF6NP6
MX70\<W?=6(YM(L]O;0X0HQ8Q&H2H**>2-?NT@@+63%LY:[FXP^"/0J\':C.*
M(SOIJ"4=#2+-02894C(%36(5<;$&[DUV2RDVDN8V\-$QTR2:]L M1G'LV<'C
M%CP>!(YL:U"F8E-.H*D0-M+X""((@A[HL<UH-+5SCEO.\="C@.= @MY*; P<
M6Q,M$K"!CH\@0G_2 SVV"8(39W;2@DX&@:9LQU+ *DG*NLK8&"?'.QK%<0_2
M8A3$@9URVE).!U'B.(#;K3350#1]L&_YU$+9WW*+32?;!XR^]Z=A>7^EK)L3
M;5CYG^9D[3R>!2'L)]-B%7GQ"=!.9_4'I1.ZK554]$G36O]%[Q^5S[$7]TN7
MQ2KVI_T3ZW9F!#.@8=O<L$(1#FMT\\[&6$AD/?/4"RW*:FQ8"8U#2'6;X9P(
MTAC@^[40^FEA)I%V\ES\!E!+ P04    " #.0\Y8S.'\Y:H(   V40  &0
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MVX?T;=_(?%T]A>XVES)/JY<KKD[YHFR@_K[(<_GXIMS [E&)T_\!4$L#!!0
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M%(;_BL6JJ9/6<@FW9 2I%TVKU$I1TVX?IGUPPDFP:C"S#TG[[V>;E&4+3;^
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M).M33_6%%NOJI-&CT%KDU=<5HX:"Y0OF^9,0>G]1.FC.GLW_ 5!+ P04
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MZ[$NJ*+I89N!XAO3U:VXTCVB><QUWP^B%NCW&>?J,*@_T/XGL?@?4$L#!!0
M   ( ,Y#SEB=7:'DO@,  % -   9    >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;*U739/B-A#]*RJG-L56[>(/C($)4#4#NY4];':*V22'5 [";H,RMD0D
M,4S^?5JR\8#+'QSV I;<_=3OM=QJS4]"/JL]@":O><;5PMEK?;AS717O(:=J
M* [ \4TJ9$XU#N7.50<)-+%.>>8&GA>Y.67<6<[MW*-<SL519XS#HR3JF.=4
M_O< F3@M'-\Y3VS8;J_-A+N<'^@.GD#_?GB4.'(KE(3EP!43G$A(%\Z]?[?V
MK8.U^(/!25T\$T-E*\2S&7Q)%HYG(H(,8FT@*/Z]P JRS"!A'/^6H$ZUIG&\
M?#ZC?[;DD<R6*EB)[$^6Z/W"F3HD@90>,[T1IU^A)#0V>+'(E/TEI\(V0N/X
MJ+3(2V>,(&>\^*>OI1 7#G[4XA"4#D'=(6QQ&)4.HUL=PM(AM,H45*P.:ZKI
M<B[%B4ACC6CFP8IIO9$^XR;O3UKB6X9^>OF%QR('\IV^@B(?R09BP6.6,6JS
M(E+R76B:D4]I"C9#QI)LJ 8R6(.F+%/OYZ[&0 R<&Y>+/A2+!BV+^@'Y*KC>
M*_*))Y!< [C(H*(1G&D\!)V(7ZD<DI'_@01>$#8$M+K=?=3@OK[=/>A@,ZJ2
M,K)XH]ZDD#53<2;440+YZWZKM,0/Y>\FQ0O$L!G15(\[=: Q+!PL#PKD"SC+
MGW_R(^^7)K5^)-CZ!X%=*1E62H9=Z,O/D(#$_2O-CL4-S0IEMX 5$XBVNWY
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MR@/2&.#[5 A]'I@%JDO4\G]02P,$%     @ SD/.6/$S@[K' P  Q1   !D
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M =XQ8/0&8%@"AN<"1B5@9)PII!@? JRPOQ!\CX2.!C9]8<PT:)!/4_W>UTK
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MD=KJO+X K0N2+:M+QWLF)2NJQY22A'+=0;7/&9//!3U!>PT]^P]02P,$%
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M*VFLVOAA;A\04,[!KJ^E-'O#!6B?I.0?4$L#!!0    ( ,Y#SEBJ]A[CO@T
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M%O#PF>-0=HIOKKQ5U5M\PW#R:<1$_H8CU;MN8;M>FJ[/(US?F&U0D=.NW?O
M)1S='MVM;4$0A'[?#I.J4HMJ&$:US< VD_H!:6?8Z]'JVD Z;)$.GSN.=:?
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MA_12UN7"B?BSW]"4Y7%'PJJMZRFD?38?K:P>-A0_;(9^_P-02P,$%     @
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M*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01ZVVBSFT!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0&\??:PD
MT-M1;R?0VU%O)]#;46\GT-M1;R?0.U#O(- [4.\@T#M0[R#0.U#O(- [4.\@
MT#M0[R#0.T8_FQ#H':AW$.@=J'<0Z!VH=_RDWG7XVI=Z[?E>XT]!/TGU<+ZW
M7!]_67Z?1)P7%YS3;45]^@M02P,$%     @ SD/.6-9((R[W 0  *R@  !,
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M;%!+ 0(4 Q0    ( ,Y#SE@\78EG[@   "L"   1              "  :\
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M2P$"% ,4    " #.0\Y8'E OUE,&   9&P  &               @(&Y$@
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ SD/.6+9'179.
M P  X0L  !@              ("!0AD  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( ,Y#SE@ZU.BPVP4  '@:   8              "
M@<8<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #.0\Y8
M4]DX,R,&  !&+   &               @('7(@  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ SD/.6-XHXR)K!P  3R,  !@
M     ("!,"D  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M ,Y#SEAS&8HI$ <  'P4   8              " @=$P  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #.0\Y88WA\_%45  #%.P  &
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M970Q,RYX;6Q02P$"% ,4    " #.0\Y8EK4M?) &  "Z$   &0
M    @(%8:@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M ,Y#SEA\#_6OI 8  #01   9              " @1]Q  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ SD/.6(L/@P>/"   IQ@  !D
M             ("!^G<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #.0\Y8U+I.J"L$  !W"0  &0              @(' @   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,Y#SECV/[9)M0T
M %<P   9              " @2*%  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ SD/.6,)3X,17!   X D  !D              ("!
M#I,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #.0\Y8
M!?EQK[$$  "$"P  &0              @(&<EP  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,Y#SECV/OMJGPX  %DL   9
M      " @82<  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ SD/.6,<<:]#( P  :0@  !D              ("!6JL  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #.0\Y8^G=$<*\+  #M(0
M&0              @(%9KP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( ,Y#SEC49 YK7 (  'T&   9              " @3^[  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ SD/.6";:+PY$
M @  B@8  !D              ("!TKT  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #.0\Y8BGD# 1$"  #=!   &0
M@(%-P   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,Y#
MSE@=Z&Q4<A$  &HV   9              " @97"  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ SD/.6!KY60HM!   !PH  !D
M         ("!/M0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #.0\Y8,18Q> D$  !="0  &0              @(&BV   >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,Y#SEAYD_@(YP(  $<&
M   9              " @>+<  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ SD/.6!5L\3(5 P  ]@8  !D              ("! .
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #.0\Y8/P[4
M/RD$  #$"@  &0              @(%,XP  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( ,Y#SEA%4/\*S@,  (X)   9
M  " @:SG  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MSD/.6%@A, ,4!P  1Q0  !D              ("!L>L  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #.0\Y8<-B)590"  ":!0  &0
M            @('\\@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( ,Y#SEB=9#,WV@,  ,<*   9              " @<?U  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ SD/.6.<L3\1[ P
MV0<  !D              ("!V/D  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #.0\Y8L1]\4Y *   V9   &0              @(&*
M_0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,Y#SE@3
M%"7<V@4  ,DH   9              " @5$( 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ SD/.6!I!T@0F P  E@H  !D
M     ("!8@X! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,Y#SE@LS@Z<? 0  ' ;   9              "
M@:XB 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ SD/.
M6(+-XC=, P  A0H  !D              ("!82<! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #.0\Y8S.'\Y:H(   V40  &0
M        @('D*@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( ,Y#SEAB,MGM?P(  -$&   9              " @<4S 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ SD/.6$@,IZ"L P  8A(
M !D              ("!>S8! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " #.0\Y89MBQH*D"  "2"0  &0              @(%>.@$
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,Y#SEB\\]YK
M[@(  $,'   9              " @3X] 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ SD/.6(]0IR:6 @  WP8  !D
M ("!8T ! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #.
M0\Y84CP/:#,$  #(#P  &0              @($P0P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( ,Y#SEA,J81A#P0  -<3   9
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M970U."YX;6Q02P$"% ,4    " #.0\Y8\3.#NL<#  #%$   &0
M    @('^7 $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M ,Y#SE@:0[C>90(  ,@%   9              " @?Q@ 0!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ SD/.6)>O*?FU'   4!0" !D
M             ("!F&,! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " #.0\Y8EVH5NFP$  "2%@  &0              @(&$@ $ >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( ,Y#SEA#_UFYL@4
M /HE   9              " @2>% 0!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ SD/.6,*9GB<M @  #@4  !D              ("!
M$(L! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #.0\Y8
M?B)/3 ($  #Z#@  &0              @(%TC0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( ,Y#SEC]SVFR@ (  )X&   9
M      " @:V1 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ SD/.6*KV'N.^#0  >\$  !D              ("!9)0! 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #.0\Y8(:PG'#$#  "/"P
M&0              @(%9H@$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( ,Y#SEA/,FXYG@8  (<N   9              " @<&E 0!X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ SD/.6"G6LLI,
M P  U!0   T              ( !EJP! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " #.0\Y8EXJ[',     3 @  "P              @ $-L $ 7W)E;',O
M+G)E;'-02P$"% ,4    " #.0\Y8X#P*;9,%  "0+0  #P
M@ 'VL $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ SD/.6)=W<N0L @
M]B@  !H              ( !MK8! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ SD/.6-9((R[W 0  *R@  !,              ( !
M&KD! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $T 30 2%0  0KL!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>202</ContextCount>
  <ElementCount>398</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Restatement of Previously Issued Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RestatementofPreviouslyIssuedFinancialStatements</Role>
      <ShortName>Restatement of Previously Issued Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Intangible and Other Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet</Role>
      <ShortName>Intangible and Other Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Restricted Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RestrictedStock</Role>
      <ShortName>Restricted Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/NetLossIncomePerShare</Role>
      <ShortName>Net (Loss) Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/RevenueRecognition</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/AcquisitionTables</Role>
      <ShortName>Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/Acquisition</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Intangible and Other Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables</Role>
      <ShortName>Intangible and Other Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/ShareholdersEquity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Restricted Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RestrictedStockTables</Role>
      <ShortName>Restricted Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/RestrictedStock</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Net (lLoss) Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/NetlLossIncomePerShareTables</Role>
      <ShortName>Net (lLoss) Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/NetLossIncomePerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Revenue Recognition - Schedule of Rollforward of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Rollforward of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Acquisition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/AcquisitionNarrativeDetails</Role>
      <ShortName>Acquisition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Acquisition - Schedule of Acquired Identifiable Assets, Liabilities Assumed and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails</Role>
      <ShortName>Acquisition - Schedule of Acquired Identifiable Assets, Liabilities Assumed and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Acquisition - Schedule of Pro-Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails</Role>
      <ShortName>Acquisition - Schedule of Pro-Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Intangible and Other Assets, Net - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails</Role>
      <ShortName>Intangible and Other Assets, Net - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Intangible and Other Assets, Net - Expected Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails</Role>
      <ShortName>Intangible and Other Assets, Net - Expected Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Intangible and Other Assets, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails</Role>
      <ShortName>Intangible and Other Assets, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Leases - Schedule of Lease Costs and Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails</Role>
      <ShortName>Leases - Schedule of Lease Costs and Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Leases - Schedule of Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Income Taxes - Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Income Taxes - Tax Attributes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails</Role>
      <ShortName>Income Taxes - Tax Attributes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Income Taxes - Components of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Income Taxes - Reconciliation of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Income Taxes - Reconciliation of Total Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Total Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Shareholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Shareholder's Equity - Declared Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/ShareholdersEquityDeclaredDividendsDetails</Role>
      <ShortName>Shareholder's Equity - Declared Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Restricted Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails</Role>
      <ShortName>Restricted Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Restricted Stock - Non-vested Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails</Role>
      <ShortName>Restricted Stock - Non-vested Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Restricted Stock - Rollforward of RSU and PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails</Role>
      <ShortName>Restricted Stock - Rollforward of RSU and PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/FairValueMeasurements</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Net (Loss) Income Per Share - Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Share - Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/NetlLossIncomePerShareTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Net (loss) Income Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/NetlossIncomePerShareNarrativeDetails</Role>
      <ShortName>Net (loss) Income Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/NetlLossIncomePerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/CommitmentsandContingencies</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="pets-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.1800petmeds.com/role/SubsequentEvents</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 11 fact(s) appearing in ix:hidden were eligible for transformation: pets:RestrictionPeriod, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  pets-20240331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="pets-20240331.htm">pets-20240331.htm</File>
    <File>pets-20240331.xsd</File>
    <File>pets-20240331_cal.xml</File>
    <File>pets-20240331_def.xml</File>
    <File>pets-20240331_lab.xml</File>
    <File>pets-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pets-20240331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="752">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pets-20240331.htm": {
   "nsprefix": "pets",
   "nsuri": "http://www.1800petmeds.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "pets-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "pets-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pets-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pets-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pets-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pets-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 325,
   "keyCustom": 73,
   "axisStandard": 25,
   "axisCustom": 1,
   "memberStandard": 34,
   "memberCustom": 30,
   "hidden": {
    "total": 15,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 10,
    "http://www.1800petmeds.com/20240331": 1
   },
   "contextCount": 202,
   "entityCount": 1,
   "segmentCount": 64,
   "elementCount": 677,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 752,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 5
   },
   "report": {
    "R1": {
     "role": "http://www.1800petmeds.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.1800petmeds.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity",
     "longName": "0000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.1800petmeds.com/role/RestatementofPreviouslyIssuedFinancialStatements",
     "longName": "0000008 - Disclosure - Restatement of Previously Issued Financial Statements",
     "shortName": "Restatement of Previously Issued Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.1800petmeds.com/role/RevenueRecognition",
     "longName": "0000010 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.1800petmeds.com/role/Acquisition",
     "longName": "0000011 - Disclosure - Acquisition",
     "shortName": "Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.1800petmeds.com/role/PropertyandEquipmentNet",
     "longName": "0000012 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "0000013 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet",
     "longName": "0000014 - Disclosure - Intangible and Other Assets, Net",
     "shortName": "Intangible and Other Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.1800petmeds.com/role/Leases",
     "longName": "0000015 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.1800petmeds.com/role/IncomeTaxes",
     "longName": "0000016 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.1800petmeds.com/role/ShareholdersEquity",
     "longName": "0000017 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.1800petmeds.com/role/RestrictedStock",
     "longName": "0000018 - Disclosure - Restricted Stock",
     "shortName": "Restricted Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.1800petmeds.com/role/FairValueMeasurements",
     "longName": "0000019 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.1800petmeds.com/role/NetLossIncomePerShare",
     "longName": "0000020 - Disclosure - Net (Loss) Income Per Share",
     "shortName": "Net (Loss) Income Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.1800petmeds.com/role/CommitmentsandContingencies",
     "longName": "0000021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.1800petmeds.com/role/EmployeeBenefitPlan",
     "longName": "0000022 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.1800petmeds.com/role/SubsequentEvents",
     "longName": "0000023 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-202",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-202",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.1800petmeds.com/role/RevenueRecognitionTables",
     "longName": "9954472 - Disclosure - Revenue Recognition (Tables)",
     "shortName": "Revenue Recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.1800petmeds.com/role/AcquisitionTables",
     "longName": "9954473 - Disclosure - Acquisition (Tables)",
     "shortName": "Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.1800petmeds.com/role/PropertyandEquipmentNetTables",
     "longName": "9954474 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9954475 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables",
     "longName": "9954476 - Disclosure - Intangible and Other Assets, Net (Tables)",
     "shortName": "Intangible and Other Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.1800petmeds.com/role/LeasesTables",
     "longName": "9954477 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.1800petmeds.com/role/IncomeTaxesTables",
     "longName": "9954478 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.1800petmeds.com/role/ShareholdersEquityTables",
     "longName": "9954479 - Disclosure - Shareholders' Equity (Tables)",
     "shortName": "Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.1800petmeds.com/role/RestrictedStockTables",
     "longName": "9954480 - Disclosure - Restricted Stock (Tables)",
     "shortName": "Restricted Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.1800petmeds.com/role/NetlLossIncomePerShareTables",
     "longName": "9954481 - Disclosure - Net (lLoss) Income Per Share (Tables)",
     "shortName": "Net (lLoss) Income Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
     "longName": "9954483 - Disclosure - Revenue Recognition - Narrative (Details)",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "pets:RevenueFromContractWithCustomerNumberOfPerformanceObligations",
      "unitRef": "performanceobligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "pets:RevenueFromContractWithCustomerNumberOfPerformanceObligations",
      "unitRef": "performanceobligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails",
     "longName": "9954484 - Disclosure - Revenue Recognition - Schedule of Rollforward of Deferred Revenue (Details)",
     "shortName": "Revenue Recognition - Schedule of Rollforward of Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
     "longName": "9954485 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)",
     "shortName": "Revenue Recognition - Schedule of Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pets:RevenueFromContractWithCustomerPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails",
     "longName": "9954486 - Disclosure - Acquisition - Narrative (Details)",
     "shortName": "Acquisition - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-66",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails",
     "longName": "9954487 - Disclosure - Acquisition - Schedule of Acquired Identifiable Assets, Liabilities Assumed and Goodwill (Details)",
     "shortName": "Acquisition - Schedule of Acquired Identifiable Assets, Liabilities Assumed and Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-66",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails",
     "longName": "9954488 - Disclosure - Acquisition - Schedule of Pro-Forma Information (Details)",
     "shortName": "Acquisition - Schedule of Pro-Forma Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-68",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-68",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails",
     "longName": "9954489 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9954490 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "pets:AccruedCreditCardFeesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "pets:AccruedCreditCardFeesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails",
     "longName": "9954491 - Disclosure - Intangible and Other Assets, Net - Schedule (Details)",
     "shortName": "Intangible and Other Assets, Net - Schedule (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails",
     "longName": "9954492 - Disclosure - Intangible and Other Assets, Net - Expected Amortization (Details)",
     "shortName": "Intangible and Other Assets, Net - Expected Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails",
     "longName": "9954493 - Disclosure - Intangible and Other Assets, Net - Narrative (Details)",
     "shortName": "Intangible and Other Assets, Net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.1800petmeds.com/role/LeasesNarrativeDetails",
     "longName": "9954494 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails",
     "longName": "9954495 - Disclosure - Leases - Schedule of Lease Costs and Activity (Details)",
     "shortName": "Leases - Schedule of Lease Costs and Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails",
     "longName": "9954496 - Disclosure - Leases - Schedule of Maturity of Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturity of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
     "longName": "9954497 - Disclosure - Income Taxes - Deferred Income Taxes (Details)",
     "shortName": "Income Taxes - Deferred Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954498 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pets:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails",
     "longName": "9954499 - Disclosure - Income Taxes - Tax Attributes (Details)",
     "shortName": "Income Taxes - Tax Attributes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "pets:DisallowedBusinessInterestExpenseCarryover",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "pets:DisallowedBusinessInterestExpenseCarryover",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails",
     "longName": "9954500 - Disclosure - Income Taxes - Components of Income Tax Provision (Details)",
     "shortName": "Income Taxes - Components of Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails",
     "longName": "9954501 - Disclosure - Income Taxes - Reconciliation of Income Tax Provision (Details)",
     "shortName": "Income Taxes - Reconciliation of Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails",
     "longName": "9954502 - Disclosure - Income Taxes - Reconciliation of Total Effective Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Total Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails",
     "longName": "9954503 - Disclosure - Shareholders' Equity - Narrative (Details)",
     "shortName": "Shareholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-115",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-115",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.1800petmeds.com/role/ShareholdersEquityDeclaredDividendsDetails",
     "longName": "9954504 - Disclosure - Shareholder's Equity - Declared Dividends (Details)",
     "shortName": "Shareholder's Equity - Declared Dividends (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-120",
      "name": "us-gaap:DividendsPayableAmountPerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-120",
      "name": "us-gaap:DividendsPayableAmountPerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
     "longName": "9954505 - Disclosure - Restricted Stock - Narrative (Details)",
     "shortName": "Restricted Stock - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
     "longName": "9954506 - Disclosure - Restricted Stock - Non-vested Restricted Stock (Details)",
     "shortName": "Restricted Stock - Non-vested Restricted Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-150",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails",
     "longName": "9954507 - Disclosure - Restricted Stock - Rollforward of RSU and PSU Activity (Details)",
     "shortName": "Restricted Stock - Rollforward of RSU and PSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-162",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-161",
      "name": "pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.1800petmeds.com/role/FairValueMeasurementsDetails",
     "longName": "9954508 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails",
     "longName": "9954509 - Disclosure - Net (Loss) Income Per Share - Basic and Diluted Net Income Per Share (Details)",
     "shortName": "Net (Loss) Income Per Share - Basic and Diluted Net Income Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.1800petmeds.com/role/NetlossIncomePerShareNarrativeDetails",
     "longName": "9954510 - Disclosure - Net (loss) Income Per Share - Narrative (Details)",
     "shortName": "Net (loss) Income Per Share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954511 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-170",
      "name": "pets:EmploymentTermInitialPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails",
     "longName": "9954512 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.1800petmeds.com/role/SubsequentEventsDetails",
     "longName": "9954513 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-194",
      "name": "pets:EmploymentAgreementEmploymentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-194",
      "name": "pets:EmploymentAgreementEmploymentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pets-20240331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "pets_A2022EmployeePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "A2022EmployeePlanMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Employee Plan",
        "label": "2022 Employee Plan [Member]",
        "documentation": "2022 Employee Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r623"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, less allowance for credit losses of $273 and $35, respectively",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247"
     ]
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued real estate taxes",
        "label": "Accrual for Taxes Other than Income Taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r89",
      "r818"
     ]
    },
    "pets_AccruedCreditCardFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "AccruedCreditCardFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued credit card fees",
        "label": "Accrued credit card fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for credit card fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued salaries and benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "pets_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Expenses And Other Current Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "pets_AccruedMerchandiseCreditsAndRewardsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "AccruedMerchandiseCreditsAndRewardsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued merchandise credits / reward program",
        "label": "Accrued merchandise credits / reward program",
        "documentation": "The amount of accrued merchandise credits and rewards classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional expenses",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "pets_AccruedSalesReturnsAndAllowancesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "AccruedSalesReturnsAndAllowancesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued sales return allowance",
        "label": "Accrued sales return allowance",
        "documentation": "Represents accrued sales returns and allowances. Used to reflect the current portion (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "pets_AccruedSeveranceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "AccruedSeveranceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued severance costs",
        "label": "Accrued Severance Costs",
        "documentation": "Accrued Severance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r169",
      "r479"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Useful Life (Years)",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r623",
      "r822"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r512",
      "r740",
      "r741",
      "r742",
      "r797",
      "r823"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r328"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r647",
      "r659",
      "r669",
      "r695"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r650",
      "r662",
      "r672",
      "r698"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r663",
      "r673",
      "r690",
      "r699",
      "r703",
      "r711"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r366"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r248",
      "r258"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47",
      "r52"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.1800petmeds.com/role/NetlossIncomePerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of real estate property (in square feet)",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r172",
      "r190",
      "r229",
      "r237",
      "r241",
      "r253",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r400",
      "r402",
      "r417",
      "r471",
      "r546",
      "r623",
      "r636",
      "r758",
      "r759",
      "r810"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r178",
      "r190",
      "r253",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r400",
      "r402",
      "r417",
      "r623",
      "r758",
      "r759",
      "r810"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total noncurrent assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r253",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r400",
      "r402",
      "r417",
      "r758",
      "r759",
      "r810"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pets_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.1800petmeds.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r655"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.1800petmeds.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r655"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.1800petmeds.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r655"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Axis]",
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Domain]",
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building Improvements",
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r617",
      "r618"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r77",
      "r398",
      "r617",
      "r618"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related costs incurred",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of equity interests acquired",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Pro-Forma Information",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723"
     ]
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill deductible for tax purposes",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate consideration",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r11"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/Acquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r399"
     ]
    },
    "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "documentation": "Amount of lease obligation assumed in business combination."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Other Receivables",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate applied to intangible assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill, Fair Value Disclosure, Discount Rate",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill, Fair Value Disclosure, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Lease Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Lease Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total purchase consideration",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets",
      "http://www.1800petmeds.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r167",
      "r598"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, at beginning of fiscal year",
        "periodEndLabel": "Cash and cash equivalents, at end of fiscal year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r110",
      "r188"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r110"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Financial Officer",
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r173",
      "r174",
      "r175",
      "r190",
      "r211",
      "r215",
      "r219",
      "r221",
      "r227",
      "r228",
      "r253",
      "r281",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r291",
      "r292",
      "r295",
      "r298",
      "r306",
      "r417",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r534",
      "r555",
      "r575",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r718",
      "r737",
      "r744"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r227",
      "r291",
      "r292",
      "r293",
      "r295",
      "r298",
      "r304",
      "r306",
      "r506",
      "r507",
      "r508",
      "r509",
      "r608",
      "r718",
      "r737"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 14)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r90",
      "r473",
      "r533"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r275",
      "r276",
      "r593",
      "r755"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividends declared per common share (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r627",
      "r628",
      "r630",
      "r631",
      "r632",
      "r633",
      "r740",
      "r741",
      "r797",
      "r821",
      "r823"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r534"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r96",
      "r534",
      "r552",
      "r823",
      "r824"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $.001 par value, 40,000 shares authorized; 21,149 and 21,084 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r475",
      "r623"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plan",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting for Share Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r40",
      "r85",
      "r86",
      "r245",
      "r592"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r40",
      "r85",
      "r86",
      "r245",
      "r502",
      "r592"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r40",
      "r85",
      "r86",
      "r245",
      "r592",
      "r721"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Concentrations",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r151"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of all products purchased",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r40",
      "r85",
      "r86",
      "r245"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r40",
      "r85",
      "r86",
      "r245",
      "r592"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r600"
     ]
    },
    "pets_ContingentLumpSumSeverancePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ContingentLumpSumSeverancePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent lump sum severance payment",
        "label": "Contingent Lump Sum Severance Payment",
        "documentation": "Contingent Lump Sum Severance Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Rollforward of Deferred Revenue",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets",
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "periodStartLabel": "Deferred revenue, beginning balance",
        "periodEndLabel": "Deferred revenue, ending balance",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r320"
     ]
    },
    "pets_ContractWithCustomerLiabilityCurrentRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ContractWithCustomerLiabilityCurrentRollForward",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract With Customer, Liability, Current [Roll Forward]",
        "label": "Contract With Customer, Liability, Current [Roll Forward]",
        "documentation": "Contract With Customer, Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue acquired with PetCareRx",
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred memberships fees received",
        "label": "Contract With Customer Liability, Increase For Deferred Fees Received",
        "documentation": "Contract With Customer Liability, Increase For Deferred Fees Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred membership fee revenue recognized",
        "negatedLabel": "Deferred membership fee revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "pets_ContractWithCustomerRenewalPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ContractWithCustomerRenewalPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual membership fees renewal period",
        "label": "Contract With Customer, Renewal Period",
        "documentation": "Contract With Customer, Renewal Period"
       }
      }
     },
     "auth_ref": []
    },
    "pets_ContractWithCustomerRevenueRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ContractWithCustomerRevenueRecognitionPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition period",
        "label": "Contract With Customer, Revenue Recognition, Period",
        "documentation": "Contract With Customer, Revenue Recognition, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r295",
      "r630",
      "r631",
      "r632",
      "r633"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r58",
      "r95",
      "r126",
      "r301"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r451"
     ]
    },
    "us-gaap_CostOfGoodsTotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsTotalMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods and Service Benchmark",
        "label": "Cost of Goods and Service Benchmark [Member]",
        "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r739",
      "r795"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r385",
      "r391",
      "r739"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current taxes",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r739",
      "r795"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Relationships -PetCareRx",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1",
     "presentation": [
      "http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, requisite service period",
        "label": "Deferred Compensation Arrangement with Individual, Requisite Service Period",
        "documentation": "Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r794",
      "r795"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r136",
      "r157",
      "r390",
      "r391",
      "r739"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax provision (benefit)",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r472"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r794",
      "r795"
     ]
    },
    "pets_DeferredTaxAssetIsRecordedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "DeferredTaxAssetIsRecordedMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributes for which a deferred tax asset is recorded",
        "label": "Deferred Tax Asset Is Recorded [Member]",
        "documentation": "Deferred Tax Asset Is Recorded"
       }
      }
     },
     "auth_ref": []
    },
    "pets_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "label": "Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs",
        "documentation": "Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r793"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "pets_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "documentation": "Deferred Tax Assets, Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r793"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r793"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r793"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt and inventory reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r793"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued sales tax liability",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r793"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pets_DeferredTaxLiabilitiesChangeInAccountingMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "DeferredTaxLiabilitiesChangeInAccountingMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax accounting method change",
        "label": "Deferred Tax Liabilities, Change In Accounting Method",
        "documentation": "Deferred Tax Liabilities, Change In Accounting Method"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r793"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r793"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r793"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of employees gross compensation eligible for match",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer match contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, matching contribution",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "pets_DefinedContributionPlanWithIndividualAge": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "DefinedContributionPlanWithIndividualAge",
     "presentation": [
      "http://www.1800petmeds.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, requisite age",
        "label": "Defined Contribution Plan With Individual Age",
        "documentation": "The minimum age that the individual is required in order to participate in the defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "pets_DelrayBeachPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "DelrayBeachPropertyMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Delray Beach Property",
        "label": "Delray Beach Property [Member]",
        "documentation": "Related to the Delray Beach Property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r53"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r232"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed Technology - PetCareRx",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "pets_DisallowedBusinessInterestExpenseCarryover": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "DisallowedBusinessInterestExpenseCarryover",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disallowed business interest expense carryover",
        "label": "Disallowed Business Interest Expense Carryover",
        "documentation": "Disallowed Business Interest Expense Carryover"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r331",
      "r359",
      "r360",
      "r362",
      "r620"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends declared",
        "label": "Dividends, Common Stock",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r128"
     ]
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsDeclaredTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Dividend Declaration",
        "label": "Dividends Declared [Table Text Block]",
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableAmountPerShare",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityDeclaredDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per Share Dividend (in dollars per share)",
        "label": "Dividends Payable, Amount Per Share",
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_DividendsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued dividends payable",
        "label": "Dividends Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityDeclaredDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Amount",
        "label": "Dividends Payable",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r142",
      "r634",
      "r818"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r655"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r655",
      "r691"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per common share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations",
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r197",
      "r198",
      "r200",
      "r201",
      "r203",
      "r209",
      "r211",
      "r219",
      "r220",
      "r221",
      "r225",
      "r413",
      "r414",
      "r467",
      "r483",
      "r602"
     ]
    },
    "pets_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per common share:",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "documentation": "Earnings Per Share, Basic and Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations",
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r197",
      "r198",
      "r200",
      "r201",
      "r203",
      "r211",
      "r219",
      "r220",
      "r221",
      "r225",
      "r413",
      "r414",
      "r467",
      "r483",
      "r602"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/NetLossIncomePerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (Loss) Income Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r222",
      "r223",
      "r224"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Effective Tax Rate (as percent)",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal rate on income before taxes (as percent)",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r375",
      "r392"
     ]
    },
    "pets_EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation of covered executives",
        "label": "Effective Income Tax Rate Reconciliation, Compensation Of Covered People Limit Deduction Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Compensation Of Covered People Limit Deduction Amount"
       }
      }
     },
     "auth_ref": []
    },
    "pets_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset adjustment",
        "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Asset Adjustment",
        "documentation": "Effective Income Tax Rate Reconciliation, Deferred Tax Asset Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible compensation (as percent)",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r796"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (as percent)",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r796"
     ]
    },
    "pets_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences (as percent)",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax adjustments (as percent)",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r796"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock shortfall adjustment",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r791"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock (windfall) shortfall adjustment (as percent)",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r791"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofTotalEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal tax benefit (as percent)",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r796"
     ]
    },
    "pets_EmployeeAndDirectorEquityCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EmployeeAndDirectorEquityCompensationPlanMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee and Director Equity Compensation Plan",
        "label": "Employee and Director Equity Compensation Plan [Member]",
        "documentation": "Related to both the employee and director equity compensation plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation costs related to restricted stock",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average restriction and forfeiture period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "pets_EmploymentAgreementEmploymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EmploymentAgreementEmploymentTerm",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employment term",
        "label": "Employment Agreement, Employment Term",
        "documentation": "Employment Agreement, Employment Term"
       }
      }
     },
     "auth_ref": []
    },
    "pets_EmploymentAgreementNonRenewalNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EmploymentAgreementNonRenewalNoticePeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non renewal notice period",
        "label": "Employment Agreement, Non Renewal Notice Period",
        "documentation": "Employment Agreement, Non Renewal Notice Period"
       }
      }
     },
     "auth_ref": []
    },
    "pets_EmploymentAgreementRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EmploymentAgreementRenewalTerm",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Employment Agreement, Renewal Term",
        "documentation": "Employment Agreement, Renewal Term"
       }
      }
     },
     "auth_ref": []
    },
    "pets_EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employment term cancellation period",
        "label": "Employment Term, Cancellation Period Prior To End Of Current Term",
        "documentation": "Employment Term, Cancellation Period Prior To End Of Current Term"
       }
      }
     },
     "auth_ref": []
    },
    "pets_EmploymentTermInitialPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EmploymentTermInitialPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial employment term",
        "label": "Employment Term, Initial Period",
        "documentation": "Employment Term, Initial Period"
       }
      }
     },
     "auth_ref": []
    },
    "pets_EmploymentTermSuccessiveRenewalPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "EmploymentTermSuccessiveRenewalPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Successive renewal employment term",
        "label": "Employment Term, Successive Renewal Period",
        "documentation": "Employment Term, Successive Renewal Period"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r161",
      "r182",
      "r183",
      "r184",
      "r192",
      "r193",
      "r194",
      "r196",
      "r204",
      "r206",
      "r226",
      "r254",
      "r257",
      "r307",
      "r363",
      "r364",
      "r365",
      "r386",
      "r387",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r441",
      "r492",
      "r493",
      "r494",
      "r512",
      "r575"
     ]
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvesteeMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investee",
        "label": "Equity Method Investee [Member]",
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r457",
      "r459",
      "r461",
      "r463",
      "r465",
      "r806",
      "r807"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority interest investment in Vetster",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r249",
      "r731",
      "r747"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r647",
      "r659",
      "r669",
      "r695"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r644",
      "r656",
      "r666",
      "r692"
     ]
    },
    "us-gaap_ErrorCorrectionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ErrorCorrectionTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/RestatementofPreviouslyIssuedFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement of Previously Issued Financial Statements",
        "label": "Error Correction [Text Block]",
        "documentation": "The entire disclosure for reporting error correction."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r19"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite-lived intangible assets useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r272"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r271",
      "r272",
      "r274",
      "r452",
      "r453"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangibles",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r453"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetExpectedAmortizationDetails",
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangibles",
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r452"
     ]
    },
    "pets_FiscalYear2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "FiscalYear2023Member",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Year 2023",
        "label": "Fiscal Year 2023 [Member]",
        "documentation": "Fiscal Year 2023"
       }
      }
     },
     "auth_ref": []
    },
    "pets_FiscalYear2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "FiscalYear2024Member",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Year 2024",
        "label": "Fiscal Year 2024 [Member]",
        "documentation": "Fiscal Year 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r663",
      "r673",
      "r699"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r663",
      "r673",
      "r699"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r663",
      "r673",
      "r699"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r663",
      "r673",
      "r699"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r663",
      "r673",
      "r699"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, fixtures and equipment",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "pets_FurnitureFixturesEquipmentAndComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "FurnitureFixturesEquipmentAndComputerSoftwareMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, Fixtures, Equipment and Computer Software",
        "label": "Furniture, Fixtures, Equipment and Computer Software [Member]",
        "documentation": "Refers to information regarding furniture, fixtures, equipment and computer software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r557"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails": {
       "parentTag": "pets_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails",
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r264",
      "r466",
      "r607",
      "r623",
      "r752",
      "r753"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r267",
      "r607"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r45"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r265",
      "r266",
      "r267",
      "r607"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r190",
      "r229",
      "r236",
      "r240",
      "r242",
      "r253",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r417",
      "r604",
      "r758"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r655"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r122"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) Income before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r102",
      "r144",
      "r229",
      "r236",
      "r240",
      "r242",
      "r468",
      "r481",
      "r604"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r368",
      "r376",
      "r378",
      "r383",
      "r388",
      "r393",
      "r394",
      "r395",
      "r511"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations",
      "http://www.1800petmeds.com/role/IncomeTaxesComponentsofIncomeTaxProvisionDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Total income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r158",
      "r205",
      "r206",
      "r233",
      "r374",
      "r389",
      "r484"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r370",
      "r371",
      "r378",
      "r379",
      "r382",
      "r384",
      "r505"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes at federal statutory rates",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible executive compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesReconciliationofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r736"
     ]
    },
    "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Finished Goods and Work in Process Inventories",
        "documentation": "The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase) decrease in operating assets and increase (decrease) in liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r725",
      "r736"
     ]
    },
    "pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use assets, net",
        "label": "Increase (Decrease) in Operating Lease Right Of Use Asset",
        "documentation": "Increase (Decrease) in Operating Lease Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid income taxes",
        "label": "Increase (Decrease) in Prepaid Taxes",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPropertyAndOtherTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales tax payable",
        "label": "Increase (Decrease) in Property and Other Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock",
     "calculation": {
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares issuable upon conversion of preferred shares (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r221"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares issuable upon the vesting of restricted stock (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r221",
      "r330"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r273"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangibles",
        "verboseLabel": "Indefinite-lived intangibles",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r119"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r663",
      "r673",
      "r690",
      "r699",
      "r703",
      "r711"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r715"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r715"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r715"
     ]
    },
    "pets_IntangibleAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "IntangibleAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible and Other Assets, Net Carrying Value",
        "label": "Intangible And Other Assets",
        "documentation": "Intangible And Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "pets_IntangibleAndOtherAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "IntangibleAndOtherAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails": {
       "parentTag": "pets_IntangibleAndOtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible and other assets, Gross Value",
        "label": "Intangible And Other Assets, Gross",
        "documentation": "Intangible And Other Assets, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible and other assets, net",
        "label": "Intangible And Other Noncurrent Assets, Net (Excluding Goodwill)",
        "documentation": "Intangible And Other Noncurrent Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible and Other Assets, Net",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangibles",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwillAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Value",
        "label": "Intangible Assets, Gross (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails_1": {
       "parentTag": "pets_IntangibleAndOtherAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangibles",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r50"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Carrying Value",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pets_IntangiblesAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "IntangiblesAndOtherAssetsAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles and Other Assets",
        "label": "Intangibles and Other Assets [Abstract]",
        "documentation": "Intangibles and Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "pets_IntangiblesAndOtherAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "IntangiblesAndOtherAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails": {
       "parentTag": "pets_IntangibleAndOtherAssets",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Amortization",
        "label": "Intangibles And Other Assets, Accumulated Amortization",
        "documentation": "Intangibles And Other Assets, Accumulated Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRevenueExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income (expense), net",
        "label": "Interest Revenue (Expense), Net",
        "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest)."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_InternetDomainNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternetDomainNamesMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internet domain names",
        "label": "Internet Domain Names [Member]",
        "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r166",
      "r177",
      "r260",
      "r261",
      "r262",
      "r450",
      "r601"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r733"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Investments",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails_1": {
       "parentTag": "pets_IntangibleAndOtherAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails": {
       "parentTag": "pets_IntangibleAndOtherAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority interest purchased, amount",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r622"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs and Activity",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Imputed Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease option to extend period",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, 2029",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Five",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, 2028",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, 2025",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, 2027",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, 2026",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "LessorOperatingLeaseRemainingWeightedAverageLeaseTerm",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Lessor, Operating Lease Remaining Weighted Average Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r190",
      "r253",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r401",
      "r402",
      "r403",
      "r417",
      "r532",
      "r603",
      "r636",
      "r758",
      "r810",
      "r811"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r143",
      "r477",
      "r623",
      "r738",
      "r748",
      "r800"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends payable in accrued expenses",
        "label": "Liabilities Assumed",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r165",
      "r190",
      "r253",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r401",
      "r402",
      "r403",
      "r417",
      "r623",
      "r758",
      "r810",
      "r811"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "pets_LumpSumSeverancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "LumpSumSeverancePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lump-sum severance payments",
        "label": "Lump Sum Severance Payments",
        "documentation": "Represents lump-sum severance payments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r612",
      "r763",
      "r819",
      "r820"
     ]
    },
    "us-gaap_MarketApproachValuationTechniqueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketApproachValuationTechniqueMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation, Market Approach",
        "label": "Valuation, Market Approach [Member]",
        "documentation": "Valuation approach using price and other relevant information generated by market transaction involving identical or comparable asset, liability, or group of assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails",
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r325",
      "r448",
      "r491",
      "r524",
      "r525",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r595",
      "r596",
      "r605",
      "r608",
      "r619",
      "r625",
      "r760",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_MeasurementInputControlPremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputControlPremiumMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Control Premium",
        "label": "Measurement Input, Control Premium [Member]",
        "documentation": "Measurement input using amount above fair value that investor seeking to acquire control of entity will pay."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "pets_MeasurementInputWeightedAverageCostOfCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "MeasurementInputWeightedAverageCostOfCapitalMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Weighted Average Cost Of Capital",
        "label": "Measurement Input, Weighted Average Cost Of Capital [Member]",
        "documentation": "Measurement Input, Weighted Average Cost Of Capital"
       }
      }
     },
     "auth_ref": []
    },
    "pets_MembershipCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "MembershipCustomersMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Membership Customers",
        "label": "Membership Customers [Member]",
        "documentation": "Membership Customers"
       }
      }
     },
     "auth_ref": []
    },
    "pets_MembershipFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "MembershipFeesMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Membership fees",
        "label": "Membership Fees [Member]",
        "documentation": "Membership Fees"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails",
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r325",
      "r448",
      "r491",
      "r524",
      "r525",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r595",
      "r596",
      "r605",
      "r608",
      "r619",
      "r625",
      "r760",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r612",
      "r763",
      "r819",
      "r820"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations",
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income",
        "terseLabel": "Net income",
        "verboseLabel": "Net (loss) income",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r112",
      "r145",
      "r163",
      "r179",
      "r180",
      "r184",
      "r190",
      "r195",
      "r197",
      "r198",
      "r200",
      "r201",
      "r205",
      "r206",
      "r218",
      "r229",
      "r236",
      "r240",
      "r242",
      "r253",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r414",
      "r417",
      "r482",
      "r554",
      "r573",
      "r574",
      "r604",
      "r635",
      "r758"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income (numerator):",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "pets_NewOrderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "NewOrderMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New order sales",
        "label": "New Order Customer [Member]",
        "documentation": "The disaggregate of revenue in new order sales."
       }
      }
     },
     "auth_ref": []
    },
    "pets_NonCompeteAgreementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "NonCompeteAgreementPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-compete term",
        "label": "Non-Compete Agreement, Period",
        "documentation": "Non-Compete Agreement, Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r663",
      "r673",
      "r690",
      "r699"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pets_NonvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "NonvestedRestrictedStockMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-vested Restricted Stock",
        "label": "Non-vested Restricted Stock [Member]",
        "documentation": "Related to non-vested restricted stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting units",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "pets_NumberOfSeverancePayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "NumberOfSeverancePayments",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of severance payments",
        "label": "Number Of Severance Payments",
        "documentation": "Number Of Severance Payments"
       }
      }
     },
     "auth_ref": []
    },
    "pets_NumberOfTenants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "NumberOfTenants",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tenants",
        "label": "Number Of Tenants",
        "documentation": "Represents number of tenants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual base salary",
        "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r236",
      "r240",
      "r242",
      "r604"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost - fixed",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r622"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for the amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r435"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r622"
     ]
    },
    "pets_OperatingLossCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "OperatingLossCarryforwardAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforward [Axis]",
        "label": "Operating Loss Carryforward [Axis]",
        "documentation": "Operating Loss Carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "pets_OperatingLossCarryforwardDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "OperatingLossCarryforwardDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforward [Domain]",
        "label": "Operating Loss Carryforward [Domain]",
        "documentation": "Operating Loss Carryforward [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "pets_OperatingLossCarryforwardsNotSubjectToLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "OperatingLossCarryforwardsNotSubjectToLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating losses - unlimited carryover",
        "label": "Operating Loss Carryforwards, Not Subject To Limitations",
        "documentation": "Operating Loss Carryforwards, Not Subject To Limitations"
       }
      }
     },
     "auth_ref": []
    },
    "pets_OperatingLossCarryforwardsSubjectToLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "OperatingLossCarryforwardsSubjectToLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating losses - limited carryover",
        "label": "Operating Loss Carryforwards, Subject To Limitations",
        "documentation": "Operating Loss Carryforwards, Subject To Limitations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r113",
      "r114",
      "r140"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pets_OtherAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "OtherAssetsPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Assets [Policy Text Block]",
        "documentation": "Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r661",
      "r671",
      "r697"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r652",
      "r664",
      "r674",
      "r700"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r652",
      "r664",
      "r674",
      "r700"
     ]
    },
    "pets_PartnerProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PartnerProgramMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner Program",
        "label": "Partner Program [Member]",
        "documentation": "Partner Program"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends paid",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of PetCareRx, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire investments",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of minority interest investment in Vetster",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PercentageOfAutomaticIncreaseInSharesAvailableForIssuance",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for issuance, automatic annual increase, percent",
        "label": "Percentage Of Automatic Increase In Shares Available For Issuance",
        "documentation": "Represents percentage of automatic increase in the amount of shares available for issuance."
       }
      }
     },
     "auth_ref": []
    },
    "pets_PercentageOfPropertyLeasedToTenants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PercentageOfPropertyLeasedToTenants",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of property leased to tenants",
        "label": "Percentage Of Property Leased To Tenants",
        "documentation": "The percentage amount of property that was leased to tenants of the property."
       }
      }
     },
     "auth_ref": []
    },
    "pets_PerformanceRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PerformanceRestrictedStockMember",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock",
        "label": "Performance Restricted Stock [Member]",
        "documentation": "Represents performance restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "pets_PerformanceRestrictedStockPriceHurdle1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PerformanceRestrictedStockPriceHurdle1Member",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock Price Hurdle 1",
        "label": "Performance Restricted Stock Price Hurdle 1 [Member]",
        "documentation": "Represents Performance Restricted Stock Price Hurdle 1."
       }
      }
     },
     "auth_ref": []
    },
    "pets_PerformanceRestrictedStockPriceHurdle2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PerformanceRestrictedStockPriceHurdle2Member",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock Price Hurdle 2",
        "label": "Performance Restricted Stock Price Hurdle 2 [Member]",
        "documentation": "Represents Performance Restricted Stock Price Hurdle 2."
       }
      }
     },
     "auth_ref": []
    },
    "pets_PerformanceRestrictedStockPriceHurdle3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PerformanceRestrictedStockPriceHurdle3Member",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock Price Hurdle 3",
        "label": "Performance Restricted Stock Price Hurdle 3 [Member]",
        "documentation": "Represents Performance Restricted Stock Price Hurdle 3."
       }
      }
     },
     "auth_ref": []
    },
    "pets_PerformanceRestrictedStockPriceHurdle4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PerformanceRestrictedStockPriceHurdle4Member",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock Price Hurdle 4",
        "label": "Performance Restricted Stock Price Hurdle 4 [Member]",
        "documentation": "Represents Performance Restricted Stock Price Hurdle 4."
       }
      }
     },
     "auth_ref": []
    },
    "pets_PerformanceRestrictedStockPriceHurdle5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PerformanceRestrictedStockPriceHurdle5Member",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock Price Hurdle 5",
        "label": "Performance Restricted Stock Price Hurdle 5 [Member]",
        "documentation": "Represents Performance Restricted Stock Price Hurdle 5."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "pets_PetCareRxIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "PetCareRxIncMember",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofRollforwardofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PetCareRx",
        "label": "PetCareRx, Inc. [Member]",
        "documentation": "PetCareRx, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, liquidation preference (in dollars per share)",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r95",
      "r737",
      "r761"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r821",
      "r823"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r291"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r534"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r291"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r534",
      "r552",
      "r823",
      "r824"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r474",
      "r623"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid income taxes",
        "label": "Prepaid Taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r606",
      "r751"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r451",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r597",
      "r610",
      "r624",
      "r726",
      "r756",
      "r757",
      "r763",
      "r819"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r451",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r597",
      "r610",
      "r624",
      "r726",
      "r756",
      "r757",
      "r763",
      "r819"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r152",
      "r155",
      "r156"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r168",
      "r480"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets",
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r469",
      "r480",
      "r623"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r152",
      "r155",
      "r478"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r259"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails",
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r323",
      "r325",
      "r354",
      "r355",
      "r356",
      "r447",
      "r448",
      "r491",
      "r524",
      "r525",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r595",
      "r596",
      "r605",
      "r608",
      "r619",
      "r625",
      "r628",
      "r754",
      "r760",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails",
      "http://www.1800petmeds.com/role/LeasesNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r323",
      "r325",
      "r354",
      "r355",
      "r356",
      "r447",
      "r448",
      "r491",
      "r524",
      "r525",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r595",
      "r596",
      "r605",
      "r608",
      "r619",
      "r625",
      "r628",
      "r754",
      "r760",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r644",
      "r656",
      "r666",
      "r692"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r442",
      "r443",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r551",
      "r553",
      "r580"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction amount",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r442"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r560"
     ]
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionRate",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of revenue generated",
        "label": "Related Party Transaction, Rate",
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r442",
      "r443",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r551",
      "r553",
      "r580",
      "r809"
     ]
    },
    "us-gaap_RentalIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RentalIncomeNonoperating",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental revenue",
        "label": "Rental Income, Nonoperating",
        "documentation": "Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "pets_ReorderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ReorderMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reorder sales",
        "label": "Reorder Customer [Member]",
        "documentation": "The disaggregate of revenue in reorder sales."
       }
      }
     },
     "auth_ref": []
    },
    "pets_ReportingUnitMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ReportingUnitMeasurementInput",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting unit measurement type",
        "label": "Reporting Unit, Measurement Input",
        "documentation": "Reporting Unit, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of fair value in excess of carrying amount",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Axis]",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r225",
      "r255",
      "r256",
      "r387",
      "r411",
      "r412",
      "r413",
      "r414",
      "r425",
      "r440",
      "r441",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r645",
      "r657",
      "r667",
      "r693"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r646",
      "r658",
      "r668",
      "r694"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r665",
      "r675",
      "r701"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Domain]",
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r225",
      "r255",
      "r256",
      "r387",
      "r411",
      "r412",
      "r413",
      "r414",
      "r425",
      "r440",
      "r441",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "pets_RestrictionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "RestrictionPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restriction period",
        "label": "Restriction Period",
        "documentation": "Period of restriction of forfeiture."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r128",
      "r476",
      "r496",
      "r501",
      "r510",
      "r535",
      "r623"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r192",
      "r193",
      "r194",
      "r196",
      "r204",
      "r206",
      "r254",
      "r257",
      "r363",
      "r364",
      "r365",
      "r386",
      "r387",
      "r404",
      "r406",
      "r407",
      "r409",
      "r412",
      "r492",
      "r494",
      "r512",
      "r823"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations",
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r235",
      "r238",
      "r239",
      "r243",
      "r244",
      "r245",
      "r318",
      "r319",
      "r451"
     ]
    },
    "pets_RevenueFromContractWithCustomerNumberOfMembershipModels": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "RevenueFromContractWithCustomerNumberOfMembershipModels",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of membership models",
        "label": "Revenue From Contract With Customer, Number Of Membership Models",
        "documentation": "Revenue From Contract With Customer, Number Of Membership Models"
       }
      }
     },
     "auth_ref": []
    },
    "pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "RevenueFromContractWithCustomerNumberOfPerformanceObligations",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Revenue From Contract With Customer, Number Of Performance Obligations",
        "documentation": "Revenue From Contract With Customer, Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "pets_RevenueFromContractWithCustomerNumberOfSalesCategories": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "RevenueFromContractWithCustomerNumberOfSalesCategories",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of sales categories",
        "label": "Revenue From Contract With Customer, Number Of Sales Categories",
        "documentation": "Revenue From Contract With Customer, Number Of Sales Categories"
       }
      }
     },
     "auth_ref": []
    },
    "pets_RevenueFromContractWithCustomerPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "RevenueFromContractWithCustomerPercentage",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, percentage",
        "label": "Revenue From Contract With Customer Percentage",
        "documentation": "Percentage of revenue from the specified category to the total revenue during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r322"
     ]
    },
    "pets_RevenueFromContractWithCustomerVariance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "RevenueFromContractWithCustomerVariance",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues, variance",
        "label": "Revenue From Contract With Customer Variance",
        "documentation": "The amount of changes in revenue in current period comparing to the same period in the previous year."
       }
      }
     },
     "auth_ref": []
    },
    "pets_RevenueFromContractWithCustomerVariancePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "RevenueFromContractWithCustomerVariancePercentage",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues, variance, percentage",
        "label": "Revenue From Contract With Customer Variance Percentage",
        "documentation": "The percentage of changes in revenue in current period comparing to the same period in the previous year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities as a result of acquisition",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r622"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "pets_SEC382LimitedUtilizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SEC382LimitedUtilizationMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec. 382 limited utilization",
        "label": "SEC 382 Limited Utilization [Member]",
        "documentation": "SEC 382 Limited Utilization"
       }
      }
     },
     "auth_ref": []
    },
    "pets_SalaryAndWageMaximumBonusPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SalaryAndWageMaximumBonusPercentage",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum bonus percentage",
        "label": "Salary And Wage, Maximum Bonus Percentage",
        "documentation": "Salary And Wage, Maximum Bonus Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "pets_SalaryAndWageOfficerAnnualBaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SalaryAndWageOfficerAnnualBaseSalary",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual base salary",
        "label": "Salary And Wage, Officer, Annual Base Salary",
        "documentation": "Salary And Wage, Officer, Annual Base Salary"
       }
      }
     },
     "auth_ref": []
    },
    "pets_SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Requisite service period",
        "label": "Salary And Wage, Officer, Sign Of Bonus, Requisite Service Period",
        "documentation": "Salary And Wage, Officer, Sign Of Bonus, Requisite Service Period"
       }
      }
     },
     "auth_ref": []
    },
    "pets_SalaryAndWageOfficerSignOnBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SalaryAndWageOfficerSignOnBonus",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sign on bonus",
        "label": "Salary And Wage, Officer, Sign On Bonus",
        "documentation": "Salary And Wage, Officer, Sign On Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "pets_SalaryAndWageTargetAnnualBonusPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SalaryAndWageTargetAnnualBonusPercentage",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Target annual bonus percentage",
        "label": "Salary And Wage, Target Annual Bonus Percentage",
        "documentation": "Salary And Wage, Target Annual Bonus Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales tax payable",
        "label": "Sales and Excise Tax Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported",
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r206",
      "r225",
      "r387",
      "r411",
      "r412",
      "r413",
      "r425",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r724",
      "r727",
      "r728",
      "r729",
      "r743",
      "r749",
      "r750",
      "r798",
      "r804",
      "r805"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionNarrativeDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofAcquiredIdentifiableAssetsLiabilitiesAssumedandGoodwillDetails",
      "http://www.1800petmeds.com/role/AcquisitionScheduleofProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r77",
      "r398"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Provision",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/NetlLossIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net (Loss) Income Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51",
      "r452"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets and Other Assets",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested Share Activity",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/AcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquired Identifiable Assets, Liabilities Assumed and Goodwill",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r558",
      "r559",
      "r560"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r125",
      "r127",
      "r128",
      "r173",
      "r174",
      "r175",
      "r227",
      "r291",
      "r292",
      "r293",
      "r295",
      "r298",
      "r304",
      "r306",
      "r506",
      "r507",
      "r508",
      "r509",
      "r608",
      "r718",
      "r737"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "pets_SevenSuppliersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SevenSuppliersMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seven Suppliers",
        "label": "Seven Suppliers [Member]",
        "documentation": "Seven Suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "pets_SeverancePaymentBaseSalaryPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SeverancePaymentBaseSalaryPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance pay equal to based salary for number of periods",
        "label": "Severance Payment, Base Salary, Period",
        "documentation": "Severance Payment, Base Salary, Period"
       }
      }
     },
     "auth_ref": []
    },
    "pets_SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance pay health insurance benefits, change in control, period",
        "label": "Severance Payment, Change In Control, Health Insurance Benefits, Period",
        "documentation": "Severance Payment, Change In Control, Health Insurance Benefits, Period"
       }
      }
     },
     "auth_ref": []
    },
    "pets_SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance pay health insurance benefits, without cause termination, period",
        "label": "Severance Payment, Termination Without Cause, Health Insurance Benefits, Period",
        "documentation": "Severance Payment, Termination Without Cause, Health Insurance Benefits, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted shares, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual grant amount",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Annual Grant Amount",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Annual Grant Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "negatedLabel": "Restricted stock forfeited or expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant issued amount",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted Stock Amount",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted Stock Amount"
       }
      }
     },
     "auth_ref": []
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, total grant date fair value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Total Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Total Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock granted (in shares)",
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of absolute stock price hurdle period, consecutive days",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Absolute Stock Price Hurdle Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Absolute Stock Price Hurdle Period"
       }
      }
     },
     "auth_ref": []
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Absolute stock price hurdle period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Hurdle Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Hurdle Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-vested restricted stock (in shares)",
        "periodStartLabel": "Non-vested restricted stock outstanding at March 31, 2023 (in shares)",
        "periodEndLabel": "Non-vested restricted stock outstanding at March 31, 2024 (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employment performance period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Performance Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Performance Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock hurdle price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance adjustment (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance adjustment (in dollars per share)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment, Weighted Average Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Performance Adjustment, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested and issued (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period"
       }
      }
     },
     "auth_ref": []
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and issued (in dollars per share)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock vested (in shares)",
        "terseLabel": "Performance restricted stock vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16"
     ]
    },
    "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subject to floor (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Subject To Floor Per Share",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Subject To Floor Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/RestrictedStockRollforwardofRSUandPSUActivityDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Three",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity",
        "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Axis]",
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Domain]",
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "pets_ShareBasedPaymentArrangementTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "ShareBasedPaymentArrangementTrancheFourMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Four",
        "label": "Share-Based Payment Arrangement, Tranche Four [Member]",
        "documentation": "Share-Based Payment Arrangement, Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting rights, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued, price per share (in dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "pets_SixSuppliersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "SixSuppliersMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Six Suppliers",
        "label": "Six Suppliers [Member]",
        "documentation": "Six Suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.1800petmeds.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IncomeTaxesNarrativeDetails",
      "http://www.1800petmeds.com/role/IncomeTaxesTaxAttributesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r173",
      "r174",
      "r175",
      "r190",
      "r211",
      "r215",
      "r219",
      "r221",
      "r227",
      "r228",
      "r253",
      "r281",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r291",
      "r292",
      "r295",
      "r298",
      "r306",
      "r417",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r534",
      "r555",
      "r575",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r718",
      "r737",
      "r744"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r27",
      "r161",
      "r182",
      "r183",
      "r184",
      "r192",
      "r193",
      "r194",
      "r196",
      "r204",
      "r206",
      "r226",
      "r254",
      "r257",
      "r307",
      "r363",
      "r364",
      "r365",
      "r386",
      "r387",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r441",
      "r492",
      "r493",
      "r494",
      "r512",
      "r575"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r226",
      "r451",
      "r504",
      "r523",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r556",
      "r557",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r575",
      "r629"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r226",
      "r451",
      "r504",
      "r523",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r556",
      "r557",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r575",
      "r629"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r648",
      "r660",
      "r670",
      "r696"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock, released in period (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock, net (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r95",
      "r96",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock, net",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r128"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets",
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r99",
      "r100",
      "r115",
      "r536",
      "r552",
      "r576",
      "r577",
      "r623",
      "r636",
      "r738",
      "r748",
      "r800",
      "r823"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r189",
      "r290",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r305",
      "r307",
      "r410",
      "r578",
      "r579",
      "r591"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r445"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r445"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r445"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r445"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r445"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.1800petmeds.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r446"
     ]
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Concentration Risk",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "pets_TermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "TermOfAgreement",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of agreement",
        "label": "Term Of Agreement",
        "documentation": "Represents term of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pets_TerminationPeriodPeriodWithinChangeInControl": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "TerminationPeriodPeriodWithinChangeInControl",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\"Good Reason\" termination period",
        "label": "Termination Period, Period Within Change In Control",
        "documentation": "Termination Period, Period Within Change In Control"
       }
      }
     },
     "auth_ref": []
    },
    "pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "The2016EmployeeEquityCompensationRestrictedStockPlanMember",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Employee Plan",
        "label": "The 2016 Employee Equity Compensation Restricted Stock Plan [Member]",
        "documentation": "represents the 2016 Employee Equity Compensation Restricted Stock Plan."
       }
      }
     },
     "auth_ref": []
    },
    "pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "The2022EmployeeEquityCompensationRestrictedStockPlanMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Employee Plan",
        "label": "The 2022 Employee Equity Compensation Restricted Stock Plan [Member]",
        "documentation": "The 2022 Employee Equity Compensation Restricted Stock Plan"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r808"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/CommitmentsandContingenciesDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "pets_TollFreeTelephoneNumberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "TollFreeTelephoneNumberMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Toll-free telephone number",
        "label": "Toll-free telephone number [Member]",
        "documentation": "Toll-free telephone number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Names - PetCareRx",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/RestrictedStockNonvestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Director Plan",
        "label": "2015 Outside Director Equity Compensation Restricted Stock Plan [Member]",
        "documentation": "Related to the 2015 Outside Director Equity Compensation Restricted Stock Plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities for uncertain tax positions",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r377"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r149",
      "r150",
      "r153",
      "r154"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Technique, Discounted Cash Flow",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/LeasesScheduleofLeaseCostsandActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs - variable",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r622"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.1800petmeds.com/role/RestrictedStockNarrativeDetails",
      "http://www.1800petmeds.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "pets_VetsterIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.1800petmeds.com/20240331",
     "localname": "VetsterIncMember",
     "presentation": [
      "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vetster Inc",
        "label": "Vetster Inc [Member]",
        "documentation": "Vetster Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations",
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Shares used in diluted computation (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r221"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares (denominator)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations",
      "http://www.1800petmeds.com/role/NetLossIncomePerShareBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding used in basic computation (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r221"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.1800petmeds.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482943/710-10-55-7"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0001040130-24-000046-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001040130-24-000046-xbrl.zip
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MI;62ST-/=GU86/G1OY/>>0AS[/F=0#:3!.SD#R-VN@8BL1VN-U$0G,52WLA
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M</MQ%/JNFIP#Z^X1W"UH\Z@'1?0.Y-7(+(,([(4['!OK%CZI-T! W&D'].X
M)K\ @EQ%RJ[OH<23:ILE:F6H^_FIVFTR#_V\<]$PBX<1*?V@^B+)>3%LBK(W
MLL2GK3?:-<C".&4-3>\([ ',(" #!/X&M3>-D/R<D'2U>S#A<E)F"1ICJ4T*
MIPMOP!>!F@W*-6S:KU$8$24JG;7CHT0)9$^X<$[ ONE8O\(,[T20,6$!.8'
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MR2BX$W0=)VK!RD2PG?#Y%QG%/?P!)\,!0U^P$P7V+:8331%-#BOG;I\D0$*
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M R7?[362(7I3DK%!(3:.2LB%:52)^9&J4)AOQ<JXAA4&9OXG; @QV\+2*VO
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M]B?]:#A46&TF!&<W C5E;I9EG"]28A;'ZH"XO4T@B^@L(R,#:T@PW@AF+MA
M0N>*45:U+L#\(>$D:IBJ*@N$,>BT?KC8DPA8%!.NNSU^>]BE/+5/K*O6Y+H&
M1]<J2#+)?#KG83*RH7L_JD)4.@$*6UH!30NN:=((G<:UBAYW= ,-@QS/1_5M
M9\M;5<4:9^T4FL^=*G;M$\?!'>4%UF/WPVXL0"X!)\H0'_M$8V%7K")+-4.)
M_2E <N$P/)G<PK9Q15/4004_/[%8\WC/ &8318D$<T)1=E4C"Y;"G1]'H4Y&
ML'C#E-Z::('$\HZK1 W$(@] #%7^.^Y$\4EY0P13/J'Z2JIB6ET;:NI?QQI>
MC[VJ6$*:Z*\MHT<O/2O:<72_3NG4I'>=%QHQ\^[,ZNJ\7VQ,37U*##YM3CA<
MUM?!MB9[_U#@/$ PZG).AF#(FXA-3PL/L/@DJQB>Y8\!ND$?:BS["J56"0$X
M!E',WB:XX(XKM_ 9'0FW^\C'?5; M$0BQ-(024BU/%7Y]C)+">L[IM8UN/W"
MA_W@LYYCUBDF0G)"->55*0,U&*">R \,)9:C[NOT*C\IMFS-AAZEJ1C4_ "/
M*T(! :.(X1SK=EB\)J\)-;=91"\B[JHT*Y/];2%'JI.LLFX2?9M)$7IS?W]?
M@Y4<Z*TB[9R_0]BD^ &_?9O7GS+YF0Q2Z4UA5^S83PG4@;9074(1/<1(QM!L
M$209^)+/Y3U%CHGUO8:UC0]>-PC&).4VYB@C%F0.__:F63BU>[O_T$]@A11Q
M<KG_*!';G2],RG/;SGA6,J8;(0]%EAJGY!%"_(%/2([,#7;J%6(=;RO.EDAN
MJS"OZIU,MZRHA&[X--:G"=4GG)6.=8H$VTQ@\H&%R(U'T"<4+<(9C7"-[$8.
M5 XG8Q/Z(&0>MR_=6^0_NA/.6BABV+_F5^9T;4O=K>85)VVE^9Z06; &"MLX
M%(O@T!A">U"[!BL,'DL#M8Y+@+!2V'G5Y:J+6*;<HFH,.JT02T>(2&ZDK0R5
M*.Q%)*A4?RM]-A2P&SO'$70B!ZHB$TQ?SE&..#'!$=6.W&KC YN ?KPDP\;A
M)JB7]V^H$%?)\.AEB:#/XV80Z)F*J>!X"KAQ&LH;1V6WG"BT0AFWKHJV)=8;
MIHER&19[F6OQ)ZN8ID!>BR!00RD<;LOQ3,-C.9H',-D!C0W:,FK0E@<SJ84Z
M0MLX5C*%VC=3J8^/D[@KG"!I8WQI (T\S$4YG!JGF-M4VL8C<?L.5>,AJ/Y?
M&;=P9YW&NV/]$I'XB*N;U(PD4B8P8\\8> !&?&'8&-5Z6J\:NFSM2M]H6$VQ
M*4&!IBMY[RF+NFL.%2730H",FVW?TC+!TB"EU?>V\P04M:L%<T89M B$DA*&
M"1T7ZC4GK-8AA"'C6052FX01K:7LE2QA9.6$'(_,DZX" S\F/HM781V^BF>M
M@5R[L5IBD9)E&;E3RAJ%/Q@#!BHBE3AOKEB7U9T:"'CLWV^UD9ZS%)@WMIV'
M0RB!EZ7*,\ ])C %)<R1C4G/MI"V#"ZRY\<21!0C;XW[/L;K&;%-%^B]?M+7
MPK>3^=SG4+T<'A;U0E\#&YM,>C-H6 4,.U>*E?6J2I,<'?FU9(FQVBZX%9['
MJ(YF@!4>@,+T(O<[%66/-\JH,$.WH+)(-!C.'DNV72NJDI3#L31Z*CA#X_%.
MHMNF4/"4.U-Q&&DE-S%R?V)HURQ,AG$+VD3NP,HOI 'Q)J%@?@<"53E:65(K
M@6^BPK 4**VYKN).,OJ;QRHX.4"MI)[)+H'&-UJLNP5;G16.<35+/XIMZ!^2
M/"JB$CYTSQ,S0[+2A[2<+$,Y'-.'#01:+G:+YL )!E%XPB# PSR/Q2,!!VL?
M(YU@5Y+_DJ:A<3==A&CY?I.A+&SF=VFUQ8-%(DRV27HQ2"8R)@=*:-K:Y>V-
M)K@2H>4IFC4>#30F&2B0"%:%/BHV-2I+C>G01HC23,ZX2(MZ6SX XZDU Q?:
M48?N6G295.$=U4"*.,P+L1D9RJ"W$FLL&-W,N+0"B"H]6O)6\E'.D>;)0BIM
M8.[R2^OZRWGK=^H9]FOS^E/SY _G\JIUW7R\@=KJT/U-(?O0=@OZ'-0Q!HC+
MF90Y?+[R2!ZK'B+FSF+?Z.(OVO2RK2H37PB%:O_,!@,'Y6I:2!9&IC'2B#0)
MMVP</B3O3J*,.N6O)-/%\E\6&D&C&PPVATAXK/W7#;4_FOH2=J(P4^7)Q=2_
MB09+CDA[/2R'#2^@RB(%)<'W#)+50*;]B &0J/6G<OY^H4?#Q/6M%+>#&29*
MEI"*- T>Y;Z/SBR?3#"\"VSI6P3L5#L2LOVHO%R3'1RNH@0Y85N;6.K7*Q&[
MTOJ:0#N :-!)W'I8K1-/W3;:EY^O3\XO?L$3_ZEUC<'XT_-VRSF_^-*ZN+F\
M_N.5 I'3XOR.G9LI];H0T*?\1F$T!A''8L2]7!%TB1-U%"03#"'K"HJ]*<+W
ML!L\9M<A\BEA=$8*2:00;"G&5PX.:W7RU?)!5>,@=ZU&F%!-.Q)4A8IP=)/=
M0QG<1&M?MEM(*?A3AFV-ECUH&3I&N+!(^2FPCU_@<V=I!CE3+4_-B(O*'K+;
MM8N:C84C5.)\(1 Q1"1:+%#D;!#M?E2:T)3M,#VTBB&HPB[9?9=8*XZ&62#&
MF#$AV4=A=0:'3G2GBJEC,="X?1D,$9 VD6Y&SE6PI4"=1MWL#E3N@>0F7[I]
ME$;(515HC&3+T1@KE,619O@CC;-$=T_7.1Q:D5?VB8J]>L4\*QT<2W!=_XSB
M<3+&H1:S.B9M$UU:P>8G4C-G=6#2CD)8+1JU*\7R)[.O-FQ_DNT76D/H1BP)
M(L=&,9H1IHL*/"F.,"0E$@K'829 )F(!*@@G^)E<:DU2B>@J[[XHQ+*82>L<
M>K3)%'PM-T#7P)*$$<G:3FYR*-6(L^ZYN2O765"+"!6=HT#BJ0Q05'W S(^*
M<P:KZ7LBSV"ZB# E0L 1S*'G,*RF4:\_CL).'$6W%=/L5J5^HVV<N<I@C!3,
M#NN(<"?F)X^4+HF]XOT[3IVR2PQ)W-WI2+O-G"BK5;6RR6+07YD%&'=U#H-G
MJX$%D>7;D'P)^<43M4&X.7$1I)74\\:/5A'#,!!N#J!G0_9%$R_-HQ*78SJX
M_5KK&0C/;2T0HX!2)V\4IST?GPSKM5?%PHFBJJV-%.43T1WK8V2(*5H42@9Q
M/P%5PWLV6S_G:JW<Y4-Q(G^ %[ :D@U1A&2XQZJZ'AL"V&A+QK:Q#9Z:<_H(
M_C$8U)Q>ZU#G6F+I(ZHO3RB/75.@CA31VL I=(,H8>L$W6Z<>%=@S=I9E "A
M!)[N,0QTC V>8K-3"GZ3$FJ!"4BCZ"D(W55D\><79Y=@O!.';__1OFE]6@?;
M_3(/558QS\53QAQ0396HIJKRV#R[B,RVI'5,3@6WB ]3/(_;)>!G"@<'%0MV
M"FBDXO0S>&1>BDG'E#N)"5.%K94G_183U;7SUJPHYV1^8<7B]?D4*@7^5*&\
MNY!&1:.AO\:&"V8U2":81@)\V,L,WE8^YE@J5+NBJZV0UI:G%-K5?!'P@5X,
M&I_#25MQ/N/<1V?*P70/!N0G.@"?3LNMS!%-"U].&O?X;.P\SB4J5M2[$-^V
MRP@)"8%"SZK3M0[6+\SZ6(+UOD>JW"_G-\V/SDWKY->+RX^7O_SQU>/^M>.]
M8]6%;UHW%I=[OZ1!W%*R;";01P3_](1EB].8_.A"):+.C*9>\3KH:>5?J-LM
M!$&=K4T K"9I+F<R.NB5(RA7'%E%NQ"8JM0Y*!@?'6E.I[^TN(SRC;ZY_-1^
MJ])--"M7AL([FY<IY4V:L(+5R29!JT,U&&+N!J,)NWXO0Q_PF#&L,Y& *T:Q
M3E,Q@3E,PJ8X&ZPMB1)K?;O  B46=^B45XTC8RG+]LI_!1YF]=2DD\M/5ZV;
M<U23%J4>/3>NQKQ%#'E*/_4JC<70]S!KZ2X*[EBA@?M0I<@!BYD(@"AZRN8P
M]&!E\&L'#-]%SD"EY102QRHJ'Y/\31H*G7M@J)2J=*14+1,H5^[3'S"'V3I_
ML(B@8B3CM0*4,8IJ_@_4-0.>A3_A"1U*E< 7<A":VK-ZJO^4Q@]U O^6-#.P
M=$%- J*F)I(5IQ.)V*._V%O;J]Z+X)8M.H/83VLZN8)YHR>[Y@&SOER!MFIJ
M[0\Y3K&: !^FFW!129)I"L&E@KQVV WFCKP(*:6'&>OF?LRXH317],JAJ:8J
M@S'!0*TVS8H[A/#I?8:6SB4](@:&Q?0<(ZF!]95 #7Q2)AV"A;ZYQJ>I728Z
M@T[1 EU'\:KQZ)L==.-.#RJS$!/&358HC,#&7>)G6" :Z,($4P(;2GAV^+GK
M=U/J+I9*)14XZU$^2#>CB+EQ7NU5*3H]W9,@5%]!ZC_L"XUX3J]04:Y8]C*E
M9F.#,^T .#MMTMVGK6:M"(ZH>QUBK8-:%*F<L2YY)E+NMHQ/N="LHIDDD>L;
M=*P/$35-LZ'_\-D?)>@,;?)D)"INRMW\S(VFW,?JIC>&5D%=VC+L (=N^T)S
M-W+\K*!<.[^X:7W\V#JY^0RVP=4U!O!O9GMT5\<!\+MQ-7+K2BV?\I3KE.Q2
M#*PG8QTX9S;@Q*9Y&,5S>,@4L[*>(E29G3JA# Z/.NG4QU>*7^N71G'AG2@%
MP6)%)^A@+#HGYQSVV&"17D$D<"V*ATD,"$!+!SS4^7CZ<(-RB4"V\#W&1EB$
M6T2OG))VQ-,J\\4X3M11J%"45([[0TX!A7ROO>)V/3..*5;:KIW Q;$A&!.&
MEK#9C?*,+ M,^:F)IU@75#_<WK;JA<HT]*WWE15;RL/#S5(N9"EY&575TPLL
MYMHMW6;-GKYFK_'4/OIVE(=E6H\YMC&O<2W3P+?>?W,WXG7(2/A]$9I7:?83
MIC0O/]$AH3*-O52\>>ZUW"SE I;2UO4WZ_E]ZZEDS4NMXU=6K522>KZ5 RE=
MCK7+:VWF]]_]\V_U@]T?+=!GDTDLN9"?RHSI+DP5BT)\L>5 ))>$%Y'C@!WF
M^ !,">+$NQR,2SO>)R7BCTX_NI=46)=2M0!ZZCOHC,#:YBRF:B?RC?B8M]&#
MT9B"C@!=KP; )A>R S'2@&B8NQUCJH7P.%&<\Q8<A?6=IV(4>MJS)Y^CE%:$
M\G>I:Q]@NFZ0$;B- L"!2XO%"\8E1!EDE'MLJN"4>ZDY@+&YPN1K?11Q#Z.Q
MB"11W*.*=D'-N/,3YNS>J)S=K]]N7_DI+PUID7\VF7X/^\+PFI@R/LY#MU:\
MLEX%SERU_<ZGU()I['F%RQY[UXP?_\"-LV>@0#=X].J>+7+47<$>%;Y@SUW^
MU071:N3<"#^8_JUZNOF1?("%"]H"@WGY>\0 "U=#C(NAKY^09,:]=Y2-I#(P
M<T(9QE&*236J@F=+ ;,\"V/9IWR'KW+ R902=%%7*4'E1P**<D6@]'7$YV#F
M>/-IF<RPMK5ZT8)?L.KOXE/KXL:Y;OWR^6-SD?'PY48+!.7V=OY4XD$@J*7P
M\F0_%=2J<.A,P9-0X#H0]XGBQWF\BV)PG,"GLTUU#*+FG/H8>4X8"V9Z?BWF
MZ/8P#YAR%[EO,;U9P=9T1E,D):::8$:(C\4<:C24"][C[+H*I1 +;C\'C^+"
MMYE#P"7Q>*A@%)A0G9_8"Y5/6D?F2++@FU36.&>X)%8T4O=7ICX0>2Z?C@^J
MVVA^Q>D5HH3S#\3DH#]Q).8^$TJD,;UJ_X*5JXY!;DPV<'60%F5&OK:A]RXR
M9,B!V]TC!5G&])>O-Y$RZ59X.!!=@C)N3[!$J.-/I04JQ*RU:\X7G["MSY.
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M+2FG,OFP=\^]0F,J: Y<KH@08R,I8FL]+<&LP8OI:7Y(&A8VXQU# .-YP6&
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MB2&V*[.@5*P^U:KODU)WM2=:J[QVMTJ,?KN8<V?EX5E/TNDYV*X")V ]&)<
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MC%[[BR>LT5;.0^\IH'K&JL** +FTBYK*M$5\)E7"C\:$%BT;F53>I"DYDU'
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MXKKS*^OHLF_!!O3O)?=#L:O/,+_4F"3P,.-DSE=7QBIIX35SC17I'&'C?.]
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MAO&&\@G<2W8!K*?[1O ;_%C5&L'!N%R:R;*G!O=N)A6!7F20-ZTPUGL2I)0
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M,#501+,MHNBWWXRZOBE8B.-&S'L8F?XGVW2!7&A]+M5)"^(Q80][9:Q<;2<
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M68%AM>P=5PO+"&HV>G3JB8>['7;AXF+,#&+26<1=M"E+U+!T&L/(7HK$F'4
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M(_<K @X@'UORU3!/&>X O=F]"[_GQB%;XV!%B#&H$E?V2U$N<I,R=83">#D
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MV5=_$2W_$&)0=BZ5F8/2HTNCN?0>[;\XO7OR\DMN$-E79QQU3&9EU<#06=S
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M4(M@:F)!N25/5@?1:8;Z =5:3(I#I%U"JS7,L1Q_D2LG%=S0E%V:GUX.GK_
M%[X%C8=TQ)%&K%''_'0P>/G:QA'UHX-!%/F'2LT=FR\3C%*X&?"4^6^'9^(U
MP#<$*E!*SE19_45F3%F!JEK2V:.D5Z#WT*#$*VYDR%V$ZQ,-=!Y/9>!HFV %
MO//>T??^_>=TN!?6=Y.]X#S=NE1$ZTVCQZS2?R$!+@L;K-&KNPG%TK]^K0PM
M)#FKQ@@(TSA!K[3Q?+NT)Y;1N;31LC.I7"56:/D7F!0(@O9[+_^T(8*T41OY
MQYH5YPM6773C>>ZD(.<MN'-C\<N7ZO/2BB?C*69-T(%,HI>[?Z+O[\/_S^.
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M4B+*H(!MP@ 7)AO$6\C/1X3GY#&;/>&9"NU_"#3Q,''EF8X0*)AG6S\8Q;&
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M*OR]9)#!R,*\%5]Z&$\$V]+P+.&Y/QL(YW?"ZA7=S[F9#!BU3)@--S9!BP,
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M^*B\T]Z+8 ,7*%%9$1@WS6>\8AU?'9<N&\<D\%WO=.S\]>3:3T*^D^[DO1I
M?]DV<QY('HB:,E3-BK>%L]E/Y=^A^2#8XOXQO<(4%ZW8)-.%V:-'0!4D2:&
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M&?P8A_G#"AXO0A_6Q+S7V6*]#8+E^M7.[K4+I%5;0CRM:PV6&T^OBMG.,=_
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MVGE;U5IEN?0OH;/'%(3=D-,L%W+*% \XBG*6<F9R9J<]LQ,MZ-H\F4A&WA(
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M+P&V'\Y0^2$U5T%TM2A=(]W:K6,4G,.$N&1U$%824;I:C*[0<V2XC-T'!^9
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M;XOO[]_'J%:F5G8E*[N&A.63XQL638'=J0534%- 7K6!H%,G0 "MBY_[4IP
MU;9:13R@0X? 6_A#B(DZ:-6;O;VO5PH?Y*G]I2VBY#W%\HRX,SN&+B>$S@B5
M.W@CW"QMVLD!F>Y*PFAE@*[1 )T>/F#8!0/4[=6[_;*ZP)4!.DONS$GB'LH
M]90!4@9(&:!3&Z"<".B@*> ^U9)W!F7=TRN#<Y;<6';$LUTMXQ"+BTHK$;EP
MLY,Q4VC/"0P*F'[SDZX6W%RMZ7S7I(#ICPU,?UZT4/CSUXL_KR#"%?[\P9A+
M5_12^/,*?_X4_*/PY]5[SN ]UU#^I/#G"VRQVBFX,\,D'@X5)O&%Y^0/A4D,
MBU.8Q*I=1^GZ[6J%]%/K^DZSA5>W[7IGJ'3]A>KZ))>5J>OUVFA0 A"8TO5*
MUY^EKG^WGV/OP0;@;T>HT.DTV[51JU5OM=):_KU2\.?#5UMZ\WMPU@:5WZF-
M.AG>_7&9J K*7B'1%]KJI1FK"T>M/#D^<:?95?C$9V:V*H)/W&GV%#[Q#F&)
MPB>^0DW?:Y]>TV/WP*#>'^I5D%BEZ0^0@6H?2M,/L.=,#1U1JOY*57VQ#%3*
MJS]F!FI8&^$HQ#1,V/:Y Z7?3\Y66[KR!TM M7"D9B^CR?BX7%0%95\*>%M)
M*'@' -52*U,KN\R574/J>%?PMB04WA5"%Q0G0+5MUEEAYW1:K=*P<PH?Y!FX
MLM<.97 @[)Q.2R\).^?P3%<%S_<(:0YE@*[1 )V\]K[30O30OE[7!V5EPY4!
M.DONS#9 ARK;;Y6%'JH,D#) R@#MGJ-/A4!'3-&WNJ $NO5^LX0<O;(ZY\F2
MV\4]ATOO]VJC;F-0:?ZK@@'*@'%#DN&IF79@$,WV!7;C/S+M*1S7A]: KA6.
MO'.=4HESIMTY"WCSFS:9&_8SFVH^_&S*9B:P+;*O,],,S8;7302W:?##VZ5K
M6EJKKB&D2%WS'<TD!YUI\"3'9MKKW-'FAJ?9CL_+7.'!#IPY/7UI>#[\Q73]
M-UCM3VT!ZYQ[#0U7XXK6;,.>TEMC-;*:L0!N]#U4O?2<-V:XGL8BR"CN4+7%
MNN!9,XM-Z%5><@NQ_?%M-[0_[:E<GLM>3"?PUE*AOG:EK[!A[6^%C%,G89VZ
MI<1'0@GT(AU :*)9!7P:<)>%B\3M%%MY]R@K'\#*]48Z=2@7C@?B+>&XS1=F
MO=5#)B$NR6>2AI;$F+I P5X8)A@%TP8!@N.U+.<5C041: )R:?J:Y2#M@5R&
M3S23WV2P)W!RD*&!R!J8&0^^!P<9BH%'(P3[OX'\&V/3,OTW5 8+XP=*\K\#
M$^5^:;PM@!Q>G1X %.2/8, $+%S"Q'"G*(ON,T/#XX$XP3.]8#8S)R9\6YN!
M(?+@$PQ^R56%7.64^<Q=  D\S03M$"T:A!9W$]A =50$<H4HS),)UR4NFS#S
MA4 VQV] (,-Z^P\N$52&[[AHH;2Q,85WC'V/9&,2N"ZNAX$4. MSHOGP3UB9
M":H$%F21)09Z^7.A3)P7V+1CTW)N'^^T)V<)WVKK/>U=3?+>@5B$GOC!](%%
M)ULPS6<X1'MBPI;O;<]W SHU[4:[XT?TA;BD]CX2F5-Q]CHF?@6K8RR![#^)
M"ZRW8MJLLSY-=2O?_-EQ/X+7X\\"ZU;PTO>0E>XXCV3% 8C_T$\' 2'FG59<
M 7</NV2]61NUTQ# T8I!::05:X?VD?YY.ZFG&RL(?YF.%B[$[$WT5G<\'O0Z
M@V%GW.H:T_%0-R8MT.'3?J\[_+\>-N)%6IQSY^A_QBY>"Z^H^*/C0;5T# TZ
M[S5-$T?[%<0+]$L:T#EY>K\''FHV#Y3=&,03B?+1]"; [('+GN"+OUO.Y$=T
M6"W.'4! -KWUQ<_PL0P.=@D/!KEFM='M!)2S1[Z-/%FQH#QB95%RY;2B1=QD
M+T.O)0SLF1A4.KL'X?0*9I:\'+>6QD08O*(18"($O/_Z.8\'8H<6A7H/L[\<
MH//S/<*?@>WCGX)E9,6 .K\,2PGS+])6FIX')T:RZP2^Y\-?T!JB*0?#:<IW
MX,>_,?_.<-GWGV#7B<K_=-P?L#5WZ;B<'4@Y:!8SZ!E>L 3KB/'#3(.H%E2W
M,ZW3WQ:@OR?T%?01X$OBHV#GR= ;T;Y)O9.=!:,/KD7@>H$!UAB<#N")VV>7
M,;1:])1OED&.^Q\,G H7K*WX2_BIVGMN\Z<86< *8X=9U_Y?PW7?Y'<?@W$=
MC.*DL6&O$/98UMN-\VHSW,78,Z>FX;Y)ZDI."9<"SZV]KT>DI,?\+S-LYOL,
M#"X;:^\,=%(@)O'PO%%KRJ=%WQ+' R^'$,1[S]VCU=UR5P3=8.D:B^4(%\Y+
MT#E^P DRXQ<7_-$1;6$?W.7!]0.7.''NH%_$MNC1,T!_O9@OR!@Q,O*5&\^P
MYF<PWOAB\ D]=*-,L/8@-T!1)DB.K% L4NFOCU0R=.U=_(U/+BB0&0-#.6UE
MA"@ZV)]VK]%:'UOAJM&7Q7- -SAV$/\-K&UX<PRP(2B= O?GQB8YJC.M)W,,
MX#FJX%55D&!1<@E%]D**&; A9M-,""& ><$39#^7Q*"@P$ 8IL$$XP[PCIWG
MNK9P/!_3%> ,H:*#O]HWD6*2GP<%9<J E318 ]2"AD3T*0:-%C1VX2,8%G#\
M9@@A(*)PS7' LP[&4D8CN")8&-"$@9-6UYZ9\^P:RSGX!G!0(,_P(3 T;#*W
M@=#/L M[CNZ<C*G$N\%KASA["J+M,HLKT[FY]*02!OUVXT,<[@KM'KT1$W[&
M;-8X"(]<&/M)SH*HT0'&^@\0[QF8@*)CC"IWCSN23D!:-_U=O"9+[W0@IN@U
M^FM2(Z_ 37,P[L!WUB0 ]D NX'J8_9R RI,V):EAX7<B*8@L Z$ML:R)J3CP
M$Q;\(6B-#60K81QFANEJ+X85A(;*Q*,#*:0H&[[)?"]TED#)R:W%J6K:]$T?
M-:Z@7F@$/<U[L\'NX#J W8D>\+RYR5[@FV#1DT(O)- 4!C[, 8[1KJ!M D='
MXWR(I@BC$X=[/18\T"+2Q(0,LYAS<&FX[Q?N<X,8QM4&$0GVK %+!C/878"J
M8O7S!F@0Q\"48DI5D4C;1,D%D)2?SC:!5+*<O8,C098.UZ8?^.M?F)@$(J[0
M8]\2^?YF]!5C[#E6X.=_)07/>P+1[<*:NLT5ZL3^G+N1,GIF-V/@E1\WQ@P6
M^\&P7HTW#R^UXEE!TY8/[PX:2,*\W:_F#_.HL4%';ON8(T:SE(CY^O#TZ5%[
M>M#N'KX^/GRY_WC[].FC]OG^Z^W7N_O;+]KC$_S@CT]?GQZSB)\?.NJ9H6.[
M>.AX(CL1MZRO$": MSUAY-B"OC%]MHCY\^@K@X(U8XJ1DK!3AVY._AW AF9O
MY+![#+0L^L1"2W)W.3_6W&ACM@PTA0?^#1UP3"5Q?TCJ[$\_,95#2?N/#+44
M;N66[FD25^1 S E>DP-!IK#QR'9U@9&<M.4*K:J)US#RP3QR,2@@ 2V$ :+R
M6C9[+62DR&;# B-#O6*)\VV\R\A83C$P@2^">4_DV&,&WW@Q3$N8><IW9Z1,
MC(070@&XAG1:,B(670Q.;X#9P3>>F>Z"QX0>LXC1-%>^UF5@.&UQUS:9 SO8
M/ D?]V"D!P(&'6)?$"?--;T?:%)GIA5=$7!2T-I>&=YT<-\(A#2P,+FB<1HC
M,<#\@YT0;T>*\.]B'+ JRD@XN1Q.]C&C]YMTTVAP'P<="HA>M+$0OKKF.8DP
M1ERMHAL/:F-A!@MY@J;] B=!P3VIAI JXJ1"SXL\JG!Y$(E0^I?34LG0-C(4
M,3DQ35IOAV)$)PZQ)%T9@P,[9:1EZY'GN>KIV7B_!*ZFLT0N"0,]Z;83@TN)
MXQ*S7%IOR)8OALMOJL6)XNLQ@S"#8!@BVBFZKUX SP@9VC+9C"<>7.?-L$#&
MB'-D2BB^7LKT(/_?H$%SIC)48(9K4VR[8. \1^FD=?OCL85'&22P?I8Q8:M?
MSR(!E_V8@EF )P\Q++^9(L*$FBGF]</Q+ -I2U$*J0QA#,?/;_K>?<%W:6V1
M*2-%MZ05@T\^I9M 8!H0\P6WT>$58^B^)V*<-#/$1#8A;/CIO;+#>J(N*"-A
M]3V,H>YC4=<M+4MFAF_MZ9=(S]]R-1^I+_[A![R=?0(E)4W]9]CS7[CEZ/[A
MH]C;=]A:9KH9YQ:GBZU_29B3M&XE1@%*38PEWEVJS,2:^B4<UG@+VD?8JM"@
M11Y<\I("1!G=,C+W&MT98,@J:C3@4\#]CXPS9GN@\PMQ4&<HM^$]NV;REV +
M(@@LFEJ,EOG]Z\1P79,GF5_Q3I^\N#D<+:PQ\('G_L,MLV4N3%\D?8'5T2(Z
MVE<'9&1(*F$6N%0?@/(3>'B#?CP^*'1#]SB9@X-JL8=96O9 UC9+WA-*:,95
M7G_UTNX,^3.TGWR.Z9BA87("WZ)R#2J02*;XC3#$D*P<?@"Y(LJO2B=6FMV,
M)%,]VYVU8TF[=V9\W-R' G>?Z\[B3.:V]GN-7K]JTS%U>%0_^U=;CL>\B!$U
M=^C&4;T1_@4O^,#=0*]'P6*7UPYQ?K#8>UPII J#RO0>D5WA%Y\B/LVJ)*(:
MSJH,0[@&J(C;=)EC'=VVLCNN+ARSJ;)2QXOV^">C6KY,V1MB*)8NXSL-#.0U
M6' *H&."5[KEWDKHSA>IOPRA*SU+DI X.N'U8M=NXNUC)49V78G)N[=?X( <
M]TW9N(NP<>%Y%FVY;;=JHW:]U:H$@NU5V3S9(L.S,,KL780<IBU?ELSAV+*,
M9A%E[@[%+M]<S,#+,E(XOR7>62G;=Q$R)P\7.QE\D5ZA\RUL"W%&6;W94_'?
M\9CJ(^.M E2P)"\D=LV]*'M8-=F4Q_MD_.2?SA([K,SNJX3G\;A%%BLH W@R
M(8LZ%0K:*)Q*UJOWNNE&!F6D#I<M62E=4B;J<DS4QI*NPB)*]5SU=D8'L3)I
MA^*N[_AW+(8)/+9/2D59MTK=)-"Q/LS^]-@7[ ^5/F1!@40\IWH)=^K*9!;,
M<:K<Y@492CK2KXX]B><XL\1M4!L-+LSVT7O[%9<Y/O+D],9O\R2:*Y/&TLUB
M\B,A..#.'BN.QNO7V\.R1A9OQP'*=FZH1UL:;\@0I[2?2I:/=VL8_X5@@6^<
M XH*= <+:NK]5AI";S<K7"%Y/L/8% [31;RP6)^%BDTOP CS8XW](A\>LM.J
MC5KM-.B5"D /?K'H\JX]%81>J*F4!RVZ,PN;2AV30\.,L=!G';!66C:3!7#*
M+%Z^D.:5PG5PVE@W/6Y#V<6#R5[4BHX9];VE3YG(RDD?!X2@"Y.',=")'E?8
M+G9*NC2IEET\HT1N1>RBR@ =069C/RDLJ#@TK55OM\HJ6ZU0LF>-[FBUST*(
M0UR.!.+:L>$)U@\CVT/"*T?UPK &I9!&*;T-2D_>3&4JOZ^L<*E^IX<H\O5F
M/SWJ:J\,]UYLL+-*3,_1BT\:V1E@I^)@1S'DQH R=8;FD\YT9N6B@F< MMXY
MGO\PD]SY";C6?WN*8+3QUU%I0P0BWNF#K5V#(8XH>''P?<+X([1#3P+M<9S"
MGTMF>QP9/-J^/2786G?*H;V?F8V8EQS(>HJX>I[O\MD6XON>1 !?G5%QY^ )
MXPMP- -R*RWCT8?_<%1 H+&(!&F>"/R3PR@6(_R@\*B(V!E\Y\3)I?6@-FHV
M,D8J25J_TLR/B%XS$Y_!)]D)$-7"0Z(VS!?<;T,(+M%( _UE;RC$FGQE%IPX
MG_Z8.Z&O(Z&3.:?).9-CP_X!*J$.L?ZS8=7E0#?Z$<$FP>$+[-898U[(KW'8
M,$^ *!<"]MI%71U.%=$3MYKP1LKI$0?KD)P .WUS'>TSVB;MWN8V"H_JW:VG
M?6<>RM/T_<$I4W%%[L7IM01Z$9U 'N6@/#-&.8'IC1"M!'-G\DFE( )!J-XD
M<+7FV#BD<NHP/B-5LK48&2C>8TR1)ERM<17K!-:44(3E<,6 QI9^9\\!QUS5
M'F_^/XF<]TF,;]!N)SXM9<,.ZKAD7(W-$.C5<$T:G\!GH$1SAZ+ORDD &HT[
M0'DC]>N$ZI>O6HTFR.8R&DW04J,)SF8TP?D,(>"*@F!7QXRANP:KHL$JJ[/#
MXD[=W)CRCT<3UM+#GD.=)<<K1]-82-H7U*\0O5I.9JG#EUS4,*:_HE1F@1^
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MG?J1S@:E94,.-^6/8R0J?B9F>GYGL,P7&NU)? 5/2@\V+YST'=1&W7I+K\K
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M;,[8(;HW'7"F;/LEBCJ0Y?4Z(M<5Y=!>>CX@PJUWB[GU+H];;U Q^\"S:%6
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M[:WA$CR'"9EZI$56%4KZJ_YERTO.7> 1@IH8=[;E/YAXN(3"<CRS@(>4<W^
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MF=)&VLL*>6SW1^)RF9IHWHQP]1JL19TOQ)^N8[^P?.0Q5$R^E AK6D'-1PX
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MDY&(R;##)!:*84^J&>=@D%RW: D2<6ZER"U8H?N(CMUR0 O((AOB"OH/AB=
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M]N>3:#LW^Y6K6_3='(O^![QI,)^D["1NRO=JC?QI.LD7]W)>'+C&LXPEI*T
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MQ9%Q5K-$>GJ.0= ?#CT0Z, ,.$7(US0CH)-N!(1WOKS9B0!BKI,TI8.;I9*
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M/^9:M>'2]A E!^.<+@<O $L.:B?RVF7WC8'S<J2?_$\[K6,6D]K^+O&ERU*
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M/P=.[Z!YKF'0GR&T-,HY*Q/E'C\Q*4&F:P_.S\\/GD5?+2]!:<^3Z?OBS_X
M!M7 (-NJ+MP\;_C53^2V489TG)J5(9';L REH[*J+^@DY>]@TV*LAKAQ,6))
MHV*4JXR&7"0"@H13DPP#;+^?T<<#!Y,FXZ^87/QA,N)R(-AV3/),DHL_2O)$
MOD^YE!=/XF?+)?%=&CV 1Z*O7B0=]@&[B?)6IK 2K2#_=X&8S:BG42$'2T:7
MF'&"@^ST)P'F#+N7/3$)]A,%_=N2X?=0DB2)DD%^U(G7D ,.8)Z0];U-*Y1
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M+:5V_$ S)!2@C,)V="M:T3N5\"B@,7G@78G13PS=F/'UU5;T=_/,FIE-^=6
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M2R0)1=6(UKB8QKV"[HWHT.:7_W_MC(AA0Q]%W^Y.XHV-R1]H?<*I\B>>V.F
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M4_O;8H(UM3O*$TC1O )*&F+4'JBHZK!FCL!ZIR>. CJ&(R"C)-RA0GPFOOW
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M;NX8G8HZ2'SGI-JF.\B$WVY2%:4=(7*\$ ("8N:%D)P,/B09TC.X;QML8[@
MY'GI=+B(SK9%$+VQKD@'GA4FFUG3S*RVD&255&ND7'OO4Q^T17#2DKGQX)8>
MF,Y?OUPN<?Z:+IMA594KZF@!#7'8YD6 E&V&%)*S*:$3W5M.[0UNC$F\'AQZ
M9/5TE-80^O<&O-V7ND<7R63V1Z(HH7FMB>&R9Q)Y&ES2.5CJ73=^(,0Q)@7/
M1ZP^DNN>+KQY+^J;1OGOYNQWM*HF7@5_I?6;19EPC-Z:]B7P,K.KJTI+,I4$
M-E;K'(?Q.NQWR_%A[QUC^J\G7X86Q<"J:-NEC[E\]R#ZW9\G@ABD5PD$%@&F
M&(3DDP7AG=697=M(O>L=3P8]QJS>^=354-(]8WE;RSHNYLV"+^KUQZR&WT]7
MIS9H// =_8O>CAA;I_JWJSL%KU]Z%6A<I7PGP9?L=,B 1;*"<LE!#*2A4/36
M!1FJ[+W2'T=TJO*[>OHO:URW_J??\R_,[@\;?5+DV2?,%%NG4BL DU <I_O6
MQ8K-N>WM?>T%;$S.?$?FW-5A_874S7A>0?N6>*X? A5M3FA# 6_;67[1KN7$
MC#QL"BGX+-'T3I\\ 6E,?OKPG.DBF.&2)IM,(/]Y>;'K:N+9Q4OLZ8%$WVSM
M9<_EW%KJ4U1*(4_"T%F3.YAZC?G6ZMTE<5(R1FD\E(T#S!X'.SDA@K(DR)'T
MU0Q56+H/OC'IVZY<VN4U=A=:]Z5TM<!W8=,5C28=(*.K8/B7@-U5"RAU%%&*
M4N)0J;C'D8U)#9^%2AT%U?$"@1V,UE*A-PXH%-7.5G/(4U,"W9JKI<!VB7JK
MH8'\VR=%JZIB_TAS1$F9[6!JH@TU BF=4PI.B#S4@9;]+,YS7Y!\.D.>+.$_
M12:]/=E= Y99H2HZ@5#LAAFGF@H(&J0.L8JL:J;>E3&'1'[/?2-3?Y9TE,<9
MLS(_4U[,\W0VW3QWN,S,_N_IGYTY<HR=,C0[N89!*"M87Y36$<*XYH7Y".R"
M><.Q,67=NQ_D0#;K^K&W)_J'19N]B[QNN<E;&^!!&\?!/0>&HNE+X7F9Q5I!
M6\6N:=8VU/Y7_!R&\;.P:0<PZ/Z%/P/*K+^_=QOEC@EYN<T>M"CH@I_\\=/O
M<U@TJ62M"+)59X=VYU5T$#@.@EBSMRYZ9W3_RPH[#N"SL*#].7D&:0]-V(>6
MU2]O<$E?X8K*S7KL30O0P&AK=1RO26QY-%YP',U5R+)8CK%BP=P[:]\%^)BV
MB)]9:7:2[M#$_&DY76SN_KCA+DU<++$45."3-1S.Y !1JP(N(D-#+67WXN8#
MX(UI(_B,)#M94D-3Z>'4(X-4+IAV SS4EK0W41.T\@A0I=22?/)6]:XL/!#B
MF(YBG)%27236C5;?U$JM(3_=,N-W$#^H52^;/_$O;#V#RS90V55MLT5PP5LP
M%06PZJ56CU'06U&3ZVU%>X]A3(<ZAB#FL\I\:(6XB9NN/YJ__HZG=S6ID@U^
MDA62S8EQ10N)O("89"PD,.4Z6-B_![XQ'?DXHRH\75;/F+/[=;'&V?52NEI$
MPZ3M'GW5\)F[_4?:*7GWL()ZM6A%H!?,DZN6$XMYNWY9"\44!.M-ZSJH-"#6
M !B+DSS0:K%WY<C^Z,9CG'^B96YEUF23,K80.Q7(*UG*5OB3)-20(GGV0$3L
MK0>[#V),2<*!F#J<Q3Z&"&=U-A^,N$*R0928P1G!)J'="!R=+, HI:E.I!2>
MPZD\-E ^5[IP1.P\6:Q]#GWL!966;[&5%7\]Y6\O:<XK:+MLE,9LL@Z@M&R]
MOWBNDDP$PM=DT91RK^1AQRF0$X&,*><W,,O.+K>SJKL#LY@8=!6N(L2@.+Y"
M%:%] EX0SV@NTH?>K<_ZCV),N<01J<@!J7!62F^BNI?E_UVLUI='1ZU5W@IK
M(4K1&C(F!RAX&8JB.&KTPO(:? ;2WL4YIGSDB&AYDCC/2KRG]B:5;.<&HP-B
MF&P$7 0TIH(V4;E$Q9;<>R>Z ^PQ92-'1,N>PCYO-GU7_K^5J&4*&K3P#HS@
MX Q):G!5>!%J=-H^2VQ^PO;-N7*6(^)E%_$.G=;\@=:M6^LE//:1MV[&-..\
M?#V=7:RI\'=N__L)N<V3WM<IP=EOS)VRG/_8K PJ+]\S.5_3#Q=O$RU_K%=0
M-J]?_7BQ7JT9'W.8H^6@J18)V:$%0Z[U#(P:JK;:1>W(U-ZIS@,AGJH^=[SN
MWGLV4IL$*;1!*H!:<TRG*R\H;P.[)4:1\%Y;V5M?'@1P3'G*(;EV5TL.)\6>
M>X?+35\;G'%<]?8J>;IZN5XOI^EBW:Z&_G7!YH-'T J5?ZP_+:^/>BWR/R<B
MVV)45>!19##L3$#,I"$;GRQ:BDH.4$I["N0QI27/2<9S2OJ\]/R4&KBZN>E6
MNZ8DT;!#0\W-8=R:?>! B."=P!2\CKJ$YV#HHZC'E-4<'4G[R7M/[_+J\_:_
MQ*_]RQ_^!U!+ P04    " #.0\Y8#EB6#Z%>   C3 0 %0   '!E=',M,C R
M-# S,S%?9&5F+GAM;.R]69=;-Y(N^MZ_PM?G]489\U"KJ\^2):NOSK(M+5FN
M.OW$A2$@L8I)JDFFAO[U-\!,*B<R22:Q-YE,]9#.@=K[0\0'("(0B/CW__WE
M;/3#)YS.AI/QWW[D?V$__H#C-,G#\?N__?CGNY?@?OS?__%O__;O_P_ __WY
M[:\_O)BD\S,<SW]X/L4PQ_S#Y^'\PP_S#_C#/R;3?PT_A1_>C,*\3*9G /^Q
M^&?/)Q^_3H?O/\Q_$$RHY<>6?YW^-2K)!>,1BI86E/0&7.82O#/H39"QR/#_
MOO^K+L49GPT4%PTH:S.XZ 5(6]![SJ/U%P\=#<?_^FO]$L,,?Z#AC6>+'__V
MXX?Y_.-??_KI\^?/?_D2IZ._3*;O?Q*,R9^6G_[Q\N-?[GS^LUQ\FGOO?UK\
M]=M'9\-5'Z3'\I_^[V^__I$^X%F X7@V#^-T]0)Z?9Y_^X?7T>B?+OY('YT-
M_SI;_/M?)RG,%PK:.(0?UGZB_@3+CT']%7 2'__+EUG^\3_^[8<?+B07IFDZ
M&>%;+#]<?OOGVU=WD0['\Y_R\.RGR\_\%$8C0KQXPOSK1_S;C[/AV<<1+G_W
M88IE+?KED"LH7>'\K_JTG_;&](& 3--Y1*#?XKA2O"'&54_?'_.W9T'&$LY'
M\X:([SZ[*=[)61BV%/"=1S= NW@0G.%9Q&E+J#>>>PWG$N1MA/61W#'V$>=G
MF&=_29.SGQ8(GT_&L\EHF.O:^L><OM;%=C8ISS^$\7N<#<=_? A3_# 995JS
M?_GO\^'\Z^9QT%MF4%=?)B_F^_]ZR&NN#8OX,QP/ZY+T*_UX^:Z*OX<!XI<Y
MCC->K%E+0*-)NO&A45TQ)]]4/ H11XO?#LYG\#Z$CX-O[Z81X"OZ=C;0127N
M@H+HM .5!6TQV4J(,N9<?-)>QKL$F2T)5\(L+BAR^0JBBI _X6@^6_ZFZD N
MY+\>Q868&XSK78@C'*#BI4C:6*,T I30""YA!*?0IN)*W6.[&M,"P<WQ7!'G
MV70YLLO)N=,>4Z:3LZ;ZG$^:B?%"4P3ZQQ\F4V(QF57TI\6*\=<TFLPP_^W'
M^?0<KWXY&<^)U;^,%B^D*8SOZS?-F' QBYY/SCY.QG6R/?LRG T<TS(GEH#K
ME$"EL) +!V^-T\EF(VQGQ%@%J"%/[MGW[^'- Q2]CC-["WP5A?9DPRU,+Q8[
MUE:@!K<LD49L6 FH(0O66E+W<&!_Q4VZDGI_E,!<F"WD8Y5,X) %\(E636==
M)&=+V(SB\5+AAI%Z!$S80=@=,. -Z0^GTVJ)3=*_?EN8KP.38UWI(F1M"9C.
M""%P!1RM*EY(;A1K3(!5.%KJ?Y79?U?Y#50T:2S?NSIG^^J<QG<V&5\'A(5+
M,H8\J) *J,@D!/)L(&=N@DB>^Y(;*_P.B%/0]GZ2[6!Z/\MY(<0P>A.&^=7X
M>?@XG(?1)3ANLDS.6V"AT%!)1^ %&<HLY&*SLCZXU%CM]P(Z!0JTD_A=.HA]
MZ? 6YS0^S+^$Z7@X?C^[1)6"%\'0>$7PA"IJ32:OMD CU8G,W<3MBKC(7CQ8
MC>04"-! QG<U+_?5_*MQFF*8X0N\^.^KBU7J1I3E[60T>CF9?@[3/,A61Y6E
MAV)Y(+C" SU4@$&5-->V%-$Z$K(CQ/ZYTCC T*5*.K :%E&YV>OS>3W(J*=#
M \D=D=9RX,;05)'("!"1VQ@GI2D,2VEM)MX!T3\+.E7;[7C"7C+OP)ZX.]0!
M#[8H*PUH72S0%E8@R*S!,ZZ2-3F)W'KSN(OBQ&FPG]0[,"06B%[-9N>87YQ/
MB9AO<#J<Y N^OL79?#I,\TNGYUD=_^\X?UU(%@6'\W/ZS$"4J*.G]=)P6<-L
MW(-33('B21>>7:1]L0O:[ /Z";"L-YUV8..L&<#?P^@<M\*OO.+.JP@RQ^JL
M245^N420CLQUX01WT??#R:TQ/TE*=J/1NXQ4^[O?_SR?S1?GF^\F:SS#Q?RJ
M&1FY>B$XGBT2/=XB"7(VG.,?./TT3'@Q\+>8)N\O%+R0P8"<DI"<M9!<1E#*
M&Z )J$%&69PPF:7F!Y9=C^FT&7U4C+C+>+TOXU\,/PTSCO/L6BAL4%(6.A8!
MR+,'Y2PC.R73CTYA5(QA-J$Q2U?A.&UF[2WYNVPP^[*!UF,2P>0,?YW,9@.,
MC.=D J2H,]FL2(MQ(FS,I9)$Q,2<;4R#&P!.6_\/E_5=Q=OVP0(?K+$R.4 :
M("B/-+20<EV<F+(E2:Z;V_OW!PL:>;]%8=("<A:TW(9J\CKO 64H7&GZJV]]
M5KK.^_WWGV[Q^E?Z<8]$M#_.S\["].ND_#&D':8,4QC/GZ4T.1_/JR4V&0W3
M$&>_A^F4]J=/Q/%Y&(YF#\E%>^";VJ2CM1AFHXRT%\-9>/]^BN\7&_[K\A8_
MX?@<K\*-(9J"V9+7S^KFSN,B^L,!+4VHD&U.N77$;1.F_0V&E<^_R,6Q5CF7
M% >K+#F4-BMPR3%(N496N0J,M9Y=]^'I*Y.M*0_NV@F-!'[H++?9=#YX6U-&
M%YD9RH7L99"0$^V:"K4'+VE==HBFT,89M-_*=Z>G7J,)_71%D1LO/%2V6COU
M3?858\/X\C<0EZ=EV\#8)2MM&ZVV/X+<G'^VA_!OJV\/R76HR(#"114L<)<Y
M6;1(%A_GQ$@K,"443,:M5O!#*W!-UEA[_>TBL,9Z^RU\&9Z=GRV!V&(9L[2I
M,*?(=<SD.IJB063ER(6,&D-IH+D;+^W/0]M+[),6,FMX1+L 0J*Z L)SCL5J
M21:!S#6+H8!C2&B*R:PP\K725KG=FY1W_:6/4'D/EEDGF9@3,@/F7]^,J@,R
MSM6U^UCMHY^_OJ-'+!88'XPS,C#(.EKBEY.TML1(JXQTTD8FLV@=2-L"ULF8
M0EVIHH,#V+40*\#++*9M(':4VK\%O,,D^C=7[;;4V5,O?2XXUZ!*753D(D#2
MBF91+@:\#0E83IAU,0F;7P4X&'4V7 PX!N;LHHZ&C*D1N\'+\^EX<:KZ<OAE
M<;CZ#2"!K0=5YW.<_C$I\\]ANMR8$\]%R4)[LC4!E-86HJ9].D85D\W).;P5
MK[H;''SHR_N/]C?7X*1'\7>0,?CS^7!4P^[?K+3,0S:<9D.H0:MZ,FFUHAU9
MTZQQB:OFQS\W$9P.(QI(N+7/CV'TRZPFR-(PGZ5T?G8^JA>\7^#'*:;APD)[
M@;,T'7Z\,-:6HEFLFT+K[#$M3E&(K4$;<$4%*"Z1\6V#Y7:KN/:F*,$^($_&
MRNU770WSO+8%_GLXPRO$E]-L&\PM(XH/Q'F \&-_5-B1@,WT>("U;B7V@@*Y
M50C28+TMD!(X56\+A,B=KEF[6IX<]^Z+G#XNZNVBOM;6]PL<3</7GS&D#TM4
MEYM^U(G';#W-<MH'%#(-'B6#8 29 8&3YU&VLK'7OJ+GP%XOZIDTEVTG%W7'
MB8S%Z47^WW#VKY\)Y3A]. O3?RVF %>86?0%N*O^IG8)?(B%\*$45F938FN3
M>A.FDS&3.E%"!SG&=_$MT5W.BVWP=10&W(3M,#' MAK=2)<&ZN@@^K<19RPV
M:ZDY8 P9%$L.0LX1?#2<%W2!B=;WN@Y#EPUQO\.R91<M=,*2V?QU^<_)),_>
M3:ZNL1L94U#. &V IB:9,W#>"! NL\"DD"RIYMQ8A:3_D$Y;C=VAP][B[L<,
M^1;QCHYY47BJ1K@B(YPL+Q]H+MA:Z "5]SJTOC)U#YRG8'P\2/0=W/2X ^U:
M3',;:'V9'(<^<6RFPDW4V%/^?=@8UR 6U%X+I:'86.^*AE)+;#A@M0"29LR@
M:K^%]$R-W2V+SIFQB]B[J!]P_O'C:(C3.Q"7)QBT1]+VQD"H$&H.CH$HDH8L
MHV:6(V%M7H#U?DA'8&$\5'VW+],VE'U7]45^KK<>%_;/LW'^?3+&LX^CR5=<
MWGF<O9N&\2RDBOSGK\L!+29,+D4882-87R*0L63!(YE=(>F8HA(FA]8ES/9#
M?'*V2H\*[."JXJ[HE]@O)^8VZ#NR>/9#?J!ZJSUR94^:-E!T%QOIGJ,0%E41
M K2/C$;!/3FIM'X4::--/'+%F]=^/D*:;JH%^WA9NH-^6Q]5_3'\LD2S+'ZG
ME"S*.PM8K+P\1TDUGD%;BB\2G;Q=*6S-&=7=9Q^@#%R/JIFTDVM#D^T"3K4;
M[@!BP16;,CA>,Y"<1@C<"(C(4S%"JN+==HI>\?0GI.I]9=O!CE/+BRQ,QG>8
M/HR'_WU^X:@F2]1C7H*1U@(YIJY>@%<0;1!>J82BN,8[R6HD)V=/-Q!X!Y4=
M[J*Z)/LVN#JR@-=A.HQMVT)O&ZFPA]![61LN\;'LN(ZU_A8:!4KE3- P <_(
MF'5!8_/*POV288,%V2<7=I%U/QP8SA9E-# _#[,/+T>3S]\B38Q;CP@IH@$5
M)"%ETD-T3AB;99*N]:V2[='U;V6TT>AFFK101P>!O]_"]%\X?_;QXW02TH>[
MN)>Y6(4GVC$18JV(I#SS9.L2:.V$%I)^66QKTFR'[$0(TX$:.EAE?L,P.Y\N
M"HB\&G\\GW\[, E:\AQC!FV]!AIY B>#@Z)1:T^<+F6KZ^J[T&,-EI.S1)L(
M_2X97!=DN)P)VR#KR!I=C^HP]F@;[6U!B3U$W]-*\2T%+V>K+8+3T5W<]/=,
M>'#(5'22!ZU;GQ7U38H-=FG?G-A%XCUPX?ED/">)O:%?#;_5?U"HN):%00Z"
M5DA:$RM:VMX<M\XR:61N'<G8!E?_YD4K/6Z@Q]Y*:!W1O WP'UB;EF-^]@FG
MX3U>).?=[.>CDD-? [ Q(4V7I&O_#^D@TC2Q.4F=\JUSE#7QSMW?_>AYT8?,
M.UA+7HW)JJ*/?/UF(K_%&4X_X6S K8S<^QJ$CXORK0*\CQ*X-LD@%T;@5O>[
M=EA!UJ/IGQ^=EBUL)/8._->UE[S_G&$Y'_TZ+#@((@K-B*[>>W+,,EK:5IFL
M=]6"R+6E5/,FS%O .C&*M%9$!XO'[^=5/G7<'R?36E_V3Y+X;& Q:Q%X@:AR
M=<Z8ANA2 1=1"])LD=B\,O9*)"?&B ;B[J!VT^)4\<UTF'# >(G!.PE9U9IC
MB0?P=83)1Q.E92DUSX*]>ON)*?N!8FU8H&")I!X6?QZ.1J_./H;A=-$QKM9D
M%RYHE4J"E%QM"&HLA'JO--2C6QF"]:QU"?352$Y,\0W$W<&]S!MKSAN<UIQ;
MLFA?EY<$<M&KX]7XER\)9[-JX$ZG7^FCS\YJ@'[@4M8VUN[SGI.%*T4M"5.+
M]XO,/0\LDI'=F"@/1WMB9.I);0TOY"S\J!NP;SM5@Z(XLJ ]".$E*"TE>.$R
M?>'5#V6.B5LKSQHW]=[7G @3&LNS@USEEU6P-,I/F%\1.\?OAW&$SV8SO&[I
M"H-:)U1@F"&,V1D:NB5?.97B1*AN>>M> =O@.A&2=*:*ABD["R)?7\*6#M*O
MM1=-?C=YAV/RE&8#Z5T(16DPEC-0)F0(5DC0,8J (3+!_%;+PQ8O.Q']=R+;
M#H[(GDTQU"$O:ZHL8=8HFF+*%0*BB)/!*HA&)@*G.-.T8Y7M:A'ML#RLPW(B
ME&@J\KM4\'LM TM/>$G+4GW@@!D,AEHRVWH(@A6PFBN>:PQ5BJVF_*T'GX@N
M]Y;9BMC1?H<3OY+%.9F^)B:%:I8LEIFW6"5$/]V*FB_^^ ZG9X-0BD8K:\HQ
M;3]*) NQJ RI..YS<"&9[<XG'O3Z4R)#]_)?09F]XXUOZ_8TNN@+]_MD/%G"
M'TA!&Q"-'*2S)(>H:['[2*N2E"HQYK+7K2..Z["<"$N:BGP%%_8..ZYB\)OP
M];(7Z<_$YH35COT=O\S??<;1)_QM,IY_F W01ENB#H"QWD67H4"L_0D]9H$Q
M&R>:7Q9[*-83XU(O*EO!M;TCH-L"?_=Y\E\8IK,!8\'%VJ\RDJQ 6452$AC
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MV7-R#=]/ID.<#50P3G+R ZV/F99+6C.]S@P28^0MRH@EJY;VZZWWGPA+^M)
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M_'7Y<X:_UCX%ETLW\U8YS 9\8KE69@\0R"('H5$PK47QYE;28@^1KY503X#
M1ZC3NXSUQ[1N+Z;C[Y-QNNXX#D((/DAK0'C:DU1R F*1$CB9UA)Y8H+U<'VO
M[:!.@-['28 5IQ+[U?=K.;R;'_E6RO#;YE.0A9*B LWK0#EWU;(F0SMJ;41Q
M:&Y?5.UA>=X ^@28?-1Z7D'H9EE1#8-\U_^0%G>&9F_"UXL\1*Z4,3Q!SE:#
M<C1:QW@$+Y0T/GFN8^MV,+T.\ 1FP/$38\4TV*]"8]/YGM+T'*__8=D*B:D@
MF5$,LBN>9CHKX$T,@-)E^E.4ANG^5_1U<$^ R4>JVQ7T/<93NFM_6,;]+BMJ
MUM00H6LY&N2*W PM) 3.)&2N&1>A!,U;]XCK=8 GP/WC)\:*:7!49WIW1WMQ
M;(G))-*'!:9YC0H9VJ2"2X ";38Y,.%;MR'N85C?*=\9"580_:B.\YZ'C\-Y
M&"WB2*_C:'A1B7F )114/(!VOE[490XB2@/%2RNB4CPS?LP\7SFJ[S3OB@(K
M6+[W\5[+(5[[S8![;DKD#(2JN=LUZ22D:,ADDY9IX[#P8XXB7OO-=SXW5?8*
M$A_J,',9(%HYOM]Q/M!%>TDT(ZY9FIQ>)_"V7A\M20E?PT;E2-;G34/Y3N*F
MREY!8M=C/8LWT\G+R?0LO!J7^I_ZQ]:U*NYY18=U*+8=6!\U)LCO<@D3!\:*
M!<5= ,>R!R^82:A8T+JKR7\4-2:((%R&&B;/O'9O%!8\5P%20!U12,=U:R?L
M4=:8V(4G>]>8V$4IQUYCPECC?$H:/,H(M!U(B(592%%JY5W@(71U4/%8:TSL
MI/XM:TSLHH:#E S8!N#W&A,[JW+GV@$/T<-!"*-S\C0;#'!>3PHDQ@N?6GB!
MIDAKT/51O.9X:TQTRY-=Q-]'6P-$*ZQV@#G6.*)3$+(2D+#>N@U,)K==D^;'
M46-B)^EO:FNP@^CZ:6LP6WH(R^.05%,X/$M@'2.(OC@RO!Q"$#D[X[6RH8=Z
M,K=A'04QVIBHK970,T_(LR<^3\[PU\EL-@A<)V:Y!\%KHTHI$:++'*2U-B:O
M#/(>BM.N!O=$./-PA:S=*UK'7)8WS,*URV4$>X\0RX8GMHFH[ *[40!E[5V\
M*QZ5&)Q&VC08E[+&A@4X'3+PR!SR'$-FK0OW;D;5+IBR]EV7?>B8\-K*0'LP
M(TNKZ 0QQ=JBP3!>G,O6=!=$N1];7\&3QAQ9'T)IJ(IC"9VL'=+/7]_1(Q;&
M?(HJV) ,>!85+=2>EE!K%)1B$\/HC4FM,X6V@'7XD$I+.DRZ54L'7O+ZT=,#
M+EV%;2!V%%C9 MYA0BO-5;LM=?;4RX$HQ"53C"PUL-8D4$I+\$%(FD7HI? Y
MF]SZ4O#!J+,AV'(,S-E%'9V$YH:C>O/B,GR01*BM$"-()GC=UCG$0M^%XF.4
MI61CVY^@74?0OTO57$EW/*L'2[@#Q_M7<C4ND7"'+D1;O7]7OP@!P14.A4G'
M$_F0HKFNK]Y^>GI^H&0[G-.OSCY.)Y\6YNWL$EDMJ")L2L"PEBJN8_/%>$B%
M"RZ++[FT/\!;A^;T.-!(\AV4V_MC4N:?PQ1IT,MO7^ G'$T6PU]TAUE&D#V7
M6DD#6,\7E"^E!I <%.Y%TKJP)%M39&MPI\>8;O320<6[E^=3DO7Y NG+X9?Z
MW3=JL^)MKMVVR0T#Y:P!^G]6C25GI!4B-6]MLA[-Z5&DD>0[*!:W=N3_.:V1
M8NM9=F0F@XC979YK2>-J&^0<:'^,K+\XX@+1$7&C322MH0(ZL#6?I71^=KYH
M/_8"/TXQ#2_3 S^.<"'V<7YV-IG.A_^S^/WZ*G&\L"!KH9G(#"U]]#UY8R5#
M2(IK%7-.M]O<[TVD5MA/CG('46J?H9*:6(S<:J=LKILKK:;",?")DP%/1IQ#
M%5U2O05H#Y(*?JAU:U?A=V I7V?UP+O(:C<H\-&HVB$J0ZR]7;4QJ79W07+B
M&Q/A^OM/3O$/%NY:B[;U2?)5 33RYQ?7&B\N)1 SEP<5>YPJ[_#T-B?,#QU.
MH]/FEQ4W_CK\=+>RW!6A),M""K)+F$<#RI!Q')C/H%T@ S=Y7GCK[7T;7.U.
MG.]YV\7)EI0I6B[)F2NU+RM#13::\" L,L9STBFUCLEOCZZO4^?F7%E_[MQ4
M(<=R\OQJ?*F;U0/[^>MOX9^3Z?-1F,T6)QL1E;2:6Y BUWNLWD$LVM-W*@F%
M2.YDZPJ?.T(\_(ET6Z),^E-8!Q;S!KA78'\/9\NXQS:0.SJO?@#<PYQ?=TJ#
MW2C73(='0C_N75"%)8B6YJ12P8"W,M)(Z@W^& K][ZG2;L/9][&S;A?5M;Z2
M\&XR&KV<(K[#$7[\,!GC[^?5:UH&XH.4OO:XPV@C^3\$*FJ228R.1^5<L=IN
M\@,VOZ9_UZ]S+4TZ$7$'@4L:.D['.+\89!WN,N">.=F?6C(H/G,R/SFG\6H&
MJ -GQH<B;>ML]+5@3I<A;?70P5[T;AHR7L>CG>&N^ +)ZPS**EH=G5-@G/>&
ML9!M\PJ>MS&</AWVDGH'D<)[G(,[VZ?2@BO%B*&<D9^0,-7C_P2VE. (N&KO
MX>\ [\0=K:X4U2^G5LZG;>!VY&#M"/4PSE5GJM^>8LWTUL%&MBML+40INA!L
M8QW-PE0[WS(-CEG%-:I"R$^19AN<J6-EV2[JZH!=S\]G\\E9;3L[6ISXS#X,
M/R[W;N&MRD$C<*TEJ)*JB4^+.L>(FDFB06@=]+\'3O_&4Z>JG'2CAPY<K<MD
M-\SO,'T83T:3]U\735R6\)@T,A0OR-"/!93DI=XV91"$\!$C<\*UOBR^ =)I
M4Z6E/AJN*+/I_)JQ6 ^EYU]_P_F'R:(E\&Q>ST_N_A87WL)BU77<%%U+9X14
M<0N&X)7@4-!&7X31)FV5HTA KG&(?KKBS[X83]0([U5U#1-?*^YUN"XGVC;(
M=C&^-Y#K?C3]VM?]:G72J4H:KU,;$&**F1O+("Y:WAHEP16I0&;CI.9:&K-5
MJ.@(R;+&2CY6KNRBB=9'#'^G+W.<7A7NT38&F;( 8Q/98886V6A$ 2^+8EJ$
MH.VMEMAK3A5N/[D_>Z6UR">MY-6!W;I^J_QSAN5\].NPX$!5<B:;($GG"6/D
M0.Y=ABQ+MF1S<]G\GO\VN([*@OVU26I/<W5T<ZIT8^2+'/U?OMQJ??8LSN;3
MD.:#S*U.6+LG:$EH?4)P61A(1.]@=8G8G#R[(3Q!&G6HHOXS(N[@'JBHE<HY
M@RFJ=M5#7]M$:N ^^*",D*RTCM[MBO$0IUC=Z7RW/(C]%-9O=/CR@E'P,EB9
M(=7> 4KZ BZZ -*Y[%TP+/C6Z?&;,)TT@9HJI(/3J^U$,6!HF6>BWO @BTW9
M3):]XAHR6;*2HQ3>MSX,W0[929.G ^5T<<]X/<6O73V[?L5LX(NU%CT#YVI%
M0K+CP EB/E?<""XPR^:WM79'>8+64L>JZF%]^AWGZ^=:B)X;'QU)Q=0PND<(
MA![(4>",\Z"Y:)\?OSV^$R149^KI8)W:V99+JJBLG( D>.VX9#/$5+N(:664
M$"IP<5S&=].UNU[LI$F>A>-DPPK:5)3,@:Q93DXX<B6#DSJ['N]Y'>1>;7<,
MWWYMWE45!UJ'!\4;EFNE1Y%HKJB8"WC+ F I23G+=$RMZ;(-KA,F37.U=+#N
M+IN#W4/P?V ]L2;+XQ-.PWN\%@%T(K-:X1P01<TKUP8BDJ-DLE;)6^&C;[T&
M[X/W!+?XWM370;F;:]>GOTTWH7Q6R19 3FB4);_),Y4A&(&<'"D?HV[,J!4P
M3I H^PK[KO[W;B]\=5I)0R/_96'(969KVE0@%#HBQ&@8.BT9-F^U=NWU_>M[
M;W7<V6H>)LL.HIRK#Z1G T:;F5?!@@Q<$WO)80W%("C%G(A2VMS\?O0:*(]?
MW2UDW- .71PI7ZU;LV<W:F-\&[$V 6G4B6P;DVN)(@:.2[)\:%GCI?@BRJW;
M7FO.Y#>^ZH06\ YD>U?S#VZB?0O=37 7,?022PC"UH(VM36R3>2HRY @.JN"
M<%A$V*[[U+VOZ4_C72ADM:[WE6;K))OU@UX3GG2T&"G"!9Y[#LK5=L>9-J8H
M A<^1)U5W'/"'SHZW!\;.I!Y=UO 3:P#Y:0NNN9,*QUK:2H&P=5.1][XXBS]
M4>J]UH!35/@>,NPB4'"-9*_+[3UN($20)0I'-HPLM9Y!!)>D .DB5R%F)W3K
M&[OW(SHA$Z #%=PEB-VOQ -.SUZ79^^GN"C"-(CH+L)F/N8 2I CXF7B0*9M
MDD8XSSG;:L+?>O ):75ON=W5H=N[BF?XNG DWDTN TOK' UT*6;/ D3E:J7D
M6FO06@ZHLI$H/'-1-I[NVV([(8ITJI:[]/'=N/ZO/X]Q6N_(O<%IHI_#>QQX
MS0P!9:"E2[4BB828M0*#(2>/!;-O'>?;&MP)$J@;Q:SP+UCO541_#],I[8B?
M.BHC>N?QG=<1O7] C0J)+JZN8GX3IO.O[Z9A/".;]4;STRB5X)KVH."YI)7$
M>"#/(H%WP<N"2EO=.@EH$Z9V!437O&GV\]<;?UG<T;/6BU0+ZEIK!>W(04 T
M4H.O"6)!"5-BZQ)%#P+:5UG1ILQ97U*T*Q4=2W71[<:WN*XEO*T9@[RV'R>;
M$'VHA;M$;7815#(B9]G35%R![O"W;#MCRJ07C75P G,=S^5%L6T0=537YBZ:
MPY2NZ4I_]]!D#^'W0PN30R&_P(%,EM7.:@Q\T18D5T(&SF-AK1,X^J+#AA(S
MAV/#+C+OY7@6<5F[I&"*3!D@-X-V[FP5;=KD1P9E:%/WBCO?VM19CZ9_+VQ?
M76WTN1XDZ(8W)^N%XK?D=ES< @\Z%60I Q*%:U\0LMB"\""#S"DYRU+8*H2S
MX>+\MQ>>OJ7P</DV/(CY!N*2:]O :%A4X]JK^Z^@\4#AWU;?'I)K7/OB.AP,
MB(R71(N/IFTH:$_KA5? /+.F"%^BW6JO/K0"[ZEJT59_NPBLL=Y^(TF=G9]=
M HE,!U.+>\L0:# E%XA!(0@L/@EF/<];.7 ;-'?CI?V6J7BPV"<M9-9XB_PM
M?+D&1)B@C44/R1C:")+EX+F*8#S-?$\L#;I%I:L;+WV$RGNPS#IV=*[M\V_I
MEP.50PUBDPFG;#7F<X;()0-4]3:1TY&KUG=E[X%S6".W>?BNE> [J!;R%C_A
M^!Q?DD">3\:+'(U_#.<?EJ4<7XTO[V74,#S]7WX7O@RBS\IPJX&KQ&L][ 2A
M?C%125J?LG.Q/5=VAGER'.I64?VM-\_.)N?C^>QUN?:[@9?&:D->GY.J)F<[
M#DYS#UY9G:5AS.36B>X[P#LY+G6CF+7N6NMSSU\Q$,M;''&N>5*;T\QM8#8Z
MN/RU3GI<O/ %SM)T^/$F723/IG"A@ =)VXQW$1Q1!;1!+,D687GKYND;(.V[
MNJQ^_$64(@='H^4)$H90>X=:"*R0E<RY1)H?&+<S3O<>;:]'D"TY<'O):"7M
M0Y\SWG2GA366V<BAR(K<HX98[YIXA2$FFI4^F@9.S,%C?<VTMS*BMXL4.PP$
M;0/C]")Z.PE_343H(9+K4)%91UE8$&"*C*!XO<MA<H)BF=)H4U)\JQMQAU;@
M5A&]%OK;16"=1O284LX;LD)I++4T0/+UVAX'9KESWI+?L9T5_S@B>CN)?6U$
M;Q>9=1K12THK)J*HP>0$BD8'08D(61>,*&5P33;#(XGH/5AY#Y99!Q[VQ;[^
MFBP!<C#&[Q<;_$7J_#)&,)"")VMH>W>^CE,E 0YK,1;#2ZZ78MEV=<!W-H7O
M0]6_/]V];=Q,"QU$^58A?(MC_!Q&%>@@:-J&."O@,==;T<:!M\F!,$5Q%36*
MU/K:P@9(I\^0A\J_@V7D)K!;A5'>8A7?=5[S0?#:2F0,F*O'(:9XB$Y[2,&D
M%$,44K<NR+HKQM,B4*<:ZJ#RUBK"OQC.4@TP+HX]7-&V-O.I=455+?]I($CZ
MCI;"PKP1T6YGX^^YXES'=%J,::J!M?=FVU]HH6_Q7?C2)KI[W^-:75C9$G"C
M..^50B>SV7-ZX]<RF7X.TWSM1E2]'BF-5B#KN:)";\!+<C"2D^13&&<%ZVYU
M7@NKW29U^Q47<2R1N.26(R3K:=2N%G\(48,F0SYEIIT+OK=1]QKW;<V)]9O/
M_I(_=/SWJC#4Y;Q]=C[_,)D.+W.:/2V)3M(^6>KM8E6OB?LB,SA+FV>.6HGF
MALUJ)(>*%#?5]9UB7'O+O)/V%K=1728Y;X.KH[LAZS =YH9("[UMI,(>0N^3
M%"R6Z&O^<ZT70_R/'+PP#+C,M<$IDT&VWF7Z)<.&^R%]<F$767?  4*!L_DP
M/:\F\_3K9<1/2BND] BTTI5:2DZ031XR2)F,U"P&PMF8 "N!'*(^< L]W6X$
MN[>0.PB7_3$G!^G9./]*GQS]G_/I<):'BVR893:H,4[5^RY<!5%CQQ%"9 &8
MRIG98$0.K:V$#9!.A TM!=]IG.RV<30P185<%O7G6.V(@QFB$PED=%%SYIAK
M7JAU/9H#%/(\F NRD^0[Z2Q><#I=Y%M>E*KX>QB=+TI1/1N-)I_#..$@^!PT
M+ZQ61W>@2 P0I%(@,BLQ:29C<X=\"UBGQY+6NNC2L'R+Y-FFX6BXP/?[I,:&
MSFFM(R?KER\?R1K#/SZ$*?X<R"5^/CFKOUE\\OED-A_X%&B-M;2\6N]IC44/
M3F(BZZO8P'32+K7O;-4 ^.E1KG]]MBY.^4LIF&K8\FHHM G?',[MB?4L__/\
MHE;2H+C@2G(U#%"/KF@I)NB!@9$B:DR.E[1=1;O]<)P.L_I62L.:F%M#OSX!
MZBGY)Z1QO,')QQ'^.CP;SE]<S)UE2OI %I<R.@?()2W:M4ME])(<S6A#SF15
MEMMW//<@V8[@GB#SNE1?!PTUMAG2ZL7YER\)9S/Z!S_CF!0[OQQ/O7O!%(V'
M*T[32RL-/O(,NEB9G%.H>?."$(W'<#JL/0HM=](&9*5EL2B*]^U7X_<7@A/<
M<F/)JI51F7HMN#9-T.0B6^8+LX6GW#K+:Q=\I\>VSK2SM@E!AT?MU8*8SZ?#
M>#['69OC]I6/;'[DOAEXC\?NQN3L?)9@G:B>9; 0DF!@HRLZREA\/L%C]ZR3
M4#*1K\)C F4$32+E<G5=BG"YE.#Z&_71';OOPHE=C]UWD?RQ'+O_?#XCV<QF
MBWK-LPNU+.J:<%VT+:YZ*&07&B7!*9/!ZJ@94RDRC8U9M ;*L1Z\[Z3M27NI
M=Q +6P7KHHXW7IXE; .PHR/XC> .<Q;?1)5;T&-_/1R$,$8J*Y+WD),)-3TE
M@(LN@,7@! \E>-/:,SL043:<TQ^&)[N(OW47IC<XIV43WWXA^_#RN-"*D%/Q
M DP*M6@[C=B95"#*$H1+Q>C;U\#7A(WN/KM_CZ:Q]"?M1-?!J=J:-),88C*L
MU+[FBD;(R5F+&#@(,K)\""'+V\'F)Y:>MX^5T$#FG?3P7I-GL VNIYR>MY/>
MMDW)>HC0^TS/,THP+;4$GPOQOS!!^!('[92U(F:3<F<'HT><GM<)%W:1=6_I
M>3G:I#.!DIS32$LDAUN:6K-(RL@2_4_[5(LC3\_;24];I>?M(N0#I.=YI:7(
M6D"Q3M$FZ!U$;BPX$:*F\=?#]B>;GK</&UH*OK7YO]8R6BR "H,0,BI SP@9
M6@F!,PN"1YV<H(&[[9KMWON:4[(*&PNU=9;!6F27--\&VVKK<%?%'\+T:ZV<
MK72^AV1[F^R7&*U7Z%,RH+U=A-T%;5 A@]&,%><,([?X>+6^QL8[I-)W$6AK
M9?_QRW/IQ"*Q!/.?\^'HLM7K,B?<&H^.)V!"Y]K8.4(]OX440J)?:6<Q;:7K
M^]_3<R?EI@J9="/-AJ;= MKMA+97LWJ23D_.W^IG.\?EPN1T E2N&1D^!L 4
M!!91N+S=FF.-JC>]Z524W52BO2WBLS_.XS\QS=]-%C1=T',V8,R45%(&68(E
M(T8:",4B*&:3M,HRR?8TX5:^]SA35QYRKMRUT%LO!^NA_CZ9KT1;+"MDS-;N
M&(43FSV"-^@A,&68X3QKY?>DR)I7/QF6M!!]ZX7DQ7 6ZOT.S,LSDE?C.4YQ
M-K_,O%^,H&:I#ES.TF'FD+FLVYODM>I;H1^+30F=(^3;[2!;O_/$J-&1L#LX
M.;CGSIBR)4?)"MB<5%W,(D2I!:#P4HC@(BUMO24MG0Y!&DN^MZI#B[3@#Y,1
MO6-VT9ZN1?&A+9[:)B%R5_B-<B*?C\)L]KK\,9^D?UWQQC.729D.@I9D)T1R
M(+SG J)RRBM35"FM,[E6 FG7%7OQW)^_+MYR$4^+J7AMC(-<AZ>8HX4MTL*F
MF+="&..-:!Y@7@^GKWS'_?6]OJWU?C(^ENS&17R\/NBZJ!:!F22$M8(I0 SU
M4GP]@(L,P62>16"66]OZ>OA:,(=O.+FGME>=2NPM]0Y.**_CN?3DMT'44=+"
M732'25=HI*Y))[+NAP7.9,%KF(7LJ.HL60LQ2 O(N#99\BBQ]2%U7]K?D)_0
MF_)W$7$72I^,R0-:W/Y^,[T,PBW@+=/K/,_<6()G(P,5E"-XHAZ7<L,D><^H
M6B>R;8#4OQ>RK]9NDZ"AR#M(6KB):6&RSU[-9N>8!T(Z8TJ4D)FB4=<^$!XY
MC5IF3*XH,J]:FY/KT1R6!VWLRD:R[IP%;\+T]72Q).9:J03?X'0!=L#J**6O
M=P5+J&T%-/A4R!<O+$1:"DT*K>,3VR$[/78TT4$'.\AUUKZ9#M,5L!""YMDQ
M<*8>T25:*6FW-(#>>-36D-W<>N]8"^84^-!&TAT$,-^$K]546HZV(JPEC&K%
MF'J10RAC/4(2M?.(R!E<Y@BHDM:&V>)NISCLOT3<@^<4B-!,W@V3G39:-]?9
M^^?'6INC?K :XP,EF7:UC003@BP>)")[+^I-=R$<%IE,Z,W(7 _S%)C3M78Z
M*(IR$^>OP_\^'^;%6=[%'[#62I-*Z,B4AL1(+DI+ [%$),>LA)@0=;SJ,=N)
M&;(2UBD0IK7T.Z@_LHK(K\_GLWD8US[3@ZRDSDD6$%84LJ1CA, PTQ?K2HR2
MJ=RZ@\<&2*='C/VDWELID;<XFY/A-+]$W>+P;-,CVYR<[02\T;'9ZAI$S^C-
MX_>+T-C/7Z\^<FF2/*N'I]<(%BS:ZIH85_/!$"T$)Q0(S4/B12IN6D^]_5$W
M/)#;A&6V#LS%80.MIT8)Y)!X;:LC,JVI*G$0F))UV2FE6IO.S<#W==C7,TOO
M.1GL4=G'<H[X9A3&OX>SBP:Q2:+FB@S#0,L[K?A>@I,Q@-%""Y6L5+YU28/K
M[S^"T\(^&7![.WZH)CJ(""VQ+(^WMD#3T5'B322'.49\N&;6J'@/L7:O;"2>
M^I 2F%(/+U3A$ /SM+2F(H0*6+)^A$K><%K8E8YWD6;K9-5WGR?O/DS.9V3/
MOQR6.>*XFO?#C"^&4TST#R\RN*XO=;>LU#J89>_H% TW+M;CK)I-EQ"\(\=#
M*RMT4MEE[399VLU1]>^&[:/>R3'HIG7J_+L/*!@WOY"G-?F*N MLY.@U6W3N
MJ"TV$L/:T=I#H<G'ZY@4W^B\[8GA$1.H'[DW7Y,J;"$> EN0.65="1 +-T F
MO0)RM"5$D9@21M<[B-O3Y4$8'CE=NI=[\XX!EWB?C?/ZA?$:5L)BC.$64E:)
MY$. 7>T-%(G949CB6=%;<63'%S]>8G0IX=8W\9]=I_!UAM)ZQK6M.9P\UD(3
M'CRB!A.5M5[F;&\'J=9H?<T+'J]V6TBL@Q.A"Y>9/KPPM[,S3M@DZO4,5L^^
MJ^'-&0U12VU"0"548X_C!H"G'7=XN"XZR$-XN""NAC'.MV;/-F/J*'S1Q7@.
M$P39@R:KDF".0<==I5*U'ELJP2EO#21K:,L-P4*LQ3:9$9;99#RSK<_&'P]O
M-\1UCIRVNZBV [K>,OHOC8,BF%+1>;",O,*+VEKU,JWR7EI$DJ%J?6=@)9#^
MS:[#ZWC26D&MXSUO<%HFT[.:K;8:G+ ZISK(K$H-GL8 /AL+TG,>,$DKTG;&
M^*8W/6%ZM-=$)Q=3SLXFX^N 8I 8"AK@1F/MM6P(D$V@.:W"U70UMOEEI-L@
MGC!KVBBF=8CG]YJG."/JKB:Q0B.U0PL^:5ZC3P$BUP8L%L%9$LF*[:)^][_G
M"=.BM18Z2$F^MM1=Y*DMJ\,F;524&8+*M,*QV@"<9PY.)9:EC4K)YM>95D-Y
MPOQIJ:0.8DVW"/TGZ67V]H\_+\$E3);6/@FF-HY7LAAP(I%E1<B*=P9S,=W:
MNC<!?>=10X4U3%6>3>>#MU4B"S\2-4?B+H,L9:5T4!"U)3\RH8@Y,>%NGURN
M9@T]]1ICZ*<KMMQXX=.,4#Y<Y@VWH&\@EH>G6\#8)9BX#07:+PV;XWY["/^V
M^O:07$.WY#8<XW+6PG#03-%"DHL%%Y( 7N'5NJ0A;I7L>&@%K@F M=??+@)K
MK+??2%)GYV?+\(>FE5Z8&OZ@<:AB"H3@&822C,R:"Q>VRE#;H+D;+^UO7]Y+
M[),6,FL8,EH "5^N <%4-^K:!->E>F,E:W".9\",WJ(/H<BM+A1L4M[UESY"
MY3U89HUGWKOAO&[_K\9Y^&F8S\/HHK4;N7V2VP@RJ-JO.F!M9RR!22Y3$HZ%
MW&+M7/GRIVL+[:^+AN[52D#_&,X_O,711:'6#\./[R:_C.=7#4&V@=K0=MH1
M7O_V50.%WD>/#K31]>JR 7*)N2@;+=#^Y0ER$>!-3/1%T_\9E/QV$O+C)<X]
M=MUA>;.+$AKSY?F'(99?OF ZKU<G7Y<R3#A=!@8<EZ@#V37,.5 2:55U,@-3
M4?CH4U+;53K;P(U[(/1K9G2JMDE[F3>V*A>P7@['89R&8703EB.;EM[LH%BL
MQJXN$&L]C<($YXDY[F*+\,P]$$Z8"@UDWL%AX]]K[[CQ^\5"Z!0-P$@+-B,9
MW;8$"%J9BL?)%-!+T;HSX[77/TW[=%\]=%!5XA+*LM[?%F Z2@*\ >0PV7L/
M5LMJ]>XAT^[F_M*L51&#BQ'(WM&@O&40LN+@K.&:%KRLL/65^QX4O"'-K1O]
M[B+*_I(I%PL5K66TWKW[/%D>,A9;E$,#(IO:#](F"(%L$E=K9B4A3<*><B17
MP>O_5&\/16Z7][BW%CHH>;D9ZNOQ,C)GN6"9!U<;5=:+DY)L($F6"S+.:'\K
M-$U:&PD[P#MMPCQ,"X=984CW2[ B2Y[)^ $;1.UOC1EB)G9;QHV7R45C<_]K
MS!7 TR;-0S71.E_MKN5\95A?0GTY.5^Z15Z8X)T1@%864)F<+J<(L^$I$.X0
MMVT/NM-K'R,3.A9N!UEI"W:^J'VJJ]G%I<RHR.SBV7)R@,EABIG,KN2LQ"Q)
M!J5UI:P; )ZVW_EP7:PM7=> &)?381LX'?F>MZ <\.[8PY2S3LU[2+8#.^(V
M+):]*H@"0O($"PF1X]:"")IY;Q(SO'4/GEX4O<UEJT[TO(M 6Y>L>#F<I3#Z
M+PS3*O1EY%OIX#WM.JG4XIC*8MWA)+ALK&-DGX3;MN":?7W5T_O?OO>2]Z2E
ML%K?5[H!2"WO.R0R%WEBP&- 4"YG\(4KX,4;1.V9C'QW[:G3TMY#A-7!VOIJ
MG"9G6-M*G\\_3*;#^=>+_O/!I>*"A:(]&0O2R O;SPJF!0]"V-PZ<7LUDJ=M
M=S70SEW.V/:<N9P9V^#JR!);A^DP)ED+O6VDPAY"[V4A61YCA$AX;"V/'PVH
M6F<EF%@@:I%01L^":=U'M%\R;##;^N3"+K+N(N!7N^\\&^=?Z9.C_W,^'<[R
M,%4!7^YU7'.),=-6J5T&Q;$B4Y&60JV]$87,V>8AOOLA]6]-M-'=JLZ9C03?
MP<D!C?;Y%/-P?KV%]&(61">U8P;!ND+63W&)-L<<R 0J3/.LF8VM[8RU8)ZV
MJ=%&1W?)XSHAS[7+<-O Z\CHV #M,+9'(T5N0X\]M=#!#K0))H'DO+:--,Q9
M6@B%!Q>")*DZE;S.1?/6Y9</0I(--LEA.+*+\%N'F5Y<=F.I&^]LAO-7L[>8
MZI/SMZZB'I-)Y'WG0MNO6-RH#@9*#EH&[G,(MX**:X(6F][4O\G15"^3KH3:
M@=UQK13'\_!Q. ^CBZOS;W&&TT^87TZF+\_GYU-<=H@;!%*F+\:!55*#4EF
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M+GI%8XR&EZ?P!$JQ*@==7$G=GAZ_U-(/3(_VGFB]O]L-[K_T[_SS:IZN,]\
MU5E&--H +]:!RD8"&I& *423-/WPL0)7;\H\;?65/@-YJ'5Z12>@XA:H(82"
M90BQU+>HM?8=V@PR,!^2=SP\5CP\A$KBE4J#>JCA#K,[4+D!*A-#*:M J(P1
M5+!K!1V$DE&(;+P7+6<E^4JE03W4^N%Y)Z#J]G[4:%D*:K#2Z+76+*#B'D1A
M,<:2,WLL%'$(E=0KE0;U4.L7T9V ZEN@UKIDK01ML(#R0==W'@8DBQE9<2[Y
M;N^6^[3Z2J6!//242N8@*MT(N/Q2/N;Z4)S@;BRSN,I9&6NPWO5[BN!"H,U
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M@=LBC8S"@DFT(BJR%C@M-!!DS*)(Q03NQ:<^*"Z21X.Y8<N1UV'GF!]FTW6
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MAH[4*%5%1$%$I00;15#$1E,CTIL1$ $).0B"=$0$%)2 #9$FTJ1&.HB(@+2
M)("-?J(2CB0YN8??F]?NS/SOS'V?>6_>G=^1=0*RRUI[K_)=N\ =X=(!L6-F
MEF8 SSH>X!+Z#^ N AL/NA(NNP%N /KP<,> P\ ZGK5G[;UN[>'C77OS\_'Q
M\JWG7[_^+Q(0W("2P/KU&X0W" JM/>AW(L)"(FL_K#7ROU5=Q\_+RR\DL%Y
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M>W.#U*'4O+(F056]4Y#TY8 ^(1FU/9/JC#71_I+LWR98Y/^49/^'8/^G7%1
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MHJ#TJ*=C$?5*=@'5QQ&D/I P7!XH5:&%>B;/JH<DGY3Q%;NEV O'1R&"#[B
M*38>"Q\; W]>"+=EH7&XR9P+>/3"V[ WEY=BL>6#F;&YKZ#%HBQ2KI'Y\PZ_
M+0\>2XC>5+\C33572PX[*=#8]W=P_ \+CM] MM0PLF&P",YG/H:P"VTL0?8&
M:&_AE)7V-;"Y'1*(7?"=[F,?]HNT7I)NWG2DJ&[J3O1XN\77\T:^WW\W4Z0K
M\?!6 ;:L,',)+F>83Z^P)?M18-QO(D-4'[ZR8\'(0+\DI[>P@U#S[LV;I&<Y
MH2JVJBKUWI%'[3\@]KS+&C0F#^>61K6E&^<V2>+(?$2%#40[IBZH&'F$3^+
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M;1T:HF46-^""C:"\2E05(G;S22U@W1."UEJ2([W?S?P^Y%6"!N1MV&)IS%V
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M'89GS3[>R!RXB9];2BTP5<5-(#)$)BNS42;S_2$ZM$.@AU/GQ*%=,96V;"N
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M-<'*F6.@8[Y>R+."^X[]23WV59I'M7,2K@_X#X\PV.G%@.UZQ#FN1NQ8.:$
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M1 68"2RDWVUEO_QUWN8'!]="#X/])A-/:@_J]W/3Q:M #NI-I[W$MR@^*\O
M%"HK/"F:49'W$N>>+(_P%2R)NA@7NJD;)E9,97ZJGH=));(1)#-XQ"/4,(QD
MB(U2;0U^=?.V\4K^]C( INB[5I\_HW_#1SO;(OVEB!;*C:@R6<%H1+5 20]@
M(YT4SC_Y>:C#-(D2M'$H5![.Z])1;OZI4M!VOO#PV<DA2<V;]Z62Z=FG/[\T
M?2<[:B_6J=1CLCU;6>BG _1__TOFLZ'$S05;)3OGW ;-RM,<.48)PS^_,0;*
MRT$3;-_BZU_H5@PHE4@[XTC5IFF6EY#1+?>@)U^Y!ILD;UJ6;#+9RV\VL[P-
MC=\G%:GS6B*B!;(C^Y 7Z^!YUM:;XLW)4HVP$6V*><T@4NZKLXV^14M5S_M7
MI;7#I6PW/#MO=FE)9SSZ_KVH)>M]&.=&*:JW%]%%,PQI\6BQM;C20S;VN/XC
M_\9@:EQ:0F^D:\(IJW/'FR4S^N^^PX;MRHMSR'AGW7AH\DNOP/%%)-E%MN.B
MFG, M =*N][)8$_9AVA5[T,2RYC>J[W4_:"1E310_Z1&%OO$#].(*48.F8>F
M^(H.ALSA8EYIQK)]?;IX'E-&ZJ@[%:@)W%$R;5?@\K1;^V%$G=F'M(G9D+!A
MQ+4?@TR9_H7YOTAB76  $1-1RPFZ6H $/ !JT9YI?!2@251)5[_S+O_%\KQ:
MXNW4-:VG5B];V>M$3MU:=LJH)7*_?!?E-OIB!^7>1;^0*JKJP?Q/TK=ZT^=G
M]7(&$VGR"O^S%)R"@!;H<08O[<Z)6@W0EK#Z\G(CIZWFNP7Q/[OAKE\R2K/,
MR\206YE$:K;CSA>EY&)U: N39F' "POH<E@DP.2<P7%MHY,>7&\NG4VJ_:G)
M4TE;[C@8,GQLFVE\8DBWRE+H2..#XH\Q]Y)5(I0MY+)'GU89TXZ+C]7V9-1^
M96F=\$ZP6'I=<"$-E_#+C/%8BZ>!X$@VA,^BN]U%@/H<'$D7QZ^U3* "3 [L
M<,.D5_WIS^<4Z/-W2'0^THIJ!-1G0@61A^61MZF7D/8($>?E!+3V8.P941UM
M^Z/A[YZ?S*\]'R")HAL@#+1;88*D/W-?TXFG+52D!X#=QU?A\TG3GYC0,_<Y
MZW$!>[R?=\C]6M/-X"_7]R'C<5&PC]VN% %PE:J(O*O!"Z)G%(1I-W!WGK12
M3E"&U5^*\D[<DT!0!@NU'PP/(8I55IAG??0NB#NAB&K&D2PFY1DDZ6<$N;O$
MX0@E-VWQM(P.)R%)ENJ+=OL0I^&M<V0%@DHCU_LIP<1Z@+\6ZC0ET><PMT5W
M?Q@S?VGFS+L*-3.?9^_4N!''4?TPTHOAE4GR8><:./6JWXP1Z)N[MGFN?]YQ
M0&ERYF.)&AM!@JG5/C90'BH:P#(3T2/.7C9DP><=T$X$1]C[U3%2\'DZ8@)5
M']3)B$E%A!DIFCW7TF'*.\RG'T;-S\;7KQO%Y4,EA92JVAB.C',6?@T]K6-S
MV4TW7F0.$X?D#2UCMSL?#+\S.2TD5*DP_Z)=/2ZY%?L5YPX;E67Z#'8-&)BK
M7T@NBYNQZ-0W,2A80IW!Q6X(K6TFV<7H<)L_KU2+89NNQAILME)>?*5@BP#'
MG@5',?@G7\?%]\-[203'*,LSQ,3C?[HW4A\HM/W*EW?:_)-L39/1VD'+5L$)
ML249$^:.^-1 0CFO7V!ZIT*7M$[#PRV7[YVQ-9)Y4OJE/SZ9(W&\B&J)S.1+
M?J9-_MB@&O@WL/I.M9]"22[H?FDA.MQI+J+QZV'54QV<@#:3;\+P*W#P @)]
MQ&2:6TDAO)8U%:\OGT]H6Y=C&L-/BI>>.%?>4ZKI')QVRI7B3T_UAHWW-* 4
MZ.4%MOTE%@)7_0QU!E<-\DHY;<]:R"UZA6<<27S4R"FC)1C2YCZ]#XG"D+2G
MP0NLK5S*C+.H1@S7B?Z%W]6]2I)]CA_25^70L;/4A&Y QF^3V/JFQK;IT\_W
M#<H>.,/'#VM/YL,F?[MY&>Y@V:.E-<L#-,M%=V/'L,<\LME[LPP5&WHXM\-S
MZHV#O_9PE&06Q)4R?(I'<X=!':;AQ3,QR!SY0E'J#1,@$1")8OQ==R*G!57,
M42HC?/MH2#NEQ?4OYH1?=4/ZM3[;89H0,5#-M"B1;KR6&"#:I+#EUVZX.SR_
MWHP#E048;(%,8+H&0"QI=TB76B\(;L%XY0:.!PJY9Z2-!+ =VL&F'0SP/!9+
MLP,1N;!(G!T,E/XU%(^$S4S=-+Q3T>_PP%&H^F>E#7 \E,D/MK7K3BPS-&F:
MX?7E)1YFIH:S"[>_8ZW>:Q0E]X-_<X!0$YH0U5L3)0P=P3!.UM%C=T%-JK$>
M67AL>.V\W]JPZ8F@0OBI>]']H+9&6@Y V 1('J8K/Y"8L2 &VPA2,]L"LY5O
M[1ZF^OY&JZ75R/VAK[ UJ($V[=:E%_8%M]/MP?%502*O#&UQ0'<:/ 6XM$";
MLZ[3"FJW4',&B/<8#AR>-!W"Z:F$&SM#$2<_#%*2^[F&X/"+Y;P==!)761DS
MP$1EN\J]X7[<<:8SG<> $K[-7#*BKC/6E?C.I**?X\U3W-4/H%H)@XX1J*RZ
MF7SDO <>%K4K[,X=9Q)KY2SYQ)\QUS66[IPX.):QN[@[0MV+W% (!LIW5FZ0
M%SK0^/55;])"T]7NZ 15W_>7QOZ>_B-XXIVF1K.F/_'GS]#'Q\7/QFSOQJC)
M=7E63;4*:;W*'O/P %[%.CYW9,MMGC"7SJB(_#^J%CTX9&27J:+ROZVT#6LB
MIZ:.*"AMMG&+&PPFH2%<A@@UV@NF.54#]5<!1T!5(1)15O[FG\KR'DSVW[VZ
MP1<SXL46(Q%9ABNFRDOVK\6\TTTI-UX(9[W>A\A=UW5?BWP>,9BM8^VI-SBR
M=RV25@0>1&M=#X:1T(XNF-%$02\R:VNY#N8"4>Z*Z)4..-790RJU<A]2 "58
ML\!H(A^9YFQ%SYL/5*,<=&AWO?C.1SJQ]V]5=H1=L..9FA&>J2.MGG^-?+%#
MGCU?6Z,$]Z!F34]-^-%/B#)W(JU_>"X@0+9Z]>E#K!U9752)46J2&4H#3",-
M$QY&(G7(VD3^,,*O&UY5^Q#$X)?B-[9QFUT=N'S4A7U(HPI0/PHM&^XF0V="
M6AM^75@A*@.\3YP.7^]Y9*BE7<V"Y>&<#GGAQ\K@%",/-]UT1CI2'8'Z6]MR
M[@8I4+>P6[US56G45 3B@1GC<L!P%A.4$QM7T-;GB5U*YE-,UMRL,M?-)]B\
M6](GO@Q6X>J_*%#]>S46#S;HZ$%;#5T:QV9^*7IL4XO,.?MDU!X?I19MVRW^
ML]OMS"V-_+-BVQM<+6A078#BU2<9IT]/!>S0PGX_""F=Y9AFX?RRN#-%^"N9
MAU=''/]1TZ%@_ZEEVFM]$8ZD@PT6T^\)K^4%PUJ'7^*SAJ.1AFJ<C96A/2ND
M\MX/:)<]IEWC5@#J1=1O PG@$."PSN)W\ZLE!_HD:#W4YS CY&Q[:RUP)-:)
M,;!WX^4.M181W36/6]@V>[98/K<2]ST1+#WY@%BP^5X@MIKV"B:Z#R&LPTA,
M$;R:KHX9E:5PN[,N)L+(,_D6?L=\!&]>#<C%C4S$J)X5RT"#K^ TD2"J(XI*
M*:%7I]3OV??0 *=R#8VT4"[+)\YL%&WQR;HM96J:)I0L!ONI1$@-8GE7UD_1
M..B.7U$JAKL>1D&4,)2?Z'50$)XP4<9!P!F#*/X6I^2?N"I*M?3K:38L?IUX
MR@^A6]9GZZ,>[Y@Z67UB6]P9MC+\^V!< :BRV7A0!=KHQDJ)I0>K'\VW J]J
M]:</$^63)&G#.R8/"WXGYRC$S<;;BE3?R;2V="L_L8+[DR;QL?62&^]W(;-3
M'8UG@T9Z/](E:TPZ*S)"W="M>J<?<FX:( NSKI<Z5#JW*.K+V<J;=DJD)5?9
M6Z8<4CV9:NNPMS8\!7#Q_65ZG+"5+^16RB X\Q75,UV\$^0XI+QJX_W8^$Q;
M8=!+'BO+MD.GZ@7/%F.>'K+Y >0H1 &DNPA08KUEG;]S!@U%-6L("L<WM5A$
MO)*MGCQ_PTY*<DJ6C1 =(1&K&ZNSH+P**T:O1%$5&6TH_L1Z3#&L;OVDGWP#
M(1XK<*\_X<:+42V^[,_S.B,G6>YW:><#]Q<P^@^AKR5P11MC. N7SK$*&8.X
M9;^.Q\D6XPDBX]92T7JA2U3$E+[G+E.LDF"GZ!]ACESLC#9$,?0MSL']F&5*
M%-=1T'.:2<??BUMU1"45"&D?ROK4?H[EBY=UM"8? SGC\3FO]8RI0$1<O&[L
MIRRIZD\IGN[=9:/;']\_XQ-<>1<I7?#X?]JG&B<,X)E@03*"@]([]1$T1ZJR
M$^*0\CKDKX_J7.H>5TO/L:6Q8#9ONRZ)".16M&WT+&M'+.QJF G+RWK8S\%-
M=QI?"B4$9*$J,)JL+X#55$T:]Q^&^"*_+W_A8CH[4RL?[2[(SM&1MO"V3[_!
M?2>M3V!,-^^Y$7_=62C&^F PT%L8_MN>[]L2MYL /L[ZTO 18?T26_.$UB<?
M2SF+I*FWGSGY"K309A=\/%T7$>!9OH75!6)/*(P7=0DUGI!^O0C.YS=K[:>B
M35X=7)YX8K'[W%[/;]VL4_2[ H_6=<.Y(J$E9"ZEC0D' XPA&)LZ-U6=T3/-
M-)+.3 NFP\W&!\),!]6A/YR*=_VO=*A_?IZ?CVR+?!$KU+9YAKM1>%9T/'$)
MS?11-%[M9H#T"/Z6<;8&Q)'F%8[3[H, T1EY<Z:':SPS@M?T_A7)^[.7R(?O
MA=OZ.)B&M-RO_X<K]^__Z\F\!8[$Q!9T,.*(NL:4#-A(5KE#:DD]-.Y;L/31
M0O8C[>+\Y:GIE0*=GL.UTO0O!TVG]B$CRP0 DX7D^Z/<$U[U_C5WMRM;?\E&
M8U&Z]R;7S2%^PY$MK)IHRER2G7M$KN"N"K9=#C$1B&'W\VT5<3>^*]ZY-&Q:
MKF3K)+7PV"08Y:D]7=I!,P/G2*[XA^^0<'(*,2&($'!"-%%X/H>O\ .:<&OE
M1#2CXQT\"V4!-%H#]5XP_)>[;?0T%'<W:;.A/%4[U\R,X_C4:1K"O59M5IPZ
M5 ^G*@\BI0_:8=-,9^A^R#OT2IQ+MREB\,5]UV4XE[YD4U]Z10#US^^IX-<:
M%2YDV- E'[4'Q6P7L0N82B[C0$1'%UV;<7:8XV4VKH5V^RZ7<BV4$ZD/D#H3
M)[[1QC_!-?_="B(P>IJ0@]$!SQ#T?8D7OHC=\U5L>36I_K%U;W2@Z_56<-!H
M;A.,\!V&KX:1'N$FD&R@+:P18+=^F9P5C:98NK'])>YM)64RESS"A+^_T!7R
M/N0(GAZ)LY\^OTF0JI/C$7UX@G>XU$R?#KY8*9X0<&K?0KM0V7?8846;$XV6
M*(586+N.)Y;&1NV"$27\#.H9ZVRDC29C"YNK; %/_'^<*I4NK7*>KOI#JP(/
M\NN77-(5AV$$&+T<<-&W:#+/[V3%%9-FT1*QY8AT!NEJ&]==:I9&]")EX2 K
M^,@Z_3U@7W]TN'[ZC;EH>A;DJ/(XR+GVI<+[F<=+ZWOML\$RM8V'?WV+W"H4
MN1DWATV.YNNF]4PE3JTQEJ%<S>F*?A];/DV*=%[&%(V/&I;*Z+RR_HVY9&XA
M;S?]V00>0V/#KT=,G1RHA2)ODR:_83-<*&BW'.?R7M9(X@5!F3K&TYC;D'?'
MCY5^QSH8O"?.2+[JZ5XTSKV3Y](7]SZC7U]-:2CG6ZG^S62-?Y,^XV'%CBL7
M#Y(^;X.!G%/8_*4=SX*4'-?;UE;GZV,T4R50^A=W)R G(6?IRII\/<'UA)>\
M?"+JO#95"E>'B6(2/17%2@FVJ3:2UC6Q#[U\?2)_6L7J96P&E/$::+Y*/_L?
M3[B0"DQNX,\$ PJ#"0DD72@GG*!OLP<[@S2M*ME4<@_=4UZ*>#91J;,^?RCD
MD]39]T&R[ZZ)<W;] S5"]6-*82MTZADD=("ASNB'\9;@CH,6NO"M:#W#E&-/
MCDL^"U4^NI!4Z-,L7%QV_1CN",X% <J4TWC'&2?EP?;OC$8$21<3)MSSKI:'
M?P-I0)1-ZLX<]GFHFU3J.K(CEU8L_?Q)@[7.+6\-%+(TBG+0/]B&Z7T? ?A9
M]_?^OJL'HP8UP*A<\#2^K\V!5!OB_,+->JF[3>,AVO["7'G()_GEQ<::-^?$
M4%<POW _6U<2J6J,9ABKTO0;3#%70_?5!FO!?@'%46>RZ [/!Q:X>MZ#Q-/7
MCBW:.7B]C7L#@>QJ,XX?M#D_<I@>B\-_FH*6D6M,/H#+Q+GF@FY3X@6LW3]C
M+RS5A5])%)9$'7F'3[([LA:8>9Z^\%^?'YHAN!E22%401I#%B"&-R"WQA$G^
M;B^OG&65=G=V?\[?MRYY-,3HX ^[;F93LIFW=RCRFG<C*9'" AH$SO2<FM*C
MN,KY&O1G\_?I^D$=BF_)R\._K<M^W+$T3?H\O^MCRD&4D9CJ? V[5TKG@E[K
M^9F7(#)2E:-2XANW%3G(L';\.XU&G0.Y"(B0%S5>9(46<^NW7\V^+?\R-*N-
MF3H>1GTX"X$_&Z!@N['C08R3#\&+I.0&ZBWZ)W6E=.F:-U=@435W8BV<'Y7G
M/:(53Z12-!ZIG[(T75B@\4*)B!8TUV3SS#HHH[#*]GW2KX4(+0$!_'Q\(&]R
MGF)%1\T?+<Z""([#&HXF:551OHV7NYF7SQNHY_JWS8[,M^IGY.(9^\R#M-P3
M2E%RP<31D/E\KJQ@0_O4RSU[EJ.WJW=<SQH*,[[4,?@\I/CG7,/!R'+*-2W<
M'-T8J8FJ^>RB6JFKIWDAV;Q#G58@U6;RNR)%/7_EI5$MEG7(Q%MX'W+RS^[D
MMG8"6#RS0^,=9G!XD_>@P=,G%=1U9BP6):9LM?C'?#X>4GNPDEO&(7@+7]F(
M8[G4=)$>RUSG04U*S3ZD.)%V>E=I_3U"F!/=Y!YE<#1).27W^6(5[R^/9R>"
MDGCW(9U=05UX7C//#E0#/1:PA8_B*"(@W(WD2'$$[6T)DV*B6%\)O=IE@]03
M9Z)RQA?2#>GSZB=D0A[Q^H<$PD^!F+>=&SJDUL.$=!:Y1+)D +$(_@*I[QXQ
M"726[#Y^H>)18MHW)W(SM#.Q!(,S6)H==ZM=_66Q"4@P^0NV!9[Q?]/-!R;%
MA/J?,)+6^BX[8QCZ$Q8"X'QGX$<7_]"?K.=S _RQW&M+&AO#LW3 C&\#H-VH
MIJCM0T*;F$?%/B38E)'.Y-\<&X94!:HA:KW\^3ZDM093B5MH)0W/UVC6X:Q:
M9$ .[21J^TIU.RIW#59&$]XS 7[0;AA>)):J,AJX1HQBBN/+OE[;AVR8H^TS
ML78]G=@@X&!2GG1I8L/Z2=0P<((!=>9!-+Y*3O](L'I4MY?X*5C=5,[9%_IA
M:63BO(_\+</"6=/!:188'N\N0KM,O@QJ'W0<I*<IP[F6^=^+UPPIN:GJ.1-O
MLL"?O;Q[:*+&O4?-=A7Q?;N1YD5/9AQF]#&$-+A!,NFK%OGFA\?GA./_N3(>
M-_@ER4-"CC'P/'OJE[G(Q?".<]WQ-I:260.QGR2&O:NV33<T6*_MW;*;.F\C
M*J;1[DR4SE9P?!R<I<=]YXIOB=UX]+V2'?N.E"'3D7P2"R6/G@:X(+B !CT2
M!W$MFGB?__(./\57[87;V\4%BXHGSV#KW[&WL5U0-!-XW:V86XN\NP_A,&6P
M[4.8?M.(]*W48=Y5%&HQ(/F^@9&P0\'K"8A EF87DB %LHW3_Z8E"-!.EYN7
MD;A6F5_!O]YL+MQQ+LBZ.OIIQ:>3Z0^_O! >FWW;;GKL;LN"^5]+[:A.S 6W
ML%?#FXU38;_'6GLGT^_1A B,*T%8PIK["<ORO8+S XIZ[5[F:1;>GRQM>RWI
M7AFU[O1/.'PNK@B^ZDUQ$Z^;YLWH5=?T>*,N1RPL4\E; ,4G6F2#5D]7SGR0
M763?>R!_E2,Z:_7RIB'ZU1I*,IVT%M@ [KSK)A4W#B(<,BT1/ZH&?5P6MQRA
M9&W*:_ HN6%D%.D,0@E< @WM)<U$@--\.L?Z<Q.YG&]3H+D'5!EGL F1P[HQ
M1O0/2ODGEQZL5)-B<EYG[=KMF.7/FP$L0F*#%#>^[228H(<CE])&3: +_SX$
MX^UX=$=+1^SH PVQ\M8C],>.LXG-.%!)@")#OIBP@!]>%2(+-,3IQ!:Y=#KF
M6K0$\MU[I(/."Z8.?X2"U_H9[.W4*P[N(W$,=L\/]6Y=UWJ7]UI#QS2A#>?+
M7,-C_-T<QI=<=V0BZ6HL6^_)KAS:(S8>O4U]R^Q;.<;PP0Z1?<BN8O,ES"$I
MO];XW6OH1O@J E0KINC %LU?[4-X7@6X5U/33EMN,D6A)06!:14-=.YE DXW
M0#)$CQ88E]++F3?HYQRGPL(G6:K66$(":K1[UE=&9YN%M9R/&J>?(+T0_259
M^96WS-_&<V^7CJ];X<A"?O!K_3"".J?%VE\O@@1M(J?2=<$&*,[M9_"]5K#0
MVX1)U?( ]5.P0FPD,A<1M0\YQ! '=8D/W)-;SMQ\/ 2SK$B^""=PTV27H,$
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M3[_QMB=E'R1"'-FL[7.?:1W+ZJ5IRF6V+T>I=;I-IP[R:<1HG+=YNF37W^C
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M+I4Y]D>P9NON8<&W1E<"_5+"7UY7<S]J/)R'6^-3WKW?2#488' *Z?T>0@3
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M<0$1C"D"&JD<N<C7PO%K;T7I*WY;E=6;#M"=R8"54[==#UM8W/G8*GPTYOK
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ME&K"N3":AW#%\GF,?DI CIL#O7O X$&*PSNCW0^.+[2,WOEY?+[TPBHRX8R
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M58_GOWN!AX\ !%:FNK^<: 9&_=",-_Z3KU\:[C%:\.+P+%#*<U]V09MI:J%
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M$NWN'NXZDJR F()%0P^AQ!F'@)!<A@*@3515:9.5^%DL.G'UYZ:90G55Y?/
MZ$L0CV33L[>231527'A!8^P<TDG \Q QRP3B@E$$=9CL_YJ4>%)#</IF'=?P
M-XF3PNYJFM. O)W[ OP=M$*7(;9&MNR$BD(CH11SZ%/)DOHBU_++OF152]/P
MK!>&$JI%\OV0I3F+ ,ZIY_9I;^8=@NV*75$;>V<(EW!.\NU]-?$GNZUO96;3
M\3P.N*O%0:O+#0-#\ 2TC#$?:P#%FT7F["2\D#2)>?3\(>]<<6CI(2F)<4E,
MIOW9U_O5EWE1 7NU7"D!NO'&"J'Y+.%\AA""B,HG^_GO_!!%'1W5>NN5;#,<
M5/PL+'B+7UV\JT] ))H2R.(*H]]"C;EJQ$YG,(2W:4]&D[TIX,^\'%]4"?OR
M3,G8*F.NNLQRUXO[^YD'ZY),6>8[F =\O(MF2JEF'$.7;[<FJK7]K..H;XB4
M5YR<,QP(F.E5,WKRX]PRA-SP$B7?C^+8\K$L_)7CFF6RX>H5M:)7_AP6TY1_
M>0NU9=>H$SM@.S0_-]^* (XEK;RE>P.=_"!TIMC@\/OMRC=0CRA;C>LNBV82
M^NK_:/K>CBWYGD;]?B(&=P5W=^#W/,V#^;)!&<_?C(C.A,?^;(MGWL2^#0_F
M5!@(/*JA][V?Q\\U ))#JV&6H^^N_?8EG1WH1.#=R7X9L8^>5RN^LZZB%U\)
MT%!=N0W/#K/<OGG'Y$?'35%H'$8"[:\&G 0U2]J6"KO!?(N[@_F'P# &5'B;
MH]H=T_IZSTNGSU!V*Y=OSS]DM';RCG=_?W-ZBYG2QK]?'6G&_3;G0=MM;U\G
MJ>>HY? OU5[ZFS>B*[U-.Q>9;Z[G*) 6-JRB"ESA/I:9.1$3X6'XJ81=!(O[
M!1O">1RX2$(\/\Y,QQ$S'U^""[(4"2YH+W2KN?N],;P_YN'\[;A^O1:#M/[I
M:)XW%T7FX)GJ\P2*)0;0A9,)*R)4*984@L6C/^UBWYY][)>2V5\6=,HG4;5]
M/A*##_RX(W#EG_'6"U^C[3SW?<16@;8] TVYS#]^D74HA00@SY/>JR-=J,?(
M$[VC34=][>).BP6T=7B)WG)H#3MP4N.,7D@ !.H^ME#;%1?&><"S4D.-=Z$G
M]6ZMK_MG'-YW^\;PMM9N;K$JIEZE>LFF>;2]S[;3D!8'V&.#;U"JHY'J1 3O
M;\"PQ56Z=$@K46-4M6)2[7K%5=65.^>C7^K]Y+@,N7T"PHV[+,+8T>_/_3.W
M.E7<.+$ZX**P5U=0[C]ZJ/%O1]AV%QLR;D,+9A88G65#N :Z!IX]UGUQ^^9)
MQ-F5JHFLVX]W=+GL;EG6:8S-#W19 KK3( \\W' =M1<B882^UVC3AN_(D;B_
M&>%KE3P5FF3]#3[QI.VGPHL!J=PU^)=-^]=O9AQ<?=?L\]<>)0^9S5725Y,&
M0S4[4$9$Q>6R(G<:/SG'\&:.PK;%NS415(E1V09, :D$FK, T+B]0C5/R54!
M?O\Z!\Y&!#&U3&=:2GK]TT,>/AWI".'R-?O!%P!Q9UA[C$UBRO(9(IPT=>8W
M48(YX$YUF^J"O]L'/A'VA;KG%P2L^?FR=2 ;XNQZSG"L!BAOE16BKL6N(I6F
M,8>]\?UIX;*]?;JV96;Q86-TK/230GXW%1(,CV7QKC/3FLYH=X%2Z35Y=YOT
MN6:FSLFQH'YH!M70O"PKG0T+D;.5D3^K\GT7(S@+71VU.Y9)U];"](3#Z.&K
ML(MLR*T& 2K_Y, 9Z^[2AVQ(!G!S/@;10%F;BES/G0BOA:(&X:^@E"QTBQ^.
MF JMI[[$J'5 8^VDI0HR7=QZ3HC5O/.K+]L7*GM;8'^"BEO3^[VHI49<:777
M0'EH.+EQM*M-[8AYM'IHI-7Q+/GL[L<?E)/"TH^N^A8>ZI"(<&QJ$W[/C>NU
M<EI-[PO&,Y/XGQMQ31\^N&_NK73!W!NU'>:SC K?GD<9:T<5FA2]3VR]WA81
M<3+Y]0A]9"%X=SYVR\EW2>7+L_3J],"BTNNQ.?(%1Y]N<8K<;4K4&AT$BG).
MF'9>Z^,0MKK^ZO^@1__(F%@,;T481RC9E<8L_EH4C9G#D^6H?5+_%"44O^HY
M+Q?5<A!W"D3<; B@Q8;0S@!KTTX#LJP!J' 0[EG*HI!6M:-B]EO9@MS.9=/C
M/"')>^$)-<?5OS1?/@?!CBJK+ $7DVJZGCQ(;I\1[R;-JIQ\.-YI-Y$I:/VL
MN!@KYEOOWX^\(L0?EZ1ZZP^CB/D*!C+KWUU$R\3[C'#Z):3U+Y;J0/Z/,OS?
MC,<>CUU3Y L.2!!-%??B+&)N)VC(. NJ;.E:#%<PH991ID/WCU965$;?J:RL
M>JX0T/E!^=-7HO(3""0 4O E)T&/GA!*EY"V0"=D'[.J2US.D5KKY?K2JCM$
MBVM,HYV/;2512F?SI- N("3"OC+X?RJL].\:#6(L;A,*CM8(]-%/^T!Y<6[\
M+TH!PR['S\6>TJAC&5:^Y[T\Y^9(#2,FK_GZ-277-CO"1Y':H&$5#<V8MHS&
M$=.SU7& 9M@7IS!\R7L$.:M8??QN_-6PJKX-I1]?^N^8=!W4#4!9C^PC8LHS
M&%)+=#[ MT.5JD;;96*=IJ$)>6_,OCH20HL<QK4FVXN\?.LCN3KGTO;S-T+U
ML$.8)]F<S/<LJ5 9(P&Z5BBBU< D=ME9C8:.^E#U<DJ?2_I;5.0,Q$SWQ^-D
MW_5I(NA=)%/HQX NTLNH:5Y?6C6UI/1T<<Z$*QOB'?I01;RHY$"IRMHS(^O2
MA-6>Y"[Y@TT@L8[T!LV/AK$0ND7=6!9((@VT6D)#X^&5U--EF6E_6/+W#K^^
M^NUY9'Z*)&^-Q(Q0)F37NH% PS$_&RG1I5 _C/68!<B@#SZ.):^)<'[+0KAW
MW85.?W]K=58)3#WMH>E^A82@^;S'ES7(^*E5>8[1NFO/(JTO'3[$*1_U]QPL
M&H(^L]<U$ $'3B!6"D'K5,E,8FFP1G#<V@//IOBH_!T('C,*EK2YK=%^)8YU
MM"IQ];/=[PVCU7<]U ^OW<U?S(*$Q)?%MW=^_X+A"/Y%H5L,CZ+'Z1T9DOR)
M30JAG]7XO/%;"5FG*^IAQ[Q75V^CB1GW3;EK=E)6I$8*E;_M&++X#K A:0EL
MR.T!ND2#(AM2X#,&LA7.:L#0<03F#HO*-JJJ"A[>Q+[(T+%//M&3FV& Q(I&
M:*CF?N!/A?D.C)O0AL&)(4@I)@9&_((^!+IZF5!,>[;FZ'TWX",IZ8B/==/[
ML/ ''HBFSD4/1,5$1<"?ULX;\(<*7ZR^"2VM ?HJ+&X8E=!A+,7,@KE9_L:0
M47DD'AS>MJB2UPP^?'IJBN)=789O<;^O^#SVZFSRW)6,.]:M'-?30FQ Q-Z"
MAXHB!::A@#S_\ES=P4J_!VS((7CBIFK(Y?4\SA514]+$RM!G@R]T#^F7L-"F
M3PWV+!X9HI\OS9=9AR:^F=(&"J2\=T-BD&+$"$W[VH8=P4.;[RTZS9K;*=RG
M_CJ=W3?W1(?A1+3<BT'UTV6()!$YGS8(T>^$CI$Y6Z&)0DZ_@0$3:M"P^-OL
M=4.SVF='\6<HS$\\;_)<RO@SC]^U[F!#/CYFR(#H'+O"AI!\P#N^AG8C/$$)
MO'(.?;GF>#O]QKN>3_1;P\4KOY]^/TS;@*!_(R["ZT)0)RA],5C^6&S#Y3N\
MS.:#/!+^@W=?"9Y3?K:JW_+74!+".+/7_Q'HHNU5&^P!N0.4=8B3A,&;@12&
M'\6/-!AT1 CS'W*IL/81$_AM$A)H%"=^:BBL^@A>+N/A)8$96\4W>W[E@!$P
M3S=A-1,H#KAX&.4B)A$##2(\1QT>+E)J M!HLEE^)KG3HZH:]^R*RYL.Z2K=
MPT.7\F^G'_DN%K@Z!W/[DD%28\BZ4+&M39JICI- SN71K"L._<,/:(G&;58)
MQU';J_*!71[&,>\I%G\8+N!"X)OD0@=:-'CJ^0_]#33&GJW]4QHF*U@^-'O8
MQ+S:NLAKL&;IG+3N$Q04B=XK_ <C?D57\,<T/*"[ 6,DD/!91@7VN1,3H:WV
MUX\EQ'?[W?^\SE/D.2LZ[-PK?_="<&?15^'\833%EW^EEVX*T*WV@IL.D)E%
M38IP -<.W5])Y8_=6G&DKOIG#OJ7G%KU<_0^%"8?$RI_KS?]=C6'AHB "0B9
M6W*ML*ULR 3H708 7G+WY;T6DX5W%!.Z!%_?^;J8OJWD/<^CV'YN5TRV8@W0
MWOW-, /WH0,U 8<RE.3J*']VYW)?P9M#+BM-,"X&!?I?Y./[NY)[9^4<M.$F
M")C02CC* USTRF?PHK_(1U29S?._83%VX[<\3ANIY\XVU1(?WQ[KTJ;-,Z2#
M0GB[&*+YTX\$ODT>:)*VEYUO<[3A_SG6'L3J#-WW>N:MTK-:>]I]^[6""\6F
MJK-VWOH;QB4:#2(T*ZN_J+ LVT)[J TFIVS32:32[WB78VD$[,8S(W^8B''.
MS[$E)8:@+PV4S,@D;RC%$@M!=6#*;&-B/WE/2:3<>MI@>RKX9]_1FE]J_ED1
MOS[*5<7*HB"V?)#^P.'UY,:0-A@'"X9''AXRUO>!E<E^)//'/LZ<E-'M3 G5
M<%CV.O*G]T OK47J"K>Y\)>+THFQE2C]S3H*6HIL9_JD^%7-18UH"R>#BK\W
MBTW2+6XDY.?F2:SK?1Y-S?O:B!D/#>D:I- U"]]8GLQ[0W^IGN^Z^N[XK.A7
MO97CJ<YA3J8;KMM7F1@*C"%HTXZKT'WN!L3NU;TV,](/>C3_*%TR)"%G%"%B
M>8LU'"CW\O#C8U>C(-QT)5KHW@D&\36N'/$Z@G23(EI;>#Y2>T \-'/8IN:4
M@4$1=J9]BMJ9QFB^9XWJE3U5(SIU"G#/^QL>XTB\5?H<33188R0WHDEHAN V
M";MR=#:_>1+:PI*KJV%#DB(,KP$?W?D^*GT^=5I-< 9U)LD2U'>M#>RAFN&V
MGN3LP#:]&NU&N-<*"<7Z)?@>5HN!M^.NH07U/F>,4!$"5R('K=HN:"TH,JKR
M3M2:,"Q,MD(^,^X"JF'^!U]3G5K7.T2/1&2Y5'E>Y^/L :2#"Z&4*I0(&S)H
M!O)+%M]M-H2\M.- !1WM*-WL'D??VG(T]?&11HO7.;VAG-/2&F.90 :+BTY&
M<XK*G@(\J3:F^*N(E;,<I$Z#^8@OV$PVQ*FL!BVJ?91UPFRS=B=D=SNY"Z 4
M6C)NSNXZLQI@I/L,%3;D4P9IC\BUL"$=HUG0Y\;_C.[7>3L=(4L\*O5#,M6R
MVKC&7P68&4(3LW'_1$\[A59W36E\X_Y]Q]O3US#I:VW\SMB=/'2+-OJVZKG.
MNJZ5.]3P:PHH2ALEPZS)F8FN^BB'.EB9W]%@:'/_PDZ!6I^\CW-0:UIPA^)B
M+DXO9W>=#7E6WHK;U 0=-R")F39A*&:#2_ QRY(-:1YA0R195D:ZH+H_ 27:
M:2GZ2C[H56VI4XDI [2,95I?]1(MP@X^5+_&"RKX?A IRY[D86+ _QFY>DBZ
M)(^B01N6;>\+S=DJ60Q;-;,GM;>Q(?_ "\\J.YNUC38==H$Q^%0VO+9XW(N\
M#3YZ#FN;^48^01RQP()/;60;Q_)YA 6T)UB'MJ?W28::L'@V*#L*[DG*]!::
M\MI?$:A3(NZB2W4LC/@#^\Q8'8^4WWO30YDJ;/"$E:/$)@9JPN^/6?C69:OP
MV!,S48F:@WF)+6,LF:N]@_D[FKMRGW 0<(L/(G9[H*P[,!;3B@TY8AP:?Y7)
MAL2 ,ET@I8A(!PTZ]U/B#JJP2-UH.N[/(@Q] ML, R(1Y'RF(OBE>BJX>94Y
M++DLH( -,;W!AOSPA+$AJO?V;Z_',?:S(<]5FO2\X0NNLN "?O6KH>>"!K>Q
M-G9V;>/TYZ[AA+TY[[' A=Y,&V!48'$[=\Y!<:GV1"CC? [=A@T9LH>M#S6Q
M(;/14"HGYTH$:-[R_J(I=KS5*JU0X$HE5\U9E"=.X<'*?[],B7&!EQZ!'G),
M8D$6<8P,DW_S^1P4!6[4('H]$OL2O@T"_D7+W+%U'C@61[F) '2%:/5,T/O=
ML91F_8(*PX@?02?]_IZK,.L'/20:U?U%;:)IM #OD*_I;,";%)#\,)\)%]>3
M7^=^PKW+PSH$I_-/H%M,< AL+*8T<3L)TTIKTFAHU*V;L;M -@L//VL\Q[KQ
M.OV&RW3EO9&4:*_#YR%11'QZXM>_!"_6Z+=T_DHGQ8[JS)J-8_=7'BSR\1N/
M;F,9D@MLR,E10(H-"=1EY4A6GNC1L+?X^Z9',Y&\FK2HN1>7$1F*ZMX+_"1$
MW6 (,].,)2;^5ET7V$ITFQ;R<1QM38CXM$Y\,@Q3VO_L7(>5 ,J1MDC$W>/'
M1Q$YE\M)0M/H)(*(%H;WUBN"E]CP7/@G@Z(C<AH6A.5/I=@^-N0EF@+Z6#P_
M+9D:SS@,3N:.W#=:LL53E.MZ;$0+6P47Z3]<ZGCZ;_%/::A.<!"$\?T-5DE]
M0&,9.UELV+<BOJ2T#B]^3;[[QS1UYE=TV%0.7F#[,_-8_<YX&":7 .(8;^A3
M6+E2%*$++=MT8L%88O@<0MG\RKR@\S>)DX?-WBHAT8=]^E;@[Z!0-+&1(-%T
M-K2Q::]+M$;3/S[XSX6ACH9H@45'T_J&!S][.9+]KXX$(,=[3W#.)?K GD(I
MY[$OV9 *6(+0-(8A/#V]6HPN<$E+1H HMAJ_YA#X6G@LL4[OAG22,F2I@E&2
MMGN>PD_S! [1U4+/(WDI_*2[*:3W,)[Y>!XTP?D;T6A8Q^,]#O_Z#7TL#27?
MCUX43=D9\5U/FFL8X&,XM$NA2P?1M*V[N!/H!;,?C'$ A+\'E)EY,!]^\2[J
M (L[A,J&V&72YOE8,M]&.69WKL_W),^LQHSNF^Y]ZGR;J"')A#*ST9Z(\36:
M#>4-Q:N9/]K1/F9Y_*9SKS??4E:9@=9&K<:/J=4NF6\J/WW3@4%J/0FZO$0A
MV  X:B]9-(.$YKU'V<F,*2V<Y/J4$&R5[?*;\N5#>2GWAV2.< ==7E+ [^?#
M+4-!*N:Y[]\M7K.\E+Y2M:M8^#?<P9[/4T)QT2IZ;OL=1HL0/$/;J'P],C:/
M8(C$LOC$F._1MRU7^*-@!ZQ[R;".BLG]]WYE*%9,<OM'K0Q?>3@$*OKI08QF
MI,S'GA3J_$H0:(B*F+4P8C%:U!_MQ@_(5[=ACBRX0ALF^4JG]3*6\6FS)<$5
M:_I''V49HZAW-!DY#T7/8+[!B"D$"D)W>8U^0 8V;=)E>JI) >ED7EZ"#?&'
MF__\O(AJ.QRE)@=;WY C-)\H]7S*RFX.?=":+7%[88YUK'M 0"'/['2^VM1
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MW:&Z%JH1"U"/T!06;P7SV9;?T#T4#$C+T^=T:RL>[Q4W)IM=Z&+M_NLY>&,
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MQ!"]<&H=P8=N"443W^ IMHW 6D2>(9^0-24F;^SGFP]!T&P5'&6>(>++.C1
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MF)(2KXS^R(S QC^:K7F$FD#<3^ 7/7OI](.=L>59D=TD/F"<G,_3<9$C<S3
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M[B.\X2FK0"/=%52:VX9Q!3A=DLTHTN#MM@SS4Q0Y%BCL%=DNV&;IU\YU'.;
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M/Z['=<PJQ5I^DRFY.B%P]5"U]?>_K@_!PO' .C8>^^L8N+X-$U3'TTK8\NN
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M\T156$_E*_MRXV.-XI*D<OGIU(8-R>."#>9O[O#^I;YDGTH49<.92H!I.<V
M2LBJ(PA'15K4!5<B+XVOS]?7U2;=:LU]9_9T@]=F^>0Z,@X)7$,PQ<^S^0,A
M$_@.8K$UR$6!+)TQW]QWMK%-S'/W[[.'JD44*JG\5QU9%=AKSR:S*G:#EN\M
M5#X^]99(V8;QP=#VK#).^1CW7ZPD[-5M6 9I[5DH%:'P_:A7U*SLDMPE&\U'
MOF4]H3RS&/\;)](+G3_XQFD/'-3;P7!C',5VN&$I#Y$-D=V'VL0Q@\3Z]42T
M"S7 .]?B8V55:?SRW!ZQ5>[K3V63' 3%)2FP_OD'6PK$1RC04(2^A_4(0<'E
M80:0]<@5+F"#W%ZL C2F/JMM;AOUNV-:H9].FG:?OI3;-W@W_Z$UR\<MO>$D
M#%.([?!@\FS#>$)8U2&F\NQA(F"'E0N$B[#A(,.LZ0U80=.AWTS?M*G'*O<W
M-OI>-UU2CLY6S#0\N..!JLH=D3*$W_K4//TDB] :/8]+QM:Z])EH]6Q-=&6=
M"FD-#'Q^RG3F1$1!5#ZZ+\O[KE3#0]ZT1^<&%[G%I58YLZ3Y6>G8*_(GNAQ9
M58A N! HM_PDN]#_Y4Q!2^O%X_[I)-7H4HOC/&,"\2=5Q-1I$VRA+L )?0S<
M9'@R3^"<@GL^ZHN(!%9$C(3HIFK6OVCM;#**#/V@$U[\O)8MQ)0 M1@QD%7X
M0H2;RG"R'ENU?:E%]KNCPOZ8*D29]XB)!R(FB;6?/N@EI;JYK.A>FMGUVES7
MN%N,_['(%*?"[C6K"!&"3"FA$E;>T@A=L\<_&O_D;DZ^_>)(Y^SE'=IG'QKK
M7$ZHL7#NX)/>_U: 6(P#5:MJ@47ZKFU80J6I"KL+6V/9Z@TZSIN7?U]_,A6T
MVZ2R?J@!QZJZRG-O837L2DN]4W>SNG7BUP;LDUO_Y%A"?G8$<TU/#^;T[9/,
MM9'FN<BEDGL+IK[P"+($L9!XY8UA--7:5Q%T)GA3*]6G53+'LGEX2_:#1T 6
M*H*5GQ8&$]N(DIMXA2%A:ZU9U41?E!QFH(9Y;APMSY>M9_6)8&P^]]L\$H52
MUGJ8JL)CG7N4=M3$"7H97B(>!VJDK*"@12!L$(]B]RG H;]7T"I@+"*#&!13
M,:/N6$.C?%*870NH0JG,J(YUV7Q-G56-$IMTBQ>72SS$\X[O5\41H$OPTI!.
M:<"S8LO+$A>$<NVO>$D!"+: /T, ,X*HM:QE>*./LI[^2@:OS+'.Q.SV[FU3
MK&L>":DL2[3TM W2/NEV72](_I2S'ZGTM2)ZDE;12Y9!4!XB@-"JDEC:SYZG
MBU2^A&V8__<;ZH\L4(G?Y-W79O08I\5WGNZ5";ML1[G#=J98&Q)$_VYTG: @
MQZI#4!(@"5TII/'-IZ09<P4'!L)Q^E.>8N\/69;'E/]I#"BT4>*^=[55NVH7
MZ>0[54N8Z0KK'G1S)6?8''Y*C:K,5&$]((9H\8$EW7/R3SX^:<Z=75YR"+O.
M'<DO\T;@<?5&XY53:G%VL5+(P?75 :"$+@[.08*.!KD8"I ,"K$ES2GX5+@@
M,_3F<Z89S2*^O\RMYWI9D.1RS9]"885E#V2ME^Z'QW7LD*#G5T_""43 #96,
M!5R0)*56?@;'>>LQ_4M J<[9HXV?1ZGD[JFIN\GKIQO.A[RV")G+['AFHTG\
M;.DS:,OX<NK(2=-D5C$1A9WDHA/ 1_.X!'QM(T<],<H@*I:.V!>X%2(^;U?T
MH4#^N4N6=^'FG3--60_1*0_WV.%(VS ZA56(O4Q,V7+I$2&U4+',_:0#3=3C
M>O+[%_0\9LQLWUH&+.2JWTA^+_-,-5=&.")4-AKR<+UP4+=PC@):,+S8$P@!
MWM>D5*#G0V%IUJFYC:'AR?K=3G"]YQZ!H475>9GS:I6QNA!W\$@P6 344%OA
MG(AO-;!8R3BJ.C&M6*LFS#MW?"BS@7UYI31P8N3ZQ'#[)HS10F^ Q#$'TTE\
MG?>%Q!XGUVTFM8I'EW<M!FXYET1\0EZRR&T+<N\D:..N*6.&FKC]]4?8 ^0&
M^Y5:1A"H@$HEU^#[L,)1/ZSK'YK'A#]>WFE5>S<S=3&5:BV7;?;NI?57(9=N
M*200-M&!3<4#Y[=AJ=#^.VE-M5 _Y--2NF8/U#7E60!\::U'Q\<Q"@)7;%$Z
MEBTYFB6-=6G4'259_-BC+Q2]J?:@P4\+, Q!F2.2##BCI6/Z- @KZ\^BKCO&
M7_<VS@W,?OYM+#3Q;'>R<U/VFNWUB7=NQQXU<7/11>@OH%]70'MMA+V*E'5G
M'F.5(X*1_*!5M\&UTOXG,]/])M/AB.E<U\<V"GO#GI0*[.*.#_?J QJIA"[[
MK&V8R"]B.ID/'5,:5=+E/O/ZS:>;JX(.V<N?UHQSFE0R\T/V7/AYYQ0?MRAR
MF,"4+6,HL3]@ 3<R281>RR)@4;ADYUE3XKA^T>E/<^-^=[(0#+OUA?M44M=
M[G%*0[JDU]4+2MJ>1.:^QAA:0B\""A5"<. !9#)&CQSE9R<9F=&AH&Y[_J9:
MRCKJO,-HE=;5E$'<D<K08)W'-WC&LD^I?.1;1O800(T^IE@,!=5CA(O?AD&!
M1!AQ9^"L2FU+L =#FN#3;&OX>>YI<8 H]?;GKSKOEB_$[^+>MW6^4T$?0'7#
M^5VC&.V8(Z,WWPI>K+5]J^OV"57RIJZE,;S)-]VUWV9/MODAQ>S?8!]-G+U+
M'Y*IMQ _.46=^TV/@AGT^:(NO*BQY[&BE[8E:!OB)[+]YW-/-)KL-/O.I4Z?
MN5HT[/#%V6C R.;>YZ0_770G<)AQACU !/P)/3B)Y0<?RLH(F:;[+P7@A355
M<_(??R2L'=% H?/&O*.EG!TST1M&7$,PS'  %G#'@ZIJ::;Z92L_GV!FX2)A
M:!<-L#K^@XDW2R$X=XK[4(3+RH>%-H>*0ZJI7"JWD0XN/U&T/#:_&D,1=&'O
M/OV1&+I;;<XD$RE96<?2ZG$Q-7#&-GAFS(2I6]9'S"3L)$V_<*75Z1W>AD75
MPB>U0"7X*A=U&T9*8//+ +KS4KCZP/K=?HN=&L^#3B0-)BTTYYUKP9_3M>XK
MB&0H^GGW^ZEL!'#]"/K'7,=_1T3C58]\2 0<AT$5Q(KY/);TXP+$\'9LAQE&
M?9FM HAT$;BU/[?M^^'N0JK+\+#UB""]>\W>LA!K;>3=6:52< E>N* (]V&_
M)S?TK3QBH**.+?:1:R+[AB$=/5O]Z,IGGX_KD;:^RCLOJB7%#^RXS.^XOXK"
M+]-SBK;XMY'R0V80=[=Q,4- / M'7<]H;FU&=@U):DC2-^R<OQG<EH_T,-_O
M\;(H];K*T#Y8]UIG-3P#4F_[VV@X#<<6#*:1Z1P)B8URFN_ UEY\GA7^_!2D
M9:EVG_-8^8^3- 1KG\H\+5[0T1:0P!WV"(TUGZ_?AB7W0&Z^&JT^9[$-L_ZX
M#?-=CQ=;+OQH,"06M!6_IY0N[#UV9%JXJ7XX",:PIS^&G@^%*1T&1&^X0EGG
M,,F?W@ZD)+6>>8?33- ?G9Z94H]S+$N?40F^]MZ<2]'APM?PH1A$)RJ#+&AJ
MC#89-3T"X9F4DJB*KA.#"A'YA(!]F9'.C8=R2TMS<DN3>:R77Y7NV;6?N!\1
M;,^9P<D4_<'FUW_&=&.U8BGE^V;?TCI_S&NE?6L84:0I)/NW-7RN\G[;6B!H
M'K:<IM(BK(D<V)/J>'$B? :R.KP1:#'68S;G8-:H]3I-O;?1FRV*A1 ZPVIN
M-DEU:]#!(G3ATJ5\2];'^^,JI"E7%C[BHXPM#%. F< W:D$;R .*V(/W&9[H
MX%%C\:?+S2]&;TR]-9-Y%EQ4(MN_4'K-<D-.)<0VE'14YY2R:<GS(.<3'XI0
MKP(+=WH$OQ$+CCZI>$(GV7FQ^!0O,5\+U)I8F81\1$ 3:$O!3S6R!89I5F<2
MNDT/T4XWJR6VB7\7Q@7.!2-J3;H3HS4_=J^,/%;R"I0[?/^ JAENJ<(#K(;\
M;QRQFD7NTY(\N@^98"IKVE0N-H4-#RPK2C-<W>@-X)*E-#+W<M$1K"?&5C3[
M3B@89.N[(Z?1>\=]/K4=O#0;.!$A^4!B.O3$>]S-FWNOG=DS9?^6&GF:O^"R
MC,U/>\@ =OSU]T1L4=.#70"J$]XXT<6HO/5MQ9W4O977%1RN'?HR9^9=!DK)
M.Z[%QR@-YK^?>!Q!*80#9W 9"$Y#'X/%;@7I(GIJX5Q?*B)@./-$2A;3@VH^
M-_X9>;XZ_OM495ZWYF5UN<)C^(#=;]^H+5QF1A.8<IQ6[9\AN7+'=N@@*+FF
M,! Q-[P#O(7 B7DM%30;I(>8]U5$Q;O>Q0:1IP]%> =U841K<FST#M[K@6'8
M3 L0!VS#YD1N_[9/(TJ@0R''U-6L4>(9M/6M$2M?^>RA^MC7 C,)J3LZ]DY\
MMVA:DPEL@8&_Y\#7MBG9 45T7Q8!K4PEBIO+Y6HFA=Y4D7+9%5<8H/QHS_3A
M.-=[C3!>>[D)*IXIMX.&H#\$(IFB W0)5@9;*[@YOS&5&?.X(WH^"E4:'J[2
M?+, +U$G%?WGT<?EPYX>A@6POB./QPC_[J@&AOG%_@2';B S%#G9,OBZS5ZB
M,"A[\F>W:)"ITN?<'1#*WY]F,Z-WCWOEY%#<N:.[KY%K7)@27)Q/4XR;P088
M&4[.<!!! .QSKHX;OOYT<KI5:F#7<9V,X,1LYTRQ'3>='M=\S<QDCD"B"6E*
MO/)W,N \/,5'&5X-IF'I*3EL25#+LLX SJ<&_$K6<%2YOU:EP@CR+$^KVCME
MH2CJ[UL3-VD(?TBL)W3 )U/F4$SY'8SC3&GH4;91:G; ;/W<V^M6" F]=2ZQ
M!DD_HR:?ST]]S)P-]CGDA(E>>W.M,LWX/8R=@K:AFO!UL.6)-%1Z?48LPO;3
MRK/6SX1U5=&>4)285*Z+=^?+EP4J .Q ZP^Z%:L>Z[L^19RK7.R%3ZI39_"9
M3(,KE;:EGLL-SI%[5"*K>X2&^3U2YZ^>OMXYR04_OJ@X_[.1+3C)X$R'\42$
ML/S[R/QMLFC;3Q@HEC 5!?T-4HT=7YU<8I50!UIBW-9\1QM4D@.5!\/+G3<4
MNW)GKRN>@20FX<@V;$$" SGBFI\5V"6\Q6.1B?1_)<O>-)SU#-*C*C)@A_BR
M2=5B'M8B(>A]0&1RZ[D6T]$GMA&;!L>*VGT99AZER5.'S44,_"XD?/SVMFNN
ML >>O W;A^9YCG8"S>>'E+O9LN.52;UY5=_=$R.="\/%++\O9.9?N7.J@Q(O
MHIC.#&(1H)4*(5AGA065USO7T\GU".;>"K<)MF%4RORYVABIY#!CJZ<R^L=_
M'[KRIBE?HW@F,=Q6);&I!:OE]]G!TAIE#[V8"9N/&06:0THQ/([VIOE?% 51
MO;/'"EV! W<GEK0;:B5I%OH= GWOQ 9D6)-=F.]-CM]VGD28,<49X>P!K"@Q
MB"R#Z<8(@D^UV >8IB.4,6/ON<\CJ(MZ VZY?&D/5I](OAIL/(K74/67S;X0
M$MN&-&!*04*JS-=3#9@AIS;GWM%$IDS[7P<;UHJ'3;V>36(<-'KSS:O5I0,!
M6) GMU#@H>';"!2*]/(G]5CU7 R69$Z%@L?$.KA$0,?NU8*DD)JC>V1V\'C-
M;AWD7__Z\'*5U7L(N(A\*6/S<Q(M:EA)1XB4(H4]@,5P%B(H]-H2:2*%B2:I
M=]SZ>"GHTZ&";['?I*G' /N@AA<>WS86#CYKA<0RMR37L,3MZK7W[1*^AMP*
MB?LVX/LX_3AK^+J&280N8K5(IJGA4@1> NUR54L/SKM++??;-[':HU='>D=Z
M\AOOQ^5\OG._5V#QFWTR&P9I1"EF$ Z<PL'0AUD/ZV:4>Q!U&!RE4NKLZ-5Q
MK="UT%?CP6]R-FV/]',G?^@TXY**&O#8R?TX"=4/G\RC.[*>(WR0X DCBC\4
M*X9@<5Q4@^YMF%CGK JM,+4D6D$[\F;ILOD*K5_QO$JXBG6ZF>5CV,OTET_C
M$*7X=.)>8S[ :@Z7VJ;#=*()W;)*1JL]F?FAH#2FFO;5PU8]P#UPX="^VK8O
M(T5!Y=Z9,)N=K2V<1.)<3%<DN<8YAW&#C!EI5L !94B7$P89K>?REK1G)0I<
M(ZQVKX2?^S L5'1^8'HN\J"O(OX>@O)]&X9KQ',3*3@O0Z MX4B".WC_U1)F
M]TA)BNJWF*+;>K27V:YOG]6_OXR]]09%@C!B1SVKDJG%.(0^ 28PK.1UY_I6
M&)0AN#6-K_,[$Z&2 R:[#JHY/?3JBY2)M[V;=/7(_JMO_)QE7\-,>UEWB927
MG R_X:F$GCR0C^[&JD2K46<PN[R\'T]-]X?&JMAL?LV>75#.O>#UZMVKO:*Y
M.NKUK')LR/HDDJX*Z"'$$$'KV;,*@";NYK7+U6\FM"),OC[VZ>,^(Y3W6BX_
MR_5V?SNA@P >ME_99!Q$<T9%L# #V!V0JR*+U!$%F):?C&V>(7!ZZSO7;#VD
MI$:LB]$!9TK3?!IU+F5>YWIR1^[A)K%A.!'-*4Z!KH1F8U7&/HB=@1-L6>8Q
M8,4!+S3]OG/\JUK*E/OE]Z4^-C>-#ZE%9N])412"83ZRWR,;-E?R&>&@Z7H?
MO@;91Q8&?]B-+KK>/#""TM6_F\EO4<PG>(0G3C7RY1IL_KC^$'N<")PG?A&D
M2XR%&ILP7#%CIA) 6$4LK'C"HK4Y>GU6S%J,53#C<\_26M'P9&EY!V6>QJ#8
MWS:6@#2E'2*PY0GK(=;/4P*M#2Q2"Y/;AF/G;/FEW=L+]^G.'K9,O".!6I6T
M@+?7Z&A*I3-$.O% &&'E-]\J"P*A EK02^X&:Y^@ SZU7IT@91=!L$4:#)AT
MC7*7++QUW\NVR?M--NF#7J/5M?34)'K\#@>1MP@_(JF+'L*J-H6+I&-K-GN'
MA<'%D^+W#GPV1KQX]2\?J1(6D\_NB;!^^45QGGO?QC#)G"T(!5O</:P<MG(_
MD$!/8M4R9:&UQ-N7"YOA))^6-S5^,H+7&OK5)K-W'2\,[.![PDM4)5(F42)+
M[GBFI B]<9QX1;WHK2X]QD[*H1;XU:-2W*.)O)CY?>.P=?L[2>[/"D=7B>^O
MOCIU-?@[(8X(A*TSQ1O9_%. T;S5JCBG9 A,@Q;,*KD0^-O3FRJ2J6=X8TEO
MRNS5IS\V]*:BU3Q[9=$CJ&\M=0%X[3]QB NFHLRKH"-M<VZMB.9/P76'2O44
MRXPKZ2P]V$SY+;U6&;97K"PD)Y=?2*#FMS,WA(*;SS YQOG0#51Z [E6JY>%
M^7/S.%L.&<7N-Q;A8>0^W3"*QLPN?<F375H>;)7$R5^8IW?^DS<R)&1 QED<
M,PS%T_I0O"!GJA)0+ ;TYNS)<YIH-2^W"@P.XQ=X4GKG=L%5"9<*;=A.:XEY
M<@V9*9'!YN]G!$6MH9*V8;4BJY%S< DP5WK6XF/HFD]CRZ,]OK/256+''ET0
M*L@\RI5W^Y(]4V("LNES(J!Z6=<Z#UH#S**M=[?M^6BL2K4<U_Q5*4PZ='E<
MY7#UBWN&/&[*NB]/X M7A:U#=B SX77^780O6'H&I%P4]C"Q=I&YIV\.;;J+
MQM<%EXQ&B*)MRGJW?%-CC1PS!O-YNE*:HJXF?S6.DVSZZ6AU?SP.\81(RJ _
M W<SI-"[QXF!6B3_/AKHW8&19R#H;?6J23T3N?YOLF<5E1JR;7PTCE17B4IG
M31Z'Y?0S Z$EL]A=G-Z2'2@AS$>L C%01"3*O+--=U21"%224[UL/1XYS08X
M^02$S/ ,',T^[6>O?B,F[EI9.HAD"Q>,Z6MEXH6W8?X(\  43FGY9#B!?VAD
MNYJ6/8V#-Z:<K1>O&AVVBPD^%);POHK!%E"#Q#:(E6:JRAXM( (7$%-8:D1%
M.5,7U 4VD U,=>(G)DN2;#NZJG8GU-7Z?GR+WK<]\"%?UW?J&W=$")P9;E,E
M=#-6$UHC>EYK4IT>#Y"S7]4M.9F<#9BX7]SS4"P^2N[(Z[4=#>L6,_75#^4B
MMF$2[,-,(U 6&/4"^VBHGH8'(LG&NL_LRH.;>WZ*2CQ[9>UE(PO+BSM^D><>
M!;+]1!XB)8XM!%ZGS;,%UVF1]$:(1T&@&8H;,_0 D?*M^LW(XET/P2Z3RN8C
MVB2I0$F#M^FVW4['NE-?1DBZ_AC%4JBXR3ZVP!+#^3M9GFDUCTJ[91\'4:Z5
MZ*6 <P<^9)4URY+EIGM\4=J,T^'6'[X7AA[^YI>MMY&3*R,=?7?'%H.AP_X,
MF=@07*(D'([PPZ6.SZH#R>7&P)=@YX)1LSQCG3JG%VXY<J$W?!>LSNFHP[O)
MG(,]RC:,M-F%?XU*-57[@Y0T=IGKO[DJTAD>T%ASO^X[>Z1Y;LT[J?(Q_'MM
MG&J^]%W83C=S- H*%?';L/=B;7+;L"\=5"V6T:6)7'9OVSX:8G4*TO--5B,V
M@,@+CM39@\Y>.S+FK&ZC;>CV4!A\->BOOJ\#D7(QHT-182&:TX]O4F-+LZ9>
M<*WBLR'X@015(U<F:9;SE,9>W!2VXX15VDJ575M):5^DZI3KH+"0R^ZP7-66
MA#$?7_5I@2WXW&(W"H:^!)R[3].:0V;5X<6B(MWJ/1XI7_KX>]=:I9:2B4JZ
M:[^5UZYW:G<L,*<"D "*S!278O-[0B+U QRAJ;$%#*H"X!+UZJE:ZRY4T]K2
M_C*O*4OZ^X*"".VB^YF1N.NM%26%.=\N&E[<V>;R]\=P?]8SK*\(J&] ?P1^
M>?"AO"RPD7TXSQ8,O;:ATRJZ++9$\ESMJ;AY6FQZH/Y.5JVYKM Q&QCK41MT
M\QBVX^ O<E8HPP2)F46*[*<Y(5E)J[*NVS!+VT=30AK1C2OOY]J<GCN8AT^D
M;R%Z9G4 '*1H F3P1Q_FT&B=I_B9NIA*>]<Q@G=C?=UMWL4"-Q\EY9.\MMHP
M ?9?:(X[RF/=N8D"]3A3G3ZT@O97R5*^KUMHES#'(2P>G'BJZNU+4OD,3G'R
M](6^K);I_JQVT=^$E5J&)IJ36OL3V]& Y,5P>;''&DUW$$=_N]30CE6;QFT1
MZ O%N,CH8'__HXRSW)IC-?<?%JJN%BX8#L%B)P "6S 26OHA.$%S)E/*NNRG
M&ML?I*1I:8Z/=[ZW7=*8;WV4+790[9&8S*/LG2^-)%5VY)XDQ(*3M G*\,H,
M\&T;1EWO(Z>?D$IHU7[.PXAHHFJ<,?((R) [C+H3YXD32#C2';=#38*3 <S'
M:8YCPH'P2. <$50;[K2_C><QE?E^"]MGHY^Q*T3?3N[-V.\*Z<JOMC]^C+S-
MZ%/MRV^,W&\I*"FAXKBES##C5,/4<P9 X%=.,8Z 7/1)<).ZRN<,ALZ92#*H
M?"FA^VW$N_>5OZ[-_N59J]/\P;CE7H%OR).F^PT/J7&FA7_#)P1@#X?04Z/7
M#E8^Q%<M?K#%JS;I6Z%Y?5.NX$2:*;.ZXUI._Y'@7D^)NSX^F>E;.XD/9E"=
M\.K(5<A#\>UDP@ 4<\_P7*LI?R,8^(HTC;:>>*44>K@WX!=C8R)K[_G7T<.3
MSM:N24/##_8F.WS /CO\SU,D^K%!V["I%KHQ*QEMY$O%D2;H*<#$[=!ZM9NC
M^\=1U>&WSLLR,V[LUNN(U*2FFJW)]%K<&L/\]2]E@G>V8=4B61#ME>?9@CLX
M1W(@H0+,:T<(M^[I<P*#*P.109\T0C5"IX+W=S&6]I[9F)86>)/K=@V#O!L7
MF\=0QTS!:R)7WU*F\'!,/QEN;#A?J=-[,\4QS_SMC 8$LBX42_X-LDZGM\2I
M^$OP]>&G$NB>K/L83>8Q4(162\72$1EMFLL;2U@1/=<ZCZE^?8][L]PW9T*%
MTL)>ABD-YND%<(FW"'1C-+ =3:8\ +87 6H0^K"D33;_[SE;' ][R/F!?N]]
MWI3(OY0,G.SISO%[ZS0_I/JEQ]Q]UWW0V;@\M/ZW2#:$&:78PCT (4F*I6S.
M*FS;9?L2>9*L9U.QO,LL[XLA[D+MM1/?)DP@&X0@); %1B%)GF5EHF_A!1&!
M^"FN3@5)FOI^XV:A"?OKD2%5.RR+U6_D5'8=$A*Z?>I\3I_^RO_S% )F*JL2
M\2]!* %4&2^D^?_=>+DT^-9FGR ALTWMP=3IA.Y;,L5;4TY-V?0-5XW=+2]5
M<E>.-V&/F"E9N'CV11"8,I. +3T!/ ^1NT8;[B;LF\&!%DP4E;P*3[FUM_"'
M]BF)QOSPOR[*;IKYN^8%AWK38Z=.^A[9L>7&\,),$VLB5Z0H)@BJ_^I-&N$L
M<"[CY7*)W6C8[UU^^55AF2BU@IP.V7?7<JHU&@/:^[DSM[+OE[O^.!':5OW\
M$G]H%<6F<@$6]_V]C$=Q-/<^]@4BA8BL]6=*/%V<TXK'AI%!=42/_&&1/6!9
MC]CW8C'0_O$)D[*D5^S!33'1KRWFXK66<4G1I?^-O?>.:JI[VP:C2"\1:5*C
MTJ4ITI02%6DB8@4!(2I=A(B @,8<I!<! 04;! 5!I40Z A(@%!&1I@)!2$(0
M5-H):CB2PAR>=\V:6?-[9\UZO^_/>?Y(6$!.]M[WOLMU[7+?5U_Y/+@O@BZI
MP$[W)/$V\WI6 :66<VV!>#'HRMILL6,PMZND($1MKJ%/OE ,&TL%3R#'8+\6
MST1UH44YFM#G0" 4/.V6<Q1Z&A9=ZCGF'N :6CN_V_+SIY/M6M;!5JLIDULU
MW&)\-?LM-N!G'RQC6\X1J C93A+"4S'(I;KYQU5!05(_G<4K.KOJ7]E%[M)K
M2<C8O'AW26W3DU0.'!QCSP/MNZUT_RMW#I6P->H2EK(+DZ2R@UMDM>>GBBD3
MFX),\CAYZWBW:%%(O?/6-S'EU\Y3;A6:L&B$^W',6=+_UL$"Z4UL-E-N&@W'
M@'@KP<]6&IRSS/K[] &)[_7I$67SCR8YU^MSKQ)=L]V$SG@=[+6T5Y[O)/G!
M<-* (Y7&^@@EF'9@Q_-8;\',5(Z3V#7[)IFZ3W<]S^_:[%F8$6Y]]=6F2Y>^
M(N0MPC"I 'A5$&;'E+!V*FAG,.;*,H#>5OYTF5)E+L7QSZ736[.Z.K-_?'''
MN0QZSLU&6K]X&7%E]AR?4G6<"XDV@QZS9H7#@[-R8NOA/P.OD>0^8'-43L?4
MKMR//]E.CPZNE7_1"0H-"KWFB#(\Y1*J^B?+;_<X K&)/<*VAQ^H 19N@W];
M=^-'J H<<UHPW\!6FQ=0TBG[+;^VVJ>J:X8/7Y"JXC/99-9F3,;W8L SR(T3
M;(N?RR<A?Y8S]U6+#D/9O9O/\F.:_S40H[N#]EZO<MM^]SWV_)^/QO9E&^[[
M9<>1/LT3RBP"VCW05U!QZ#IB%SQ:%3O(@_968? K3HE 'MY>=R3;OZDQ9_'E
M]1*-QM/!TC$V^;GO^7QF\-=@AK@%\$,ED,!PP04&Z,T3UJ/EFY)OC";^Z5?B
MG!EI$3LZYO9@Z5O.J90LX7-? P_;--ITT#OJU7YI\:WM)LIS'Y%H3X&JI,44
M)K(;+;*.\'/.;+*[$T%%?!6R< LL)N]WE#/LW0I;<<_NO-2#"B81YM<DA#09
MRY"9*D]$G>E,CTRT,/B'OB6I>-JQXKF%/@K'<R3R3<9;T$4?^J57%Q@/W-KN
M;[.^K6 7:O)MQ1:O#S,A"[R,%TZ86T<*RHQ5R"#*/@VEC9<;[5^FW7EV_FW)
M\Q<3M:^*LY_>\8VQB G@6YW^G]0<^8BA3/!$W[(M\?U4\%19)J3AO$AE'_"
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M#-")BE^_?_<>_J-\=)+14G^GGK'M?$>OUIT&#4NVPYQ\(;)C&=J9M-##-N?
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MKR[S=)@:%?YP:)6,(GF,&&A4@[_.WZM.%2HUJ]_U42>J<5.'P"E\Y"0=!88
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MD$GJ0(^K3#@PD1Q52G5#NG%9^RQE<L'LEM7D/:[UQWV)"/VKW2U?1TS;9L:
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M_^H8Z&V04+N\#<)_>*%*KKK<X.7[X85SX)C_N-WE!:"*1/N%65/<*&]+?6L
MNYX3@@L1,A\"2=MPFD6M>32J,N[@8'#+2<N*IO.!URZ_+E[Y>N!%QY%S>[_.
M+"+"LE+?3A.2-S9"D18FK<;,V?2BOFO/*QB?C>V#*2<DA$^JBH^IA?\I%'^D
MLQNK'*4QT<F$-!C=!\[<^%#U<-<PZD2RYP%^W7-'/*(5SV:$#CDLNA5LAB9!
MS'3E\Q<!)%&>012F,^^1X\)G/2-E/&7%P^3CWMT="][[&6+\B AIE^-/&<N;
M?UCMR.QP)Z:'/PYV"3A6%9BG<,_A*C.FL_%._72CRWZ^[:>_7R:2E]-0HE9Z
M@?OFJ2(\=0CH_&(R*L[?OYSTYX'!I=2S[*&:C@69I C-73$'1'3N@NA%?E!N
M&IM<R4&!$XS(> OKLG,A[.MY3Z'<+TNS$]L%/Z1JR^?(R[]3#@*ZK/1 XNU:
MQ4R9J(E."C[S.45C_JWCV;<94U,R'PU7[ ^_Z.7+F8HQTJITI.?U#-S&*'2U
M0\;,T@XO/=DXKA;DW7F]@>=L]I>3HHBU")NJM=J).[E1,/[P.B*^:+JATU.4
MK.#_L(9MUWF@Q>1$2/?UOSF&E5>1\HL'%6M=!,G$5#@\X?<$)'52A?'J 2I:
M(]8+!Y*2(AX8%(K?87Q(>!B6,5ZQAM!Z1M(FT:A$2$=P,0O6,0%N!2E@.9Y0
M.W#'Z):=-11\4QHOEW9\\$)-E QQ>:?YU!XQ@MK>S,>#!;\WK=787&N@*N.%
M?N"W-3-YI<S,COHU\?AGYHLAP-8)]><U3R[Z/&CMU%1%W(VNP I U'9 $F>.
MG8:#^I3!\)])C06IP%<!E/A(EQ'$U:,.BH8-.S+$$9=/GL_K)&22-N/%SU/&
M.1CH,]U Q FWSULN!6<7=&E4B3$C]>[Y7\:=7YXF>:]^/)I]+%#S[.<>+[?)
M(]43GNX?JNV,KAA6EA<GGMJ_Y6K YAO_W&@@SLCQ=FWDR_NYCAA:64?,[@-[
MUA$Z6GQK:\](=S%0J@%/M&P=8=>WCG@P0$9QRHO^7S^^4;B<) S0B@#PFMQB
M*(PE?F]\,"J-%<QTXN6\P@F")0V%7140W@#9$<'_NF7H2HB^;P9MDZJC4H/A
ML=3CVY]U7RUIG8<?@E_M1UIU\#T >'1UHT3M)9+*]V',3X761(K 6_5X5U;>
MC5OSF]5MKIZ]S_#UQ1X61]RBVD2-<J1J&.B,=43 P)@F;:"'FBHW>![*Z2:(
MA3MAO1KKZ\]YYR[-=FL_]TW'GSFUU*E%"R=VDB M D=9C^V/$X=;SH=([=2:
M8@J,"]J(B5/H*I#WY@K.5'KE<G#(!)8A%^]G\LCQYJ?X,F3VUODG>PN1W_U2
MWX.:Z1P]YKZV-=/.3+Z@O9</:"8;E=URM/NT8[]CF=NTVZ7[SJMNRN=N*G L
M!F'L00 ]"9!NZ:(CT[J-!-KEWVPCB/&4<7L^#0_5D;:YG>N/B)3.'E"NK:E;
M?#NZK,DV^JB:B*C:G1"IEW@5.9FZ4?I%>$,E;\/]+<29;?0:!:D1.3*,MB:K
ME]-ZIS05!#-Q^Y]W"7ED5AM_U;"M.]OPB!)U]U53CV*/M@AC60B&GI#6Q@45
M?YZH.AQ3^=]_1M-R": S6@DRH2Y2;MUIW3["<:"S34YLG%!]^?5OGN%3U?@'
M=U8[4A'<IF<D0=Y^>(K.P;CU&Q)2RZTHQ/G W<C!#Q3PP8;:[W@NT_E3Y6^A
M8"GO>H_WCH_E]P7MVUUE6Z"1_OK,YK!,RL#X &.9C*44T=#QI !JW%J-%^3?
M_4B\OJ+(>1?_76M#@?%=,PM9PEKSA/N?DRXC%K6(<WT\D:YUA* E?@)=0^1(
MD[LQ(H!/4+[L+SJZ8Q+?8\/4E5-12IWY:7KW-6\P?2E93^!'/*LL%OTI1"D'
M\Q80:M6&#!AY'41Q7 "$+=-;3>)X%%*"%-1AJ^L+<GS@$D 8NQ?!:#B*^/Z"
MV)4Y$<03?0,+9ANWC(2=Q/*$\V%]-H8N%E\^T!"_%!*,.\F4<ZF-G='],BQ4
M^3SY*Z%Z@F*MO7)GN#S1GZ**,A2V6&:@.=($GL3&^9*]EUM1$&PH_)K@:AQ^
M#T<']O?E=8Y<%?+Q&(]FWY:$QI&*1<J7:Z\F5*)\4I)W&]Y X/\,G==<(+-M
M.08;H-"?*L0;0?'_B7P+]J0;V4=8:KB=T'V1817P_,3Q7N^K0TTSB^$7<U)7
M,+"_XD@3Z0!G6Q'+ZO,ZXC(R^9'YO&G)BJ5.AY5\(NW(VL<RPV8;P0>'5AC"
M2MGO('7OE-?R]2\1:RZIG)U0,)/-0PIQ:WB2$[P)-)\&J!G'056XY9_NH"))
MKW\'E'Q>.!>20G.$_!K'YM_+5^X*W"1&TM%&^P#M) +HG@F#F/;3'%&&02*J
M-I(L9*'-#**G?S@!9>L=&#ZG^T?+LP"]_]*]&H\!I:S:L,,?#NK>:90XM0<Y
M=%GG'G2?R:!%MB?593*0W5B1*"=BAFY>9^NN^M>F@F9_+58].<SNH*+ANF #
MSY$+7\(MCTZM?/RIGDM9&O;-UKY[)]'EE/7F_5N4%!!5-M<>)?5DWJ;8Q2]Q
M;K[B^('/*Q-*WU=1YUU5=M4[.OICFZJ/G=\E-;9MWZE)7""TWQM<Q!MX<=S
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M!M?[O54U-W%\,/52T&?$*GB%!YV]6*H[XJHOV&0XV U8T1P0WSF%IGN;IE'
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M!AZP4I\?%%/HZ_W%LXUUU:FUKF[=J?"\\IR(1KI/M,Z&TD/Y.Z;7GAA'8;R
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M#O]\_OG\\_E?^!%;'OH_4$L#!!0    ( ,Y#SEAB&E:4R2<! /7)"P 5
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MXRCV(2(."SB/2$3HHMKL>2?7P7A6M#3%B;U^8)DTQ,$J!8];\F"UI:^F-BQ
M/JQ0Y@523]6T; ')%^@8 Y(ST+%V 5J@KU/08P]<OP#0K#T(UO]\)8#O\/1:
M@%?>!.QAU6P/<CRI\Y'C-P?"_V6!PBP[@CTDNKW"XHAZNTBW27VK5O2?EX^/
M!:=9/>!7Z1(IOUU^_?:92[HJ^X#R8!.K^YH^Z#, &@[ &\%#^8N>D7@>&C4K
MT2HJ>KK['"#@>\/!_VO/5%26UI*M>)[>K,:BLOC[UJ+ZBWH+G5.VN,'/OY<]
M]?$^*^ER5:X++HZI_*KB#^<,%,51ION2!7'P5.YL<EOZX+OD -0L6/B4-84]
M\B&7G/[I;O7TJQBI_88IVWZZJN//\N%J"MM]MKJOZ7VTC&>+#WF55<^_KY9K
M83@5SQ^SI=@0%A[A/(P#"EE, X@"GD#,HA@BSW=Q[*0LQEAERSI)8>(MJJ$)
M-D1!0U5M9SH-R_#JM2*LWGK5E5-Y<9Z596 YBG>;Y2C^LEV.IT><90&>%:A;
M<N<?-' D?!1K%B__SG$A\6CM&N)PY!":0DZH"Y$3!C#A@0>9XQ+LDY#&J:_L
M'SA&8>)%UI $DJ:\W/,U#I]'\5 XO(^54F]U[0MXWHY3E%3C]#Q68K-#L?+4
MZAUOAX09/+4>?7&^P^@0WSMGS,$']?1&652+KV).>/O-Q(BF?II$T/7#!"+,
M8AA[40C]%/NN[Z*(<Z4M>6_<R<^*XL,KJTQ^39\YEE9+'3_P_?WJ 6>YXDK:
MQV)84XR04/?<9RB<\JHY(<K0H4Z\TCO0B7]MM^#]T6990"=$Z);-J5^;^5FN
M\B<Q :OB^7>\7#?G.U[RXHF7BXABC!Q/+!CN,X@BWX>81PQB!SMIY#$6IXF.
M%^8TJ8F7U(8P*!J">OZ6 8C4'"UV!-=;:5N9-T1!1]6>4^6\9):\*0.$9G6C
MG!=XWW^B\(;IRJ6%4*'\/6_^O,JO'WDA*.1W[_!C5N'E)2EKI^U"[()BX3($
MW<0A$+DH@#%R,$Q=CQ,7NYB$H=Y*5B4]\<I^TW'R"V M+R#+P:KC!N"R%%9&
M?0&=M8^"-]VCO\AGEQDFV3*K,E[^65<O*$^ JIZ8 E9=O=&A]+Z/TH81T'("
MOG>\6/31Z@-@3;TH$YY9W>@"<JA^M$?0]^/^EK-B^7SWC=-UD57/G_]9W109
MY>_N\[L;\?4K:);SHTRL201Q+JC++[QC 'S&Q3]Y!6HNP+M[:7.I:0@%3,Z[
MM>W!H:<!%)&XD#YO*K8V.WYM-6F-7-IGAI[-FZTF8M^1K?B&F?W0A0&]6ST\
M\KRL39/+HI!S*\]D\J;W*F?94\;6>/F5__<Z*[.*?Q.FBV"AB>!T%U'DN:&#
M79@&-(7(BQ.8!)X'0X3BU$64B)G0L2QL,#6QIA L9CEG@,HK\8RL:]/Z43QR
M(8X7+4.@;#B2X3V");,@P%$3HV9QS VWGB;:!!/VV0,]_IIDBBV'%V##(VB9
M!#?#,V <<F@#,LMAB:-8>I'011L@G@IOM#*VF6K]RI=UF#LNJN=;0;D4YI7@
MXM/F4ML)B2,4/(8^"APH_A_#V"$<8B+4J9?X:9HB';5YCN#$*K$E#VKZH,>
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MV+$$2LG3!2AKKD!6LP76@B]Y)&L9 V^RO'U",[K69";43)&)\=53>'UH-]R
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M7E:<]_9!-TY"-_:). L1"E'J<TB(AV""O)CQ) XX3E5SG89)3;P4&X)21UT
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MLI=[]1<Q=/5>'#<^XJRH38ROXFS]<57(41<\BECHN!%TN1.)(T*0P@0S![(
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M#;T I43)A:!#=/KS@.0"E)(-8=9+/K9' 8U-4!5#!5-@ F2T3?UY0=&P$R8
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MMHI'C/P.%\5SVC0G*[^LJF]K\@]Q<+I=?<H>LL:16RY0S)) EN[R*&(0I5$
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M6EZGO9\M$M]-W2@)8!IX(40X"&'"95$E+XX\CAAUF%+DH0'MB9=VRPEXE*R
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MO!+'R::WZ(Z(92W3X+0<AN6==X::L:+S,1%VBS@??<)L!SQY0&FZMRR<D.'
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M"'.>$.+ .(TX1,A%,"8I@4[JX0C%:< ]I7LF58(3:[66*""2*GC<D-7)K5)
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ML& 84H1"B(3(U?9,0!ZI7Q,>IH51V\)7G&[:#?'L^C2U#9G =E#=;]VG:<:
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MC"D\'DSD>1K%*@*+TD2HWMQR<Q(5&<Q4E#9+"YJSR,10F1#WG6/6UT K9_G
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M0)_5A-9N>IKD#1P05]P=.@@MA;*!Q[,4VG:>D%_4S5PD%TB-NDZS""SG4KG
MX<35<K*@;:%KMV:36M:7KO$$820HY*D*8\=Q 8LBS&"*6!B3A.4\3\TJ6\^)
M>#;X$M(?O-HUM9H'\FVBHFD-ZP6 ]-RSN6(;!K9.I?20+S(FC[-BU LD%JX^
MO2[D>;GIR+46KMS]']O[[]M]C3?L8REVG&^^[G=UR?C[4KHI\N&H>M;=\[ 7
M]\M2*_E*]$J,$L*DQD+!:0Z1:HE=\#"'G(1YD48,Y50_$.V2,\^:'P5A GJV
MFM%*!DZ'TR>@X>J]%JYFIJ6!M&/L"&W+VNE<@?.B3-7:RB+&[O1!&'B#K_5
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M;:9Q5B(;!0JF9+**%EQ==+&0P918P[C!Y+46P8-?#NUP5$^)+B.(AP&+B["
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MM$5)KA/<-0SI@F@:[GNT2W*/D _XFZ[%=0^W@9E>$'8[(^X=?C,S[PBOT8_
M7!K+?2(<H7'R 7&UIMTF^;WJ>TY;*O+G-6]2I#=L&*]>"9)0E$41Q(E <JM,
M4ICS.(68YA&)LR()B5:MI@E1SY^+(0M-]1T>T#;;-&M!B%F4,!:',,6!_!R+
M(( DE?],&$]YGA>(%/'J!Z_(]K5 '!)_LS#J12!<0V.Z3SE2OP$'^@T\MSKP
M&$<C3.1U%)/0(KEH9,($A)?Q":-[+8LX]M6F;$X"-^QC^:?ZJ9]H&O(L"9)"
M^N92;HAXB"'A&$.*N;2OF&9Y8=11YSHIST;U0/@&B(YN\];S?^W+)_/V_B.0
MZ=D!-T"8:?^!9B-Y3]5#KO6T<*ZJ)JX36K8R8E+@L^J'Z3O,C^^:LZ#[QX?_
MW/[QR^:I?+>IF?SW(7E&\R!O?!7/>MH0!_?E8[EYN &2!?#+E[M/JO-D74H0
M=!OZ:J Q?:CG#@@S/9W$ /SN--E'7U:K4[Z)I1<[[],3<7CRIWG'S+28KRI%
M!\L=%5[?=6,!CPU[,RX(HPA&F#"("D)@SK((9I2D <$Q*T*S9$4-HIXU_,!"
ME_?6,@%Z+G3:R=KCJ?=Q=HV2F?H[ ,@^V49#8M=Y-V,D7R<%1P.$J]DX.O?:
MUB[6Y8;7];OM(Y$DFL;BAPF/GYBD78H2'XLHJ71MY<="-9\[AOSEW_:/G)T=
M#:P02G*11SGDH0K*!RR#!0Y2*"A%!><XB<SF GCEUGL$ICNM4BTT<7=:M>&&
M>P2_STO/DKV9IV!F GNVP8!O<&0<##GOCA-!SWO;B'/09ZIC7\4[S@XA7=:7
M+H"TLW)5G[PN7/VZ .SGQ;1+$+4XE%5=V=67YA_E[ON[?;W;/O+J&]_P/^3'
MJ.D'L@I(P=,BXY )G$.4, QS2J75S^(LS K"LT0KY5J/G._-XF:SEY[18[-O
MKK^73TU#.E"U+*C35<F#P6'?-'P:IZ=.03$SFSUIH&B#GO@-Z,AWW96< F)P
MOND4&,M^B/, ,CN?U)9W] 1R>I7ESABU)3HY1=2_RYE?K.+CRI@VEM=J"VBV
MZ,*>4'-<HU@! UZ\[ OM8/#GIHP1?VV_0P,8#4="9Q7;@-.6_O?W[5K>4;=M
MQ%8BBO(@2E.8$76\$Z,48A)R*+> ").8<*J2L/3+\L])&'D YN7W]^J6MO-&
M1_;_:8YT=IHE'R/8<$1HH(9)1!&)(>*TZ0>=01*'+ Q$2D+I*;4NAMS\5[LE
M$'I)3M^,M/U^9X.2TR0(PDR-"T0%1"D-81$D"*8$!R%C22HRTH'R07J[BT'2
M$UL<$-V XAP1S;X8[?HWX':WJTJRWS5[Y-T6W&&W=0;797(6(#PCL' X\)J
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M1?-&M'98N.I.:TA]V9:U=M"<];&U7&9V?%KMZG]^;I9O8Y49"WB:,.E]HI!
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M']+F@6R\/TEU^HO2CVD\Q^[1*0 ;1Q1C#,UX:9W7 6$<D>HBW.+8>]8@%P<
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M'0+R2\?/K_K>JL_2_^DZ0O_0;'DM7\!6!ZC63:/WR70)#>N=J]$&",1&&>[
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ME"$<8HERG_@HYJ&/99SGZEP&V+*!Y"??UFM^JAOON25=U[ZTQ$%[(52O1K'
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M"[F28;48IC1&%K$=Q=$&(W?K9<%>]K-M\R"A4>I3%.",(1QSH>(&'J'<5W]
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M).H95-+!Q]],]T'SI%I%%,_ZS6H18Y*$7&"D?*%0=A\KN_>5=\P$CGTBDRS
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M1]A7FR%-*4<R"PFF29#D!%2+.4AMZBL>1;NIC?9^%T23'IYW9*$NP^L=5TH
MWNWLY>\1=MST!Y+1U;7.(*UY[W1,Q#ZYT#%ZR0*D\4YLWI-2?/NI8N=V;D"6
MY&$<13X*,98(LX2B//>ELFHBA(C3..%&0&87UI_Z]J8C"  </*.$83-U(!K,
M,'>T;C08TG^,ST P$A( HWB=L':XB4=".T)(O"S)("3BF=?FPT"\S/,!Z.'
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MCYV^.W% H5/@9/7B=81WJ%FWCWIB,@1=[(S<PZ;N0F1H?M-.6B ZV&61+*'
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MIPZTB!U.,TS-*<R-348G*%LQAA.MS(86X&Q9D#%TM#,FH];1"\R^R+OVF[*
MX=-^UUQS6MDTPK[-.6*1?,<7QAS%H4<0]AV;17;@^+![%EU $[N?$M;*V#/;
MG8!7KSNY40N&3&@,<PZ5LB7D@]4&-1?3#*EE*%3IA)DU AE2]CJP&'Q>H]=1
M<<?JS6:?"V_P<7=8RQ0TZ U ]PH3&U\);!7(\E;-<KTM-JN/GQ;O6YETP+3T
M'C*&=W(S/,!,4I4"LV\3AC75:Z34O>Q\794&5;MHL33\M&:-S"D_"AO/OK!-
M65#ZM#Y40]]73NQY(281"K OK]?Q %'BA&+KY%Q.9$]]1VG:L0+6U)4Q%;)U
M 6VAA>P]G+$OOX!U,3VDJ>VIAJB V7 '"^:[ERAH9ZH(I@=IWOJ7895O2E\4
M/@(SZCP[BIV;;M[E53.4QR0Y;4\;F:Q[RPX92]8%4JO#PF=>9TZ+@BXGX8[K
M!@YRX\!%GL=3%,=)@FC"0TYBFGAQJ&+RHR69NG:&BNU+'"V;=R.0\KCQ-/<[
MB5G)@[D0*&_*KL.8SGV.18"TG(KXZ>Q0QN//XFZ,T50[(W,+PEW5FZ<UXU6?
M?[JIYI)4VV@:DSA*W0B%3B*O[00IHJ&<A)00&A+"@M!7NC,[@#-UW"&1K0:Z
MGG.C[F;Z*!IV(H84!T89]W4V&&8HJC;"$_2M/IN=*ZC8MF*5QS5ZLGXX;0]?
M3]NO3-Z@%S(OZ(M\K9JO7-=V0\>AR'6$<7II&"/"78IXX'EQ$,1V3)5NR?:B
M3&R?$A;EIZV5U\#6H4(&=!_MI*C?0HTI#K-/B6@)2*O!M!8&=08T6S6ANUZ?
MU2]R9\LEEK7I_@K\9:CGZI">O>U6.S\\7Z?5(?DOFJP./JQ9/2D[=KRF.4LO
M1GW+M,A2XCRQSSM6;8PDHG;*@P!A0F1KI0@C$G/IGHA'":7$#0)06:4Z]L3^
MJI $%:+41FL]9ID<2UG6+57R6$(@8!4F@%^U%,=$K,&<'82P*=JXPCDP5>\)
M0)ZW$!1.R4V%J,82&I'/\HDY-@[>;0^;_0MCY]D/->)YDNS7XS[Y(4O/*@MQ
MHS#A*7$1IHDXLW@,H]CC-@ILYKB)G:2NI]ZJ7E^.B;V1E,JJQ2KJ* $!Q AV
M%<*J>3B#^2(ADW5)66N*2S-ZHC6"NY"LX'78-1DE&!##S4.T7I27G:.\HS[W
MIJ+ \4SUQHDCEI\ODAS/P46L:6 YS5%:Q?SO]3,KWY OZ2\Y%5S6NXC#]Z;,
MF"VR]3[[A]&L>8;E*Q+$-*(I0Z'#Q<80NA&*Y!S<,.8AYP&/*095H^@*,O'.
MT!2I'NDOBS9S=G+K3YK+R7ORRB^P_:0VY6K1ZAQ$PK:+1J*Z"8XL@Y-"69=2
MR?880BY+"M9ZM.B;43)M<";82)9,C0W3%6/>R6(CR;H9/C9V/3U?)]9X(TQY
M?;R9J^-Z7AHFGH.(2QSAS+B+J.O$"#.,DR1.<0+KE-Z)-+&WDH95 NN/(1IF
M2\T/&>$ &)?JJ0]V'H.J&?(.W3BSFO^@NM?V/?R!+@-N_Q]]$']Z]4?]-^*7
M6!R47_WQ'U!+ P04    " #.0\Y80$O7G#6N   O- @ %0   '!E=',M,C R
M-# S,S%?<')E+GAM;.R]:7.;29(F^'U^16[MU_6NN(^V[AY3ZFB3359*)JFJ
M9O8++ X/"5,@H 9 I=2_?CQ @C<I'/'B#?:N57>*(BF$A_L3'NX>?OS+?_]^
M-OOE&RY7T\7\7__$_XG]Z1><IT6>SC__ZY_^^ND-N#_]]W_[;__M7_XO@/_Y
MZX???GFU2.=G.%__\G*)88WYES^FZR^_K+_@+W]?+/\Q_19^>3\+Z[)8G@'\
MV^:?O5Q\_;&<?OZR_D4PH;:_MOWI\I^CDEPP'J%H:4%);\!E+L$[@]X$&8L,
M_\_G?]:E...S@>*B 65M!A>] &D+>L]YM/[B0V?3^3_^N?XGAA7^0MN;KS9_
M_=<_?5FOO_[SG__\QQ]__-/WN)S]TV+Y^<^",?GG[6__Z?+7O]_[_3_DYK>Y
M]_[/FY]>_>IJ^M OTL?R/__/O_SV,7W!LP#3^6H=YJDNL)K^\VKSS=\6*:PW
M7/\I7;\\^AOU;[#]-:C? DX\X?_T?97_]&__[9=?+MBQ7,SP Y9?ZI]__?#V
MUI+<,?85UV>85_^4%F=_KK_SYY<+P@11N_G7ZQ]?\5__M)J>?9WA]GM?EEC^
M]4_T[U90Q<KDQ9K_]\4__//UTE^7N"*\;+;Z&WWC\M_750XB [^O<9[Q8G?;
M16:+=.N79I6WBZM_.0L19YOO3C).)YM/?1%7ZV5(ZXFVQK'(,Q3E,RA>$D1#
M(.0JV:RXS(SGV[NN5*^([(TH5IC^Z?/BVY_I@TDD0M8O*DODAAWWEKM@S6%T
M;\_>)_K=252AJ!@0HB**E8P.@LX)"FII>$I".GX4V3=7NTWU39&^6*9?%LN,
M2U(>V^7",MT3[VW87O[&G[^&)7T0I"_3V16/RW)QUD)6ZT4#SEV(A<C]TR^T
MZX++)>;?+J3RZ.8V.UN32L7-;[:0^(OY_#S,/N#7Q7(]\4HF4X0"+4EK*A81
MG"H&8HY&V9 YEC:2O[GJ3@@0_2/@8$Z.C(27Y\O*J#?350JS_X5A^7J>7]$%
M/"F%!^FE Q-H(TIS \$Y#19+MD:R$L-Q:'ALY9T0(?M%1!..=J(?WN-RNLC;
M#81@3"9C"3@S9%&A<A"Y"A""X Z9<3:+)@KBUK([X4'UBX?C>=D)&#XMPWPU
MK8R_5',14W(Y<"(_,:!+CT-DD8%+J411C%2*M3$5[JR\$R1T_Y XBJ,CH^+U
M?#U=_W@SG>'OYV<1EQ,7LPTJ9$">Z-*S29&_901@RDP&S9DO>!0:[JZX$PI,
MOR@XBH-=2/\#?IY6)LS7OX<SG"0R?ZU.&A)J,H #[20&7<AM3-[JR"73J@$"
M;J^Z$PIL[R@X@I-=(.'M/"V6I,(VC/](_,>7B_/Y>OGCY2+CQ >33.0!DB*C
M1S&E(4IM@04CK<_")QL: .-)(G;"B>L=)^WXW 5L/H7O;S.Q;UJF%T&K2TWH
MB1&*7"C(A'=0*M)&G*F[B5X+.@JQB29Y9/F=H.)[ATH+WG8!DA<YDPA6EW_\
M-ITCGV29T'/'P*M,AA)S#GQD"-*R4HI@)>GC7)%'E]XM9,5Z1\>Q3.T)&2_I
MRW?+3XL_YI.")J!%<JO(DB(KFFL(7C 0#HMCWIO";#M<7"^\&RHZCF2V8&A/
MF-C<C>^6[Y>+;]-YP@F2Z90R;4&D[.O5*"$XG@"M*YS\<)DQM@/&G=5W0T?'
M4<YFK.T)(N\7JW68_;_3KQO;B0N&Q7L/GJ6Z"Q-H%YK48/"%;D7D]$GM ')K
M[=W@T7'(LQ%;QPZ%USTL,6SH+LYFHPH'C(8\L.0X>*0+$85.B=PS2W;3<>'O
M&ZOM!H".8YP'LVYDD=>W\MG[+XOY-@2CBL82C $K-[K,2'"%W*CL*XB3$<$?
M]VA[=\7=1-]Q+/,H%HXL_H^8SI<$72[BI^EZ5J%;;1IF(!6KR=H1!GQ($8(6
M*@2.68CCK(2[*^XF_HZ#F$>Q<&3Q?UJ&FH_T\<=97,PFGG&T'@M896KL72L(
MTA'UQ1@=8G8Z'Z?Q;RVWF^ [CEL>SKQ.#OWK[^E+F'_&BX!K<D+2]0188KVS
M#-U9)4M@.F5DRA:67).#?W/5W3#0<4SR:%9VX0[\'6>S_S$G9_<CAA7=8_GM
M:G5.%QE/,C*A'&2>"JBL$ +W KQ5G!">5%(M8@F/++\;.+J/0K9@;A<H^=MB
M=DX"6&X>[):KB8XY.,/(L1&!8(Y%@-.T 9%3="(4U.HXC?'@LKNE2W4??3R&
MF5V@X3+)Y^+9OEZ#)(1SVH<(V4M4D"VO[W8Z@Y,HP 2KF5>Y)AXW ,7#J^^&
MC>YCD U8VP5$WL[ITX@=TV_X*JS#Y;8FKEBAK%.@62%+*58C2>8$R<F,4EK-
M;0N]\?#JNT&D^T!D ]9V 9&-]GL9UOAYL?PQJ;F!5B8%*2@.2I9--A@2BQ+F
MPI23YKB,RP<6W0T0W8<>#V=D%SCX>!9FLU_/5],YKE:3HKW!0@AV680*8P4.
MBR4CR3B/W 5ACDNK>V#1W7#0<03R6$9V@8/79[C\3%?>OR\7?ZR_O%R<?0WS
M'Q/CLY3%14@J5E-9J/I6'\!GK4IR#ET32_/!Q7?#1<?AR5:,'1D?;U-9OCC/
M4_J-%^LUKBYD\&86/D\X%JF5DI 877@J\@+!V )&L2R-=<S8XU(A'E][-W1T
M'+ULQ-9.$K3?3.<?UV?KU\OE8OER042DJ]U$*ZS.AA0@LV0]>]I2(%L)F G(
MK61&X'&QC)_3L!M8.HYX-F9S%S?.QR\XFVWU(8H4=3(2<D*Z)5,6$(7G(!-1
M3D8TTU&V,#QNK+D;*#H.@1[)QBY \/X\SJ;IS6P1UA-!3E2T&$&9)(@/L;[<
M:PLZ"FZTLMGK%L;&C25W@T#W@<Y#F=@% @BZ9S6?>)'^\?$+L6WU[GQ=*\OK
M"\^DA"RY8N166^9!U:]"XH1G$8T.SD<F30-(/$7#;C6!W8<]F[&Y$X-C=9V.
MCOG7'Q\J)3A/^ F_KW^E7_X';0H]3Y*@+Y@#)61-_^$"LHI,(QK4[KA\BIU)
MV0U"'4='AV%Z'^J'MK4,L[?SC-__!_Z8>"9%L9YNT,+I!K7DHCFAZ#S0-X7.
M2.>A21C]]K*[(:3[X.@QS!P9#2\(WWEC8E=CVM'V8\$ R=9^"D8Z<L\=ATC^
M>=1,(L?CS-%;R^TF_8XCH8<SKY/;Y+IB_@U]9S7QV8NH?02MR>]6/$L"KG?@
M8D:E#/K0J!_%G85W0T+'L= 6#.T*$Q>E\Q>;X$0W=R("YXQ7 YM!K'Z6ML&F
MR+B)_CAK]-&E=\-%Q['0-DQMAHQ_^?,]1OY&WSBBN]0FE/=V7KN$;3[N-LF[
M-9JZ]QFM>DX]3=R1[:?J/B9W5[@"3/062^1TW+6L#V)90& Q $M%*&.RQ[NU
M#??Y\N0*1UWZ%_'7-]/EV=L\X9'SQ*("@T0E>4$> C($YC7'&&.0>-SQOK7<
M./VGV@GKUOU_,!_'MOHN"-\D#^8<O)4V@C5(5Q0R0ZI-%_!1!3)D$%$>9_G?
M6&R<UE.#"G]O'O8A^M\N6Q9.;)&\!,4@U:H1%2,Q@E6KE2P4SZ)6[,@.0W<6
M'*?7U* 0.(B7'=_I+Q?SU6(VS9MH1YC5;I<?OR!Q\)#+_?$/:]=9<B=RC[SN
MSU?P.82ODTTI9C7IWI4WTSDM-B6[;G'14N@*4%F7(HM(P%%94)XG")$[,O-R
MB<9F+DIZXE"5L(H;J5\N>G&R<+9>;;]S?<3VH>M0O;%=X\5J16R]VJ4BOS:%
M;"&'JO5TH@O/T%^-I.U[(I"\G\:[O$W!.+;$8$C8JI8&[![QDKE-_66BX+6J
MS3S*@&0DY6) N<S <U>;!:=0?"XBNJ<RK0['S!U"QH7.,9)]$"3'L+D#K+P,
MJR\OYKG^\?H_SJ??PJQ&W5^L7X;E\L=T_OEO87:.$UF<5"$4"-G7,A>-=+U*
M!T1SH@O<V"!:8V<GPGK TE$ 6 PMC0X@]B*EVK9I]0$3TI;B#'_']3:-6;EB
MG7")+#6A065?^_^Q#-XDEKBAX^>?:GYTD%9Z@IYQW*3A -6,]QW@Z.W\&U&]
MJ'4T\^GJ"^9_7RSR:H*%*Y&3!:D8(_9X4ROP):2L.*,#85AHK9L>IF0<_VHX
M[#3@=P>H>;_$KV&:7W__BO,5DG)]M_Z"RUO<F@0OLL["0]SDQA)CP$EM0$:7
M4PB1_O=4-?0A$-J!K'%Z 0^'I]:2Z =<G\)W7$U8]$DD8H9$)'7JF2-;$NET
M5*I5D(:YUE?9S?7'Z1,\.%SVYVT'N+@-:I]M3-QE2#;K^A1)]IHVDHCWWH>$
MZ/13W9:.]KS&Z1T\H%%S,'</A\9B'68-H?'[8I[N<,0E3787UY"YKZ%03_NP
M])6/3'/G) OZJ0R0PU%RGY8>K."&+OJ1S.Y G[Q?+K[B<OWC_2S4Z1NY.H=?
M:P",K/F),#IIY@NDH&N]%X\0K*D9<&3 1UV$2*7YO?,X/3WXY,=*_-Y5U(C]
M(T)I\P[SEB0Q_SPE-W!K?MW@U 7G</WZ>YJ=URS=:N__,9W-)M$RIQ49^C&0
MH:]2J-FZA4&TV>2,@:S^.WGRCSRI'[9^#^JH$:).)84.=-85W8:,,R.#A3H:
MBFQZHML'9H".1BTZ,UH\V=_Z$/VT%W(&=LD;ZZ*#V-H!'-Z1!@VUQ<5O&%;X
MH<XR?%?^2GY@9=*D:,Y4%AEX#O497Y!]SYP F;"^!+-@2NL@SI,$]>![-P9.
M.P%T@*97E\O6\H S)!_Q2F].4 0=F!; E42ZCZT'YP/Y ]:R))!PX)_*I#T$
M2H]3TX-3WAA'C5C? 8CNLF>2;#'HB&#Z?U</@07O9($L:V*1#2'$UM"Y2T,/
MOGICP!S%YFX\]HF(I@:W/6CF%+& "7 1%5EC&=&C\.')CC6'@Z,'(Z:A-[X7
M(SL0_V_3$*>SZ7J**S+7-_6,7Q8S8OJJNH'K'U>L2<(P7HN-O-,>%)>LGA%2
M@9D9$8+!)%K[X;O2-JX'-7BZSB BZN""NK&ON_%3#,4HISD8)<D9+"Z!%Y&#
M3<JD@D5K]E3RZ)%@ZRJE9QCI/PZQ8T31 :BV*0'OPX^:#[ -HW,3&6,Y@Q)8
M1\,7<@"4*2"MU4EF)P0?*A'C-B7=@.DH.3^2AW$$TSN SL<PVYRQU]_3=%5-
M_SO;"=K:$JT DQ3M2=9)?CF22A>.#EI*(3[93^.@Y-NG21KWXAL(3"W%,'9$
MF@[&\ARW20&K;4#T<BLW&#B)/*? 2@&KZSM?=AZB2.1<ZB!ULDP8=Z>KTV-U
M7;LN.:[AW1@\ W*[ \UT.[BUW<BVO>Y$N!Q15%XQK PCM]-A<I"S55%%M(RU
M]MV>IFC<^.) >JFA$#J U,O%?,.2OT_77UZ>K]:+,US>VY,5UB : S)%\EJT
M(FN2!SHUQ#.NZ0<L/M7RY:#$Z!WH&C?L.!"\F@ND Y#=9]6$F6@]^2D@@ZFE
M;)R#"QC!R\2SHMT%,V 8H8N4H8$ ="2S.XA%/:)A;\168R@\NX0@G*ZVGS;5
MO;4@611:".O4DZ,?&]YT>\:T3V&$#Q<>:"N8OA33Q$1:(2<R P.I4Z6=@&"$
MA<"TYJB0-&WK2ZY'*_PDP:6]F-V!1JI=_J;K3:NV6KA$5S0= IRGNA46?,':
M@YR809#7M<P[HP>O%+<F!:]S\ZJQQ\GIQN0>#D>MA-&!_GF*0ZQ([\D7-9HI
M4,9(B"4:2"RDC!@D/MG>^; 2[Z->5DYA:0^'JD:BZ !4[[?K;K9T44RYZ3+!
M1 ;,N1J429 %&!&TR*1R%5=,MC:8'B!C['KZ-A*^7\%Q%+L[0,R-)K87] ?F
M)..%@P\JTD%2 GQ2C#@CL*CLN&"ML_3OTC#V8^X@6#F*T1T Y47.F_?L,'L?
MIOGM_&7X.B4;:\*]=\7099N5+&3VVPPA>04\9&ZT+DFGYET7'B9E7#MZ(-BT
M8'L'Z/F ZS"=8WX=EG,RV58O4CH_.Y_5OCJOL$S3=#W).9)RC)&X9$EQNI)K
M\E4$JUF):)QWS5N^_)RJ<6WJ@3#56!@=P.L^HR8Q)5'?EX'NXP#*I@">ZT [
M*%YCL@F?[#?<QH@>UW@>"#Y',KL#G_YG7L6D8*Z#2A5HH^EN%BG2+8UT-XO@
M5/28@GZJ<>$0F6[=!*Q/$B4Z7BS-8';")GCO-[+X@NMI(G/FUD:.[(AW^Y,'
M;X_WQ$9.V2NOD#:29&4#-YSP(FN??%8,D$[2V04E6&F=0WB27GFSV>*/RNPW
MB^6KQ7E<E_/9_3XX5P^&.H2 I.JCRY:."E=U?J:O/23K4+P@I&N=L[07@6-'
M!AKCZ)X!/YBP.K"[;@= Z-2_6VX8FC<N[GM<;@;C3().P6J#9%[4>H@@R#QP
M="EDEH1GP0D6!V@<L@-E8T<:!L;> .+I#G07HY=>G*^_+);3_\0\D4E$'Y@$
MGVO3KV@MT+$IX%FMX\F":?%4S_'CP7:7HK'C$B<%V5'BZ!1<;U>K<]H)1LX*
M>@Z&&_*9.'H(M98T,<V]9-JD)V=5M +6!35C!R9& -4!8N@44#<'Q65MC N1
MSD<=+:F")M>I. ?&Q^!K@Y\@6L<I?D+2V$&+$:!UJ$"ZP]=O4_*4\T98%S^H
ML^0F66K-O$Z  >L%3XPCHS* R-DX+6J(IG6,?@>RQHUHG!AGQPNF ZS=>,-Z
MW)BT-OND$+A$4L_*:8B;#FBUJC:S7'AN_=R\ UD[8:WYM.J38:VU8/K"VCV;
MTB7G!=)6"DO5-W:,E+5ED)%ERXL60K7.('Z"G)VPU7SH]1C8.DH0/6+JTJ2,
MK&AFB"F"U4Y#6CGPTFN0V88035%*#9'']P I.V&I^?3L\;!T@ !ZQ-%-^U$E
M5"4+NL1K,J)"S.!T85""-%DZ:TIH7S%SY+!MWGS8]GB0.E06SV1JTA5#5XMR
MF91//SWVL>B13QWBH6B7#31Z)+KHX'2UX,U6'%X)[2$Q4WN\% W>! FH#7+2
M.S:XUJDFCY!R?%[--YR?XQLZ=P]5C]&J%ST6:V<:^K_:;'H2O'0&G0#2M;6"
M+&EPV7/0*FGKZ*3(W+I;\P%DCOLLU (Y]]-NAI55%Q?CBA3]9HQ"?<''Y;=I
MPM7'Q8Q,1>XC)PT,29"!J)"7FNZH(1A50DC&,MW>9G^,FG'??88 5R/.=X"A
M?U\N5JOWRT69KB>*\4!\0&#*U[)JAW62L8%D4-:.L):\C,:@N;'\N \W0Z#D
M4-YVD+-U58!XU=MARQ"I<R:$%Z@M]4'5<%I(5H/!@(@<LS*MAYL\2LRXSS)#
M0*8-WWO0*SBGG<Q(.[[(9W7@S[KNZQM>[FLB;!&1UZ-@-ZV*:N&&40R(6XA"
MN<3OCM4^7M<\3=*X)E CP=_50 VET &H7N1ON%Q/5]=LFM146!U,)D5:3;;:
MMCIBBB!M-,*CS<*W'M!ZGXIQ#9QAH',DKSM RRNDE=-T(P?Z>H8;@=!1.%O0
MQO[S<M*S<3;7P3'66$7FFK/@8G!@;#*%:ZZU:)VOMPM=XQI#PR"JN3PZP-@]
M3DV"]5QXR:'$4@ON?8" G@&/+)EH<@BL=3GQ/2+&M8N&0<]QG.[)I+ZP&W\C
MWV!24,9D9:*KEP50AK@2:R.:&(I@23.K<;!&8M=DC)N",J@9?2"O.X#+[XOY
MXO8NMI,.MPRBHX-<((<L:U%BKD$&KA6$'#VCR]FKU#K/]Z=$C9ME,@24VLJA
M@ROK[9P^"U?KRP#IY6[JO 7IG10.B7S/(BA%'(KU.4=*SG+,&;5J78?U*#'C
M>F.-A7YO$FX+"70 I>VPJ8=Y-3&>-N!,!!ZXV%3:TP4M+$1NC&?<#'&[/4G1
MN'[:L*!J*(L.D/7X1AAG7*<<0215I]4C@^!$3>=CN3A.]J!NG?%V')X&\]*&
MQ5,;"71@2%V;@-NWP.G\G#9U_1K^*Y;%$J\&$.'J]7?B'XEO.@_+'V_)F-B,
MFZFOB(O9;,./"P4^2=P&SKVHYH2O/6CI5#D5P17&0](A^M+^QAQL.^.F;0YA
MO/4B^VZ. 6WQ\AC_BG.L#U-6\"(TJ]E?M4L@>>+@2TQ ?GJ,BA5K8^MLO$=(
M&3>S<SCX'<?S'BYC7-_PHT.T6>52P$G,H)BD2P5C!)M]3!RER*9U.L\M L9-
MVAS$Q3R8OQWHE6U;FVWF^W6PSY$]P+,%IHRN6:8"'+,)A.;"**8Y-I_3^A@M
M(V=E#H&9)FSO0+?<W<>O835-$R-UMLY8*,0#4#:3B6D](XFS(J-4-H;6.N9!
M0L:-0K21\4^ LS_#.T3-J^GL?(UY4G@JP5@'S O2G8&^"C[4B]5G[[@UP;8N
M&GZ$E'%##2=!SB%,[P [?\<ZJQCSBV_D WS&W\_/(B[?E7OI[)N#<:VK1?$\
MDK7F7:RNM-#@E,Y0IXM&.BKTW]9AAX,(W4UC/:M,WN$%]MQ0.?'1,!&S![2B
M-N1"\CU%I!,H943EB@^ZM=.V%X'CWILG ,PQ$-U+>OU"\U+]WR\#LB&D4E(!
MKQ4G1A8'4=:Z?I\3C\JG7$ZD*A\C<=S+N1MX-I%@!P"]493V:OIMFG&>KXT4
M3#/Z(T^,$U+S9,'Q6I M38V%!PW"&V39%[J&!JR4?Y2NW33E,RN.:"R.9U@K
M^/)+F'_&U72^V?7MUJ*W=G5<\>!3RPQ=3;CS%MOWH'RB(RKC&HLS!CA+M?RF
M-BT5:(%GTF69::%MZ_*$G0@[ON?RY2*?:@/#"2I>BI26]+(19$)H!)<PTI6
M-A57##;OCG6;@F[Z2#;"POVVRP?SNX,;\8KZ"XZ01OZZF-=C^^+[=#5Q3,N<
M6 *N4WW K5DF,G+PUCB=;#:B>93D28(ZP=(!DGX,-$>SO0,,W=G#J\59F,XG
M#G-AMC:R*9DV@2S4'B02G'51VB)LQM9-?A\DI!/,'"_HNT&VH[G> 71N-^/Z
M"U9W8V)RK.<G0M:V=AW)Y/4&KH"C5<4+R4WSMB\/T3%R2/]X\3[9^.P 7G>
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MK'9]85\#WI404FW81'<QN5PE.?"%_*[D@ZS#/E%CZV*-W2@;5RD-B*:[NFD
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M3 ;>?"#PDP2-JZJ:X>*N(FHGA([5S.^XK@.]+US9][C<:-9#U,S#']1*S>Q
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MZ.IK$$P]H+R&D5C'JJN.],'_.*=/>_WMT%#2O<]HUU/A*>(:::R[BUQ!R9G
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M.2ZZ<MQ3Q9D.0<Y(CG&N,1G:3W1T8Z-6SA +G6/-)W ]3LYN<'IN$?A6_.\
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M37\E1_1=>4.;JD8>OIV__IYPM:I^Z7+YH_;3/JNO2Q.7LK;1U/@^)\=4BMK
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MZX9F9FO%:B"J=42(T3!T6C+4K><-WUM^V@CA9%5^<SP>)]<.(/%T1==ZQNC
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MH7BFA$!GS_X$]PQ\#]MQ%W+=U)-@#P+4/\%)]2JNE[7+]N,RW=LD:LR>A5B
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M5N"K?9K0T)6VS2UWWOD9T-=6"_MG%PY3X3;@JWC<7H.%@>W'\#6GE(:P%4U
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M;WZ/7OV@_L1L*__]C_\#4$L#!!0    ( ,Y#SEB?:5/2^Q4  ,IU   8
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M2;M<B2TW>?8XUF35V#K6]!IZA0\.>C<6>0+Y8/2(1E*VCE#$2F1"_#L:7==
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MDD3CT4?R7$A+'C/ @!ZDY!,? :B#5+LAB[-8!A)E(N5GA8R8&E="C^G5FC2
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MT89<^N-AD]U0IUSJZJ1X#9$&R_5\/63[KGKN;+NR[W\9N>]^D?D_4$L#!!0
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MJ.&&HUS:DJ+^81S2IHO*$C4XT:H!T _20+A'<> J668A:LB>B*6/PL<J =/
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MA4U.JZ+1+R&,]HS_@MHS^LMM_P]02P,$%     @ SD/.6! B'O4O&   D(X
M !@   !P971S+3(P,C0P,S,Q>&5X>#DW,2YH=&WM/6MSVS:VW^^OP$WG=J49
MV8T=ITGL;&8<1^EZ;F)G;#=M/^U )"0AH0@N0-K1_?7W/  2U#MQ&JNI.SL;
M2R*)@X/S?O'YN)QD+YZ/E4Q?_-?S_][9$:],4DU47HK$*EFJ5%1.YR/Q6ZK<
M1[&SXZ\Z,<74ZM&X%/L/]P_$;\9^U->2?R]UF:D7X3G/?^+/SW^B19X/3#I]
M\3S5UT*G_WR@'P\>I>KQTX,T>?;HX.F^?)H\43^K@T?#O:<'@\=R^.^]!W K
M7,[WN'*:J7\^F.A\9ZQP_<,G^T5Y=*/3<GRX]_#A_SQH75>J3^6.S/0H/R1H
MX=>A@;WYGQ.3&7OXPT/Z[PA_V1G*B<ZFA_^XTA/EQ)FZ$1=F(O-_])S,W8Y3
M5@_Y0J?_3\&*L#A]O&%H#N YF<Y5@(Y!ZG\:ZX$NQ;,GNWO/?\+KPY[JG3%@
M@![[HGW%XMTD@%EE__3M/)G=SCYNYYTJWP)A]#\55CG7$Z=YLKOU0/=_[Y_\
M>G7ZOB].SM^^ZY]='E^=GI^)B_[)^?O^Q1_BW?F;TY,_MF$;],1#7<)JR6KB
MHHUU^L.A2DI]K<1Y4IJ!LF+_<0_Y\E%W;CNKR.R;\P:!?S76#DA))15MX<1,
M"I4[66J3BPN5F&MEI^*= 5Q,1>?''Y[N[S\\XH_T8>^H*^@B)^!>^!<(\WPX
MU E^8X9B$:V*#FPN8YQE4W&CR['0I1.N&CB=:FFU@BO#6O0 5R\F\U2H3T4F
M=>[$S5CE?@GXH+-,#)2PZC^51CB,%;(JQ\8".M*>D$[(H@#(Y2!3/5$:X93Z
M")?[30*T !T0UQP>Y(VT*3^PD#K%6V?WNBO>94HZ7'T(% !7A//]]H=Z1,R2
MPKXLP7]8Y:FR>%4C"H_O#KP'+X0L2YF, 7UC0"+@JE..53CP[<3;*S74N<9O
MD5L(AW>)P9H=AD"3B+PT@@\(.9$%"3 @? '"<N+ C, _Q]94H[&I2O@3^)X9
M>1?I/JN0PG4>_R#@K^,\5Y_$<3B=X[)4KO1L :QXG'S,S4VFTI$BJP76WDR8
M[/HM?):(#&@N9)J"5;23J6%Y^.AG0!D=G8;SRLO#G;VGQ6>8&B> IX'5MU-O
M>[O?AAP6K7[40L?>P]W])[C_M]HE,DNJC/$/)_-:YS)/M,Q 9EJ@'%@W4>(M
MR*W**C@@5V4E2+*[).S3G,A977MBD@@6T!M15Z\MZTE\@_3P$KP'?TAG<A#O
M4U%8H+TRFX+8ARL][:'@7R;CAW #K#8CUT5:632_$:;C6GD@^K1)=\5EE8QK
M!=)C[E' ?* 'YF$/^FDB4T5*#]G0JA'H%MR%S('?<B!RG59P0C5;H=8!W5D
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M)IW"/^-RDKWX?U!+ 0(4 Q0    ( ,Y#SEA>A(01/28" !1P%P 1
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M '!E=',M,C R-# S,S%?9S$N:G!G4$L! A0#%     @ SD/.6&(:5I3))P$
M]<D+ !4              ( !\8($ '!E=',M,C R-# S,S%?;&%B+GAM;%!+
M 0(4 Q0    ( ,Y#SEA 2]><-:X  "\T"  5              "  >VJ!0!P
M971S+3(P,C0P,S,Q7W!R92YX;6Q02P$"% ,4    " #.0\Y8GVE3TOL5  #*
M=0  &               @ %5608 <&5T<RTR,#(T,#,S,7AE>'@Q.3$N:'1M
M4$L! A0#%     @ SD/.6,LG\M!+!   JR   !@              ( !AF\&
M '!E=',M,C R-# S,S%X97AX,C$Q+FAT;5!+ 0(4 Q0    ( ,Y#SE@*H#,?
M1 ,  #4+   8              "  0=T!@!P971S+3(P,C0P,S,Q>&5X>#(S
M,2YH=&U02P$"% ,4    " #.0\Y8:[QY%OT'  !I*   &
M@ &!=P8 <&5T<RTR,#(T,#,S,7AE>'@S,3$N:'1M4$L! A0#%     @ SD/.
M6#W7V0D8"   F"D  !@              ( !M'\& '!E=',M,C R-# S,S%X
M97AX,S$R+FAT;5!+ 0(4 Q0    ( ,Y#SECO__K3F00  ,X7   8
M      "  0*(!@!P971S+3(P,C0P,S,Q>&5X>#,R,2YH=&U02P$"% ,4
M" #.0\Y8+2;\$_ 1  # ;0  %P              @ '1C 8 <&5T<RTR,#(T
M,#,S,7AE>'@T,BYH=&U02P$"% ,4    " #.0\Y8$"(>]2\8  "0C@  &
M            @ 'VG@8 <&5T<RTR,#(T,#,S,7AE>'@Y-S$N:'1M4$L%!@
0   /  \ ^P,  %NW!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>pets-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pets="http://www.1800petmeds.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pets-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>2024-06-13</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pets:FurnitureFixturesEquipmentAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pets:FurnitureFixturesEquipmentAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pets:MeasurementInputWeightedAverageCostOfCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputControlPremiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">pets:DelrayBeachPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">pets:SevenSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">pets:SixSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pets:PartnerProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:ReorderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:ReorderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:NewOrderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:NewOrderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:MembershipFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:ReorderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:NewOrderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:ReorderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pets:NewOrderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-03</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pets:TollFreeTelephoneNumberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pets:TollFreeTelephoneNumberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pets:VetsterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pets:VetsterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:SEC382LimitedUtilizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:SEC382LimitedUtilizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pets:PetCareRxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:SEC382LimitedUtilizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:DeferredTaxAssetIsRecordedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pets:OperatingLossCarryforwardAxis">pets:SEC382LimitedUtilizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>1998-04-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <startDate>1998-04-01</startDate>
            <endDate>1998-04-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>2023-05-22</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pets:FiscalYear2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pets:FiscalYear2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:A2022EmployeePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">pets:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:NonvestedRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:EmployeeAndDirectorEquityCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:NonvestedRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:EmployeeAndDirectorEquityCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:NonvestedRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:EmployeeAndDirectorEquityCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:NonvestedRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:EmployeeAndDirectorEquityCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockPriceHurdle5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pets:PerformanceRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-13</startDate>
            <endDate>2023-01-13</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-29</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-29</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pets:The2022EmployeeEquityCompensationRestrictedStockPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-29</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-29</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-29</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-29</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="reporting_unit">
        <measure>pets:reporting_unit</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="tenant">
        <measure>pets:tenant</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>pets:performanceObligation</measure>
    </unit>
    <unit id="model">
        <measure>pets:model</measure>
    </unit>
    <unit id="category">
        <measure>pets:category</measure>
    </unit>
    <unit id="payment">
        <measure>pets:payment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-32">0001040130</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-36" id="f-317">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-43" id="f-331">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-43" id="f-558">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <pets:RestrictionPeriod contextRef="c-130" id="f-736">P1Y</pets:RestrictionPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-136" id="f-746">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-158" id="f-794">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-136"
      decimals="INF"
      id="f-838"
      unitRef="number">0.333333333333333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-193" id="f-933">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-199" decimals="4" id="f-934" unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-200" decimals="4" id="f-935" unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-201" decimals="4" id="f-936" unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">000-28827</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">PETMED EXPRESS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">65-0680967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">420 South Congress Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Delray Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">33445</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">526-4444</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, PETS $.001 Par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">PETS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-29" unitRef="usd">209200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">20606692</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Information to be set forth in our proxy statement relating to our 2024 Annual Meeting of Shareholders is incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of our fiscal year ended March 31, 2024.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-36">49</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-37">RSM US LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-38">Fort Lauderdale, Florida</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">55296000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-40" unitRef="usd">104086000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">273000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">35000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">3283000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-44" unitRef="usd">1740000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryFinishedGoods contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">28556000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">19023000</us-gaap:InventoryFinishedGoods>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">6325000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-48" unitRef="usd">4719000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidTaxes contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">188000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">863000</us-gaap:PrepaidTaxes>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">93648000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">130431000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">26657000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-54" unitRef="usd">26178000</us-gaap:PropertyPlantAndEquipmentNet>
    <pets:IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">16503000</pets:IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill>
    <pets:IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">5860000</pets:IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">26658000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">1432000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">4986000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">5009000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AssetsNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">76236000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">37047000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">169884000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">167478000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">37024000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">25208000</us-gaap:AccountsPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">25012000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">26113000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <pets:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">7060000</pets:AccruedExpensesAndOtherCurrentLiabilities>
    <pets:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">6191000</pets:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">459000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">2603000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">72158000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">57512000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">995000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">73153000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">57512000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-83" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-84" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-85"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-86"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-87" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-88" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-89" unitRef="shares">3000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="-3" id="f-90" unitRef="shares">3000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="-3" id="f-91" unitRef="shares">3000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="-3" id="f-92" unitRef="shares">3000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="c-4"
      decimals="INF"
      id="f-93"
      unitRef="usdPerShare">4</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="c-5"
      decimals="INF"
      id="f-94"
      unitRef="usdPerShare">4</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">9000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">9000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-97"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-98"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-99" unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-100" unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-101" unitRef="shares">21149000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-102" unitRef="shares">21149000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-3" id="f-103" unitRef="shares">21084000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-3" id="f-104" unitRef="shares">21084000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">21000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">21000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">25146000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">18277000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">71555000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">91659000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">96731000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">109966000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">169884000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">167478000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">281064000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-6" decimals="-3" id="f-116" unitRef="usd">256579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-117" unitRef="usd">272282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">202416000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">185844000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-7" decimals="-3" id="f-120" unitRef="usd">195341000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">78648000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-6" decimals="-3" id="f-122" unitRef="usd">70735000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-7" decimals="-3" id="f-123" unitRef="usd">76941000</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">55246000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">41714000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-126" unitRef="usd">31114000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">24508000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-6" decimals="-3" id="f-128" unitRef="usd">19424000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-7" decimals="-3" id="f-129" unitRef="usd">18799000</us-gaap:AdvertisingExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">7056000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">3546000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-132" unitRef="usd">2738000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">86810000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-134" unitRef="usd">64684000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-135" unitRef="usd">52651000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-8162000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">6051000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-138" unitRef="usd">24290000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestRevenueExpenseNet contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">511000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet contextRef="c-6" decimals="-3" id="f-140" unitRef="usd">450000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet contextRef="c-7" decimals="-3" id="f-141" unitRef="usd">-1131000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">1378000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">944000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">1026000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">1889000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-146" unitRef="usd">1394000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-147" unitRef="usd">-105000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">-6273000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-149" unitRef="usd">7445000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-150" unitRef="usd">24185000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">1191000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-152" unitRef="usd">2305000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-153" unitRef="usd">5469000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-7464000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-155" unitRef="usd">5140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-156" unitRef="usd">18716000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-157"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-158"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-159"
      unitRef="usdPerShare">0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-161"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-162"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-163" unitRef="shares">20395959</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-164" unitRef="shares">20274786</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-165" unitRef="shares">20175930</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-166" unitRef="shares">20395959</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-167" unitRef="shares">20339002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-168" unitRef="shares">20357820</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">0.60</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-6"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">1.20</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-7"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">1.20</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:SharesOutstanding contextRef="c-8" decimals="-3" id="f-172" unitRef="shares">3000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-173" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-9" decimals="-3" id="f-174" unitRef="shares">20269000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-175" unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-176" unitRef="usd">7111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-177" unitRef="usd">117789000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-178" unitRef="usd">124929000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="-3" id="f-179" unitRef="shares">710000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="-3" id="f-180" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-7" decimals="-3" id="f-181" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-182" unitRef="usd">4549000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-183" unitRef="usd">4549000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DividendsCommonStock contextRef="c-15" decimals="-3" id="f-184" unitRef="usd">24745000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock contextRef="c-7" decimals="-3" id="f-185" unitRef="usd">24745000</us-gaap:DividendsCommonStock>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-186" unitRef="usd">18716000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-187" unitRef="usd">18716000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c-16" decimals="-3" id="f-188" unitRef="shares">3000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-189" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-17" decimals="-3" id="f-190" unitRef="shares">20979000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-191" unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-192" unitRef="usd">11660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-193" unitRef="usd">111760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-194" unitRef="usd">123450000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-21" decimals="-3" id="f-195" unitRef="shares">105000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-21" decimals="-3" id="f-196" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-6" decimals="-3" id="f-197" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-22" decimals="-3" id="f-198" unitRef="usd">6617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-199" unitRef="usd">6617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DividendsCommonStock contextRef="c-23" decimals="-3" id="f-200" unitRef="usd">25241000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock contextRef="c-6" decimals="-3" id="f-201" unitRef="usd">25241000</us-gaap:DividendsCommonStock>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-202" unitRef="usd">5140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-203" unitRef="usd">5140000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c-24" decimals="-3" id="f-204" unitRef="shares">3000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-205" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-25" decimals="-3" id="f-206" unitRef="shares">21084000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-207" unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-208" unitRef="usd">18277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-209" unitRef="usd">91659000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-210" unitRef="usd">109966000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-28" decimals="-3" id="f-211" unitRef="shares">64000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-29" decimals="-3" id="f-212" unitRef="usd">6869000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">6869000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DividendsCommonStock contextRef="c-30" decimals="-3" id="f-214" unitRef="usd">12640000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">12640000</us-gaap:DividendsCommonStock>
    <us-gaap:NetIncomeLoss contextRef="c-30" decimals="-3" id="f-216" unitRef="usd">-7464000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">-7464000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c-31" decimals="-3" id="f-218" unitRef="shares">3000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-219" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-32" decimals="-3" id="f-220" unitRef="shares">21148000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-221" unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-222" unitRef="usd">25146000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-223" unitRef="usd">71555000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-224" unitRef="usd">96731000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">-7464000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-226" unitRef="usd">5140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-227" unitRef="usd">18716000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">7056000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-229" unitRef="usd">3546000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-230" unitRef="usd">2738000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">6869000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-3" id="f-232" unitRef="usd">6617000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-233" unitRef="usd">4549000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">292000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-235" unitRef="usd">-1630000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-236" unitRef="usd">-846000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">324000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-6" decimals="-3" id="f-238" unitRef="usd">214000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-7" decimals="-3" id="f-239" unitRef="usd">165000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">1742000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">41000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-3" id="f-242" unitRef="usd">-509000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">6417000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories contextRef="c-6" decimals="-3" id="f-244" unitRef="usd">-13432000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories contextRef="c-7" decimals="-3" id="f-245" unitRef="usd">-1965000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">-675000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes contextRef="c-6" decimals="-3" id="f-247" unitRef="usd">182000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes contextRef="c-7" decimals="-3" id="f-248" unitRef="usd">-278000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">185000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-6" decimals="-3" id="f-250" unitRef="usd">-147000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-251" unitRef="usd">363000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <pets:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">-788000</pets:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <pets:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-253" unitRef="usd">0</pets:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <pets:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-254" unitRef="usd">0</pets:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">6102000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-6" decimals="-3" id="f-256" unitRef="usd">-2292000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-257" unitRef="usd">-12048000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">-1101000</us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable>
    <us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable contextRef="c-6" decimals="-3" id="f-259" unitRef="usd">1956000</us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable>
    <us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable contextRef="c-7" decimals="-3" id="f-260" unitRef="usd">2928000</us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">276000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-6" decimals="-3" id="f-262" unitRef="usd">896000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-7" decimals="-3" id="f-263" unitRef="usd">-93000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">-766000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-265" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">-390000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-6" decimals="-3" id="f-268" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-269" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">4317000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-271" unitRef="usd">27803000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-272" unitRef="usd">18498000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">300000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="c-6" decimals="-3" id="f-274" unitRef="usd">5000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="c-7" decimals="-3" id="f-275" unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">35859000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-6" decimals="-3" id="f-277" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-7" decimals="-3" id="f-278" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">4511000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-280" unitRef="usd">5260000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-281" unitRef="usd">1752000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">-40670000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-283" unitRef="usd">-10260000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-284" unitRef="usd">-1752000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">12437000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-6" decimals="-3" id="f-286" unitRef="usd">24537000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-7" decimals="-3" id="f-287" unitRef="usd">24384000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">-12437000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-289" unitRef="usd">-24537000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-290" unitRef="usd">-24384000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">-48790000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-6" decimals="-3" id="f-292" unitRef="usd">-6994000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-293" unitRef="usd">-7638000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-294" unitRef="usd">104086000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-20" decimals="-3" id="f-295" unitRef="usd">111080000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-12" decimals="-3" id="f-296" unitRef="usd">118718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-297" unitRef="usd">55296000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-298" unitRef="usd">104086000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-20" decimals="-3" id="f-299" unitRef="usd">111080000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">130000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-6" decimals="-3" id="f-301" unitRef="usd">4312000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-3" id="f-302" unitRef="usd">6085000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:LiabilitiesAssumed1 contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">1466000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1 contextRef="c-6" decimals="-3" id="f-304" unitRef="usd">1262000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1 contextRef="c-7" decimals="-3" id="f-305" unitRef="usd">558000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:ErrorCorrectionTextBlock contextRef="c-1" id="f-306">Restatement of Previously Issued Financial Statements&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the third quarter of fiscal year 2024, we reviewed the accounting treatment related to previously reported sales tax accruals as well as the accounting treatment related to the valuation of the deferred tax asset associated with our acquisition of PetCareRx in April 2023. As a result of this review, management determined that we incorrectly applied United States Generally Accepted Accounting Principles (U.S. GAAP) as it relates to the sales tax liability and improperly valued the deferred tax asset and goodwill included in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We corrected the misstatements relating to sales tax accruals by recording sales tax accruals as of the end of each of the affected periods using a legal liability approach under Accounting Standards Codification Topic 405, Liabilities. The restated sales tax accrual amounts assume that (i) customers who have not yet provided certificates or other documentation of exemption from sales tax are taxable, (ii) total potential interest and penalty assessments may be imposed, and (iii) we will not receive waivers of interest and penalties or other benefits under agreements we may obtain with jurisdictions from our outreach with voluntary disclosures. We will continue to accrue interest on any outstanding liabilities until the voluntary disclosure agreements are settled. These accrual amounts have been, and will continue to be, adjusted in future periods as and if we obtain any waivers of interest and penalties or other benefits from our voluntary disclosures and as and if we obtain additional documentation from customers supporting exemption from sales tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, we have corrected misstatements relating to the deferred tax asset we recognized in connection with our acquisition of PetCareRx on April 3, 2023. In the accounting for that acquisition, it was determined that we incorrectly valued deferred tax assets associated with loss carryforwards of PetCareRx under section 382 of the Internal Revenue Code. As a result of this error, we recorded a decrease in the amount of our deferred tax assets and a corresponding increase in the amount of goodwill in each of the affected periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The misstatements that appeared in our previously issued financial statements were material, and we also corrected other immaterial errors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As described in additional detail in the Explanatory Note in our Amendment No. 1 on Form 10-K/A to our Annual Report on Form 10-K for the year ended March 31, 2023, originally filed with the SEC on May 23, 2023, we restated our audited consolidated financial statements as of and for the years ended March 31, 2023, 2022 and 2021, as well as our unaudited condensed consolidated quarterly financial information for the quarterly periods within the fiscal years ended March 31, 2023 and 2022, to reflect the correction of the misstatements relating to sales tax accruals and other immaterial adjustments, and to make corresponding disclosures. We also filed with the SEC (i) an Amendment No. 1 on Form 10-Q/A to our Quarterly Report on Form 10-Q for the three months ended June 30, 2023, originally filed with the SEC on August 2, 2023,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; to restate our unaudited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;condensed consolidated financial statements as of and for the three months ended June 30, 2023 and 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and (ii) an Amendment No. 1 on Form 10-Q/A to our Quarterly Report on Form 10-Q for the three months ended September 30, 2023, originally filed with the SEC on October 31, 2023, to restate our unaudited condensed consolidated financial statements as of and for the three and six months ended September 30, 2023 and 2022, in each case to reflect the correction of the misstatements relating to sales tax accruals and the valuation of deferred tax assets associated with our acquisition of PetCareRx in April 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The restated prior-year results are reflected in the consolidated financial results disclosed within this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:ErrorCorrectionTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-307">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;PetMed Express, Inc. and subsidiaries, d/b/a PetMeds&#xae; (collectively, the "Company"), is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats, and horses. The Company markets and sells directly to consumers through its websites, toll-free numbers, and mobile application. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Founded in 1996, the Company's executive headquarters offices are currently located in Delray Beach, Florida. The Company has a March 31 fiscal year and references herein to fiscal 2024, 2023, or 2022 refer to the Company's fiscal years ended March&#160;31, 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include PetMed Express, Inc. and its  wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification ("ASC") Topic 805 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Business Combinations"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The purchase price is allocated to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company&#x2019;s unaudited condensed consolidated financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;      Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain obligations assumed. Acquisition-related transaction costs incurred by the Company are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March&#160;31, 2024 and 2023 consisted of the Company&#x2019;s cash accounts and money market accounts with a maturity of three months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times,  may exceed federally insured limits. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $72 thousand and $48 thousand at March&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of thirty years. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from &lt;span style="-sec-ix-hidden:f-317"&gt;three&lt;/span&gt; to ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. Goodwill is not amortized but instead is tested for impairment annually on January 1, or more frequently if events or changes in circumstances indicate goodwill might be impaired. When testing goodwill for impairment, the Company has the option to choose whether it will apply a qualitative assessment first and then a quantitative assessment, if necessary, or to apply the quantitative assessment directly. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company performed its annual goodwill impairment testing as of January 1, 2024 using a &lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;quantitative &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;assessment and at that time concluded there was no impairment. Since then, the Company&#x2019;s stock price decreased from $7.56 at December 31, 2023 to $4.79 at March 31, 2024.  The Company considered the decrease in its stock price to be indicative of a risk that the carrying amount of goodwill may not be recoverable.  Therefore, the Company performed a quantitative impairment assessment as of March 31, 2024.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Based on the assessment, the Company concluded that goodwill was not impaired because the estimated fair value of the reporting unit exceeded its carrying value by approximately 27%.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;We estimated fair value using discounted cash flow and public company market approaches with a 70% and 30% weighting, respectively.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;A key assumption under the cash flow approach was a 27% weighted average cost of capital.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;A key assumption under the public company market approach was a 10% control premium.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquired definite-lived intangible assets in the acquisition (see Note 4) that will be amortized based on their estimated useful lives in accordance with ASC Topic 350 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). These definite-lived intangible assets are being amortized over periods ranging from &lt;span style="-sec-ix-hidden:f-331"&gt;three&lt;/span&gt; to seven years. Acquired trade name is not being amortized and is subject to an annual review for impairment consistent with the existing intangible assets in fiscal 2024. Following the Company's annual impairment testing in fiscal 2024, it concluded there was no impairment of its intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets consist of the initial minority interest investment in Vetster. Details can be found in Note 16 below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's advertising expense consists primarily of Internet marketing and direct mail/print, . Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for leases in accordance with ASC Topic 842 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Leases")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are reported as right-of-use (&#x201c;ROU&#x201d;) assets, current lease liabilities and long-term lease liabilities on the unaudited Condensed Consolidated Balance Sheets.  The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#x2019;s lease agreements do not contain any residual value guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 48% of our Delray Beach property, or approximately 88,000 square feet was leased to two tenants. At&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2024,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the leases with these two tenants had a remaining weighted average lease term of one year. The Company recorded approximately $1.2 million , $0.7 million and $0.7 million in rental revenue in fiscal 2024, 2023 and 2022, respectively, which was included in other income. In 2024, the Company recorded $0.5 million of rental revenue associated with a PetCareRx lease which expired in April 2024. The Company expects to receive the following future lease payments, under the current lease agreements, over the next five years: $617 thousand in fiscal 2025; $112 thousand in fiscal 2026, and $0 thousand in fiscal 2027, 2028 and 2029. As of March 31, 2024, both leases were being negotiated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC Topic 220 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reporting Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. For the fiscal years ended March&#160;31, 2024, 2023 and 2022, the Company had no components of comprehensive income and therefore does not report comprehensive income or Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the provisions of ASC Topic 740 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by &#x201c;Accounting for Uncertainty in Income Taxes&#x201d; guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies &#x201c;Accounting for Uncertainty in Income Taxes&#x201d; guidance to all tax positions for which the statute of limitations remains open. The Company had no liabilities for uncertain tax positions for either fiscal 2024 or fiscal 2023. The Company files tax returns in the U.S. federal jurisdiction and Florida,  Arizona, California, Connecticut, Idaho, Maryland, Michigan, Oklahoma, South Carolina, Virginia, Wisconsin, New Jersey, Georgia, Indiana, New York and the District of Columbia. With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending March&#160;31, 2020, or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our product lines to obtain the lowest cost. There were seven and six suppliers from which we purchased approximately 78%  and 69% of all products in fiscal 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting for Share Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Based Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The compensation expense related to all of the Company&#x2019;s stock-based compensation arrangements is recorded as a component of general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company&#x2019;s consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-308">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include PetMed Express, Inc. and its  wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-309">&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification ("ASC") Topic 805 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Business Combinations"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The purchase price is allocated to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company&#x2019;s unaudited condensed consolidated financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;      Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain obligations assumed. Acquisition-related transaction costs incurred by the Company are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-310">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March&#160;31, 2024 and 2023 consisted of the Company&#x2019;s cash accounts and money market accounts with a maturity of three months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times,  may exceed federally insured limits. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-311">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-312">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="c-4" decimals="-3" id="f-313" unitRef="usd">72000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-5" decimals="-3" id="f-314" unitRef="usd">48000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-315">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of thirty years. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from &lt;span style="-sec-ix-hidden:f-317"&gt;three&lt;/span&gt; to ten years.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-35" id="f-316">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-37" id="f-318">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-319">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-320">&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. Goodwill is not amortized but instead is tested for impairment annually on January 1, or more frequently if events or changes in circumstances indicate goodwill might be impaired. When testing goodwill for impairment, the Company has the option to choose whether it will apply a qualitative assessment first and then a quantitative assessment, if necessary, or to apply the quantitative assessment directly. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company performed its annual goodwill impairment testing as of January 1, 2024 using a &lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;quantitative &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;assessment and at that time concluded there was no impairment. Since then, the Company&#x2019;s stock price decreased from $7.56 at December 31, 2023 to $4.79 at March 31, 2024.  The Company considered the decrease in its stock price to be indicative of a risk that the carrying amount of goodwill may not be recoverable.  Therefore, the Company performed a quantitative impairment assessment as of March 31, 2024.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Based on the assessment, the Company concluded that goodwill was not impaired because the estimated fair value of the reporting unit exceeded its carrying value by approximately 27%.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;We estimated fair value using discounted cash flow and public company market approaches with a 70% and 30% weighting, respectively.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;A key assumption under the cash flow approach was a 27% weighted average cost of capital.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;A key assumption under the public company market approach was a 10% control premium.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-1"
      decimals="INF"
      id="f-321"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-322" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:SharePrice
      contextRef="c-38"
      decimals="2"
      id="f-323"
      unitRef="usdPerShare">7.56</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-4"
      decimals="2"
      id="f-324"
      unitRef="usdPerShare">4.79</us-gaap:SharePrice>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount contextRef="c-4" decimals="2" id="f-325" unitRef="number">0.27</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <pets:ReportingUnitMeasurementInput contextRef="c-39" decimals="2" id="f-326" unitRef="number">0.70</pets:ReportingUnitMeasurementInput>
    <pets:ReportingUnitMeasurementInput contextRef="c-40" decimals="2" id="f-327" unitRef="number">0.30</pets:ReportingUnitMeasurementInput>
    <pets:ReportingUnitMeasurementInput contextRef="c-41" decimals="2" id="f-328" unitRef="number">0.27</pets:ReportingUnitMeasurementInput>
    <pets:ReportingUnitMeasurementInput contextRef="c-42" decimals="2" id="f-329" unitRef="number">0.10</pets:ReportingUnitMeasurementInput>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-330">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquired definite-lived intangible assets in the acquisition (see Note 4) that will be amortized based on their estimated useful lives in accordance with ASC Topic 350 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&#x201d;). These definite-lived intangible assets are being amortized over periods ranging from &lt;span style="-sec-ix-hidden:f-331"&gt;three&lt;/span&gt; to seven years. Acquired trade name is not being amortized and is subject to an annual review for impairment consistent with the existing intangible assets in fiscal 2024.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-44" id="f-332">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <pets:OtherAssetsPolicyTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;Other assets consist of the initial minority interest investment in Vetster.</pets:OtherAssetsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-334">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-335">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;The Company's advertising expense consists primarily of Internet marketing and direct mail/print, . Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for leases in accordance with ASC Topic 842 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Leases")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are reported as right-of-use (&#x201c;ROU&#x201d;) assets, current lease liabilities and long-term lease liabilities on the unaudited Condensed Consolidated Balance Sheets.  The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#x2019;s lease agreements do not contain any residual value guarantees.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <pets:PercentageOfPropertyLeasedToTenants contextRef="c-45" decimals="2" id="f-337" unitRef="number">0.48</pets:PercentageOfPropertyLeasedToTenants>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-46" decimals="-3" id="f-338" unitRef="sqft">88000</us-gaap:AreaOfRealEstateProperty>
    <pets:NumberOfTenants
      contextRef="c-45"
      decimals="INF"
      id="f-339"
      unitRef="tenant">2</pets:NumberOfTenants>
    <pets:NumberOfTenants
      contextRef="c-45"
      decimals="INF"
      id="f-340"
      unitRef="tenant">2</pets:NumberOfTenants>
    <pets:LessorOperatingLeaseRemainingWeightedAverageLeaseTerm contextRef="c-45" id="f-341">P1Y</pets:LessorOperatingLeaseRemainingWeightedAverageLeaseTerm>
    <us-gaap:RentalIncomeNonoperating contextRef="c-45" decimals="-5" id="f-342" unitRef="usd">1200000</us-gaap:RentalIncomeNonoperating>
    <us-gaap:RentalIncomeNonoperating contextRef="c-47" decimals="-5" id="f-343" unitRef="usd">700000</us-gaap:RentalIncomeNonoperating>
    <us-gaap:RentalIncomeNonoperating contextRef="c-48" decimals="-5" id="f-344" unitRef="usd">700000</us-gaap:RentalIncomeNonoperating>
    <us-gaap:RentalIncomeNonoperating contextRef="c-49" decimals="-5" id="f-345" unitRef="usd">500000</us-gaap:RentalIncomeNonoperating>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths contextRef="c-46" decimals="-3" id="f-346" unitRef="usd">617000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears contextRef="c-46" decimals="-3" id="f-347" unitRef="usd">112000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears contextRef="c-46" decimals="-3" id="f-348" unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears contextRef="c-46" decimals="-3" id="f-349" unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears contextRef="c-46" decimals="-3" id="f-350" unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-351">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC Topic 220 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reporting Comprehensive Income&lt;/span&gt;&#x201d;) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-352">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the provisions of ASC Topic 740 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by &#x201c;Accounting for Uncertainty in Income Taxes&#x201d; guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies &#x201c;Accounting for Uncertainty in Income Taxes&#x201d; guidance to all tax positions for which the statute of limitations remains open. The Company had no liabilities for uncertain tax positions for either fiscal 2024 or fiscal 2023. The Company files tax returns in the U.S. federal jurisdiction and Florida,  Arizona, California, Connecticut, Idaho, Maryland, Michigan, Oklahoma, South Carolina, Virginia, Wisconsin, New Jersey, Georgia, Indiana, New York and the District of Columbia. With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending March&#160;31, 2020, or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-353" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-354" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-355">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Concentrations&lt;/span&gt;&lt;/div&gt;The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our product lines to obtain the lowest cost.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-50" decimals="2" id="f-356" unitRef="number">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-51" decimals="2" id="f-357" unitRef="number">0.69</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c-1" id="f-358">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting for Share Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Based Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The compensation expense related to all of the Company&#x2019;s stock-based compensation arrangements is recorded as a component of general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-359">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company&#x2019;s consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-360">Revenue Recognition&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; ("Revenue from Contracts with Customers")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company generates revenue by selling prescription and non-prescription pet medication products, pet food, supplements, supplies, membership fees, and veterinary services. Certain pet supplies offered on the Company&#x2019;s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product. Customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are based on historical patterns, however this is not considered a key judgment. Revenue is recognized when control transfers to the customer at the point in time at which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time when the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Virtually all the Company&#x2019;s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales. Revenue is recorded net of sales tax, discounts and return allowances. Return allowances are estimated using historical experience and not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given its responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:31.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Membership fees represent the amounts recognized periodically from two membership models. The first is the PetPlus membership for PetCareRx customers, the second is a partner membership provided through PetCareRx. These memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup which represent a single stand-ready performance obligation to provide these benefits. The PetPlus membership fee is an upfront annual charge and automatically renews one year from the initial enrollment date. The Company recognizes the revenue ratably over the term of the PetPlus membership which is generally one year. As shown in the following table, under the PetPlus program, the Company recognized  $7.0 million deferred annual membership fees in the twelve months ended March&#160;31, 2024, and had $2.6 million of deferred revenue as of the year ended March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;( amounts in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue acquired with PetCareRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred memberships fees received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred membership fee revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:31.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to annual membership fees earned under the PetPlus program, the Company also earns membership fees on a month-to-month basis under its PetCareRx partner membership program.  For the twelve months ended March&#160;31, 2024, membership fees earned under the partner program were $2.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no material contract asset or liability balances at March&#160;31, 2024 and March&#160;31, 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates sales in the following two categories: reorder sales vs new order sales vs membership fees. The following table illustrates sales by various classifications:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.855%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (Decrease)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Sales (In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reorder sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New order sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Membership fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/m&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.855%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (Decrease)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Sales (In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reorder sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New order sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company changed the definition of a new customer on April 1, 2022, to include anyone who has not ordered over the past thirty-six months. The reorder and new order sales amounts for the years ended March&#160;31, 2022 reflect this new customer definition change. Under the previous definition of a new customer, reorder and new order sales were $249.4 million and $22.9 million, respectively, for the  year ended March&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains an allowance for credit losses that the Company estimates will arise from customers&#x2019; inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. The Company determines its estimates of the uncollectability of accounts receivable by analyzing historical bad debts and current economic trends in compliance with the provisions of ASC Topic 326 ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses"). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for credit losses was approximately $273 thousand  and $35 thousand at March&#160;31, 2024 and March&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <pets:RevenueFromContractWithCustomerNumberOfPerformanceObligations
      contextRef="c-4"
      decimals="INF"
      id="f-361"
      unitRef="performanceobligation">1</pets:RevenueFromContractWithCustomerNumberOfPerformanceObligations>
    <pets:RevenueFromContractWithCustomerNumberOfMembershipModels contextRef="c-4" decimals="INF" id="f-362" unitRef="model">2</pets:RevenueFromContractWithCustomerNumberOfMembershipModels>
    <pets:ContractWithCustomerRenewalPeriod contextRef="c-52" id="f-363">P1Y</pets:ContractWithCustomerRenewalPeriod>
    <pets:ContractWithCustomerRevenueRecognitionPeriod contextRef="c-52" id="f-364">P1Y</pets:ContractWithCustomerRevenueRecognitionPeriod>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-365">As shown in the following table, under the PetPlus program, the Company recognized  $7.0 million deferred annual membership fees in the twelve months ended March&#160;31, 2024, and had $2.6 million of deferred revenue as of the year ended March&#160;31, 2024.&lt;div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;( amounts in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue acquired with PetCareRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred memberships fees received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred membership fee revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-53" decimals="-5" id="f-366" unitRef="usd">7000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-52" decimals="-5" id="f-367" unitRef="usd">2600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-5" id="f-368" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination contextRef="c-54" decimals="-5" id="f-369" unitRef="usd">3000000.0</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <pets:ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived contextRef="c-53" decimals="-5" id="f-370" unitRef="usd">6600000</pets:ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-53" decimals="-5" id="f-371" unitRef="usd">7000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-5" id="f-372" unitRef="usd">2600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-55" decimals="-5" id="f-373" unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerNumberOfSalesCategories
      contextRef="c-4"
      decimals="INF"
      id="f-374"
      unitRef="category">2</pets:RevenueFromContractWithCustomerNumberOfSalesCategories>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-375">The following table illustrates sales by various classifications:&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.855%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (Decrease)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Sales (In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reorder sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New order sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Membership fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/m&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.855%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (Decrease)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Sales (In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reorder sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New order sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-56" decimals="-3" id="f-376" unitRef="usd">246977000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-56" decimals="3" id="f-377" unitRef="number">0.879</pets:RevenueFromContractWithCustomerPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-57" decimals="-3" id="f-378" unitRef="usd">232380000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-57" decimals="3" id="f-379" unitRef="number">0.906</pets:RevenueFromContractWithCustomerPercentage>
    <pets:RevenueFromContractWithCustomerVariance contextRef="c-56" decimals="-3" id="f-380" unitRef="usd">14597000</pets:RevenueFromContractWithCustomerVariance>
    <pets:RevenueFromContractWithCustomerVariancePercentage contextRef="c-56" decimals="3" id="f-381" unitRef="number">0.063</pets:RevenueFromContractWithCustomerVariancePercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-58" decimals="-3" id="f-382" unitRef="usd">24304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-58" decimals="3" id="f-383" unitRef="number">0.086</pets:RevenueFromContractWithCustomerPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-59" decimals="-3" id="f-384" unitRef="usd">24199000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-59" decimals="3" id="f-385" unitRef="number">0.094</pets:RevenueFromContractWithCustomerPercentage>
    <pets:RevenueFromContractWithCustomerVariance contextRef="c-58" decimals="-3" id="f-386" unitRef="usd">105000</pets:RevenueFromContractWithCustomerVariance>
    <pets:RevenueFromContractWithCustomerVariancePercentage contextRef="c-58" decimals="3" id="f-387" unitRef="number">0.004</pets:RevenueFromContractWithCustomerVariancePercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-60" decimals="-3" id="f-388" unitRef="usd">9783000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-60" decimals="3" id="f-389" unitRef="number">0.035</pets:RevenueFromContractWithCustomerPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-61" decimals="-3" id="f-390" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-61" decimals="3" id="f-391" unitRef="number">0</pets:RevenueFromContractWithCustomerPercentage>
    <pets:RevenueFromContractWithCustomerVariance contextRef="c-60" decimals="-3" id="f-392" unitRef="usd">9783000</pets:RevenueFromContractWithCustomerVariance>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-393" unitRef="usd">281064000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-1" decimals="3" id="f-394" unitRef="number">1.000</pets:RevenueFromContractWithCustomerPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-6" decimals="-3" id="f-395" unitRef="usd">256579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-6" decimals="3" id="f-396" unitRef="number">1.000</pets:RevenueFromContractWithCustomerPercentage>
    <pets:RevenueFromContractWithCustomerVariance contextRef="c-1" decimals="-3" id="f-397" unitRef="usd">24485000</pets:RevenueFromContractWithCustomerVariance>
    <pets:RevenueFromContractWithCustomerVariancePercentage contextRef="c-1" decimals="3" id="f-398" unitRef="number">0.095</pets:RevenueFromContractWithCustomerVariancePercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-57" decimals="-3" id="f-399" unitRef="usd">232380000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-57" decimals="3" id="f-400" unitRef="number">0.906</pets:RevenueFromContractWithCustomerPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-62" decimals="-3" id="f-401" unitRef="usd">243490000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-62" decimals="3" id="f-402" unitRef="number">0.894</pets:RevenueFromContractWithCustomerPercentage>
    <pets:RevenueFromContractWithCustomerVariance contextRef="c-57" decimals="-3" id="f-403" unitRef="usd">-11110000</pets:RevenueFromContractWithCustomerVariance>
    <pets:RevenueFromContractWithCustomerVariancePercentage contextRef="c-57" decimals="3" id="f-404" unitRef="number">-0.046</pets:RevenueFromContractWithCustomerVariancePercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-59" decimals="-3" id="f-405" unitRef="usd">24199000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-59" decimals="3" id="f-406" unitRef="number">0.094</pets:RevenueFromContractWithCustomerPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-63" decimals="-3" id="f-407" unitRef="usd">28792000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-63" decimals="3" id="f-408" unitRef="number">0.106</pets:RevenueFromContractWithCustomerPercentage>
    <pets:RevenueFromContractWithCustomerVariance contextRef="c-59" decimals="-3" id="f-409" unitRef="usd">-4593000</pets:RevenueFromContractWithCustomerVariance>
    <pets:RevenueFromContractWithCustomerVariancePercentage contextRef="c-59" decimals="3" id="f-410" unitRef="number">-0.160</pets:RevenueFromContractWithCustomerVariancePercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-6" decimals="-3" id="f-411" unitRef="usd">256579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-6" decimals="3" id="f-412" unitRef="number">1.000</pets:RevenueFromContractWithCustomerPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-413" unitRef="usd">272282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pets:RevenueFromContractWithCustomerPercentage contextRef="c-7" decimals="3" id="f-414" unitRef="number">1.000</pets:RevenueFromContractWithCustomerPercentage>
    <pets:RevenueFromContractWithCustomerVariance contextRef="c-6" decimals="-3" id="f-415" unitRef="usd">-15703000</pets:RevenueFromContractWithCustomerVariance>
    <pets:RevenueFromContractWithCustomerVariancePercentage contextRef="c-6" decimals="3" id="f-416" unitRef="number">-0.058</pets:RevenueFromContractWithCustomerVariancePercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-64" decimals="-5" id="f-417" unitRef="usd">249400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-65" decimals="-5" id="f-418" unitRef="usd">22900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-3" id="f-419" unitRef="usd">273000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-3" id="f-420" unitRef="usd">35000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-421">Acquisition&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April&#160;3, 2023, the Company acquired 100% of the issued and outstanding equity interests of PetCareRx, a New York corporation and a leading supplier of pet food, pet medications, and supplies.  The acquisition was completed pursuant to an Agreement and Plan of Merger ("Merger Agreement") by and among the Company, Harry Merger Sub, Inc., a New York corporation and a wholly-owned subsidiary of the Company ("Merger Sub"), PetCareRx and Jeanette Loeb (as representative of the PetCareRx equity holders). The Merger Agreement provided for the Company&#x2019;s acquisition of PetCareRx pursuant to the merger of Merger Sub with and into PetCareRx, with PetCareRx as the surviving corporation. The aggregate purchase price consideration was $36.1 million and was funded from the Company's cash on hand.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The acquisition of PetCareRx allowed the Company to significantly expand its product catalog, most notably in non-medication products, including food. In addition, PetCareRx brings increased distribution capability and experience, geographic diversity, technology enhancements, additional vendor relationships and a long-tenured and experienced staff.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company recognized goodwill of approximately $26.7 million, which is calculated as the excess of the consideration exchanged and liabilities assumed as compared to the fair value of the identifiable assets acquired.  Goodwill recognized in the transaction represents synergies or scale achieved by significantly increasing the customer base without adding corresponding levels of additional overhead, the value of additional vendor relationships, including the food manufacturing relationships, a broader product catalog, and an assembled and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;experienced workforce. These items represent intangible assets that do not qualify for separate recognition.  No goodwill is deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The values assigned to the assets acquired and liabilities assumed are based on their estimates of fair value available as of April&#160;3, 2023, as calculated by an independent third-party firm. The selected rates of returns were chosen in consideration of the individual risk profiles of the assets, as well as the resulting weighted average return on assets. Intangible assets are considered to be riskier than the overall business, so the Company included a premium to the investment rate of return on the identified intangible discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair values of intangible assets acquired consist of a trade name, customer relationships, and developed technology, which were estimated by applying various discounted cash flow models such as the relief from royalty rate for the trade name, the multi-period excess earnings method for the customer relationships, and the cost to replace method for the developed technology. The fair value measurements were based on significant inputs that are not observable (Level 3). The assumptions made by management in determining the fair value of intangible assets included a discount rate of 12% based on the weighted average cost of capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As a result of the acquisition, the Company performed an Internal Revenue Code Section 382 analysis to determine if the net operating losses carried forward will have a utilization limitation. Refer to Note 9 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The table below outlines the purchase price allocation of the purchase for PetCareRx to the acquired identifiable assets, liabilities assumed and goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company incurred a total of $1.7 million in acquisition related costs that were expensed as incurred and recorded in general and administrative expenses in the Company&#x2019;s Condensed Consolidated Statements of Operations, of which $0.5 million was recorded in fiscal year 2023, and $1.2 million was recorded for the twelve months ended March&#160;31, 2024. These costs include banking, legal, accounting, and consulting fees related to the acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Supplemental Pro Forma Information (As Restated)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The supplemental pro forma financial information presented below is for illustrative purposes only, does not include the pro forma adjustments that would be required under Regulation S-X of the Exchange Act for pro forma financial information, is not necessarily indicative of the financial position or results of operations that &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;would have been realized if the PetCareRx acquisition had been completed on April 1, 2022, does not reflect synergies that might have been achieved, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that the Company believes are reasonable under the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the PetCareRx acquisition had occurred on April 1, 2021 to give effect to certain events that the Company believes to be directly attributable to the acquisition. These pro forma adjustments primarily include:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt"&gt;A decrease in depreciation expense that would have been recognized due to acquired identifiable fixed assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;A decrease in amortization expense that would have been recognized due to acquired identifiable intangible assets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt"&gt;A decrease in payroll costs and benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The supplemental pro forma financial information for the prior period twelve months ended March&#160;31, 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.879%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.920%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c-66"
      decimals="INF"
      id="f-422"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-67" decimals="-5" id="f-423" unitRef="usd">36100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Goodwill contextRef="c-66" decimals="-5" id="f-424" unitRef="usd">26700000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount contextRef="c-66" decimals="INF" id="f-425" unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate contextRef="c-66" decimals="2" id="f-426" unitRef="number">0.12</pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillFairValueDisclosureDiscountRate>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-427">&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The table below outlines the purchase price allocation of the purchase for PetCareRx to the acquired identifiable assets, liabilities assumed and goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-66" decimals="-3" id="f-428" unitRef="usd">220000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-66" decimals="-3" id="f-429" unitRef="usd">125000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables contextRef="c-66" decimals="-3" id="f-430" unitRef="usd">506000</pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-66" decimals="-3" id="f-431" unitRef="usd">3116000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-66" decimals="-3" id="f-432" unitRef="usd">835000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-66" decimals="-3" id="f-433" unitRef="usd">1065000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets contextRef="c-66" decimals="-3" id="f-434" unitRef="usd">270000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:Goodwill contextRef="c-66" decimals="-3" id="f-435" unitRef="usd">26657000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-66" decimals="-3" id="f-436" unitRef="usd">12300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets contextRef="c-66" decimals="-3" id="f-437" unitRef="usd">2220000</pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-66" decimals="-3" id="f-438" unitRef="usd">80000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill contextRef="c-66" decimals="-3" id="f-439" unitRef="usd">47394000</pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-66" decimals="-3" id="f-440" unitRef="usd">5713000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent contextRef="c-66" decimals="-3" id="f-441" unitRef="usd">131000</pets:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue contextRef="c-66" decimals="-3" id="f-442" unitRef="usd">2993000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther contextRef="c-66" decimals="-3" id="f-443" unitRef="usd">258000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation contextRef="c-66" decimals="-3" id="f-444" unitRef="usd">2220000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-66" decimals="-3" id="f-445" unitRef="usd">11315000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-66" decimals="-3" id="f-446" unitRef="usd">36079000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-66" decimals="-5" id="f-447" unitRef="usd">1700000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-68" decimals="-5" id="f-448" unitRef="usd">500000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-54" decimals="-5" id="f-449" unitRef="usd">1200000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c-1" id="f-450">&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The supplemental pro forma financial information for the prior period twelve months ended March&#160;31, 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.879%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.920%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-68" decimals="-3" id="f-451" unitRef="usd">300230000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-69" decimals="-3" id="f-452" unitRef="usd">311480000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-68" decimals="-3" id="f-453" unitRef="usd">-261000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-69" decimals="-3" id="f-454" unitRef="usd">13613000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-455">Property and Equipment, Net&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major classifications of property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $5.1 million, $3.5 million and $2.7 million for the twelve months ended March&#160;31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated its tangible property and equipment for indicators of impairment as of March&#160;31, 2024 and concluded that no impairment existed.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-456">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major classifications of property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-35" decimals="-3" id="f-457" unitRef="usd">14999000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-70" decimals="-3" id="f-458" unitRef="usd">14997000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-71" decimals="-3" id="f-459" unitRef="usd">3700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-72" decimals="-3" id="f-460" unitRef="usd">3700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-73" decimals="-3" id="f-461" unitRef="usd">4511000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-74" decimals="-3" id="f-462" unitRef="usd">3917000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-75" decimals="-3" id="f-463" unitRef="usd">14246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-76" decimals="-3" id="f-464" unitRef="usd">9391000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-77" decimals="-3" id="f-465" unitRef="usd">9329000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-78" decimals="-3" id="f-466" unitRef="usd">9404000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-467" unitRef="usd">46785000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-468" unitRef="usd">41409000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-469" unitRef="usd">20128000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-470" unitRef="usd">15231000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-471" unitRef="usd">26657000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-472" unitRef="usd">26178000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-473" unitRef="usd">5100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-5" id="f-474" unitRef="usd">3500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-5" id="f-475" unitRef="usd">2700000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-476">Intangible and Other Assets, Net&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets and other assets, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.664%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Useful Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Toll-free telephone number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internet domain names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Names - PetCareRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships -PetCareRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology - PetCareRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Minority interest investment in Vetster&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Toll-free telephone number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internet domain names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Minority interest investment in Vetster&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company evaluated its intangible assets for indicators of impairment as of March&#160;31, 2024 and concluded that no impairment existed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amortization expense for intangible assets was $2.0&#160;million for the twelve months ended March&#160;31, 2024 and zero for the twelve months ended March&#160;31, 2023 and 2022, respectively. The indefinite life intangibles are not &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;being amortized and are subject to an annual review for impairment in accordance with the ASC Topic 350 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes expected amortization of our intangible assets at March 31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.757%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ending March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;19, 2022, the Company engaged in a three-year partnership agreement with Vetster Inc. (&#x201c;Vetster&#x201d;), a Canadian veterinary telehealth company. The Company also purchased a 5% minority interest in Vetster in the amount of $5.0&#160;million and received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, the Company became the exclusive e-commerce provider for Vetster, and Vetster became the exclusive provider of telehealth and telemedicine services to the Company. The minority interest investment is being valued on the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cost basis and the investment will be evaluated periodically for any impairment. On&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; October 3, 2023, the Company purchased additional shares in Vetster in the amount of $0.3&#160;million. This increased the minority interest investment to $5.3&#160;million. Following this round, the Company&#x2019;s minority ownership changed to approximately 4.8% of Vetster&#x2019;s outstanding shares.  The minority interest investment is being valued on the cost basis.  At March&#160;31, 2024, we evaluated the investment in accordance with ASC Topic 321 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Equity Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and determined it was not impaired.   &lt;/span&gt;&lt;/div&gt;Under the terms of the agreement, Vetster earns from 10% to 20% of revenue generated from its customers on orders fulfilled by the Company.  For the years ended March 31, 2024 and 2023, the Company earned approximately $0.8&#160;million and $0.4&#160;million in net sales for orders placed through Vetster and incurred fees to Vetster of approximately $153&#160;thousand and $80&#160;thousand, respectively.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-477">&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets and other assets, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.664%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Useful Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Toll-free telephone number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internet domain names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Names - PetCareRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships -PetCareRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology - PetCareRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Minority interest investment in Vetster&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Toll-free telephone number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internet domain names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Minority interest investment in Vetster&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-79" decimals="-3" id="f-478" unitRef="usd">375000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-79" decimals="-3" id="f-479" unitRef="usd">375000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-80" decimals="-3" id="f-480" unitRef="usd">485000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-80" decimals="-3" id="f-481" unitRef="usd">485000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-81" decimals="-3" id="f-482" unitRef="usd">2600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-81" decimals="-3" id="f-483" unitRef="usd">2600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-82" id="f-484">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-82" decimals="-3" id="f-485" unitRef="usd">6700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-82" decimals="-3" id="f-486" unitRef="usd">957000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-82" decimals="-3" id="f-487" unitRef="usd">5743000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-83" id="f-488">P6Y3M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-84" id="f-489">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-84" decimals="-3" id="f-490" unitRef="usd">3000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-84" decimals="-3" id="f-491" unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-84" decimals="-3" id="f-492" unitRef="usd">2000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-85" id="f-493">P2Y3M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-4" decimals="-3" id="f-494" unitRef="usd">13160000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-495" unitRef="usd">1957000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-496" unitRef="usd">11203000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Investments contextRef="c-4" decimals="-3" id="f-497" unitRef="usd">5300000</us-gaap:Investments>
    <us-gaap:EquityMethodInvestments contextRef="c-4" decimals="-3" id="f-498" unitRef="usd">5300000</us-gaap:EquityMethodInvestments>
    <pets:IntangibleAndOtherAssetsGross contextRef="c-4" decimals="-3" id="f-499" unitRef="usd">18460000</pets:IntangibleAndOtherAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-500" unitRef="usd">1957000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <pets:IntangibleAndOtherAssets contextRef="c-4" decimals="-3" id="f-501" unitRef="usd">16503000</pets:IntangibleAndOtherAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-86" decimals="-3" id="f-502" unitRef="usd">375000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-86" decimals="-3" id="f-503" unitRef="usd">375000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-87" decimals="-3" id="f-504" unitRef="usd">485000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-87" decimals="-3" id="f-505" unitRef="usd">485000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-5" decimals="-3" id="f-506" unitRef="usd">860000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-507" unitRef="usd">860000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Investments contextRef="c-5" decimals="-3" id="f-508" unitRef="usd">5000000</us-gaap:Investments>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="-3" id="f-509" unitRef="usd">5000000</us-gaap:EquityMethodInvestments>
    <pets:IntangibleAndOtherAssetsGross contextRef="c-5" decimals="-3" id="f-510" unitRef="usd">5860000</pets:IntangibleAndOtherAssetsGross>
    <pets:IntangiblesAndOtherAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-511" unitRef="usd">0</pets:IntangiblesAndOtherAssetsAccumulatedAmortization>
    <pets:IntangibleAndOtherAssets contextRef="c-5" decimals="-3" id="f-512" unitRef="usd">5860000</pets:IntangibleAndOtherAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-513" unitRef="usd">2000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-5" id="f-514" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-515">&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes expected amortization of our intangible assets at March 31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.757%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ending March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-3" id="f-516" unitRef="usd">1957000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-3" id="f-517" unitRef="usd">1957000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-3" id="f-518" unitRef="usd">957000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-3" id="f-519" unitRef="usd">957000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-3" id="f-520" unitRef="usd">957000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-4" decimals="-3" id="f-521" unitRef="usd">957000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-522" unitRef="usd">7743000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pets:TermOfAgreement contextRef="c-88" id="f-523">P3Y</pets:TermOfAgreement>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-89" decimals="2" id="f-524" unitRef="number">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-88" decimals="-5" id="f-525" unitRef="usd">5000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-90" decimals="-5" id="f-526" unitRef="usd">300000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-4" decimals="-3" id="f-527" unitRef="usd">5300000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-91" decimals="3" id="f-528" unitRef="number">0.048</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RelatedPartyTransactionRate contextRef="c-92" decimals="2" id="f-529" unitRef="number">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="c-93" decimals="2" id="f-530" unitRef="number">0.20</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-94" decimals="-5" id="f-531" unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-95" decimals="-5" id="f-532" unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-1" decimals="-3" id="f-533" unitRef="usd">153000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-6" decimals="-3" id="f-534" unitRef="usd">80000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-535">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major classifications of accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued credit card fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued merchandise credits / reward program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales return allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued real estate taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-536">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major classifications of accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued credit card fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued merchandise credits / reward program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales return allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued real estate taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <pets:AccruedCreditCardFeesCurrent contextRef="c-4" decimals="-3" id="f-537" unitRef="usd">397000</pets:AccruedCreditCardFeesCurrent>
    <pets:AccruedCreditCardFeesCurrent contextRef="c-5" decimals="-3" id="f-538" unitRef="usd">401000</pets:AccruedCreditCardFeesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-4" decimals="-3" id="f-539" unitRef="usd">1530000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-5" decimals="-3" id="f-540" unitRef="usd">1564000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <pets:AccruedMerchandiseCreditsAndRewardsCurrent contextRef="c-4" decimals="-3" id="f-541" unitRef="usd">1849000</pets:AccruedMerchandiseCreditsAndRewardsCurrent>
    <pets:AccruedMerchandiseCreditsAndRewardsCurrent contextRef="c-5" decimals="-3" id="f-542" unitRef="usd">1660000</pets:AccruedMerchandiseCreditsAndRewardsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-543" unitRef="usd">222000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-544" unitRef="usd">559000</us-gaap:AccruedProfessionalFeesCurrent>
    <pets:AccruedSalesReturnsAndAllowancesCurrent contextRef="c-4" decimals="-3" id="f-545" unitRef="usd">318000</pets:AccruedSalesReturnsAndAllowancesCurrent>
    <pets:AccruedSalesReturnsAndAllowancesCurrent contextRef="c-5" decimals="-3" id="f-546" unitRef="usd">221000</pets:AccruedSalesReturnsAndAllowancesCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="c-4" decimals="-3" id="f-547" unitRef="usd">1466000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="c-5" decimals="-3" id="f-548" unitRef="usd">1262000</us-gaap:DividendsPayableCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-549" unitRef="usd">142000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent contextRef="c-5" decimals="-3" id="f-550" unitRef="usd">118000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-551" unitRef="usd">1136000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-552" unitRef="usd">406000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <pets:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-553" unitRef="usd">7060000</pets:AccruedExpensesAndOtherCurrentLiabilities>
    <pets:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-5" decimals="-3" id="f-554" unitRef="usd">6191000</pets:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-555">Leases&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s leasing activities primarily consist of real estate leases acquired during the acquisition of PetCareRx for use in the business operations.  The leases had initial terms ranging from 5 years to 10 years. Some of the initial lease terms have already matured and the remaining leases have maturity dates ranging from fiscal year 2024 to 2028. The Company assesses whether each lease is an operating lease or a finance lease at the lease commencement date. The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Variable Lease Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s leases require payments for taxes, insurance, and other costs applicable to the property, in addition to the minimum lease payment. These costs are considered variable costs which are based on actual expenses incurred by the lessor. Therefore, these amounts are not included in the calculation of the right-of-use assets and lease liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements which provide for fixed and scheduled escalations, which are included in the calculation of the right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Options to Extend or Terminate Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s leases may contain an option to extend the lease term for periods from &lt;span style="-sec-ix-hidden:f-558"&gt;one&lt;/span&gt; to five years The exercise of lease renewal options is at the Company&#x2019;s sole discretion. If it is reasonably certain that the Company will exercise such options, the periods covered by such options are included in the lease term and are recognized as part of the Company&#x2019;s right-of-use assets and lease liabilities. The Company&#x2019;s leases do not generally contain options to early terminate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Lease items&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities on the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discount Rate and Lease Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the weighted average remaining lease term and discount rate for the Company&#x2019;s operating leases were 3 years and 3.6%, respectively. As the rate implicit in the lease is generally not readily determinable for the Company&#x2019;s operating leases, the Company uses its estimated incremental borrowing rate based on the information available at the date of acquisition, April&#160;3, 2023, in determining the present value of future payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Costs and Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease costs as recorded in the general and administrative costs and activity for the twelve months ended March&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.304%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Twelve months ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Operating lease cost - fixed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Operating lease costs - variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information for the twelve months ended March&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.314%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Twelve months ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash paid for the amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities as a result of acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturity of Lease Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity of the Company&#x2019;s lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating lease liabilities recognized on the Company&#x2019;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.299%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.670%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-43" id="f-556">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-44" id="f-557">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-44" id="f-559">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-560">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-4" decimals="3" id="f-561" unitRef="number">0.036</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-562">&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease costs as recorded in the general and administrative costs and activity for the twelve months ended March&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.304%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Twelve months ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Operating lease cost - fixed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Operating lease costs - variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information for the twelve months ended March&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.314%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Twelve months ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash paid for the amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities as a result of acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-563" unitRef="usd">853000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-564" unitRef="usd">65000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-565" unitRef="usd">918000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-566" unitRef="usd">832000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-567" unitRef="usd">2220000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-568">&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity of the Company&#x2019;s lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating lease liabilities recognized on the Company&#x2019;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.299%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.670%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-569" unitRef="usd">501000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-570" unitRef="usd">488000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-571" unitRef="usd">502000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-572" unitRef="usd">42000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-573" unitRef="usd">1533000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-574" unitRef="usd">79000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-575" unitRef="usd">1454000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-576">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad debt and inventory reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax accounting method change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2024, the Company had $11.3&#160;million of federal net operating loss carryforwards which begin to expire in fiscal 2024. The Company also had $9.0&#160;million in state net operating loss carryforwards which begin to expire in fiscal 2026. In fiscal 2024 the Company acquired PetCareRx, a loss corporation. The tax attributes acquired are subject to Internal Revenue Code Section 382 which limits the utilization annually. The Company has determined the utilization of the state loss carryforwards is not likely to be realized. As a result, the Company has recorded a valuation allowance of $0.6&#160;million for the tax effected value of these state losses. Outlined below are the tax attributes acquired and the balances remaining as of March 31, 2024 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.980%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PetCareRx Tax Attributes Acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sec. 382 limited utilization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Attributes for which a deferred tax asset is recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating losses - limited carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Beginning in FY 2024 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating losses - unlimited carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,501&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,501&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;None &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disallowed business interest expense carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;None &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Beginning in FY 2026 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.980%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Attribute as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sec. 382 limited utilization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Attributes for which a deferred tax asset is recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating losses - limited carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,114&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Beginning in FY 2025 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating losses - unlimited carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,501&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,501&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;None &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disallowed business interest expense carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;None &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Beginning in FY 2026 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax provision consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax provision (benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income tax provision computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes at federal statutory rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock shortfall adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In fiscal 2024, the Company recognized non-deductible executive stock compensation of approximately $1.8&#160;million. This includes adjusting the deferred tax assets by a cumulative $1.0&#160;million to account for future limitations under Sec. 162(m). This limits deductions for compensation of covered executives to $1.0&#160;million per individual.  In fiscal 2023, the Company recognized a stock compensation shortfall charge of approximately $171 thousand, and recognized a one-time charge of approximately $124 thousand, related to a return to provision true up from the fiscal 2022 income tax provision. In fiscal 2022, the Company recognized a stock compensation shortfall charge of approximately $31 thousand, and recognized a one-time benefit of approximately $184&#160;thousand, related to a return to provision true up from the fiscal 2021 income tax provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The differences between the effective income tax rate and the statutory U.S. federal income tax rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal rate on income before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock shortfall adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Effective Tax Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-577">The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are as follows (in thousands):&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad debt and inventory reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax accounting method change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-4" decimals="-3" id="f-578" unitRef="usd">5126000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-5" decimals="-3" id="f-579" unitRef="usd">5910000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c-4" decimals="-3" id="f-580" unitRef="usd">225000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c-5" decimals="-3" id="f-581" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-4" decimals="-3" id="f-582" unitRef="usd">680000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-5" decimals="-3" id="f-583" unitRef="usd">1605000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-4" decimals="-3" id="f-584" unitRef="usd">31000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-5" decimals="-3" id="f-585" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-4" decimals="-3" id="f-586" unitRef="usd">440000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-5" decimals="-3" id="f-587" unitRef="usd">21000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <pets:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-4" decimals="-3" id="f-588" unitRef="usd">317000</pets:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <pets:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-5" decimals="-3" id="f-589" unitRef="usd">0</pets:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <pets:DeferredTaxAssetsLeaseLiabilities contextRef="c-4" decimals="-3" id="f-590" unitRef="usd">376000</pets:DeferredTaxAssetsLeaseLiabilities>
    <pets:DeferredTaxAssetsLeaseLiabilities contextRef="c-5" decimals="-3" id="f-591" unitRef="usd">0</pets:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-592" unitRef="usd">3001000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-593" unitRef="usd">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-594" unitRef="usd">10195000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-595" unitRef="usd">7536000</us-gaap:DeferredTaxAssetsGross>
    <pets:DeferredTaxLiabilitiesChangeInAccountingMethod contextRef="c-4" decimals="-3" id="f-596" unitRef="usd">541000</pets:DeferredTaxLiabilitiesChangeInAccountingMethod>
    <pets:DeferredTaxLiabilitiesChangeInAccountingMethod contextRef="c-5" decimals="-3" id="f-597" unitRef="usd">0</pets:DeferredTaxLiabilitiesChangeInAccountingMethod>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-4" decimals="-3" id="f-598" unitRef="usd">2627000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-5" decimals="-3" id="f-599" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-600" unitRef="usd">1041000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-601" unitRef="usd">2527000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-602" unitRef="usd">376000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-603" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-3" id="f-604" unitRef="usd">4585000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="-3" id="f-605" unitRef="usd">2527000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-606" unitRef="usd">624000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-607" unitRef="usd">0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-608" unitRef="usd">4986000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-609" unitRef="usd">5009000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-96" decimals="-5" id="f-610" unitRef="usd">11300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-97" decimals="-5" id="f-611" unitRef="usd">9000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-98" decimals="-5" id="f-612" unitRef="usd">600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-613">Outlined below are the tax attributes acquired and the balances remaining as of March 31, 2024 (in thousands).&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.980%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PetCareRx Tax Attributes Acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sec. 382 limited utilization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Attributes for which a deferred tax asset is recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating losses - limited carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Beginning in FY 2024 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating losses - unlimited carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,501&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,501&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;None &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disallowed business interest expense carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;None &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Beginning in FY 2026 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.980%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Attribute as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sec. 382 limited utilization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Attributes for which a deferred tax asset is recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating losses - limited carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,114&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Beginning in FY 2025 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating losses - unlimited carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,501&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,501&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;None &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disallowed business interest expense carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;None &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Beginning in FY 2026 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <pets:OperatingLossCarryforwardsSubjectToLimitations contextRef="c-99" decimals="-3" id="f-614" unitRef="usd">85454000</pets:OperatingLossCarryforwardsSubjectToLimitations>
    <pets:OperatingLossCarryforwardsSubjectToLimitations contextRef="c-100" decimals="-3" id="f-615" unitRef="usd">83300000</pets:OperatingLossCarryforwardsSubjectToLimitations>
    <pets:OperatingLossCarryforwardsSubjectToLimitations contextRef="c-101" decimals="-3" id="f-616" unitRef="usd">2154000</pets:OperatingLossCarryforwardsSubjectToLimitations>
    <pets:OperatingLossCarryforwardsNotSubjectToLimitations contextRef="c-102" decimals="-3" id="f-617" unitRef="usd">10501000</pets:OperatingLossCarryforwardsNotSubjectToLimitations>
    <pets:OperatingLossCarryforwardsNotSubjectToLimitations contextRef="c-103" decimals="-3" id="f-618" unitRef="usd">10501000</pets:OperatingLossCarryforwardsNotSubjectToLimitations>
    <pets:DisallowedBusinessInterestExpenseCarryover contextRef="c-104" decimals="-3" id="f-619" unitRef="usd">1855000</pets:DisallowedBusinessInterestExpenseCarryover>
    <pets:DisallowedBusinessInterestExpenseCarryover contextRef="c-105" decimals="-3" id="f-620" unitRef="usd">1855000</pets:DisallowedBusinessInterestExpenseCarryover>
    <us-gaap:OperatingLossCarryforwards contextRef="c-106" decimals="-3" id="f-621" unitRef="usd">11040000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-107" decimals="-3" id="f-622" unitRef="usd">2066000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-108" decimals="-3" id="f-623" unitRef="usd">8974000</us-gaap:OperatingLossCarryforwards>
    <pets:OperatingLossCarryforwardsSubjectToLimitations contextRef="c-109" decimals="-3" id="f-624" unitRef="usd">84114000</pets:OperatingLossCarryforwardsSubjectToLimitations>
    <pets:OperatingLossCarryforwardsSubjectToLimitations contextRef="c-110" decimals="-3" id="f-625" unitRef="usd">83300000</pets:OperatingLossCarryforwardsSubjectToLimitations>
    <pets:OperatingLossCarryforwardsSubjectToLimitations contextRef="c-111" decimals="-3" id="f-626" unitRef="usd">814000</pets:OperatingLossCarryforwardsSubjectToLimitations>
    <pets:OperatingLossCarryforwardsNotSubjectToLimitations contextRef="c-96" decimals="-3" id="f-627" unitRef="usd">10501000</pets:OperatingLossCarryforwardsNotSubjectToLimitations>
    <pets:OperatingLossCarryforwardsNotSubjectToLimitations contextRef="c-112" decimals="-3" id="f-628" unitRef="usd">10501000</pets:OperatingLossCarryforwardsNotSubjectToLimitations>
    <pets:DisallowedBusinessInterestExpenseCarryover contextRef="c-4" decimals="-3" id="f-629" unitRef="usd">0</pets:DisallowedBusinessInterestExpenseCarryover>
    <pets:DisallowedBusinessInterestExpenseCarryover contextRef="c-113" decimals="-3" id="f-630" unitRef="usd">0</pets:DisallowedBusinessInterestExpenseCarryover>
    <us-gaap:OperatingLossCarryforwards contextRef="c-98" decimals="-3" id="f-631" unitRef="usd">11040000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-114" decimals="-3" id="f-632" unitRef="usd">2066000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-97" decimals="-3" id="f-633" unitRef="usd">8974000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-634">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax provision consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax provision (benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-635" unitRef="usd">490000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-636" unitRef="usd">2623000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-637" unitRef="usd">5802000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-638" unitRef="usd">408000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-639" unitRef="usd">1312000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-640" unitRef="usd">514000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-641" unitRef="usd">898000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-642" unitRef="usd">3934000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-643" unitRef="usd">6316000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-644" unitRef="usd">412000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-645" unitRef="usd">-453000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-646" unitRef="usd">-778000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-647" unitRef="usd">-119000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-648" unitRef="usd">-1176000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-649" unitRef="usd">-69000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-650" unitRef="usd">293000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-6" decimals="-3" id="f-651" unitRef="usd">-1629000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-7" decimals="-3" id="f-652" unitRef="usd">-847000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-653" unitRef="usd">1191000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-654" unitRef="usd">2305000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-655" unitRef="usd">5469000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-656">&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income tax provision computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes at federal statutory rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock shortfall adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The differences between the effective income tax rate and the statutory U.S. federal income tax rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal rate on income before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock shortfall adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Effective Tax Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-657" unitRef="usd">-1317000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="-3" id="f-658" unitRef="usd">1564000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-7" decimals="-3" id="f-659" unitRef="usd">5078000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-660" unitRef="usd">304000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-6" decimals="-3" id="f-661" unitRef="usd">107000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-7" decimals="-3" id="f-662" unitRef="usd">428000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-663" unitRef="usd">1771000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-664" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-7" decimals="-3" id="f-665" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="-3" id="f-666" unitRef="usd">105000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-6" decimals="-3" id="f-667" unitRef="usd">340000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-7" decimals="-3" id="f-668" unitRef="usd">116000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-1" decimals="-3" id="f-669" unitRef="usd">281000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-6" decimals="-3" id="f-670" unitRef="usd">171000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-7" decimals="-3" id="f-671" unitRef="usd">31000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c-1" decimals="-3" id="f-672" unitRef="usd">47000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c-6" decimals="-3" id="f-673" unitRef="usd">0</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c-7" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-1" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-6" decimals="-3" id="f-676" unitRef="usd">124000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-7" decimals="-3" id="f-677" unitRef="usd">-184000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-678" unitRef="usd">1191000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-679" unitRef="usd">2305000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-680" unitRef="usd">5469000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-5" id="f-681" unitRef="usd">1800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <pets:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment contextRef="c-1" decimals="-5" id="f-682" unitRef="usd">1000000</pets:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetAdjustment>
    <pets:EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount contextRef="c-1" decimals="-5" id="f-683" unitRef="usd">1000000</pets:EffectiveIncomeTaxRateReconciliationCompensationOfCoveredPeopleLimitDeductionAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-6" decimals="-3" id="f-684" unitRef="usd">171000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-6" decimals="-3" id="f-685" unitRef="usd">124000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-7" decimals="-3" id="f-686" unitRef="usd">31000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-7" decimals="-3" id="f-687" unitRef="usd">-184000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-688" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="3" id="f-689" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-7" decimals="3" id="f-690" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-691" unitRef="number">-0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-6" decimals="3" id="f-692" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-7" decimals="3" id="f-693" unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-694" unitRef="number">-0.282</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-6" decimals="3" id="f-695" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-7" decimals="3" id="f-696" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <pets:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent contextRef="c-1" decimals="3" id="f-697" unitRef="number">-0.017</pets:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <pets:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent contextRef="c-6" decimals="3" id="f-698" unitRef="number">0.046</pets:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <pets:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent contextRef="c-7" decimals="3" id="f-699" unitRef="number">0.005</pets:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-1" decimals="3" id="f-700" unitRef="number">-0.045</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-6" decimals="3" id="f-701" unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-7" decimals="3" id="f-702" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c-1" decimals="3" id="f-703" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c-6" decimals="3" id="f-704" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c-7" decimals="3" id="f-705" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-706" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-6" decimals="3" id="f-707" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-7" decimals="3" id="f-708" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-709" unitRef="number">-0.190</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-6" decimals="3" id="f-710" unitRef="number">0.310</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-7" decimals="3" id="f-711" unitRef="number">0.226</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-712">Shareholders&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Equity&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 1998, the Company issued 250,000 shares of its $.001 par value preferred stock at a price of $4.00 per share, less issuance costs of $112 thousand. Each share of the preferred stock is convertible into approximately 4.05 shares of common stock at the election of the shareholder. The shares have a liquidation value of $4.00 per share and may pay dividends at the sole discretion of the Company. The Company does not anticipate paying dividends to the preferred shareholders in the foreseeable future. Each share of preferred stock is entitled to one vote on all matters submitted to a vote of shareholders of the Company. At March&#160;31, 2024 and 2023, 2,500 shares of the convertible preferred stock remained unconverted and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company&#x2019;s financial performance. During fiscal 2024, our Board of Directors declared the following dividends:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.254%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Declaration Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;br/&gt;Dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Record Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Amount&lt;br/&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 22, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 6, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6,352&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 12, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 14, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6,344&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 18, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-115"
      decimals="INF"
      id="f-713"
      unitRef="shares">250000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-115"
      decimals="INF"
      id="f-714"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-115"
      decimals="2"
      id="f-715"
      unitRef="usdPerShare">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-116" decimals="-3" id="f-716" unitRef="usd">112000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="c-115" decimals="2" id="f-717" unitRef="shares">4.05</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="c-115"
      decimals="2"
      id="f-718"
      unitRef="usdPerShare">4.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-117"
      decimals="INF"
      id="f-719"
      unitRef="shares">2500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-118"
      decimals="INF"
      id="f-720"
      unitRef="shares">2500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DividendsDeclaredTableTextBlock contextRef="c-1" id="f-721">During fiscal 2024, our Board of Directors declared the following dividends:&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.254%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Declaration Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;br/&gt;Dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Record Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Amount&lt;br/&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 22, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 6, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6,352&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 12, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 14, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6,344&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 18, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="c-119"
      decimals="2"
      id="f-722"
      unitRef="usdPerShare">0.30</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c-119" decimals="-3" id="f-723" unitRef="usd">6352000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="c-120"
      decimals="2"
      id="f-724"
      unitRef="usdPerShare">0.30</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c-120" decimals="-3" id="f-725" unitRef="usd">6344000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-726">Restricted Stock&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2015, the Company&#x2019;s 2015 Outside Director Equity Compensation Restricted Stock Plan (&#x201c;2015 Director Plan&#x201d;) became effective upon the approval of the plan by the Company&#x2019;s shareholders. The 2015 Director Plan authorized 400,000 shares of the Company's common stock available for issuance under the plan and provides for an automatic increase every year in the amount of shares available for issuance under the plan of 10% of the shares authorized under the plan. In July 2016, the Company&#x2019;s 2016 Employee Equity Compensation Restricted Stock Plan (&#x201c;2016 Employee Plan&#x201d;) became effective upon the approval of the plan by the Company&#x2019;s shareholders. The 2016 Employee Plan authorized 1,000,000 shares of the Company's Common stock available for issuance under the plan. In July 2022, the Company&#x2019;s 2022 Employee Equity Compensation Restricted Stock Plan (&#x201c;2022 Employee Plan&#x201d;) became effective upon the approval of the plan by the Company&#x2019;s shareholders. The 2022 Employee Plan replaced the 2016 Employee Plan, and as of April 2023 no further awards were granted, or will be granted, under the 2016 Employee Plan. The 2022 Employee Plan authorized 1,000,000 shares of the Company's common stock available for issuance.The value of the restricted stock is determined based on the market value of the stock at the issuance date. The restriction period or forfeiture period is determined by the Company&#x2019;s Compensation and Human Capital Committee and is to be no less than 1 year and no more than ten years unless otherwise specified by the Compensation and Human Capital Committee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Based Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) (ASU 2016-09). At March&#160;31, 2024, the Company had 957,260 common shares issued under the 2016 Employee Plan, 255,251 common shares issued under the 2015 Director Plan and 149,488 common shares issued under the 2022 Employee Plan. As of March 31, 2024, all shares in the 2022 Employee Plan, 2016 Employee Plan and 2015 Director Plan were issued subject to a restriction or forfeiture or vesting period that lapses ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over a &lt;span style="-sec-ix-hidden:f-736"&gt;one&lt;/span&gt; to three-year restriction period, with the exception of performance restricted shares which were issued to the Company's former Chief Executive Officer and the Company's Chief Financial Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company issued 90,000 restricted shares and 510,000 performance restricted shares to the Company&#x2019;s former CEO, in accordance with the former CEO&#x2019;s employment agreement, under the 2016 Employee Plan.  The performance restricted shares were based on achieving absolute stock hurdles within the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three-year period from the grant date. If the shares met the absolute stock price hurdle, they would have only been released from restrictions on the third anniversary of the date of grant. As of March&#160;31, 2024, none of the performance stock hurdles were met, and subsequent to March 31, 2024 the performance restricted shares were forfeited and cancelled as a result of the former CEO's cessation of employment with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company issued 13,000 restricted shares and 3,000 performance restricted shares to the Company's CFO, in accordance with the CFO's employment agreement, under the 2016 Employee Plan. One-third of the restricted shares will vest on each of the first three anniversaries of the date of grant, subject to the CFO&#x2019;s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Lato',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance restricted shares were based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue, and on June 8, 2023 the Company determined that the performance criteria was not attained over the applicable performance period and the performance restricted shares were forfeited. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, the Company granted the Company's CFO 11,750 RSUs under the 2022 Employee Plan, of which 3,750 RSUs were awarded in recognition of the CFO&#x2019;s contributions during fiscal year 2023 and the remaining 8,000 awarded as a part of the equity award cycle for fiscal year 2024. One-third of the RSUs will vest on each of the first &lt;span style="-sec-ix-hidden:f-746"&gt;three&lt;/span&gt; anniversaries of the date of grant, subject to the CFO&#x2019;s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Lato',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in June 2023, the CFO was awarded 8,000 PSUs with a market condition.  The CFO will earn shares of our common stock pursuant to the PSUs based on the Company&#x2019;s total shareholder return (&#x201c;TSR&#x201d;) relative to the S&amp;amp;P 600 Specialty Retail Index (&#x201c;Index&#x201d;) over an overall three-year performance period consisting of the 2024 through 2026 fiscal years, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt"&gt;100% of the target number of shares, which is 8,000 shares, will be earned if the Company&#x2019;s TSR is equal to or greater than the 75th percentile of the Index (the &#x201c;maximum target payout&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt"&gt;50% of the target number of shares, which is 4,000 shares, will be earned if the Company&#x2019;s TSR is equal to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;at least the 50th percentile of the Index; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt"&gt;25% of the target number of shares, which is 2,000 shares, will be earned if the Company&#x2019;s TSR is equal to at least the 25th percentile of the Index (the &#x201c;minimum threshold&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt"&gt;No shares will be earned if the TSR is less than the 25th percentile of the Index, and the payout is capped at 2,000 shares if absolute TSR is negative, regardless of relative position to the Index; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt"&gt;Linear scaling will be used to determine the number of shares earned for performance between the maximum target payout level and the minimum threshold payout level. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; Subsequent to March 31, 2024, 3,917 of the RSUs granted in June 2023 and all PSUs granted granted in June 2023 were forfeited and cancelled in connection with the CFO's Transition and Separation Agreement - see Note 16, Subsequent Events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal years ended March&#160;31, 2024, 2023, and 2022, the Company recognized compensation expense related to the 2016 and 2022 Employee Plan and the 2015 Director Plan of $6.9 million, $6.6 million, and $4.5 million, respectively. All stock-based compensation expense is recognized as a payroll-related expense and it is included within the general and administrative expenses line item within the Company&#x2019;s Consolidated Statements of (Loss) Income, and the offset is included in the additional paid-in capital line item of the Company&#x2019;s Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Awards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended March 31, 2024, restricted stock award ("RSA") activity under the Plans was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.462%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2016 Employee&lt;br/&gt;Plan&lt;br/&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2015 Director&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 Employee Plan Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Plans&lt;br/&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,829&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted and issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,742&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,765&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,343)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,418)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,332)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,093)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,914)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,127)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,334)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,375)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605,343&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,076&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703,126&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2024 and 2023, there were 703,126 and 752,829, restricted shares subject to restriction and forfeiture outstanding, respectively. During the fiscal years ended March&#160;31, 2024 and 2023, the Company released from restrictions, net of forfeitures, 64,390 and 99,390 restricted shares, respectively. The weighted-average grant date fair value of restricted shares was $14.75 and $21.57 for fiscal years 2024 and 2023, respectively.  The total fair value of restricted shares released from restrictions was $1.4 million and $2.4 million for fiscal years 2024 and 2023, respectively.  At March&#160;31, 2024 and 2023, there were $3.2 million and $9.1 million of unrecognized compensation costs related to the restricted stock subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 7 months and 1.6 years for fiscal 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company first granted restricted stock units ("RSUs") in the year ended March 31, 2024. The fair value assigned to RSUs is the market price of the Company&#x2019;s stock on the grant date.  The vesting period for employees and members of the Board of Directors ranges from &lt;span style="-sec-ix-hidden:f-794"&gt;one&lt;/span&gt; to three years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended March 31, 2024, RSU activity under the Plans was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;&#160;Grant Date&lt;br/&gt;&#160;Fair Value Per RSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,880&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,800)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,080&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The total grant-date fair value of RSUs granted during the twelve months ended March&#160;31, 2024 and 2023 was $1.1 million and zero, respectively.  For the twelve months ended March&#160;31, 2024 and 2023, the Company recorded stock-based compensation related to RSUs of $0.3 million and zero, respectively. At March&#160;31, 2024 and 2023, there were $0.8 million and zero of unrecognized compensation costs related to RSUs subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 2.3 years and 0 years for fiscal 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Performance Stock Units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company first granted performance stock units ("PSUs") in the year ended March 31, 2024.  The fair value assigned to PSUs is determined using the market price of the Company&#x2019;s stock on the grant date for awards with a performance condition, and by using a Monte Carlo simulation for awards with a market condition. Existing PSUs with a performance condition vest over one year.  Existing PSUs with a market condition vest over three years. Stock-based compensation costs associated with PSUs with a performance condition are re-assessed each reporting period based upon the estimated performance attainment on the reporting date until the performance conditions are met. The ultimate number of shares of common stock that are issued to an employee is the result of the actual performance of the Company at the end of the performance period compared to the performance targets and generally ranges from 0% to 200% of the initial PSU grant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended March 31, 2024, PSU activity under the Plans was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 37pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;&#160;Grant Date&lt;br/&gt;&#160;Fair Value Per PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested PSUs outstanding at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The total grant-date fair value of PSUs granted during the twelve months ended March&#160;31, 2024 and 2023 was $126 thousand and zero, respectively. For the twelve months ended March&#160;31, 2024 and 2023, the Company recorded stock-based compensation related to PSUs of $64 thousand and zero, respectively. At March&#160;31, 2024 and 2023, there were $62 thousand and zero of unrecognized compensation costs related to PSUs subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 1.6 years and 0 years for fiscal 2024 and 2023, respectively&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-121"
      decimals="INF"
      id="f-727"
      unitRef="shares">400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pets:PercentageOfAutomaticIncreaseInSharesAvailableForIssuance contextRef="c-122" decimals="2" id="f-728" unitRef="number">0.10</pets:PercentageOfAutomaticIncreaseInSharesAvailableForIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-123"
      decimals="INF"
      id="f-729"
      unitRef="shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-124"
      decimals="INF"
      id="f-730"
      unitRef="shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pets:RestrictionPeriod contextRef="c-125" id="f-731">P1Y</pets:RestrictionPeriod>
    <pets:RestrictionPeriod contextRef="c-126" id="f-732">P10Y</pets:RestrictionPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-127" decimals="0" id="f-733" unitRef="shares">957260</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-128" decimals="0" id="f-734" unitRef="shares">255251</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-129" decimals="0" id="f-735" unitRef="shares">149488</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pets:RestrictionPeriod contextRef="c-131" id="f-737">P3Y</pets:RestrictionPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-132" decimals="0" id="f-738" unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-133" decimals="0" id="f-739" unitRef="shares">510000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod contextRef="c-133" id="f-740">P3Y</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-134" decimals="0" id="f-741" unitRef="shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-135" decimals="0" id="f-742" unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-136"
      decimals="INF"
      id="f-743"
      unitRef="shares">11750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-137"
      decimals="INF"
      id="f-744"
      unitRef="shares">3750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-138"
      decimals="INF"
      id="f-745"
      unitRef="shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-139"
      decimals="INF"
      id="f-747"
      unitRef="shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-139" id="f-748">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-140" decimals="2" id="f-749" unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-140"
      decimals="INF"
      id="f-750"
      unitRef="shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-141" decimals="2" id="f-751" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-141"
      decimals="INF"
      id="f-752"
      unitRef="shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-142" decimals="2" id="f-753" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-142"
      decimals="INF"
      id="f-754"
      unitRef="shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-143" decimals="2" id="f-755" unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-143"
      decimals="INF"
      id="f-756"
      unitRef="shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-144"
      decimals="INF"
      id="f-757"
      unitRef="shares">3917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-758" unitRef="usd">6900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-5" id="f-759" unitRef="usd">6600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-5" id="f-760" unitRef="usd">4500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c-1" id="f-761">&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended March 31, 2024, restricted stock award ("RSA") activity under the Plans was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.462%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2016 Employee&lt;br/&gt;Plan&lt;br/&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2015 Director&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 Employee Plan Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Plans&lt;br/&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,829&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted and issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,742&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,765&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,343)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,418)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,332)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,093)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,914)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,127)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,334)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,375)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605,343&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,076&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703,126&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-145"
      decimals="INF"
      id="f-762"
      unitRef="shares">684200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-146"
      decimals="INF"
      id="f-763"
      unitRef="shares">68629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-147"
      decimals="INF"
      id="f-764"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-148"
      decimals="INF"
      id="f-765"
      unitRef="shares">752829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-149"
      decimals="INF"
      id="f-766"
      unitRef="shares">12400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-150"
      decimals="INF"
      id="f-767"
      unitRef="shares">1623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-151"
      decimals="INF"
      id="f-768"
      unitRef="shares">89742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-152"
      decimals="INF"
      id="f-769"
      unitRef="shares">103765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-149"
      decimals="INF"
      id="f-770"
      unitRef="shares">76343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-150"
      decimals="INF"
      id="f-771"
      unitRef="shares">29418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-151"
      decimals="INF"
      id="f-772"
      unitRef="shares">8332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-152"
      decimals="INF"
      id="f-773"
      unitRef="shares">114093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-149"
      decimals="INF"
      id="f-774"
      unitRef="shares">14914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-150"
      decimals="INF"
      id="f-775"
      unitRef="shares">17127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-151"
      decimals="INF"
      id="f-776"
      unitRef="shares">7334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-152"
      decimals="INF"
      id="f-777"
      unitRef="shares">39375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-127"
      decimals="INF"
      id="f-778"
      unitRef="shares">605343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-128"
      decimals="INF"
      id="f-779"
      unitRef="shares">23707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-129"
      decimals="INF"
      id="f-780"
      unitRef="shares">74076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-153"
      decimals="INF"
      id="f-781"
      unitRef="shares">703126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-154" decimals="0" id="f-782" unitRef="shares">703126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-155" decimals="0" id="f-783" unitRef="shares">752829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-156" decimals="0" id="f-784" unitRef="shares">64390</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-157" decimals="0" id="f-785" unitRef="shares">99390</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-156"
      decimals="2"
      id="f-786"
      unitRef="usdPerShare">14.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-157"
      decimals="2"
      id="f-787"
      unitRef="usdPerShare">21.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-156" decimals="-5" id="f-788" unitRef="usd">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-157" decimals="-5" id="f-789" unitRef="usd">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-154" decimals="-5" id="f-790" unitRef="usd">3200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-155" decimals="-5" id="f-791" unitRef="usd">9100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-156" id="f-792">P7M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-157" id="f-793">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-159" id="f-795">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-796">RSU activity under the Plans was as follows:&lt;div style="padding-left:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;&#160;Grant Date&lt;br/&gt;&#160;Fair Value Per RSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,880&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,800)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,080&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="c-160" decimals="0" id="f-797" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="c-160"
      decimals="2"
      id="f-798"
      unitRef="usdPerShare">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-161" decimals="0" id="f-799" unitRef="shares">88880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-161"
      decimals="2"
      id="f-800"
      unitRef="usdPerShare">12.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod contextRef="c-161" decimals="0" id="f-801" unitRef="shares">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-161"
      decimals="2"
      id="f-802"
      unitRef="usdPerShare">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-161" decimals="0" id="f-803" unitRef="shares">3800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-161"
      decimals="2"
      id="f-804"
      unitRef="usdPerShare">13.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="c-162" decimals="0" id="f-805" unitRef="shares">85080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="c-162"
      decimals="2"
      id="f-806"
      unitRef="usdPerShare">12.75</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue contextRef="c-161" decimals="-5" id="f-807" unitRef="usd">1100000</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue contextRef="c-163" decimals="-5" id="f-808" unitRef="usd">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-161" decimals="-5" id="f-809" unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-163" decimals="INF" id="f-810" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-160" decimals="INF" id="f-811" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-163" id="f-812">P0Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-164" id="f-813">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-165" id="f-814">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-92" decimals="2" id="f-815" unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-93" decimals="2" id="f-816" unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="c-1" id="f-817">&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended March 31, 2024, PSU activity under the Plans was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 37pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;&#160;Grant Date&lt;br/&gt;&#160;Fair Value Per PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested PSUs outstanding at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2013;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="c-166" decimals="0" id="f-818" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="c-166"
      decimals="2"
      id="f-819"
      unitRef="usdPerShare">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-167" decimals="0" id="f-820" unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-167"
      decimals="2"
      id="f-821"
      unitRef="usdPerShare">10.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod contextRef="c-167" decimals="0" id="f-822" unitRef="shares">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-167"
      decimals="2"
      id="f-823"
      unitRef="usdPerShare">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-167" decimals="0" id="f-824" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-167"
      decimals="2"
      id="f-825"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment contextRef="c-167" decimals="0" id="f-826" unitRef="shares">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustment>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue
      contextRef="c-167"
      decimals="2"
      id="f-827"
      unitRef="usdPerShare">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="c-168" decimals="0" id="f-828" unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="c-168"
      decimals="2"
      id="f-829"
      unitRef="usdPerShare">10.48</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue contextRef="c-167" decimals="-3" id="f-830" unitRef="usd">126000</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue contextRef="c-169" decimals="-5" id="f-831" unitRef="usd">0</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedTotalGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-167" decimals="-3" id="f-832" unitRef="usd">64000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-169" decimals="INF" id="f-833" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-168" decimals="-3" id="f-834" unitRef="usd">62000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-166" decimals="-3" id="f-835" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-167" id="f-836">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-169" id="f-837">P0Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-839">Fair Value Measurements&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries cash and cash equivalents and investments at fair value in the Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Fair Value Measurements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs which are supported by little or no market activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At March&#160;31, 2024 and 2023 the Company had invested the majority of its $55.3 million and $104.1 million cash and cash equivalents balance in money market funds which are classified within Level 1.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-840" unitRef="usd">55300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-5" id="f-841" unitRef="usd">104100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-842">Net (Loss) Income Per Share&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the provisions of ASC Topic 260 (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) basic net (loss) income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net (loss) income per common share includes the dilutive &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock, and convertible preferred shares issued by the Company represent the only dilutive effect reflected in diluted weighted average shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income (numerator):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (denominator)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding used in basic computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,395,959&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,274,786&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,175,930&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable upon the vesting of restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,091&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,765&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable upon conversion of preferred shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,125&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in diluted computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,395,959&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,357,820&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per common share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2024, 2023, and 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 827,863, 745,854, and 220,727 shares of common restricted stock, respectively, were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted (net loss)/net income per common share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-843">The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for per share amounts):&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income (numerator):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (denominator)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding used in basic computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,395,959&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,274,786&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,175,930&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable upon the vesting of restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,091&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,765&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable upon conversion of preferred shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,125&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in diluted computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,395,959&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,357,820&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per common share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-844" unitRef="usd">-7464000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-845" unitRef="usd">5140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-846" unitRef="usd">18716000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-847" unitRef="shares">20395959</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-848" unitRef="shares">20274786</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-849" unitRef="shares">20175930</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="0" id="f-850" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-6" decimals="0" id="f-851" unitRef="shares">54091</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-7" decimals="0" id="f-852" unitRef="shares">171765</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="c-1" decimals="0" id="f-853" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="c-6" decimals="0" id="f-854" unitRef="shares">10125</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="c-7" decimals="0" id="f-855" unitRef="shares">10125</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-856" unitRef="shares">20395959</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-857" unitRef="shares">20339002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-858" unitRef="shares">20357820</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-859"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-860"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-861"
      unitRef="usdPerShare">0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-862"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-863"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-864"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-865" unitRef="shares">827863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="0" id="f-866" unitRef="shares">745854</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-867" unitRef="shares">220727</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-868">Commitments and Contingencies&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal Matters and Routine Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has settled complaints that had been filed with various states&#x2019; pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company also intends to vigorously defend its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred. From time to time, the Company may be involved in and subject to disputes and legal proceedings, as well as demands, claims and threatened litigation that arise in the ordinary course of its business. These proceedings may include allegations involving business practices, infringement of intellectual property, employment or other matters. The ultimate outcome of any legal proceeding is often uncertain, there can be no assurance that the Company will be successful in any legal proceeding, and unfavorable outcomes could have a negative impact on our results of operations and financial condition. In accordance with ASC Topic 450-20 ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loss Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"), the Company records a liability in its financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews the status of each significant matter each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the financial statements not misleading. If the loss is not probable and cannot be reasonably estimated, a liability is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;not recorded in the Company&#x2019;s financial statements. Gain contingencies are not recorded until they are realized. Legal costs related to any legal matters are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 25, 2021,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Board of Directors appointed Mathew N. Hulett ("Mr. Hulett&#x201d;) as Chief Executive Officer and President of the Company and as a member of the Board of Directors. These appointments and the employment agreement were effective as of August 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The employment agreement was for an initial term of three (3) years commencing on August 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and automatically renewed for successive one (1) year terms, or for longer periods as mutually agreed upon by the parties, unless the employment agreement was expressly cancelled by either Mr. Hulett or the Company sixty (60) days prior to the end of the then current term, or was otherwise terminated as provided in the agreement. The employment agreement provided that Mr. Hulett received an annual base salary of $500 thousand, subject to periodic review for increases with the approval of the Board of Directors, and was be eligible to participate in the standard employee benefit plans generally available to executives and employees of the Company, including health insurance, life and disability insurance, restricted stock under the Company&#x2019;s equity compensation plan(s), 401(k) plan, and paid time off and paid holidays. The employment agreement also provided that the Company will reimburse Mr. Hulett for his documented business expenses incurred in connection with his employment pursuant to the Company's standard reimbursement expense policy and practices. The employment agreement contained certain rights of Mr. Hulett and the Company to terminate Mr. Hulett&#x2019;s employment, including termination by the Company for &#x201c;Cause&#x201d; as defined in the employment agreement, and termination by Mr. Hulett for &#x201c;Good Reason&#x201d; as defined in the employment agreement within twelve (12) months of a Change in Control as defined in the employment agreement. Mr. Hulett was also entitled to severance pay equal to twelve (12) months of Mr. Hulett&#x2019;s current base salary and eighteen (18) months of health insurance benefits in the event of his termination by the Company without Cause, or termination by Mr. Hulett for Good Reason within twelve (12) months of a Change in Control. The foregoing severance benefits are conditioned upon Mr. Hulett&#x2019;s execution of a release of claims and compliance with certain restrictive covenants. The employment agreement contains customary non-disclosure and non-solicitation provisions as well as a one (1) year non-compete following the termination of the agreement. Subsequent to March 31, 2024 the employment agreement with Mr. Hulett was terminated (See Note 16 - Subsequent Events, for a description of the Transition and Separation Agreement with Mr. Hulett).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;30, 2021,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mr. Hulett also received an award of 90,000 shares of restricted stock under the Company&#x2019;s 2016 Employee Plan, which stock restrictions will lapse pro rata on each of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 30, 2022,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 30, 2023,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 30, 2024,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which are subject to forfeiture in the event of termination of employment (except as provided in the restricted stock agreement). Mr. Hulett also received an award of 510,000 shares of performance restricted stock under the 2016 Employee Plan, which stock restrictions will lapse on the third anniversary of the date of grant based on (i) achieving absolute stock price hurdles within the three-year period from the date of grant, and (ii) continued employment through the performance period of three years from the date of grant, in accordance with the following schedule: 85,000 shares at the stock hurdle price of $40 per share, 107,000 shares at the stock hurdle price of $45 per share, 106,000 shares at the stock hurdle price of $50, 106,000 shares at the stock hurdle price of $55, and 106,000 shares at the stock hurdle price of $60.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Should none of the absolute stock price hurdles be met during the three-year period from the date of grant, no shares would vest (as defined in the performance restricted stock agreement). Once the absolute stock price hurdle is achieved, it will be considered to have met the absolute stock price hurdle, regardless of the stock price on the third anniversary of the date of grant. The absolute stock price hurdle would be considered to have been met if the average closing stock price of the Company is at or above the absolute stock price hurdle for a period of ninety (90) consecutive trading days. If the shares would be considered to have met the absolute stock price hurdle, they will only vest on the third anniversary of date of grant, subject to Mr. Hulett&#x2019;s continued employment through the performance period of three years from the date of grant (except as provided in the performance restricted stock agreement). As of March&#160;31, 2024,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;none of the performance restricted stock vested, as no performance stock price hurdles were met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;14, 2022, the Board of Directors appointed Christine Chambers ("Ms. Chambers") to serve as the Company&#x2019;s Chief Financial Officer and to assume the duties of principal financial officer and principal accounting officer effective August&#160;3, 2022 (&#x201c;Effective Date&#x201d;). The Company entered into an offer letter with Ms. Chambers &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to set the terms and conditions of Ms. Chambers&#x2019; employment as Chief Financial Officer of the Company. Ms. Chambers will receive an annual base salary of $375 thousand and received a one-time sign-on bonus in the amount of $50 thousand, subject to pro rata repayment if Ms. Chambers terminated employment with the Company within the first twelve months of employment. Ms. Chambers received an initial equity award  under the 2016 Employee Plan consisting of (i) an award of 13,000 restricted shares, and (ii) 3,000 performance restricted shares, which performance restricted shares will be based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue as of the fiscal year ended March&#160;31, 2024. The shares for each grant will be released from restriction equally over a three (3) year period on the anniversary of the grant date, subject to the attainment of performance criteria in the case of the performance restricted shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with Mr. Rosenbloom&#x2019;s transition services and subsequent separation from employment with the Company, on August&#160;2, 2022 the Company and Mr. Rosenbloom entered into a CFO Transition and Separation Agreement (the "Separation Agreement&#x201d;) pursuant to which Mr. Rosenbloom remained in his current position as CFO of the Company through and including August&#160;2, 2022, and following the termination of his status as CFO, Mr. Rosenbloom continued to serve as an employee of the Company to provide transition services to the Company through his date of termination. His employment ended on December&#160;31, 2022 ("Separation Date&#x201d;). While Mr. Rosenbloom served as an employee of the Company, he continued to receive his current base salary and benefits as was in effect. The Separation Agreement provided that Mr. Rosenbloom would be paid two lump-sum severance payments of $182 thousand each, with the first such payment to be paid on the Company&#x2019;s next payroll date following the Separation Date, and was paid January 13, 2023, and the second paid on the Company&#x2019;s next payroll date six-months following the Separation Date, subject to his compliance with the terms and conditions of his then existing employment agreement, and the Separation Agreement. In exchange for the Company&#x2019;s agreement to make the severance payments, Mr. Rosenbloom granted the Company a full release of any and all claims that he may have against the Company and its affiliates and related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as a part of the Separation Agreement, the Company confirmed that the 13,275 restricted shares held by Mr. Rosenbloom under the 2016 Employee Plan were released from restriction and forfeiture on December&#160;31, 2022, Under the Separation Agreement, Mr. Rosenbloom&#x2019;s existing non-compete obligation was reduced to a period of twelve (12) months.&lt;/span&gt;&lt;/div&gt;In connection with the separation of the Company's former Chief Financial Officer, the Company paid the remaining $182 thousand payment with respect to the severance, pursuant to the Separation Agreement in fiscal year 2024.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pets:EmploymentTermInitialPeriod contextRef="c-170" id="f-869">P3Y</pets:EmploymentTermInitialPeriod>
    <pets:EmploymentTermSuccessiveRenewalPeriod contextRef="c-170" id="f-870">P1Y</pets:EmploymentTermSuccessiveRenewalPeriod>
    <pets:EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm contextRef="c-170" id="f-871">P60D</pets:EmploymentTermCancellationPeriodPriorToEndOfCurrentTerm>
    <us-gaap:OfficersCompensation contextRef="c-170" decimals="-3" id="f-872" unitRef="usd">500000</us-gaap:OfficersCompensation>
    <pets:TerminationPeriodPeriodWithinChangeInControl contextRef="c-170" id="f-873">P12M</pets:TerminationPeriodPeriodWithinChangeInControl>
    <pets:SeverancePaymentBaseSalaryPeriod contextRef="c-170" id="f-874">P12M</pets:SeverancePaymentBaseSalaryPeriod>
    <pets:SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod contextRef="c-170" id="f-875">P18M</pets:SeverancePaymentTerminationWithoutCauseHealthInsuranceBenefitsPeriod>
    <pets:SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod contextRef="c-170" id="f-876">P12M</pets:SeverancePaymentChangeInControlHealthInsuranceBenefitsPeriod>
    <pets:NonCompeteAgreementPeriod contextRef="c-170" id="f-877">P1Y</pets:NonCompeteAgreementPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-171" decimals="0" id="f-878" unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-172" decimals="0" id="f-879" unitRef="shares">510000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod contextRef="c-172" id="f-880">P3Y</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod contextRef="c-172" id="f-881">P3Y</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-173"
      decimals="INF"
      id="f-882"
      unitRef="shares">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-174"
      decimals="INF"
      id="f-883"
      unitRef="usdPerShare">40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-175"
      decimals="INF"
      id="f-884"
      unitRef="shares">107000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-176"
      decimals="INF"
      id="f-885"
      unitRef="usdPerShare">45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-177"
      decimals="INF"
      id="f-886"
      unitRef="shares">106000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-178"
      decimals="INF"
      id="f-887"
      unitRef="usdPerShare">50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-179"
      decimals="INF"
      id="f-888"
      unitRef="shares">106000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-180"
      decimals="INF"
      id="f-889"
      unitRef="usdPerShare">55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-181"
      decimals="INF"
      id="f-890"
      unitRef="shares">106000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-182"
      decimals="INF"
      id="f-891"
      unitRef="usdPerShare">60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod contextRef="c-172" id="f-892">P3Y</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedHurdlePeriod>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod contextRef="c-172" id="f-893">P90D</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAbsoluteStockPriceHurdlePeriod>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod contextRef="c-172" id="f-894">P3Y</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedPerformancePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-183"
      decimals="INF"
      id="f-895"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:OfficersCompensation contextRef="c-184" decimals="-3" id="f-896" unitRef="usd">375000</us-gaap:OfficersCompensation>
    <pets:SalaryAndWageOfficerSignOnBonus contextRef="c-184" decimals="-3" id="f-897" unitRef="usd">50000</pets:SalaryAndWageOfficerSignOnBonus>
    <pets:SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod contextRef="c-184" id="f-898">P12M</pets:SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-185" decimals="0" id="f-899" unitRef="shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-186" decimals="0" id="f-900" unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-186" id="f-901">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <pets:NumberOfSeverancePayments
      contextRef="c-187"
      decimals="INF"
      id="f-902"
      unitRef="payment">2</pets:NumberOfSeverancePayments>
    <pets:LumpSumSeverancePayments contextRef="c-188" decimals="-3" id="f-903" unitRef="usd">182000</pets:LumpSumSeverancePayments>
    <pets:ContingentLumpSumSeverancePayment contextRef="c-189" decimals="-3" id="f-904" unitRef="usd">182000</pets:ContingentLumpSumSeverancePayment>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-190" decimals="0" id="f-905" unitRef="shares">13275</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <pets:NonCompeteAgreementPeriod contextRef="c-189" id="f-906">P12M</pets:NonCompeteAgreementPeriod>
    <pets:AccruedSeveranceCosts contextRef="c-191" decimals="-3" id="f-907" unitRef="usd">182000</pets:AccruedSeveranceCosts>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-908">Employee Benefit Plan&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 401(k) Savings Plan for eligible employees. The plan is a defined contribution plan that is administered by the Company. All regular, full-time employees are eligible for voluntary participation upon completing 90 days of service and having attained the age of 21. The plan provides for growth in savings through contributions and income from investments. It is subject to the provisions of the Employee Retirement Income Security Act of 1974&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as amended. Plan participants are allowed to contribute a specified percentage of their base salary. The Company matches 100% of the first 4% of the employee's contribution. The matching contribution is funded subsequent to the calendar year. During the fiscal years ended March&#160;31, 2024, 2023, and 2022, the Company recorded $350 thousand, $289 thousand, and $238 thousand, respectively, of 401(k) matching contribution and administration expense to general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1 contextRef="c-1" id="f-909">P90D</us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1>
    <pets:DefinedContributionPlanWithIndividualAge contextRef="c-1" id="f-910">P21Y</pets:DefinedContributionPlanWithIndividualAge>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="c-1" decimals="2" id="f-911" unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c-1" decimals="2" id="f-912" unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="c-1" decimals="-3" id="f-913" unitRef="usd">350000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="c-6" decimals="-3" id="f-914" unitRef="usd">289000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="c-7" decimals="-3" id="f-915" unitRef="usd">238000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-916">Subsequent Events&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Transition and Separation Agreement with Matthew Hulett&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 29, 2024, the Company and Mathew Hulett entered into a Transition and Separation Agreement pursuant to which Mr. Hulett resigned as President and Chief Executive Officer, and also as a director, of the Company effective April 29, 2024 (the &#x201c;Hulett Agreement&#x201d;). Under the terms of the Hulett Agreement, Mr. Hulett remained employed by the Company through May 10, 2024 to assist the Company in transition matters, and the Company will pay Mr. Hulett severance compensation thereafter in the form of the continuation of his base salary &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and reimbursement of COBRA premiums through August 30, 2024, which was the scheduled expiration date of his employment agreement. The Hulett Agreement also provided that the Company cancelled the 510,000 performance restricted shares granted in August 2021, and accelerated the vesting of Mr. Hulett&#x2019;s remaining unvested shares of restricted common stock (consisting of 30,000 shares) previously granted under a Restricted Stock Agreement between the Company and Mr. Hulett which would have otherwise vested on August 30, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Appointment of Sandra Campos as Chief Executive Officer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 29, 2024, the Company appointed Sandra Campos, an existing director of the Company, as the Company&#x2019;s new Chief Executive Officer and President. On the same date, the Company and Ms. Campos entered into an Executive Employment Agreement setting forth the terms under which Ms. Campos was employed by the Company as Chief Executive Officer and President (the &#x201c;Employment Agreement&#x201d;). Ms. Campos will continue to serve as a director of the Company for so long as she remains Chief Executive Officer and President.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ms. Campos&#x2019; Employment Agreement provides for an initial employment term of 3 years and for automatic renewal for successive 1-year terms thereafter unless either party provides notice of non renewal at least 60 days prior to the end of the then-current term. As provided in the Employment Agreement, Ms. Campos will serve the Company on a full-time basis and will receive an annual base salary of $550,000, which may be increased in the discretion of the board of directors (but may not be decreased other than as part of a proportionate reduction in management salaries and wages applicable to all senior management). Ms. Campos will receive a signing bonus of $120,000, which is subject to repayment if Ms. Campos leaves the Company within one year under circumstances detailed in the Employment Agreement. Ms. Campos will also receive customary expense reimbursement (in accordance with the Company&#x2019;s standard policies), and will receive the medical, health, and other benefits provided to Company employees generally, including participation in the Company&#x2019;s 401(k) plan on the same basis as other employees generally. The Employment Agreement provides that Ms. Campos will be eligible to receive an annual performance bonus based on annual performance goals determined by the Company&#x2019;s board of directors, with a target annual bonus of 100% of Ms. Campos&#x2019; base salary and a maximum bonus of 200% of base salary. The agreement includes customary restrictive covenants, including confidentiality and non-solicitation covenants and a one-year post-employment non-compete restriction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Employment Agreement, Ms. Campos will be entitled to equity grants under the Company&#x2019;s current or future equity plan, as follows: On April 29, 2024, Ms. Campos received a grant of restricted stock units (&#x201c;RSUs&#x201d;) under the Company&#x2019;s 2022 Employee Equity Compensation Plan for a number of RSUs equal to $2.0&#160;million divided by the closing price of the Company&#x2019;s common stock on the Nasdaq Stock Market on the date of grant. Such RSUs will vest in one-third increments on each of the first 3 anniversaries of the date of grant so long as Ms. Campos continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. Thereafter, Ms. Campos will be entitled to annual grants of RSUs and performance stock units (&#x201c;PSUs&#x201d;) having an aggregate value per grant of $750,000 for the annual RSU grant and $750,000 for the annual PSU grant, with such value being calculated based on the closing price of the Company&#x2019;s common stock on the date of grant but subject to a floor of $4.00 per share. The RSUs included in any such annual grants will vest in the same manner as the initial RSU grant, and the PSUs will have a 3-year performance period and such performance goals and other terms as shall be determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Appointment of Justin L. Mennen as a Director&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2024, the Board of Directors (the &#x201c;Board&#x201d;) of PetMed Express, Inc. (the &#x201c;Company&#x201d;), appointed Justin L. Mennen to serve as a director of the Company beginning June 3, 2024. Mr. Mennen will hold this position until the 2024 annual meeting of the Company&#x2019;s stockholders or until his successor is elected and qualified, subject to his earlier resignation or removal. Mr. Mennen has been appointed to serve on the Board&#x2019;s Audit Committee and Corporate Governance and Nominating Committee. In connection with his appointment to the Board, Mr. Mennen will receive compensation in accordance with the Company&#x2019;s Non-Employee Director Compensation Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Transition and Separation Agreement with Christine Chambers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 31, 2024, PetMed Express, Inc. (the &#x201c;Company&#x201d;) entered into a Transition and Separation Agreement (the &#x201c;Chambers Agreement&#x201d;) with Christine Chambers, the Company&#x2019;s Chief Financial Officer, Treasurer, and Secretary, pursuant to which the Company and Ms. Chambers agreed to the mutual termination of Ms. Chambers&#x2019; employment with the Company following a transition period.  Under the terms of the Agreement, the Company and Ms. Chambers mutually agreed to terminate the Executive Employment Agreement, dated August 3, 2022, between the Company and Ms. Chambers effective immediately (notwithstanding the scheduled expiration date of August 3, 2024), provided that Ms. Chambers will continue to serve as the Company&#x2019;s Chief Financial Officer, Secretary, and Treasurer on a full-time basis for a transition period (the &#x201c;Transition Period&#x201d;) that will end on the fifth business day after the Company files its Quarterly Report on Form 10-Q for the Company&#x2019;s fiscal quarter ending June 30, 2024, or, if earlier, upon the fifteenth day after written notice by the Company of the earlier termination of the Transition Period. Ms. Chambers will work with and cooperate with the Company in transitioning her duties and responsibilities to such successor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Chambers Agreement provides that, during the Transition Period, Ms. Chambers will continue to receive her current base salary and benefits, and upon the completion of the Transition Period and contingent on Ms. Chambers&#x2019; complying with the terms of the Chambers Agreement, the Company will accelerate the vesting of all unvested restricted shares and restricted stock units that were originally scheduled to vest on or before August 3, 2025. Ms. Chambers has agreed to a customary general release and waiver of claims against the Company in exchange for the Company&#x2019;s covenants and agreements set forth in the Chambers Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="c-192"
      decimals="INF"
      id="f-917"
      unitRef="shares">510000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-193"
      decimals="-4"
      id="f-918"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <pets:EmploymentAgreementEmploymentTerm contextRef="c-194" id="f-919">P3Y</pets:EmploymentAgreementEmploymentTerm>
    <pets:EmploymentAgreementRenewalTerm contextRef="c-194" id="f-920">P1Y</pets:EmploymentAgreementRenewalTerm>
    <pets:EmploymentAgreementNonRenewalNoticePeriod contextRef="c-194" id="f-921">P60D</pets:EmploymentAgreementNonRenewalNoticePeriod>
    <pets:SalaryAndWageOfficerAnnualBaseSalary contextRef="c-192" decimals="-4" id="f-922" unitRef="usd">550000</pets:SalaryAndWageOfficerAnnualBaseSalary>
    <pets:SalaryAndWageOfficerSignOnBonus contextRef="c-192" decimals="-3" id="f-923" unitRef="usd">120000</pets:SalaryAndWageOfficerSignOnBonus>
    <pets:SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod contextRef="c-192" id="f-924">P1Y</pets:SalaryAndWageOfficerSignOfBonusRequisiteServicePeriod>
    <pets:SalaryAndWageTargetAnnualBonusPercentage contextRef="c-194" decimals="2" id="f-925" unitRef="number">1</pets:SalaryAndWageTargetAnnualBonusPercentage>
    <pets:SalaryAndWageMaximumBonusPercentage contextRef="c-194" decimals="2" id="f-926" unitRef="number">2</pets:SalaryAndWageMaximumBonusPercentage>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount contextRef="c-195" decimals="-5" id="f-927" unitRef="usd">2000000</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedStockAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-193" id="f-928">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount contextRef="c-196" decimals="-4" id="f-929" unitRef="usd">750000</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount contextRef="c-197" decimals="-4" id="f-930" unitRef="usd">750000</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAnnualGrantAmount>
    <pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare
      contextRef="c-194"
      decimals="2"
      id="f-931"
      unitRef="usdPerShare">4.00</pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardSubjectToFloorPerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-198" id="f-932">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-202" id="f-937">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-202" id="f-938">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-202" id="f-939">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-202" id="f-940">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-941">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
